<SEC-DOCUMENT>0001724521-26-000034.txt : 20260505
<SEC-HEADER>0001724521-26-000034.hdr.sgml : 20260505
<ACCEPTANCE-DATETIME>20260505161152
ACCESSION NUMBER:		0001724521-26-000034
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		76
CONFORMED PERIOD OF REPORT:	20260331
FILED AS OF DATE:		20260505
DATE AS OF CHANGE:		20260505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arcus Biosciences, Inc.
		CENTRAL INDEX KEY:			0001724521
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				473898435
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38419
		FILM NUMBER:		26943242

	BUSINESS ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
		BUSINESS PHONE:		(510) 694-6200

	MAIL ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>rcus-20260331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019cd33b-55e2-7686-a45d-3e64ec40f088,g:5cd5bcae-d38e-4438-9e12-43823d2921f9,d:a317198098a84e059b141ad74d9b0930-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:rcus="http://arcusbio.com/20260331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>rcus-20260331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0001724521</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-26">12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-27">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-28">2026</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-29">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-31" name="us-gaap:RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList" id="f-443">http://fasb.org/us-gaap/2025#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-14" name="us-gaap:RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList" id="f-444">http://fasb.org/us-gaap/2025#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-187" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-592">462</ix:nonNumeric><ix:nonNumeric contextRef="c-185" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-593">795</ix:nonNumeric><ix:nonNumeric contextRef="c-189" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-594">304</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="rcus-20260331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>rcus:segment</xbrli:measure></xbrli:unit><xbrli:unit id="member"><xbrli:measure>rcus:member</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="program"><xbrli:measure>rcus:program</xbrli:measure></xbrli:unit><xbrli:unit id="position"><xbrli:measure>rcus:position</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherCollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherCollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherCollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherCollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rcus:CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:CommonStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:AmendedGileadCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:AmendedGileadCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:AmendedGileadCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:AmendedGileadCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:STAR221DevelopmentActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:TaihoCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:STAR121DevelopmentActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:TaihoCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:TaihoCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:TaihoCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:TaihoCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AstraZenecaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AstraZenecaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AstraZenecaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AstraZenecaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AstraZenecaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AntiPDOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:WuXiBiologicsLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:WuXiBiologicsLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AntiPDOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:WuXiBiologicsLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AntiPDOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AntiCDThirtyNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:WuXiBiologicsLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:WuXiBiologicsLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AntiCDThirtyNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:WuXiBiologicsLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AntiCDThirtyNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:AbmunoLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:AbmunoLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:GileadCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:GileadCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:RDServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:GileadCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:RDServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:GileadCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AccessRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:GileadCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AccessRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:GileadCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:GileadCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:GileadCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:TaihoCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:TaihoCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:DevelopmentServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AccessRightsAndOptionContinuationPeriodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:RightsToCertainStudiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:RDServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:RDServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AccessRightsAndOptionContinuationPeriodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AccessRightsAndOptionContinuationPeriodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AccessRightsAndOptionContinuationPeriodsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-01</xbrli:startDate><xbrli:endDate>2026-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AccessRightsAndOptionContinuationPeriodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AccessRightsAndOptionContinuationPeriodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:RightsToCertainStudiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:STAR221DevelopmentActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:TaihoCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentActivitiesForInflammationProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentActivitiesForInflammationProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:RDServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rcus:HerculesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rcus:HerculesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rcus:HerculesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rcus:HerculesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rcus:DebtInstrumentTrancheTypeAxis">rcus:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rcus:HerculesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rcus:DebtInstrumentTrancheTypeAxis">rcus:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rcus:HerculesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rcus:DebtInstrumentTrancheTypeAxis">rcus:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rcus:HerculesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="rcus:DebtInstrumentTrancheTypeAxis">rcus:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rcus:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rcus:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rcus:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rcus:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rcus:RobertC.GoeltzIIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rcus:RobertC.GoeltzIIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rcus:JuanJaenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rcus:JuanJaenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rcus:JenniferJarrettMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001724521</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rcus:JenniferJarrettMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ia317198098a84e059b141ad74d9b0930_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March 31, 2026</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from _____________to </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">_______________ </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38419</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">Arcus Biosciences, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:53.067%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">47-3898435</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">3928 Point Eden Way</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Hayward</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-11">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">94545</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">510</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">694-6200</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">Titles of Each Class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">Name of Each Exchange on which Registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, Par Value $0.0001 Per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">RCUS</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">The New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">   No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">   No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:23.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-21">o</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">o</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">  No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">x</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">As of April&#160;30, 2026, the registrant had <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">125,773,162</ix:nonFraction> shares of common stock, $0.0001 par value per share, outstanding.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:18pt;padding-left:6pt;padding-right:6pt;text-align:center"><span><br/></span></div></div></div><div id="ia317198098a84e059b141ad74d9b0930_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARCUS BIOSCIENCES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:80.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_10">RISK FACTOR SUMMARY</a></span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_10">i</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_13">PART I.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_13">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_19">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_22">Condensed Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_22">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_25">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_25">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_28">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_28">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_31">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_31">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_34">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_34">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_82">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_82">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_82">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_109">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_109">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_109">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_112">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_112">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_112">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_115">PART II.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_115">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_118">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_118">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_118">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_121">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_121">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_121">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_124">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_124">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_124">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_127">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_127">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_127">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_130">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_130">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_130">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_133">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_133">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_133">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_139">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_139">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_139">62</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_142">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia317198098a84e059b141ad74d9b0930_142">63</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:18pt;padding-left:6pt;padding-right:6pt;text-align:center"><span><br/></span></div></div></div><div id="ia317198098a84e059b141ad74d9b0930_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTOR SUMMARY</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the key risks and uncertainties that make an investment in our securities speculative and risky. The below summary does not contain all of the information that may be important to you, and you should read this summary together with the more detailed description of the risks set forth under "Part II. Item 1A. Risk Factors" of the Quarterly Report. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Limited Operating History, Financial Position and Capital Requirements </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.37pt">We have a history of operating losses, have never generated any revenue from product sales and anticipate that we will continue to incur significant losses for the foreseeable future. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.37pt">We may need to obtain additional funding. If we do not receive or are unable to raise additional capital when needed, we may be forced to restrict our operations or delay, reduce or eliminate our product development programs. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operating activities may be restricted as a result of covenants related to the indebtedness under our loan and security agreement with Hercules Capital, Inc. ("Hercules"), as amended, and we may be required to repay the outstanding indebtedness in an event of default, which could have a materially adverse effect on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery and Development of our Investigational Products </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.37pt">If we are unable to obtain regulatory approval for our investigational products, or experience significant delays in doing so, our business will be materially harmed. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.37pt">Preliminary, topline and interim data from our clinical studies that we announce or publish from time to time are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.37pt">Enrollment and retention of subjects in clinical trials is expensive and time consuming and can be made more difficult or rendered impossible by competing treatments, clinical trials of competing investigational products, geopolitical instability and public health epidemics, each of which could result in significant delays and additional costs in our product development activities, or in the failure of such activities.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.37pt">Serious adverse events ("AEs"), undesirable side effects or other unexpected properties of our investigational products may be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our investigational products or limitations on the use of our investigational products or, if discovered following marketing approval, revocation of marketing authorizations or subsequent limitations on the use of our investigational products.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.37pt">Certain of our investigational products may require companion diagnostics in certain indications. Failure to successfully develop, validate and obtain regulatory clearance or approval for such tests could harm our product development strategy or prevent us from realizing the full commercial potential of our investigational products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reliance on Third Parties, Manufacturing and Commercialization</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect to depend on collaborations for the development of our investigational products. If our collaboration efforts are not successful, the scope of our development efforts may be limited and our business could be adversely affected.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.37pt">We rely on third parties to conduct our clinical trials and perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.37pt">Even if we receive marketing approval for one or more of our investigational products, we may not be successful in commercializing our investigational products. Our commercial success is dependent, in part, on obtaining coverage and reimbursement for a product from a government or other third-party payor, which coverage may be delayed or may not be sufficient to cover our costs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.37pt">Obtaining and maintaining regulatory approval of investigational products in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. Even if our investigational products are approved by the U.S. Food and Drug Administration ("FDA"), they may never be approved or commercialized outside the United States ("U.S."), which would limit our ability to realize their full market potential.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.37pt">Any investigational products for which we intend to seek approval as biologic products may face competition sooner than anticipated.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our In-Licenses and Other Strategic Agreements</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.37pt">We are currently party to several in-license agreements under which we acquired rights to use, develop, manufacture and/or commercialize certain of our investigational products. If we breach our obligations under these agreements, we may be required to pay damages, lose our rights to these investigational products or both, which would adversely affect our business and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.37pt">If we are unable to obtain and maintain sufficient intellectual property protection for our investigational products, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.37pt">We may become involved in lawsuits alleging that we have infringed the intellectual property rights of third parties or to protect or enforce our patents or other intellectual property, which litigation could be expensive, time consuming and adversely affect our ability to develop or commercialize our investigational products.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.37pt">Changes in patent law in the U.S. and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our investigational products. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.37pt">We may rely on trade secret and proprietary know-how which can be difficult to trace and enforce, and if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Business Operations and Industry</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.37pt">We expect to expand our business operations and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.37pt">We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us. If their investigational products are shown to be safer or more effective than ours, then our commercial opportunity will be reduced or eliminated. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.37pt">Our internal information technology systems, and those of our third-party contract research organizations ("CROs") and other third parties upon which we rely, are subject to failure, security breaches and other disruptions, which could result in a material disruption of our investigational products&#8217; development programs, jeopardize sensitive information, prevent us from accessing critical information or result in a loss of our assets, and potentially expose us to notification obligations, loss, liability or reputational damage and otherwise adversely affect our business.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.37pt">Failure to comply with data privacy and data protection laws, regulations or other obligations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict, and may have a significant adverse effect on our business and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><div id="ia317198098a84e059b141ad74d9b0930_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="ia317198098a84e059b141ad74d9b0930_16"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements</span></div><div id="ia317198098a84e059b141ad74d9b0930_19"></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARCUS BIOSCIENCES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per share amounts)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.445%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Revenues:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">License and development services </span></div><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(Includes $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-30">10</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-31">20</ix:nonFraction> from a related party)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-32">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-33">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Other collaboration</span></div><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(Includes $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-34">5</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-35">8</ix:nonFraction> from a related party)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-36">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-37">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-38">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-39">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development </span></div><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(Includes $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="rcus:ResearchAndDevelopmentExpenseRecoveries" format="ixt:fixed-zero" scale="6" id="f-40">&#8212;</ix:nonFraction> and ($<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="rcus:ResearchAndDevelopmentExpenseRecoveries" scale="6" id="f-41">5</ix:nonFraction>) from a related party)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-42">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-43">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">General and administrative</span></div><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(Includes $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:fixed-zero" scale="6" id="f-44">&#8212;</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:fixed-zero" scale="0" id="f-45">&#8212;</ix:nonFraction> from a related party)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-46">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-47">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingExpenses" scale="6" id="f-48">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:OperatingExpenses" scale="6" id="f-49">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-50">134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-51">122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Non-operating income (expense):</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Interest and other income, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="rcus:InterestAndOtherIncomeExpenseNonoperatingNet" scale="6" id="f-52">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="rcus:InterestAndOtherIncomeExpenseNonoperatingNet" scale="6" id="f-53">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InterestExpenseNonoperating" scale="6" id="f-54">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:InterestExpenseNonoperating" scale="6" id="f-55">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Total non-operating income, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-56">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-57">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Loss before income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-58">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-59">112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-62">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-63">112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Net loss per share:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-64"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-65">1.02</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-66"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-67">1.14</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Shares used to compute net loss per share:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-68"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-69">125.4</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-70"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-71">98.4</ix:nonFraction></ix:nonFraction></span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ia317198098a84e059b141ad74d9b0930_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARCUS BIOSCIENCES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.627%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-72">128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-73">112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-74">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="f-75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-76">129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-77">112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ia317198098a84e059b141ad74d9b0930_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARCUS BIOSCIENCES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per share amounts)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2025</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:700;line-height:120%">ASSETS</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-78">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-79">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="f-80">621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="f-81">759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Receivable from collaboration partners</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="f-82">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="f-83">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-84">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-85">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:AssetsCurrent" scale="6" id="f-86">844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-87">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Long-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="f-88">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="f-89">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-90">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-91">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Other noncurrent assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-92">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-93">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:Assets" scale="6" id="f-94">997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-95">1,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:700;line-height:120%">LIABILITIES AND STOCKHOLDERS' EQUITY</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts payable ($<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-96">11</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-97">24</ix:nonFraction> to a related party)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-98">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-99">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Deferred revenue ($<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-100">27</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-101">35</ix:nonFraction> to a related party)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-102">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-103">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-104">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-105">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="f-106">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="f-107">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue, noncurrent ($<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-108">36</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-109">43</ix:nonFraction> to a related party)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-110">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-111">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-112">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-113">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-114">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-115">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Commitments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-14" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-116"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-15" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-117"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Common stock and additional paid-in capital: $<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-118"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-119">0.0001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="f-120"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="f-121">400.0</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-122"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-123">125.5</ix:nonFraction></ix:nonFraction> shares in 2026 and <ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-124"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-125">125.3</ix:nonFraction></ix:nonFraction> shares in 2025 issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="f-126">2,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="f-127">2,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-128">1,613</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-129">1,485</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-130">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="f-131">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-132">524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-133">631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="f-134">997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-135">1,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ia317198098a84e059b141ad74d9b0930_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARCUS BIOSCIENCES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">Number of shares of common stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">Common stock and additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">Accumulated deficit </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">comprehensive loss</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">stockholders&#8217; equity </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-136">92.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-137">1,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-138">1,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="f-139">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-140">485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">Issuance of common stock (see Note 3, Related party - Gilead Sciences, Inc. and Note 13, Stockholders' equity)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="f-141">13.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-142">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-143">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">Issuance of common stock in connection with our equity award programs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="f-144">0.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-145">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-146">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-147">112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-148">112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">Balance at March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-149">105.9</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-150">1,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-151">1,244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="f-152">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-153">531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">Balance at December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-154">125.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-155">2,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-156">1,485</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="f-157">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-158">631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">Issuance of common stock in connection with our equity award programs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="f-159">0.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-160">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-161">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-162">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-163">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-164">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-165">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-166">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-167">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">Balance at March 31, 2026</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-168">125.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-169">2,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-170">1,613</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-171">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="f-172">524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ia317198098a84e059b141ad74d9b0930_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARCUS BIOSCIENCES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="f-173">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="f-174">112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-175">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-176">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-177">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-178">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Noncash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="f-179">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="f-180">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of discounts on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="6" id="f-181">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="6" id="f-182">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Other items, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="f-183">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" format="ixt:fixed-zero" scale="6" id="f-184">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Receivable from collaboration partners ($<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" format="ixt:fixed-zero" scale="6" id="f-185">&#8212;</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="6" id="f-186">2</ix:nonFraction> from a related party)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span id="i69d1a1b436a64d5780f257dbf63fcd46_12-1-1-1-122951"></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="6" id="f-187">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="6" id="f-188">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="6" id="f-189">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:fixed-zero" scale="6" id="f-190">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Accounts payable (($<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="f-191">13</ix:nonFraction>) and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:fixed-zero" scale="6" id="f-192">&#8212;</ix:nonFraction> to a related party)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="f-193">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="f-194">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:17.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Deferred revenue (($<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="f-195">15</ix:nonFraction>) and ($<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="f-196">28</ix:nonFraction>) to a related party)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="f-197">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="f-198">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="6" id="f-199">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="6" id="f-200">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-201">138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-202">132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="f-203">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="f-204">353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="rcus:ProceedsFromMaturityOfMarketableSecurities" scale="6" id="f-205">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="rcus:ProceedsFromMaturityOfMarketableSecurities" scale="6" id="f-206">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from sales of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="rcus:ProceedsFromSaleOfMarketableSecurities" scale="6" id="f-207">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="rcus:ProceedsFromSaleOfMarketableSecurities" scale="6" id="f-208">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-209">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-210">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-211">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-212">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from issuance of common stock ($<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="6" id="f-213">&#8212;</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-214">14</ix:nonFraction> from a related party)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="6" id="f-215">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="f-216">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from issuance of common stock pursuant to equity award plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="f-217">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:fixed-zero" scale="6" id="f-218">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-219">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-220">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-221">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-222">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="f-223">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="f-224">153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="f-225">204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="f-226">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ia317198098a84e059b141ad74d9b0930_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARCUS BIOSCIENCES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="ia317198098a84e059b141ad74d9b0930_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. <ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-227" continuedAt="f-227-1" escape="true">Organization, liquidity and capital resources</ix:nonNumeric></span></div><ix:continuation id="f-227-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Arcus Biosciences, Inc. (referred to as "Arcus," "we," "our," "us," or the "Company") is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Our most advanced molecules are in Phase 3 registrational studies for various cancer indications and we expect our next wave of clinical-stage molecules to come from our inflammation and autoimmune disease programs. Our vision is to leverage our internal small-molecule discovery capabilities to create, develop and commercialize highly differentiated therapies that can have a meaningful impact on patients.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We operate and manage our business as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-228"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-229">one</ix:nonFraction></ix:nonFraction> reportable and operating segment, which is the business of developing and commercializing highly differentiated therapies that have a meaningful impact on patients. See Note 15, Business segment, for more information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026, we had cash, cash equivalents and marketable securities of $<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-6" name="us-gaap:InvestmentsAndCash" scale="6" id="f-230">876</ix:nonFraction> million, which we believe will be sufficient to fund our planned operations for a period of at least twelve months following the date of filing of this report.</span></div></ix:continuation><div id="ia317198098a84e059b141ad74d9b0930_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-231" continuedAt="f-231-1" escape="true">Summary of significant accounting policies</ix:nonNumeric></span></div><ix:continuation id="f-231-1" continuedAt="f-231-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-233" continuedAt="f-233-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-232" continuedAt="f-232-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These interim financial statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2025 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on February&#160;25, 2026. There have been no significant changes to our summary of significant accounting policies as disclosed in that filing. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and include all normal and recurring adjustments that management believes are necessary for a fair presentation of the periods presented. The Condensed Consolidated Balance Sheet as of December&#160;31, 2025 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements.</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-233-1"><ix:continuation id="f-232-1">Operating results for the three months ended March&#160;31, 2026 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2026 or for any future period.</ix:continuation></ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-234" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed and updated each period to reflect current information. Actual results may differ materially from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-235" continuedAt="f-235-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2024-03 &#8212; Income Statement &#8212; Reporting Comprehensive Income &#8212; Expense Disaggregation Disclosures (Subtopic 220-40) &#8212; Disaggregation of Income Statement Expenses. This ASU requires disclosure, in the notes to financial statements, of specified information about certain costs and expenses. We plan to adopt this guidance beginning with our 2027 Annual Report to be filed in early 2028 and all quarterly and Annual Reports thereafter. We expect the adoption of this standard to result in increased disclosures in the Notes to our Consolidated Financial Statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><ix:continuation id="f-235-1"><ix:continuation id="f-231-2"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the FASB issued ASU 2025-07 &#8212; Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract. This ASU refines the scope of the guidance on derivatives in Topic 815 and clarifies the guidance on share-based payments from a customer in ASC 606. We have adopted this standard during the current quarter with no significant impact on our Consolidated Financial Statements.</span></div></ix:continuation></ix:continuation><div id="ia317198098a84e059b141ad74d9b0930_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-236" continuedAt="f-236-1" escape="true">Related party - Gilead Sciences, Inc.</ix:nonNumeric></span></div><ix:continuation id="f-236-1" continuedAt="f-236-2"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we and Gilead Sciences, Inc. ("Gilead") entered into an Option, License and Collaboration Agreement (the "Gilead Collaboration Agreement"), Common Stock Purchase Agreement (the "Stock Purchase Agreement"), and Investor Rights Agreement (the "Investor Rights Agreement").</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Gilead Collaboration Agreement was amended in 2021 (the "First Gilead Collaboration Agreement Amendment"), in 2023 (the "Second Gilead Collaboration Agreement Amendment"), in 2024 (the "Third Gilead Collaboration Agreement Amendment") and (the "Fourth Gilead Collaboration Agreement Amendment"), and in 2025 (the "Fifth Gilead Collaboration Agreement Amendment"). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Stock Purchase Agreement was amended in 2021 (the "First Stock Purchase Agreement Amendment"), in 2023 (the "Second Stock Purchase Agreement Amendment"), and was amended and restated in 2024 (the "Third Stock Purchase Agreement Amendment").</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Investor Rights Agreement was amended in 2022 (the "First Investor Rights Agreement Amendment") and was amended and restated in 2024 (the "Second Investor Rights Agreement Amendment").</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We refer to these agreements collectively as the "Gilead Agreements".</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Purchase and Investor Rights Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter 2025, through our underwritten offering, Gilead purchased <ix:nonFraction unitRef="shares" contextRef="c-47" decimals="-5" name="rcus:SaleOfStockNumberOfSharesAcquiredInTransaction" scale="6" id="f-237">1.4</ix:nonFraction> million shares of our common stock for total gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-238">15</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Investor Rights Agreement entered into in 2020 and subsequent amendments, Gilead has the right to designate <ix:nonFraction unitRef="member" contextRef="c-49" decimals="INF" name="rcus:NumberOfBoardMembers" format="ixt-sec:numwordsen" scale="0" id="f-239">three</ix:nonFraction> members of our board of directors and registration rights for shares that it purchases. Gilead has exercised its rights to appoint all <ix:nonFraction unitRef="member" contextRef="c-49" decimals="INF" name="rcus:NumberOfBoardMembers" format="ixt-sec:numwordsen" scale="0" id="f-240">three</ix:nonFraction> board members and we have registered all shares purchased to date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026, Gilead held approximately <ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="rcus:PercentageOfOutstandingCommonStockOwned" scale="-2" id="f-241">25.0</ix:nonFraction>% of our outstanding common stock. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into the Gilead Collaboration Agreement, which gave Gilead an exclusive license to develop and commercialize zimberelimab (the anti-PD-1 program) in certain markets and time-limited options to acquire exclusive licenses to develop and commercialize any of our then-current and future clinical programs arising during the <ix:nonNumeric contextRef="c-50" name="rcus:CollaborationTermForCurrentAndFutureClinicalPrograms" format="ixt-sec:durwordsen" id="f-242">10-year</ix:nonNumeric> collaboration term, contingent upon $<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="rcus:OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement" scale="6" id="f-243"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="rcus:OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement" scale="6" id="f-244"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="rcus:OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement" scale="6" id="f-245"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="rcus:OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement" scale="6" id="f-246">100</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> million option continuation payments payable on each of the second, fourth, sixth and eighth anniversaries of the agreement. The period to determine Gilead's option rights under the Gilead Collaboration Agreement will end on July 14, 2026, following Gilead&#8217;s decision to not make the option continuation payment due on the sixth anniversary. Upon closing of the transaction in 2020, Gilead made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-6" name="rcus:UpfrontCashPayment" scale="6" id="f-247">175</ix:nonFraction> million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we entered into the First Gilead Collaboration Agreement Amendment pursuant to which Gilead exercised its option to <ix:nonFraction unitRef="program" contextRef="c-52" decimals="INF" name="rcus:NumberOfExerciseOptionToPrograms" format="ixt-sec:numwordsen" scale="0" id="f-248">three</ix:nonFraction> programs&#8212;providing Gilead with exclusive licenses to develop and commercialize domvanalimab and AB308 (collectively, the anti-TIGIT program), etrumadenant (the adenosine receptor antagonist program) and quemliclustat (the CD73 program), in certain markets&#8212;for a total payment of $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" name="rcus:OptionPaymentReceived" scale="6" id="f-249">725</ix:nonFraction> million that was received in 2022. The amendment also (i) provided for a slight reduction in the royalties for these <ix:nonFraction unitRef="program" contextRef="c-52" decimals="INF" name="rcus:NumberOfExerciseOptionToPrograms" format="ixt-sec:numwordsen" scale="0" id="f-250">three</ix:nonFraction> programs, such that Gilead will pay us tiered royalties as a percentage of revenues ranging from the mid-teens to the low twenties; and (ii) removed the $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" name="rcus:RemoveOptionContinuationPaymentUnderAgreement" scale="6" id="f-251">100</ix:nonFraction> million option continuation payment that was otherwise due on the second anniversary of the Gilead Collaboration Agreement. With respect to domvanalimab, we are also eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-6" name="rcus:PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab" scale="6" id="f-252">500</ix:nonFraction> million in potential U.S. regulatory approval milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gilead's option to acquire exclusive licenses to develop and commercialize AB801 (an investigational small molecule AXL inhibitor) and AB598 (an investigational anti-CD39 monoclonal antibody), will expire after a prescribed period following the achievement of a clinical development milestone in such program and our delivery to Gilead of the requisite data package. Gilead may exercise its option to these programs at any time prior to expiration of the option and will pay Arcus an option fee of $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-6" name="rcus:OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption" scale="6" id="f-253">150</ix:nonFraction> million per program. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><ix:continuation id="f-236-2"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For each program that Gilead opts in to, both companies will co-develop and equally share global development costs, subject to certain opt-out rights that we have, caps on our spending and related subsequent adjustments, and certain other exceptions. For each program, provided we have not exercised our opt-out rights, we have the option to co-promote in the U.S. with equal sharing of related profits and losses. Gilead has the right to exclusively commercialize outside of the U.S., subject to the rights of our existing partners in any territories and will pay us tiered royalties as a percentage of revenues ranging from the high teens to the low twenties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the First Gilead Collaboration Agreement Amendment, Gilead also has option rights to <ix:nonFraction unitRef="program" contextRef="c-55" decimals="INF" name="rcus:NumberOfResearchPrograms" format="ixt-sec:numwordsen" scale="0" id="f-254">two</ix:nonFraction> oncology research programs for which we will lead discovery and early development activities. With respect to these <ix:nonFraction unitRef="program" contextRef="c-55" decimals="INF" name="rcus:NumberOfResearchPrograms" format="ixt-sec:numwordsen" scale="0" id="f-255">two</ix:nonFraction> research programs, Gilead has the right to exercise its option, on a program-by-program basis, either (i) upon our completion of certain investigational new drug ("IND")-enabling activities for an option payment of $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-6" name="rcus:OptionPaymentUponCompletionOfCertainINDEnablingActivities" scale="6" id="f-256">60</ix:nonFraction> million or (ii) following the achievement of a clinical development milestone for an option payment of $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-6" name="rcus:OptionPaymentUponAchievementOfCertainDevelopmentMilestones" scale="6" id="f-257">150</ix:nonFraction> million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we entered into the Second Gilead Collaboration Agreement Amendment pursuant to which we expanded our collaboration to provide Gilead with options to license up to <ix:nonFraction unitRef="program" contextRef="c-57" decimals="INF" name="rcus:NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments" format="ixt-sec:numwordsen" scale="0" id="f-258">four</ix:nonFraction> jointly selected research-stage programs that target inflammatory diseases for which we will lead discovery and early development activities. We will receive an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="rcus:UpfrontCashPayment" scale="6" id="f-259">17.5</ix:nonFraction> million for each initiated program and Gilead will have an option to license each program at two separate, prespecified time points. We received a total upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-6" name="rcus:TotalUpfrontCashPayment" scale="6" id="f-260">35</ix:nonFraction> million for an initial <ix:nonFraction unitRef="program" contextRef="c-58" decimals="INF" name="rcus:NumberOfResearchPrograms" format="ixt-sec:numwordsen" scale="0" id="f-261">two</ix:nonFraction> research programs in 2023. Gilead&#8217;s options to the other <ix:nonFraction unitRef="program" contextRef="c-58" decimals="INF" name="rcus:NumberOfResearchPrograms" format="ixt-sec:numwordsen" scale="0" id="f-262">two</ix:nonFraction> research programs, as amended under the Fourth Gilead Collaboration Agreement Amendment expired in May 2025. For the <ix:nonFraction unitRef="program" contextRef="c-59" decimals="INF" name="rcus:NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments" format="ixt-sec:numwordsen" scale="0" id="f-263">two</ix:nonFraction> research programs, including AB102 (an investigational MRGPRX2 antagonist), Gilead has the right, on a program-by-program basis, either (i) to exercise its option upon our completion of certain IND-enabling activities for an option payment of $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-6" name="rcus:OptionPaymentUponCompletionOfCertainINDEnablingActivities" scale="6" id="f-264">45</ix:nonFraction> million or (ii) to extend its option and exercise it following the achievement of a clinical development milestone for an option payment of $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-6" name="rcus:OptionPaymentUponAchievementOfCertainDevelopmentMilestones" scale="6" id="f-265">150</ix:nonFraction> million. If Gilead exercises its option at the earlier time point for the first <ix:nonFraction unitRef="program" contextRef="c-59" decimals="INF" name="rcus:NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments" format="ixt-sec:numwordsen" scale="0" id="f-266">two</ix:nonFraction> programs, we would be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-6" name="rcus:RegulatoryAndCommercialMilestonePaymentsReceived" scale="6" id="f-267">375</ix:nonFraction> million in regulatory and commercial milestone payments as well as tiered royalties for each optioned program. For any other program option exercise by Gilead, the parties would have rights to co-develop and share global development costs and to co-promote and share profits in the U.S. for that program. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, we entered into the Third Gilead Collaboration Agreement Amendment. The Third Gilead Collaboration Agreement Amendment, among other things, (i) required Gilead to pay the $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-6" name="rcus:OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement" scale="6" id="f-268">100</ix:nonFraction> million option continuation payment due on the fourth anniversary of the Gilead Collaboration Agreement, which was received in 2024, (ii) provides that we will operationalize and fund the Phase 3 PRISM-1 study evaluating quemliclustat in pancreatic cancer subject to Gilead's right to reinstate the study as part of the parties' joint development activities upon regulatory approval, (iii) provides that we will solely fund our share of PACIFIC-8, subject to Gilead&#8217;s right to reinstate PACIFIC-8 as part of the parties&#8217; joint development activities for the TIGIT Program upon regulatory approval, and (iv) provides that we will fund certain other activities. All other terms of the existing collaboration agreements, remain unchanged.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026, Gilead has licenses to domvanalimab, AB308, quemliclustat and zimberelimab. In the second quarter 2025, Gilead returned its license to the adenosine receptor antagonist program, which includes etrumadenant. After July 14, 2026, Gilead will maintain its existing time-limited options to programs including AB801, AB598, AB102 and an investigational TNF small molecule inhibitor. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2026 and 2025, under the Gilead Agreements we recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-269">15</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-270">28</ix:nonFraction> million, respectively. For a more detailed discussion on revenues recognized under the Gilead Agreements, see Note 5, Revenues, for more information.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2025, we recognized net reimbursements from Gilead of $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-6" sign="-" name="rcus:RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts" scale="6" id="f-271">5</ix:nonFraction> million. Expenses and reimbursements from Gilead are recognized in Operating expense, allocated between Research and Development ("R&amp;D") and General and Administrative ("G&amp;A") based upon the activity that generated the net expense or reimbursement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> At March&#160;31, 2026 and December&#160;31, 2025, we had net payables to Gilead of $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-272">11</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-273">24</ix:nonFraction> million, respectively, recorded in Accounts payable on our Condensed Consolidated Balance Sheets.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ia317198098a84e059b141ad74d9b0930_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-274" continuedAt="f-274-1" escape="true">License and collaborations</ix:nonNumeric></span></div><ix:continuation id="f-274-1" continuedAt="f-274-2"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We enter into licensing agreements, strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain investigational products. These arrangements: may be collaborative and involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities; are performed with no guarantee of either technological or commercial success; and are each unique in nature. Such arrangements may include: non-refundable upfront payments; payments for options to acquire certain rights; potential development and regulatory milestone payments and/or sales-based milestone payments; royalty payments; revenue or profit-sharing arrangements; expense reimbursements; and cost-sharing arrangements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line items in the Condensed Consolidated Statements of Operations, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our significant arrangements are discussed below. For a more detailed discussion on revenues recognized under these arrangements, see Note 5, Revenues.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gilead Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3, Related party - Gilead Sciences, Inc., for more information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taiho Collaboration </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into an agreement with Taiho Pharmaceutical Co., Ltd ("Taiho" and the "Taiho Agreement") pursuant to which Taiho obtained an exclusive option to in-license development and commercialization rights to programs for Japan and certain other Asian countries, excluding China (the "Taiho Territory") for which IND-enabling studies had begun during a <ix:nonNumeric contextRef="c-64" name="rcus:OptionPeriod" format="ixt-sec:durwordsen" id="f-275">five-year</ix:nonNumeric> term which ended in September 2022, for an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-6" name="rcus:NonRefundableAndNonCreditableCashPayments" scale="6" id="f-276">35</ix:nonFraction> million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For each option to a program that Taiho exercises, except for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">casdatifan (the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">HIF-2&#945; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">program) discussed below</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, they will be obligated to make a payment of $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-6" name="rcus:PaymentForOptionsExercised" scale="6" id="f-277">3</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" name="rcus:PaymentForOptionsExercised" scale="6" id="f-278">15</ix:nonFraction> million, depending on the development stage of the optioned program. Upon exercise, Taiho is solely responsible for continued development and commercialization in the Taiho Territory, unless they opt to participate in a global study, in which case they would become obligated to reimburse us for their portion of the global study costs. In addition, for each optioned program we would be eligible to receive clinical and regulatory milestones of up to $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" name="rcus:AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement" scale="6" id="f-279">130</ix:nonFraction> million and commercial milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-6" name="rcus:ContingentMilestonePaymentsReceivable" scale="6" id="f-280">145</ix:nonFraction> million with the achievement of certain sales thresholds in the Taiho Territory. We will also receive royalties ranging from high single-digits to mid-teens on net sales of licensed products in the Taiho Territory. Royalties will be payable by product and country commencing on the first commercial sale and ending upon the later of: (a) <ix:nonNumeric contextRef="c-64" name="rcus:RoyaltiesPayableTerm" format="ixt-sec:duryear" id="f-281">10</ix:nonNumeric> years; and (b) expiration of the last-to-expire valid claim of our patents covering the manufacture, use or sale.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, Taiho opted to participate in two global Phase 3 trials of domvanalimab and zimberelimab combinations, STAR-121 and STAR-221, and in 2024, Taiho opted to participate in the global Phase 3 trial of quemliclustat, PRISM-1. For each of these trials, Taiho became obligated to reimburse us for their portion of the global trial costs, and to make milestone payments contingent upon successfully satisfying the related clinical milestones. The clinical milestones were met: for domvanalimab and zimberelimab for the STAR-221 trial in 2023, and Taiho became obligated to pay us $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="rcus:MilestonePayments" scale="6" id="f-282">28</ix:nonFraction> million; domvanalimab and zimberelimab for the STAR-121 trial in 2024, and Taiho became obligated to pay us $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="rcus:MilestonePayments" scale="6" id="f-283">26</ix:nonFraction> million; and for quemliclustat for the PRISM-1 trial in the first quarter 2025, and became obligated to make milestone payments totaling $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-6" name="rcus:MilestonePayments" scale="6" id="f-284">19</ix:nonFraction> million. All the milestone payments due have been fully received. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter 2025, Taiho exercised its option for </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">HIF-2&#945;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> inhibitor program (including casdatifan) for the Taiho Territory, for an option payment of $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-6" name="rcus:PaymentForOptionsExercised" scale="6" id="f-285">15</ix:nonFraction> million. We and Taiho concurrently entered into the Second Amendment where: (i) we will lead development for two indications in Japan and be responsible for the global study costs; (ii) we may also be eligible to receive clinical and regulatory milestones of up to $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-6" name="rcus:AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement" scale="6" id="f-286">172</ix:nonFraction> million, commercial milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-6" name="rcus:ContingentMilestonePaymentsReceivable" scale="6" id="f-287">145</ix:nonFraction> million upon the achievement of certain sales thresholds in the Taiho Territory and royalties ranging from high single-digits to mid-teens on net sales of the licensed product in the Taiho Territory. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of these arrangements, a portion of these clinical milestones were determined to be advance cost sharing payments for Taiho's share of the related global study R&amp;D costs under the collaboration and are deferred and recognized as a reduction in R&amp;D expense as the related global studies are performed, calculated as an estimated percentage of completion based on the estimated total ef</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">fort for the programs. See Note 5, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenues, for more information.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026, Taiho has licenses for the Taiho Territory to (i) HIF-2&#945; inhibitor program (including casdatifan); (ii) anti-TIGIT program (including domvanalimab and AB308); (iii) anti-PD-1 program (including zimberelimab); (iv) CD73 program (including quemliclustat); and (v) adenosine receptor antagonist program (including etrumadenant).</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><ix:continuation id="f-274-2" continuedAt="f-274-3"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under this arrangement, for the three months ended March&#160;31, 2026, we recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-288">2</ix:nonFraction> million. We recognized net reimbursements including amortization of advance cost share payments from Taiho for the three months ended March&#160;31, 2026 and 2025 of $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-6" name="rcus:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="f-289">5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-6" name="rcus:ReimbursementOfResearchAndDevelopmentExpense" scale="6" id="f-290">9</ix:nonFraction> million, respectively, recognized as a reduction in R&amp;D expense.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2026 and December&#160;31, 2025, we had $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-6" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="f-291">3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="6" id="f-292">10</ix:nonFraction>&#160;million, respectively, related to this arrangement recorded in Receivable from collaboration partners on our Condensed Consolidated Balance Sheets. At March&#160;31, 2026 and December&#160;31, 2025, we had liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-6" name="us-gaap:OtherLiabilities" scale="6" id="f-293">23</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="us-gaap:OtherLiabilities" scale="6" id="f-294">44</ix:nonFraction> million, respectively related to certain advance cost sharing payments under this arrangement recorded in Other liabilities, allocated between current and noncurrent based on the expected timing of future recognition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca Collaboration </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a collaboration with AstraZeneca to evaluate domvanalimab, our investigational anti-TIGIT antibody, in combination with AstraZeneca&#8217;s durvalumab in a registrational Phase 3 clinical trial in patients with unresectable Stage 3 non-small cell lung cancer ("NSCLC"), known as the PACIFIC-8 trial. The terms of this agreement were amended in 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration, as amended, each company will retain existing rights to their respective molecules and any future commercial economics. AstraZeneca will conduct the trial, and each company will supply their respective investigational product to support the trial. We may be obligated to pay milestones of up to $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-6" name="rcus:MilestonePayments" scale="6" id="f-295">24</ix:nonFraction>&#160;million upon the achievement of certain clinical trial progress milestones or under certain circumstances if the agreement is terminated early and we will reimburse AstraZeneca annually for a portion of the trial costs. The portion of the costs that we consider to be unavoidable is accrued as incurred and milestones that are deemed probable of occurring are accrued in advance of the achievement of the milestone.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to January 2024, the PACIFIC-8 trial formed part of the Arcus and Gilead joint development program for domvanalimab and our portion of the trial costs was shared with Gilead. Under the Third Gilead Collaboration Agreement Amendment, we agreed to solely fund our share of PACIFIC-8, subject to Gilead&#8217;s right to reinstate PACIFIC-8 as part of the parties&#8217; joint development activities for the TIGIT Program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We recognized R&amp;D expense for the three months ended March&#160;31, 2026 and 2025 of $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-296">5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-297">4</ix:nonFraction> million, respectively, under this arrangement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2026 and December&#160;31, 2025, we have recognized a total liability of $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-298">17</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-299">12</ix:nonFraction> million, respectively, related to our obligation to AstraZeneca including the first milestone, recorded in Other current liabilities and Other noncurrent liabilities on our Condensed Consolidated Balance Sheets based on the expected timing of payment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">WuXi Biologics License - anti-PD-1 </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into an agreement with WuXi Biologics Ireland Limited ("WuXi Biologics") which, as amended, provides us with exclusive rights to (i) develop, use and manufacture products that include an anti-PD-1 antibody, including zimberelimab, worldwide and (ii) commercialize any such products worldwide, except in Greater China. As of March&#160;31, 2026, under this arrangement, we may incur (i) additional regulatory milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="rcus:ClinicalRegulatoryMilestonePayments" scale="6" id="f-300">50</ix:nonFraction>&#160;million and commercialization milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="rcus:ClinicalRegulatoryAndCommercializationMilestonePayments" scale="6" id="f-301">375</ix:nonFraction> million, (ii) tiered royalties that range from the high single-digits to low teens on net sales of the licensed products and (iii) fees related to any sublicenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We did <ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-6" name="rcus:MilestoneExpense" format="ixt:fixed-zero" scale="0" id="f-302"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-6" name="rcus:MilestoneExpense" format="ixt:fixed-zero" scale="0" id="f-303">not</ix:nonFraction></ix:nonFraction> have any milestones or royalties due under this arrangement for the three months ended March&#160;31, 2026 and 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">WuXi Biologics License - anti-CD39</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into an agreement with WuXi Biologics, under which we obtained the exclusive worldwide license to develop and commercialize anti-CD39 antibodies discovered under this arrangement. As of March&#160;31, 2026, under this arrangement we may incur additional clinical and regulatory milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-6" name="rcus:AdditionalClinicalRegulatoryAndCommercializationMilestonePayments" scale="6" id="f-304">14</ix:nonFraction> million and royalty payments in the low single digits on net sales of the licensed products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We did <ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-6" name="rcus:MilestoneExpense" format="ixt:fixed-zero" scale="0" id="f-305"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-6" name="rcus:MilestoneExpense" format="ixt:fixed-zero" scale="0" id="f-306">not</ix:nonFraction></ix:nonFraction> have any milestones or royalties due under this arrangement for the three months ended March&#160;31, 2026 and 2025. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><ix:continuation id="f-274-3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Abmuno License</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we entered into an agreement (the "Abmuno Agreement") with Abmuno Therapeutics LLC ("Abmuno"), under which we obtained the exclusive worldwide license to develop, use, manufacture, and commercialize products that include an anti-TIGIT antibody, including domvanalimab. As of March&#160;31, 2026, under this arrangement we may incur additional clinical, regulatory and commercialization milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-6" name="rcus:AdditionalClinicalRegulatoryAndCommercializationMilestonePayments" scale="6" id="f-307">88</ix:nonFraction> million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We did <ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-6" name="rcus:MilestoneExpense" format="ixt:fixed-zero" scale="0" id="f-308"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-6" name="rcus:MilestoneExpense" format="ixt:fixed-zero" scale="0" id="f-309">not</ix:nonFraction></ix:nonFraction> have any milestones or royalties due under this arrangement for the three months ended March&#160;31, 2026 and 2025.</span></div></ix:continuation><div id="ia317198098a84e059b141ad74d9b0930_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-310" continuedAt="f-310-1" escape="true">Revenues </ix:nonNumeric></span></div><ix:continuation id="f-310-1" continuedAt="f-310-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-311" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenues by collaboration, category of revenue, and the method of recognition (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Over time</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Point in time</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Collaboration</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License and development services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-312">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-313">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D services</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-314">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-315">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Access rights</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-316">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-317">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-318">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-319">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 2.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Taiho Collaboration</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-320">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-321">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-322">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-323">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues from collaborations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="6" id="f-324">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="6" id="f-325">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues from a customer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-326">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-327">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from Gilead accounted for <ix:nonFraction unitRef="number" contextRef="c-101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-328">88</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-102" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-329">100</ix:nonFraction>% of Total revenues for the three months ended March&#160;31, 2026 and 2025, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="f-330" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the revenue recognized as a result of changes in the deferred revenue balance (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.051%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from amounts in deferred revenue at the beginning of the period</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-331">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-332">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We had $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-333">79</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-334">78</ix:nonFraction>&#160;million of deferred revenue remaining on our Condensed Consolidated Balance Sheets at March&#160;31, 2026 and December&#160;31, 2025, respectively, allocated between current and noncurrent based on the expected timing of future recognition.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from the Gilead Collaboration</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Termination of rights to etrumadenant</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter 2025, Gilead terminated its rights to etrumadenant (the adenosine receptor antagonist program), which we determined was a significant reduction in the scope of the arrangement, which met the accounting definition of a contract modification and we accounted for this as both a modification of the existing contract and the creation of a new contract. Under the applicable accounting rules for such contract modifications, we did not adjust the accounting for completed performance obligations that were distinct from the modified goods or services. Accordingly, we allocated the updated transaction price of $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-6" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-335">256</ix:nonFraction> million, which was comprised of the deferred revenue remaining as of the modification date, to the remaining unsatisfied and partially satisfied performance obligations and updated the measure of progress as of the modification date, which resulted in a cumulative catch-up to revenue of $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-6" name="rcus:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice" scale="6" id="f-336">143</ix:nonFraction> million for the quarter ended June 30, 2025. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><ix:continuation id="f-310-2" continuedAt="f-310-3"><ix:nonNumeric contextRef="c-1" name="rcus:ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock" id="f-337" continuedAt="f-337-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of the updated transaction price to the remaining unsatisfied and partially satisfied performance obligations (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Allocation to performance obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Distinct</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Combined</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-6" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-338">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Development services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-6" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-339">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Access right and option continuation periods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-340">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Rights to certain studies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-341">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.44pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total transaction price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-6" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-342">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for each performance obligation as follows:</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Development Services - Etrumadenant, Quemliclustat and Domvanalimab</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Gilead Collaboration Agreement, Gilead obtained options to the exclusive rights: to our adenosine receptor antagonist program, etrumadenant; to our CD73 program, quemliclustat; and to our anti-TIGIT program, domvanalimab and AB308. Effective December 2021, under the First Gilead Collaboration Agreement Amendment, Gilead exercised these options and obtained exclusive licenses to these programs for a total non-refundable payment totaling $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="rcus:DeferredRevenueNonRefundablePayment" scale="6" id="f-343">725</ix:nonFraction>&#160;million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We determined the standalone selling price of each license using a discounted cash flow method and the R&amp;D services for each program, using an expected cost-plus margin approach. For domvanalimab, we determined that the license was distinct based on an evaluation of the delivery of the license, noting that the program was in the later stages of development and the ongoing R&amp;D services do not significantly modify or customize the related intellectual property. Accordingly, we recognized the allocated transaction price as revenue in the year ended December 31, 2021. For etrumadenant and quemliclustat programs, we determined that the license and R&amp;D services were combined at the inception of the agreement based on an evaluation of the delivery of the license, due to the early stage of the technology and the specialized nature of our know-how. We recognize the amounts allocated to R&amp;D services for domvanalimab and the combined license and R&amp;D for etrumadenant and quemliclustat as each performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for each program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2026 and 2025, we recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-344">8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-345">20</ix:nonFraction> million, respectively, within License and development services revenue in our Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Access Rights and Option Continuation Periods</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Gilead Collaboration Agreement entered into in 2020 and related amendments, Gilead has exclusive access to our current programs as well as any future programs for a period of <ix:nonNumeric contextRef="c-112" name="rcus:CurrentAndFutureProgramsExclusiveAccessPeriod" format="ixt-sec:durwordsen" id="f-346">ten years</ix:nonNumeric>, contingent upon option continuation payments totaling $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-6" name="rcus:ContingentMilestonePaymentsReceivable" scale="6" id="f-347">300</ix:nonFraction> million, consisting of a $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-6" name="rcus:OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement" scale="6" id="f-348">100</ix:nonFraction> million payment on each of the fourth (paid in third quarter 2024), sixth, and eighth anniversaries of the Gilead Collaboration Agreement. Following Gilead&#8217;s decision to not make the option continuation payment due on the sixth anniversary, on July 14, 2026, Gilead will lose certain rights to access and obtain licenses to the programs arising from our R&amp;D pipeline. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The standalone selling price of the ongoing R&amp;D pipeline access and the option continuation material rights were determined using an expected cost-plus margin approach, with the option continuation material rights probability-adjusted for the likelihood of exercise. We use a time-elapsed input method to measure progress toward satisfying the access rights performance obligation, which is the method we believe most faithfully depicts our performance in transferring the promised services during the time period in which Gilead has access to our R&amp;D pipeline. Accordingly, the revenue allocated to the initial four-year access rights performance obligation was recognized using this input method over the remaining period through July 2024, and for the fourth anniversary access rights continuation, over the two-year period commencing July 2024. For the option continuation material rights, following Gilead's decision in April 2026 to not make the continuation payment, we will recognize the $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-349">18</ix:nonFraction> million of revenue allocated to those material rights.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2026 and 2025, we recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-350">3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-351">6</ix:nonFraction> million, respectively, within Other collaboration revenue in our Condensed Consolidated Statements of Operations. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><ix:continuation id="f-310-3" continuedAt="f-310-4"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rights to Certain Studies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 2024, under the Third Gilead Collaboration Agreement Amendment, we will solely fund certain studies, but Gilead retains exclusive rights to reinstate into the collaboration each study beginning at specified time-points for a payment amount based on the cost incurred. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that these are material rights and we estimated the standalone selling price of these performance obligations using a discounted cash flow method probability-adjusted for the likelihood of exercise. We recognize the amount allocated to each right if and when the related study is reinstated into the parties' co-development plans or if the option effectively lapses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2026, we recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-352">2</ix:nonFraction> million within License and development services revenue in our Condensed Consolidated Statements of Operations. As of March&#160;31, 2026, we had $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-353">14</ix:nonFraction> million of deferred revenue on our Condensed Consolidated Balance Sheet related to these performance obligations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">R&amp;D Services - Inflammation Programs </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we entered into the Second Gilead Collaboration Agreement Amendment pursuant to which we expanded our collaboration to provide Gilead with options to license two jointly selected research-stage programs that target inflammatory diseases for which we will lead discovery and early development activities, see Note 3, Related party - Gilead Sciences, Inc., for more information. We received a total upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-354">35</ix:nonFraction> million. We determined that the Second Gilead Collaboration Agreement Amendment represented a separate contract. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We determined that we have two separate distinct performance obligations to perform R&amp;D services for Gilead related to discovery and early development activities for each research program for which they have made an upfront payment and, at the amendment closing date, we allocated the transaction price of $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-355">35</ix:nonFraction> million equally to the two performance obligations created by this amendment based upon the respective standalone selling prices. The standalone selling prices of these obligations were determined using an expected cost-plus margin approach. We recognize the amounts allocated to these services as the performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for the program. The options to acquire additional licenses or services did not result in additional performance obligations because they did not provide a material right at contract inception, primarily due to the very early stages of the programs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2026 and 2025, we recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-356">2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-357">2</ix:nonFraction> million, respectively, within Other collaboration revenue in our Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from the Taiho Collaboration</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Casdatifan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter 2025, Taiho exercised its option under the collaboration arrangement and obtained an exclusive license to casdatifan (the HIF-2&#945; inhibitor) for the Taiho Territory and concurrently entered into the second amendment whereby we will lead development for two indications in Japan including the global Phase 3 trial of casdatifan PEAK-1. In exchange, Taiho made an option exercise payment of $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-6" name="rcus:PaymentForOptionExercise" scale="6" id="f-358">15</ix:nonFraction>&#160;million which was received in fourth quarter 2025. We determined that the option exercise and amendment represented a single contract under which we have two separate distinct performance obligations, a license with a customer and R&amp;D services for a collaborative partner related to the global study activities. </span></div><ix:continuation id="f-337-1"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of the transaction price of $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-6" name="rcus:PaymentForOptionExercise" scale="6" id="f-359">15</ix:nonFraction>&#160;million to the performance obligations (in millions):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Allocation to performance obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Distinct</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Combined</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-6" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-360">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-6" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-361">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.44pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total transaction price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-6" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-362">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the license for casdatifan was distinct based on an evaluation of the delivery of the license, noting that the program was in the later stages of development and the ongoing R&amp;D services do not significantly modify or customize the related intellectual property. We determined the standalone selling price of this license using a discounted cash flow method. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We recognized as revenue the allocated transaction price of $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-363">7</ix:nonFraction>&#160;million in the fourth quarter 2025, within License and development services revenue in our Condensed Consolidated Statements of Operations.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><ix:continuation id="f-310-4" continuedAt="f-310-5"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The standalone selling price of the R&amp;D services obligation was determined using an expected cost-plus margin approach. We recognize the amounts allocated to these services as the performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for the program. We determined that these services are with a collaborative partner and not a customer and in accordance with our policy recognize these amounts as R&amp;D expense reimbursements. See Note 4, License and collaborations, for more information.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-310-5">For the three months ended March&#160;31, 2026, we recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-364">2</ix:nonFraction>&#160;million within License and development services revenue in our Condensed Consolidated Statements of Operations related to programs optioned by Taiho.</ix:continuation> </span></div><div id="ia317198098a84e059b141ad74d9b0930_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-365" continuedAt="f-365-1" escape="true">Income taxes</ix:nonNumeric></span></div><ix:continuation id="f-365-1"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision or benefit for interim periods is determined using an estimate of our annual effective tax rate, adjusted for discrete items, if any, that are taken into consideration in the relevant period. Each quarter, we update the estimate of the annual effective tax rate, and if the estimated tax rate changes, we record a cumulative adjustment to the provision or benefit.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We did not record a provision for income taxes for the three months ended March&#160;31, 2026 and 2025 because of forecasted full year net operating losses ("NOLs"), which consider the timing of recognition of deferred revenue for tax purposes and the effects of the option to capitalize and amortize U.S. R&amp;D expenses as allowed by the One Big Beautiful Bill Act of 2025 ("OBBBA"), which was enacted on July 4, 2025. The effective tax rate differs from the U.S. statutory tax rate primarily due to the valuation allowances on our deferred tax assets and state income taxes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026 and December&#160;31, 2025, we have provided a valuation allowance against U.S. federal and state deferred tax assets. We continue to evaluate the realizability of deferred tax assets and the related valuation allowance. If our assessment of the deferred tax assets or the corresponding valuation allowance were to change, we would record the related adjustment to income during the period in which we make the determination. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We recognize interest and penalties associated with uncertain tax benefits as part of the income tax provision. To date, we have not recognized any interest and penalties, nor have we accrued for or made payments for interest and penalties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have not been audited by the Internal Revenue Service, any state, or foreign tax authority. We are subject to taxation in the U.S. and in Australia. Due to NOLs and research credit carryforwards, all of our tax years, from 2015 to 2025, remain open to U.S. federal and California state tax examinations. In addition, our fiscal years from 2021 to 2025 are open to examination in Australia.</span></div></ix:continuation><div id="ia317198098a84e059b141ad74d9b0930_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-366" continuedAt="f-366-1" escape="true">Net loss per share</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-367" escape="true"><ix:continuation id="f-366-1" continuedAt="f-366-2"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potentially dilutive securities excluded from the computation of diluted net loss per share calculations because they would have been antidilutive (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Common stock options issued and outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-368">18.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-126" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-369">18.0</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-127" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-370">4.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-128" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-371">4.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock purchase plan shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-129" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-372">0.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-130" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-373">0.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total potentially dilutive securities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-374">23.4</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-375">22.6</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-366-2">We have also excluded from the calculation at March&#160;31, 2025 the effect of Gilead&#8217;s right to purchase additional shares of our common stock, which expired in July 2025, as these rights had no intrinsic value.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="ia317198098a84e059b141ad74d9b0930_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-376" continuedAt="f-376-1" escape="true">Stock-based compensation </ix:nonNumeric></span></div><ix:continuation id="f-376-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-377" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the components of stock-based compensation expense recognized in our Condensed Consolidated Statements of Operations (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.051%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-378">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-379">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-380">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-381">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-382">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-383">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="ia317198098a84e059b141ad74d9b0930_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. <ix:nonNumeric contextRef="c-1" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="f-384" continuedAt="f-384-1" escape="true">Cash, cash equivalents and marketable securities </ix:nonNumeric></span></div><ix:continuation id="f-384-1" continuedAt="f-384-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-385" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, gross unrealized gains and losses and the fair value of our cash, cash equivalents and marketable securities, all of which are considered available for sale, by type of securities (in millions): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Types of securities as of March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gain</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Loss </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-386">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-387">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-388">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-389">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-390">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-391">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-392">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-393">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate securities and commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-394">395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-395">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-396">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-397">394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-398">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-399">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-400">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-401">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-402">877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-403">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-404">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-405">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Types of securities as of December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gain</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Loss </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-406">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-407">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-408">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-409">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-410">359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-411">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-412">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-413">359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate securities and commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-414">487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-415">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-416">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-417">487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-418">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-419">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-420">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-421">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-422">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-423">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-424">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-425">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="f-426" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair values of our cash, cash equivalents and marketable securities by location in the Condensed Consolidated Balance Sheets and contractual maturity (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Location in Condensed Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Contractual Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-427">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-428">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Within one year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="f-429">621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="f-430">759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Between one and three years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="f-431">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="f-432">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="rcus:CashCashEquivalentsAndAvailableForSaleInvestments" scale="6" id="f-433">876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="rcus:CashCashEquivalentsAndAvailableForSaleInvestments" format="ixt:num-dot-decimal" scale="6" id="f-434">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains or losses recognized on the sale of available-for-sale marketable securities were not material for the three months ended March&#160;31, 2026 and 2025 and are included in Interest and other income, net, in the Condensed Consolidated Statements of Operations. The cost of a security sold is determined using the specific-identification method.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We limit the credit risk associated with our investments by placing them with banks and institutions we believe are highly creditworthy and investing in highly rated investments. We held a total of <ix:nonFraction unitRef="position" contextRef="c-14" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="f-435">100</ix:nonFraction> and <ix:nonFraction unitRef="position" contextRef="c-15" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="f-436">31</ix:nonFraction> positions in securities which were in unrealized loss positions as of March&#160;31, 2026 and December&#160;31, 2025, respectively. We do not intend to sell our securities with unrealized loss positions and have concluded we will not be required to sell the securities before recovery of the amortized cost for the investment at maturity. <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ProvisionForLoanLossesExpensed" format="ixt-sec:numwordsen" scale="0" id="f-437"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="INF" name="us-gaap:ProvisionForLoanLossesExpensed" format="ixt-sec:numwordsen" scale="0" id="f-438"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="INF" name="us-gaap:ProvisionForLoanLossesExpensed" format="ixt-sec:numwordsen" scale="0" id="f-439">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> credit related losses have been recognized for any of the periods presented.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><ix:continuation id="f-384-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="f-440" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the Condensed Consolidated Balance Sheets to the total shown in the Condensed Consolidated Statements of Cash Flows (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-441">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-442">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-443"><span style="-sec-ix-hidden:f-444">Restricted cash (included in Other noncurrent assets)</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="f-445">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="f-446">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="f-447">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="6" id="f-448">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash at March&#160;31, 2026 and 2025 represents cash balances held as security in connection with our facility lease agreements.</span></div></ix:continuation><div id="ia317198098a84e059b141ad74d9b0930_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 10. <ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-449" continuedAt="f-449-1" escape="true">Condensed consolidated balance sheet components</ix:nonNumeric></span></div><ix:continuation id="f-449-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="f-450" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="rcus:PrepaidExpensesAndOtherCurrentAssets" scale="6" id="f-451">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="rcus:PrepaidExpensesAndOtherCurrentAssets" scale="6" id="f-452">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:InterestReceivableCurrent" scale="6" id="f-453">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:InterestReceivableCurrent" scale="6" id="f-454">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-455">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-456">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="f-457" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consisted of the following (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued research and development</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="rcus:AccruedResearchAndDevelopmentExpensesCurrent" scale="6" id="f-458">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="rcus:AccruedResearchAndDevelopmentExpensesCurrent" scale="6" id="f-459">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued personnel expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-460">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-461">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:TaxesPayableCurrent" scale="6" id="f-462">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:TaxesPayableCurrent" scale="6" id="f-463">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-464">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-465">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="6" id="f-466">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="6" id="f-467">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-468">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-469">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="ia317198098a84e059b141ad74d9b0930_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 11. <ix:nonNumeric contextRef="c-1" name="us-gaap:LongTermDebtTextBlock" id="f-470" continuedAt="f-470-1" escape="true">Long-term debt</ix:nonNumeric></span></div><ix:continuation id="f-470-1" continuedAt="f-470-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-471" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our borrowings (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt (Contractual maturity 2030)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="f-472">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="f-473">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized discounts, issuance costs, charges and payment-in-kind interest, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:fixed-zero" scale="6" id="f-474">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="f-475">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-476">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-477">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, we entered into a loan and security agreement with Hercules which we subsequently amended in the fourth quarter 2025 (the "Hercules Agreement"). Under the Hercules Agreement, Hercules agreed to lend us up to $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-478">250</ix:nonFraction> million in term loans in various tranches subject to minimum draw requirements. At closing, we drew $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" scale="6" id="f-479">50</ix:nonFraction> million and we drew an additional $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-6" name="rcus:DebtInstrumentAdditionalCommittedAmount" scale="6" id="f-480">50</ix:nonFraction> million in the second quarter 2025. The remaining $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-6" name="rcus:DebtInstrumentFaceAmountContingentlyAvailable" scale="6" id="f-481">150</ix:nonFraction>&#160;million is available as follows: (i) $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-6" name="rcus:DebtInstrumentFaceAmountContingentlyAvailable" scale="6" id="f-482">50</ix:nonFraction>&#160;million will be available upon the achievement of certain Biologic License Application ("BLA") enabling clinical milestones related to our ongoing Phase 3 studies, drawable through the earlier of March 15, 2028 or <ix:nonNumeric contextRef="c-148" name="rcus:DebtInstrumentMilestoneAchievementPeriod" format="ixt-sec:durday" id="f-483">90</ix:nonNumeric> days following the achievement of the applicable milestone; (ii) $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="rcus:DebtInstrumentFaceAmountContingentlyAvailable" scale="6" id="f-484">50</ix:nonFraction>&#160;million will be available upon the FDA's approval of a BLA or New Drug Application ("NDA") for an Arcus investigational product, drawable through the earlier of December 15, 2028 or <ix:nonNumeric contextRef="c-150" name="rcus:DebtInstrumentMilestoneAchievementPeriod" format="ixt-sec:durday" id="f-485">90</ix:nonNumeric> days following such approval; and (iii) $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="rcus:DebtInstrumentAdditionalCommittedAmount" scale="6" id="f-486">50</ix:nonFraction> million remains available through the loan's maturity date, subject to lender approval. Any amounts from future expired tranches that were not drawn will remain available through the loan's maturity date, subject to lender approval and the achievement of any milestones associated with the original tranches.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2026 and 2025, we recognized $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="f-487">3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="f-488">2</ix:nonFraction> million of interest expense, respectively. The effective interest rate of the debt, including amortization of the debt discount and issuance costs </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><ix:continuation id="f-470-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and payment-in-kind interest, was <ix:nonFraction unitRef="number" contextRef="c-15" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-489">12.85</ix:nonFraction>% commencing with the modification which occurred in the fourth quarter 2025, compared to <ix:nonFraction unitRef="number" contextRef="c-103" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-490">13.08</ix:nonFraction>% commencing the second quarter 2025 and <ix:nonFraction unitRef="number" contextRef="c-31" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-491">13.39</ix:nonFraction>% for all periods prior to the second quarter 2025.</span></div></ix:continuation><div id="ia317198098a84e059b141ad74d9b0930_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-492" continuedAt="f-492-1" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="f-492-1"><ix:nonNumeric contextRef="c-1" name="rcus:ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock" id="f-493" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash and non-cash information related to our operating leases (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in measurement of lease liabilities</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="rcus:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" scale="6" id="f-494">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="rcus:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" scale="6" id="f-495">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026 and December&#160;31, 2025, we have provided deposits for letters of credit totaling $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:SecurityDeposit" scale="6" id="f-496"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:SecurityDeposit" scale="6" id="f-497">3</ix:nonFraction></ix:nonFraction> million to secure our obligations under our leases, which are included in Other noncurrent assets on the Condensed Consolidated Balance Sheets.</span></div></ix:continuation><div id="ia317198098a84e059b141ad74d9b0930_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 13. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-498" continuedAt="f-498-1" escape="true">Stockholders' equity</ix:nonNumeric></span></div><ix:continuation id="f-498-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Underwritten Offering</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter 2025, we sold through an underwritten offering, <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" id="f-499">13.6</ix:nonFraction> million shares of our common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-31" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-500">11.00</ix:nonFraction> per share, for total gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-501">150</ix:nonFraction> million, before deducting underwriting discounts, commissions and offering expenses. As part of this underwritten offering, Gilead purchased <ix:nonFraction unitRef="shares" contextRef="c-47" decimals="-5" name="rcus:SaleOfStockNumberOfSharesAcquiredInTransaction" scale="6" id="f-502">1.4</ix:nonFraction> million shares of our common stock for total gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-503">15</ix:nonFraction>&#160;million.</span></div></ix:continuation><div id="ia317198098a84e059b141ad74d9b0930_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 14. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-504" continuedAt="f-504-1" escape="true">Fair value measurements</ix:nonNumeric></span></div><ix:continuation id="f-504-1" continuedAt="f-504-2"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1 inputs include unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><ix:continuation id="f-504-2" continuedAt="f-504-3"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</span></div><ix:nonNumeric contextRef="c-1" name="rcus:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-505" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair value measurement as of March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="f-506">171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-507">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-508">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="f-509">171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-510">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="f-511">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-512">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="f-513">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate securities and commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-514">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="f-515">394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-516">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="f-517">394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-518">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="f-519">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-520">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="f-521">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-522">171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-523">705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-524">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-525">876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair value measurement as of December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="f-526">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-527">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-528">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="f-529">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-530">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="f-531">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-532">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="f-533">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate securities and commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-534">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="f-535">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-536">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="f-537">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-538">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="f-539">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:fixed-zero" scale="6" id="f-540">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="f-541">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-542">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-543">855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-544">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-545">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-term debt</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-504-3">We determine the fair value of our long-term debt, for disclosure purposes only, based on other inputs that are observable, and thus categorized as Level 2 in the fair value hierarchy. As of March&#160;31, 2026 and December&#160;31, 2025, the estimated fair value of our long-term debt approximated the carrying amount.</ix:continuation> </span></div><div id="ia317198098a84e059b141ad74d9b0930_79"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Note 15. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-546" continuedAt="f-546-1" escape="true">Business segment</ix:nonNumeric></span></div><ix:continuation id="f-546-1"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We operate and manage our business as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-547"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-548">one</ix:nonFraction></ix:nonFraction> reportable and operating segment, which is the business of developing and commercializing highly differentiated therapies that have a meaningful impact on patients. Our chief operating decision maker ("CODM") is the Chief Executive Officer, who decides how to allocate resources and assesses segment performance based on the net loss reported in the Condensed Consolidated Statements of Operations.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-549" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below is a summary of the segment net loss, including significant segment expenses (in millions):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 2.44pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-550">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-551">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted for expense (income):</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9.36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Late-stage development programs </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-6" name="rcus:LateStageDevelopmentPrograms" scale="6" id="f-552">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-6" name="rcus:LateStageDevelopmentPrograms" scale="6" id="f-553">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9.36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Early-stage development and preclinical programs </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-6" name="rcus:EarlyStageDevelopmentAndPreclinicalPrograms" scale="6" id="f-554">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-6" name="rcus:EarlyStageDevelopmentAndPreclinicalPrograms" scale="6" id="f-555">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and personnel costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-6" name="us-gaap:LaborAndRelatedExpense" scale="6" id="f-556">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-6" name="us-gaap:LaborAndRelatedExpense" scale="6" id="f-557">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-558">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-559">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-6" sign="-" name="us-gaap:InterestExpenseNonoperating" scale="6" id="f-560">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-6" sign="-" name="us-gaap:InterestExpenseNonoperating" scale="6" id="f-561">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9.36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other segment items </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-6" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-562">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-6" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-563">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Partnership reimbursements</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-6" sign="-" name="rcus:PartnershipReimbursements" scale="6" id="f-564">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-6" sign="-" name="rcus:PartnershipReimbursements" scale="6" id="f-565">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Segment net loss and Consolidated net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-566">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-567">112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">(1) R&amp;D expenses incurred related to a Phase 3 clinical program intended to result in registration of a new product. This includes all unallocated program-level expense not directly attributable to a specific clinical trial once the related program enters into one or more Phase 3 clinical trials.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">(2) R&amp;D expenses incurred for activities ranging from early-stage development and preclinical to Phase 2 clinical trials. This includes all unallocated program-level expense not directly attributable to a specific clinical trial unless the related program has entered into one or more Phase 3 clinical trials.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">(3) Other segment items includes non-allocated program costs and other G&amp;A costs.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total segment assets at March&#160;31, 2026 and 2025 were $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-8" name="us-gaap:Assets" scale="9" id="f-568">1.0</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-8" name="us-gaap:Assets" scale="9" id="f-569">1.2</ix:nonFraction> billion, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="ia317198098a84e059b141ad74d9b0930_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited Condensed Consolidated Financial Statements and related notes in Part I, Item 1 of this Quarterly Report on Form 10-Q and with our audited Consolidated Financial Statements and related notes thereto for the year ended December&#160;31, 2025, included in our Annual Report on Form 10-K filed with the SEC on February&#160;25, 2026. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Forward-Looking Statements and Website Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The discussion contained herein and other parts of this report contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations, and intentions. The words "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would", "advance", "future", "prepare" or the negative version of these words and similar expressions are intended to identify forward-looking statements. Such statements reflect our beliefs and opinions on the relevant subject based upon information available to us as of the date of this Quarterly Report on Form 10-Q. While we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Our actual results could differ materially from those discussed in these forward-looking and other statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this report titled "Risk Factors." </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">We intend to use our website www.arcusbio.com as a means of disclosing material non-public information and for complying with our disclosure obligations under the Regulation FD. Such disclosures will be included on the company&#8217;s website under the heading "Investors &amp; Media." Accordingly, investors should monitor such portions of the company&#8217;s website, in addition to following the company&#8217;s press releases, SEC filings and public conference calls and webcasts (if any). The information contained on, or that may be accessed through our website is not part of, and is not incorporated into, this Quarterly Report on Form 10-Q.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="ia317198098a84e059b141ad74d9b0930_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Our most advanced molecules are in Phase 3 registrational studies for various cancer indications and we expect our next wave of clinical-stage molecules to come from our inflammation and autoimmune disease programs. Our vision is to leverage our internal small-molecule discovery capabilities to create, develop and commercialize highly differentiated therapies that can have a meaningful impact on patients. </span></div><div id="ia317198098a84e059b141ad74d9b0930_88"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Our Clinical Product Portfolio</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following chart summarizes our current clinical and late pre-clinical stage portfolio:</span></div><div style="margin-top:6pt;text-align:center"><img src="rcus-20260331_g1.jpg" alt="Pipeline2.jpg" style="height:445px;margin-bottom:5pt;vertical-align:text-bottom;width:660px" id="i-1"/></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">*Taiho has development and commercial rights in Japan and other countries in Asia, excluding China, for casdatifan (the &#8220;Taiho Territory&#8221;).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8224;If approved, Gilead and Arcus will share co-promotion rights in the U.S. and Gilead holds commercialization rights outside of the U.S. subject to Taiho&#8217;s rights for the Taiho Territory.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8225;Gilead retains/holds time-limited option rights.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="ia317198098a84e059b141ad74d9b0930_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Significant Developments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the recent significant developments affecting our business:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Developments</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2026, we announced that the period for Gilead&#8217;s option rights under the Gilead Collaboration Agreement entered into in 2020, as amended, will end on July 14, 2026, following Gilead&#8217;s decision to not make the option continuation payment. Accordingly, Gilead will not have option rights to additional programs in our early-stage pipeline, including the CCR6, CD89 and CD40L programs, but will maintain its existing time-limited options to programs including AB801 (an investigational small molecule AXL inhibitor), AB598 (an investigational anti-CD39 monoclonal antibody), AB102 (an investigational MRGPRX2 antagonist), and an investigational TNF small molecule inhibitor. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HIF-2&#945; Program (casdatifan)</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2026, we and AstraZeneca agreed not to re-open enrollment in eVOLVE-RCC02, a Phase 1b/3 study sponsored and operationalized by AstraZeneca, evaluating casdatifan in combination with volrustomig, AstraZeneca's investigational anti-PD-1/CTLA-4 bispecific antibody, in first-line, advanced/metastatic clear cell renal cell carcinoma.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TIGIT Program (domvanalimab)</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2026, we announced the discontinuation of the Phase 3 STAR-121 study due to futility. STAR-121 evaluated domvanalimab plus the anti-PD-1 antibody zimberelimab and chemotherapy versus pembrolizumab plus chemotherapy as a first-line treatment for metastatic NSCLC. </span></div><div id="ia317198098a84e059b141ad74d9b0930_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Components of Operating Results </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated any revenue from product sales and do not expect to generate any revenue from product sales for the foreseeable future. All revenue recognized to date has been through research, collaboration and license arrangements with strategic partners.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Development Services Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our license and development services revenue consists of amounts recognized from the portions of the nonrefundable upfront payments received from Gilead and Taiho and allocated to performance obligations for licenses or R&amp;D activities performed by us as we develop our investigational products under the terms of our collaboration agreements. License and development services revenues are recognized based upon the timing of the delivery of a license or service if delivery is complete, or based on estimates of each performance obligation's percentage of completion at the period end if it is still in process. We calculate percentage of completion as a ratio of effort incurred to date on each performance obligation to the total estimated effort to be incurred to satisfy that performance obligation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Collaboration Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other collaboration revenue consists primarily of amounts recognized from the portions of the nonrefundable upfront payments received from Gilead and Taiho and allocated to performance obligations relating to their access to our investigational pipeline or our obligation to perform certain discovery and early development activities. Revenue related to access rights is recognized over the period of access, and revenue related to discovery and early development activities is recognized as the performance obligation is satisfied.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our R&amp;D expenses consist of costs incurred in connection with the R&amp;D of our pipeline programs. These expenses include preclinical and clinical expenses, payroll and stock-based compensation for our personnel in R&amp;D, laboratory supplies, product licenses, consulting costs, contract research, and fixed asset depreciation. Shared facility expenses are allocated to functional groups proportionally based on usage. Under certain collaboration agreements we agree to share R&amp;D expenses with our partners. Such cost sharing arrangements may result in receiving reimbursement from our partners or require that we reimburse our partners for qualified expenses. We expense both internal and external R&amp;D costs as they are incurred. We record advance payments for services that will be used or rendered for future R&amp;D activities as prepaid expenses and recognize them as an expense as the related services are performed. We recognize reimbursement for shared costs incurred by us and reimbursed by our partners as a reduction in R&amp;D expense as the underlying costs are incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate all our costs by investigational product, as a significant amount of R&amp;D expenses include internal costs, such as payroll and other personnel expenses, and certain external costs that are not recorded at the investigational product level. In particular, with respect to internal costs, several of our departments support multiple R&amp;D programs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The level of our future R&amp;D investment will depend on a number of factors and uncertainties including the breadth of our clinical programs, the outcome of our efforts, and our collaboration activities. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expect R&amp;D expenses to decline in the near term relative to what we have incurred as we wind down studies for domvanalimab. Streamlining initiatives we have undertaken across our R&amp;D operations in connection with this wind-down, together with efficiencies we are pursuing across our programs outside the Gilead collaboration, are expected to further reduce costs. These decreases will be partially offset by our increased investment in the development of casdatifan and advancement of our small-molecule inflammation and immunology programs.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> We solely own casdatifan and lead its global development and commercialization, working with strategic partners in certain regions. As we advance our clinical-stage programs, including casdatifan, and prepare to seek regulatory approval, we may need to expand our late-stage development and commercial capabilities, which will require increased investment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under our arrangements with WuXi Biologics, Abmuno and AstraZeneca, we may incur additional clinical and regulatory milestone payments based on the development progress of our investigational products. We may also be required to pay royalties in the event of a successful product launch and our receipt of commercial revenues. Therefore, we are unable to predict the timing or the final cost to complete our clinical programs or validation of our manufacturing and supply processes and delays may occur due to numerous factors. Factors that could cause or contribute to delays or additional costs include, but are not limited to, those discussed in "Part II, Item 1A. Risk Factors" of the Quarterly Report. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">G&amp;A expenses consist principally of personnel-related costs including payroll and stock-based compensation for personnel in executive, finance, human resources, information technology, business and corporate development, and other administrative functions. Shared facility expenses are allocated to functional groups proportionally based on usage. Our G&amp;A expenses also include professional fees for legal, consulting, and accounting services, rent and other facilities costs, fixed asset depreciation, and other general operating expenses not otherwise classified as R&amp;D expenses. We do not anticipate significant changes in our G&amp;A expenses in the near term.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Operating Income, net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income, net consists primarily of interest earned on our investments in fixed-income marketable securities, and interest expense on the Hercules Agreement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="ia317198098a84e059b141ad74d9b0930_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.687%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Change</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenues:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License and development services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other collaboration</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">4</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">151&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">150&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">1</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(134)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(122)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">10</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(128)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(112)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">14</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(128)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(112)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">14</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9.5pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.5pt">Not meaningful</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Revenues</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in Total revenues for the three months ended March&#160;31, 2026 was primarily driven by lower development services revenue from the Gilead Collaboration</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See Note 5, Revenues, to our Condensed Consolidated Financial Statements in Part I, Item 1 of this report for further discussion of the amount and timing of revenues recognized from our license and collaboration agreements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We group all of our R&amp;D activities and the related expenditures into categories as described below:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Included as of March 31, 2026</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Category</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Program Level Expenses</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Key Clinical<br/>Trials</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Late-stage development programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses incurred related to a Phase 3 clinical program intended to result in registration of a new product. This includes all unallocated program-level expense not directly attributable to a specific clinical trial once the related program enters into one or more Phase 3 clinical trials.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">casdatifan**<br/>quemliclustat<br/>domvanalimab<br/>zimberelimab<br/></span><span style="font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">PEAK-1<br/>PRISM-1<br/>PACIFIC-8<br/>STAR-121*<br/>STAR-221*<br/>ARC-10*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Early-stage development and preclinical programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses incurred for activities ranging from early-stage development and preclinical to Phase 2 clinical trials. This includes all unallocated program-level expense not directly attributable to a specific clinical trial unless the related program has entered into one or more Phase 3 clinical trials.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">casdatifan**<br/>etrumadenant<br/>AB598<br/>AB801</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ARC-7*</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ARC-8</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ARC-9*</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ARC-20</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ARC-25</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ARC-26*</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ARC-27</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">EDGE-Gastric*</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">EDGE-Lung*</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">eVOLVE*</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">STELLAR-009*</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">VELOCITY-HNSCC***</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">VELOCITY-Lung</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and personnel costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Internal costs, such as salaries, non-cash stock-based compensation, and other personnel expenses for our R&amp;D employees that are not allocated to specific programs or trials.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Facilities, depreciation, and other external costs that are not recorded at the investigational product level.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Partnership reimbursements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursements from our collaboration partners for shared costs incurred by us and recognized as a reduction in R&amp;D expense.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Study discontinued or substantially completed</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Casdatifan moved from early-stage development and preclinical to a late-stage development program in the third quarter 2025.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">***&#160;&#160;&#160;&#160;Head and Neck Squamous Cell Carcinoma ("HNSCC")</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our R&amp;D expenses by category (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.839%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Category</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Late-stage development programs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">60&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Early-stage development and preclinical programs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and personnel costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Partnership reimbursements</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.44pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">122&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">122&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses were flat for the three months ended March&#160;31, 2026, with (i) late-stage development programs increasing due to our investment in casdatifan and our Phase 3 PRISM-1 study for quemliclustat, partially offset by the wind-down of studies related to domvanalimab, (ii) early-stage development activities decreasing primarily due to the absence of prior year Phase 2 study costs for domvanalimab, and (iii) partnership reimbursements decreasing, primarily due to Gilead-led activities representing a larger share of total joint development costs and a shift towards programs fully funded by us. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expense by quarter may fluctuate due to the timing of clinical manufacturing and standard-of-care therapeutic purchases</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> with a corresponding impact on reimbursements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expect R&amp;D expenses to decline in the near term relative to what we have incurred as we wind down studies for domvanalimab. Streamlining initiatives we have undertaken across our R&amp;D operations in connection with this wind-down, together with efficiencies we are pursuing across our programs outside the Gilead collaboration, are expected to further reduce costs. These decreases will be partially offset by our increased investment in the development of casdatifan and advancement of our small-molecule inflammation and immunology programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The increase in G&amp;A expenses for the three months ended March&#160;31, 2026, was primarily due to a $2&#160;million increase in non-cash stock-based compensation, which was primarily attributable to a separation agreement with an officer.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Operating Income, net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in Non-operating income, net for the three months ended March&#160;31, 2026, was primarily due to: lower yields and a lower average balance for our investment portfolio; and higher interest expense on our long-term debt due to the additional drawdown under our agreement with Hercules at the end of the second quarter 2025.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There was no Income tax expense for the three months ended March&#160;31, 2026 or 2025 due to forecasted full year NOLs.</span></div><div id="ia317198098a84e059b141ad74d9b0930_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and investments are held in a variety of interest-bearing instruments, including money market funds, U.S. government treasury and agency obligations, investments in corporate securities and certificates of deposit. Based on our existing business plan, we believe that our cash, cash equivalents, and marketable securities as of March&#160;31, 2026 will be sufficient to fund our planned level of operations until at least the second half of 2028.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have financed our operations primarily from the sale of our equity securities, upfront or milestone payments from our research, collaboration and license agreements with our strategic partners including Gilead and debt financing. We will need substantial additional funding to support our continuing operations and pursue our development strategy. Until such time that we can generate significant revenue from sales of our investigational products, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including existing or potential collaborations with other companies or other strategic transactions. See "Item 1A. Risk Factors" for a discussion of the factors that could impact our liquidity.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into an equity distribution agreement pursuant to which we may, from time to time, sell shares of our common stock having an aggregate offering price of up to $200 million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have a $250 million term loan facility with Hercules. Under this facility, $100 million has been drawn. Additional tranches totaling $150 million will be available to support strategic initiatives, subject to the achievement of certain clinical and regulatory milestones and lender approval. See Note 11, Long-term debt, in Part I, Item 1, to our Condensed Consolidated Financial Statements for further discussion. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2025, we issued, through two underwritten offerings, 29.4 million shares of our common stock for total gross proceeds of approximately $438 million, before deducting underwriting discounts, commissions and offering expense. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activities for each of the periods presented below (in millions): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Net cash provided by (used in):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(138)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(132)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $138 million for the three months ended March&#160;31, 2026 compared to $132 million for the same period in the prior year. The change in operating cash flows is primarily due to the timing of receipts from Taiho for development milestones.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by investing activities for the three months ended March&#160;31, 2026 was primarily due to net proceeds from marketable securities of $114&#160;million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by investing activities for the three months ended March&#160;31, 2025 was primarily due to net proceeds from marketable securities of $33&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities for the three months ended March&#160;31, 2026 was due to proceeds of $3 million for stock issued under our equity award plans.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities for the three months ended March&#160;31, 2025 was due to net proceeds of $142 million from issuance of our common stock under the February 2025 underwritten offering.</span></div><div id="ia317198098a84e059b141ad74d9b0930_103"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our contractual obligations outside the ordinary course of business during the three months ended March&#160;31, 2026, as compared to those disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2025.</span></div><div id="ia317198098a84e059b141ad74d9b0930_106"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Judgments and Estimates </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements have been prepared in accordance with U.S. GAAP. The preparation of these Condensed Consolidated Financial Statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements, as well as the reported revenue and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our critical accounting policies and estimates, from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="ia317198098a84e059b141ad74d9b0930_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from changes in interest rates and foreign currency exchange rates. Our market risks have not changed materially from those discussed in our Annual Report on Form 10-K filed with the SEC on February&#160;25, 2026.</span></div><div id="ia317198098a84e059b141ad74d9b0930_112"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934, as amended ("Exchange Act") reports is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon, and as of the date of this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended March&#160;31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="ia317198098a84e059b141ad74d9b0930_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="ia317198098a84e059b141ad74d9b0930_118"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.</span></div><div id="ia317198098a84e059b141ad74d9b0930_121"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should consider carefully the following risk factors, together with all the other information in this report, including our Condensed Consolidated Financial Statements and notes thereto, and in our other public filings with the SEC. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Limited Operating History, Financial Position and Capital Requirements </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of operating losses, have never generated any revenue from product sales and anticipate that we will continue to incur significant losses for the foreseeable future. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company with a limited operating history that may make it difficult to evaluate the success of our business to date and to assess our future viability. All of our investigational products are in development, and none have been approved for commercial sale, nor have we ever generated any revenue from product sales. Our revenues to date have been primarily from upfront and milestone payments, R&amp;D support and clinical materials reimbursement from our strategic partners. For the three months ended March&#160;31, 2026 and year ended December&#160;31, 2025, we had net losses of $128 million and $353 million, respectively. As of March&#160;31, 2026, we had an accumulated deficit of $1.6 billion. While we may receive income from year to year under the Gilead Agreements and the Taiho Agreement, we generally expect to incur substantial and increasing levels of operating losses over the next several years and for the foreseeable future as we advance our investigational products. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable on a sustained basis, we must develop and eventually commercialize a product with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our investigational products, obtaining marketing approval for these investigational products, manufacturing, marketing and selling those products for which we may obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in these activities, and even if we succeed in commercializing one or more of our investigational products, we may never generate revenues that are significant or large enough to achieve sustained profitability. In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. If we do achieve profitability from product sales, we may not be able to sustain or increase profitability on a quarterly or annual basis, and we will continue to incur substantial R&amp;D and other expenditures to develop and market additional investigational products. Our failure to become and remain profitable on a sustained basis would decrease the value of the company and could impair our ability to raise capital, maintain our R&amp;D efforts, expand our business or continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to obtain additional funding. If we do not receive or are unable to raise additional capital when needed, we may be forced to restrict our operations or delay, reduce or eliminate our product development programs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The development of biopharmaceutical investigational products is capital intensive. Since our inception, we have used substantial amounts of cash to fund our operations and expect our expenses to increase substantially during the next few years as our investigational products advance through large late-stage or registrational clinical trials. If we obtain marketing approval for any of our investigational products, we expect to incur significant commercialization expenses related to marketing, sales, manufacturing and distribution.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026, we had $876 million of cash, cash equivalents and marketable securities, which we believe will be sufficient to provide funding until at least the second half of 2028. This is based on disciplined prioritization of our resources to these programs. For example, we have paused further development for etrumadenant in third-line metastatic colorectal cancer to focus our resources on our late-stage clinical portfolio and research programs. However, we cannot guarantee that we will not need additional capital and if so, that we will be able to obtain additional capital in sufficient </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">amounts or on terms acceptable to us, if at all. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate some or all of our R&amp;D programs or future commercialization efforts. In addition, if we need and are able to raise additional capital, raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our intellectual property or investigational products. For example, if we decide in the future to issue debt or equity securities ranking senior to shares of our common stock or otherwise incur additional indebtedness, it is possible that these securities or indebtedness will be governed by an indenture or other instrument containing covenants restricting our operating flexibility. Additionally, any convertible or exchangeable securities that we issue in the future may have rights, preferences and privileges more favorable than those of our common stock and may result in dilution to stockholders. Because our decision to issue debt or equity securities in any future offering or otherwise incur indebtedness will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future offerings or financings, any of which could reduce the market price of shares of our common stock and dilute their value. Our future capital requirements will depend on many factors related to the cost and timing of developing our investigational products, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.15pt">the number, scope, rate of progress and costs of clinical programs and investigational products, as well as drug discovery, preclinical development activities, and laboratory testing;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the scope of any cost sharing arrangements with our strategic partners;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing and amount of milestone payments and option fees we receive under the Gilead Collaboration Agreement and the Taiho Agreement;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost, timing and outcome of regulatory review of our investigational products; and </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost associated with commercializing our investigational products, if they receive marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating activities may be restricted as a result of covenants related to the indebtedness under our loan and security agreement with Hercules Capital, Inc., as amended, and we may be required to repay the outstanding indebtedness in an event of default, which could have a materially adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024, we entered into the Hercules Agreement, with Hercules as administrative agent and collateral agent, and the lenders listed in the Hercules Agreement (collectively, the "Lenders"). The Hercules Agreement was subsequently amended in December 2025 (the "Hercules Amendment"). The Hercules Agreement provided a secured term facility of up to $250 million in four tranches, subject to customary terms and conditions, of which $100 million had been drawn down by us. The Hercules Amendment amended the terms for the remaining $150 million term loan commitments available under the loan facility, subject to customary terms and conditions. The Hercules Agreement, as amended, is secured by substantially all of our assets, subject to certain exclusions. The maturity date of the Hercules Agreement is September 2030, with an interest-only period until September 2028, which may be extended to September 2030, subject to achieving certain specified regulatory approval milestones. Until we have repaid all outstanding obligations, the Hercules Agreement, as amended, subjects us to various customary covenants, including, among other things, requirements as to financial reporting and minimum cash (beginning July 2027) and net product revenue (following achievement of certain regulatory milestones), and certain advisory management rights for the Lenders and Hercules. The minimum cash covenant is conditionally waived if our market capitalization exceeds a specified threshold, and the minimum net product revenue covenant may be satisfied through alternative measures based on our market capitalization and cash position. In addition, the Hercules Agreement contains customary restrictions on our ability to incur additional indebtedness, to incur liens on our property and assets, to make certain investments, to repurchase or redeem any capital stock or other equity interest other than certain permitted investments, to declare or pay any cash dividends or other distributions on capital stock other than from the Company&#8217;s subsidiaries to the Company or another subsidiary of the Company, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity other than certain permitted acquisitions, to change our line of business and to enter into any change in control transaction. Our business may be adversely affected by these restrictions on our ability to operate our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be required to repay the outstanding indebtedness under the loan facility if an event of default occurs and is continuing under the Hercules Agreement. An event of default will occur if, among other things, we fail to make payments under the Hercules Agreement; we breach any of our covenants under the Hercules Agreement, subject to specified cure periods with respect to certain breaches; a material adverse effect has occurred; any of our representations or warranties is false or misleading in any material respect; we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings; or we default on certain contracts with third parties, which would permit Hercules to accelerate the maturity of such indebtedness under the Hercules Agreement. We may not have enough available cash or be able to raise additional funds through equity or debt financings to repay such indebtedness at the time any such event of default occurs. In this case, we may be required to limit or reduce our activities necessary to commercialize our investigational products, or delay or limit clinical trials for our investigational products. Hercules could also exercise its rights as collateral </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">agent to enforce its security interest in the collateral. Our business, financial condition and results of operations could be materially adversely affected as a result of any of these events.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery and Development of our Investigational Products </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain regulatory approval for our investigational products, or experience significant delays in doing so, our business will be materially harmed. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for sale and our investigational products must be approved by the FDA in the U.S. and similar regulatory authorities outside the U.S., such as the European Medicines Agency ("EMA"), prior to commercialization. The process of obtaining marketing approvals, both in the U.S. and abroad, is expensive and takes many years, if approval is obtained at all, and can vary substantially based upon a variety of factors. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the investigational product&#8217;s safety and efficacy, or with respect to biological investigational products, safety, purity and potency. Securing marketing approval also requires, among other things, the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities, among other requirements. Our investigational products may not be effective, may be only moderately effective, may not have an acceptable durability of response, may not have an acceptable risk-benefit profile or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude us from obtaining marketing approval or limit their commercial use. Our investigational products may not be approved even if they achieve their primary endpoints in any Phase 3 clinical trials or other registrational trials we or our collaborators conduct.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and in determining when or whether marketing approval will be obtained for any of our investigational products. Regulatory authorities may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of an investigational product. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may also cause delays in or prevent the approval of an application. For example, since we utilize intra-portfolio combinations, regulatory authorities may disagree that we have sufficiently demonstrated the contribution of each investigational product or other agent in our combination trials to any observed therapeutic effects and require further studies to further characterize the activity of each component within the combination. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or comparable regulatory authorities can delay, limit or deny approval of an investigational product for many reasons, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">such authorities may disagree with the design or execution of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">negative or ambiguous results from our clinical trials or results may not meet the level of statistical significance or persuasiveness required by the FDA or comparable foreign regulatory authorities for approval;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs similar to our investigational products;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the population studied in our clinical trials may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">such authorities may not accept clinical data from trials that are conducted at clinical facilities or in countries where the standard of care is potentially different from that of their own country;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be unable to demonstrate that an investigational product&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">such authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">such authorities may not agree that the data collected from clinical trials of our investigational products are acceptable or sufficient to support the submission of a BLA, NDA or other submission or to obtain regulatory approval in the U.S. or elsewhere;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">such authorities may disagree with us regarding the formulation, labeling and/or the product specifications of our investigational products;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">such authorities may find deficiencies in the manufacturing processes or facilities of the third-party manufacturers with which we contract for clinical and commercial supplies; or</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">such authorities may not accept a submission due to, among other reasons, the content or formatting of the submission.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to establish any long-term supply agreements with third-party manufacturers or to do so on acceptable terms, which increases the risk of failing to timely obtain sufficient quantities of our investigational products or such quantities at an acceptable cost.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to obtain marketing approvals for any of our investigational products, those approvals may be for indications that are not as broad as desired or may contain other limitations that would adversely affect our ability to generate revenue from sales of those products. Moreover, if we are not able to differentiate our product against other approved products within the same class of drugs our business would be materially harmed and our ability to generate revenue from that class of drugs would be severely impaired. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that investigational product and would materially adversely impact our business and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in obtaining approval or if we fail to obtain approval of our investigational products, the commercial prospects for our investigational products may be harmed and our ability to generate revenues will be materially impaired.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical drug development is a lengthy, expensive and uncertain process. If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our investigational products, if approved, may be delayed and the credibility of our management team may be adversely affected and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The R&amp;D of drugs and biological products is an extremely risky undertaking. Only a small percentage of investigational products that enter the development process ever receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of any investigational product, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety, purity, potency and/or efficacy of our investigational products in humans. Clinical testing is expensive, can take many years to complete and its outcome is uncertain. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, from time to time, we may provide guidance regarding the expected timing or costs of various scientific, clinical, regulatory and other product development goals; including goals regarding the commencement or completion of, or the availability of data from, scientific studies and clinical trials and the submission of regulatory filings. Any such guidance will be based on a variety of assumptions, such as the rate of events in a trial. The actual timing or cost of these goals can vary dramatically compared to our guidance, in some cases for reasons beyond our control. If we do not meet such guidance the commercialization of our products may be delayed and the credibility of our management team may be adversely affected and, as a result, our stock price may decline.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of preclinical studies and early clinical trials are not always predictive of future results. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The results of preclinical and early clinical trials of our investigational products and other products with the same mechanism of action may not be predictive of the results of later-stage clinical trials. For example, we presented data from our Phase 2 EDGE-Gastric study that evaluated the same combination as our Phase 3 STAR-221 study. Despite results from EDGE-Gastric showing median overall survival ("OS") beyond two years, which exceeded benchmarks from other Phase 3 studies showing median OS of 13-14 months, the Phase 3 STAR-221 was discontinued after our interim analysis in December 2025 showed no benefit over standard of care. Accordingly, data from Phase 2 studies (such as ARC-8 and ARC-20) may not be predictive of the results of any of our Phase 3 studies even if evaluating the same regimen and setting. Clinical trial failure may result from a multitude of factors including flaws in study design, dose selection, placebo effect, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits. As such, failure in clinical trials can occur at any stage of testing. A number of companies in the biopharmaceutical industry have suffered setbacks in the advancement of clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Based upon negative or inconclusive results, we may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. In addition, data obtained from clinical trials are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may further delay, limit or prevent marketing approval. In particular, results from uncontrolled trials, meaning trials in which there is no control group such as a placebo group, are inherently difficult to interpret. This difficulty is compounded in any of our clinical trials in which two or more investigational products that have not yet been approved are being evaluated. Accordingly, the data generated during preclinical or early clinical trials evaluating our investigational products may not be predictive of future clinical trial results </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">for these or other investigational products when studied in a randomized environment or larger patient populations or with different study designs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any difficulties or delays in the commencement or completion, or the termination or suspension, of our current or planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue or adversely affect our commercial prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining approval from regulatory authorities for the commercialization of any of our investigational products, we must conduct extensive clinical trials to demonstrate the safety purity, potency, or efficacy of our investigational candidate in humans. Before we can initiate clinical trials for any investigational products in the U.S. or in other jurisdictions, we must submit the results of preclinical studies to the FDA or comparable regulatory authorities along with other information, including information about the investigational product&#8217;s chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an IND or similar regulatory submission. The FDA or comparable foreign regulatory authorities may require us to conduct additional preclinical studies for any investigational product before it allows us to initiate clinical trials under any IND or similar regulatory submission, which may lead to delays and increase the costs of our preclinical development programs. Moreover, even if we commence clinical trials, issues may arise that could cause regulatory authorities to suspend or terminate such clinical trials. Any such delays in the commencement or completion of our ongoing and planned clinical trials for our investigational products could significantly affect our product development timelines and product development costs and harm our financial position. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not know whether our planned clinical trials will begin on time or be completed on schedule, if at all. The timing for commencement, data readouts and completion of clinical trials can be delayed for a number of reasons, including delays related to: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining allowance or approval from regulatory authorities to commence a trial or reaching a consensus with regulatory authorities on trial design; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA or comparable foreign regulatory authorities disagreeing as to the implementation of our clinical trials; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in identifying, recruiting and training suitable clinical investigators;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining approval from one or more institutional review boards ("IRBs"), or ethics committees at clinical trial sites; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">IRB refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes or amendments to the clinical trial protocol; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical sites deviating from the trial protocol or dropping out of a trial; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">failure by our CROs to perform in accordance with good clinical practice ("GCP") requirements or applicable regulatory rules and guidelines in other countries;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">manufacturing sufficient quantities of our investigational products, or obtaining sufficient quantities of combination therapies for use in clinical trials; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">subjects failing to enroll or remain in our trials at the rate we expect, or failing to return for post-treatment follow-up, including subjects failing to remain in our trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">patients choosing an alternative product for the indications for which we are developing our investigational products or participating in competing clinical trials; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">lack of adequate funding to continue a clinical trial or costs being greater than we anticipate; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">subjects experiencing severe or serious unexpected drug-related adverse effects; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">occurrence of serious AEs in trials of the same class of agents conducted by other companies that could be considered similar to our investigational products; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">selection of clinical endpoints that require prolonged periods of clinical observation or extended analysis of the resulting data; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">failure of our Contract Manufacturing Organization ("CMO") to produce clinical trial materials in sufficient quantities in accordance with current Good Manufacturing Practice ("cGMP"), regulations or other applicable requirements; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">third parties being unwilling or unable to satisfy their contractual obligations to us in a timely manner.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or applicable clinical trial protocols, adverse findings from inspections of clinical trial sites by the FDA or comparable foreign regulatory authorities, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using an investigational product, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to regulators or to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, conducting clinical trials in foreign countries, as we continue to do for our investigational</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">products, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled subjects in foreign countries to adhere to clinical protocols as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, and political and economic risks, including war, relevant to such foreign countries. In addition, many of the factors that cause, or lead to, the termination, suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of an investigational product. Any resulting delays to our clinical trials could shorten any period during which we may have the exclusive right to commercialize our investigational products. In such cases, our competitors may be able to bring products to market before we do, and the commercial viability of our investigational products could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preliminary, topline, and interim data from our clinical studies that we announce or publish from time to time are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we publish preliminary, topline or interim data from our clinical studies. Such publications are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. For example, topline and preliminary data remain subject to audit confirmation and verification procedures that may result in the final data being materially different from the topline or preliminary data we previously published. Interim data are also subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. As a result, interim, topline and preliminary results that we report may differ from future results of the same studies and should be viewed with caution until the final data are available. As such material changes between previously reported topline, preliminary and interim results and final data could significantly harm our business prospects and our stock price may decline.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Most of our clinical trials are open-label studies and may be susceptible to bias.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Most of our early phase clinical trials, as well as some of our Phase 3 trials, are open-label studies in which both the patient and investigator know whether the patient is receiving the investigational products or either an existing approved drug or placebo. Open-label clinical trials are susceptible to bias that may exaggerate any therapeutic effect or overestimate the risk associated with the investigational product. Patients may perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. Investigators may interpret the information of the treated group more favorably given their awareness of the treatment regimen or may attribute safety risks to the investigational product. If regulatory agencies feel that we have not implemented sufficient controls to prevent such biases or that the controls we have implemented were ineffective, we may experience delays or negative outcomes in our applications for drug approval. In addition, the FDA and other regulatory authorities may disfavor the use of open-label studies, or otherwise not agree that the results from open-label studies, regardless of outcome, will support submission of an application for marketing approval in the indications we are targeting, and we may be required to conduct blinded trials evaluating our investigational products before we are able to obtain marketing approval of our investigational products, if ever.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enrollment and retention of subjects in clinical trials is expensive and time consuming and can be made more difficult or rendered impossible by competing treatments, clinical trials of competing investigational products, geopolitical instability and public health epidemics, each of which could result in significant delays and additional costs in our product development activities, or in the failure of such activities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may encounter delays in enrolling, or be unable to enroll and maintain, a sufficient number of subjects to complete any of our clinical trials. Patient enrollment and retention in clinical trials are a significant factor in the timing and cost of clinical trials and depends on many factors, including among other things, the size of the patient population required for analysis of the trial&#8217;s primary endpoints, the nature of the trial protocol, our ability to recruit clinical trial investigators with the appropriate competencies and experience, the existing body of safety and efficacy data with respect to the investigational product (including data that we report in our other clinical trials using the same investigational products) or with respect to other investigational products with the same mechanism of action as our investigational products, the number and nature of competing products or investigational products and ongoing clinical trials of competing investigational products for the same indication, the proximity of subjects to clinical trial sites, the eligibility criteria for the clinical trial and our ability to obtain and maintain subject consents. See "Item 1. Business - Competition" in our Annual Report on Form 10-K filed with the SEC on February&#160;25, 2026, for additional information regarding competing programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Geopolitical instability and public health outbreaks may also have an adverse impact on our clinical trial operations. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our investigational products. In addition, we expect to rely on CROs</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and clinical trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we will have limited influence over their actual performance. Failures in planned subject enrollment or retention may result in increased costs or program delays and could render further development impossible. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Serious adverse events, undesirable side effects or other unexpected properties of our investigational products may be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our investigational products or limitations on the use of our investigational products or, if discovered following marketing approval, revocation of marketing authorizations or subsequent limitations on the use of our investigational products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to develop our investigational products and initiate later phase clinical trials of our investigational products or initiate clinical trials to evaluate different combination regimens involving our investigational products, serious AEs, undesirable side effects or unexpected characteristics may emerge causing us to abandon these investigational products or limit their development to more narrow uses or subpopulations in which the serious AEs, undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Even if our investigational products initially show promise in early clinical trials, the side effects of drugs are frequently only detectable after they are tested in larger, Phase 3 clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval. Different AEs may also emerge, or the same or similar AEs but with increased incidence and/or severity, when our investigational products are used in different combination regimens. For example, we and AstraZeneca agreed not to re-open enrollment in the eVOLVE-RCC02 trial following observations of potential immune-mediated AEs. Sometimes, it can be difficult to determine if the serious adverse or unexpected side effects were caused by our investigational product or another product or factor, especially in oncology subjects who may suffer from other medical conditions and be taking other medications. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, adverse developments in clinical trials of investigational products conducted by others or AEs associated with commercial products offered by others may cause the FDA or other regulatory oversight bodies to suspend or terminate our clinical trials or change the requirements for approval of any of our investigational products, or otherwise adversely affect the clinical and commercial development of our investigational products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if any of our investigational products receives regulatory approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result. For example, the FDA could require us to adopt a risk evaluation and mitigation strategy ("REMS") to ensure that the benefits of treatment with such investigational product outweigh the risks, which REMS may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and more costly than what is typical for the industry. We may also be required to engage in similar actions, such as patient education, certification of health care professionals or specific monitoring, if we or others later identify undesirable side effects caused by any product that we develop. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other potentially significant negative consequences associated with AEs include:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">IRBs, ethics committees, or safety monitoring committees may recommend that enrollment or dosing be placed on hold or that additional safety measures be implemented for ongoing clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be required to suspend marketing of a product, or we may decide to remove such product from the marketplace; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory authorities may withdraw or change their approvals of a product;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory authorities may require additional warnings or contraindications on the label or limit access of a product to selective specialized centers with additional safety reporting and with requirements that patients be geographically close to these centers for all or part of their treatment;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be required to create a medication guide outlining the risks of a product for patients, or to conduct post-marketing studies; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be required to change the way a product is dosed, distributed, or administered, or conduct additional clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be subject to limitations on how we may promote the product;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we could be subject to fines, injunctions, or the imposition of criminal or civil penalties, or be sued and held liable for harm caused to subjects or patients; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a product may become less competitive, and our reputation may suffer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could diminish the usage or otherwise limit the commercial success of our investigational products and prevent us from achieving or maintaining market acceptance of our investigational products, if approved by the FDA or other regulatory authorities. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse findings from clinical trials conducted by third parties investigating the same investigational products as us in different territories or different investigational products directed to the same target as one of our programs could adversely affect our development program. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Lack of efficacy, AEs, undesirable side effects, or other adverse findings may emerge in clinical trials conducted by third parties investigating the same investigational products as us in different territories or different investigational products directed to the same target as one of our programs. For example, we and Gloria Biosciences each licensed our rights to the same anti-PD-1 antibody (which we refer to as zimberelimab) from WuXi Biologics. Gloria Biosciences refers to this antibody as GLS-010 and is conducting clinical trials with GLS-010 in China. We have no control over their clinical trials or development program, and adverse findings from the results or their conduct of clinical trials could adversely affect our development of zimberelimab or even the viability of zimberelimab as an investigational product. We may be required to report Gloria Biosciences' AEs or unexpected side effects to the FDA or comparable foreign regulatory authorities, which could, among other things, order us to cease further development of zimberelimab. We may face similar risks from any independent development conducted with our investigational products by Gilead and Taiho, following any exercise of their respective options to our programs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, we have no control over the clinical trials or development programs of third parties developing investigational products directed to the same target as one of our programs. Adverse findings or clinical trial results from such trials could adversely affect the commercial prospects of our investigational products and cause our stock price to fluctuate or decline. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development of combination therapies may present more or different challenges than development of single agent therapies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our investigational products are being pursued in combination with one or more investigational products. The development of combination therapies may be more complex than the development of single agent therapies and generally requires that sponsors demonstrate the contribution of each investigational product to the claimed effect and the safety and efficacy of the combination as a whole. This requirement may make the design and conduct of clinical trials more complex, requiring more clinical trial subjects. We also may not be able to meet the FDA&#8217;s current or future approval standards required for combination therapies or combination products, if we decided to administer or package a combination therapy as a single drug product. For example, under the "combination rule", the FDA may not file or approve a fixed-dose combination product unless each component of a proposed drug product is shown to make a contribution to the claimed effects and the dosage of each component (amount, frequency, duration) is safe and effective for the intended population. To satisfy these requirements, the FDA may recommend we conduct a clinical factorial study, designed to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">assess the effects attributable to each drug in the combination product. Moreover, the applicable requirements for approval of a combination therapy may differ from country to country.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the event that one of our investigational products were to fail to demonstrate sufficient safety and efficacy or establish its contribution to the claimed effects of a combination therapy, we would need to identify alternatives. For example, we expect that our anti-PD-1 antibody, zimberelimab, will form the backbone of many of the investigational combination therapies we are pursuing. If we are unable to demonstrate the contribution of zimberelimab to the claimed effects of an investigational combination therapy, we would need to identify an anti-PD-1 antibody for use in such combination therapy. In the event we are unable to do so or are unable to do so on commercially reasonable terms, our business and prospects would be materially harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain of our investigational products may require companion diagnostics in certain indications. Failure to successfully develop, validate and obtain regulatory clearance or approval for such tests could harm our product development strategy or prevent us from realizing the full commercial potential of our investigational products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Companion diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities as a medical device and may require separate regulatory authorization prior to commercialization of either the companion diagnostic or the relevant investigational product. According to FDA guidance, if the FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or cleared for that indication. Depending on the data from our clinical trials, we may utilize diagnostic tests during our clinical trial enrollment process to help identify patients with characteristics that we believe will be most likely to respond to our investigational products, which may be incorporated into future Phase 3 trials to help identify eligible patients. In addition, we have significant efforts directed to identifying changes in various cells and proteins to understand their relationship, if any, to the clinical activity observed in our clinical trials and to assess if such cells and/or proteins could be used as predictive biomarkers to select for patients more likely to respond to our investigational products. However, we cannot be certain that we will be able to identify any such biomarkers, that such biomarkers will result in us identifying the appropriate patients for our investigational products or that we or any third-party collaborators will be able to validate any diagnostic tests incorporating any predictive biomarkers we may identify. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not have any plans to develop diagnostic tests internally. We are therefore dependent on the sustained cooperation and effort of third-party collaborators in developing and, if our investigational products are approved for use only with an approved companion diagnostic test, obtaining approval and commercializing these tests. If these parties are unable to successfully develop and obtain marketing authorization for companion diagnostics for use with any of our investigational products, or experience delays in doing so, the development of our investigational products may be adversely affected and we may not be able to obtain marketing authorization for these investigational products. Furthermore, our ability to market and sell, as well as the commercial success, of any of our investigational products that require a companion diagnostic will be tied to, and dependent upon, the receipt of required regulatory authorization and the continued ability of such third parties to make the companion diagnostic commercially available on reasonable terms in the relevant geographies. Any failure to develop, validate, obtain and maintain marketing authorization and supply for a companion diagnostic we need will harm our business prospects. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The design or execution of our ongoing and future clinical trials may not support marketing approval. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The design or execution of a clinical trial can determine whether its results will support marketing approval, and flaws in the design or execution of a clinical trial may not become apparent until the clinical trial is well advanced. In some instances, there can be significant variability in safety or efficacy results between different trials with the same investigational product due to numerous factors, including differences in trial protocols, size and type of the patient populations, variable adherence to the dosing regimen or other protocol requirements and the rate of dropout among clinical trial participants. The FDA or comparable foreign regulatory authorities may disagree with our trial designs and our interpretation of data from preclinical studies or clinical trials. Even if we adhere to guidance or advice given by the FDA or comparable foreign regulatory authorities, such adherence does not guarantee that the FDA will agree with our trial designs or data interpretations or prevent the FDA from changing the requirements for the approval of any investigational product. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have conducted, and continue to conduct, portions of our clinical trials outside the U.S., and the FDA may not accept data from trials conducted in foreign locations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted, and we expect to continue to conduct, portions of our clinical trials outside the U.S. Although the FDA may accept data from clinical trials conducted outside the U.S., acceptance of these data is subject to certain conditions imposed by the FDA. For example, in cases where data from foreign clinical trials are intended to serve as the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">sole basis for regulatory approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, if the study was not otherwise subject to an IND, the FDA will not accept the data as support for an application for regulatory approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign regulatory authorities have similar requirements for clinical data gathered outside of their respective jurisdictions. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. We cannot assure you that the FDA will accept data from trials conducted outside the U.S. If the FDA does not accept the data from such clinical trials, we would likely need to conduct additional trials, which would be costly and time-consuming and delay or permanently halt our development of our investigational products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA and other government agencies caused by funding shortages, staffing limitations or policy changes could hinder their ability to hire, retain or deploy key leadership and other personnel, prevent new or modified products from being developed, reviewed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA and foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s or foreign regulatory authorities&#8217; ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s or foreign regulatory authorities&#8217; ability to perform routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund R&amp;D activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and biologics, or modifications to approved drugs and biologics, to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. In addition, the current U.S. Presidential administration has issued certain policies and Executive Orders directed towards reducing the employee headcount and costs associated with U.S. administrative agencies, including the FDA, and it remains unclear the degree to which these efforts may limit or otherwise adversely affect the FDA's ability to conduct routine activities. If a prolonged government shutdown occurs, or if funding shortages, staffing limitations or similar factors hinder or prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, such events could significantly impact the ability of the FDA or other such regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reliance on Third Parties, Manufacturing and Commercialization </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to depend on collaborations for the development of our investigational products. If our collaboration efforts are not successful, the scope of our development efforts may be limited and our business could be adversely affected. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy for fully developing our investigational products is to leverage collaborations to expand the breadth of our clinical development plans. The success of these arrangements will depend, among other things, on our ability to attract collaborators with the resources and/or expertise to broaden the clinical plans for our investigational products, our ability to reach a definitive agreement for a collaboration, our collaborators' cooperation and ability to successfully and timely meet their responsibilities with regards to a clinical program. We cannot predict how productive we will be in forming new collaborations or the success of any collaboration that we enter into.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, for certain of our investigational products for which Gilead has exercised or elects to exercise its option rights, we will be dependent on Gilead for the successful development and commercialization of those investigational products, if approved. Our partnership with Gilead poses a number of risks that could materially impact the success of these programs including, but not limited to, conflicts and disagreements regarding: the combinations or indications to pursue, the interpretation of clinical data, the commercial potential of any optioned investigational products, the interpretation of financial provisions or the ownership of intellectual property developed during the collaboration for such investigational products. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we are not successful in managing our collaborations, the scope of our development efforts may be impaired and our business could be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct our clinical trials and perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are and expect to remain dependent on third parties, such as CROs, clinical investigators and consultants, to conduct our ongoing clinical trials and any future clinical trials of our investigational products. The timing of the initiation and completion of these trials will therefore be partially controlled by such third parties and may result in delays to our development programs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There is no guarantee that any CROs, investigators or other third parties that help conduct or participate in our clinical trials will devote adequate time and resources to such trials or perform as contractually required. While we have and will have agreements governing the activities of our CROs, investigators and other consultants, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards and requirements, and our reliance on our CROs and other third parties does not relieve us of our regulatory responsibilities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If any of these third parties fails to meet expected deadlines, fails to adhere to our clinical protocols, fails to meet regulatory requirements or guidelines (including any GCPs or comparable requirements enforced by the FDA or comparable foreign regulatory authorities), or otherwise performs in a substandard manner, our ability to use data generated from our clinical trials may be jeopardized, the timelines for our clinical trials may be extended or delayed, or our development activities may be suspended or terminated. If any of our clinical trial sites terminates for any reason, we may experience the loss of follow-up information on subjects enrolled in our ongoing clinical trials unless we are able to transfer those subjects to another qualified clinical trial site. In addition, our CROs have the right to terminate their agreements with us in the event of an uncured material breach and under other specified circumstances, and if so terminated, we may not be able to enter into arrangements with alternative third parties on commercially reasonable terms or at all. Switching or adding additional CROs, investigators and other third parties involves additional cost and requires our management&#8217;s time and focus.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, the utility of certain data from the clinical trial may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any NDA or BLA we submit to the FDA, or equivalent marketing application to other regulatory authorities outside the U.S. Any such delay or rejection could prevent us from commercializing our investigational products, which would have a material adverse impact on our business, financial condition and prospects. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supply by third parties of the investigational products, standard-of-care drugs or comparator agents used in our clinical trials may become limited or interrupted, or more costly, which could delay, prevent or impair our development efforts. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing biologics, especially in large quantities, is often complex and may require the use of innovative technologies to handle living cells. We rely, and expect to continue to rely, on third-parties for the manufacture and supply of our investigational products for preclinical and clinical testing, as well as for commercial manufacture if any of our investigational products are approved. If any of these third-parties fail to perform these activities for us, nonclinical or clinical development of our investigational products could be delayed, which could have an adverse effect on our business, financial condition, results of operations, and/or growth prospects. Further, we currently have limited manufacturing arrangements for our investigational products and expect that each of our investigational products will only be covered by single source suppliers for the foreseeable future. Our reliance on limited manufacturing arrangements increases the risk that we will not have and may not be able to obtain sufficient quantities of our investigational products for use in our clinical trials and, if approved, commercial activities. For example, WuXi Biologics, located in China, is currently our sole manufacturer of zimberelimab and domvanalimab. We regularly assess our supply needs against our manufactured quantities, however, if WuXi Biologics, or any other manufacturer that we rely on, is unable or unwilling to provide the quantity of material we require, there is no guarantee that any reserves we have of our investigational products will be sufficient for our future clinical development plans. If any reserves we have are depleted and we are unable to establish a reliable source of supply, our development efforts, and if approved, commercial activities, could be delayed or impaired. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any supply chain challenges may affect our ability to supply clinical sites with our investigational products and any standard-of-care drugs and comparator agents that we use in our clinical trials. These supply chain challenges can </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">include longer lead times for the manufacturers of our investigational products to obtain raw materials, longer timeframes to procure or lack of supply for standard-of-care drugs or comparator agents used in our clinical trials, and transit delays at each point in the manufacturing, supply or distribution chain. For example, certain standard-of-care therapies for our Phase 3 trials are challenging to source, including carboplatin, fluorouracil, oxaliplatin and cabozantinib. If we are unable to source these drugs, we may be prevented from enrolling subjects into our clinical trials, may incur increased costs for our clinical trials, and may otherwise be delayed, prevented or impaired in our development efforts. See the risk factor titled "Unfavorable global economic, political and trade conditions could adversely affect our business, financial condition or results of operations and may exacerbate the effects of the risks described herein." </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our manufacturing partners are subject to extensive regulation. In the event any of our manufacturers fail to comply with such regulations or perform its obligations, our business may be adversely affected and we may need to delay or halt the development of our investigational products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not control the manufacturing process of our contract manufacturing partners and are completely dependent on them for compliance with cGMP requirements for manufacture of our investigational products, including assuring that their processes have adequate quality control, quality assurance and qualified personnel. In the event that any of our manufacturers fail to comply with regulatory requirements, such as the requirement to implement and operate quality systems to control and assure the quality of investigational products and products approved for sale and other requirements imposed by cGMP regulations, or if any of our manufacturers fail to perform its obligations to us in relation to quality, timing or otherwise, we may be forced to suspend or terminate our development activities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In particular, we currently do not have the capabilities or resources to manufacture our investigational products ourselves and any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. In some cases, the technical skills or technology required to manufacture our investigational products may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third-party and a feasible alternative may not exist. If we are required to change manufacturers for any reason, including as a result of geopolitical tensions, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines, and we may be required to conduct additional clinical trials or perform additional development activities to demonstrate comparability of lots of our investigational products to those produced by prior manufacturers. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our or a third-party&#8217;s failure to execute on our manufacturing requirements on commercially reasonable terms and in compliance with cGMP or other regulatory requirements could adversely affect our business in a number of ways, including: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">an inability to initiate or complete clinical trials of our investigational products in a timely manner; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in submitting regulatory applications, or receiving regulatory approvals, for our investigational products; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">subjecting third-party manufacturing facilities to additional inspections by regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">requirements to cease development or to recall batches of our investigational products; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">in the event of approval to market and commercialize an investigational product, an inability to meet commercial demands. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, clinical trial investigators, CROs, consultants, vendors, collaboration partners and any potential commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, clinical trial investigators, CROs, consultants, vendors, collaboration partners and any potential commercial partners. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: (i) FDA laws and regulations or those of comparable foreign regulatory authorities, including those laws that require the reporting of true, complete and accurate information, (ii) manufacturing standards, (iii) federal and state health and data privacy, security, fraud and abuse, government price reporting, transparency reporting requirements, and other healthcare laws and regulations in the U.S. and abroad, or (iv) laws that require the true, complete and accurate reporting of financial information or data. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, as well as a disclosure program and other applicable policies and procedures, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval for any investigational product, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Following potential approval of any our investigational products, the FDA may impose significant restrictions on a product&#8217;s indicated uses or marketing or impose ongoing requirements for potentially costly and time-consuming post-approval studies, post-market surveillance or clinical trials to monitor the safety and efficacy of the product. The FDA may also require a REMS as a condition of approval of our investigational products, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our investigational products, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our products will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCP requirements for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our products, including AEs of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">fines, restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds on clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">product seizure or detention, or refusal to permit the import or export of our products; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any event or penalty described above may inhibit our ability to commercialize our investigational products and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if any of our investigational products are approved, our product labeling, advertising and promotion will be subject to regulatory requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made about drug and biological products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. If we receive marketing approval for an investigational product, physicians may nevertheless, in their independent medical judgment, prescribe it to their patients in a manner that is inconsistent with the approved label. The FDA does not regulate the behavior of physicians in their choice of treatments but the FDA does restrict manufacturer&#8217;s communications on the subject of off-label use of their products. If we are found to have promoted such off-label uses, we may become subject to liability. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our investigational products. We also cannot predict the likelihood, nature or extent of new government regulations. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive marketing approval, we may not be successful in commercializing our investigational products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have no sales, marketing or distribution capabilities or experience. If any of our investigational products ultimately obtains regulatory approval, we, whether alone or in collaboration with Gilead for programs that we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">commercialize together, may not be able to effectively or successfully market the product due to a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the imposition by regulatory authorities of significant restrictions on a product&#8217;s indicated uses, marketing or distribution;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the imposition by regulatory authorities of costly and time-consuming post-approval studies, post-market surveillance or additional clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our failure to establish sales and marketing capabilities; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the failure of our products to achieve the degree of market acceptance by physicians, patients, hospitals, cancer treatment centers, healthcare payors and others in the medical community necessary for commercial success; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">unfavorable pricing regulations or third-party coverage and reimbursement policies; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">inaccuracies in our estimates of the addressable patient population resulting in a smaller sales opportunity than we believed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may fail to obtain orphan drug designations from the FDA for our investigational products, and even if we obtain such designations, we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities in some jurisdictions, including the U.S., may designate biologics or drugs designed to address relatively small patient populations as "orphan drugs." Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biologic intended to treat a rare disease or condition, which is defined as one occurring in a patient population of fewer than 200,000 in the U.S., or a patient population greater than 200,000 in the U.S., where there is no reasonable expectation that the cost of developing the drug or biologic will be recovered from sales in the U.S. In the U.S., orphan designation entitles a party to financial incentives such as opportunities for grant funding for clinical trial costs, tax advantages and user-fee waivers. In addition, if an investigational product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including an NDA or BLA, to market the same drug for the same approved use or indication within such disease or condition for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In June 2025, the FDA granted orphan drug designation to quemliclustat for the treatment of pancreatic cancer. We may seek orphan drug designations for quemliclustat in other diseases or conditions or for our other investigational products. There can be no assurances that we will be able to obtain such designations. Even if we, or any future collaborators, obtain orphan drug designation for an investigational product, we, or they, may not be able to obtain or maintain orphan drug exclusivity for that investigational product. Further, even if we, or any future collaborators, obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active ingredients may be approved for the same indications or uses. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same indication or use within the same rare disease or condition if the FDA concludes that the later drug is clinically superior for such indication or use, in that it is shown to be safer, more effective or makes a major contribution to patient care, or the manufacturer of the product with orphan exclusivity is unable to maintain sufficient product quantity to meet the needs related to the approved indication or use of the patient population with the relevant rare disease or condition. Orphan drug designation neither shortens the development or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive marketing approval for one or more of our investigational products, our commercial success is dependent on obtaining coverage and reimbursement for a product from a government or other third-party payor, which coverage may be delayed or may not be sufficient to cover our costs</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success is dependent on obtaining coverage and reimbursement for any product for which we receive approval from private or government third-party payors, which is a time-consuming and costly process that could require us and any collaborators to provide supporting scientific, clinical and cost effectiveness data for the use of our products to the payor. There may be significant delays in obtaining such coverage and reimbursement for newly approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a product will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">manufacture, sale and distribution expenses. Interim reimbursement levels for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Obtaining reimbursement for our products may be particularly difficult because of the higher prices often associated with branded therapeutics and therapeutics administered under the supervision of a physician. Additionally, our collaborators will be required to obtain coverage and reimbursement for any related companion diagnostics tests they develop separate and apart from the coverage and reimbursement we seek for our investigational products, once approved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement may also impact the demand for, and the price of, any product for which we obtain marketing approval. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with those medications. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement is critical to new product acceptance and we expect to experience pricing pressures in connection with the sale of any of our investigational products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Increasing efforts by governmental and third-party payors in the U.S. and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for recently approved products and, as a result, they may not cover or provide adequate payment. Even if we show improved efficacy or improved convenience of administration, third-party payors may deny or revoke the reimbursement status of our investigational products, if approved, or establish prices for our investigational products at levels that are too low to enable us to realize an appropriate return on our investment. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our investigational products, and may not be able to obtain a satisfactory financial return. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">No uniform policy for coverage and reimbursement for products exists among third-party payors in the U.S. Therefore, coverage and reimbursement for products can differ significantly from payor to payor, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance or that step edits or other conditions on reimbursement will not be imposed. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to obtain coverage and reimbursement approval for any of our investigational products, if approved, could have a material adverse effect on the demand for that investigational product, and on our business and our overall financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining regulatory</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">approval of investigational products in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. Even if our investigational products are approved by the FDA, they may never be approved or commercialized outside the U.S., which would limit our ability to realize their full market potential. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any products within a country, we or our collaborators must establish and comply with numerous and varying regulatory requirements of such country regarding safety and efficacy. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us or our collaborators and may require additional preclinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. However, obtaining and maintaining regulatory approval of investigational products in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, the approval of zimberelimab for the treatment of recurrent or refractory classical Hodgkin&#8217;s Lymphoma in China by Gloria Biosciences does not improve the chances of FDA approval for any BLA that we may submit for zimberelimab in the U.S. in any indication. In addition, our or our collaborators&#8217; failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any investigational products approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we or our collaborators fail to comply with regulatory requirements in international markets or fail to obtain and maintain required approvals, our ability to realize the full market potential of our products will be harmed. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any investigational products for which we intend to seek approval as biologic products may face competition sooner than anticipated. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Biologics Price Competition and Innovation Act ("BPCIA") created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until twelve years from the date on which the reference product was first licensed. During this twelve-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The law is complex and is still being interpreted and implemented by the FDA. As a result, any such processes could have a material adverse effect on the future commercial prospects for our biological products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of our current and future investigational products approved as a biological product under a BLA should qualify for the twelve-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our investigational products to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, could be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products will depend on a number of marketplace and regulatory factors. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our In-Licenses and Other Strategic Agreements </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently party to several in-license agreements under which we acquired rights to use, develop, manufacture and/or commercialize certain of our investigational products. If we breach our obligations under these agreements, we may be required to pay damages, lose our rights to these investigational products or both, which would adversely affect our business and prospects. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We rely, in part, on license and other strategic agreements, which subject us to various obligations, including diligence obligations with respect to development and commercialization activities, reporting and notification obligations, payment obligations for achievement of certain milestones and royalties on product sales, negative covenants and other material obligations. We may need to devote substantial time and attention to ensuring that we are compliant with our obligations under these agreements. If we fail to comply with the obligations under our license agreements or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and our licensors may have the right to terminate the license. If our license agreements are terminated, we may not be able to develop, manufacture, market or sell the products covered by our agreements and those being tested or approved in combination with such products. Such an occurrence could materially adversely affect the value of the investigational product being developed under any such agreement and any other investigational products being developed or tested in combination. Domvanalimab, which we in-licensed from Abmuno, is being evaluated in the Phase 3 PACIFIC-8 trial. Zimberelimab, which we in-licensed from WuXi Biologics, is being evaluated in several of our early-phase trials, including ARC-20. In the event we breach any of our license agreements with Abmuno and/or WuXi Biologics, and our license agreements are terminated, we would have to cease these development activities, or we would have to negotiate a new or reinstated agreement, which may not be available to us on equally favorable terms, or at all. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreements under which we license intellectual property or technology to or from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our collaborations or other strategic partnerships on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected investigational products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not realize the benefits of any acquisitions, in-license or other collaborations or strategic alliances that we enter into. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into in-license agreements with multiple licensors and option agreements to enable the development and commercialization of our investigational products worldwide. We are also parties to several clinical collaboration agreements to support the development of our investigational products in additional settings and/or indications. In the future, we may seek to enter into acquisitions or additional licensing or clinical collaboration </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">arrangements with third parties to expand our pipeline or that we believe will complement or augment our development and commercialization efforts with respect to our investigational products and any future investigational products that we may develop. These transactions can entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products, investigational products or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. As a result, if we enter into in-license, acquisition or collaboration agreements, or strategic partnerships, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain sufficient intellectual property protection for our investigational products, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part on our ability to obtain and maintain patent protection in the U.S. and other countries with respect to our investigational products and research programs. We seek to protect our proprietary position by filing patent applications in the U.S. and abroad related to our novel discoveries and technologies that are important to our business, however, we cannot predict: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">if and when patents may issue based on our patent applications; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the scope of protection of any patent issuing based on our patent applications; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether the claims of any patent issuing based on our patent applications will protect our investigational products and their intended uses or prevent others from commercializing competitive technologies or products; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether or not third parties will find ways to invalidate or circumvent our patent rights; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; and/or</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether we will need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and enforcing patents is expensive and time-consuming and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Even if we successfully file and prosecute a patent application, we may not be able to maintain and/or enforce the issued patent. We may determine that filing or maintaining such a patent or any action to enforce a patent may be too high or not in the best interest of our company or our stockholders. It is also possible that we will fail to identify patentable aspects of our R&amp;D results before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our R&amp;D output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such results before a patent application is filed, thereby jeopardizing our ability to seek patent protection. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We also cannot be certain that the claims in our pending patent applications directed to our investigational products and/or technologies will be considered patentable by the U.S. Patent and Trademark Office ("USPTO") or by patent offices in foreign countries. One aspect of the determination of patentability of our inventions depends on the scope and content of the "prior art," information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention. There may be prior art of which we are not aware that may affect the patentability of our patent claims or, if issued, affect the validity or enforceability of a patent claim. Even if the patents do issue based on our patent applications, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, patents in our portfolio may not adequately exclude third parties from practicing relevant technology or prevent others from designing around our claims. If the breadth or strength of our intellectual property position with respect to our investigational </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">products is threatened, it could dissuade companies from collaborating with us to develop and threaten our ability to commercialize our investigational products. In the event of litigation or administrative proceedings, we cannot be certain that the claims in any of our issued patents will be considered valid by courts in the U.S. or foreign countries. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits alleging that we have infringed the intellectual property rights of third parties or to protect or enforce our patents or other intellectual property, which litigation could be expensive, time consuming and adversely affect our ability to develop or commercialize our investigational products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our investigational products. Third parties may assert infringement claims against us based on existing or future intellectual property rights. If we were sued for patent infringement, we would need to demonstrate that our investigational products, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity may be difficult. For example, in the U.S., proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. If we are found to infringe a third-party&#8217;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing investigational product or product. Alternatively, we may be required to obtain a license from such third-party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing investigational product. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our investigational products or force us to cease some of our business operations, which could materially harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may find that competitors are infringing our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against which we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, we cannot assure you that we will have sufficient financial or other resources to defend or pursue such litigation, which typically last for years before they are concluded. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on our business and operations. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, know-how or trade </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">secrets of others in their work for us, we may become subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">While we may litigate to defend ourselves against these claims, even if we are successful, litigation could result in substantial costs and could be a distraction to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our investigational products, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights outside of the U.S. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Patents are of national or regional effect, and filing, prosecuting and defending patents on all of our investigational products throughout the world would be prohibitively expensive. As such, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Further, the legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals or biologics, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. In addition, certain developing countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. Further, we file patent applications in Russia and the Eurasian patent office, which is headquartered in Moscow. Sanctions against Russia may make it difficult to file and maintain patents in these countries, and Russia has taken actions against "unfriendly" countries, including the U.S., which may adversely affect the scope of and/or our ability to enforce our intellectual property rights. In any of these countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third-party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent law in the U.S. and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our investigational products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. However, the patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation, resulting in court decisions, including Supreme Court decisions, which have increased uncertainties as to the ability to obtain and enforce patent rights in the future. Changes in either the patent laws or interpretation of the patent laws in the U.S. and other countries could increase the uncertainties and costs. For example, in September 2011 the Leahy-Smith America Invents Act (the "America Invents Act") was signed into law and included a number of significant changes to U.S. patent law as then existed. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">review, and derivation proceedings. After March 2013, under the America Invents Act, the U.S. transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third-party was the first to invent the claimed invention. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in 2012, the European Patent Package, or EU Patent Package, regulations were passed with the goal of providing a single pan-European Unitary Patent and a new European Unified Patent Court ("UPC"), for litigation involving </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">European patents. Implementation of the EU Patent Package occurred on June 1, 2023. Under the UPC, all European patents, including those issued prior to ratification of the European Patent Package, will by default automatically fall under the jurisdiction of the UPC. The UPC will provide our competitors with a new forum to centrally revoke our European patents, and allow for the possibility of a competitor to obtain pan-European injunctions. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize our technology and investigational products and, resultantly, on our business, financial condition, prospects and results of operations. It will be several years before we will understand the scope of patent rights that will be recognized and the strength of patent remedies that will be provided by the UPC. Under the EU Patent Package as currently proposed, we will have the right to opt our patents out of the UPC over the first seven years of the court&#8217;s existence, but doing so may preclude us from realizing the benefits of the new unified court. Moreover, if we do not meet all of the formalities and requirements for opt-out under the UPC, our future European patents could remain under the jurisdiction of the UPC.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may rely on trade secret and proprietary know-how which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technology and investigational products, we may also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. Elements of our investigational product, including processes for their preparation and manufacture, may involve proprietary know-how, information, or technology that is not covered by patents, and thus for these aspects we may consider trade secrets and know-how to be our primary intellectual property. Any disclosure, either intentional or unintentional, by our employees, third parties with which we share our facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Trade secrets and know-how can be difficult to protect. We require our employees to enter into written employment agreements containing provisions of confidentiality and obligations to assign to us any inventions generated in the course of their employment. We further seek to protect our potential trade secrets, proprietary know-how, and information in part, by entering into non-disclosure and confidentiality agreements with parties who are given access to them, such as our corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. With our consultants, contractors, and outside scientific collaborators, these agreements typically include invention assignment obligations. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third-party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third-party, our competitive position would be harmed. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our investigational products or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position on our investigational products for an adequate amount of time. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Patent rights are of limited duration. Given the amount of time required for the development, testing and regulatory review of new investigational products, patents protecting such candidates might expire before or shortly after such investigational products are commercialized. Even if patents covering our investigational products are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic products. A patent term extension based on regulatory delay may be available in the U.S. However, only a single patent can be extended for each marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the period of the patent term extension does not extend to the full scope of the claim, but instead only to the scope of the product as approved. Laws governing analogous patent term extensions in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Additionally, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Business Operations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to expand our business operations and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expect to grow our business operations, including adding employees in sales and marketing, if any of our investigational products receives marketing approval. To manage our anticipated future growth, we must: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">identify, recruit, integrate, maintain and motivate additional qualified personnel; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">manage our development efforts effectively, including the initiation and conduct of clinical trials for our investigational products; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">improve our operational, financial and management controls, reporting systems and procedures. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to develop, manufacture and commercialize our investigational products will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert financial and other resources, as well as a disproportionate amount of its attention, away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our investigational products and, accordingly, may not achieve our research, development and commercialization goals. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biopharmaceuticals industry depends upon our ability to attract, retain and motivate highly skilled and experienced personnel with scientific, medical, regulatory, manufacturing and management skills and experience. We conduct our operations in the San Francisco Bay Area, a region that is home to many other biopharmaceutical companies as well as many academic and research institutions, resulting in fierce competition for qualified personnel and rapidly increasing wages. Our industry also has experienced a high rate of turnover in recent years. While we have expanded a number of our in-office roles to permit remote work arrangements, allowing us to seek talent from outside the San Francisco Bay Area, we still may not be able to attract or retain qualified personnel in the future due to the intense competition for a limited number of qualified personnel among biopharmaceutical companies. Many of the other biopharmaceutical companies we compete with have greater financial and other resources, different risk profiles and a longer history in the industry than we do. Our competitors may provide higher compensation, more diverse opportunities and/or better opportunities for career advancement. Any or all of these competing factors may limit our ability to continue to attract and retain high quality personnel, which could negatively affect our ability to successfully develop and commercialize our investigational products and to grow our business and operations as currently contemplated. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on the services of our founders, Terry Rosen, Ph.D., who serves as our Chief Executive Officer, and Juan Jaen, Ph.D., who serves as our President. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the services of our founders, Terry Rosen, Ph.D., who serves as our Chief Executive Officer, and Juan Jaen, Ph.D., who serves as our President. Although we have entered into employment agreements with them, they are not for a specific term, and each of them may terminate their employment with us at any time, though we are not aware of any present intention of either of these individuals to leave us. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Drs. Rosen and Jaen have significant experience identifying and developing biopharmaceuticals. We believe that their drug discovery and development experience, and overall biopharmaceutical company management experience, would be difficult to replace. However, the historical results, past performance and/or acquisitions of companies with which they were affiliated do not necessarily predict or guarantee similar results for our company. Further, Drs. Rosen and Jaen have certain other business and personal commitments outside of serving as the Chief Executive Officer and President of Arcus, including serving on the boards of other companies and foundations, which may result in diversion of their focus and attention on our company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us. If their investigational products are shown to be safer or more effective than ours, then our commercial opportunity will be reduced or eliminated. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We compete in the segments of the pharmaceutical, biotechnology and other related markets that develop drugs and biologics for the treatment of cancer and inflammatory and autoimmune diseases, which are highly competitive with rapidly changing standards of care. As such, our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop or that would render any products that we may develop obsolete or non-competitive. Our competitors also may obtain marketing approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of several pharmaceutical companies developing products in the same class as our investigational products, some of which are further along in development than our corresponding assets. See "Item 1. Business-Competition" in our Annual Report on Form 10-K filed with the SEC on February&#160;25, 2026, for additional information regarding our competitors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As more investigational products within a particular class of drugs proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change. Consequently, the results of our clinical trials for investigational products in that class will likely need to show a risk benefit profile that is competitive with or more favorable than those products and investigational products in order to obtain marketing approval or, if approved, a product label that is favorable for commercialization. If the risk benefit profile is not competitive with those products or investigational products, or if the approval of other agents for an indication or patient population significantly alters the standard of care with which we tested our investigational products, we may have developed a product that is not commercially viable, that we are not able to sell profitably or that is unable to achieve favorable pricing or reimbursement. In such circumstances, our future product revenue and financial condition would be materially and adversely affected. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal information technology systems, and those of our third-party CROs and other third parties upon which we rely, are subject to failure, security breaches and other disruptions, which could result in a material disruption of our investigational products&#8217; development programs, jeopardize sensitive information, prevent us from accessing critical information or result in a loss of our assets, and potentially expose us to notification obligations, loss, liability or reputational damage and otherwise adversely affect our business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit confidential information, including but not limited to intellectual property, proprietary business information and personal information (collectively, "Confidential Information"). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We also have outsourced elements of our operations to third parties, and as a result we manage a number of third-party contractors and other parties who have access to our Confidential Information.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to monitor these third parties&#8217; information</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">security practices is limited, and these third parties may not have adequate information security measures in place. If the third parties we rely on experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if these third parties fail to satisfy their privacy- or security-</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such an award. In addition, supply chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, given the size and complexity and the increasing amounts of Confidential Information that they maintain, our internal information technology systems and those of our third-party CROs and other third parties upon which we rely are vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners, and/or other third parties, or from cyberattacks by malicious third parties (including the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering/phishing and other means to affect service reliability and threaten the confidentiality, integrity and availability of information and other assets), which may compromise our system infrastructure, lead to data leakage, impair key business processes or other critical business operations, delay our development programs, or result in the loss of assets or other liability. Additionally, our information technology systems and Confidential Information are vulnerable to cybersecurity risks and threats, including malicious code embedded in open-source software, or misconfigurations, "bugs" or other vulnerabilities in commercial software that is integrated into our (or our suppliers&#8217; or service providers&#8217;) information technology systems, products or services. Our reliance on internet technology and the number of our employees who are working remotely has increased the opportunities for cybercriminals to exploit vulnerabilities. There can be no assurance that our cybersecurity risk management program and processes, including our policies, controls or procedures, will be fully implemented, complied with or effective in protecting our systems and information.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Further, we cannot assure you that our data protection efforts and our investment in information technology will prevent breakdowns, data leakages, breaches in our systems or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or financial condition. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, as the cyber threat landscape evolves, these attacks are growing in frequency, sophistication and intensity, and becoming increasingly difficult to detect as threat actors use techniques and tools - including artificial intelligence ("AI") - that can circumvent security controls and remove forensic evidence. There can be no assurance that we and our third-party CROs and other third parties upon which we rely will be successful in detecting, preventing or fully recovering systems or data from all breakdowns, service interruptions, attacks or breaches of systems that could adversely affect our business and operations and/or result in the loss or disclosure of Confidential Information or other assets, which could result in financial, legal, business or reputational harm to us. Ransomware attacks have risen dramatically and we may be forced to pay to unlock our data and information, re-access our systems and resume our ability to conduct business operations. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. The loss of clinical trial data for our investigational products could significantly increase our costs to recover or reproduce the data and result in delays in our development programs, impair our ability to obtain marketing approval and reduce the commercial opportunity for our investigational products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We take steps designed to detect, mitigate, and remediate vulnerabilities in our information systems (such as our hardware and/or software, including that of any third parties we rely), but we may not be able to detect and remediate all such vulnerabilities including on a timely basis. Further, we may experience delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, significant disruptions of our internal information technology systems or security breaches could result in the loss, misappropriation, and/or unauthorized access, use, or disclosure of, or the prevention of access to, Confidential Information, which could result in legal claims or proceedings (such as class actions), regulatory investigations and enforcement actions, fines and penalties, negative reputational impacts that cause us to lose existing or future partners, collaborators and/or customers, and/or significant incident response, system restoration or remediation and future compliance costs. In particular, any such event that leads to unauthorized access, use, or disclosure of personal information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain insurance coverage to insure against losses suffered as a result of malicious intrusions and cyberattacks, such coverage may be insufficient to fully compensate us for the loss or there may be disputes with our insurers about the availability of insurance coverage for our claims. Cyber insurance may become increasingly difficult to maintain and we may not be able to maintain coverage at a reasonable cost or in an amount adequate to compensate for any loss or satisfy any liability that may arise. Our contracts may not contain limitations of liability, and even where they do, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our Confidential Information could be leaked, disclosed, or revealed as a result of or in connection with the use of generative AI technologies by our employees, personnel, or the third parties upon whom we rely. Any Confidential Information (including confidential, competitive, proprietary, or personal information) that is inputted into a third-party generative AI platform could be leaked or disclosed to others, including if Confidential Information is used to train the third parties&#8217; AI model.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic, political and trade conditions could adversely affect our business, financial condition or results of operations and may exacerbate the effects of the risks described herein. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current global economic conditions are highly volatile due to a number of reasons, including geopolitical instability, such as trade war, the military conflicts between Russia and Ukraine, the conflicts between Israel and Hamas, recent inflation that increased our operating expenses and disruptions in the capital and credit markets that may reduce our ability to raise additional capital when needed on acceptable terms, if at all. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging international trade relations, new legislation and tariffs may also adversely impact our operations and/or financial condition by limiting or preventing the activities of third parties that we engage, increasing import costs or increasing the cost of our operations. New or increased tariffs, export controls or other trade barriers could result in higher prices for the materials we use and, if any of our investigational products are approved, could materially impact our supply chain and manufacturing costs for such products. Recent congressional legislative actions, proposed executive orders, sanctions, tariffs and other measures discourage contracting with Chinese companies on the development or manufacturing of pharmaceutical products and may restrict trade with China. For example, the U.S. BIOSECURE Act, which was enacted in December 2025, prohibits federal agencies from procuring or using any biotechnology equipment or services from "biotechnology companies of concern", or entering into, extending, or renewing any contracts with entities that use such biotechnology equipment or services from "biotechnology companies of concern." Congress has interpreted a "biotechnology company of concern" as an entity that is under the control of a foreign adversary and that poses a risk to national security based on its research or multiomic data collection (e.g., collection of genomic information). While the U.S. BIOSECURE Act has a grandfathering period of five years for existing contracts, and has carveouts for manufacture of drugs for supply under Medicaid and Medicare Part B, subject to the Secretary of Veterans Affairs&#8217; discretion, the impact of the U.S. BIOSECURE Act on the biotechnology industry is uncertain. WuXi Biologics, located in China, is currently our sole manufacturer of zimberelimab and domvanalimab. If WuXi Biologics becomes subject to trade restrictions, sanctions, increased tariffs or other regulatory requirements by the U.S. government (including designation as a "biotechnology company of concern" under the U.S. BIOSECURE Act), or if the U.S. or Chinese government take retaliatory actions due to recent or increased tensions between the U.S. and mainland China, it could materially impact our ability to obtain additional supply of zimberelimab and domvanalimab or significantly increase our manufacturing costs. Finding a replacement manufacturer could require significant effort and/or be prohibitively expensive, and we may not be able to do so in a timely manner which could have an adverse impact on our operations, operating results and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the recent inflationary environment related to increased aggregate demand and supply chain constraints has increased our operating expenses and may continue to affect our operating expenses. Economic conditions may also strain our suppliers, possibly resulting in supply disruptions that impact our ongoing clinical trials and other operations. A significant worsening of global economic conditions could materially increase these risks we face.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any new or prolonged downturn of global economic conditions could harm our business operations, and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our future profitability may depend, in part, on our ability to commercialize our investigational products in foreign markets for which we may rely on collaboration with third parties. We are not permitted to market or promote any of our investigational products before we receive marketing approval from the applicable regulatory authority in that foreign market, and we may never receive such marketing approval for any of our investigational products. To obtain marketing approval in many foreign countries, we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our investigational products, and we cannot predict success in these jurisdictions. If we obtain </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">approval of our investigational products and ultimately commercialize our investigational products in foreign markets, we would be subject to additional risks and uncertainties, including: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our customers&#8217; ability to obtain reimbursement for our investigational products in foreign markets; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our inability to directly control commercial activities because we are relying on third parties;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">different medical practices and customs in foreign countries affecting acceptance in the marketplace; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">import or export licensing requirements; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">longer accounts receivable collection times; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">longer lead times for shipping; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">language barriers for technical training; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">reduced protection of intellectual property rights in some foreign countries; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the existence of additional potentially relevant third-party intellectual property rights; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">foreign currency exchange rate fluctuations; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Foreign sales of our investigational products could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or the third parties upon which we depend may be adversely affected by earthquakes, fires or other natural disasters. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our headquarters and main research facility are located in the San Francisco Bay Area, which in the past has experienced severe earthquakes and fires. In addition, fires and other natural disasters may increase in frequency and severity over time due to climate change. If these earthquakes, fires, other natural disasters, terrorism and similar unforeseen events beyond our control were to prevent us from using all or a significant portion of our headquarters or research facility, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. We do not have a disaster recovery or business continuity plan in place and may incur substantial expenses as a result of the absence or limited nature of our internal or third-party service provider disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. Furthermore, integral parties in our supply chain are operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe AEs. If such an event were to affect our supply chain, it could have a material adverse effect on our ability to conduct our clinical trials, our development plans and business. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred substantial losses during our history and our ability to generate profits in the future is uncertain. Unused NOL carryforwards from the tax year ended December 31, 2017 and prior tax years will carry forward to offset future taxable income, if any, until such unused NOLs expire. Unused NOLs generated after December 31, 2017, under current tax law, will not expire. Our NOLs may be carried forward indefinitely. In addition, the future deductibility of such NOLs will be limited to 80% of current year taxable income in any given year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Both our current and our future unused losses (and tax credit carryforwards) may be subject to further limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the "IRC"), if we undergo an "ownership change," generally defined as a greater than 50 percentage point change (by value) in our equity ownership by certain stockholders over a three-year period. We performed an analysis under IRC Sections 382 and 383 through March 31, 2024 with respect to our NOL and credit carryforwards. We concluded that an ownership change, as defined under IRC Section 382, occurred in previous years, but that such ownership change did not result in the expiration of our NOL or credit carryforwards prior to utilization. We may incur additional ownership changes in the future in connection with any equity issuance. If we experience any such ownership change, we may be limited in our ability to use our NOL and credit carryforwards and be required to make material cash tax payments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited. For example, California recently enacted a franchise tax law limiting the usability of California state NOLs to offset taxable income for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">tax years beginning on or after January 1, 2024 and January 1, 2027. Similar laws in the future could accelerate or permanently increase state taxes owed. Therefore, even if we attain sustained profitability, we may be unable to use all or a material portion of our NOLs and other tax attributes, which could adversely affect our future cash flows. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws and regulations or exposure to additional tax liabilities could adversely affect our financial results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. We actively monitor legislative and regulatory developments that may affect our tax liability in order to identify and evaluate if such proposals would have a material impact, whether detrimental or beneficial, on our financial results. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. For example, the provisions of the Tax Cuts and Jobs Act of 2017, as amended by the OBBBA, eliminate the option to currently deduct non-U.S. R&amp;D expenditures and require taxpayers to capitalize and amortize non-U.S. R&amp;D expenditures over fifteen years. We cannot predict whether, when, in what form, or with what effective dates, tax laws, regulations and rulings may be enacted, promulgated or issued, which could result in an increase in our or our stockholders&#8217; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Industry </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit our commercialization of any investigational products that we may develop. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of our investigational products in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. If we cannot successfully defend ourselves against claims that our investigational products or products caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, product liability claims may result in: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delay or termination of clinical trials; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">decreased demand for any investigational products or products that we may develop; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">injury to our reputation and significant negative media attention; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">withdrawal of clinical trial subjects; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">initiation of investigations by regulators; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">significant costs to defend the related litigation and diversion of management&#8217;s time and our resources;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">substantial monetary awards to study subjects or patients; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">loss of revenue; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the inability to commercialize any products that we may develop. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain product liability insurance coverage, it may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as our investigational products advance through clinical trials and if we successfully commercialize any products. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to comply with data privacy and data protection laws, regulations, or other obligations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We and third parties upon whom we rely may be subject to federal, state, and foreign data protection, privacy, and information security laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations. In the U.S., numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">subject to privacy and security requirements under Health Insurance Portability and Accountability Act ("HIPAA"). While we do not believe that we are currently acting as a covered entity or business associate under HIPAA and thus are not directly regulated under HIPAA, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The legislative and regulatory landscape for privacy and data security continues to evolve, and we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data security in the U.S., the European Union (the "EU"), the United Kingdom (the "UK") and other jurisdictions. This increased focus on privacy and data security issues may negatively affect our operating results and our business. For example, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020 (collectively, "CCPA") applies to personal information of consumers, business representatives, and employees who are California residents, and requires businesses to provide specific disclosures in privacy notices and honor requests of such individuals to exercise certain privacy rights. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Foreign data protection laws also apply to health-related and other personal data obtained outside the U.S. The EU General Data Protection Regulation (the "EU GDPR"), the UK General Data Protection Regulation (the "UK GDPR" and, together with the EU GDPR, the "GDPR") and Canada&#8217;s Personal Information Protection and Electronic Documents Act ("PIPEDA"), or the applicable provincial alternatives, impose strict requirements, including the obligation to appoint data protection officers in certain circumstances, rights for individuals to be "forgotten" and to data portability, and the obligation to make public notification of significant data breaches. Under the GDPR, data protection authorities can impose temporary or definitive bans on data processing and other corrective actions or fines of up to 4% of our total worldwide turnover or up to &#8364;20 million under the EU GDPR/&#163;17.5 million under the UK GDPR (in either case, whichever is higher), or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests. In Canada, PIPEDA and various related provincial laws, as well as Canada&#8217;s Anti-Spam Legislation ("CASL"), may apply to our operations. We also target customers in Asia and may be subject to new and emerging data privacy regimes, including China&#8217;s Personal Information Protection Law ("PIPL"). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We also expect that there will continue to be new laws, regulations and industry standards governing the privacy, data protection and information security proposed and enacted in various jurisdictions of consumer health data. For example, Washington&#8217;s My Health My Data Act ("MHMD") broadly defines consumer health data, places restrictions on processing such data (including imposing stringent requirements for consent), provides consumers certain rights with respect to their health data, and creates a private right of action to allow individuals to sue for violations of the law. Consumer health data is defined to include personal information that is linked or reasonably linkable to a consumer and that identifies a consumer&#8217;s past, present, or future physical or mental health status; consumer health data also includes information that is derived or extrapolated from non-health information, such as algorithms and machine learning. Other states, including Connecticut and Nevada, have also passed similar laws regulating consumer health data, and given the increased focus on the use of health data by entities that are not subject to HIPAA, additional states are expected to pass consumer health privacy laws.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we may transfer personal data from Europe and other jurisdictions to the U.S. or other countries. Certain jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, in the European Economic Area ("EEA") and the UK the GDPR restricts the transfer of personal data to the U.S. and other countries whose privacy laws it generally believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the U.S. in compliance with law, such as the EEA standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant organizations based in the U.S. who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the U.S. We expect the existing legal complexity and uncertainty regarding international personal data transfers to continue, and international transfers to the U.S., China, and to other jurisdictions more generally to continue to be subject to enhanced scrutiny by regulators. As the regulatory guidance and enforcement landscape in relation to data transfers continue to develop, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are also bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. For example, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. We publish privacy policies, notices and other statements regarding data privacy and security. If these policies, notices or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators or other adverse consequences.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Obligations related to data privacy and security (and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources, which may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. In addition, these obligations may require us to change our business model. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our failure (or that of the third parties upon whom we rely) to comply with U.S. and foreign data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Claims that we or the third parties upon whom we rely have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis; if viable, these claims carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including, as relevant, clinical trials); inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business operations expose us to broadly applicable fraud and abuse, transparency, government price reporting, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to various U.S. federal and state health care laws, including fraud and abuse, transparency and other healthcare laws and regulations, and similar laws in other jurisdictions in which we conduct our business. These laws may impact, among other things, our research and proposed sales, marketing and education programs and constrain the business of financial arrangements and relationships with healthcare providers, physicians and other parties through which we market, sell and distribute our products for which we obtain marketing approval. The laws that may affect our ability to operate include, but are not limited to the federal Anti-Kickback Statute; federal civil and criminal false claims laws, such as the False Claims Act; HIPAA; federal and state consumer protection and unfair competition laws; the federal transparency requirements under the Physician Payments Sunshine Act ("Sunshine Act"); state and foreign law equivalents of each of these federal laws; and state and foreign laws that require pharmaceutical companies to implement compliance programs. Many of these laws are discussed in detail under "Item 1. Business&#8212;Government Regulation&#8212;Other U.S. Healthcare Laws and Compliance Requirements" in our Annual Report on Form 10-K filed with the SEC on February&#160;25, 2026.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have continued their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Responding to investigations can be time-and resource-consuming and can divert management&#8217;s attention from the business. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. We have entered into consulting and advisory board arrangements with physicians and other healthcare providers, including some who could influence the use of our investigational products, if approved. Because of the complex and far-reaching nature of these laws, regulatory agencies may view these transactions as prohibited arrangements that must be restructured, or discontinued, or for which we could be subject to other significant civil, criminal and administrative penalties such as fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could substantially disrupt our operations. If any of the physicians or other healthcare providers or entities with which we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict, and may have a significant adverse effect on our business and results of operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of investigational products, restrict or regulate post-approval activities, and affect the ability to profitably sell investigational products for which marketing approval is obtained. Among policy makers and payors in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the U.S., the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. Current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we may receive for any investigational products approved for sale. New and changing laws and regulations may also create uncertainty about how such laws and regulations will be interpreted and applied. If we are found to have violated laws and regulations, it could materially adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Various initiatives are discussed in detail under "Item 1. Business&#8212;Government Regulation&#8212;Healthcare Reform" in our Annual Report on Form 10-K filed with the SEC on February&#160;25, 2026. More recently, the OBBBA, which was enacted in July 2025, imposes significant reductions in the funding of the Medicaid program. Such reductions are expected to decrease the number of persons enrolled in Medicaid and reduce the services covered by Medicaid, which could adversely affect our sales of any investigational product that we commercialize.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Trump administration has issued executive orders that address the pricing of pharmaceuticals in the U.S. and propose a so-called most favored nation pricing policy, which would tie the price of drugs in the U.S. to the lowest price in a group of other countries. While it is unclear whether and how the Trump proposals will be implemented, the Trump policies are likely to have a negative impact on the pharmaceutical industry. Even proposals or executive actions that are ultimately deemed unlawful could negatively impact the U.S. pharmaceutical sector and our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the federal government and the individual states in the U.S. have become increasingly active in developing proposals, passing legislation and implementing regulations designed to control drug pricing, including price or patient reimbursement constraints, discounts, formulary flexibility, marketing cost disclosure, drug price increase reporting, and other transparency measures. Some states have enacted legislation creating so-called prescription drug affordability boards, which ultimately may attempt to impose price limits on certain drugs in these states, while some states are also seeking to implement general, across the board price caps for pharmaceuticals, or are seeking to regulate drug distribution. Some measures are designed to encourage importation from other countries. These types of initiatives may result in additional reductions in Medicare, Medicaid, and other healthcare funding, and may otherwise affect the prices we may obtain for our investigational products that receive approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage and payment criteria and in additional downward pressure on the price that we receive for any approved drug. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs. Additional state and federal healthcare reform measures may be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our investigational products or additional pricing pressures. We cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations (collectively, "Trade Laws") prohibit, among other things, companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving (directly or indirectly) corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase over time. We expect to rely on third parties for research, preclinical studies, and clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other marketing approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We, and the third parties with which we share our facilities, are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Each of our operations involves the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Each of our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. We could be held liable for any resulting damages in the event of contamination or injury resulting from the use of hazardous materials by us or the third parties with which we share our facilities, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our R&amp;D. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Owning our Common Stock </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The stock price of our common stock has been and may continue to be volatile or may decline regardless of our operating performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock has fluctuated and may fluctuate significantly in response to numerous factors, many of which are beyond our control, including: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">overall performance of the equity markets; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our operating performance and the performance of other similar companies; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">results from our ongoing clinical trials and future clinical trials with our current and future investigational products or of our competitors; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in our projected operating results that we provide to the public, our failure to meet these projections or changes in recommendations by securities analysts that elect to follow our common stock; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory, trade or legal developments in the U.S. and other countries, including changes in tariffs or other trade restrictions and the changes in the structure of healthcare payment systems; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the level of expenses related to future investigational products or clinical development programs; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our failure to achieve product development goals in the timeframe we announce; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">announcements of acquisitions, strategic alliances or significant agreements by us or by our competitors; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">recruitment or departure of key personnel; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the economy as a whole and market conditions in our industry; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">trading activity by a limited number of stockholders who together beneficially own a significant portion of our outstanding common stock; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the size of our market float; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any other factors discussed in this report. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many immuno-oncology ("IO") companies. Stock prices of many IO companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. In the past, stockholders have filed securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business and adversely affect our business. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The amount of our future losses is uncertain and our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly and annual operating results may fluctuate significantly in the future due to a variety of factors, many of which are outside of our control and may be difficult to predict, including the following: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing and success or failure of clinical trials for our investigational products or competing investigational products, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our progress towards the achievement of any product development goals or milestones we announce, including any delays or failures which lead to the suspension or termination of any clinical trial or development program;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing and cost of, and level of investment in, R&amp;D activities relating to our investigational products, which may change from time to time; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">option fees received by us in connection with option exercises by Gilead and/or Taiho pursuant to their respective option agreements and/or payments received by us from Gilead or Taiho in connection with the achievement of certain development and/or regulatory milestones;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">amounts payable by us in connection with the achievement of development, regulatory and commercial milestones under our in-license and other strategic agreements; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to attract, hire and retain qualified personnel; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expenditures that we will or may incur to develop additional investigational products; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to obtain marketing approval for our investigational products, and the timing and scope of any such approvals we may receive; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the changing and volatile U.S. and global economic environments</span><span style="color:#000000;font-family:'Aptos',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">including the impact of tariffs, inflation and rising interest rates, and domestic or international political instability; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">future accounting pronouncements or changes in our accounting policies. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The concentration of our stock ownership will likely limit our stockholders&#8217; ability to influence corporate matters, including the ability to influence the outcome of director elections and other matters requiring stockholder approval. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Based upon shares outstanding as of March&#160;31, 2026, our executive officers, directors and the holders of more than 5% of our outstanding common stock, in the aggregate, beneficially owned approximately 39.3% of our common stock. In particular, as of March&#160;31, 2026, Gilead owns approximately 25.0% of our outstanding common stock and we have appointed its three designees to our board of directors pursuant to the terms of the Investor Rights Agreement. As a result, these stockholders, acting together, have significant influence over all matters that require approval by our stockholders, including the election of directors and approval of significant corporate transactions. Corporate actions might be taken even if other stockholders oppose them. This concentration of ownership might also have the effect of delaying or preventing a change of control of our company that other stockholders may view as beneficial. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our status as a Delaware corporation and the anti-takeover provisions of the Delaware General Corporation Law may discourage, delay or prevent a change in control by prohibiting us from engaging in a business combination with an interested stockholder for a period of three years after the person becomes an interested stockholder, even if a change of control would be beneficial to our existing stockholders. In addition, our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that may make the acquisition of our company more difficult, including the following: </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a classified board of directors with three-year staggered terms, which could delay the ability of stockholders to change the membership of a majority of our board of directors; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ability of our board of directors to issue shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of our board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the requirement that a special meeting of stockholders may be called only by a majority vote of our entire board of directors, the chairman of our board of directors or our chief executive officer, which could delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the requirement for the affirmative vote of holders of at least 66</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> 2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8260;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">% of the voting power of all of the then-outstanding shares of the voting stock, voting together as a single class, to amend the provisions of our amended and restated certificate of incorporation relating to the management of our business or our amended and restated bylaws, which may inhibit the ability of an acquirer to effect such amendments to facilitate an unsolicited takeover attempt; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">advance notice procedures with which stockholders must comply to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of us. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a Delaware corporation, we are subject to Section 203 of the Delaware General Corporation Law. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time. A Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this provision. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including delay or impede a merger, tender offer or proxy contest involving our company. The existence of these provisions could negatively affect the price of our common stock and limit opportunities for our stockholders to realize value in a corporate transaction. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and our bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our bylaws or any action asserting a claim against us that is governed by the internal affairs doctrine. In addition, to prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our bylaws provide that the federal district courts of the U.S. will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees and may discourage these types of lawsuits. While the Delaware courts have determined that these types of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of these provisions, which may require significant additional costs associated with resolving such action in other jurisdictions, and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of substantial amounts of our shares may cause the price of our common stock to decline. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The price of our common stock could decline if there are substantial sales of our common stock, including any sales by us, our directors, executive officers, significant stockholders or the sales agents under the equity distribution agreement, or if there is a large number of shares of our common stock available for sale and the market perceives that sales will occur. We have also registered shares of common stock that we have issued and may issue under our employee equity incentive plans. These shares can be sold freely in the public market upon issuance, subject to vesting conditions and, in the case of our affiliates, volume limitations under Rule 144 under the Securities Act.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired, which could result in sanctions or other penalties that would harm our business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of the New York Stock Exchange. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal controls over financial reporting. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with U.S. GAAP. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. Accordingly, we cannot assure you that we will not in the future identify one or more material weaknesses in our internal control over financial reporting, which may have a negative impact on our ability to timely and accurately produce financial statements, may result in a material misstatement of our Consolidated Financial Statements or may negatively impact the confidence level of our stockholders and other market participants with respect to our reported financial information.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that we have adequate internal controls over financial reporting is a costly and time-consuming effort that needs to be re-evaluated frequently. Further, remote work arrangements have led to changes in work patterns that can make it more difficult to properly perform our controls and may create risks that result in deficiencies in the design of our controls. To the extent necessary, implementing any changes to our internal controls may distract our officers and employees, entail substantial costs to modify our existing processes and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and harm our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="ia317198098a84e059b141ad74d9b0930_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ia317198098a84e059b141ad74d9b0930_127"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ia317198098a84e059b141ad74d9b0930_130"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ia317198098a84e059b141ad74d9b0930_133"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rule 10b5-1 Trading Arrangements</span></div><ix:nonNumeric contextRef="c-1" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-570" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The <ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-571">adoption</ix:nonNumeric>, modification or <ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-572"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-573">termination</ix:nonNumeric></ix:nonNumeric> of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers and directors for the three months ended March&#160;31, 2026, which are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"/><td style="width:31.419%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.868%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.640%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.868%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.868%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.335%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.868%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Name and Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Action</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total Shares to be Sold</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-185" name="ecd:TrdArrIndName" id="f-574">Robert C. Goeltz II</ix:nonNumeric></span></div><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-185" name="ecd:TrdArrIndTitle" id="f-575">Chief Financial Officer</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-185" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-576">Adoption</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-185" name="ecd:TrdArrAdoptionDate" id="f-577">January 26, 2026</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-186" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-578">56,163</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-185" name="ecd:TrdArrExpirationDate" id="f-579">March 31, 2028</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-187" name="ecd:TrdArrIndName" id="f-580">Juan Jaen</ix:nonNumeric></span></div><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-187" name="ecd:TrdArrIndTitle" id="f-581">President</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-187" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-582">Adoption</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-187" name="ecd:TrdArrAdoptionDate" id="f-583">February 27, 2026</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-188" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-584">139,781</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-187" name="ecd:TrdArrExpirationDate" id="f-585">June 4, 2027</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-189" name="ecd:TrdArrIndName" id="f-586">Jennifer Jarrett</ix:nonNumeric></span></div><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-189" name="ecd:TrdArrIndTitle" id="f-587">Chief Operating Officer</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-189" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-588">Adoption</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-189" name="ecd:TrdArrAdoptionDate" id="f-589">January 23, 2026</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-190" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-590">188,277</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-189" name="ecd:TrdArrExpirationDate" id="f-591">November 23, 2026</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="ia317198098a84e059b141ad74d9b0930_139"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The documents listed below are incorporated by reference or are filed with this Quarterly Report on Form 10-Q, in each case as indicated therein (numbered in accordance with Item 601 of Regulation S-K).</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.995%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Incorporated by Reference</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Form</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">File No.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Filing Date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1724521/000156459018012447/rcus-ex31_541.htm">Amended and Restated Certificate of Incorporation</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">001-38419</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">May 9, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1724521/000156459020026867/rcus-ex31_7.htm">Amended and Restated Bylaws</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">001-38419</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">May 26, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex101.htm">Separation Agreement, between the Registrant and Jennifer Jarrett, dated March 20, 2026</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a2026q1exhibit311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a2026q1exhibit312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a2026q1exhibit321.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">32.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a2026q1exhibit322.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Instance Document &#8211; The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (formatted as inline XBRL and contained in exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.5pt">Filed herewith.</span></div><div style="margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.5pt">This certification is deemed furnished but not filed for purposes of section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div style="margin-top:3pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="-sec-extract:summary;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="ia317198098a84e059b141ad74d9b0930_142"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia317198098a84e059b141ad74d9b0930_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARCUS BIOSCIENCES, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">May 5, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Terry Rosen</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Terry Rosen, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Chief Executive Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Principal Executive Officer)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">May 5, 2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Alexander Azoy</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Alexander Azoy</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Chief Accounting Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Principal Accounting Officer)</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i590e8941fba94eb79ee488cdd90f8348_1"></div><div style="min-height:99.36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 10.1</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">March 20, 2026</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Jennifer Jarrett</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Dear Ms. Jarrett&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">This letter sets forth the substance of your separation and release agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) with Arcus Biosciences, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in connection with your resignation from the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">SEPARATION. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Your last day of work with the Company and your employment termination date will be March 30, 2026 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Separation Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  You resign your position of Chief Operating Officer of the Company effective on the Separation Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">ACCRUED SALARY AND PAID TIME OFF.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> On the Separation Date, the Company will pay you all accrued salary and all accrued and unused vacation earned through the Separation Date, subject to standard payroll deductions and withholdings. You are entitled to this payment by law.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">ADVISORY SERVICES. </font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(a).</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.7pt">You and the Company have agreed that you will make yourself available for periodic calls with the Company for a period through June 30, 2026 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Advisory Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) following your Separation Date in order to support an orderly transition of your responsibilities (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Advisory Services</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). In consideration for such Advisory Services to the Company, the Company will extend the post-termination option exercise period for each of your currently outstanding Company stock options during which you may continue to exercise any vested options from three (3) months to twelve (12) months from the Separation Date. You acknowledge and agree that all equity awards held by you will cease vesting as of the Separation Date and the unvested portions thereof shall be forfeited as of the Separation Date.  This Agreement documents the amendment of your vested options on the terms set forth in this paragraph. You acknowledge that each &#8220;incentive stock option&#8221; within the meaning of Section 422 of the Internal Revenue Service of 1986, as amended, shall cease to constitute an incentive stock option upon your signature to this Agreement (or, if earlier, the 30th day after you receive a copy of this Agreement) and will no longer be eligible for the potential tax advantages associated with incentive stock options. In all other respects, your equity awards shall continue to be governed by their respective grant notices, stock option agreements, RSU agreements and plan documents.</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(b).</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.02pt">You acknowledge and agree that there is no additional consideration specifically attributable to your Advisory Services. Furthermore, during the Advisory Period, you will have no responsibilities to, or authority to act on behalf of, the Company other than to be reasonably available to provide advisory services as requested by the Company during the Advisory Period. You will have no authority to bind the Company to any contractual obligations, whether written, oral or implied, except with the prior written </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.36pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Page 2</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">authorization of an officer of the Company. You agree not to represent or purport to represent the Company in any manner whatsoever to any third party unless authorized in advance by the Company, in writing, to do so.</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(c).</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.7pt">By your signature below, you further represent, warrant and covenant that the Advisory Services will not conflict with any obligations to your subsequent employer during the Advisory Period or if such third-party consent is required, that such consent has been properly obtained prior to your execution of this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">OTHER COMPENSATION OR BENEFITS.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> You acknowledge that, except as expressly provided in this Agreement, you have not earned and will not receive from the Company any additional compensation (including base salary, bonus, incentive compensation, or equity), severance, or benefits before or after the Separation Date, with the exception of any vested right you may have under the express terms of a written ERISA-qualified benefit plan (e.g., 401(k) account) or any vested stock options.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">EXPENSE REIMBURSEMENTS.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> You agree that, within ten (10) days after the Separation Date, you will submit your final documented expense reimbursement statement reflecting all business expenses you incurred through the Separation Date, if any, for which you seek reimbursement. The Company will reimburse you for these expenses pursuant to its regular business practice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">RELEASE OF CLAIMS. </font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(a).</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:19.7pt">General Release of Claims. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> In exchange for the consideration provided to you under this Agreement to which you would not otherwise be entitled, you hereby generally and completely release the Company, and its affiliated, related, parent and subsidiary entities, and its and their current and former directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, insurers, affiliates, and assigns from any and all claims, liabilities, demands, causes of action, and obligations, both known and unknown, arising from or in any way related to events, acts, conduct, or omissions occurring at any time prior to and including the date you sign this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(b).</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:19.02pt">Scope of Release. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> This general release includes, but is not limited to&#58; (i) all claims arising from or in any way related to your employment with the Company or the termination of that employment&#59; (ii) all claims related to your compensation or benefits from the Company, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership, equity, or profits interests in the Company&#59; (iii)&#160;all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing&#59; (iv)&#160;all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy&#59; and (v) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys&#8217; fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the California Labor Code (as amended), the California Family Rights Act, the Age Discrimination in Employment Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">ADEA</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and the California Fair </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.36pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Page 3</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Employment and Housing Act (as amended). </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">You acknowledge that you have been advised, as required by California Government Code Section 12964.5(b)(4), that you have the right to consult an attorney regarding this Agreement and that you were given a reasonable time period of not less than five business days in which to do so.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> You further acknowledge and agree that, in the event you sign this Agreement prior to the end of the reasonable time period provided by the Company, your decision to accept such shortening of time is knowing and voluntary and is not induced by the Company through fraud, misrepresentation, or a threat to withdraw or alter the offer prior to the expiration of the reasonable time period, or by providing different terms to employees who sign such an agreement prior to the expiration of the time period.</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(c).</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:19.7pt">ADEA Release.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> You acknowledge that you are knowingly and voluntarily waiving and releasing any rights you have under the ADEA, and that the consideration given for the waiver and releases you have given in this Agreement is in addition to anything of value to which you were already entitled. You further acknowledge that you have been advised, as required by the ADEA, that&#58; (i) your waiver and release does not apply to any rights or claims arising after the date you sign this Agreement&#59; (ii) you should consult with an attorney prior to signing this Agreement (although you may choose voluntarily not to do so)&#59; (iii) you have twenty-one (21) days to consider this Agreement (although you may choose voluntarily to sign it sooner)&#59; (iv) you have seven (7) days following the date you sign this Agreement to revoke this Agreement (in a written revocation sent to the Company)&#59; and (v)&#160;this Agreement will not be effective until the date upon which the revocation period has expired, which will be the eighth day after you sign this Agreement provided that you do not revoke it (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(d).</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:19.02pt">Section 1542 Waiver.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> In giving the release herein, which includes claims which may be unknown to you at present, you acknowledge that you have read and understand Section 1542 of the California Civil Code, which reads as follows&#58;  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;  You hereby expressly waive and relinquish all rights and benefits under that section and any law of any other jurisdiction of similar effect with respect to your release of claims herein, including but not limited to your release of unknown claims.</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(e).</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:19.7pt">Exceptions.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">  Notwithstanding the foregoing, you are not releasing the Company hereby from&#58; (i) any obligation to indemnify you pursuant to the Articles and Bylaws of the Company, any valid fully executed indemnification agreement with the Company, applicable law, or applicable directors and officers liability insurance&#59; (ii) any claims that cannot be waived by law&#59; or (iii) any claims for breach of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(f).</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.03pt">Protected Rights.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">  You understand that nothing in this Agreement limits your ability to file a charge or complaint with the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.36pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Page 4</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">the Occupational Safety and Health Administration, the California Department of Fair Employment and Housing, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Government Agencies</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). You further understand this Agreement does not limit your ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. While this Agreement does not limit your right to receive an award for information provided to the Securities and Exchange Commission, you understand and agree that, to the maximum extent permitted by law, you are otherwise waiving any and all rights you may have to individual relief based on any claims that you have released and any rights you have waived by signing this Agreement.  Nothing in this Agreement (i) prevents you from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that you have reason to believe is unlawful&#59; or (ii) waives any rights you may have under Section 7 of the National Labor Relations Act to engage in protected concerted activity, including speech.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">RETURN OF COMPANY PROPERTY.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> You represent and warrant that you have returned to the Company all Company documents (and all copies thereof) and other Company property in your possession or control, including, but not limited to, Company files, notes, drawings, records, plans, forecasts, reports, studies, analyses, proposals, agreements, drafts, financial and operational information, research and development information, sales and marketing information, customer lists, prospect information, pipeline reports, sales reports, personnel information, specifications, code, software, databases, computer-recorded information, tangible property and equipment (including, but not limited to, computing and electronic devices, mobile telephones, servers), credit cards, entry cards, identification badges and keys&#59; and any materials of any kind which contain or embody any proprietary or confidential information of the Company (and all reproductions or embodiments thereof in whole or in part). You further represent that you have made a diligent search to locate any such documents, property and information. If you have used any personally owned computer or other electronic device, server, or e-mail system to receive, store, review, prepare or transmit any Company confidential or proprietary data, materials or information, within five (5) days after the Separation Date, you shall provide the Company with a computer-useable copy of such information and then permanently delete and expunge such Company confidential or proprietary information from those systems&#59; and you agree to provide the Company access to your system as requested to verify that the necessary copying and&#47;or deletion is completed. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Your timely compliance with this paragraph is a condition to your receipt of the benefits provided under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">CONFIDENTIAL INFORMATION OBLIGATIONS.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> You acknowledge and reaffirm your continuing obligations under your Proprietary Information and Inventions Agreement, a copy of which is attached hereto as Exhibit&#160;A and incorporated herein by reference.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">NON-DISPARAGEMENT.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> Except to the extent permitted by the Protected Rights Section above, you agree not to disparage the Company, its officers, directors, employees, shareholders, parents, subsidiaries, affiliates, and agents, in any manner likely to be harmful to its or their business, business reputation, or personal reputation&#59; provided that you may respond accurately and fully to any request for information if required by legal process or in connection with a government investigation. In addition, nothing in this provision or this Agreement </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.36pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Page 5</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">prohibits or restrains you from making disclosures protected under the whistleblower provisions of federal or state law or from exercising your rights to engage in protected speech under Section 7 of the National Labor Relations Act, if applicable. The Company agrees not to, and will instruct its directors and executive officers not to, disparage you in any manner likely to be harmful to your business or personal reputation&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided that</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> the Company and its directors and employees may respond accurately and fully to any request for information if required by legal process or in connection with a government investigation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">NO VOLUNTARY ADVERSE ACTION. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">You agree that you will not voluntarily (except in response to legal compulsion or as permitted under the section of this Agreement entitled &#8220;Protected Rights&#8221;) assist any person in bringing or pursuing any proposed or pending litigation, arbitration, administrative claim or other formal proceeding against the Company, its parent or subsidiary entities, affiliates, officers, directors, employees or agents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">COOPERATION. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">You agree to cooperate fully with the Company in connection with its actual or contemplated defense, prosecution, or investigation of any claims or demands by or against third parties, or other matters arising from events, acts, or failures to act that occurred during the period of your employment by the Company. Such cooperation includes, without limitation, making yourself available to the Company upon reasonable notice, without subpoena, to provide complete, truthful and accurate information in witness interviews, depositions, and trial testimony. The Company will reimburse you for reasonable out-of-pocket expenses you incur in connection with any such cooperation (excluding foregone wages) and will make reasonable efforts to accommodate your scheduling needs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">NO ADMISSIONS. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">You understand and agree that the promises and payments in consideration of this Agreement shall not be construed to be an admission of any liability or obligation by the Company to you or to any other person, and that the Company makes no such admission.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">REPRESENTATIONS. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">You hereby represent that you have&#58; been paid all compensation owed and for all hours worked&#59; received all leave and leave benefits and protections for which you are eligible pursuant to the Family and Medical Leave Act, the California Family Rights Act, or otherwise&#59; and not suffered any on-the-job injury for which you have not already filed a workers&#8217; compensation claim.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">DISPUTE RESOLUTION.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> You and the Company agree that any and all disputes, claims, or controversies of any nature whatsoever arising from, or relating to, this Agreement or its interpretation, enforcement, breach, performance or execution, your employment or the termination of such employment (including, but not limited to, any statutory claims) (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Claims</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Claim</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), shall be resolved, pursuant to the Federal Arbitration Act, 9 U.S.C. &#167;1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration in a mutually acceptable location conducted before a single neutral arbitrator by JAMS, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">JAMS</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or its successor, under the then applicable JAMS Arbitration Rules and Procedures for Employment Disputes (available at http&#58;&#47;&#47;www.jamsadr.com&#47;rules-employment-arbitration&#47;).  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">By agreeing to this arbitration procedure, both you and the Company waive the right to have any Claim resolved through a trial by jury or judge or an administrative proceeding.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">  You will have the right to be represented by legal counsel at any arbitration proceeding, at your own expense.  This paragraph shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended, to the extent such claims are not permitted by applicable law to be submitted to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.36pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Page 6</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">mandatory arbitration and the applicable law(s) are not preempted by the Federal Arbitration Act or otherwise invalid (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Excluded Claims</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  In the event you intend to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be publicly filed with a court, while any other claims will remain subject to mandatory arbitration.  The arbitrator shall have sole authority for determining if a Claim is subject to arbitration, and any other procedural questions related to the dispute and bearing on the final disposition.  In addition, the arbitrator shall&#58;  (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding&#59; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator&#8217;s essential findings and conclusions on which the award is based.  The Company shall pay all JAMS arbitration fees. Nothing in this Agreement shall prevent you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any arbitration.  Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">MISCELLANEOUS.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> This Agreement, including Exhibit A, constitutes the complete, final and exclusive embodiment of the entire agreement between you and the Company with regard to its subject matter. It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations. This Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company.  This Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns. If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Agreement and the provision in question will be modified by the court so as to be rendered enforceable to the fullest extent permitted by law, consistent with the intent of the parties. This Agreement will be deemed to have been entered into and will be construed and enforced in accordance with the laws of the State of California without regard to conflict of laws principles. Any ambiguity in this Agreement shall not be construed against either party as the drafter. Any waiver of a breach of this Agreement shall be in writing and shall not be deemed to be a waiver of any successive breach. This Agreement may be executed in counterparts and electronic or facsimile signatures will suffice as original signatures.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">If this Agreement is acceptable to you, please sign below and return the original to me. You have twenty-one (21) calendar days to decide whether to accept this Agreement, and the Company&#8217;s offer contained herein will automatically expire if you do not sign and return it within that timeframe.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">We wish you the best in your future endeavors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Sincerely,</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Terry Rosen&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Terry Rosen</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">CEO</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:99.36pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Page 7</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:24pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">I HAVE READ, UNDERSTAND AND AGREE FULLY TO THE FOREGOING AGREEMENT&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jennifer Jarrett&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Jennifer Jarrett</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">March 22, 2026&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Date</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><div id="i590e8941fba94eb79ee488cdd90f8348_4"></div><hr style="page-break-after:always"><div style="min-height:85.68pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">EMPLOYEE CONFIDENTIAL INFORMATION</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">AND INVENTIONS ASSIGNMENT AGREEMENT</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>a2026q1exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i7b3ee5878e504cd4a182acc5e5f8d34e_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Terry Rosen, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Form 10-Q of Arcus Biosciences, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;5, 2026</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Terry Rosen</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Terry Rosen, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>a2026q1exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i53bca2f7512447a9888e78837865c171_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Robert C. Goeltz II, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Form 10-Q of Arcus Biosciences, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;5, 2026</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert C. Goeltz II</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Robert C. Goeltz II</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>a2026q1exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="id483191689c04304bbeb1cdde96e3b38_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Arcus Biosciences, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending March&#160;31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;5, 2026</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Terry Rosen</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Terry Rosen, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>a2026q1exhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i0e14e9ceec574b2bbbd5e9f2d04d35b4_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Arcus Biosciences, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending March&#160;31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;5, 2026</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert C. Goeltz II</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Robert C. Goeltz II</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>rcus-20260331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019cd33b-55e2-7686-a45d-3e64ec40f088,g:5cd5bcae-d38e-4438-9e12-43823d2921f9-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rcus="http://arcusbio.com/20260331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://arcusbio.com/20260331">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rcus-20260331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rcus-20260331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rcus-20260331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rcus-20260331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://arcusbio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>9952151 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsParenthetical" roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical">
        <link:definition>9952152 - Statement - Condensed Consolidated Statements of Operations (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>9952153 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>9952154 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952155 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>9952156 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>9952157 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsParenthetical" roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical">
        <link:definition>9952158 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationLiquidityandCapitalResources" roleURI="http://arcusbio.com/role/OrganizationLiquidityandCapitalResources">
        <link:definition>9952159 - Disclosure - Organization, Liquidity and Capital Resources</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://arcusbio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952160 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyGileadSciencesInc" roleURI="http://arcusbio.com/role/RelatedPartyGileadSciencesInc">
        <link:definition>9952161 - Disclosure - Related Party - Gilead Sciences, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborations" roleURI="http://arcusbio.com/role/LicenseandCollaborations">
        <link:definition>9952162 - Disclosure - License and Collaborations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://arcusbio.com/role/Revenues">
        <link:definition>9952163 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://arcusbio.com/role/IncomeTaxes">
        <link:definition>9952164 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://arcusbio.com/role/NetLossPerShare">
        <link:definition>9952165 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://arcusbio.com/role/StockBasedCompensation">
        <link:definition>9952166 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandMarketableSecurities" roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecurities">
        <link:definition>9952167 - Disclosure - Cash, Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetComponents" roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponents">
        <link:definition>9952168 - Disclosure - Condensed Consolidated Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://arcusbio.com/role/LongTermDebt">
        <link:definition>9952169 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://arcusbio.com/role/Leases">
        <link:definition>9952170 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://arcusbio.com/role/StockholdersEquity">
        <link:definition>9952171 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://arcusbio.com/role/FairValueMeasurements">
        <link:definition>9952172 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessSegment" roleURI="http://arcusbio.com/role/BusinessSegment">
        <link:definition>9952173 - Disclosure - Business Segment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://arcusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://arcusbio.com/role/RevenuesTables">
        <link:definition>9955512 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://arcusbio.com/role/NetLossPerShareTables">
        <link:definition>9955513 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://arcusbio.com/role/StockBasedCompensationTables">
        <link:definition>9955514 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandMarketableSecuritiesTables" roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesTables">
        <link:definition>9955515 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetComponentsTables" roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsTables">
        <link:definition>9955516 - Disclosure - Condensed Consolidated Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtTables" roleURI="http://arcusbio.com/role/LongTermDebtTables">
        <link:definition>9955517 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://arcusbio.com/role/LeasesTables">
        <link:definition>9955518 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://arcusbio.com/role/FairValueMeasurementsTables">
        <link:definition>9955519 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessSegmentTables" roleURI="http://arcusbio.com/role/BusinessSegmentTables">
        <link:definition>9955520 - Disclosure - Business Segment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails" roleURI="http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails">
        <link:definition>9955521 - Disclosure - Organization, Liquidity and Capital Resources - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyGileadSciencesIncDetails" roleURI="http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails">
        <link:definition>9955522 - Disclosure - Related Party - Gilead Sciences, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationsDetails" roleURI="http://arcusbio.com/role/LicenseandCollaborationsDetails">
        <link:definition>9955523 - Disclosure - License and Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails" roleURI="http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails">
        <link:definition>9955524 - Disclosure - Revenues - Summary of Revenues by Collaboration, Category of Revenue and Method of Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesAdditionalInformationDetails" roleURI="http://arcusbio.com/role/RevenuesAdditionalInformationDetails">
        <link:definition>9955525 - Disclosure - Revenues - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesSummaryofRevenueRecognizedasaResultofChangesinDeferredRevenueDetails" roleURI="http://arcusbio.com/role/RevenuesSummaryofRevenueRecognizedasaResultofChangesinDeferredRevenueDetails">
        <link:definition>9955526 - Disclosure - Revenues - Summary of Revenue Recognized as a Result of Changes in Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails" roleURI="http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails">
        <link:definition>9955527 - Disclosure - Revenues - Summary of Transaction Price and Allocation of Transaction Price to the Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetIncomeLossperShareDetails" roleURI="http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetIncomeLossperShareDetails">
        <link:definition>9955528 - Disclosure - Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Income (Loss) per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationDetails" roleURI="http://arcusbio.com/role/StockBasedCompensationDetails">
        <link:definition>9955529 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails" roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails">
        <link:definition>9955530 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Our Cash, Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandMarketableSecuritiesSummaryofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesDetails" roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesDetails">
        <link:definition>9955531 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Summary of Fair Values of Our Cash, Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetails" roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>9955532 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandMarketableSecuritiesSummaryofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>9955533 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Summary of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails" roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails">
        <link:definition>9955534 - Disclosure - Condensed Consolidated Balance Sheet Components - Summary of Prepaid and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails" roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails">
        <link:definition>9955535 - Disclosure - Condensed Consolidated Balance Sheet Components - Summary of Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtSummaryofLongTermDebtInstrumentsDetails" roleURI="http://arcusbio.com/role/LongTermDebtSummaryofLongTermDebtInstrumentsDetails">
        <link:definition>9955536 - Disclosure - Long-Term Debt - Summary of Long-Term Debt Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtAdditionalInformationDetails" roleURI="http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails">
        <link:definition>9955537 - Disclosure - Long-Term Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofCashandNoncashInformationRelatedtoOperatingLeasesDetails" roleURI="http://arcusbio.com/role/LeasesSummaryofCashandNoncashInformationRelatedtoOperatingLeasesDetails">
        <link:definition>9955538 - Disclosure - Leases - Summary of Cash and Non-cash Information Related to Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://arcusbio.com/role/LeasesAdditionalInformationDetails">
        <link:definition>9955539 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://arcusbio.com/role/StockholdersEquityDetails">
        <link:definition>9955540 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://arcusbio.com/role/FairValueMeasurementsDetails">
        <link:definition>9955541 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessSegmentAdditionalInformationDetails" roleURI="http://arcusbio.com/role/BusinessSegmentAdditionalInformationDetails">
        <link:definition>9955542 - Disclosure - Business Segment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessSegmentSummaryofSegmentReportingInformationDetails" roleURI="http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails">
        <link:definition>9955543 - Disclosure - Business Segment - Summary of Segment Reporting Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="rcus_LicenseAndDevelopmentServicesMember" abstract="true" name="LicenseAndDevelopmentServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_OtherCollaborationRevenueMember" abstract="true" name="OtherCollaborationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_InterestAndOtherIncomeExpenseNonoperatingNet" abstract="false" name="InterestAndOtherIncomeExpenseNonoperatingNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_ResearchAndDevelopmentExpenseRecoveries" abstract="false" name="ResearchAndDevelopmentExpenseRecoveries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_EquityAwardProgramsMember" abstract="true" name="EquityAwardProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_ProceedsFromMaturityOfMarketableSecurities" abstract="false" name="ProceedsFromMaturityOfMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_ProceedsFromSaleOfMarketableSecurities" abstract="false" name="ProceedsFromSaleOfMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_LicenseAndCollaborationAgreementsAbstract" abstract="true" name="LicenseAndCollaborationAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract" abstract="true" name="CashCashEquivalentsAndMarketableSecuritiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock" abstract="false" name="ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock" abstract="false" name="ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" abstract="false" name="FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rcus_OrganizationTable" abstract="true" name="OrganizationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember" abstract="true" name="CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_OrganizationLineItems" abstract="true" name="OrganizationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rcus_CommonStockPurchaseAgreementMember" abstract="true" name="CommonStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_OptionLicenseAndCollaborationAgreementMember" abstract="true" name="OptionLicenseAndCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_AmendedGileadCollaborationAgreementMember" abstract="true" name="AmendedGileadCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_GileadSciencesIncMember" abstract="true" name="GileadSciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_SaleOfStockNumberOfSharesAcquiredInTransaction" abstract="false" name="SaleOfStockNumberOfSharesAcquiredInTransaction" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rcus_NumberOfBoardMembers" abstract="false" name="NumberOfBoardMembers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rcus_PercentageOfOutstandingCommonStockOwned" abstract="false" name="PercentageOfOutstandingCommonStockOwned" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rcus_CollaborationTermForCurrentAndFutureClinicalPrograms" abstract="false" name="CollaborationTermForCurrentAndFutureClinicalPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rcus_OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement" abstract="false" name="OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement" abstract="false" name="OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement" abstract="false" name="OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement" abstract="false" name="OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_UpfrontCashPayment" abstract="false" name="UpfrontCashPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_NumberOfExerciseOptionToPrograms" abstract="false" name="NumberOfExerciseOptionToPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rcus_OptionPaymentReceived" abstract="false" name="OptionPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_RemoveOptionContinuationPaymentUnderAgreement" abstract="false" name="RemoveOptionContinuationPaymentUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab" abstract="false" name="PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption" abstract="false" name="OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_NumberOfResearchPrograms" abstract="false" name="NumberOfResearchPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rcus_OptionPaymentUponCompletionOfCertainINDEnablingActivities" abstract="false" name="OptionPaymentUponCompletionOfCertainINDEnablingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones" abstract="false" name="OptionPaymentUponAchievementOfCertainDevelopmentMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments" abstract="false" name="NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rcus_TotalUpfrontCashPayment" abstract="false" name="TotalUpfrontCashPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_RegulatoryAndCommercialMilestonePaymentsReceived" abstract="false" name="RegulatoryAndCommercialMilestonePaymentsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts" abstract="false" name="RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_LicenseAndCollaborationAgreementsTable" abstract="true" name="LicenseAndCollaborationAgreementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="rcus_TaihoPharmaceuticalCoLtdMember" abstract="true" name="TaihoPharmaceuticalCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_STAR221DevelopmentActivitiesMember" abstract="true" name="STAR221DevelopmentActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_STAR121DevelopmentActivitiesMember" abstract="true" name="STAR121DevelopmentActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_AbmunoLicenseAgreementMember" abstract="true" name="AbmunoLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_WuXiBiologicsLicenseAgreementMember" abstract="true" name="WuXiBiologicsLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_OptionAndLicenseAgreementMember" abstract="true" name="OptionAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_TaihoCollaborationAgreementMember" abstract="true" name="TaihoCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_AstraZenecaAgreementMember" abstract="true" name="AstraZenecaAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_AntiPDOneMember" abstract="true" name="AntiPDOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_AntiCDThirtyNineMember" abstract="true" name="AntiCDThirtyNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_LicenseAndCollaborationAgreementsLineItems" abstract="true" name="LicenseAndCollaborationAgreementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rcus_OptionPeriod" abstract="false" name="OptionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rcus_NonRefundableAndNonCreditableCashPayments" abstract="false" name="NonRefundableAndNonCreditableCashPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_PaymentForOptionsExercised" abstract="false" name="PaymentForOptionsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement" abstract="false" name="AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_ContingentMilestonePaymentsReceivable" abstract="false" name="ContingentMilestonePaymentsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_RoyaltiesPayableTerm" abstract="false" name="RoyaltiesPayableTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rcus_MilestonePayments" abstract="false" name="MilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_ReimbursementOfResearchAndDevelopmentExpense" abstract="false" name="ReimbursementOfResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_ClinicalRegulatoryMilestonePayments" abstract="false" name="ClinicalRegulatoryMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_ClinicalRegulatoryAndCommercializationMilestonePayments" abstract="false" name="ClinicalRegulatoryAndCommercializationMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments" abstract="false" name="AdditionalClinicalRegulatoryAndCommercializationMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_MilestoneExpense" abstract="false" name="MilestoneExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_RDServicesMember" abstract="true" name="RDServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_AccessRightsMember" abstract="true" name="AccessRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_OtherServicesMember" abstract="true" name="OtherServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_GileadCollaborationMember" abstract="true" name="GileadCollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_TaihoCollaborationMember" abstract="true" name="TaihoCollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_AccessRightsAndOptionContinuationPeriodsMember" abstract="true" name="AccessRightsAndOptionContinuationPeriodsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_RightsToCertainStudiesMember" abstract="true" name="RightsToCertainStudiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember" abstract="true" name="ResearchAndDevelopmentActivitiesForInflammationProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice" abstract="false" name="ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_DeferredRevenueNonRefundablePayment" abstract="false" name="DeferredRevenueNonRefundablePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_CurrentAndFutureProgramsExclusiveAccessPeriod" abstract="false" name="CurrentAndFutureProgramsExclusiveAccessPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement" abstract="false" name="OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_PaymentForOptionExercise" abstract="false" name="PaymentForOptionExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_DevelopmentServicesMember" abstract="true" name="DevelopmentServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_CorporateSecuritiesAndCommercialPaperMember" abstract="true" name="CorporateSecuritiesAndCommercialPaperMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_CashCashEquivalentsAndAvailableForSaleInvestments" abstract="false" name="CashCashEquivalentsAndAvailableForSaleInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_PrepaidExpensesAndOtherCurrentAssets" abstract="false" name="PrepaidExpensesAndOtherCurrentAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_AccruedResearchAndDevelopmentExpensesCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_HerculesAgreementMember" abstract="true" name="HerculesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_DebtInstrumentTrancheTypeAxis" abstract="true" name="DebtInstrumentTrancheTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="rcus_DebtInstrumentTrancheTypeDomain" abstract="true" name="DebtInstrumentTrancheTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_TrancheOneMember" abstract="true" name="TrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_TrancheTwoMember" abstract="true" name="TrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_DebtInstrumentAdditionalCommittedAmount" abstract="false" name="DebtInstrumentAdditionalCommittedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_DebtInstrumentFaceAmountContingentlyAvailable" abstract="false" name="DebtInstrumentFaceAmountContingentlyAvailable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_DebtInstrumentMilestoneAchievementPeriod" abstract="false" name="DebtInstrumentMilestoneAchievementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" abstract="false" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_LateStageDevelopmentPrograms" abstract="false" name="LateStageDevelopmentPrograms" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_EarlyStageDevelopmentAndPreclinicalPrograms" abstract="false" name="EarlyStageDevelopmentAndPreclinicalPrograms" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_PartnershipReimbursements" abstract="false" name="PartnershipReimbursements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rcus_RobertC.GoeltzIIMember" abstract="true" name="RobertC.GoeltzIIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_JuanJaenMember" abstract="true" name="JuanJaenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rcus_JenniferJarrettMember" abstract="true" name="JenniferJarrettMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>rcus-20260331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019cd33b-55e2-7686-a45d-3e64ec40f088,g:5cd5bcae-d38e-4438-9e12-43823d2921f9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item"/>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="rcus-20260331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cd33b-5697-7292-ad07-87399312528e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019cd33b-5697-7120-a40b-eb478a171dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019cd33b-5697-7292-ad07-87399312528e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019cd33b-5697-7120-a40b-eb478a171dcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cd33b-5697-7709-82a0-f39dfce86eff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019cd33b-5697-7292-ad07-87399312528e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cd33b-5697-7709-82a0-f39dfce86eff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cd33b-5697-7328-a43f-ad403ce91760" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019cd33b-5697-7a4e-95ae-eabc7e89329d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cd33b-5697-7328-a43f-ad403ce91760" xlink:to="loc_us-gaap_OperatingIncomeLoss_019cd33b-5697-7a4e-95ae-eabc7e89329d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019cd33b-5697-7809-9720-21f9b8472467" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cd33b-5697-7328-a43f-ad403ce91760" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019cd33b-5697-7809-9720-21f9b8472467" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019cd33b-5697-71c1-8e0e-cb3f431a351a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019cd33b-5697-7763-b07f-d4ec73fe21a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_019cd33b-5697-71c1-8e0e-cb3f431a351a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019cd33b-5697-7763-b07f-d4ec73fe21a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019cd33b-5697-7bb9-9d52-5da63fe3b146" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_019cd33b-5697-71c1-8e0e-cb3f431a351a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019cd33b-5697-7bb9-9d52-5da63fe3b146" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019cd33b-5697-702f-9d30-2d5a9b19faaf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_InterestAndOtherIncomeExpenseNonoperatingNet_019cd33b-5697-72b7-b509-47f0fdc58998" xlink:href="rcus-20260331.xsd#rcus_InterestAndOtherIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_019cd33b-5697-702f-9d30-2d5a9b19faaf" xlink:to="loc_rcus_InterestAndOtherIncomeExpenseNonoperatingNet_019cd33b-5697-72b7-b509-47f0fdc58998" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_019cd33b-5697-7322-8b06-9b9dbbf725c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_019cd33b-5697-702f-9d30-2d5a9b19faaf" xlink:to="loc_us-gaap_InterestExpenseNonoperating_019cd33b-5697-7322-8b06-9b9dbbf725c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019cd33b-5697-73b4-96c7-adf608c33bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019cd33b-5697-7026-9183-f85a343546cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_019cd33b-5697-73b4-96c7-adf608c33bf8" xlink:to="loc_us-gaap_OperatingExpenses_019cd33b-5697-7026-9183-f85a343546cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019cd33b-5697-72b6-a6b8-9ea348f20ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_019cd33b-5697-73b4-96c7-adf608c33bf8" xlink:to="loc_us-gaap_Revenues_019cd33b-5697-72b6-a6b8-9ea348f20ee8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="rcus-20260331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_019cd33b-5697-7ad5-bd0e-c3e851d3e7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cd33b-5697-7a31-9069-46fbc5716acc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019cd33b-5697-7ad5-bd0e-c3e851d3e7fa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cd33b-5697-7a31-9069-46fbc5716acc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cd33b-5697-7d8d-b302-e0958ef2ac19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_019cd33b-5697-7ad5-bd0e-c3e851d3e7fa" xlink:to="loc_us-gaap_NetIncomeLoss_019cd33b-5697-7d8d-b302-e0958ef2ac19" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="rcus-20260331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cd33b-5697-7ccb-a29f-87df85b69a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_019cd33b-5697-7792-bc4b-0563b42fd08e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cd33b-5697-7ccb-a29f-87df85b69a3a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_019cd33b-5697-7792-bc4b-0563b42fd08e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019cd33b-5697-77e3-ba4d-99e0961384f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cd33b-5697-7ccb-a29f-87df85b69a3a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019cd33b-5697-77e3-ba4d-99e0961384f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_019cd33b-5697-760a-abd0-ad500d032193" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cd33b-5697-7ccb-a29f-87df85b69a3a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_019cd33b-5697-760a-abd0-ad500d032193" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019cd33b-5697-7656-bc58-106bf8eca5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cd33b-5697-7ccb-a29f-87df85b69a3a" xlink:to="loc_us-gaap_StockholdersEquity_019cd33b-5697-7656-bc58-106bf8eca5bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_019cd33b-5697-7807-84ce-2a968ec82252" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cd33b-5697-7ccb-a29f-87df85b69a3a" xlink:to="loc_us-gaap_LongTermDebt_019cd33b-5697-7807-84ce-2a968ec82252" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019cd33b-5697-780e-b531-70e67c36057f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cd33b-5697-7ccb-a29f-87df85b69a3a" xlink:to="loc_us-gaap_LiabilitiesCurrent_019cd33b-5697-780e-b531-70e67c36057f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019cd33b-5697-7b76-897b-4a1ea4d55145" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019cd33b-5697-7f7f-b10d-dc2324f50fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019cd33b-5697-7b76-897b-4a1ea4d55145" xlink:to="loc_us-gaap_AssetsCurrent_019cd33b-5697-7f7f-b10d-dc2324f50fb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_019cd33b-5697-713f-ac04-53d32225a19c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019cd33b-5697-7b76-897b-4a1ea4d55145" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_019cd33b-5697-713f-ac04-53d32225a19c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019cd33b-5697-779a-b6d3-f193fa4d0e61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019cd33b-5697-7b76-897b-4a1ea4d55145" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019cd33b-5697-779a-b6d3-f193fa4d0e61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_019cd33b-5697-7a00-b1f9-2c05484630f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_019cd33b-5697-7b76-897b-4a1ea4d55145" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_019cd33b-5697-7a00-b1f9-2c05484630f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019cd33b-5697-7322-9aeb-82568da42249" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cd33b-5697-7516-acfd-826c1a8c6d31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019cd33b-5697-7322-9aeb-82568da42249" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cd33b-5697-7516-acfd-826c1a8c6d31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019cd33b-5697-78bf-8c87-7f0d43932243" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019cd33b-5697-7322-9aeb-82568da42249" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019cd33b-5697-78bf-8c87-7f0d43932243" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_019cd33b-5697-74d5-b40f-2778277808bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019cd33b-5697-7322-9aeb-82568da42249" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_019cd33b-5697-74d5-b40f-2778277808bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cd33b-5697-7a3f-97bc-03a7c620e77d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_019cd33b-5697-7322-9aeb-82568da42249" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cd33b-5697-7a3f-97bc-03a7c620e77d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019cd33b-5697-7cc4-b8ae-b026867a0956" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019cd33b-5697-76ba-aa91-877af08234ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019cd33b-5697-7cc4-b8ae-b026867a0956" xlink:to="loc_us-gaap_CommonStockValue_019cd33b-5697-76ba-aa91-877af08234ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019cd33b-5697-700a-a9e5-4cedcbc58acb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019cd33b-5697-7cc4-b8ae-b026867a0956" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019cd33b-5697-700a-a9e5-4cedcbc58acb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019db20d-6e56-77e4-840f-81835b6c15d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_019cd33b-5697-7cc4-b8ae-b026867a0956" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019db20d-6e56-77e4-840f-81835b6c15d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019cd33b-5697-7434-938b-a3a3442c2498" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_019cd33b-5697-7923-884d-9e82068dda23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019cd33b-5697-7434-938b-a3a3442c2498" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_019cd33b-5697-7923-884d-9e82068dda23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_019cd33b-5697-7601-ab07-71d6c4abe6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019cd33b-5697-7434-938b-a3a3442c2498" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_019cd33b-5697-7601-ab07-71d6c4abe6bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019cd33b-5697-7f8d-9306-d10a220a9815" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_019cd33b-5697-7434-938b-a3a3442c2498" xlink:to="loc_us-gaap_AccountsPayableCurrent_019cd33b-5697-7f8d-9306-d10a220a9815" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="rcus-20260331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cd33b-5741-77ec-947f-92d269a26167" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cd33b-5741-7e50-afad-9a6ffe760c40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cd33b-5741-77ec-947f-92d269a26167" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cd33b-5741-7e50-afad-9a6ffe760c40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cd33b-5741-7563-bd56-c780ba6ba29e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cd33b-5741-77ec-947f-92d269a26167" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cd33b-5741-7563-bd56-c780ba6ba29e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cd33b-5741-79b1-b44e-55f8b0c3735d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cd33b-5741-77ec-947f-92d269a26167" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cd33b-5741-79b1-b44e-55f8b0c3735d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cd33b-5697-7919-9843-a82cd03dec12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ProceedsFromMaturityOfMarketableSecurities_019cd33b-5697-7086-a1b6-886eccafce26" xlink:href="rcus-20260331.xsd#rcus_ProceedsFromMaturityOfMarketableSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cd33b-5697-7919-9843-a82cd03dec12" xlink:to="loc_rcus_ProceedsFromMaturityOfMarketableSecurities_019cd33b-5697-7086-a1b6-886eccafce26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019cd33b-5697-7d12-9985-7927dbac6a88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cd33b-5697-7919-9843-a82cd03dec12" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019cd33b-5697-7d12-9985-7927dbac6a88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ProceedsFromSaleOfMarketableSecurities_019cd33b-5697-743b-bb10-764001ff24b0" xlink:href="rcus-20260331.xsd#rcus_ProceedsFromSaleOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cd33b-5697-7919-9843-a82cd03dec12" xlink:to="loc_rcus_ProceedsFromSaleOfMarketableSecurities_019cd33b-5697-743b-bb10-764001ff24b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_019cd33b-5697-76d2-8d61-9fdb0177ad3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cd33b-5697-7919-9843-a82cd03dec12" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_019cd33b-5697-76d2-8d61-9fdb0177ad3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cd33b-5697-757c-8ee4-343dfdd0ad23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019cd33b-5697-76c9-9768-6f5d5b3f3337" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cd33b-5697-757c-8ee4-343dfdd0ad23" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019cd33b-5697-76c9-9768-6f5d5b3f3337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_019cd33b-5697-7988-b149-18bfe295218a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cd33b-5697-757c-8ee4-343dfdd0ad23" xlink:to="loc_us-gaap_DepreciationAndAmortization_019cd33b-5697-7988-b149-18bfe295218a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019cd33b-5741-7c0e-ac29-7e7a596b82b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cd33b-5697-757c-8ee4-343dfdd0ad23" xlink:to="loc_us-gaap_ProfitLoss_019cd33b-5741-7c0e-ac29-7e7a596b82b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019cd33b-5741-7bd6-b238-34b380760b15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cd33b-5697-757c-8ee4-343dfdd0ad23" xlink:to="loc_us-gaap_ShareBasedCompensation_019cd33b-5741-7bd6-b238-34b380760b15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_019cd33b-5741-7c12-a02b-736dc309c637" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cd33b-5697-757c-8ee4-343dfdd0ad23" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_019cd33b-5741-7c12-a02b-736dc309c637" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_019cd33b-5741-7c32-bcba-10ad38c0f21b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cd33b-5697-757c-8ee4-343dfdd0ad23" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_019cd33b-5741-7c32-bcba-10ad38c0f21b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019cd33b-5741-76b6-82e7-2d6078e644e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cd33b-5697-757c-8ee4-343dfdd0ad23" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019cd33b-5741-76b6-82e7-2d6078e644e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019cd33b-5741-78d1-a449-102b46f68758" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cd33b-5697-757c-8ee4-343dfdd0ad23" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019cd33b-5741-78d1-a449-102b46f68758" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_019cd33b-5741-7542-83eb-872f9437fcb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cd33b-5697-757c-8ee4-343dfdd0ad23" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_019cd33b-5741-7542-83eb-872f9437fcb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_019cd33b-5741-7d96-a211-a1d2345db00e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cd33b-5697-757c-8ee4-343dfdd0ad23" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_019cd33b-5741-7d96-a211-a1d2345db00e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_019cd33b-5741-77e4-8e35-c4422fc61c04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cd33b-5697-757c-8ee4-343dfdd0ad23" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_019cd33b-5741-77e4-8e35-c4422fc61c04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cd33b-5741-7485-a61f-2442ff56fa51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019cd33b-5742-7086-8369-0ff3b05e3ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cd33b-5741-7485-a61f-2442ff56fa51" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019cd33b-5742-7086-8369-0ff3b05e3ea1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019cd33b-5742-7664-9c61-91559bd9fdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cd33b-5741-7485-a61f-2442ff56fa51" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019cd33b-5742-7664-9c61-91559bd9fdcb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"/>
  <link:calculationLink xlink:role="http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019cd33b-5742-7a35-acd5-4b698c0d2160" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019cd33b-5742-7dc4-b2e5-7e397cc82cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_019cd33b-5742-7a35-acd5-4b698c0d2160" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019cd33b-5742-7dc4-b2e5-7e397cc82cd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_019cd33b-5742-76c9-a061-90c2c72318cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_019cd33b-5742-7a35-acd5-4b698c0d2160" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_019cd33b-5742-76c9-a061-90c2c72318cf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019cd33b-5742-7945-899a-9da7d33950fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019cd33b-5742-76ab-8129-cef102abf3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019cd33b-5742-7945-899a-9da7d33950fa" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019cd33b-5742-76ab-8129-cef102abf3fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019cd33b-5742-7233-9b11-9796fae31a96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019cd33b-5742-7945-899a-9da7d33950fa" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019cd33b-5742-7233-9b11-9796fae31a96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019cd33b-5742-72cc-add7-8bc131ac87ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019cd33b-5742-7945-899a-9da7d33950fa" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019cd33b-5742-72cc-add7-8bc131ac87ab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#CashCashEquivalentsandMarketableSecuritiesSummaryofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndAvailableForSaleInvestments_019cd33b-5742-743b-aea1-06beb848116d" xlink:href="rcus-20260331.xsd#rcus_CashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019cd33b-5742-7627-b04f-c4a8626214d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_rcus_CashCashEquivalentsAndAvailableForSaleInvestments_019cd33b-5742-743b-aea1-06beb848116d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019cd33b-5742-7627-b04f-c4a8626214d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_019cd33b-5742-788e-af2e-0f5a767d4210" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_rcus_CashCashEquivalentsAndAvailableForSaleInvestments_019cd33b-5742-743b-aea1-06beb848116d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_019cd33b-5742-788e-af2e-0f5a767d4210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019cd33b-5742-7454-a740-6d84bcd1501a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_rcus_CashCashEquivalentsAndAvailableForSaleInvestments_019cd33b-5742-743b-aea1-06beb848116d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019cd33b-5742-7454-a740-6d84bcd1501a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#CashCashEquivalentsandMarketableSecuritiesSummaryofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019cd33b-5742-79d3-9693-800a3fbced33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cd33b-5742-739f-9ac7-4db4130f58ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019cd33b-5742-79d3-9693-800a3fbced33" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cd33b-5742-739f-9ac7-4db4130f58ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_019cd33b-5742-73f8-abb4-6363bf626119" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019cd33b-5742-79d3-9693-800a3fbced33" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_019cd33b-5742-73f8-abb4-6363bf626119" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cd33b-5742-740e-b3cd-22eece40dce0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_019cd33b-5742-7e4a-a496-aa28137b1a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cd33b-5742-740e-b3cd-22eece40dce0" xlink:to="loc_us-gaap_InterestReceivableCurrent_019cd33b-5742-7e4a-a496-aa28137b1a6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PrepaidExpensesAndOtherCurrentAssets_019cd33b-5742-7c0c-97f2-c48153f9f171" xlink:href="rcus-20260331.xsd#rcus_PrepaidExpensesAndOtherCurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cd33b-5742-740e-b3cd-22eece40dce0" xlink:to="loc_rcus_PrepaidExpensesAndOtherCurrentAssets_019cd33b-5742-7c0c-97f2-c48153f9f171" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_019cd33b-5742-7154-ac41-d044c77ed4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_019cd33b-5742-7ab3-b3d8-1162aad1128a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_019cd33b-5742-7154-ac41-d044c77ed4ab" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_019cd33b-5742-7ab3-b3d8-1162aad1128a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_019cd33b-5742-7fdc-84d1-7f3d6d7747d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_019cd33b-5742-7154-ac41-d044c77ed4ab" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_019cd33b-5742-7fdc-84d1-7f3d6d7747d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AccruedResearchAndDevelopmentExpensesCurrent_019cd33b-5742-7d62-b472-435f461da197" xlink:href="rcus-20260331.xsd#rcus_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_019cd33b-5742-7154-ac41-d044c77ed4ab" xlink:to="loc_rcus_AccruedResearchAndDevelopmentExpensesCurrent_019cd33b-5742-7d62-b472-435f461da197" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019cd33b-5742-76dd-b8f0-c88d7bc8c0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_019cd33b-5742-7154-ac41-d044c77ed4ab" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019cd33b-5742-76dd-b8f0-c88d7bc8c0c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_019cfa6b-47a6-7d44-a936-d7d5499779e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_019cd33b-5742-7154-ac41-d044c77ed4ab" xlink:to="loc_us-gaap_TaxesPayableCurrent_019cfa6b-47a6-7d44-a936-d7d5499779e7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/LongTermDebtSummaryofLongTermDebtInstrumentsDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#LongTermDebtSummaryofLongTermDebtInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://arcusbio.com/role/LongTermDebtSummaryofLongTermDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_019cd33b-5742-7a01-a446-eff0747c87b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_019cd33b-5742-722a-b8ed-6235c3d94ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_019cd33b-5742-7a01-a446-eff0747c87b5" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_019cd33b-5742-722a-b8ed-6235c3d94ef4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_019cd33b-5742-74f0-a03e-fccaf2eb3c34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_019cd33b-5742-7a01-a446-eff0747c87b5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_019cd33b-5742-74f0-a03e-fccaf2eb3c34" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://arcusbio.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_019cd33b-5742-708e-9095-c6a4a7dc876c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_019cd33b-5742-7de6-8d07-08ad044784e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_019cd33b-5742-708e-9095-c6a4a7dc876c" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_019cd33b-5742-7de6-8d07-08ad044784e0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#BusinessSegmentSummaryofSegmentReportingInformationDetails"/>
  <link:calculationLink xlink:role="http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cd33b-5742-736f-844f-cc3ad6466a05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019cd33b-5742-7b3a-8f82-61814b8aab7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019cd33b-5742-736f-844f-cc3ad6466a05" xlink:to="loc_us-gaap_Revenues_019cd33b-5742-7b3a-8f82-61814b8aab7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LateStageDevelopmentPrograms_019cd33b-5742-787f-a3c2-5627169711d8" xlink:href="rcus-20260331.xsd#rcus_LateStageDevelopmentPrograms"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019cd33b-5742-736f-844f-cc3ad6466a05" xlink:to="loc_rcus_LateStageDevelopmentPrograms_019cd33b-5742-787f-a3c2-5627169711d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_EarlyStageDevelopmentAndPreclinicalPrograms_019cd33b-5742-7489-8bbe-7b44dce78d77" xlink:href="rcus-20260331.xsd#rcus_EarlyStageDevelopmentAndPreclinicalPrograms"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019cd33b-5742-736f-844f-cc3ad6466a05" xlink:to="loc_rcus_EarlyStageDevelopmentAndPreclinicalPrograms_019cd33b-5742-7489-8bbe-7b44dce78d77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_019cd33b-5742-75ac-9bec-b86de4608125" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019cd33b-5742-736f-844f-cc3ad6466a05" xlink:to="loc_us-gaap_LaborAndRelatedExpense_019cd33b-5742-75ac-9bec-b86de4608125" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_019cd33b-5742-7cd2-b79e-da0516e7cf90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019cd33b-5742-736f-844f-cc3ad6466a05" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_019cd33b-5742-7cd2-b79e-da0516e7cf90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_019cd33b-5742-7997-88b0-aa0c3e27cf58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019cd33b-5742-736f-844f-cc3ad6466a05" xlink:to="loc_us-gaap_InterestExpenseNonoperating_019cd33b-5742-7997-88b0-aa0c3e27cf58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_019cd33b-5742-7510-9c76-eed655e2201c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019cd33b-5742-736f-844f-cc3ad6466a05" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_019cd33b-5742-7510-9c76-eed655e2201c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PartnershipReimbursements_019cfa9c-e56d-7011-bbf2-cbb0820c3130" xlink:href="rcus-20260331.xsd#rcus_PartnershipReimbursements"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_019cd33b-5742-736f-844f-cc3ad6466a05" xlink:to="loc_rcus_PartnershipReimbursements_019cfa9c-e56d-7011-bbf2-cbb0820c3130" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>rcus-20260331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019cd33b-55e2-7686-a45d-3e64ec40f088,g:5cd5bcae-d38e-4438-9e12-43823d2921f9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="rcus-20260331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019cd33b-5697-791c-bc84-57758dec985c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:to="loc_us-gaap_StatementTable_019cd33b-5697-791c-bc84-57758dec985c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019cd33b-5697-71a1-881c-0332b5c0486c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019cd33b-5697-791c-bc84-57758dec985c" xlink:to="loc_srt_ProductOrServiceAxis_019cd33b-5697-71a1-881c-0332b5c0486c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019cd33b-5697-71a1-881c-0332b5c0486c_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019cd33b-5697-71a1-881c-0332b5c0486c" xlink:to="loc_srt_ProductsAndServicesDomain_019cd33b-5697-71a1-881c-0332b5c0486c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019cd33b-5697-7568-ad9c-6c1a373be1db" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019cd33b-5697-71a1-881c-0332b5c0486c" xlink:to="loc_srt_ProductsAndServicesDomain_019cd33b-5697-7568-ad9c-6c1a373be1db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndDevelopmentServicesMember_019d18e5-3e4f-7676-b1fd-2d7f0577a4f6" xlink:href="rcus-20260331.xsd#rcus_LicenseAndDevelopmentServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019cd33b-5697-7568-ad9c-6c1a373be1db" xlink:to="loc_rcus_LicenseAndDevelopmentServicesMember_019d18e5-3e4f-7676-b1fd-2d7f0577a4f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OtherCollaborationRevenueMember_019cd33b-5697-7637-a188-b60438121af9" xlink:href="rcus-20260331.xsd#rcus_OtherCollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019cd33b-5697-7568-ad9c-6c1a373be1db" xlink:to="loc_rcus_OtherCollaborationRevenueMember_019cd33b-5697-7637-a188-b60438121af9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_019cd33b-5697-7849-87d5-8ee12a11947b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:to="loc_us-gaap_RevenuesAbstract_019cd33b-5697-7849-87d5-8ee12a11947b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019cd33b-5697-7d75-ac17-83485fd06e68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_019cd33b-5697-7849-87d5-8ee12a11947b" xlink:to="loc_us-gaap_Revenues_019cd33b-5697-7d75-ac17-83485fd06e68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_019cd33b-5697-7489-82fa-e8ea33b5cdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:to="loc_us-gaap_OperatingExpensesAbstract_019cd33b-5697-7489-82fa-e8ea33b5cdfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019cd33b-5697-7e84-8f65-4ee05e4e5c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019cd33b-5697-7489-82fa-e8ea33b5cdfa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019cd33b-5697-7e84-8f65-4ee05e4e5c2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019cd33b-5697-7ad0-a5c4-2e6ab08372cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019cd33b-5697-7489-82fa-e8ea33b5cdfa" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019cd33b-5697-7ad0-a5c4-2e6ab08372cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019cd33b-5697-7be3-84b2-a5ebb6fb149b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019cd33b-5697-7489-82fa-e8ea33b5cdfa" xlink:to="loc_us-gaap_OperatingExpenses_019cd33b-5697-7be3-84b2-a5ebb6fb149b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019cd33b-5697-7a66-9fee-faf093aad4d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:to="loc_us-gaap_OperatingIncomeLoss_019cd33b-5697-7a66-9fee-faf093aad4d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_019cd33b-5697-7116-8776-5d0d58a89b65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_019cd33b-5697-7116-8776-5d0d58a89b65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_InterestAndOtherIncomeExpenseNonoperatingNet_019cd33b-5697-7079-b8a4-fe104b054d76" xlink:href="rcus-20260331.xsd#rcus_InterestAndOtherIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_019cd33b-5697-7116-8776-5d0d58a89b65" xlink:to="loc_rcus_InterestAndOtherIncomeExpenseNonoperatingNet_019cd33b-5697-7079-b8a4-fe104b054d76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_019cd33b-5697-7a64-8e4a-fe9b522d5c41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_019cd33b-5697-7116-8776-5d0d58a89b65" xlink:to="loc_us-gaap_InterestExpenseNonoperating_019cd33b-5697-7a64-8e4a-fe9b522d5c41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019cd33b-5697-7ad8-85da-84df3b5cbaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_019cd33b-5697-7116-8776-5d0d58a89b65" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019cd33b-5697-7ad8-85da-84df3b5cbaf5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cd33b-5697-7e58-9461-0e532f6d7fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cd33b-5697-7e58-9461-0e532f6d7fd8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019cd33b-5697-7302-849b-62fbfc2b18e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019cd33b-5697-7302-849b-62fbfc2b18e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cd33b-5697-7a2d-b6a7-da4300373c60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:to="loc_us-gaap_NetIncomeLoss_019cd33b-5697-7a2d-b6a7-da4300373c60" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019cf973-c92d-7137-be9a-85309aaf3fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:to="loc_us-gaap_EarningsPerShareBasic_019cf973-c92d-7137-be9a-85309aaf3fd6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019cf973-c92d-74c7-a176-7068566f0afd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019cf973-c92d-74c7-a176-7068566f0afd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019cd33b-5697-7d4c-bb45-61fc84b6c683" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019cd33b-5697-7d4c-bb45-61fc84b6c683" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019cd33b-5697-7aa9-b45a-a18fea59cda8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019cd33b-5697-7aa9-b45a-a18fea59cda8" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical" xlink:type="simple" xlink:href="rcus-20260331.xsd#CondensedConsolidatedStatementsofOperationsParenthetical"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019cd33b-5697-7d95-9038-6061d15df217" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019cd33b-5697-7283-835e-aabf62f4fa23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-7d95-9038-6061d15df217" xlink:to="loc_us-gaap_StatementTable_019cd33b-5697-7283-835e-aabf62f4fa23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019cd33b-5697-712a-92fd-eb5342eaa5ff" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019cd33b-5697-7283-835e-aabf62f4fa23" xlink:to="loc_srt_ProductOrServiceAxis_019cd33b-5697-712a-92fd-eb5342eaa5ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019cd33b-5697-712a-92fd-eb5342eaa5ff_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019cd33b-5697-712a-92fd-eb5342eaa5ff" xlink:to="loc_srt_ProductsAndServicesDomain_019cd33b-5697-712a-92fd-eb5342eaa5ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019cd33b-5697-7f7e-8807-437f5cd5d787" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019cd33b-5697-712a-92fd-eb5342eaa5ff" xlink:to="loc_srt_ProductsAndServicesDomain_019cd33b-5697-7f7e-8807-437f5cd5d787" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndDevelopmentServicesMember_019d4e0a-3fb2-7298-adf0-0d9c36682851" xlink:href="rcus-20260331.xsd#rcus_LicenseAndDevelopmentServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019cd33b-5697-7f7e-8807-437f5cd5d787" xlink:to="loc_rcus_LicenseAndDevelopmentServicesMember_019d4e0a-3fb2-7298-adf0-0d9c36682851" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OtherCollaborationRevenueMember_019cd33b-5697-7060-bda1-c3354278d1fd" xlink:href="rcus-20260331.xsd#rcus_OtherCollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019cd33b-5697-7f7e-8807-437f5cd5d787" xlink:to="loc_rcus_OtherCollaborationRevenueMember_019cd33b-5697-7060-bda1-c3354278d1fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5697-71b9-97d1-0c7c24441ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019cd33b-5697-7283-835e-aabf62f4fa23" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5697-71b9-97d1-0c7c24441ce5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019cd33b-5697-71b9-97d1-0c7c24441ce5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5697-71b9-97d1-0c7c24441ce5" xlink:to="loc_us-gaap_RelatedPartyDomain_019cd33b-5697-71b9-97d1-0c7c24441ce5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019cd33b-5697-744c-bd04-d4b0a672e2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5697-71b9-97d1-0c7c24441ce5" xlink:to="loc_us-gaap_RelatedPartyDomain_019cd33b-5697-744c-bd04-d4b0a672e2a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019cd33b-5697-7ced-aa3a-b2e04536cb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019cd33b-5697-744c-bd04-d4b0a672e2a9" xlink:to="loc_us-gaap_RelatedPartyMember_019cd33b-5697-7ced-aa3a-b2e04536cb4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019cd33b-5697-7761-92bb-38e7df85ab0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-7d95-9038-6061d15df217" xlink:to="loc_us-gaap_Revenues_019cd33b-5697-7761-92bb-38e7df85ab0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ResearchAndDevelopmentExpenseRecoveries_019cd33b-5697-76ff-a840-4a1052315434" xlink:href="rcus-20260331.xsd#rcus_ResearchAndDevelopmentExpenseRecoveries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-7d95-9038-6061d15df217" xlink:to="loc_rcus_ResearchAndDevelopmentExpenseRecoveries_019cd33b-5697-76ff-a840-4a1052315434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019cd33b-5697-7e01-a9fe-4a7263c5123f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-7d95-9038-6061d15df217" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019cd33b-5697-7e01-a9fe-4a7263c5123f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="rcus-20260331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019cd33b-5697-7d38-a021-d0537932153d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019cd33b-5697-7380-880b-d6dcb99b0327" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-7d38-a021-d0537932153d" xlink:to="loc_us-gaap_StatementTable_019cd33b-5697-7380-880b-d6dcb99b0327" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5697-7482-8dcd-ad3b0eb24211" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019cd33b-5697-7380-880b-d6dcb99b0327" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5697-7482-8dcd-ad3b0eb24211" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019cd33b-5697-7482-8dcd-ad3b0eb24211_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5697-7482-8dcd-ad3b0eb24211" xlink:to="loc_us-gaap_RelatedPartyDomain_019cd33b-5697-7482-8dcd-ad3b0eb24211_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019cd33b-5697-7215-befa-21895a17868a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5697-7482-8dcd-ad3b0eb24211" xlink:to="loc_us-gaap_RelatedPartyDomain_019cd33b-5697-7215-befa-21895a17868a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019cd33b-5697-7152-933d-eb8a2265a7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019cd33b-5697-7215-befa-21895a17868a" xlink:to="loc_us-gaap_RelatedPartyMember_019cd33b-5697-7152-933d-eb8a2265a7f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019cd33b-5697-7719-a525-0d046fa7a2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-7d38-a021-d0537932153d" xlink:to="loc_us-gaap_AccountsPayableCurrent_019cd33b-5697-7719-a525-0d046fa7a2cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_019cd33b-5697-78e6-b61d-c72cf1a5b3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-7d38-a021-d0537932153d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_019cd33b-5697-78e6-b61d-c72cf1a5b3c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_019cd33b-5697-7347-b0db-b3ad4a58b036" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-7d38-a021-d0537932153d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_019cd33b-5697-7347-b0db-b3ad4a58b036" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019cd33b-5697-749e-aa05-4538d5897cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-7d38-a021-d0537932153d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019cd33b-5697-749e-aa05-4538d5897cfa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_019cd33b-5697-74bb-a8f8-8e0c6884420f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-7d38-a021-d0537932153d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_019cd33b-5697-74bb-a8f8-8e0c6884420f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_019cd33b-5697-7cde-b07c-d65897654347" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-7d38-a021-d0537932153d" xlink:to="loc_us-gaap_CommonStockSharesIssued_019cd33b-5697-7cde-b07c-d65897654347" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019cd33b-5697-7f38-aac8-efb0549bb958" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-7d38-a021-d0537932153d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019cd33b-5697-7f38-aac8-efb0549bb958" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="rcus-20260331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019cd33b-5697-76b2-ba18-e0549e22ee4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019cd33b-5697-7ef8-86e4-547ce089da8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-76b2-ba18-e0549e22ee4f" xlink:to="loc_us-gaap_StatementTable_019cd33b-5697-7ef8-86e4-547ce089da8c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019cd33b-5697-79c7-94b4-1f31ae94c0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019cd33b-5697-7ef8-86e4-547ce089da8c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019cd33b-5697-79c7-94b4-1f31ae94c0cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019cd33b-5697-79c7-94b4-1f31ae94c0cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019cd33b-5697-79c7-94b4-1f31ae94c0cd" xlink:to="loc_us-gaap_EquityComponentDomain_019cd33b-5697-79c7-94b4-1f31ae94c0cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019cd33b-5697-78be-8760-13db77984fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019cd33b-5697-79c7-94b4-1f31ae94c0cd" xlink:to="loc_us-gaap_EquityComponentDomain_019cd33b-5697-78be-8760-13db77984fe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019cd33b-5697-7d5c-81db-a20a91541179" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019cd33b-5697-78be-8760-13db77984fe2" xlink:to="loc_us-gaap_CommonStockMember_019cd33b-5697-7d5c-81db-a20a91541179" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_019cd33b-5697-7a11-8724-be77d87750df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019cd33b-5697-78be-8760-13db77984fe2" xlink:to="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_019cd33b-5697-7a11-8724-be77d87750df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_019cd33b-5697-7a2e-a969-5bd75d0029a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019cd33b-5697-78be-8760-13db77984fe2" xlink:to="loc_us-gaap_RetainedEarningsMember_019cd33b-5697-7a2e-a969-5bd75d0029a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019cd33b-5697-7701-b216-d9e7e7bc4dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_019cd33b-5697-78be-8760-13db77984fe2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019cd33b-5697-7701-b216-d9e7e7bc4dc0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019cd33b-5697-701d-9886-3c771331898a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019cd33b-5697-7ef8-86e4-547ce089da8c" xlink:to="loc_us-gaap_PlanNameAxis_019cd33b-5697-701d-9886-3c771331898a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019cd33b-5697-701d-9886-3c771331898a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_019cd33b-5697-701d-9886-3c771331898a" xlink:to="loc_us-gaap_PlanNameDomain_019cd33b-5697-701d-9886-3c771331898a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019cd33b-5697-7a11-970d-f61f2f086645" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_019cd33b-5697-701d-9886-3c771331898a" xlink:to="loc_us-gaap_PlanNameDomain_019cd33b-5697-7a11-970d-f61f2f086645" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_EquityAwardProgramsMember_019cd33b-5697-7f85-8160-c7c70bd8a415" xlink:href="rcus-20260331.xsd#rcus_EquityAwardProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_019cd33b-5697-7a11-970d-f61f2f086645" xlink:to="loc_rcus_EquityAwardProgramsMember_019cd33b-5697-7f85-8160-c7c70bd8a415" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cd33b-5697-7e45-a479-9a759bd7e16d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-76b2-ba18-e0549e22ee4f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cd33b-5697-7e45-a479-9a759bd7e16d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019cd33b-5697-7188-b4e1-77b140c313c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cd33b-5697-7e45-a479-9a759bd7e16d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019cd33b-5697-7188-b4e1-77b140c313c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019cd33b-5697-79b5-8a34-8662045df1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cd33b-5697-7e45-a479-9a759bd7e16d" xlink:to="loc_us-gaap_StockholdersEquity_019cd33b-5697-79b5-8a34-8662045df1dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019cd33b-5697-7157-b16e-07733ddc3154" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cd33b-5697-7e45-a479-9a759bd7e16d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019cd33b-5697-7157-b16e-07733ddc3154" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019cd33b-5697-7751-b375-56b9078adb38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cd33b-5697-7e45-a479-9a759bd7e16d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019cd33b-5697-7751-b375-56b9078adb38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019cd33b-5697-7071-b2ea-10f134de098d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cd33b-5697-7e45-a479-9a759bd7e16d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019cd33b-5697-7071-b2ea-10f134de098d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019cd33b-5697-736f-8cae-aae91ac3562c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cd33b-5697-7e45-a479-9a759bd7e16d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019cd33b-5697-736f-8cae-aae91ac3562c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cd33b-5697-7ffd-8c0a-6619e8f6ec71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cd33b-5697-7e45-a479-9a759bd7e16d" xlink:to="loc_us-gaap_NetIncomeLoss_019cd33b-5697-7ffd-8c0a-6619e8f6ec71" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019cd33b-5697-785d-ab94-36fadc28a207" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019cd33b-5697-7c2c-8282-4ed6af1d197a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="rcus-20260331.xsd#CondensedConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019cd33b-5742-7a57-8200-2d95661c6c49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019cd33b-5742-74ee-8025-45819c147a20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5742-7a57-8200-2d95661c6c49" xlink:to="loc_us-gaap_StatementTable_019cd33b-5742-74ee-8025-45819c147a20" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5742-7805-9320-cdd453c61ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_019cd33b-5742-74ee-8025-45819c147a20" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5742-7805-9320-cdd453c61ce4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019cd33b-5742-7805-9320-cdd453c61ce4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5742-7805-9320-cdd453c61ce4" xlink:to="loc_us-gaap_RelatedPartyDomain_019cd33b-5742-7805-9320-cdd453c61ce4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019cd33b-5742-71b8-a720-d03b19ecee53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5742-7805-9320-cdd453c61ce4" xlink:to="loc_us-gaap_RelatedPartyDomain_019cd33b-5742-71b8-a720-d03b19ecee53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019cd33b-5742-7740-a033-5e4db09477c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019cd33b-5742-71b8-a720-d03b19ecee53" xlink:to="loc_us-gaap_RelatedPartyMember_019cd33b-5742-7740-a033-5e4db09477c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_019cd33b-5742-7641-a37e-6d3e4da0cd82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5742-7a57-8200-2d95661c6c49" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_019cd33b-5742-7641-a37e-6d3e4da0cd82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019cd33b-5742-7ff0-9355-cd732b76bf3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5742-7a57-8200-2d95661c6c49" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019cd33b-5742-7ff0-9355-cd732b76bf3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_019cd33b-5742-749c-ade2-495109a7d2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5742-7a57-8200-2d95661c6c49" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_019cd33b-5742-749c-ade2-495109a7d2a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019cd33b-5742-7017-9cc6-609500290e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5742-7a57-8200-2d95661c6c49" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019cd33b-5742-7017-9cc6-609500290e0a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OrganizationLineItems_019cf9b5-a519-7583-ad27-728ef371e4d2" xlink:href="rcus-20260331.xsd#rcus_OrganizationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OrganizationTable_019cf9b3-28ef-7225-bce5-92da55f2e525" xlink:href="rcus-20260331.xsd#rcus_OrganizationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rcus_OrganizationLineItems_019cf9b5-a519-7583-ad27-728ef371e4d2" xlink:to="loc_rcus_OrganizationTable_019cf9b3-28ef-7225-bce5-92da55f2e525" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_019cf9b5-a519-775f-93d3-d342dfd2f0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rcus_OrganizationTable_019cf9b3-28ef-7225-bce5-92da55f2e525" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_019cf9b5-a519-775f-93d3-d342dfd2f0b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_019cf9b5-a519-775f-93d3-d342dfd2f0b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_019cf9b5-a519-775f-93d3-d342dfd2f0b9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_019cf9b5-a519-775f-93d3-d342dfd2f0b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_019cf9b5-a519-7790-90e0-c44b18b3e494" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_019cf9b5-a519-775f-93d3-d342dfd2f0b9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_019cf9b5-a519-7790-90e0-c44b18b3e494" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember_019cf9b5-a519-7cb0-811d-e7673f184df5" xlink:href="rcus-20260331.xsd#rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_019cf9b5-a519-7790-90e0-c44b18b3e494" xlink:to="loc_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember_019cf9b5-a519-7cb0-811d-e7673f184df5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_019cf9b5-a519-7129-974d-d7ad95cc8f11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_OrganizationLineItems_019cf9b5-a519-7583-ad27-728ef371e4d2" xlink:to="loc_us-gaap_NumberOfOperatingSegments_019cf9b5-a519-7129-974d-d7ad95cc8f11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_019cf9b5-a519-7af4-b599-fd98fe1f9368" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_OrganizationLineItems_019cf9b5-a519-7583-ad27-728ef371e4d2" xlink:to="loc_us-gaap_NumberOfReportableSegments_019cf9b5-a519-7af4-b599-fd98fe1f9368" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_019cf9b5-a519-7dd8-8a95-cea03026d492" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAndCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_OrganizationLineItems_019cf9b5-a519-7583-ad27-728ef371e4d2" xlink:to="loc_us-gaap_InvestmentsAndCash_019cf9b5-a519-7dd8-8a95-cea03026d492" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#RelatedPartyGileadSciencesIncDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cd33b-5742-7fc0-8fc2-44f7706dd1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cd33b-5742-7fc0-8fc2-44f7706dd1dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_019cd33b-5742-77c6-8d23-c0b5c8f91db5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cd33b-5742-7fc0-8fc2-44f7706dd1dd" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_019cd33b-5742-77c6-8d23-c0b5c8f91db5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_019cd33b-5742-77c6-8d23-c0b5c8f91db5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_019cd33b-5742-77c6-8d23-c0b5c8f91db5" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_019cd33b-5742-77c6-8d23-c0b5c8f91db5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_019cd33b-5742-75b1-883e-b461e8dc5fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_019cd33b-5742-77c6-8d23-c0b5c8f91db5" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_019cd33b-5742-75b1-883e-b461e8dc5fe1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CommonStockPurchaseAgreementMember_019cd33b-5742-741f-b872-4f5b74c1aaeb" xlink:href="rcus-20260331.xsd#rcus_CommonStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019cd33b-5742-75b1-883e-b461e8dc5fe1" xlink:to="loc_rcus_CommonStockPurchaseAgreementMember_019cd33b-5742-741f-b872-4f5b74c1aaeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionLicenseAndCollaborationAgreementMember_019cd33b-5742-7dd1-bddb-75b6c07dc9c4" xlink:href="rcus-20260331.xsd#rcus_OptionLicenseAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019cd33b-5742-75b1-883e-b461e8dc5fe1" xlink:to="loc_rcus_OptionLicenseAndCollaborationAgreementMember_019cd33b-5742-7dd1-bddb-75b6c07dc9c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AmendedGileadCollaborationAgreementMember_019cd33b-5742-706c-ba4e-9164bdecd0d7" xlink:href="rcus-20260331.xsd#rcus_AmendedGileadCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019cd33b-5742-75b1-883e-b461e8dc5fe1" xlink:to="loc_rcus_AmendedGileadCollaborationAgreementMember_019cd33b-5742-706c-ba4e-9164bdecd0d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5742-7a4c-82c3-a339f3851d45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cd33b-5742-7fc0-8fc2-44f7706dd1dd" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5742-7a4c-82c3-a339f3851d45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019cd33b-5742-7a4c-82c3-a339f3851d45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5742-7a4c-82c3-a339f3851d45" xlink:to="loc_us-gaap_RelatedPartyDomain_019cd33b-5742-7a4c-82c3-a339f3851d45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019cd33b-5742-769e-a61c-347b5ddfe6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5742-7a4c-82c3-a339f3851d45" xlink:to="loc_us-gaap_RelatedPartyDomain_019cd33b-5742-769e-a61c-347b5ddfe6a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019cd33b-5742-780b-af14-23e889130823" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_019cd33b-5742-769e-a61c-347b5ddfe6a0" xlink:to="loc_us-gaap_RelatedPartyMember_019cd33b-5742-780b-af14-23e889130823" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019cd33b-5742-7420-a58c-7c1e11936c03" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cd33b-5742-7fc0-8fc2-44f7706dd1dd" xlink:to="loc_dei_LegalEntityAxis_019cd33b-5742-7420-a58c-7c1e11936c03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019cd33b-5742-7420-a58c-7c1e11936c03_default" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_019cd33b-5742-7420-a58c-7c1e11936c03" xlink:to="loc_dei_EntityDomain_019cd33b-5742-7420-a58c-7c1e11936c03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019cd33b-5742-72e9-a740-07eceee40306" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_019cd33b-5742-7420-a58c-7c1e11936c03" xlink:to="loc_dei_EntityDomain_019cd33b-5742-72e9-a740-07eceee40306" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadSciencesIncMember_019cd33b-5742-7d3f-ad36-1e135254c5fd" xlink:href="rcus-20260331.xsd#rcus_GileadSciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_019cd33b-5742-72e9-a740-07eceee40306" xlink:to="loc_rcus_GileadSciencesIncMember_019cd33b-5742-7d3f-ad36-1e135254c5fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019cd33b-5742-732a-ad66-287f3658b970" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cd33b-5742-7fc0-8fc2-44f7706dd1dd" xlink:to="loc_srt_CounterpartyNameAxis_019cd33b-5742-732a-ad66-287f3658b970" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019cd33b-5742-732a-ad66-287f3658b970_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_019cd33b-5742-732a-ad66-287f3658b970" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019cd33b-5742-732a-ad66-287f3658b970_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019cd33b-5742-7231-80b3-ebfac19dfeca" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_019cd33b-5742-732a-ad66-287f3658b970" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019cd33b-5742-7231-80b3-ebfac19dfeca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadSciencesIncMember_019cd33b-5742-7eae-9868-8a1d1dd7034c" xlink:href="rcus-20260331.xsd#rcus_GileadSciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019cd33b-5742-7231-80b3-ebfac19dfeca" xlink:to="loc_rcus_GileadSciencesIncMember_019cd33b-5742-7eae-9868-8a1d1dd7034c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019cd33b-5742-7170-a6ca-4d585dc3738c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cd33b-5742-7fc0-8fc2-44f7706dd1dd" xlink:to="loc_srt_RangeAxis_019cd33b-5742-7170-a6ca-4d585dc3738c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019cd33b-5742-7170-a6ca-4d585dc3738c_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019cd33b-5742-7170-a6ca-4d585dc3738c" xlink:to="loc_srt_RangeMember_019cd33b-5742-7170-a6ca-4d585dc3738c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019cd33b-5742-79d6-afe3-87a63edc5ddb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019cd33b-5742-7170-a6ca-4d585dc3738c" xlink:to="loc_srt_RangeMember_019cd33b-5742-79d6-afe3-87a63edc5ddb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019cd33b-5742-71b4-bb41-50195c82df36" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019cd33b-5742-79d6-afe3-87a63edc5ddb" xlink:to="loc_srt_MaximumMember_019cd33b-5742-71b4-bb41-50195c82df36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_019cd33b-5742-7620-9c37-48acb0fe0b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cd33b-5742-7fc0-8fc2-44f7706dd1dd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_019cd33b-5742-7620-9c37-48acb0fe0b3f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019cd33b-5742-7620-9c37-48acb0fe0b3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019cd33b-5742-7620-9c37-48acb0fe0b3f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019cd33b-5742-7620-9c37-48acb0fe0b3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019cd33b-5742-71f8-abee-7ab29ab90b26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019cd33b-5742-7620-9c37-48acb0fe0b3f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019cd33b-5742-71f8-abee-7ab29ab90b26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019cd33b-5742-75fa-b810-33545b17e8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019cd33b-5742-71f8-abee-7ab29ab90b26" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019cd33b-5742-75fa-b810-33545b17e8fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_SaleOfStockNumberOfSharesAcquiredInTransaction_019cd33b-5742-71f4-90d2-32c72522e1bd" xlink:href="rcus-20260331.xsd#rcus_SaleOfStockNumberOfSharesAcquiredInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_SaleOfStockNumberOfSharesAcquiredInTransaction_019cd33b-5742-71f4-90d2-32c72522e1bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019cd33b-5742-7656-9c64-7ca106f57e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019cd33b-5742-7656-9c64-7ca106f57e8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NumberOfBoardMembers_019cd33b-5742-7fdb-a291-189c87bed3e7" xlink:href="rcus-20260331.xsd#rcus_NumberOfBoardMembers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_NumberOfBoardMembers_019cd33b-5742-7fdb-a291-189c87bed3e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PercentageOfOutstandingCommonStockOwned_019cd33b-5742-72d8-90ed-4c2aee7a327e" xlink:href="rcus-20260331.xsd#rcus_PercentageOfOutstandingCommonStockOwned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_PercentageOfOutstandingCommonStockOwned_019cd33b-5742-72d8-90ed-4c2aee7a327e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms_019cd33b-5742-7190-81c7-a6b78acf8018" xlink:href="rcus-20260331.xsd#rcus_CollaborationTermForCurrentAndFutureClinicalPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms_019cd33b-5742-7190-81c7-a6b78acf8018" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement_019cd33b-5742-7af8-9d8d-65ec749ffda0" xlink:href="rcus-20260331.xsd#rcus_OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement_019cd33b-5742-7af8-9d8d-65ec749ffda0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement_019cd33b-5742-7d1f-8f8b-4efe2489e54b" xlink:href="rcus-20260331.xsd#rcus_OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement_019cd33b-5742-7d1f-8f8b-4efe2489e54b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement_019cd33b-5742-7cfe-85cf-313b9790bb2f" xlink:href="rcus-20260331.xsd#rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement_019cd33b-5742-7cfe-85cf-313b9790bb2f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement_019cd33b-5742-7de5-9997-f3c0da1736a0" xlink:href="rcus-20260331.xsd#rcus_OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement_019cd33b-5742-7de5-9997-f3c0da1736a0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_UpfrontCashPayment_019cd33b-5742-777b-a3a3-bf8f2f7a5d87" xlink:href="rcus-20260331.xsd#rcus_UpfrontCashPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_UpfrontCashPayment_019cd33b-5742-777b-a3a3-bf8f2f7a5d87" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NumberOfExerciseOptionToPrograms_019cd33b-5742-7f53-90eb-0566ceb28251" xlink:href="rcus-20260331.xsd#rcus_NumberOfExerciseOptionToPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_NumberOfExerciseOptionToPrograms_019cd33b-5742-7f53-90eb-0566ceb28251" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionPaymentReceived_019cd33b-5742-7c7a-9543-e6be96ea45f3" xlink:href="rcus-20260331.xsd#rcus_OptionPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_OptionPaymentReceived_019cd33b-5742-7c7a-9543-e6be96ea45f3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RemoveOptionContinuationPaymentUnderAgreement_019cd33b-5742-7e64-86f4-67abe76b6f4e" xlink:href="rcus-20260331.xsd#rcus_RemoveOptionContinuationPaymentUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_RemoveOptionContinuationPaymentUnderAgreement_019cd33b-5742-7e64-86f4-67abe76b6f4e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab_019cd33b-5742-74e5-8dc3-4baea8e50ca1" xlink:href="rcus-20260331.xsd#rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab_019cd33b-5742-74e5-8dc3-4baea8e50ca1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption_019cd33b-5742-74ea-bb22-472e6a5f5182" xlink:href="rcus-20260331.xsd#rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption_019cd33b-5742-74ea-bb22-472e6a5f5182" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NumberOfResearchPrograms_019cd33b-5742-7b2d-92f3-80a0a253a923" xlink:href="rcus-20260331.xsd#rcus_NumberOfResearchPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_NumberOfResearchPrograms_019cd33b-5742-7b2d-92f3-80a0a253a923" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionPaymentUponCompletionOfCertainINDEnablingActivities_019cd33b-5742-78f5-8f2d-60e5f8c2e9de" xlink:href="rcus-20260331.xsd#rcus_OptionPaymentUponCompletionOfCertainINDEnablingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_OptionPaymentUponCompletionOfCertainINDEnablingActivities_019cd33b-5742-78f5-8f2d-60e5f8c2e9de" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones_019cd33b-5742-7574-a961-efe6e151c185" xlink:href="rcus-20260331.xsd#rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones_019cd33b-5742-7574-a961-efe6e151c185" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments_019cd33b-5742-7805-90e0-98b952c3d18d" xlink:href="rcus-20260331.xsd#rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments_019cd33b-5742-7805-90e0-98b952c3d18d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TotalUpfrontCashPayment_019cd33b-5742-79e7-b3ee-6cb8cadf9ce2" xlink:href="rcus-20260331.xsd#rcus_TotalUpfrontCashPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_TotalUpfrontCashPayment_019cd33b-5742-79e7-b3ee-6cb8cadf9ce2" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RegulatoryAndCommercialMilestonePaymentsReceived_019cd33b-5742-7261-9c5c-c3d953e77644" xlink:href="rcus-20260331.xsd#rcus_RegulatoryAndCommercialMilestonePaymentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_RegulatoryAndCommercialMilestonePaymentsReceived_019cd33b-5742-7261-9c5c-c3d953e77644" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_019cd33b-5742-7c17-950d-101e7f543c52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_019cd33b-5742-7c17-950d-101e7f543c52" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts_019cd33b-5742-7e74-a28d-d8235b5e172f" xlink:href="rcus-20260331.xsd#rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts_019cd33b-5742-7e74-a28d-d8235b5e172f" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019cd33b-5742-799b-93d0-12e430f5ed06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_us-gaap_AccountsPayableCurrent_019cd33b-5742-799b-93d0-12e430f5ed06" xlink:type="arc" order="23"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/LicenseandCollaborationsDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#LicenseandCollaborationsDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/LicenseandCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:href="rcus-20260331.xsd#rcus_LicenseAndCollaborationAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndCollaborationAgreementsTable_019cd33b-5742-7836-911d-b990b7fd8f6e" xlink:href="rcus-20260331.xsd#rcus_LicenseAndCollaborationAgreementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_LicenseAndCollaborationAgreementsTable_019cd33b-5742-7836-911d-b990b7fd8f6e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019d995c-d263-793f-9c58-4a023e84a9bb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsTable_019cd33b-5742-7836-911d-b990b7fd8f6e" xlink:to="loc_srt_CounterpartyNameAxis_019d995c-d263-793f-9c58-4a023e84a9bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d995c-d263-793f-9c58-4a023e84a9bb_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_019d995c-d263-793f-9c58-4a023e84a9bb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d995c-d263-793f-9c58-4a023e84a9bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d995c-d263-74a3-b855-d73533394a8e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_019d995c-d263-793f-9c58-4a023e84a9bb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d995c-d263-74a3-b855-d73533394a8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoPharmaceuticalCoLtdMember_019d995c-d263-7e63-afce-6b9884272109" xlink:href="rcus-20260331.xsd#rcus_TaihoPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d995c-d263-74a3-b855-d73533394a8e" xlink:to="loc_rcus_TaihoPharmaceuticalCoLtdMember_019d995c-d263-7e63-afce-6b9884272109" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_STAR221DevelopmentActivitiesMember_019d995c-d263-74a7-acfb-f3e69f8423ab" xlink:href="rcus-20260331.xsd#rcus_STAR221DevelopmentActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d995c-d263-74a3-b855-d73533394a8e" xlink:to="loc_rcus_STAR221DevelopmentActivitiesMember_019d995c-d263-74a7-acfb-f3e69f8423ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_STAR121DevelopmentActivitiesMember_019d995c-d263-7f3f-b7e8-fafc51656a4a" xlink:href="rcus-20260331.xsd#rcus_STAR121DevelopmentActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d995c-d263-74a3-b855-d73533394a8e" xlink:to="loc_rcus_STAR121DevelopmentActivitiesMember_019d995c-d263-7f3f-b7e8-fafc51656a4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AbmunoLicenseAgreementMember_019d995d-788d-73b8-bafe-17b7d9fc53d6" xlink:href="rcus-20260331.xsd#rcus_AbmunoLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d995c-d263-74a3-b855-d73533394a8e" xlink:to="loc_rcus_AbmunoLicenseAgreementMember_019d995d-788d-73b8-bafe-17b7d9fc53d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_WuXiBiologicsLicenseAgreementMember_019d995d-788d-73b4-bc39-fd8f1e53b019" xlink:href="rcus-20260331.xsd#rcus_WuXiBiologicsLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d995c-d263-74a3-b855-d73533394a8e" xlink:to="loc_rcus_WuXiBiologicsLicenseAgreementMember_019d995d-788d-73b4-bc39-fd8f1e53b019" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_019d995c-d263-78cd-9ed9-102e2edb1b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsTable_019cd33b-5742-7836-911d-b990b7fd8f6e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_019d995c-d263-78cd-9ed9-102e2edb1b6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019d995c-d263-78cd-9ed9-102e2edb1b6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019d995c-d263-78cd-9ed9-102e2edb1b6d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019d995c-d263-78cd-9ed9-102e2edb1b6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019d995c-d263-7649-8bbb-7312a992c014" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019d995c-d263-78cd-9ed9-102e2edb1b6d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019d995c-d263-7649-8bbb-7312a992c014" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionAndLicenseAgreementMember_019d995c-d263-7e03-aba1-0ffcae4b760b" xlink:href="rcus-20260331.xsd#rcus_OptionAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019d995c-d263-7649-8bbb-7312a992c014" xlink:to="loc_rcus_OptionAndLicenseAgreementMember_019d995c-d263-7e03-aba1-0ffcae4b760b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoCollaborationAgreementMember_019d995c-d263-76c6-911f-1d97b1ebbb50" xlink:href="rcus-20260331.xsd#rcus_TaihoCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019d995c-d263-7649-8bbb-7312a992c014" xlink:to="loc_rcus_TaihoCollaborationAgreementMember_019d995c-d263-76c6-911f-1d97b1ebbb50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AstraZenecaAgreementMember_019d995d-3b45-7f67-bd37-7b942665f224" xlink:href="rcus-20260331.xsd#rcus_AstraZenecaAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019d995c-d263-7649-8bbb-7312a992c014" xlink:to="loc_rcus_AstraZenecaAgreementMember_019d995d-3b45-7f67-bd37-7b942665f224" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019d995c-d263-7b45-889d-d064932ec058" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsTable_019cd33b-5742-7836-911d-b990b7fd8f6e" xlink:to="loc_srt_RangeAxis_019d995c-d263-7b45-889d-d064932ec058" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019d995c-d263-7b45-889d-d064932ec058_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_019d995c-d263-7b45-889d-d064932ec058" xlink:to="loc_srt_RangeMember_019d995c-d263-7b45-889d-d064932ec058_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019d995c-d263-7d7c-bdbf-77d722496b28" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_019d995c-d263-7b45-889d-d064932ec058" xlink:to="loc_srt_RangeMember_019d995c-d263-7d7c-bdbf-77d722496b28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019d995c-d263-75ec-a7fb-ba9745ee7297" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019d995c-d263-7d7c-bdbf-77d722496b28" xlink:to="loc_srt_MinimumMember_019d995c-d263-75ec-a7fb-ba9745ee7297" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019d995c-d263-79f6-923e-1a85ef505aca" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_019d995c-d263-7d7c-bdbf-77d722496b28" xlink:to="loc_srt_MaximumMember_019d995c-d263-79f6-923e-1a85ef505aca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019d995d-788d-785b-a529-6db425e4315f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsTable_019cd33b-5742-7836-911d-b990b7fd8f6e" xlink:to="loc_srt_ProductOrServiceAxis_019d995d-788d-785b-a529-6db425e4315f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019d995d-788d-785b-a529-6db425e4315f_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019d995d-788d-785b-a529-6db425e4315f" xlink:to="loc_srt_ProductsAndServicesDomain_019d995d-788d-785b-a529-6db425e4315f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019d995d-788d-75a2-bce5-0ccfea75814f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019d995d-788d-785b-a529-6db425e4315f" xlink:to="loc_srt_ProductsAndServicesDomain_019d995d-788d-75a2-bce5-0ccfea75814f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AntiPDOneMember_019d995d-788d-76aa-8088-5e0186d620ca" xlink:href="rcus-20260331.xsd#rcus_AntiPDOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019d995d-788d-75a2-bce5-0ccfea75814f" xlink:to="loc_rcus_AntiPDOneMember_019d995d-788d-76aa-8088-5e0186d620ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AntiCDThirtyNineMember_019d995d-788d-7094-b633-0fb01a7cfb37" xlink:href="rcus-20260331.xsd#rcus_AntiCDThirtyNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019d995d-788d-75a2-bce5-0ccfea75814f" xlink:to="loc_rcus_AntiCDThirtyNineMember_019d995d-788d-7094-b633-0fb01a7cfb37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionPeriod_019d995c-d263-7cb8-b775-e56b3d29a528" xlink:href="rcus-20260331.xsd#rcus_OptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_OptionPeriod_019d995c-d263-7cb8-b775-e56b3d29a528" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NonRefundableAndNonCreditableCashPayments_019d995c-d263-787c-bb11-d7c4bf5bae81" xlink:href="rcus-20260331.xsd#rcus_NonRefundableAndNonCreditableCashPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_NonRefundableAndNonCreditableCashPayments_019d995c-d263-787c-bb11-d7c4bf5bae81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PaymentForOptionsExercised_019d995c-d263-7f30-9404-ab46ce1a0dff" xlink:href="rcus-20260331.xsd#rcus_PaymentForOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_PaymentForOptionsExercised_019d995c-d263-7f30-9404-ab46ce1a0dff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement_019d995c-d263-7054-8d16-029b08856ec7" xlink:href="rcus-20260331.xsd#rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement_019d995c-d263-7054-8d16-029b08856ec7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ContingentMilestonePaymentsReceivable_019d995c-d263-70d3-9011-e7c186bd48dc" xlink:href="rcus-20260331.xsd#rcus_ContingentMilestonePaymentsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_ContingentMilestonePaymentsReceivable_019d995c-d263-70d3-9011-e7c186bd48dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RoyaltiesPayableTerm_019d995c-d263-773f-b04b-e130d4124262" xlink:href="rcus-20260331.xsd#rcus_RoyaltiesPayableTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_RoyaltiesPayableTerm_019d995c-d263-773f-b04b-e130d4124262" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_MilestonePayments_019d995c-d263-78e0-b7f4-0b7964b08aad" xlink:href="rcus-20260331.xsd#rcus_MilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_MilestonePayments_019d995c-d263-78e0-b7f4-0b7964b08aad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d995d-3b45-7d50-b244-228bc7b114fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d995d-3b45-7d50-b244-228bc7b114fa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ReimbursementOfResearchAndDevelopmentExpense_019d995d-3b45-755a-b480-e322636c5a4a" xlink:href="rcus-20260331.xsd#rcus_ReimbursementOfResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_ReimbursementOfResearchAndDevelopmentExpense_019d995d-3b45-755a-b480-e322636c5a4a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_019d995d-3b45-70ad-9d3a-8aae545e065a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_019d995d-3b45-70ad-9d3a-8aae545e065a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_019d995d-3b45-75e8-95f6-476685e3afc3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_us-gaap_OtherLiabilities_019d995d-3b45-75e8-95f6-476685e3afc3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019d995d-3b45-7b5a-9e5c-f8aa1d34ad3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019d995d-3b45-7b5a-9e5c-f8aa1d34ad3e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_019d995d-788d-736b-9513-06871e8146fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_019d995d-788d-736b-9513-06871e8146fb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_019d995d-788d-7fd8-b2b2-70836364740a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_019d995d-788d-7fd8-b2b2-70836364740a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ClinicalRegulatoryMilestonePayments_019d995d-788d-736d-8c52-01d533c87337" xlink:href="rcus-20260331.xsd#rcus_ClinicalRegulatoryMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_ClinicalRegulatoryMilestonePayments_019d995d-788d-736d-8c52-01d533c87337" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments_019d995d-788d-7f98-8011-e826def3632e" xlink:href="rcus-20260331.xsd#rcus_ClinicalRegulatoryAndCommercializationMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments_019d995d-788d-7f98-8011-e826def3632e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments_019d995d-788d-7642-ab5f-2e51bc7126b2" xlink:href="rcus-20260331.xsd#rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments_019d995d-788d-7642-ab5f-2e51bc7126b2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_MilestoneExpense_019d995d-788d-791e-a247-3421da548300" xlink:href="rcus-20260331.xsd#rcus_MilestoneExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_MilestoneExpense_019d995d-788d-791e-a247-3421da548300" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019cd33b-5742-7d7c-9519-3094234207dc" xlink:href="rcus-20260331.xsd#rcus_LicenseAndCollaborationAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-7528-8eaa-1f7e3886b878" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019cd33b-5742-7d7c-9519-3094234207dc" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-7528-8eaa-1f7e3886b878" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019cd33b-5742-7251-8929-ac854057a427" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-7528-8eaa-1f7e3886b878" xlink:to="loc_srt_ProductOrServiceAxis_019cd33b-5742-7251-8929-ac854057a427" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019cd33b-5742-7251-8929-ac854057a427_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019cd33b-5742-7251-8929-ac854057a427" xlink:to="loc_srt_ProductsAndServicesDomain_019cd33b-5742-7251-8929-ac854057a427_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019cd33b-5742-7a1a-80f5-125902963d7d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019cd33b-5742-7251-8929-ac854057a427" xlink:to="loc_srt_ProductsAndServicesDomain_019cd33b-5742-7a1a-80f5-125902963d7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndDevelopmentServicesMember_019cd33b-5742-79f1-8c0b-d980a00b9389" xlink:href="rcus-20260331.xsd#rcus_LicenseAndDevelopmentServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019cd33b-5742-7a1a-80f5-125902963d7d" xlink:to="loc_rcus_LicenseAndDevelopmentServicesMember_019cd33b-5742-79f1-8c0b-d980a00b9389" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RDServicesMember_019d184d-6179-7173-ad43-172bbbe18e2e" xlink:href="rcus-20260331.xsd#rcus_RDServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019cd33b-5742-7a1a-80f5-125902963d7d" xlink:to="loc_rcus_RDServicesMember_019d184d-6179-7173-ad43-172bbbe18e2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AccessRightsMember_019d99a9-e3ba-7515-a43e-65f052b88679" xlink:href="rcus-20260331.xsd#rcus_AccessRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019cd33b-5742-7a1a-80f5-125902963d7d" xlink:to="loc_rcus_AccessRightsMember_019d99a9-e3ba-7515-a43e-65f052b88679" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OtherServicesMember_019cd33b-5742-78c3-b483-894a9d1d3477" xlink:href="rcus-20260331.xsd#rcus_OtherServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019cd33b-5742-7a1a-80f5-125902963d7d" xlink:to="loc_rcus_OtherServicesMember_019cd33b-5742-78c3-b483-894a9d1d3477" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_019dd125-fc65-7726-a7eb-cbe2c31e9fac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019cd33b-5742-7a1a-80f5-125902963d7d" xlink:to="loc_us-gaap_LicenseMember_019dd125-fc65-7726-a7eb-cbe2c31e9fac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_019cd33b-5742-775a-a2d9-074575299665" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-7528-8eaa-1f7e3886b878" xlink:to="loc_us-gaap_TypeOfArrangementAxis_019cd33b-5742-775a-a2d9-074575299665" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019cd33b-5742-775a-a2d9-074575299665_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019cd33b-5742-775a-a2d9-074575299665" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019cd33b-5742-775a-a2d9-074575299665_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019cd33b-5742-79e9-8d59-c3badc3f2588" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019cd33b-5742-775a-a2d9-074575299665" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019cd33b-5742-79e9-8d59-c3badc3f2588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadCollaborationMember_019cd33b-5742-7370-848a-283e476d6b9b" xlink:href="rcus-20260331.xsd#rcus_GileadCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019cd33b-5742-79e9-8d59-c3badc3f2588" xlink:to="loc_rcus_GileadCollaborationMember_019cd33b-5742-7370-848a-283e476d6b9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoCollaborationMember_019cd33b-5742-72ac-a673-e462c03da071" xlink:href="rcus-20260331.xsd#rcus_TaihoCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019cd33b-5742-79e9-8d59-c3badc3f2588" xlink:to="loc_rcus_TaihoCollaborationMember_019cd33b-5742-72ac-a673-e462c03da071" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_019cd33b-5742-78f7-bdaa-807ff0ad88d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-7528-8eaa-1f7e3886b878" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_019cd33b-5742-78f7-bdaa-807ff0ad88d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_019cd33b-5742-78f7-bdaa-807ff0ad88d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_019cd33b-5742-78f7-bdaa-807ff0ad88d0" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_019cd33b-5742-78f7-bdaa-807ff0ad88d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_019cd33b-5742-77d6-97d1-2d23e5ebb4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_019cd33b-5742-78f7-bdaa-807ff0ad88d0" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_019cd33b-5742-77d6-97d1-2d23e5ebb4d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_019cd33b-5742-7ebf-9320-cce7256fab1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_019cd33b-5742-77d6-97d1-2d23e5ebb4d2" xlink:to="loc_us-gaap_TransferredOverTimeMember_019cd33b-5742-7ebf-9320-cce7256fab1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019cd33b-5742-7c6f-8fe3-ff59a61eacee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019cd33b-5742-7d7c-9519-3094234207dc" xlink:to="loc_us-gaap_Revenues_019cd33b-5742-7c6f-8fe3-ff59a61eacee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_019cd33b-5742-7a36-81de-da9315bd563d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019cd33b-5742-7d7c-9519-3094234207dc" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_019cd33b-5742-7a36-81de-da9315bd563d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019cd33b-5742-7a31-9afc-be3977320fff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019cd33b-5742-7d7c-9519-3094234207dc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019cd33b-5742-7a31-9afc-be3977320fff" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/RevenuesAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#RevenuesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/RevenuesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_019dd193-7f18-75f2-841b-1e52949eafe6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-79f9-8701-9875f3ab7146" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019dd193-7f18-75f2-841b-1e52949eafe6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-79f9-8701-9875f3ab7146" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019dd193-7f18-7912-8e79-cef00971bee8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-79f9-8701-9875f3ab7146" xlink:to="loc_srt_CounterpartyNameAxis_019dd193-7f18-7912-8e79-cef00971bee8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019dd193-7f18-7912-8e79-cef00971bee8_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_019dd193-7f18-7912-8e79-cef00971bee8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019dd193-7f18-7912-8e79-cef00971bee8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019dd193-7f18-7bc0-87e2-b6a38090cc8a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_019dd193-7f18-7912-8e79-cef00971bee8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019dd193-7f18-7bc0-87e2-b6a38090cc8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadSciencesIncMember_019dd193-7f18-7e2c-b27d-d73d5318c58e" xlink:href="rcus-20260331.xsd#rcus_GileadSciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019dd193-7f18-7bc0-87e2-b6a38090cc8a" xlink:to="loc_rcus_GileadSciencesIncMember_019dd193-7f18-7e2c-b27d-d73d5318c58e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_STAR221DevelopmentActivitiesMember_019dd194-2ea9-751b-ba52-80dc452ec521" xlink:href="rcus-20260331.xsd#rcus_STAR221DevelopmentActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019dd193-7f18-7bc0-87e2-b6a38090cc8a" xlink:to="loc_rcus_STAR221DevelopmentActivitiesMember_019dd194-2ea9-751b-ba52-80dc452ec521" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoPharmaceuticalCoLtdMember_019dd194-461f-7a24-bab1-a95336f353f7" xlink:href="rcus-20260331.xsd#rcus_TaihoPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019dd193-7f18-7bc0-87e2-b6a38090cc8a" xlink:to="loc_rcus_TaihoPharmaceuticalCoLtdMember_019dd194-461f-7a24-bab1-a95336f353f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019dd193-7f18-7abc-bd70-551dd53618d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-79f9-8701-9875f3ab7146" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019dd193-7f18-7abc-bd70-551dd53618d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019dd193-7f18-7abc-bd70-551dd53618d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019dd193-7f18-7abc-bd70-551dd53618d0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019dd193-7f18-7abc-bd70-551dd53618d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019dd193-7f18-7476-81b0-e9ee83a9da94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019dd193-7f18-7abc-bd70-551dd53618d0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019dd193-7f18-7476-81b0-e9ee83a9da94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_019dd193-7f18-76df-bd36-4ac78d93be8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019dd193-7f18-7476-81b0-e9ee83a9da94" xlink:to="loc_us-gaap_SalesRevenueNetMember_019dd193-7f18-76df-bd36-4ac78d93be8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_019dd193-7f18-7bdf-a066-2e505f2953bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-79f9-8701-9875f3ab7146" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_019dd193-7f18-7bdf-a066-2e505f2953bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_019dd193-7f18-7bdf-a066-2e505f2953bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_019dd193-7f18-7bdf-a066-2e505f2953bb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_019dd193-7f18-7bdf-a066-2e505f2953bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_019dd193-7f18-7899-9e48-40d70c26eadf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_019dd193-7f18-7bdf-a066-2e505f2953bb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_019dd193-7f18-7899-9e48-40d70c26eadf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_019dd193-7f18-7394-bd24-7497888bd676" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_019dd193-7f18-7899-9e48-40d70c26eadf" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_019dd193-7f18-7394-bd24-7497888bd676" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_019dd193-dc02-7ba0-91c9-bd66d8a0e035" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-79f9-8701-9875f3ab7146" xlink:to="loc_us-gaap_TypeOfArrangementAxis_019dd193-dc02-7ba0-91c9-bd66d8a0e035" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019dd193-dc02-7ba0-91c9-bd66d8a0e035_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019dd193-dc02-7ba0-91c9-bd66d8a0e035" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019dd193-dc02-7ba0-91c9-bd66d8a0e035_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019dd193-dc02-7a6c-853a-76684a5b11da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019dd193-dc02-7ba0-91c9-bd66d8a0e035" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019dd193-dc02-7a6c-853a-76684a5b11da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RDServicesMember_019dd193-dc02-7198-8ca3-187881e6281a" xlink:href="rcus-20260331.xsd#rcus_RDServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019dd193-dc02-7a6c-853a-76684a5b11da" xlink:to="loc_rcus_RDServicesMember_019dd193-dc02-7198-8ca3-187881e6281a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AccessRightsAndOptionContinuationPeriodsMember_019dd193-ff8d-7356-81a8-a55b02028b83" xlink:href="rcus-20260331.xsd#rcus_AccessRightsAndOptionContinuationPeriodsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019dd193-dc02-7a6c-853a-76684a5b11da" xlink:to="loc_rcus_AccessRightsAndOptionContinuationPeriodsMember_019dd193-ff8d-7356-81a8-a55b02028b83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadCollaborationMember_019dd194-2ea9-7308-9611-3e99724f0734" xlink:href="rcus-20260331.xsd#rcus_GileadCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019dd193-dc02-7a6c-853a-76684a5b11da" xlink:to="loc_rcus_GileadCollaborationMember_019dd194-2ea9-7308-9611-3e99724f0734" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RightsToCertainStudiesMember_019dd194-2ea9-718f-bc86-98cb845cdff0" xlink:href="rcus-20260331.xsd#rcus_RightsToCertainStudiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019dd193-dc02-7a6c-853a-76684a5b11da" xlink:to="loc_rcus_RightsToCertainStudiesMember_019dd194-2ea9-718f-bc86-98cb845cdff0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoCollaborationAgreementMember_019dd194-2ea9-730d-9177-4f65eac02765" xlink:href="rcus-20260331.xsd#rcus_TaihoCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019dd193-dc02-7a6c-853a-76684a5b11da" xlink:to="loc_rcus_TaihoCollaborationAgreementMember_019dd194-2ea9-730d-9177-4f65eac02765" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember_019dd194-2ea9-71bc-bfa2-c8e37f0adf22" xlink:href="rcus-20260331.xsd#rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019dd193-dc02-7a6c-853a-76684a5b11da" xlink:to="loc_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember_019dd194-2ea9-71bc-bfa2-c8e37f0adf22" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionAndLicenseAgreementMember_019dd194-461f-74c8-86b5-3847f7dbb2e8" xlink:href="rcus-20260331.xsd#rcus_OptionAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019dd193-dc02-7a6c-853a-76684a5b11da" xlink:to="loc_rcus_OptionAndLicenseAgreementMember_019dd194-461f-74c8-86b5-3847f7dbb2e8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoCollaborationMember_019dd194-6f33-724b-aa8b-e535f543913c" xlink:href="rcus-20260331.xsd#rcus_TaihoCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019dd193-dc02-7a6c-853a-76684a5b11da" xlink:to="loc_rcus_TaihoCollaborationMember_019dd194-6f33-724b-aa8b-e535f543913c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019dd194-2ea9-73d9-93ee-ed7435590088" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-79f9-8701-9875f3ab7146" xlink:to="loc_srt_ProductOrServiceAxis_019dd194-2ea9-73d9-93ee-ed7435590088" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019dd194-2ea9-73d9-93ee-ed7435590088_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019dd194-2ea9-73d9-93ee-ed7435590088" xlink:to="loc_srt_ProductsAndServicesDomain_019dd194-2ea9-73d9-93ee-ed7435590088_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019dd194-2ea9-747f-abff-7b65576beb76" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019dd194-2ea9-73d9-93ee-ed7435590088" xlink:to="loc_srt_ProductsAndServicesDomain_019dd194-2ea9-747f-abff-7b65576beb76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OtherServicesMember_019dd194-2ea9-7353-9561-4196c8c5f740" xlink:href="rcus-20260331.xsd#rcus_OtherServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019dd194-2ea9-747f-abff-7b65576beb76" xlink:to="loc_rcus_OtherServicesMember_019dd194-2ea9-7353-9561-4196c8c5f740" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndDevelopmentServicesMember_019dd194-6f33-7a0f-bd94-f2265ab0d0b4" xlink:href="rcus-20260331.xsd#rcus_LicenseAndDevelopmentServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019dd194-2ea9-747f-abff-7b65576beb76" xlink:to="loc_rcus_LicenseAndDevelopmentServicesMember_019dd194-6f33-7a0f-bd94-f2265ab0d0b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_019dd194-2ea9-72bd-9df4-7c1b7215416b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-79f9-8701-9875f3ab7146" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_019dd194-2ea9-72bd-9df4-7c1b7215416b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_019dd194-2ea9-72bd-9df4-7c1b7215416b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_019dd194-2ea9-72bd-9df4-7c1b7215416b" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_019dd194-2ea9-72bd-9df4-7c1b7215416b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_019dd194-2ea9-7433-8f4d-e51715721b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_019dd194-2ea9-72bd-9df4-7c1b7215416b" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_019dd194-2ea9-7433-8f4d-e51715721b8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_019dd194-2ea9-706a-9e70-a50edd2e9089" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_019dd194-2ea9-7433-8f4d-e51715721b8f" xlink:to="loc_us-gaap_TransferredOverTimeMember_019dd194-2ea9-706a-9e70-a50edd2e9089" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_019dd6e3-0472-72e2-84ad-57f29a8e18d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-79f9-8701-9875f3ab7146" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_019dd6e3-0472-72e2-84ad-57f29a8e18d4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_019dd6e3-0472-72e2-84ad-57f29a8e18d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_019dd6e3-0472-72e2-84ad-57f29a8e18d4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_019dd6e3-0472-72e2-84ad-57f29a8e18d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_019dd6e3-0472-71c8-ae16-a6e328b02e37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_019dd6e3-0472-72e2-84ad-57f29a8e18d4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_019dd6e3-0472-71c8-ae16-a6e328b02e37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_019dd6e3-2883-764c-9e59-9a919761466d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_019dd6e3-0472-71c8-ae16-a6e328b02e37" xlink:to="loc_us-gaap_SubsequentEventMember_019dd6e3-2883-764c-9e59-9a919761466d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_019dd193-7f18-7aa0-ae6c-c9c0102f6668" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019dd193-7f18-75f2-841b-1e52949eafe6" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_019dd193-7f18-7aa0-ae6c-c9c0102f6668" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_019dd193-9ca8-79f6-99d6-dd5a7ce2f586" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019dd193-7f18-75f2-841b-1e52949eafe6" xlink:to="loc_us-gaap_ContractWithCustomerLiability_019dd193-9ca8-79f6-99d6-dd5a7ce2f586" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_019dd193-9ca8-73af-b294-8a229f926640" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019dd193-7f18-75f2-841b-1e52949eafe6" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_019dd193-9ca8-73af-b294-8a229f926640" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice_019dd193-9ca8-7e70-a840-3d8efeaeeb93" xlink:href="rcus-20260331.xsd#rcus_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019dd193-7f18-75f2-841b-1e52949eafe6" xlink:to="loc_rcus_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice_019dd193-9ca8-7e70-a840-3d8efeaeeb93" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_DeferredRevenueNonRefundablePayment_019dd193-dc02-7322-a6ec-1a3eb7fd2c7c" xlink:href="rcus-20260331.xsd#rcus_DeferredRevenueNonRefundablePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019dd193-7f18-75f2-841b-1e52949eafe6" xlink:to="loc_rcus_DeferredRevenueNonRefundablePayment_019dd193-dc02-7322-a6ec-1a3eb7fd2c7c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019dd193-dc02-73bf-9b7f-eeb55922f3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019dd193-7f18-75f2-841b-1e52949eafe6" xlink:to="loc_us-gaap_Revenues_019dd193-dc02-73bf-9b7f-eeb55922f3a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod_019dd193-ff8d-7f89-a8a9-953aee74bf05" xlink:href="rcus-20260331.xsd#rcus_CurrentAndFutureProgramsExclusiveAccessPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019dd193-7f18-75f2-841b-1e52949eafe6" xlink:to="loc_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod_019dd193-ff8d-7f89-a8a9-953aee74bf05" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ContingentMilestonePaymentsReceivable_019dd193-ff8d-778a-a2bf-8276966c4751" xlink:href="rcus-20260331.xsd#rcus_ContingentMilestonePaymentsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019dd193-7f18-75f2-841b-1e52949eafe6" xlink:to="loc_rcus_ContingentMilestonePaymentsReceivable_019dd193-ff8d-778a-a2bf-8276966c4751" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement_019dd193-ff8d-75b4-89ef-14f7b423b794" xlink:href="rcus-20260331.xsd#rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019dd193-7f18-75f2-841b-1e52949eafe6" xlink:to="loc_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement_019dd193-ff8d-75b4-89ef-14f7b423b794" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PaymentForOptionExercise_019dd194-461f-76ac-b018-732a8bbb804d" xlink:href="rcus-20260331.xsd#rcus_PaymentForOptionExercise"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019dd193-7f18-75f2-841b-1e52949eafe6" xlink:to="loc_rcus_PaymentForOptionExercise_019dd194-461f-76ac-b018-732a8bbb804d" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_019d185f-8bbb-73d4-999c-bf59d3d70936" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_019cd33b-5742-7963-833c-2891c0830428" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_019d185f-8bbb-73d4-999c-bf59d3d70936" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_019cd33b-5742-7963-833c-2891c0830428" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019d185f-d58c-732d-91bf-dd45fb7d1e57" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_019cd33b-5742-7963-833c-2891c0830428" xlink:to="loc_srt_ProductOrServiceAxis_019d185f-d58c-732d-91bf-dd45fb7d1e57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019d185f-d58c-732d-91bf-dd45fb7d1e57_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_019d185f-d58c-732d-91bf-dd45fb7d1e57" xlink:to="loc_srt_ProductsAndServicesDomain_019d185f-d58c-732d-91bf-dd45fb7d1e57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019d185f-d58c-7c8f-ba7b-189175defbd2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_019d185f-d58c-732d-91bf-dd45fb7d1e57" xlink:to="loc_srt_ProductsAndServicesDomain_019d185f-d58c-7c8f-ba7b-189175defbd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndDevelopmentServicesMember_019d185f-d58c-7521-aafa-4a50ca6889c5" xlink:href="rcus-20260331.xsd#rcus_LicenseAndDevelopmentServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019d185f-d58c-7c8f-ba7b-189175defbd2" xlink:to="loc_rcus_LicenseAndDevelopmentServicesMember_019d185f-d58c-7521-aafa-4a50ca6889c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_019dd18f-4a4d-7cbe-9eec-7620e2c7126d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndDevelopmentServicesMember_019d185f-d58c-7521-aafa-4a50ca6889c5" xlink:to="loc_us-gaap_LicenseMember_019dd18f-4a4d-7cbe-9eec-7620e2c7126d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_DevelopmentServicesMember_019dd190-0122-7b08-8f4a-28c503f567fa" xlink:href="rcus-20260331.xsd#rcus_DevelopmentServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_LicenseAndDevelopmentServicesMember_019d185f-d58c-7521-aafa-4a50ca6889c5" xlink:to="loc_rcus_DevelopmentServicesMember_019dd190-0122-7b08-8f4a-28c503f567fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RDServicesMember_019d1876-bd3c-71cf-877f-5dd903dd26fc" xlink:href="rcus-20260331.xsd#rcus_RDServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019d185f-d58c-7c8f-ba7b-189175defbd2" xlink:to="loc_rcus_RDServicesMember_019d1876-bd3c-71cf-877f-5dd903dd26fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AccessRightsAndOptionContinuationPeriodsMember_019d185f-d58c-7c42-92fe-0ff05a5f7e0b" xlink:href="rcus-20260331.xsd#rcus_AccessRightsAndOptionContinuationPeriodsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019d185f-d58c-7c8f-ba7b-189175defbd2" xlink:to="loc_rcus_AccessRightsAndOptionContinuationPeriodsMember_019d185f-d58c-7c42-92fe-0ff05a5f7e0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RightsToCertainStudiesMember_019d185f-d58c-74f6-8228-5fa3ec646c1a" xlink:href="rcus-20260331.xsd#rcus_RightsToCertainStudiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_019d185f-d58c-7c8f-ba7b-189175defbd2" xlink:to="loc_rcus_RightsToCertainStudiesMember_019d185f-d58c-74f6-8228-5fa3ec646c1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019d1876-bd3c-73da-a3b0-4f6372105f7e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_019cd33b-5742-7963-833c-2891c0830428" xlink:to="loc_srt_CounterpartyNameAxis_019d1876-bd3c-73da-a3b0-4f6372105f7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d1876-bd3c-73da-a3b0-4f6372105f7e_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_019d1876-bd3c-73da-a3b0-4f6372105f7e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d1876-bd3c-73da-a3b0-4f6372105f7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d1876-bd3c-7275-bffd-98ec96abd9bc" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_019d1876-bd3c-73da-a3b0-4f6372105f7e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d1876-bd3c-7275-bffd-98ec96abd9bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoPharmaceuticalCoLtdMember_019d1876-bd3c-792d-b8be-648d21d0d769" xlink:href="rcus-20260331.xsd#rcus_TaihoPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d1876-bd3c-7275-bffd-98ec96abd9bc" xlink:to="loc_rcus_TaihoPharmaceuticalCoLtdMember_019d1876-bd3c-792d-b8be-648d21d0d769" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_019d185f-d58c-79e5-afc4-ee0859dc08cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_019d185f-8bbb-73d4-999c-bf59d3d70936" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_019d185f-d58c-79e5-afc4-ee0859dc08cc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetIncomeLossperShareDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetIncomeLossperShareDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetIncomeLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019cd33b-5742-7ecf-b72a-f1512b002da1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019cd33b-5742-7e8e-8cbb-4645de17ccb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019cd33b-5742-7ecf-b72a-f1512b002da1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019cd33b-5742-7e8e-8cbb-4645de17ccb9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019cd33b-5742-7176-aa52-baafadea95f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019cd33b-5742-7e8e-8cbb-4645de17ccb9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019cd33b-5742-7176-aa52-baafadea95f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cd33b-5742-7176-aa52-baafadea95f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019cd33b-5742-7176-aa52-baafadea95f2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cd33b-5742-7176-aa52-baafadea95f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cd33b-5742-7e4d-88f1-1f754766f3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019cd33b-5742-7176-aa52-baafadea95f2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cd33b-5742-7e4d-88f1-1f754766f3f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_019cd33b-5742-795b-becf-f884b01b873f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cd33b-5742-7e4d-88f1-1f754766f3f9" xlink:to="loc_us-gaap_StockCompensationPlanMember_019cd33b-5742-795b-becf-f884b01b873f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019cd33b-5742-7f32-9b1d-bc18b64a3423" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cd33b-5742-7e4d-88f1-1f754766f3f9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019cd33b-5742-7f32-9b1d-bc18b64a3423" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019cd33b-5742-7960-826e-9812403e4bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cd33b-5742-7e4d-88f1-1f754766f3f9" xlink:to="loc_us-gaap_EmployeeStockMember_019cd33b-5742-7960-826e-9812403e4bf1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019cd33b-5742-7206-9f73-5709f380a910" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019cd33b-5742-7ecf-b72a-f1512b002da1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019cd33b-5742-7206-9f73-5709f380a910" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/StockBasedCompensationDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#StockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/StockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019cd33b-5742-7729-aae8-0db6c3159898" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019cd33b-5742-7be4-b42e-9c7841e975aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019cd33b-5742-7729-aae8-0db6c3159898" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019cd33b-5742-7be4-b42e-9c7841e975aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_019cd33b-5742-7e36-b216-fde305c479cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019cd33b-5742-7be4-b42e-9c7841e975aa" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_019cd33b-5742-7e36-b216-fde305c479cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019cd33b-5742-7e36-b216-fde305c479cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019cd33b-5742-7e36-b216-fde305c479cc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019cd33b-5742-7e36-b216-fde305c479cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019cd33b-5742-7a02-a4e0-ba65b8dd9be1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019cd33b-5742-7e36-b216-fde305c479cc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019cd33b-5742-7a02-a4e0-ba65b8dd9be1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019cd33b-5742-72b8-a069-b384882d074a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019cd33b-5742-7a02-a4e0-ba65b8dd9be1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019cd33b-5742-72b8-a069-b384882d074a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019cd33b-5742-7f14-a9ca-861bbbc39fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019cd33b-5742-7a02-a4e0-ba65b8dd9be1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019cd33b-5742-7f14-a9ca-861bbbc39fe1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019cd33b-5742-7837-9240-cb7f0bb866f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019cd33b-5742-7729-aae8-0db6c3159898" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019cd33b-5742-7837-9240-cb7f0bb866f7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019cd33b-5742-7ad0-8014-69e1cd88cea3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019cd33b-5742-7a90-8ef4-5b54c726414b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019cd33b-5742-7ad0-8014-69e1cd88cea3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019cd33b-5742-7a90-8ef4-5b54c726414b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019cd33b-5742-7f91-86e4-15395b09e9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019cd33b-5742-7a90-8ef4-5b54c726414b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019cd33b-5742-7f91-86e4-15395b09e9d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-7f91-86e4-15395b09e9d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019cd33b-5742-7f91-86e4-15395b09e9d0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-7f91-86e4-15395b09e9d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-712b-99e4-2e203669075a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019cd33b-5742-7f91-86e4-15395b09e9d0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-712b-99e4-2e203669075a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_019cd33b-5742-7a96-8d8d-65915bb12798" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-712b-99e4-2e203669075a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_019cd33b-5742-7a96-8d8d-65915bb12798" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_019cd33b-5742-77be-ae16-8345bca44a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-712b-99e4-2e203669075a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_019cd33b-5742-77be-ae16-8345bca44a7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CorporateSecuritiesAndCommercialPaperMember_019cd33b-5742-711c-86a0-c9ca1adf8152" xlink:href="rcus-20260331.xsd#rcus_CorporateSecuritiesAndCommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-712b-99e4-2e203669075a" xlink:to="loc_rcus_CorporateSecuritiesAndCommercialPaperMember_019cd33b-5742-711c-86a0-c9ca1adf8152" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_019cd33b-5742-7c96-a638-f00e8d6bf346" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-712b-99e4-2e203669075a" xlink:to="loc_us-gaap_CertificatesOfDepositMember_019cd33b-5742-7c96-a638-f00e8d6bf346" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019cd33b-5742-78bd-991b-bee8d6049d33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019cd33b-5742-7ad0-8014-69e1cd88cea3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019cd33b-5742-78bd-991b-bee8d6049d33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019cd33b-5742-7183-a7d3-7d3d98164db3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019cd33b-5742-7ad0-8014-69e1cd88cea3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019cd33b-5742-7183-a7d3-7d3d98164db3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019cd33b-5742-7285-b0a4-5f245825733e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019cd33b-5742-7ad0-8014-69e1cd88cea3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019cd33b-5742-7285-b0a4-5f245825733e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019cd33b-5742-7c69-9712-10249466dd8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019cd33b-5742-7ad0-8014-69e1cd88cea3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019cd33b-5742-7c69-9712-10249466dd8d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#LongTermDebtAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019d18b0-cfa0-70f9-addb-384603393cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019cd33b-5742-7330-8eb0-8c860d25b806" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d18b0-cfa0-70f9-addb-384603393cbc" xlink:to="loc_us-gaap_DebtInstrumentTable_019cd33b-5742-7330-8eb0-8c860d25b806" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019d18b0-cfa0-749b-bae4-eb8bb9e3bcdc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019cd33b-5742-7330-8eb0-8c860d25b806" xlink:to="loc_us-gaap_DebtInstrumentAxis_019d18b0-cfa0-749b-bae4-eb8bb9e3bcdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019d18b0-cfa0-749b-bae4-eb8bb9e3bcdc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_019d18b0-cfa0-749b-bae4-eb8bb9e3bcdc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019d18b0-cfa0-749b-bae4-eb8bb9e3bcdc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019d18b0-cfa0-7a0f-a88d-dc2f79410602" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_019d18b0-cfa0-749b-bae4-eb8bb9e3bcdc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019d18b0-cfa0-7a0f-a88d-dc2f79410602" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_HerculesAgreementMember_019d18b0-cfa0-7044-81e1-ef6301a3a487" xlink:href="rcus-20260331.xsd#rcus_HerculesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019d18b0-cfa0-7a0f-a88d-dc2f79410602" xlink:to="loc_rcus_HerculesAgreementMember_019d18b0-cfa0-7044-81e1-ef6301a3a487" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019d18b0-cfa0-70ff-8fe4-7fa0cf0a299d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019cd33b-5742-7330-8eb0-8c860d25b806" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019d18b0-cfa0-70ff-8fe4-7fa0cf0a299d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019d18b0-cfa0-70ff-8fe4-7fa0cf0a299d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019d18b0-cfa0-70ff-8fe4-7fa0cf0a299d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019d18b0-cfa0-70ff-8fe4-7fa0cf0a299d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019d18b0-cfa0-72ad-b2f1-e4acad0f99ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019d18b0-cfa0-70ff-8fe4-7fa0cf0a299d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019d18b0-cfa0-72ad-b2f1-e4acad0f99ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_019d18b0-cfa0-77fe-83ac-3bb38339dbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019d18b0-cfa0-72ad-b2f1-e4acad0f99ec" xlink:to="loc_us-gaap_SecuredDebtMember_019d18b0-cfa0-77fe-83ac-3bb38339dbb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_DebtInstrumentTrancheTypeAxis_019d18b0-cfa0-7588-856e-b47ca3a4e179" xlink:href="rcus-20260331.xsd#rcus_DebtInstrumentTrancheTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_019cd33b-5742-7330-8eb0-8c860d25b806" xlink:to="loc_rcus_DebtInstrumentTrancheTypeAxis_019d18b0-cfa0-7588-856e-b47ca3a4e179" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_DebtInstrumentTrancheTypeDomain_019d18b0-cfa0-7588-856e-b47ca3a4e179_default" xlink:href="rcus-20260331.xsd#rcus_DebtInstrumentTrancheTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rcus_DebtInstrumentTrancheTypeAxis_019d18b0-cfa0-7588-856e-b47ca3a4e179" xlink:to="loc_rcus_DebtInstrumentTrancheTypeDomain_019d18b0-cfa0-7588-856e-b47ca3a4e179_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_DebtInstrumentTrancheTypeDomain_019d18b0-cfa0-7a43-a125-d4855b9067b8" xlink:href="rcus-20260331.xsd#rcus_DebtInstrumentTrancheTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rcus_DebtInstrumentTrancheTypeAxis_019d18b0-cfa0-7588-856e-b47ca3a4e179" xlink:to="loc_rcus_DebtInstrumentTrancheTypeDomain_019d18b0-cfa0-7a43-a125-d4855b9067b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TrancheOneMember_019d18b0-cfa0-7711-99c0-3a0c123af078" xlink:href="rcus-20260331.xsd#rcus_TrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_DebtInstrumentTrancheTypeDomain_019d18b0-cfa0-7a43-a125-d4855b9067b8" xlink:to="loc_rcus_TrancheOneMember_019d18b0-cfa0-7711-99c0-3a0c123af078" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TrancheTwoMember_019d18b0-cfa0-747e-b0fe-9a75265308cb" xlink:href="rcus-20260331.xsd#rcus_TrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rcus_DebtInstrumentTrancheTypeDomain_019d18b0-cfa0-7a43-a125-d4855b9067b8" xlink:to="loc_rcus_TrancheTwoMember_019d18b0-cfa0-747e-b0fe-9a75265308cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_019d18b0-cfa0-7203-91c1-8fd46ea78154" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d18b0-cfa0-70f9-addb-384603393cbc" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_019d18b0-cfa0-7203-91c1-8fd46ea78154" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_019d18b0-cfa0-725b-bacf-eb91c68131b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d18b0-cfa0-70f9-addb-384603393cbc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_019d18b0-cfa0-725b-bacf-eb91c68131b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_DebtInstrumentAdditionalCommittedAmount_019d18b0-cfa0-7fbd-85f3-f5f13218a191" xlink:href="rcus-20260331.xsd#rcus_DebtInstrumentAdditionalCommittedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d18b0-cfa0-70f9-addb-384603393cbc" xlink:to="loc_rcus_DebtInstrumentAdditionalCommittedAmount_019d18b0-cfa0-7fbd-85f3-f5f13218a191" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_DebtInstrumentFaceAmountContingentlyAvailable_019d18b0-cfa0-769c-8466-4fb36bcb6fdf" xlink:href="rcus-20260331.xsd#rcus_DebtInstrumentFaceAmountContingentlyAvailable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d18b0-cfa0-70f9-addb-384603393cbc" xlink:to="loc_rcus_DebtInstrumentFaceAmountContingentlyAvailable_019d18b0-cfa0-769c-8466-4fb36bcb6fdf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_DebtInstrumentMilestoneAchievementPeriod_019d18b0-cfa0-75c5-bc2b-d7e4c7d60831" xlink:href="rcus-20260331.xsd#rcus_DebtInstrumentMilestoneAchievementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d18b0-cfa0-70f9-addb-384603393cbc" xlink:to="loc_rcus_DebtInstrumentMilestoneAchievementPeriod_019d18b0-cfa0-75c5-bc2b-d7e4c7d60831" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_019d18b0-cfa0-72ef-98ca-0a259abd8953" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d18b0-cfa0-70f9-addb-384603393cbc" xlink:to="loc_us-gaap_InterestExpenseDebt_019d18b0-cfa0-72ef-98ca-0a259abd8953" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_019d18b0-cfa0-7b3a-888f-7d5a17f7d649" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d18b0-cfa0-70f9-addb-384603393cbc" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_019d18b0-cfa0-7b3a-888f-7d5a17f7d649" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_019cd33b-5742-76fc-b12a-69e6721af936" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_019cd33b-5742-7cb0-b44f-98d245a488e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cd33b-5742-76fc-b12a-69e6721af936" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_019cd33b-5742-7cb0-b44f-98d245a488e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019cd33b-5742-7e37-9c3c-d7082d2d54b6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cd33b-5742-7cb0-b44f-98d245a488e3" xlink:to="loc_dei_LegalEntityAxis_019cd33b-5742-7e37-9c3c-d7082d2d54b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019cd33b-5742-7e37-9c3c-d7082d2d54b6_default" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_019cd33b-5742-7e37-9c3c-d7082d2d54b6" xlink:to="loc_dei_EntityDomain_019cd33b-5742-7e37-9c3c-d7082d2d54b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019cd33b-5742-7562-8f57-5793e7244536" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_019cd33b-5742-7e37-9c3c-d7082d2d54b6" xlink:to="loc_dei_EntityDomain_019cd33b-5742-7562-8f57-5793e7244536" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadSciencesIncMember_019cd33b-5742-7a69-8da0-32e075cb4d42" xlink:href="rcus-20260331.xsd#rcus_GileadSciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_019cd33b-5742-7562-8f57-5793e7244536" xlink:to="loc_rcus_GileadSciencesIncMember_019cd33b-5742-7a69-8da0-32e075cb4d42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019cd33b-5742-743a-866a-5e1a93f0f05d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cd33b-5742-7cb0-b44f-98d245a488e3" xlink:to="loc_srt_CounterpartyNameAxis_019cd33b-5742-743a-866a-5e1a93f0f05d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019cd33b-5742-743a-866a-5e1a93f0f05d_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_019cd33b-5742-743a-866a-5e1a93f0f05d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019cd33b-5742-743a-866a-5e1a93f0f05d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019cd33b-5742-70a0-afe0-0c07b91088ef" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_019cd33b-5742-743a-866a-5e1a93f0f05d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019cd33b-5742-70a0-afe0-0c07b91088ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadSciencesIncMember_019cd33b-5742-789f-80d7-42f14e590b82" xlink:href="rcus-20260331.xsd#rcus_GileadSciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019cd33b-5742-70a0-afe0-0c07b91088ef" xlink:to="loc_rcus_GileadSciencesIncMember_019cd33b-5742-789f-80d7-42f14e590b82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019cd33b-5742-7aa3-94be-cccfc3a70b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cd33b-5742-76fc-b12a-69e6721af936" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019cd33b-5742-7aa3-94be-cccfc3a70b0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019cd33b-5742-7241-b764-ab98aecfd66b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cd33b-5742-76fc-b12a-69e6721af936" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019cd33b-5742-7241-b764-ab98aecfd66b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019cd33b-5742-7528-91ea-41c65008c5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cd33b-5742-76fc-b12a-69e6721af936" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019cd33b-5742-7528-91ea-41c65008c5d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_SaleOfStockNumberOfSharesAcquiredInTransaction_019cd33b-5742-7cbd-b349-641c7a0aa7f5" xlink:href="rcus-20260331.xsd#rcus_SaleOfStockNumberOfSharesAcquiredInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cd33b-5742-76fc-b12a-69e6721af936" xlink:to="loc_rcus_SaleOfStockNumberOfSharesAcquiredInTransaction_019cd33b-5742-7cbd-b349-641c7a0aa7f5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cd33b-5742-7a49-9f7a-a7671a5076f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cd33b-5742-7ad2-9409-d063dbc81c32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cd33b-5742-7a49-9f7a-a7671a5076f4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cd33b-5742-7ad2-9409-d063dbc81c32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cd33b-5742-7ec2-aa80-bcb68e567886" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cd33b-5742-7ad2-9409-d063dbc81c32" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cd33b-5742-7ec2-aa80-bcb68e567886" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cd33b-5742-7ec2-aa80-bcb68e567886_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cd33b-5742-7ec2-aa80-bcb68e567886" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cd33b-5742-7ec2-aa80-bcb68e567886_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cd33b-5742-7227-a12e-8710c580b735" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cd33b-5742-7ec2-aa80-bcb68e567886" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cd33b-5742-7227-a12e-8710c580b735" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_019cd33b-5742-7b43-9e50-8a47ff62eabc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cd33b-5742-7227-a12e-8710c580b735" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_019cd33b-5742-7b43-9e50-8a47ff62eabc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_019cd33b-5742-75a0-8961-02b0bf92e9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cd33b-5742-7227-a12e-8710c580b735" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_019cd33b-5742-75a0-8961-02b0bf92e9c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019cd33b-5742-7069-819c-7aba7a54ef70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cd33b-5742-7227-a12e-8710c580b735" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019cd33b-5742-7069-819c-7aba7a54ef70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019cd33b-5742-7e0c-b849-47d9ee973bba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cd33b-5742-7ad2-9409-d063dbc81c32" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019cd33b-5742-7e0c-b849-47d9ee973bba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-7e0c-b849-47d9ee973bba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019cd33b-5742-7e0c-b849-47d9ee973bba" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-7e0c-b849-47d9ee973bba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-7602-b104-959b5a4b9b34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019cd33b-5742-7e0c-b849-47d9ee973bba" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-7602-b104-959b5a4b9b34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_019cd33b-5742-79eb-9f41-979c72a8fa7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-7602-b104-959b5a4b9b34" xlink:to="loc_us-gaap_MoneyMarketFundsMember_019cd33b-5742-79eb-9f41-979c72a8fa7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_019cd33b-5742-7e91-8e89-88e20ccde690" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-7602-b104-959b5a4b9b34" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_019cd33b-5742-7e91-8e89-88e20ccde690" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CorporateSecuritiesAndCommercialPaperMember_019cd33b-5742-7e2a-9d16-14758d660ead" xlink:href="rcus-20260331.xsd#rcus_CorporateSecuritiesAndCommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-7602-b104-959b5a4b9b34" xlink:to="loc_rcus_CorporateSecuritiesAndCommercialPaperMember_019cd33b-5742-7e2a-9d16-14758d660ead" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_019cd33b-5742-79ac-bfea-37a81360f4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-7602-b104-959b5a4b9b34" xlink:to="loc_us-gaap_CertificatesOfDepositMember_019cd33b-5742-79ac-bfea-37a81360f4e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_019cd33b-5742-70ef-9777-5f57ec549077" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cd33b-5742-7a49-9f7a-a7671a5076f4" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_019cd33b-5742-70ef-9777-5f57ec549077" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_019cd33b-5742-78cf-9ff7-8197bd7dfe07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cd33b-5742-7a49-9f7a-a7671a5076f4" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_019cd33b-5742-78cf-9ff7-8197bd7dfe07" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/BusinessSegmentAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#BusinessSegmentAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/BusinessSegmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019cd33b-5742-7eac-b06b-8e7b6f5b7842" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019cd33b-5742-7509-ad33-0bc2daa68171" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019cd33b-5742-7eac-b06b-8e7b6f5b7842" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019cd33b-5742-7509-ad33-0bc2daa68171" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019cd33b-5742-7513-b85a-cd623e46b098" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019cd33b-5742-7509-ad33-0bc2daa68171" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019cd33b-5742-7513-b85a-cd623e46b098" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019cd33b-5742-7513-b85a-cd623e46b098_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019cd33b-5742-7513-b85a-cd623e46b098" xlink:to="loc_us-gaap_SegmentDomain_019cd33b-5742-7513-b85a-cd623e46b098_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019cd33b-5742-79c3-a492-064a363cd4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019cd33b-5742-7513-b85a-cd623e46b098" xlink:to="loc_us-gaap_SegmentDomain_019cd33b-5742-79c3-a492-064a363cd4ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ReportableSegmentMember_019cd33b-5742-7e33-ba72-9b9b4d92f889" xlink:href="rcus-20260331.xsd#rcus_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019cd33b-5742-79c3-a492-064a363cd4ae" xlink:to="loc_rcus_ReportableSegmentMember_019cd33b-5742-7e33-ba72-9b9b4d92f889" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_019cd33b-5742-7330-97df-ca035f909b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019cd33b-5742-7eac-b06b-8e7b6f5b7842" xlink:to="loc_us-gaap_NumberOfReportableSegments_019cd33b-5742-7330-97df-ca035f909b5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_019cd33b-5742-710d-90f3-3fe4f74d56a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019cd33b-5742-7eac-b06b-8e7b6f5b7842" xlink:to="loc_us-gaap_NumberOfOperatingSegments_019cd33b-5742-710d-90f3-3fe4f74d56a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019cd33b-5742-7c90-b391-996e27393559" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019cd33b-5742-7eac-b06b-8e7b6f5b7842" xlink:to="loc_us-gaap_Assets_019cd33b-5742-7c90-b391-996e27393559" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#BusinessSegmentSummaryofSegmentReportingInformationDetails"/>
  <link:definitionLink xlink:role="http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019cd33b-5742-7d7a-8654-0963ffe5519f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019cd33b-5742-7183-91cc-c308b53eda63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019cd33b-5742-7d7a-8654-0963ffe5519f" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019cd33b-5742-7183-91cc-c308b53eda63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019cd33b-5742-742a-bf68-a4ba9a7b1a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019cd33b-5742-7183-91cc-c308b53eda63" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019cd33b-5742-742a-bf68-a4ba9a7b1a0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019cd33b-5742-742a-bf68-a4ba9a7b1a0c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019cd33b-5742-742a-bf68-a4ba9a7b1a0c" xlink:to="loc_us-gaap_SegmentDomain_019cd33b-5742-742a-bf68-a4ba9a7b1a0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019cd33b-5742-71cf-a40c-fa7f03afbbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019cd33b-5742-742a-bf68-a4ba9a7b1a0c" xlink:to="loc_us-gaap_SegmentDomain_019cd33b-5742-71cf-a40c-fa7f03afbbb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ReportableSegmentMember_019cd33b-5742-7161-8521-8dfa7775b5b8" xlink:href="rcus-20260331.xsd#rcus_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_019cd33b-5742-71cf-a40c-fa7f03afbbb0" xlink:to="loc_rcus_ReportableSegmentMember_019cd33b-5742-7161-8521-8dfa7775b5b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019cd33b-5742-7104-a785-98184f64f884" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019cd33b-5742-7d7a-8654-0963ffe5519f" xlink:to="loc_us-gaap_Revenues_019cd33b-5742-7104-a785-98184f64f884" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_019cd33b-5742-7cf0-9ebc-749685ed5684" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019cd33b-5742-7d7a-8654-0963ffe5519f" xlink:to="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_019cd33b-5742-7cf0-9ebc-749685ed5684" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LateStageDevelopmentPrograms_019cd33b-5742-753c-b8ce-a709e91c0bff" xlink:href="rcus-20260331.xsd#rcus_LateStageDevelopmentPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_019cd33b-5742-7cf0-9ebc-749685ed5684" xlink:to="loc_rcus_LateStageDevelopmentPrograms_019cd33b-5742-753c-b8ce-a709e91c0bff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_EarlyStageDevelopmentAndPreclinicalPrograms_019cd33b-5742-7e4d-9d36-7f216697405c" xlink:href="rcus-20260331.xsd#rcus_EarlyStageDevelopmentAndPreclinicalPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_019cd33b-5742-7cf0-9ebc-749685ed5684" xlink:to="loc_rcus_EarlyStageDevelopmentAndPreclinicalPrograms_019cd33b-5742-7e4d-9d36-7f216697405c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_019cd33b-5742-7ba5-b502-cd36dba2efb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_019cd33b-5742-7cf0-9ebc-749685ed5684" xlink:to="loc_us-gaap_LaborAndRelatedExpense_019cd33b-5742-7ba5-b502-cd36dba2efb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_019cd33b-5742-7aaa-91b2-728a53165a15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_019cd33b-5742-7cf0-9ebc-749685ed5684" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_019cd33b-5742-7aaa-91b2-728a53165a15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_019dd136-a8d1-7232-99e9-c7612e523beb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_019cd33b-5742-7cf0-9ebc-749685ed5684" xlink:to="loc_us-gaap_InterestExpenseNonoperating_019dd136-a8d1-7232-99e9-c7612e523beb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_019cd33b-5742-77b4-b70e-98c94e91a529" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_019cd33b-5742-7cf0-9ebc-749685ed5684" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_019cd33b-5742-77b4-b70e-98c94e91a529" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PartnershipReimbursements_019cfa98-cd5e-72ee-9b4b-f82db64e8578" xlink:href="rcus-20260331.xsd#rcus_PartnershipReimbursements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_019cd33b-5742-7cf0-9ebc-749685ed5684" xlink:to="loc_rcus_PartnershipReimbursements_019cfa98-cd5e-72ee-9b4b-f82db64e8578" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cd33b-5742-779a-ba4c-5b5e9d71ebb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019cd33b-5742-7d7a-8654-0963ffe5519f" xlink:to="loc_us-gaap_NetIncomeLoss_019cd33b-5742-779a-ba4c-5b5e9d71ebb4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RobertC.GoeltzIIMember_019cd33b-55e3-76a6-8e9c-f4c954d04590" xlink:href="rcus-20260331.xsd#rcus_RobertC.GoeltzIIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rcus_RobertC.GoeltzIIMember_019cd33b-55e3-76a6-8e9c-f4c954d04590" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_JuanJaenMember_019cd33b-55e2-7082-947f-3e692d2fcc96" xlink:href="rcus-20260331.xsd#rcus_JuanJaenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rcus_JuanJaenMember_019cd33b-55e2-7082-947f-3e692d2fcc96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_JenniferJarrettMember_019cd33b-5742-7dab-bc3c-ea684c5dc52b" xlink:href="rcus-20260331.xsd#rcus_JenniferJarrettMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rcus_JenniferJarrettMember_019cd33b-5742-7dab-bc3c-ea684c5dc52b" xlink:type="arc" order="4"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>rcus-20260331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019cd33b-55e2-7686-a45d-3e64ec40f088,g:5cd5bcae-d38e-4438-9e12-43823d2921f9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_rcus_LicenseAndCollaborationAgreementsLineItems_019cd33b-57f4-7431-9d28-70f3fb67622d_terseLabel_en-US" xlink:label="lab_rcus_LicenseAndCollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_rcus_LicenseAndCollaborationAgreementsLineItems_label_en-US" xlink:label="lab_rcus_LicenseAndCollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License and Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_rcus_LicenseAndCollaborationAgreementsLineItems_documentation_en-US" xlink:label="lab_rcus_LicenseAndCollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndCollaborationAgreementsLineItems" xlink:href="rcus-20260331.xsd#rcus_LicenseAndCollaborationAgreementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems" xlink:to="lab_rcus_LicenseAndCollaborationAgreementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_019cd33b-57f4-7347-bdd2-054fb55bf14c_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_019cd33b-5742-78b2-9b8b-13dfcb3121c2_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_019cd33b-57f4-7504-a4f2-be080e5e76bc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Our Cash, Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_019cd33b-57f4-7b27-80c1-677534bf9663_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019cd33b-5742-71d1-9ddc-1b939f0fc188_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_019cd33b-57f4-733f-8e2c-328657161777_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember_019cf9b4-1b38-74d7-8bb8-c5bc261f6650_terseLabel_en-US" xlink:label="lab_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Cash Equivalents and Investments in Marketable Securities</link:label>
    <link:label id="lab_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember_label_en-US" xlink:label="lab_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Cash Equivalents And Investments In Marketable Securities [Member]</link:label>
    <link:label id="lab_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember_documentation_en-US" xlink:label="lab_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and investments in marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember" xlink:href="rcus-20260331.xsd#rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember" xlink:to="lab_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019cd33b-5742-738a-8449-f7550b7e7da8_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_019cd33b-57f4-7ffb-b8f6-7499bacee8f5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable (($13) and $&#8212; to a related party)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_019cd33b-57f4-71a1-a9c8-bc308b3fea5f_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_DebtInstrumentTrancheTypeAxis_019d18b0-cfa0-7373-b8d2-94691fb6823c_terseLabel_en-US" xlink:label="lab_rcus_DebtInstrumentTrancheTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche Type [Axis]</link:label>
    <link:label id="lab_rcus_DebtInstrumentTrancheTypeAxis_label_en-US" xlink:label="lab_rcus_DebtInstrumentTrancheTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche Type [Axis]</link:label>
    <link:label id="lab_rcus_DebtInstrumentTrancheTypeAxis_documentation_en-US" xlink:label="lab_rcus_DebtInstrumentTrancheTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_DebtInstrumentTrancheTypeAxis" xlink:href="rcus-20260331.xsd#rcus_DebtInstrumentTrancheTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_DebtInstrumentTrancheTypeAxis" xlink:to="lab_rcus_DebtInstrumentTrancheTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_019cd33b-57f4-787a-bce7-d872dd2d7ade_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivable from collaboration partners</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_019cd33b-5742-7958-9fa3-3ca14c6422b3_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock options issued and outstanding</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_019cfa2e-114b-775f-9902-e67847cb2a93_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019cd33b-5742-7130-98e5-bf3bba569954_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_019cd33b-57f4-733c-84de-650b1ea0016a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_019cd33b-57f4-70ee-8bc6-9c31366ef5b8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party - Gilead Sciences, Inc.</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_019cd33b-5742-744b-a13e-6c417ef0c887_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_019cd33b-57f4-7f9f-8eb5-f23fe9c9b8a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_GileadCollaborationMember_019cd33b-5742-79cb-8ed5-b9936c3bc5bd_terseLabel_en-US" xlink:label="lab_rcus_GileadCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gilead Collaboration</link:label>
    <link:label id="lab_rcus_GileadCollaborationMember_label_en-US" xlink:label="lab_rcus_GileadCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gilead Collaboration [Member]</link:label>
    <link:label id="lab_rcus_GileadCollaborationMember_documentation_en-US" xlink:label="lab_rcus_GileadCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gilead Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadCollaborationMember" xlink:href="rcus-20260331.xsd#rcus_GileadCollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_GileadCollaborationMember" xlink:to="lab_rcus_GileadCollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019cd33b-57f4-7ace-9832-b07a975c3f6d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_019cd33b-5742-7914-a962-bfaea8c1f193_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Segment Reporting Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_019cd33b-57f4-7d54-a4ac-3208af1eacbc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Fair Values of Our Cash, Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, and Investment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_019cd33b-5742-733d-b300-05e29f021084_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total transaction price</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_019cd33b-5742-7c80-add9-6d2cbb85e6a2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_019cd33b-57f4-76d2-95e7-8b8ad1ef00a6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues from collaborations</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_019cd33b-5742-7cdd-8b60-9b280dfacbbe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unamortized discounts, issuance costs, charges and payment-in-kind interest, net</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_019d18e3-21e5-715d-97da-ce42996abde3_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_019cd33b-57f4-77c0-86c3-a7737e248696_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OptionPaymentUponCompletionOfCertainINDEnablingActivities_019cd33b-57f4-746a-92e2-6793afffa71b_terseLabel_en-US" xlink:label="lab_rcus_OptionPaymentUponCompletionOfCertainINDEnablingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option payment upon completion of certain IND-enabling activities</link:label>
    <link:label id="lab_rcus_OptionPaymentUponCompletionOfCertainINDEnablingActivities_label_en-US" xlink:label="lab_rcus_OptionPaymentUponCompletionOfCertainINDEnablingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Payment Upon Completion Of certain IND-enabling Activities</link:label>
    <link:label id="lab_rcus_OptionPaymentUponCompletionOfCertainINDEnablingActivities_documentation_en-US" xlink:label="lab_rcus_OptionPaymentUponCompletionOfCertainINDEnablingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option payment upon completion of certain IND-enabling activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionPaymentUponCompletionOfCertainINDEnablingActivities" xlink:href="rcus-20260331.xsd#rcus_OptionPaymentUponCompletionOfCertainINDEnablingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OptionPaymentUponCompletionOfCertainINDEnablingActivities" xlink:to="lab_rcus_OptionPaymentUponCompletionOfCertainINDEnablingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019cd33b-57f4-7982-8f7b-eb15d6d84e76_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_019cd33b-57f4-71e3-a109-9af035b4d51c_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_019cd33b-57f4-7913-9589-7cff583c6b6f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_019cd33b-57f4-756d-a85f-e85965f3cd7a_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_019cd33b-57f4-7c25-b9ff-156eeb3ad7b9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_019cd33b-5742-702d-9c2d-66fec0ec8aa4_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_019cd33b-57f4-72b7-9fd3-1856e640eb3a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019cd33b-5742-756b-80d8-e22a42738bc6_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting, Asset Reconciling Item [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Asset Reconciling Item [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:to="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019cd33b-57f4-77f1-b8f9-af9dc52c9b0c_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_019cd33b-5742-7323-9bbc-85c055016186_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_019cd33b-5742-7680-9db5-2169a9244ac5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019cd33b-57f4-7d7b-905c-d37c4b70c6c5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_019cd33b-5742-77b6-aef0-8306b49b635b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_AccruedResearchAndDevelopmentExpensesCurrent_019cd33b-5742-75c9-994b-a29b2c93cebc_terseLabel_en-US" xlink:label="lab_rcus_AccruedResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued research and development</link:label>
    <link:label id="lab_rcus_AccruedResearchAndDevelopmentExpensesCurrent_label_en-US" xlink:label="lab_rcus_AccruedResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Expenses Current</link:label>
    <link:label id="lab_rcus_AccruedResearchAndDevelopmentExpensesCurrent_documentation_en-US" xlink:label="lab_rcus_AccruedResearchAndDevelopmentExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued research and development expenses current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AccruedResearchAndDevelopmentExpensesCurrent" xlink:href="rcus-20260331.xsd#rcus_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="lab_rcus_AccruedResearchAndDevelopmentExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_NumberOfBoardMembers_019cd33b-57f4-705e-b5ce-785ed11f65cd_terseLabel_en-US" xlink:label="lab_rcus_NumberOfBoardMembers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of board members</link:label>
    <link:label id="lab_rcus_NumberOfBoardMembers_label_en-US" xlink:label="lab_rcus_NumberOfBoardMembers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Board Members</link:label>
    <link:label id="lab_rcus_NumberOfBoardMembers_documentation_en-US" xlink:label="lab_rcus_NumberOfBoardMembers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Board Members</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NumberOfBoardMembers" xlink:href="rcus-20260331.xsd#rcus_NumberOfBoardMembers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_NumberOfBoardMembers" xlink:to="lab_rcus_NumberOfBoardMembers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019cd33b-5742-7b52-a6e2-c4fe4a8f06e8_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019cd33b-5742-7603-a61b-13d8cbf2856f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019cd33b-5742-7592-b539-f8a1eab9ab0f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_019cd33b-5742-78e0-abee-f770527b7e07_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-operating income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_019cd33b-57f4-7b73-9120-bbd04b3ff536_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019cd33b-5742-76f0-8883-7405af520552_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_019cd33b-5742-75c4-846f-0d0473168d37_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_019cd33b-57f4-7ccf-9b10-e28b17f2b487_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_019cd33b-5742-7bd8-a97d-7957368f61ed_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_019cd33b-57f4-7975-867e-a38c6182afdc_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_019cd33b-57f4-7f07-a5ad-d9297ff30583_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement_019cd33b-57f4-75f9-bd3b-eb06a62dd1ab_terseLabel_en-US" xlink:label="lab_rcus_OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option continuation payment due upon fourth anniversary of agreement</link:label>
    <link:label id="lab_rcus_OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement_label_en-US" xlink:label="lab_rcus_OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Continuation Payment Due Upon Fourth Anniversary Of Agreement</link:label>
    <link:label id="lab_rcus_OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement_documentation_en-US" xlink:label="lab_rcus_OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option continuation payment due upon Fourth anniversary of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement" xlink:href="rcus-20260331.xsd#rcus_OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement" xlink:to="lab_rcus_OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_RemoveOptionContinuationPaymentUnderAgreement_019cd33b-57f4-7e09-9357-4e15dfdb0001_terseLabel_en-US" xlink:label="lab_rcus_RemoveOptionContinuationPaymentUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Removal of option continuation payment under agreement</link:label>
    <link:label id="lab_rcus_RemoveOptionContinuationPaymentUnderAgreement_label_en-US" xlink:label="lab_rcus_RemoveOptionContinuationPaymentUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remove Option Continuation Payment Under Agreement</link:label>
    <link:label id="lab_rcus_RemoveOptionContinuationPaymentUnderAgreement_documentation_en-US" xlink:label="lab_rcus_RemoveOptionContinuationPaymentUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Remove option continuation payment under agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RemoveOptionContinuationPaymentUnderAgreement" xlink:href="rcus-20260331.xsd#rcus_RemoveOptionContinuationPaymentUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_RemoveOptionContinuationPaymentUnderAgreement" xlink:to="lab_rcus_RemoveOptionContinuationPaymentUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_019cd33b-57f4-7d3e-bae0-6715f1dfdfec_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_019cd33b-5742-7bc3-be2f-eff421ebb40b_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cd33b-5742-7fe7-8c29-e71774b92279_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_019cd33b-57f4-7a86-b5d6-b3ac4650c64d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_019cd33b-5742-7943-bc76-628d73b23986_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_019cd33b-5742-74c1-a8e1-06dff02438d5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_STAR221DevelopmentActivitiesMember_019cd33b-57f4-76be-90fc-b5f0e3e955d6_terseLabel_en-US" xlink:label="lab_rcus_STAR221DevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STAR-221 Development Activities</link:label>
    <link:label id="lab_rcus_STAR221DevelopmentActivitiesMember_label_en-US" xlink:label="lab_rcus_STAR221DevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">STAR-221 Development Activities [Member]</link:label>
    <link:label id="lab_rcus_STAR221DevelopmentActivitiesMember_documentation_en-US" xlink:label="lab_rcus_STAR221DevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">STAR-221 Development Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_STAR221DevelopmentActivitiesMember" xlink:href="rcus-20260331.xsd#rcus_STAR221DevelopmentActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_STAR221DevelopmentActivitiesMember" xlink:to="lab_rcus_STAR221DevelopmentActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ProceedsFromMaturityOfMarketableSecurities_019cd33b-5742-78d2-9368-8cb6d6f50f80_terseLabel_en-US" xlink:label="lab_rcus_ProceedsFromMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_rcus_ProceedsFromMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_rcus_ProceedsFromMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Maturity Of Marketable Securities</link:label>
    <link:label id="lab_rcus_ProceedsFromMaturityOfMarketableSecurities_documentation_en-US" xlink:label="lab_rcus_ProceedsFromMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from maturity of marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ProceedsFromMaturityOfMarketableSecurities" xlink:href="rcus-20260331.xsd#rcus_ProceedsFromMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ProceedsFromMaturityOfMarketableSecurities" xlink:to="lab_rcus_ProceedsFromMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_EarlyStageDevelopmentAndPreclinicalPrograms_019cd33b-57f4-7b53-93a9-3ec8d9d2590d_terseLabel_en-US" xlink:label="lab_rcus_EarlyStageDevelopmentAndPreclinicalPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Early-stage development and preclinical programs</link:label>
    <link:label id="lab_rcus_EarlyStageDevelopmentAndPreclinicalPrograms_label_en-US" xlink:label="lab_rcus_EarlyStageDevelopmentAndPreclinicalPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Early Stage Development And Preclinical Programs</link:label>
    <link:label id="lab_rcus_EarlyStageDevelopmentAndPreclinicalPrograms_documentation_en-US" xlink:label="lab_rcus_EarlyStageDevelopmentAndPreclinicalPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Early Stage Development And Preclinical Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_EarlyStageDevelopmentAndPreclinicalPrograms" xlink:href="rcus-20260331.xsd#rcus_EarlyStageDevelopmentAndPreclinicalPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_EarlyStageDevelopmentAndPreclinicalPrograms" xlink:to="lab_rcus_EarlyStageDevelopmentAndPreclinicalPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_TotalUpfrontCashPayment_019cd33b-5742-7777-9cf0-156777b4072a_terseLabel_en-US" xlink:label="lab_rcus_TotalUpfrontCashPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total upfront cash payment</link:label>
    <link:label id="lab_rcus_TotalUpfrontCashPayment_label_en-US" xlink:label="lab_rcus_TotalUpfrontCashPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Upfront Cash Payment</link:label>
    <link:label id="lab_rcus_TotalUpfrontCashPayment_documentation_en-US" xlink:label="lab_rcus_TotalUpfrontCashPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Upfront Cash Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TotalUpfrontCashPayment" xlink:href="rcus-20260331.xsd#rcus_TotalUpfrontCashPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_TotalUpfrontCashPayment" xlink:to="lab_rcus_TotalUpfrontCashPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_019cd33b-57f4-7e6c-b1a3-20b6bc2bbf1a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_019cd33b-5742-78e1-87ad-d715be6382d7_terseLabel_en-US" xlink:label="lab_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assets and Liabilities Measured On Recurring Basis [Table Text Block]</link:label>
    <link:label id="lab_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_documentation_en-US" xlink:label="lab_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value assets and liabilities measured on recurring basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="rcus-20260331.xsd#rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_019cd33b-57f4-7273-b01d-a58576ad3aa4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_019cd33b-5742-75a5-9832-1e155e97cd6e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_019cd33b-5742-78a2-a655-8c9fba40b8e6_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_STAR121DevelopmentActivitiesMember_019cd33b-57f4-786e-9911-120548ea6209_terseLabel_en-US" xlink:label="lab_rcus_STAR121DevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STAR-121 Development Activities</link:label>
    <link:label id="lab_rcus_STAR121DevelopmentActivitiesMember_label_en-US" xlink:label="lab_rcus_STAR121DevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">STAR-121 Development Activities [Member]</link:label>
    <link:label id="lab_rcus_STAR121DevelopmentActivitiesMember_documentation_en-US" xlink:label="lab_rcus_STAR121DevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">STAR-121 Development Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_STAR121DevelopmentActivitiesMember" xlink:href="rcus-20260331.xsd#rcus_STAR121DevelopmentActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_STAR121DevelopmentActivitiesMember" xlink:to="lab_rcus_STAR121DevelopmentActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList_019cd33b-5742-7a71-838b-29f15eb6b74a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_019cd33b-57f4-7756-ac22-ee8ee5086c94_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_019cd33b-57f4-77d6-8fcd-08e3d6a88b77_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_019cd33b-57f4-7d2c-97b1-91055092f155_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_AstraZenecaAgreementMember_019cd33b-5742-7268-9323-36be3cfaa03a_terseLabel_en-US" xlink:label="lab_rcus_AstraZenecaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AstraZeneca Agreement</link:label>
    <link:label id="lab_rcus_AstraZenecaAgreementMember_label_en-US" xlink:label="lab_rcus_AstraZenecaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Astra Zeneca Agreement [Member]</link:label>
    <link:label id="lab_rcus_AstraZenecaAgreementMember_documentation_en-US" xlink:label="lab_rcus_AstraZenecaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AstraZeneca Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AstraZenecaAgreementMember" xlink:href="rcus-20260331.xsd#rcus_AstraZenecaAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_AstraZenecaAgreementMember" xlink:to="lab_rcus_AstraZenecaAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_019cd33b-5742-7f66-a1b8-28fb154334f6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_RightsToCertainStudiesMember_019cd33b-57f4-73bf-b86e-db2661d3b9dd_terseLabel_en-US" xlink:label="lab_rcus_RightsToCertainStudiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rights to certain studies</link:label>
    <link:label id="lab_rcus_RightsToCertainStudiesMember_label_en-US" xlink:label="lab_rcus_RightsToCertainStudiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rights To Certain Studies [Member]</link:label>
    <link:label id="lab_rcus_RightsToCertainStudiesMember_documentation_en-US" xlink:label="lab_rcus_RightsToCertainStudiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rights To Certain Studies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RightsToCertainStudiesMember" xlink:href="rcus-20260331.xsd#rcus_RightsToCertainStudiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_RightsToCertainStudiesMember" xlink:to="lab_rcus_RightsToCertainStudiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_019cd33b-57f4-7114-943b-d1d318bedff3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_019cd33b-57f4-7b98-9abc-c9d344ce67cb_terseLabel_en-US" xlink:label="lab_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Marketable Securities [Abstract]</link:label>
    <link:label id="lab_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_label_en-US" xlink:label="lab_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Marketable Securities [Abstract]</link:label>
    <link:label id="lab_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_documentation_en-US" xlink:label="lab_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:href="rcus-20260331.xsd#rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="lab_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OptionLicenseAndCollaborationAgreementMember_019cd33b-57f4-7140-8e1c-a7f768771546_terseLabel_en-US" xlink:label="lab_rcus_OptionLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gilead Collaboration Agreement</link:label>
    <link:label id="lab_rcus_OptionLicenseAndCollaborationAgreementMember_label_en-US" xlink:label="lab_rcus_OptionLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option License And Collaboration Agreement [Member]</link:label>
    <link:label id="lab_rcus_OptionLicenseAndCollaborationAgreementMember_documentation_en-US" xlink:label="lab_rcus_OptionLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option, license and collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionLicenseAndCollaborationAgreementMember" xlink:href="rcus-20260331.xsd#rcus_OptionLicenseAndCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OptionLicenseAndCollaborationAgreementMember" xlink:to="lab_rcus_OptionLicenseAndCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_DevelopmentServicesMember_019d185f-d58c-7614-af4a-4aadc64a7af3_terseLabel_en-US" xlink:label="lab_rcus_DevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development services</link:label>
    <link:label id="lab_rcus_DevelopmentServicesMember_label_en-US" xlink:label="lab_rcus_DevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Services [Member]</link:label>
    <link:label id="lab_rcus_DevelopmentServicesMember_documentation_en-US" xlink:label="lab_rcus_DevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_DevelopmentServicesMember" xlink:href="rcus-20260331.xsd#rcus_DevelopmentServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_DevelopmentServicesMember" xlink:to="lab_rcus_DevelopmentServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_019cd33b-57f4-7110-bd91-85bcf38dcecd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, noncurrent ($36 and $43 to a related party)</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_019cd33b-57f4-78df-8a9f-e9cc81fa52ac_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_019cd33b-5742-74ff-9750-f2f61e04c94d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_019cd33b-5742-7bfe-a146-dc1d7654213f_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_019cd33b-57f4-79fb-9185-6cf20498eb58_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_AccessRightsMember_019cd33b-5742-7a77-98e4-c25dde9b6cbf_terseLabel_en-US" xlink:label="lab_rcus_AccessRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Access rights</link:label>
    <link:label id="lab_rcus_AccessRightsMember_label_en-US" xlink:label="lab_rcus_AccessRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Access Rights [Member]</link:label>
    <link:label id="lab_rcus_AccessRightsMember_documentation_en-US" xlink:label="lab_rcus_AccessRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Access Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AccessRightsMember" xlink:href="rcus-20260331.xsd#rcus_AccessRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_AccessRightsMember" xlink:to="lab_rcus_AccessRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement_019cd33b-57f4-7367-869b-72d2e4ffee8a_terseLabel_en-US" xlink:label="lab_rcus_OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option continuation payment due upon second anniversary of agreement</link:label>
    <link:label id="lab_rcus_OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement_label_en-US" xlink:label="lab_rcus_OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Continuation Payment Due Upon Second Anniversary Of Agreement</link:label>
    <link:label id="lab_rcus_OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement_documentation_en-US" xlink:label="lab_rcus_OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option continuation payment due upon second anniversary of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement" xlink:href="rcus-20260331.xsd#rcus_OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement" xlink:to="lab_rcus_OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_019cd33b-57f4-7fe4-9385-b23fd3c7cfe5_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_019cd33b-57f4-7177-9e95-35d1d1138306_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019cd33b-57f4-79e6-8f8d-cb97c99a3eb3_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_TaihoPharmaceuticalCoLtdMember_019cd33b-57f4-78b4-8a84-5c1d666c7be9_terseLabel_en-US" xlink:label="lab_rcus_TaihoPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taiho Pharmaceutical Co., Ltd</link:label>
    <link:label id="lab_rcus_TaihoPharmaceuticalCoLtdMember_label_en-US" xlink:label="lab_rcus_TaihoPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taiho Pharmaceutical Co Ltd [Member]</link:label>
    <link:label id="lab_rcus_TaihoPharmaceuticalCoLtdMember_documentation_en-US" xlink:label="lab_rcus_TaihoPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Taiho Pharmaceutical Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoPharmaceuticalCoLtdMember" xlink:href="rcus-20260331.xsd#rcus_TaihoPharmaceuticalCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_TaihoPharmaceuticalCoLtdMember" xlink:to="lab_rcus_TaihoPharmaceuticalCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement_019cd33b-5742-7f1b-b685-b2d061766d1d_terseLabel_en-US" xlink:label="lab_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option continuation payment due upon sixth anniversary of agreement</link:label>
    <link:label id="lab_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement_label_en-US" xlink:label="lab_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Continuation Payment Due Upon Sixth Anniversary Of Agreement</link:label>
    <link:label id="lab_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement_documentation_en-US" xlink:label="lab_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option continuation payment due upon Sixth anniversary of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement" xlink:href="rcus-20260331.xsd#rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement" xlink:to="lab_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments_019cd33b-57f4-7970-947f-1a52dea434b9_terseLabel_en-US" xlink:label="lab_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional clinical, regulatory and commercialization milestone payments</link:label>
    <link:label id="lab_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments_label_en-US" xlink:label="lab_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Clinical Regulatory And Commercialization Milestone Payments</link:label>
    <link:label id="lab_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments_documentation_en-US" xlink:label="lab_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional clinical regulatory and commercialization milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments" xlink:href="rcus-20260331.xsd#rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments" xlink:to="lab_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019cd33b-57f4-7eeb-b94c-283e3d64dd91_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cd33b-57f4-7bee-b810-23f2dc752a1a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_019cd33b-57f4-762f-b3d9-3d6c51f590ca_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other segment items</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:to="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_019cd33b-57f4-73aa-81a0-4608dc5836b3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_019cd33b-5742-7342-adce-77cc87b85b43_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units issued</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_019cd33b-57f4-70fe-83e8-808dabdf6aa5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments_019cd33b-5742-72fa-8f95-79a515d03b33_terseLabel_en-US" xlink:label="lab_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of programs, eligible to receive regulatory and commercial milestone payments</link:label>
    <link:label id="lab_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments_label_en-US" xlink:label="lab_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Programs, Eligible To Receive Regulatory And Commercial Milestone Payments</link:label>
    <link:label id="lab_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments_documentation_en-US" xlink:label="lab_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of programs, eligible to receive regulatory and commercial milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments" xlink:href="rcus-20260331.xsd#rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments" xlink:to="lab_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019cd33b-57f4-72db-b20c-f16ec885e44a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019cd33b-57f4-7842-8bc0-3dfeda1ad17a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development cost recorded within research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_019cd33b-57f4-74a0-8de2-ed070929c0e9_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019cd33b-57f4-7e11-adeb-3fe2f258b93a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_019cd33b-5742-7426-8b5c-75f1a11fcc8e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_CorporateSecuritiesAndCommercialPaperMember_019cd33b-57f4-76e1-a615-3c135c12c3e4_terseLabel_en-US" xlink:label="lab_rcus_CorporateSecuritiesAndCommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate securities and commercial paper</link:label>
    <link:label id="lab_rcus_CorporateSecuritiesAndCommercialPaperMember_label_en-US" xlink:label="lab_rcus_CorporateSecuritiesAndCommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Securities And Commercial Paper [Member]</link:label>
    <link:label id="lab_rcus_CorporateSecuritiesAndCommercialPaperMember_documentation_en-US" xlink:label="lab_rcus_CorporateSecuritiesAndCommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate securities and commercial paper.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CorporateSecuritiesAndCommercialPaperMember" xlink:href="rcus-20260331.xsd#rcus_CorporateSecuritiesAndCommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_CorporateSecuritiesAndCommercialPaperMember" xlink:to="lab_rcus_CorporateSecuritiesAndCommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_019cd33b-57f4-7807-8765-f2f6500c6318_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_019cd33b-57f4-770e-a977-3cf8ea7354e2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_019cd33b-57f4-7d30-97af-1dbb09d3c372_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_019cd33b-57f4-7540-86df-1d69eed0f0ac_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_AntiPDOneMember_019cd33b-57f4-79a0-85c9-0d38f2811c15_terseLabel_en-US" xlink:label="lab_rcus_AntiPDOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">anti-PD-1</link:label>
    <link:label id="lab_rcus_AntiPDOneMember_label_en-US" xlink:label="lab_rcus_AntiPDOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anti P D One [Member]</link:label>
    <link:label id="lab_rcus_AntiPDOneMember_documentation_en-US" xlink:label="lab_rcus_AntiPDOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Anti PD one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AntiPDOneMember" xlink:href="rcus-20260331.xsd#rcus_AntiPDOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_AntiPDOneMember" xlink:to="lab_rcus_AntiPDOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_019cd33b-5742-7505-b27b-5f94cc9c4232_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_019cd33b-57f4-7451-b479-e8a1b21de495_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of secured debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_UpfrontCashPayment_019cd33b-57f4-7b52-97b0-fb812b8a3874_terseLabel_en-US" xlink:label="lab_rcus_UpfrontCashPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront cash payment</link:label>
    <link:label id="lab_rcus_UpfrontCashPayment_label_en-US" xlink:label="lab_rcus_UpfrontCashPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Cash Payment</link:label>
    <link:label id="lab_rcus_UpfrontCashPayment_documentation_en-US" xlink:label="lab_rcus_UpfrontCashPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront cash payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_UpfrontCashPayment" xlink:href="rcus-20260331.xsd#rcus_UpfrontCashPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_UpfrontCashPayment" xlink:to="lab_rcus_UpfrontCashPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_019cd33b-57f4-7302-9749-80a11bc6637f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Revenues by Collaboration, Category of Revenue and Method of Recognition</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_RegulatoryAndCommercialMilestonePaymentsReceived_019cd33b-57f4-76d2-bb83-dd84c51d3c1d_terseLabel_en-US" xlink:label="lab_rcus_RegulatoryAndCommercialMilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regulatory and commercial milestone payments received</link:label>
    <link:label id="lab_rcus_RegulatoryAndCommercialMilestonePaymentsReceived_label_en-US" xlink:label="lab_rcus_RegulatoryAndCommercialMilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory And Commercial Milestone Payments Received</link:label>
    <link:label id="lab_rcus_RegulatoryAndCommercialMilestonePaymentsReceived_documentation_en-US" xlink:label="lab_rcus_RegulatoryAndCommercialMilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regulatory and commercial milestone payments received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RegulatoryAndCommercialMilestonePaymentsReceived" xlink:href="rcus-20260331.xsd#rcus_RegulatoryAndCommercialMilestonePaymentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_RegulatoryAndCommercialMilestonePaymentsReceived" xlink:to="lab_rcus_RegulatoryAndCommercialMilestonePaymentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_DebtInstrumentMilestoneAchievementPeriod_019d18b0-cfa0-7f55-af2c-cb87def77fd3_terseLabel_en-US" xlink:label="lab_rcus_DebtInstrumentMilestoneAchievementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, milestone achievement period</link:label>
    <link:label id="lab_rcus_DebtInstrumentMilestoneAchievementPeriod_label_en-US" xlink:label="lab_rcus_DebtInstrumentMilestoneAchievementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Milestone Achievement Period</link:label>
    <link:label id="lab_rcus_DebtInstrumentMilestoneAchievementPeriod_documentation_en-US" xlink:label="lab_rcus_DebtInstrumentMilestoneAchievementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Milestone Achievement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_DebtInstrumentMilestoneAchievementPeriod" xlink:href="rcus-20260331.xsd#rcus_DebtInstrumentMilestoneAchievementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_DebtInstrumentMilestoneAchievementPeriod" xlink:to="lab_rcus_DebtInstrumentMilestoneAchievementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cd33b-57f4-72ac-bf7a-98e7c7b7ac20_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice_019cd33b-5742-7a7b-83cd-fa69bc536b5d_terseLabel_en-US" xlink:label="lab_rcus_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability, cumulative catch-up adjustment to revenue, change in measure of progress and change in estimate of transaction price</link:label>
    <link:label id="lab_rcus_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice_label_en-US" xlink:label="lab_rcus_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Cumulative Catch-up Adjustment To Revenue, Change In Measure Of Progress And Change In Estimate Of Transaction Price</link:label>
    <link:label id="lab_rcus_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice_documentation_en-US" xlink:label="lab_rcus_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Cumulative Catch-up Adjustment To Revenue, Change In Measure Of Progress And Change In Estimate Of Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice" xlink:href="rcus-20260331.xsd#rcus_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice" xlink:to="lab_rcus_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_019cd33b-57f4-70f5-a36c-9e83323981fb_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cd33b-5742-76d7-bc13-bf32c9a1d17f_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cd33b-5742-7ca5-a2f8-c7dba5acc7c2_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_019cd33b-57f4-72d4-aef6-8bf144992691_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, interest rate, effective percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019cd33b-5742-763b-b1dc-95ea45fd7b56_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cd33b-5742-70af-8ca5-079494157b42_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_019cd33b-57f4-779a-93cf-e33793cf088d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_019cd33b-57f4-7723-bcf0-ea0cc527a423_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_019cd33b-57f4-789b-a629-d152136f9c67_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_TrancheTwoMember_019d18b0-cfa0-7034-bcd9-1d0acea1c2cc_terseLabel_en-US" xlink:label="lab_rcus_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_rcus_TrancheTwoMember_label_en-US" xlink:label="lab_rcus_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche Two [Member]</link:label>
    <link:label id="lab_rcus_TrancheTwoMember_documentation_en-US" xlink:label="lab_rcus_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TrancheTwoMember" xlink:href="rcus-20260331.xsd#rcus_TrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_TrancheTwoMember" xlink:to="lab_rcus_TrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_019cfa68-c5ce-7104-8885-a78d6f8c5fa7_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_019cd33b-5742-7ba4-a794-831fdf67faf5_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cd33b-5742-7980-a698-b3d32184cbfd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_019cd33b-5742-7802-a5bb-e9334b08cdbf_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod_019cd33b-5742-7216-a714-ce2319d5b806_terseLabel_en-US" xlink:label="lab_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current and future programs exclusive access period</link:label>
    <link:label id="lab_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod_label_en-US" xlink:label="lab_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current And Future Programs Exclusive Access Period</link:label>
    <link:label id="lab_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod_documentation_en-US" xlink:label="lab_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current and future programs exclusive access period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod" xlink:href="rcus-20260331.xsd#rcus_CurrentAndFutureProgramsExclusiveAccessPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod" xlink:to="lab_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts_019cd33b-5742-7064-a5f7-5622ae1cc60b_terseLabel_en-US" xlink:label="lab_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement from related party for shared costs</link:label>
    <link:label id="lab_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts_label_en-US" xlink:label="lab_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction Reimbursement From Related Party For Shared Costs</link:label>
    <link:label id="lab_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts_documentation_en-US" xlink:label="lab_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related party transaction reimbursement from related party for shared costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts" xlink:href="rcus-20260331.xsd#rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts" xlink:to="lab_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_019cd33b-57f4-7124-86e5-38578ba331ee_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_019cd33b-57f4-761b-81eb-2b852529b7c6_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cd33b-57f4-75d1-8f90-8dd336981f2b_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_019cd33b-5742-71e1-8a67-5bb42a7c9ae4_terseLabel_en-US" xlink:label="lab_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in measurement of lease liabilities</link:label>
    <link:label id="lab_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_label_en-US" xlink:label="lab_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Paid For Amounts Included In Measurement Of Lease Liabilities</link:label>
    <link:label id="lab_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_documentation_en-US" xlink:label="lab_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in measurement of lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:href="rcus-20260331.xsd#rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:to="lab_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019cd33b-5742-77c2-ae6f-0239e1f0dfa0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncash lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments_019cd33b-57f4-7289-9219-92fc828cc108_terseLabel_en-US" xlink:label="lab_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical, regulatory and commercialization milestone payments</link:label>
    <link:label id="lab_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments_label_en-US" xlink:label="lab_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Regulatory And Commercialization Milestone Payments</link:label>
    <link:label id="lab_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments_documentation_en-US" xlink:label="lab_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical regulatory and commercialization milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments" xlink:href="rcus-20260331.xsd#rcus_ClinicalRegulatoryAndCommercializationMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments" xlink:to="lab_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019cd33b-57f4-74d8-986f-36e7fdee8fbe_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_LicenseAndCollaborationAgreementsTable_019cd33b-57f4-71d4-bf91-35000150a629_terseLabel_en-US" xlink:label="lab_rcus_LicenseAndCollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_rcus_LicenseAndCollaborationAgreementsTable_label_en-US" xlink:label="lab_rcus_LicenseAndCollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License and Collaboration Agreements [Table]</link:label>
    <link:label id="lab_rcus_LicenseAndCollaborationAgreementsTable_documentation_en-US" xlink:label="lab_rcus_LicenseAndCollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndCollaborationAgreementsTable" xlink:href="rcus-20260331.xsd#rcus_LicenseAndCollaborationAgreementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsTable" xlink:to="lab_rcus_LicenseAndCollaborationAgreementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock_019cd33b-5742-7c10-9c1b-df9f266e9c9c_terseLabel_en-US" xlink:label="lab_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Transaction Price and Allocation of Transaction Price to the Performance Obligations</link:label>
    <link:label id="lab_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock_label_en-US" xlink:label="lab_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Transaction Price And Allocated To Transaction Price To Performance Obligations [Table Text Block]</link:label>
    <link:label id="lab_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock_documentation_en-US" xlink:label="lab_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of transaction price and allocated to transaction price to performance obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock" xlink:href="rcus-20260331.xsd#rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock" xlink:to="lab_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_TrancheOneMember_019d18b0-cfa0-7a49-97b6-efa45de24d5d_terseLabel_en-US" xlink:label="lab_rcus_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_rcus_TrancheOneMember_label_en-US" xlink:label="lab_rcus_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche One [Member]</link:label>
    <link:label id="lab_rcus_TrancheOneMember_documentation_en-US" xlink:label="lab_rcus_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TrancheOneMember" xlink:href="rcus-20260331.xsd#rcus_TrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_TrancheOneMember" xlink:to="lab_rcus_TrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_019cd33b-57f4-7e13-a3dd-d9e77c9d446e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Revenue Recognized as a Result of Changes in Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019cd33b-57f4-706f-9c0b-e67dfb0f65fb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_019cd33b-5742-7e46-8489-64dafe5135cc_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative (Includes $&#8212; and $&#8212; from a related party)</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_019cd33b-5742-737e-8d36-f6e063dcaf86_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cd33b-57f4-7672-bbba-25679b2ef20b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_019cd33b-57f4-782f-827a-a6088d1133cb_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_019cd33b-5742-7e4d-be83-781c08952390_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement_019cd33b-57f4-79ce-b360-4b526f1aba86_terseLabel_en-US" xlink:label="lab_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional clinical and regulatory milestone payments receivable</link:label>
    <link:label id="lab_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement_label_en-US" xlink:label="lab_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Clinical And Milestone Payments Received Under License Agreement</link:label>
    <link:label id="lab_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement_documentation_en-US" xlink:label="lab_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional clinical and milestone payments received under license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:href="rcus-20260331.xsd#rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:to="lab_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilities_019cd33b-5742-7cf4-a276-c27a1cc38e1d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilities_label_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities" xlink:to="lab_us-gaap_OtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_NumberOfResearchPrograms_019cd33b-57f4-7e29-a0ef-aa160a90bcd5_terseLabel_en-US" xlink:label="lab_rcus_NumberOfResearchPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of research programs</link:label>
    <link:label id="lab_rcus_NumberOfResearchPrograms_label_en-US" xlink:label="lab_rcus_NumberOfResearchPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Research Programs</link:label>
    <link:label id="lab_rcus_NumberOfResearchPrograms_documentation_en-US" xlink:label="lab_rcus_NumberOfResearchPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of research programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NumberOfResearchPrograms" xlink:href="rcus-20260331.xsd#rcus_NumberOfResearchPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_NumberOfResearchPrograms" xlink:to="lab_rcus_NumberOfResearchPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_RDServicesMember_019cd33b-57f4-79db-80c1-79079d6baa4d_terseLabel_en-US" xlink:label="lab_rcus_RDServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">R&amp;D services</link:label>
    <link:label id="lab_rcus_RDServicesMember_label_en-US" xlink:label="lab_rcus_RDServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">R&amp;D Services [Member]</link:label>
    <link:label id="lab_rcus_RDServicesMember_documentation_en-US" xlink:label="lab_rcus_RDServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">R&amp;D Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RDServicesMember" xlink:href="rcus-20260331.xsd#rcus_RDServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_RDServicesMember" xlink:to="lab_rcus_RDServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_019cd33b-5742-7d94-a5f2-ac784a952ba7_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_InterestAndOtherIncomeExpenseNonoperatingNet_019cd33b-5742-76ea-8094-a3c579ea5965_terseLabel_en-US" xlink:label="lab_rcus_InterestAndOtherIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_rcus_InterestAndOtherIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_rcus_InterestAndOtherIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest and Other Income Expense Nonoperating Net</link:label>
    <link:label id="lab_rcus_InterestAndOtherIncomeExpenseNonoperatingNet_documentation_en-US" xlink:label="lab_rcus_InterestAndOtherIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest and other income (expense) nonoperating net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_InterestAndOtherIncomeExpenseNonoperatingNet" xlink:href="rcus-20260331.xsd#rcus_InterestAndOtherIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_InterestAndOtherIncomeExpenseNonoperatingNet" xlink:to="lab_rcus_InterestAndOtherIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_019cd33b-57f4-727b-ba7c-915a9b635f99_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_LateStageDevelopmentPrograms_019cd33b-57f4-7d37-b61c-df8e0c27c7c6_terseLabel_en-US" xlink:label="lab_rcus_LateStageDevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Late-stage development programs</link:label>
    <link:label id="lab_rcus_LateStageDevelopmentPrograms_label_en-US" xlink:label="lab_rcus_LateStageDevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Late Stage Development Programs</link:label>
    <link:label id="lab_rcus_LateStageDevelopmentPrograms_documentation_en-US" xlink:label="lab_rcus_LateStageDevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Late Stage Development Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LateStageDevelopmentPrograms" xlink:href="rcus-20260331.xsd#rcus_LateStageDevelopmentPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_LateStageDevelopmentPrograms" xlink:to="lab_rcus_LateStageDevelopmentPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_TaihoCollaborationAgreementMember_019cd33b-57f4-7426-95e6-e901cdf5ce4c_terseLabel_en-US" xlink:label="lab_rcus_TaihoCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taiho Collaboration Agreement</link:label>
    <link:label id="lab_rcus_TaihoCollaborationAgreementMember_label_en-US" xlink:label="lab_rcus_TaihoCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taiho Collaboration Agreement [Member]</link:label>
    <link:label id="lab_rcus_TaihoCollaborationAgreementMember_documentation_en-US" xlink:label="lab_rcus_TaihoCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Taiho Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoCollaborationAgreementMember" xlink:href="rcus-20260331.xsd#rcus_TaihoCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_TaihoCollaborationAgreementMember" xlink:to="lab_rcus_TaihoCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_019cd33b-5742-7d88-bc4b-bfb4c5094533_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_019cd33b-57f4-7f7d-b2a1-596181ea69bc_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Liquidity and Capital Resources</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAndCash_019cd33b-5742-7810-8ebb-e4060ec6aa74_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments and Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAndCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndCash" xlink:to="lab_us-gaap_InvestmentsAndCash" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_AmendedGileadCollaborationAgreementMember_019cd33b-57f4-71fd-be68-748068e7ecd6_terseLabel_en-US" xlink:label="lab_rcus_AmendedGileadCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amended Gilead Collaboration Agreement</link:label>
    <link:label id="lab_rcus_AmendedGileadCollaborationAgreementMember_label_en-US" xlink:label="lab_rcus_AmendedGileadCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended Gilead Collaboration Agreement [Member]</link:label>
    <link:label id="lab_rcus_AmendedGileadCollaborationAgreementMember_documentation_en-US" xlink:label="lab_rcus_AmendedGileadCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amended gilead collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AmendedGileadCollaborationAgreementMember" xlink:href="rcus-20260331.xsd#rcus_AmendedGileadCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_AmendedGileadCollaborationAgreementMember" xlink:to="lab_rcus_AmendedGileadCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_019cd33b-5742-77f8-a5ca-d538d05e916c_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019cd33b-57f4-78c6-8623-fee5ebe42feb_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_019cd33b-57f4-710e-8080-7cd74066dce3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_019cd33b-5742-7556-9f80-58c5bf4bea2e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019cd33b-57f4-7940-9592-3f21c2e6a2fc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_019cd33b-57f4-7268-9706-1c1baa65d2d7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_019cd33b-57f4-7254-9a19-38ea3feb4117_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ReportableSegmentMember_019cd33b-57f4-781f-8679-aaa3e48d3ff1_terseLabel_en-US" xlink:label="lab_rcus_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable segment</link:label>
    <link:label id="lab_rcus_ReportableSegmentMember_label_en-US" xlink:label="lab_rcus_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_rcus_ReportableSegmentMember_documentation_en-US" xlink:label="lab_rcus_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ReportableSegmentMember" xlink:href="rcus-20260331.xsd#rcus_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ReportableSegmentMember" xlink:to="lab_rcus_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_019cd33b-57f4-7609-b048-c792459a7be4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_019cd33b-57f4-7d39-87b1-b3da6edccf8a_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_019cd33b-57f4-711c-9616-f92024d46fce_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cd33b-5742-76f8-b936-80471d6c923d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_019cd33b-57f4-7fcf-a91f-2bdb12da4003_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019cd33b-57f4-7a9d-8a95-3899f5696312_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_019cd33b-57f4-7554-8bb9-fedf502a7041_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_019cd33b-57f4-7975-9ed6-d9c0dc52c2cb_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OtherServicesMember_019cd33b-57f4-7366-9205-0f0886d3a633_terseLabel_en-US" xlink:label="lab_rcus_OtherServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_rcus_OtherServicesMember_label_en-US" xlink:label="lab_rcus_OtherServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Services [Member]</link:label>
    <link:label id="lab_rcus_OtherServicesMember_documentation_en-US" xlink:label="lab_rcus_OtherServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OtherServicesMember" xlink:href="rcus-20260331.xsd#rcus_OtherServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OtherServicesMember" xlink:to="lab_rcus_OtherServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_019cd33b-57f4-7436-9b8f-7a2bdf943db3_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjusted for expense (income):</link:label>
    <link:label id="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_label_en-US" xlink:label="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:to="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_019cd33b-5742-7447-b550-c7b8e32cf2a1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Segment</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cd33b-57f4-7d79-b170-dc4c841d3564_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_019cd33b-57f4-7c9a-b8e8-48f3bfe8d812_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-7ce3-adf9-034d8da3b793_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_MilestonePayments_019cd33b-57f4-7167-8fb5-c6cbd7df3488_terseLabel_en-US" xlink:label="lab_rcus_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_rcus_MilestonePayments_label_en-US" xlink:label="lab_rcus_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payments</link:label>
    <link:label id="lab_rcus_MilestonePayments_documentation_en-US" xlink:label="lab_rcus_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_MilestonePayments" xlink:href="rcus-20260331.xsd#rcus_MilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_MilestonePayments" xlink:to="lab_rcus_MilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cd33b-57f4-7352-a18c-7d7813000c29_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ContingentMilestonePaymentsReceivable_019cd33b-57f4-707f-a5da-fd4360025780_terseLabel_en-US" xlink:label="lab_rcus_ContingentMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent milestone payments receivable</link:label>
    <link:label id="lab_rcus_ContingentMilestonePaymentsReceivable_label_en-US" xlink:label="lab_rcus_ContingentMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Milestone Payments Receivable</link:label>
    <link:label id="lab_rcus_ContingentMilestonePaymentsReceivable_documentation_en-US" xlink:label="lab_rcus_ContingentMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent milestone payments receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ContingentMilestonePaymentsReceivable" xlink:href="rcus-20260331.xsd#rcus_ContingentMilestonePaymentsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ContingentMilestonePaymentsReceivable" xlink:to="lab_rcus_ContingentMilestonePaymentsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cd33b-57f4-7a55-939a-192c1e502b30_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_019cd33b-57f4-7daa-93fc-a09e088d0d58_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_019cd33b-57f4-7637-8ae6-35bed0222365_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019cd33b-5742-7613-b8c8-12a6fbf8697f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_019cd33b-57f4-72a8-a632-e0ef214f0102_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_019cd33b-57f4-7e16-b6ea-4e543e3b0571_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_019cd33b-57f4-7dd6-924d-70050a5d76d7_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019cd33b-57f4-7041-ac34-460412a07806_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_WuXiBiologicsLicenseAgreementMember_019cd33b-57f4-7518-9bbb-3bdfef8a4af4_terseLabel_en-US" xlink:label="lab_rcus_WuXiBiologicsLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">WuXi Biologics License Agreement</link:label>
    <link:label id="lab_rcus_WuXiBiologicsLicenseAgreementMember_label_en-US" xlink:label="lab_rcus_WuXiBiologicsLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Wu Xi Biologics License Agreement [Member]</link:label>
    <link:label id="lab_rcus_WuXiBiologicsLicenseAgreementMember_documentation_en-US" xlink:label="lab_rcus_WuXiBiologicsLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">WuXi Biologics license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_WuXiBiologicsLicenseAgreementMember" xlink:href="rcus-20260331.xsd#rcus_WuXiBiologicsLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_WuXiBiologicsLicenseAgreementMember" xlink:to="lab_rcus_WuXiBiologicsLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_019cd33b-57f4-73a4-9fdc-b8717ab966df_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue ($27 and $35 to a related party)</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_019cd33b-57f4-70b7-9fc9-9bf2315cd480_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_019cd33b-57f4-7580-9345-7ccf2e46d81b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_AccessRightsAndOptionContinuationPeriodsMember_019cd33b-57f4-704f-aa57-7a25128d1f8b_terseLabel_en-US" xlink:label="lab_rcus_AccessRightsAndOptionContinuationPeriodsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Access right and option continuation periods</link:label>
    <link:label id="lab_rcus_AccessRightsAndOptionContinuationPeriodsMember_label_en-US" xlink:label="lab_rcus_AccessRightsAndOptionContinuationPeriodsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Access Rights And Option Continuation Periods [Member]</link:label>
    <link:label id="lab_rcus_AccessRightsAndOptionContinuationPeriodsMember_documentation_en-US" xlink:label="lab_rcus_AccessRightsAndOptionContinuationPeriodsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Access Rights And Option Continuation Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AccessRightsAndOptionContinuationPeriodsMember" xlink:href="rcus-20260331.xsd#rcus_AccessRightsAndOptionContinuationPeriodsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_AccessRightsAndOptionContinuationPeriodsMember" xlink:to="lab_rcus_AccessRightsAndOptionContinuationPeriodsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_019cd33b-57f4-71ee-97ee-35d8c4dc06d4_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019cd33b-57f4-737c-87a2-7bd4748e2314_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019cd33b-5742-72c1-a5e8-207944360a3b_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_019cd33b-57f4-71a8-8f8c-468bfc203a60_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other items, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Other Item</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_019cd33b-5742-7e2e-88e7-e5cf413bca49_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_019cd33b-57f4-7e12-8343-84ecf4c3e7c4_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_NonRefundableAndNonCreditableCashPayments_019cd33b-57f4-7540-a3be-9674136c805b_terseLabel_en-US" xlink:label="lab_rcus_NonRefundableAndNonCreditableCashPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non refundable and non creditable cash payments</link:label>
    <link:label id="lab_rcus_NonRefundableAndNonCreditableCashPayments_label_en-US" xlink:label="lab_rcus_NonRefundableAndNonCreditableCashPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Refundable And Non Creditable Cash Payments</link:label>
    <link:label id="lab_rcus_NonRefundableAndNonCreditableCashPayments_documentation_en-US" xlink:label="lab_rcus_NonRefundableAndNonCreditableCashPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non refundable and non creditable cash payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NonRefundableAndNonCreditableCashPayments" xlink:href="rcus-20260331.xsd#rcus_NonRefundableAndNonCreditableCashPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_NonRefundableAndNonCreditableCashPayments" xlink:to="lab_rcus_NonRefundableAndNonCreditableCashPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_019cd33b-57f4-793e-9487-2550c2665db9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_019cf9b4-1b38-7b6c-b9d9-66eba4ca74b4_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_019cd33b-57f4-7b0d-9daa-a608a399f38b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_019cd33b-5742-723f-9ed4-0aa216b9cd2f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_019cd33b-5742-73a1-b21c-69442a37d89a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019cd33b-57f4-717a-b39a-5e041b4c074f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_019cd33b-57f4-7cee-8499-854322b35478_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development (Includes $&#8212; and ($5) from a related party)</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019cd33b-57f4-7b79-9d59-71b889cd2ee2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_019cd33b-5742-7aa3-8d66-ef8f3fa0d27e_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_JuanJaenMember_label_en-US" xlink:label="lab_rcus_JuanJaenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Juan Jaen [Member]</link:label>
    <link:label id="lab_rcus_JuanJaenMember_documentation_en-US" xlink:label="lab_rcus_JuanJaenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Juan Jaen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_JuanJaenMember" xlink:href="rcus-20260331.xsd#rcus_JuanJaenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_JuanJaenMember" xlink:to="lab_rcus_JuanJaenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_MilestoneExpense_019cd33b-57f4-749c-ab7e-2c7dc1f72ba2_terseLabel_en-US" xlink:label="lab_rcus_MilestoneExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development milestone expense</link:label>
    <link:label id="lab_rcus_MilestoneExpense_label_en-US" xlink:label="lab_rcus_MilestoneExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Expense</link:label>
    <link:label id="lab_rcus_MilestoneExpense_documentation_en-US" xlink:label="lab_rcus_MilestoneExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_MilestoneExpense" xlink:href="rcus-20260331.xsd#rcus_MilestoneExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_MilestoneExpense" xlink:to="lab_rcus_MilestoneExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019cd33b-57f4-7344-ab70-b9a2db5287f1_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_019cd33b-5742-75f3-99e7-8bd96288d827_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_019cd33b-57f4-7f20-bb13-027b0c69fd6c_terseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation and personnel costs</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_019cd33b-5742-7576-9d7f-2ae7d41ebdb4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Long-Term Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_NumberOfExerciseOptionToPrograms_019cd33b-5742-7cf8-b55e-6b930a569578_terseLabel_en-US" xlink:label="lab_rcus_NumberOfExerciseOptionToPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of exercise option to programs</link:label>
    <link:label id="lab_rcus_NumberOfExerciseOptionToPrograms_label_en-US" xlink:label="lab_rcus_NumberOfExerciseOptionToPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Exercise Option To Programs</link:label>
    <link:label id="lab_rcus_NumberOfExerciseOptionToPrograms_documentation_en-US" xlink:label="lab_rcus_NumberOfExerciseOptionToPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of exercise option to programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NumberOfExerciseOptionToPrograms" xlink:href="rcus-20260331.xsd#rcus_NumberOfExerciseOptionToPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_NumberOfExerciseOptionToPrograms" xlink:to="lab_rcus_NumberOfExerciseOptionToPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-726a-a0da-6699dc81bfc8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement_019cd33b-57f4-7ce8-9fed-3c1bfd002531_terseLabel_en-US" xlink:label="lab_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option continuation payment receivable upon sixth anniversary of agreement</link:label>
    <link:label id="lab_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement_label_en-US" xlink:label="lab_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Continuation Payment Receivable Upon Sixth Anniversary Of Agreement</link:label>
    <link:label id="lab_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement_documentation_en-US" xlink:label="lab_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option continuation payment receivable upon sixth anniversary of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement" xlink:href="rcus-20260331.xsd#rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement" xlink:to="lab_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_019cd33b-57f4-7361-b787-d325c40a11ab_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_019cd33b-5742-7700-a795-8de96482441c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_PaymentForOptionExercise_019cfa2b-5133-7e53-bd46-0c4e19f87daa_terseLabel_en-US" xlink:label="lab_rcus_PaymentForOptionExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment for option exercise</link:label>
    <link:label id="lab_rcus_PaymentForOptionExercise_label_en-US" xlink:label="lab_rcus_PaymentForOptionExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment For Option Exercise</link:label>
    <link:label id="lab_rcus_PaymentForOptionExercise_documentation_en-US" xlink:label="lab_rcus_PaymentForOptionExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment for option exercise.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PaymentForOptionExercise" xlink:href="rcus-20260331.xsd#rcus_PaymentForOptionExercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_PaymentForOptionExercise" xlink:to="lab_rcus_PaymentForOptionExercise" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_019cd33b-57f4-7718-9f1d-0cd370d34127_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of positions in securities in unrealized loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms_019cd33b-5742-7e18-ba88-5a633495800a_terseLabel_en-US" xlink:label="lab_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration term for current and future clinical programs</link:label>
    <link:label id="lab_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms_label_en-US" xlink:label="lab_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Term For Current And Future Clinical Programs</link:label>
    <link:label id="lab_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms_documentation_en-US" xlink:label="lab_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration term for current and future clinical programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms" xlink:href="rcus-20260331.xsd#rcus_CollaborationTermForCurrentAndFutureClinicalPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms" xlink:to="lab_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_019cd33b-57f4-7259-aa3e-f734b97cbb1d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_019cd33b-57f4-7b0b-b323-63153eba24fe_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_019cd33b-57f4-7b06-85cc-7ea2a2e2b7e1_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019cd33b-57f4-79ed-a2a7-c3efd5c28a4f_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of discounts on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-57f4-780b-8624-86c7c53f88f6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_019cd33b-5742-750f-822f-b9d0ea3b505a_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_PartnershipReimbursements_019cd33b-57f4-7403-9278-1103d281bcee_terseLabel_en-US" xlink:label="lab_rcus_PartnershipReimbursements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Partnership reimbursements</link:label>
    <link:label id="lab_rcus_PartnershipReimbursements_label_en-US" xlink:label="lab_rcus_PartnershipReimbursements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Partnership Reimbursements</link:label>
    <link:label id="lab_rcus_PartnershipReimbursements_documentation_en-US" xlink:label="lab_rcus_PartnershipReimbursements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Partnership Reimbursements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PartnershipReimbursements" xlink:href="rcus-20260331.xsd#rcus_PartnershipReimbursements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_PartnershipReimbursements" xlink:to="lab_rcus_PartnershipReimbursements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_019cd33b-57f4-7e75-a10b-21568e0d1d2c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Prepaid and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_019cd33b-5742-75c1-a940-3e491738377a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, debt</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019cd33b-5742-7620-bc7b-846df197f3a0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Award Types</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_019cd33b-57f4-7bb2-af14-a2c0b968fc85_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_019cd33b-5742-7275-a4b0-4e5835c685b9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_019cd33b-5742-7efb-9dfb-2a7b3fcfba0b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_019cd33b-57f4-7d5f-b91b-46e66d4cc42b_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificate of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_019cd33b-5742-7573-ba96-0ccbfb97c4ef_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized from amounts in deferred revenue at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_AntiCDThirtyNineMember_019cd33b-5742-730c-aed3-f8edfe6285d7_terseLabel_en-US" xlink:label="lab_rcus_AntiCDThirtyNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">anti-CD39</link:label>
    <link:label id="lab_rcus_AntiCDThirtyNineMember_label_en-US" xlink:label="lab_rcus_AntiCDThirtyNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anti C D Thirty Nine [Member]</link:label>
    <link:label id="lab_rcus_AntiCDThirtyNineMember_documentation_en-US" xlink:label="lab_rcus_AntiCDThirtyNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Anti CD thirty nine.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AntiCDThirtyNineMember" xlink:href="rcus-20260331.xsd#rcus_AntiCDThirtyNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_AntiCDThirtyNineMember" xlink:to="lab_rcus_AntiCDThirtyNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_019cd33b-57f4-7753-8b56-4bfec5e309aa_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash (included in Other noncurrent assets)</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_019cd33b-57f4-7322-b738-a770e85a7cb9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan shares</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_019cd33b-5742-71ff-88c2-dc804fa8f0e9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019cd33b-5742-7702-84aa-8e64ca2fa511_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_DebtInstrumentFaceAmountContingentlyAvailable_019cd33b-57f4-7d94-97c4-c8177c18fba5_terseLabel_en-US" xlink:label="lab_rcus_DebtInstrumentFaceAmountContingentlyAvailable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount, contingently available</link:label>
    <link:label id="lab_rcus_DebtInstrumentFaceAmountContingentlyAvailable_label_en-US" xlink:label="lab_rcus_DebtInstrumentFaceAmountContingentlyAvailable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount, Contingently Available</link:label>
    <link:label id="lab_rcus_DebtInstrumentFaceAmountContingentlyAvailable_documentation_en-US" xlink:label="lab_rcus_DebtInstrumentFaceAmountContingentlyAvailable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount, Contingently Available</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_DebtInstrumentFaceAmountContingentlyAvailable" xlink:href="rcus-20260331.xsd#rcus_DebtInstrumentFaceAmountContingentlyAvailable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_DebtInstrumentFaceAmountContingentlyAvailable" xlink:to="lab_rcus_DebtInstrumentFaceAmountContingentlyAvailable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019cd33b-57f4-7f7a-a673-8a09858956a4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-720a-9981-524eb133e2fa_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_019cd33b-5742-749c-b60e-4e6369f42172_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_019cd33b-57f4-7f12-90fa-75fd3c137723_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_AbmunoLicenseAgreementMember_019cd33b-57f4-76b0-93f7-0c5daf0c794a_terseLabel_en-US" xlink:label="lab_rcus_AbmunoLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Abmuno License Agreement</link:label>
    <link:label id="lab_rcus_AbmunoLicenseAgreementMember_label_en-US" xlink:label="lab_rcus_AbmunoLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Abmuno License Agreement [Member]</link:label>
    <link:label id="lab_rcus_AbmunoLicenseAgreementMember_documentation_en-US" xlink:label="lab_rcus_AbmunoLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Abmuno license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AbmunoLicenseAgreementMember" xlink:href="rcus-20260331.xsd#rcus_AbmunoLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_AbmunoLicenseAgreementMember" xlink:to="lab_rcus_AbmunoLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cd33b-57f4-7498-982d-99fb386d585e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_019cf9b4-1b38-77eb-9870-0abecbc9b865_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_019cd33b-5742-74e9-90f4-a564b86a3993_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecurityDeposit_019cd33b-57f4-7fae-9973-cd69b28ed2b3_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposits for letters of credit</link:label>
    <link:label id="lab_us-gaap_SecurityDeposit_label_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember_019cd33b-57f4-74d1-8ccf-52ce931c15ce_terseLabel_en-US" xlink:label="lab_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">R&amp;D Activities for Inflammation Programs</link:label>
    <link:label id="lab_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember_label_en-US" xlink:label="lab_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Activities For Inflammation Programs [Member]</link:label>
    <link:label id="lab_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember_documentation_en-US" xlink:label="lab_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development activities for inflammation programs member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember" xlink:href="rcus-20260331.xsd#rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember" xlink:to="lab_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ProceedsFromSaleOfMarketableSecurities_019cd33b-5742-7ddb-a98e-efc0ba8b2997_terseLabel_en-US" xlink:label="lab_rcus_ProceedsFromSaleOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales of marketable securities</link:label>
    <link:label id="lab_rcus_ProceedsFromSaleOfMarketableSecurities_label_en-US" xlink:label="lab_rcus_ProceedsFromSaleOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Sale Of Marketable Securities</link:label>
    <link:label id="lab_rcus_ProceedsFromSaleOfMarketableSecurities_documentation_en-US" xlink:label="lab_rcus_ProceedsFromSaleOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from sale of marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ProceedsFromSaleOfMarketableSecurities" xlink:href="rcus-20260331.xsd#rcus_ProceedsFromSaleOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ProceedsFromSaleOfMarketableSecurities" xlink:to="lab_rcus_ProceedsFromSaleOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_SaleOfStockNumberOfSharesAcquiredInTransaction_019cd33b-5742-7a2d-b279-9d87e93fe661_terseLabel_en-US" xlink:label="lab_rcus_SaleOfStockNumberOfSharesAcquiredInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, number of shares acquired in transaction (in shares)</link:label>
    <link:label id="lab_rcus_SaleOfStockNumberOfSharesAcquiredInTransaction_label_en-US" xlink:label="lab_rcus_SaleOfStockNumberOfSharesAcquiredInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Number Of Shares Acquired In Transaction</link:label>
    <link:label id="lab_rcus_SaleOfStockNumberOfSharesAcquiredInTransaction_documentation_en-US" xlink:label="lab_rcus_SaleOfStockNumberOfSharesAcquiredInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Number Of Shares Acquired In Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_SaleOfStockNumberOfSharesAcquiredInTransaction" xlink:href="rcus-20260331.xsd#rcus_SaleOfStockNumberOfSharesAcquiredInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_SaleOfStockNumberOfSharesAcquiredInTransaction" xlink:to="lab_rcus_SaleOfStockNumberOfSharesAcquiredInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_019cd33b-5742-7d59-bade-9f8c6d7f9fc0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable ($11 and $24 to a related party)</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_019cd33b-5742-7fd8-9f6f-6d29aabbb345_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable, current</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_GileadSciencesIncMember_019cd33b-57f4-7497-959a-4502a9374d33_terseLabel_en-US" xlink:label="lab_rcus_GileadSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gilead</link:label>
    <link:label id="lab_rcus_GileadSciencesIncMember_label_en-US" xlink:label="lab_rcus_GileadSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gilead Sciences Inc [Member]</link:label>
    <link:label id="lab_rcus_GileadSciencesIncMember_documentation_en-US" xlink:label="lab_rcus_GileadSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gilead Sciences, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadSciencesIncMember" xlink:href="rcus-20260331.xsd#rcus_GileadSciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_GileadSciencesIncMember" xlink:to="lab_rcus_GileadSciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_019cd33b-57f4-7956-89c6-5501575cf660_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_019cd33b-57f4-7624-96a4-c8d655e80acf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 125.5 shares in 2026 and 125.3 shares in 2025 issued and outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_HerculesAgreementMember_019cd33b-57f4-78aa-be09-ef81d892fef2_terseLabel_en-US" xlink:label="lab_rcus_HerculesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hercules Agreement</link:label>
    <link:label id="lab_rcus_HerculesAgreementMember_label_en-US" xlink:label="lab_rcus_HerculesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hercules Agreement [Member]</link:label>
    <link:label id="lab_rcus_HerculesAgreementMember_documentation_en-US" xlink:label="lab_rcus_HerculesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hercules Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_HerculesAgreementMember" xlink:href="rcus-20260331.xsd#rcus_HerculesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_HerculesAgreementMember" xlink:to="lab_rcus_HerculesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_PaymentForOptionsExercised_019cd33b-5742-74f5-ad8e-59187c3074ab_terseLabel_en-US" xlink:label="lab_rcus_PaymentForOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment for option exercise</link:label>
    <link:label id="lab_rcus_PaymentForOptionsExercised_label_en-US" xlink:label="lab_rcus_PaymentForOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment For Options Exercised</link:label>
    <link:label id="lab_rcus_PaymentForOptionsExercised_documentation_en-US" xlink:label="lab_rcus_PaymentForOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment for option exercise.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PaymentForOptionsExercised" xlink:href="rcus-20260331.xsd#rcus_PaymentForOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_PaymentForOptionsExercised" xlink:to="lab_rcus_PaymentForOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019cd33b-5742-7740-be69-12c3836369f2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used to compute net loss per share, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_019cd33b-57f4-7813-a54b-29160ad68862_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019cd33b-57f4-735a-854e-4ab64a8123d5_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_019cd33b-57f4-744d-8152-008132a766c4_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_019cd33b-57f4-7df1-9182-30668b97ad3e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_019cd33b-5742-7c86-a79c-eb77f8041a46_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_019cd33b-5742-7ea9-940d-b0e4d11f53c9_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_019cd33b-5742-7447-86ff-07b6b44bdf3d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019cd33b-5742-76a2-9838-75161f7c0574_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OptionPeriod_019cd33b-57f4-7cc9-80fb-3888ba55e42c_terseLabel_en-US" xlink:label="lab_rcus_OptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option period</link:label>
    <link:label id="lab_rcus_OptionPeriod_label_en-US" xlink:label="lab_rcus_OptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Period</link:label>
    <link:label id="lab_rcus_OptionPeriod_documentation_en-US" xlink:label="lab_rcus_OptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionPeriod" xlink:href="rcus-20260331.xsd#rcus_OptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OptionPeriod" xlink:to="lab_rcus_OptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_019cd33b-5742-7a5b-a97a-cdc243bd9123_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, and Marketable Security [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_019cd33b-5742-73a1-a6e7-db7a99e6e301_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_019cd33b-57f4-762d-be8a-453241498601_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Condensed Consolidated Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_019cd33b-5742-7f91-89f0-c55b2fe452f7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_RobertC.GoeltzIIMember_label_en-US" xlink:label="lab_rcus_RobertC.GoeltzIIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Robert C. Goeltz II [Member]</link:label>
    <link:label id="lab_rcus_RobertC.GoeltzIIMember_documentation_en-US" xlink:label="lab_rcus_RobertC.GoeltzIIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Robert C. Goeltz II</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RobertC.GoeltzIIMember" xlink:href="rcus-20260331.xsd#rcus_RobertC.GoeltzIIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_RobertC.GoeltzIIMember" xlink:to="lab_rcus_RobertC.GoeltzIIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019cd33b-57f4-7b61-9377-759bbb095e2d_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_019cd33b-57f4-7b49-94f6-4ba1cf36b286_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_019cd33b-57f4-76ac-86a0-24852647175c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_019cd33b-57f4-74bb-a12f-3dd25e633622_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_019cd33b-5742-77dd-9ab9-c884703f80ab_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock ($&#8212; and $14 from a related party)</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_019cd33b-5742-786c-980e-237b4112d08f_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ResearchAndDevelopmentExpenseRecoveries_019cd33b-57f4-7b0e-a8b7-162917eed3d1_terseLabel_en-US" xlink:label="lab_rcus_ResearchAndDevelopmentExpenseRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense, net of recoveries</link:label>
    <link:label id="lab_rcus_ResearchAndDevelopmentExpenseRecoveries_label_en-US" xlink:label="lab_rcus_ResearchAndDevelopmentExpenseRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Recoveries</link:label>
    <link:label id="lab_rcus_ResearchAndDevelopmentExpenseRecoveries_documentation_en-US" xlink:label="lab_rcus_ResearchAndDevelopmentExpenseRecoveries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Recoveries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ResearchAndDevelopmentExpenseRecoveries" xlink:href="rcus-20260331.xsd#rcus_ResearchAndDevelopmentExpenseRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ResearchAndDevelopmentExpenseRecoveries" xlink:to="lab_rcus_ResearchAndDevelopmentExpenseRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019cd33b-5742-7576-82b0-5ad56dcc4209_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019cd33b-5742-7f19-847a-bf4d277510e8_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenues from a customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_019cd33b-57f4-7143-96b8-aadc58c663c1_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_019cd33b-57f4-78c1-a545-559dd3bc7b4f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019cd33b-5742-7c2a-90b9-34887a9cd1ad_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_019cd33b-57f4-79a1-b107-ec604db744a8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_019cd33b-5742-7680-9c5c-d283deb1e11b_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019cd33b-57f4-71f0-90c8-d29b09f0e83d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock pursuant to equity award plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_PercentageOfOutstandingCommonStockOwned_019cd33b-5742-7e71-8768-d3806408f6b8_terseLabel_en-US" xlink:label="lab_rcus_PercentageOfOutstandingCommonStockOwned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of outstanding common stock held</link:label>
    <link:label id="lab_rcus_PercentageOfOutstandingCommonStockOwned_label_en-US" xlink:label="lab_rcus_PercentageOfOutstandingCommonStockOwned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Outstanding Common Stock Owned</link:label>
    <link:label id="lab_rcus_PercentageOfOutstandingCommonStockOwned_documentation_en-US" xlink:label="lab_rcus_PercentageOfOutstandingCommonStockOwned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of outstanding common stock owned.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PercentageOfOutstandingCommonStockOwned" xlink:href="rcus-20260331.xsd#rcus_PercentageOfOutstandingCommonStockOwned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_PercentageOfOutstandingCommonStockOwned" xlink:to="lab_rcus_PercentageOfOutstandingCommonStockOwned" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_019cd33b-5742-747e-9284-288c947ff572_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cd33b-57f4-7ae7-89d4-5fcdb9fde763_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_019cd33b-57f4-7cc3-a737-c59580ef17df_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OtherCollaborationRevenueMember_019cd33b-5742-713b-91db-ffae1d97eccf_terseLabel_en-US" xlink:label="lab_rcus_OtherCollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other collaboration</link:label>
    <link:label id="lab_rcus_OtherCollaborationRevenueMember_019dd161-08b7-7ae3-a76c-77f1c89f6348_verboseLabel_en-US" xlink:label="lab_rcus_OtherCollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other collaboration</link:label>
    <link:label id="lab_rcus_OtherCollaborationRevenueMember_label_en-US" xlink:label="lab_rcus_OtherCollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Collaboration Revenue [Member]</link:label>
    <link:label id="lab_rcus_OtherCollaborationRevenueMember_documentation_en-US" xlink:label="lab_rcus_OtherCollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Collaboration Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OtherCollaborationRevenueMember" xlink:href="rcus-20260331.xsd#rcus_OtherCollaborationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OtherCollaborationRevenueMember" xlink:to="lab_rcus_OtherCollaborationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_019cd33b-57f4-765c-a9fe-d21a72618f15_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_JenniferJarrettMember_label_en-US" xlink:label="lab_rcus_JenniferJarrettMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jennifer Jarrett [Member]</link:label>
    <link:label id="lab_rcus_JenniferJarrettMember_documentation_en-US" xlink:label="lab_rcus_JenniferJarrettMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Jennifer Jarrett</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_JenniferJarrettMember" xlink:href="rcus-20260331.xsd#rcus_JenniferJarrettMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_JenniferJarrettMember" xlink:to="lab_rcus_JenniferJarrettMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019cd33b-57f4-7573-91fe-66acbd40af7d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cd33b-57f4-75de-aa40-ff951a8e8cec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_019cd33b-57f4-7b9e-abae-bfc6976e5a90_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_EquityAwardProgramsMember_019cd33b-57f4-70fd-8301-2921688cd6eb_terseLabel_en-US" xlink:label="lab_rcus_EquityAwardProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award Programs</link:label>
    <link:label id="lab_rcus_EquityAwardProgramsMember_label_en-US" xlink:label="lab_rcus_EquityAwardProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award Programs [Member]</link:label>
    <link:label id="lab_rcus_EquityAwardProgramsMember_documentation_en-US" xlink:label="lab_rcus_EquityAwardProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Award Programs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_EquityAwardProgramsMember" xlink:href="rcus-20260331.xsd#rcus_EquityAwardProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_EquityAwardProgramsMember" xlink:to="lab_rcus_EquityAwardProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_019cd33b-57f4-7b5b-8362-734e26288e11_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019cd33b-57f4-7038-b333-6068e4f543ad_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019cd33b-57f4-72fb-99ab-8c9e3f15bb34_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OrganizationTable_019cf9b3-28ef-7b77-b767-fd6dedb8541b_terseLabel_en-US" xlink:label="lab_rcus_OrganizationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization [Table]</link:label>
    <link:label id="lab_rcus_OrganizationTable_label_en-US" xlink:label="lab_rcus_OrganizationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization [Table]</link:label>
    <link:label id="lab_rcus_OrganizationTable_documentation_en-US" xlink:label="lab_rcus_OrganizationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OrganizationTable" xlink:href="rcus-20260331.xsd#rcus_OrganizationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OrganizationTable" xlink:to="lab_rcus_OrganizationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_019cd33b-5742-7ee5-948a-5bd7f6c7a5da_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-operating income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019cd33b-5742-7505-8311-6a44a865c4a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019cd33b-5742-72e3-822d-2c0e5df6dae5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_019cd33b-5742-7eba-99b9-3eb8726d056e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue (($15) and ($28) to a related party)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_019cd33b-5742-78ef-8956-061d54eb53c1_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab_019cd33b-57f4-74cb-8503-c9f90c6fd2a6_terseLabel_en-US" xlink:label="lab_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential regulatory approval milestones payment receivable related to domvanalimab</link:label>
    <link:label id="lab_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab_label_en-US" xlink:label="lab_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Regulatory Approval Milestones Payment Receivable Related To Domvanalimab</link:label>
    <link:label id="lab_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab_documentation_en-US" xlink:label="lab_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential regulatory approval milestones payment receivable related to domvanalimab.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab" xlink:href="rcus-20260331.xsd#rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab" xlink:to="lab_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_LicenseAndDevelopmentServicesMember_019cd33b-57f4-7294-b15a-33767538a686_terseLabel_en-US" xlink:label="lab_rcus_LicenseAndDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and development services</link:label>
    <link:label id="lab_rcus_LicenseAndDevelopmentServicesMember_label_en-US" xlink:label="lab_rcus_LicenseAndDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Development Services [Member]</link:label>
    <link:label id="lab_rcus_LicenseAndDevelopmentServicesMember_documentation_en-US" xlink:label="lab_rcus_LicenseAndDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Development Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndDevelopmentServicesMember" xlink:href="rcus-20260331.xsd#rcus_LicenseAndDevelopmentServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_LicenseAndDevelopmentServicesMember" xlink:to="lab_rcus_LicenseAndDevelopmentServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_CommonStockPurchaseAgreementMember_019cd33b-5742-7130-b7f4-1296fa7e2677_terseLabel_en-US" xlink:label="lab_rcus_CommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Agreement</link:label>
    <link:label id="lab_rcus_CommonStockPurchaseAgreementMember_label_en-US" xlink:label="lab_rcus_CommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_rcus_CommonStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_rcus_CommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CommonStockPurchaseAgreementMember" xlink:href="rcus-20260331.xsd#rcus_CommonStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_CommonStockPurchaseAgreementMember" xlink:to="lab_rcus_CommonStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ClinicalRegulatoryMilestonePayments_019cd33b-5742-798d-bc4f-3943a7725f09_terseLabel_en-US" xlink:label="lab_rcus_ClinicalRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical regulatory milestone payments</link:label>
    <link:label id="lab_rcus_ClinicalRegulatoryMilestonePayments_label_en-US" xlink:label="lab_rcus_ClinicalRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Regulatory Milestone Payments</link:label>
    <link:label id="lab_rcus_ClinicalRegulatoryMilestonePayments_documentation_en-US" xlink:label="lab_rcus_ClinicalRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Regulatory Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ClinicalRegulatoryMilestonePayments" xlink:href="rcus-20260331.xsd#rcus_ClinicalRegulatoryMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ClinicalRegulatoryMilestonePayments" xlink:to="lab_rcus_ClinicalRegulatoryMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_019cd33b-57f4-709f-b136-346bee0a1c12_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt (Contractual maturity 2030)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_019cd33b-57f4-752c-99ff-f968edd158c6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued personnel expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_019cd33b-57f4-78db-b5a2-030387624aad_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_019cd33b-5742-703e-bfe5-96dfabe03c31_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_019cd33b-57f4-7ec6-bcea-6dfd9dc35a57_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_019cd33b-57f4-72b5-abc0-cfc6eadd8e05_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_019cd33b-57f4-720f-9fd2-5dd58ba03732_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_019cd33b-57f4-7583-b486-ecab10dec6f3_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_019cd33b-57f4-7c71-b741-1a8ce9b9a177_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_019cd33b-57f4-793c-9a4d-cc0e683bb121_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_019cd33b-57f4-7208-a34a-05f7f33267b0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_019cd33b-57f4-7393-b567-dc987b6f2a83_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_CashCashEquivalentsAndAvailableForSaleInvestments_019cd33b-57f4-7f30-b757-78e0c4208a85_totalLabel_en-US" xlink:label="lab_rcus_CashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents and marketable securities</link:label>
    <link:label id="lab_rcus_CashCashEquivalentsAndAvailableForSaleInvestments_label_en-US" xlink:label="lab_rcus_CashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Cash Equivalents And Available For Sale Investments</link:label>
    <link:label id="lab_rcus_CashCashEquivalentsAndAvailableForSaleInvestments_documentation_en-US" xlink:label="lab_rcus_CashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and available for sale investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndAvailableForSaleInvestments" xlink:href="rcus-20260331.xsd#rcus_CashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_CashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="lab_rcus_CashCashEquivalentsAndAvailableForSaleInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_019cd33b-5742-7a8a-b591-7dd00eca3969_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_019cd33b-5742-7b96-b94b-6d53a733a727_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_019cd33b-57f4-73d2-b373-df972786e495_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over time</link:label>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transferred over Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredOverTimeMember" xlink:to="lab_us-gaap_TransferredOverTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement_019cd33b-5742-7cf4-8383-98a143b34e5f_terseLabel_en-US" xlink:label="lab_rcus_OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option continuation payment due upon eighth anniversary of agreement</link:label>
    <link:label id="lab_rcus_OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement_label_en-US" xlink:label="lab_rcus_OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Continuation Payment Due Upon Eighth Anniversary Of Agreement</link:label>
    <link:label id="lab_rcus_OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement_documentation_en-US" xlink:label="lab_rcus_OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option continuation payment due upon Eighth anniversary of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement" xlink:href="rcus-20260331.xsd#rcus_OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement" xlink:to="lab_rcus_OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_019cd33b-57f4-7aac-9b6a-3bc21b0e8dad_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_019cd33b-5742-7a42-8c22-4a7e43ac93d9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_019cd33b-57f4-7469-92ba-ccc283e05522_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_LicenseAndCollaborationAgreementsAbstract_019cd33b-57f4-7d87-839a-f1b9dee7aa4f_terseLabel_en-US" xlink:label="lab_rcus_LicenseAndCollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Abstract]</link:label>
    <link:label id="lab_rcus_LicenseAndCollaborationAgreementsAbstract_label_en-US" xlink:label="lab_rcus_LicenseAndCollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License and Collaboration Agreements [Abstract]</link:label>
    <link:label id="lab_rcus_LicenseAndCollaborationAgreementsAbstract_documentation_en-US" xlink:label="lab_rcus_LicenseAndCollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndCollaborationAgreementsAbstract" xlink:href="rcus-20260331.xsd#rcus_LicenseAndCollaborationAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsAbstract" xlink:to="lab_rcus_LicenseAndCollaborationAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cd33b-57f4-7b9a-98b9-ad36741e3539_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_019cd33b-5742-7307-9f3f-45338fadf511_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and Collaborations</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cd33b-5742-763c-87f7-529937c712bb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_019cd33b-5742-7aa9-ba93-6cec60e175f3_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_019cd33b-5742-7b17-977f-b16a1f170056_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_DebtInstrumentTrancheTypeDomain_019d18b0-cfa0-7639-85f5-f796e6399beb_terseLabel_en-US" xlink:label="lab_rcus_DebtInstrumentTrancheTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche Type [Domain]</link:label>
    <link:label id="lab_rcus_DebtInstrumentTrancheTypeDomain_label_en-US" xlink:label="lab_rcus_DebtInstrumentTrancheTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche Type [Domain]</link:label>
    <link:label id="lab_rcus_DebtInstrumentTrancheTypeDomain_documentation_en-US" xlink:label="lab_rcus_DebtInstrumentTrancheTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Tranche Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_DebtInstrumentTrancheTypeDomain" xlink:href="rcus-20260331.xsd#rcus_DebtInstrumentTrancheTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_DebtInstrumentTrancheTypeDomain" xlink:to="lab_rcus_DebtInstrumentTrancheTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones_019cd33b-57f4-7dad-bb0e-8a1586b7dab5_terseLabel_en-US" xlink:label="lab_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option payment upon achievement of certain development milestones</link:label>
    <link:label id="lab_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones_label_en-US" xlink:label="lab_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Payment Upon Achievement Of Certain Development Milestones</link:label>
    <link:label id="lab_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones_documentation_en-US" xlink:label="lab_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option payment upon achievement of certain development milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones" xlink:href="rcus-20260331.xsd#rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones" xlink:to="lab_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_019cd33b-5742-72d7-8652-7cbba31ce2e7_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019cd33b-57f4-705a-be1a-3b115aaae173_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_019cd33b-5742-75f2-bddc-eccce56b2981_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019cd33b-57f4-7095-99fe-077d11ac72d3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_019cd33b-57f4-7d62-8b4d-d9f21b290ea1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock_019cd33b-57f4-789f-b783-b2f4aa0337c5_terseLabel_en-US" xlink:label="lab_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Cash and Non-cash Information Related to Operating Leases</link:label>
    <link:label id="lab_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Supplemental Cash Flow Disclosures And Non-Cash Financing Activities Related To Operating Leases [Table Text Block]</link:label>
    <link:label id="lab_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock_documentation_en-US" xlink:label="lab_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of supplemental cash flow disclosures and non-cash financing activities related to operating leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock" xlink:href="rcus-20260331.xsd#rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock" xlink:to="lab_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_019cd33b-5742-7654-a45c-b038c334a265_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cd33b-5742-7f2c-8367-54cd91fd7aa4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_019cd33b-57f4-7e65-ae28-454996d02f01_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Receivable from collaboration partners ($&#8212; and $2 from a related party)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_019cd33b-57f4-71a8-94ca-5b76f0a90ae4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Receivable from collaboration partners</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForLoanLossesExpensed_019cd33b-5742-72c5-b108-81c082177930_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForLoanLossesExpensed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit related losses</link:label>
    <link:label id="lab_us-gaap_ProvisionForLoanLossesExpensed_label_en-US" xlink:label="lab_us-gaap_ProvisionForLoanLossesExpensed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivable, Credit Loss, Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLoanLossesExpensed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForLoanLossesExpensed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForLoanLossesExpensed" xlink:to="lab_us-gaap_ProvisionForLoanLossesExpensed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_019cd33b-57f4-784a-ad3e-069bc7b0d9bc_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OptionAndLicenseAgreementMember_019cd33b-57f4-756f-95cd-e1fb33e97eb3_terseLabel_en-US" xlink:label="lab_rcus_OptionAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taiho Agreement</link:label>
    <link:label id="lab_rcus_OptionAndLicenseAgreementMember_label_en-US" xlink:label="lab_rcus_OptionAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option And License Agreement [Member]</link:label>
    <link:label id="lab_rcus_OptionAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_rcus_OptionAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option and license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionAndLicenseAgreementMember" xlink:href="rcus-20260331.xsd#rcus_OptionAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OptionAndLicenseAgreementMember" xlink:to="lab_rcus_OptionAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019cd33b-57f4-7eee-ac44-26b6af9bdf01_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used to compute net loss per share, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019cd33b-57f4-7065-899e-9ec169a004bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_019cd33b-57f4-7e15-b1f6-eab9e9d047c0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_019cd33b-5742-7a47-947f-f4ec8a2061f2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock and additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Including Additional Paid in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_019cd33b-57f4-76fb-bc0b-7d95d21a202d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_DebtInstrumentAdditionalCommittedAmount_019cd33b-5742-72a6-afb6-15516775b7b0_terseLabel_en-US" xlink:label="lab_rcus_DebtInstrumentAdditionalCommittedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, additional committed amount</link:label>
    <link:label id="lab_rcus_DebtInstrumentAdditionalCommittedAmount_label_en-US" xlink:label="lab_rcus_DebtInstrumentAdditionalCommittedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Committed Amount</link:label>
    <link:label id="lab_rcus_DebtInstrumentAdditionalCommittedAmount_documentation_en-US" xlink:label="lab_rcus_DebtInstrumentAdditionalCommittedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Committed Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_DebtInstrumentAdditionalCommittedAmount" xlink:href="rcus-20260331.xsd#rcus_DebtInstrumentAdditionalCommittedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_DebtInstrumentAdditionalCommittedAmount" xlink:to="lab_rcus_DebtInstrumentAdditionalCommittedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption_019cd33b-5742-70c1-b5e6-f212752d5c7c_terseLabel_en-US" xlink:label="lab_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option fee per program for all other programs entering clinical development to exercise option</link:label>
    <link:label id="lab_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption_label_en-US" xlink:label="lab_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Fee Per Program For All Other Programs Entering Clinical Development To Exercise Option</link:label>
    <link:label id="lab_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption_documentation_en-US" xlink:label="lab_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option fee per program for all other programs entering clinical development to exercise option.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption" xlink:href="rcus-20260331.xsd#rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption" xlink:to="lab_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_019cd33b-57f4-7747-b262-60fa02ea2841_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_019cd33b-5742-7c45-a9b0-03d94ca45393_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_019cd33b-57f4-706e-a3c2-5f765e26c772_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_019cd33b-57f4-70d1-a31e-e7f7c2a0fa12_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_019cd33b-57f4-769c-8b8d-46334247039b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_019cd33b-5742-77aa-8d4d-1511b4bca81f_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_019cd33b-5742-7ed8-bd76-4f467d6f18d3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_RoyaltiesPayableTerm_019cd33b-5742-7f36-b5b4-6c6451d3210b_terseLabel_en-US" xlink:label="lab_rcus_RoyaltiesPayableTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties payable term</link:label>
    <link:label id="lab_rcus_RoyaltiesPayableTerm_label_en-US" xlink:label="lab_rcus_RoyaltiesPayableTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalties Payable Term</link:label>
    <link:label id="lab_rcus_RoyaltiesPayableTerm_documentation_en-US" xlink:label="lab_rcus_RoyaltiesPayableTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalties Payable Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RoyaltiesPayableTerm" xlink:href="rcus-20260331.xsd#rcus_RoyaltiesPayableTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_RoyaltiesPayableTerm" xlink:to="lab_rcus_RoyaltiesPayableTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_ReimbursementOfResearchAndDevelopmentExpense_019cd33b-57f4-7910-af0f-c5aa21a271c9_terseLabel_en-US" xlink:label="lab_rcus_ReimbursementOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement of research and development expense</link:label>
    <link:label id="lab_rcus_ReimbursementOfResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_rcus_ReimbursementOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Of Research And Development Expense</link:label>
    <link:label id="lab_rcus_ReimbursementOfResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_rcus_ReimbursementOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reimbursement of research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ReimbursementOfResearchAndDevelopmentExpense" xlink:href="rcus-20260331.xsd#rcus_ReimbursementOfResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_ReimbursementOfResearchAndDevelopmentExpense" xlink:to="lab_rcus_ReimbursementOfResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_019cd33b-57f4-78cc-a3d5-360d6811447d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_PrepaidExpensesAndOtherCurrentAssets_019cd33b-5742-7c51-9637-575547b7f286_terseLabel_en-US" xlink:label="lab_rcus_PrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_rcus_PrepaidExpensesAndOtherCurrentAssets_label_en-US" xlink:label="lab_rcus_PrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expenses And Other Current Assets</link:label>
    <link:label id="lab_rcus_PrepaidExpensesAndOtherCurrentAssets_documentation_en-US" xlink:label="lab_rcus_PrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PrepaidExpensesAndOtherCurrentAssets" xlink:href="rcus-20260331.xsd#rcus_PrepaidExpensesAndOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_PrepaidExpensesAndOtherCurrentAssets" xlink:to="lab_rcus_PrepaidExpensesAndOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_TaihoCollaborationMember_019cd33b-5742-7ef1-b63e-2e76ac96f75b_terseLabel_en-US" xlink:label="lab_rcus_TaihoCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taiho Collaboration</link:label>
    <link:label id="lab_rcus_TaihoCollaborationMember_label_en-US" xlink:label="lab_rcus_TaihoCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taiho Collaboration [Member]</link:label>
    <link:label id="lab_rcus_TaihoCollaborationMember_documentation_en-US" xlink:label="lab_rcus_TaihoCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Taiho Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoCollaborationMember" xlink:href="rcus-20260331.xsd#rcus_TaihoCollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_TaihoCollaborationMember" xlink:to="lab_rcus_TaihoCollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_019cd33b-5742-7187-9260-652c6bbdea7d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_019cd33b-5742-718d-8462-b14cd2380b8f_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_019cd33b-5742-75ab-ab68-42a3da052e85_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_019cd33b-57f4-7d7b-9516-2075c285fd56_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_019cd33b-57f4-7206-8492-8bb44a60018a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_DeferredRevenueNonRefundablePayment_019cd33b-57f4-7f45-b15a-07ebaa7c22e4_terseLabel_en-US" xlink:label="lab_rcus_DeferredRevenueNonRefundablePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, non-refundable payment</link:label>
    <link:label id="lab_rcus_DeferredRevenueNonRefundablePayment_label_en-US" xlink:label="lab_rcus_DeferredRevenueNonRefundablePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Non-Refundable Payment</link:label>
    <link:label id="lab_rcus_DeferredRevenueNonRefundablePayment_documentation_en-US" xlink:label="lab_rcus_DeferredRevenueNonRefundablePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Non-Refundable Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_DeferredRevenueNonRefundablePayment" xlink:href="rcus-20260331.xsd#rcus_DeferredRevenueNonRefundablePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_DeferredRevenueNonRefundablePayment" xlink:to="lab_rcus_DeferredRevenueNonRefundablePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_019cd33b-5742-7c59-9638-cd958eb08a04_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cd33b-5742-71fe-8bf7-42a7c5883c48_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OptionPaymentReceived_019cd33b-5742-7087-8c1c-4b3c44ca5eea_terseLabel_en-US" xlink:label="lab_rcus_OptionPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option payments received</link:label>
    <link:label id="lab_rcus_OptionPaymentReceived_label_en-US" xlink:label="lab_rcus_OptionPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Payment Received</link:label>
    <link:label id="lab_rcus_OptionPaymentReceived_documentation_en-US" xlink:label="lab_rcus_OptionPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option payment received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionPaymentReceived" xlink:href="rcus-20260331.xsd#rcus_OptionPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OptionPaymentReceived" xlink:to="lab_rcus_OptionPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_rcus_OrganizationLineItems_019cf9b4-1b38-72a9-b5db-d18ada25465d_terseLabel_en-US" xlink:label="lab_rcus_OrganizationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization [Line Items]</link:label>
    <link:label id="lab_rcus_OrganizationLineItems_label_en-US" xlink:label="lab_rcus_OrganizationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization [Line Items]</link:label>
    <link:label id="lab_rcus_OrganizationLineItems_documentation_en-US" xlink:label="lab_rcus_OrganizationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OrganizationLineItems" xlink:href="rcus-20260331.xsd#rcus_OrganizationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rcus_OrganizationLineItems" xlink:to="lab_rcus_OrganizationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_019cd33b-57f4-7f02-a192-91e49564538c_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_019cd33b-5742-7647-a1f2-4946731f964c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019cd33b-5742-759f-9aed-a4ed5fee8c59_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019cd33b-57f4-7cd1-ba52-ba6e4f1005ce_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cd33b-5742-77ef-9e94-3f96d1bc6b3e_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>rcus-20260331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019cd33b-55e2-7686-a45d-3e64ec40f088,g:5cd5bcae-d38e-4438-9e12-43823d2921f9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://arcusbio.com/role/Cover" xlink:type="simple" xlink:href="rcus-20260331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019cd33b-5697-78b6-989e-43619a0dce33" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_DocumentType_019cd33b-5697-78b6-989e-43619a0dce33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_019cd33b-5697-7573-849d-90e16ec9613a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_DocumentQuarterlyReport_019cd33b-5697-7573-849d-90e16ec9613a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019cd33b-5697-7397-9265-362db3e8097a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_DocumentPeriodEndDate_019cd33b-5697-7397-9265-362db3e8097a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_019cd33b-5697-791c-a434-e9b28e00cabc" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_DocumentTransitionReport_019cd33b-5697-791c-a434-e9b28e00cabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019cd33b-5697-79bc-9755-9597e137b655" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_EntityFileNumber_019cd33b-5697-79bc-9755-9597e137b655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019cd33b-5697-732d-8018-c0845e84f6b6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_EntityRegistrantName_019cd33b-5697-732d-8018-c0845e84f6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019cd33b-5697-70f6-bbb1-50989a12da67" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019cd33b-5697-70f6-bbb1-50989a12da67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019cd33b-5697-7908-aca2-2a23d6326ef3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_EntityTaxIdentificationNumber_019cd33b-5697-7908-aca2-2a23d6326ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019cd33b-5697-7442-94ab-da0d1fb79770" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_EntityAddressAddressLine1_019cd33b-5697-7442-94ab-da0d1fb79770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019cd33b-5697-74cb-83e6-618fc61c85fb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_EntityAddressCityOrTown_019cd33b-5697-74cb-83e6-618fc61c85fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019cd33b-5697-79d2-91eb-ba9aa16381c4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_EntityAddressStateOrProvince_019cd33b-5697-79d2-91eb-ba9aa16381c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019cd33b-5697-79c7-9ac8-05169d0cd1b7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_EntityAddressPostalZipCode_019cd33b-5697-79c7-9ac8-05169d0cd1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019cd33b-5697-70b7-9e2d-8d07f7716ee9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_CityAreaCode_019cd33b-5697-70b7-9e2d-8d07f7716ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019cd33b-5697-747e-9874-5d24b24ff0fe" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_LocalPhoneNumber_019cd33b-5697-747e-9874-5d24b24ff0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019cd33b-5697-7564-b833-b2b3c7b510ae" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_Security12bTitle_019cd33b-5697-7564-b833-b2b3c7b510ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019cd33b-5697-716d-99f2-6352d9f937d8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_TradingSymbol_019cd33b-5697-716d-99f2-6352d9f937d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019cd33b-5697-75fb-a458-5839e8b1d8e3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_SecurityExchangeName_019cd33b-5697-75fb-a458-5839e8b1d8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_019cd33b-5697-7c6a-a797-f701cf38be9c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_EntityCurrentReportingStatus_019cd33b-5697-7c6a-a797-f701cf38be9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_019cd33b-5697-72a5-9402-fec69f47b410" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_EntityInteractiveDataCurrent_019cd33b-5697-72a5-9402-fec69f47b410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_019cd33b-5697-7cd5-bb41-3e313e990eaf" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_EntityFilerCategory_019cd33b-5697-7cd5-bb41-3e313e990eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_019cd33b-5697-78ef-aee3-98339ff93d53" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_EntitySmallBusiness_019cd33b-5697-78ef-aee3-98339ff93d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019cd33b-5697-7c7d-b360-e174ec400d66" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_EntityEmergingGrowthCompany_019cd33b-5697-7c7d-b360-e174ec400d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_019cd33b-5697-7364-aaab-9f1d3d06fa26" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_EntityShellCompany_019cd33b-5697-7364-aaab-9f1d3d06fa26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_019cd33b-5697-73b9-834e-9545c9c9ac7f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_019cd33b-5697-73b9-834e-9545c9c9ac7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019cd33b-5697-778f-b874-d372cbf634f7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_EntityCentralIndexKey_019cd33b-5697-778f-b874-d372cbf634f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_019cd33b-5697-7463-80ed-d6bddeb05211" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_CurrentFiscalYearEndDate_019cd33b-5697-7463-80ed-d6bddeb05211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019cd33b-5697-757c-9f73-60736026de92" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_AmendmentFlag_019cd33b-5697-757c-9f73-60736026de92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_019cd33b-5697-7bc6-a06b-98dfcc4f1a2c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_DocumentFiscalYearFocus_019cd33b-5697-7bc6-a06b-98dfcc4f1a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_019cd33b-5697-7736-992c-6a16f40b8bb6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019cd33b-5697-7e48-8930-6f959394c201" xlink:to="loc_dei_DocumentFiscalPeriodFocus_019cd33b-5697-7736-992c-6a16f40b8bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="rcus-20260331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_019cd33b-5697-72e9-9fc5-4d0be6fe4797" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019cd33b-5697-791c-bc84-57758dec985c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019cd33b-5697-72e9-9fc5-4d0be6fe4797" xlink:to="loc_us-gaap_StatementTable_019cd33b-5697-791c-bc84-57758dec985c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019cd33b-5697-71a1-881c-0332b5c0486c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019cd33b-5697-791c-bc84-57758dec985c" xlink:to="loc_srt_ProductOrServiceAxis_019cd33b-5697-71a1-881c-0332b5c0486c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019cd33b-5697-7568-ad9c-6c1a373be1db" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019cd33b-5697-71a1-881c-0332b5c0486c" xlink:to="loc_srt_ProductsAndServicesDomain_019cd33b-5697-7568-ad9c-6c1a373be1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndDevelopmentServicesMember_019d18e5-3e4f-7676-b1fd-2d7f0577a4f6" xlink:href="rcus-20260331.xsd#rcus_LicenseAndDevelopmentServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019cd33b-5697-7568-ad9c-6c1a373be1db" xlink:to="loc_rcus_LicenseAndDevelopmentServicesMember_019d18e5-3e4f-7676-b1fd-2d7f0577a4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OtherCollaborationRevenueMember_019cd33b-5697-7637-a188-b60438121af9" xlink:href="rcus-20260331.xsd#rcus_OtherCollaborationRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019cd33b-5697-7568-ad9c-6c1a373be1db" xlink:to="loc_rcus_OtherCollaborationRevenueMember_019cd33b-5697-7637-a188-b60438121af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019cd33b-5697-791c-bc84-57758dec985c" xlink:to="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_019cd33b-5697-7849-87d5-8ee12a11947b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:to="loc_us-gaap_RevenuesAbstract_019cd33b-5697-7849-87d5-8ee12a11947b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019cd33b-5697-7d75-ac17-83485fd06e68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_019cd33b-5697-7849-87d5-8ee12a11947b" xlink:to="loc_us-gaap_Revenues_019cd33b-5697-7d75-ac17-83485fd06e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_019cd33b-5697-7489-82fa-e8ea33b5cdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:to="loc_us-gaap_OperatingExpensesAbstract_019cd33b-5697-7489-82fa-e8ea33b5cdfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_019cd33b-5697-7e84-8f65-4ee05e4e5c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019cd33b-5697-7489-82fa-e8ea33b5cdfa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_019cd33b-5697-7e84-8f65-4ee05e4e5c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019cd33b-5697-7ad0-a5c4-2e6ab08372cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019cd33b-5697-7489-82fa-e8ea33b5cdfa" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019cd33b-5697-7ad0-a5c4-2e6ab08372cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019cd33b-5697-7be3-84b2-a5ebb6fb149b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_019cd33b-5697-7489-82fa-e8ea33b5cdfa" xlink:to="loc_us-gaap_OperatingExpenses_019cd33b-5697-7be3-84b2-a5ebb6fb149b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_019cd33b-5697-7a66-9fee-faf093aad4d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:to="loc_us-gaap_OperatingIncomeLoss_019cd33b-5697-7a66-9fee-faf093aad4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_019cd33b-5697-7116-8776-5d0d58a89b65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_019cd33b-5697-7116-8776-5d0d58a89b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_InterestAndOtherIncomeExpenseNonoperatingNet_019cd33b-5697-7079-b8a4-fe104b054d76" xlink:href="rcus-20260331.xsd#rcus_InterestAndOtherIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_019cd33b-5697-7116-8776-5d0d58a89b65" xlink:to="loc_rcus_InterestAndOtherIncomeExpenseNonoperatingNet_019cd33b-5697-7079-b8a4-fe104b054d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_019cd33b-5697-7a64-8e4a-fe9b522d5c41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_019cd33b-5697-7116-8776-5d0d58a89b65" xlink:to="loc_us-gaap_InterestExpenseNonoperating_019cd33b-5697-7a64-8e4a-fe9b522d5c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_019cd33b-5697-7ad8-85da-84df3b5cbaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_019cd33b-5697-7116-8776-5d0d58a89b65" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_019cd33b-5697-7ad8-85da-84df3b5cbaf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cd33b-5697-7e58-9461-0e532f6d7fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_019cd33b-5697-7e58-9461-0e532f6d7fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019cd33b-5697-7302-849b-62fbfc2b18e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019cd33b-5697-7302-849b-62fbfc2b18e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cd33b-5697-7a2d-b6a7-da4300373c60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:to="loc_us-gaap_NetIncomeLoss_019cd33b-5697-7a2d-b6a7-da4300373c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019cf973-c92d-7137-be9a-85309aaf3fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:to="loc_us-gaap_EarningsPerShareBasic_019cf973-c92d-7137-be9a-85309aaf3fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019cf973-c92d-74c7-a176-7068566f0afd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019cf973-c92d-74c7-a176-7068566f0afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019cd33b-5697-7d4c-bb45-61fc84b6c683" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_019cd33b-5697-7d4c-bb45-61fc84b6c683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019cd33b-5697-7aa9-b45a-a18fea59cda8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-764c-af2b-3d5096ed0e18" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_019cd33b-5697-7aa9-b45a-a18fea59cda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical" xlink:type="simple" xlink:href="rcus-20260331.xsd#CondensedConsolidatedStatementsofOperationsParenthetical"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_019cd33b-5697-7b3e-a1bb-167fd4d656fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019cd33b-5697-7283-835e-aabf62f4fa23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019cd33b-5697-7b3e-a1bb-167fd4d656fc" xlink:to="loc_us-gaap_StatementTable_019cd33b-5697-7283-835e-aabf62f4fa23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019cd33b-5697-712a-92fd-eb5342eaa5ff" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019cd33b-5697-7283-835e-aabf62f4fa23" xlink:to="loc_srt_ProductOrServiceAxis_019cd33b-5697-712a-92fd-eb5342eaa5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019cd33b-5697-7f7e-8807-437f5cd5d787" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019cd33b-5697-712a-92fd-eb5342eaa5ff" xlink:to="loc_srt_ProductsAndServicesDomain_019cd33b-5697-7f7e-8807-437f5cd5d787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndDevelopmentServicesMember_019d4e0a-3fb2-7298-adf0-0d9c36682851" xlink:href="rcus-20260331.xsd#rcus_LicenseAndDevelopmentServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019cd33b-5697-7f7e-8807-437f5cd5d787" xlink:to="loc_rcus_LicenseAndDevelopmentServicesMember_019d4e0a-3fb2-7298-adf0-0d9c36682851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OtherCollaborationRevenueMember_019cd33b-5697-7060-bda1-c3354278d1fd" xlink:href="rcus-20260331.xsd#rcus_OtherCollaborationRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019cd33b-5697-7f7e-8807-437f5cd5d787" xlink:to="loc_rcus_OtherCollaborationRevenueMember_019cd33b-5697-7060-bda1-c3354278d1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5697-71b9-97d1-0c7c24441ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019cd33b-5697-7283-835e-aabf62f4fa23" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5697-71b9-97d1-0c7c24441ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019cd33b-5697-744c-bd04-d4b0a672e2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5697-71b9-97d1-0c7c24441ce5" xlink:to="loc_us-gaap_RelatedPartyDomain_019cd33b-5697-744c-bd04-d4b0a672e2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019cd33b-5697-7ced-aa3a-b2e04536cb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019cd33b-5697-744c-bd04-d4b0a672e2a9" xlink:to="loc_us-gaap_RelatedPartyMember_019cd33b-5697-7ced-aa3a-b2e04536cb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019cd33b-5697-7d95-9038-6061d15df217" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019cd33b-5697-7283-835e-aabf62f4fa23" xlink:to="loc_us-gaap_StatementLineItems_019cd33b-5697-7d95-9038-6061d15df217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019cd33b-5697-7761-92bb-38e7df85ab0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-7d95-9038-6061d15df217" xlink:to="loc_us-gaap_Revenues_019cd33b-5697-7761-92bb-38e7df85ab0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ResearchAndDevelopmentExpenseRecoveries_019cd33b-5697-76ff-a840-4a1052315434" xlink:href="rcus-20260331.xsd#rcus_ResearchAndDevelopmentExpenseRecoveries"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-7d95-9038-6061d15df217" xlink:to="loc_rcus_ResearchAndDevelopmentExpenseRecoveries_019cd33b-5697-76ff-a840-4a1052315434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_019cd33b-5697-7e01-a9fe-4a7263c5123f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-7d95-9038-6061d15df217" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_019cd33b-5697-7e01-a9fe-4a7263c5123f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="rcus-20260331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_019cd33b-5697-76cd-b76a-c7e41c08d737" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cd33b-5697-7d77-ab49-37ac7c62a920" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019cd33b-5697-76cd-b76a-c7e41c08d737" xlink:to="loc_us-gaap_NetIncomeLoss_019cd33b-5697-7d77-ab49-37ac7c62a920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cd33b-5697-755e-ac1a-b93c7ac53daf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019cd33b-5697-76cd-b76a-c7e41c08d737" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_019cd33b-5697-755e-ac1a-b93c7ac53daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_019cd33b-5697-7dc3-b397-a59b207b8e36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_019cd33b-5697-76cd-b76a-c7e41c08d737" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_019cd33b-5697-7dc3-b397-a59b207b8e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="rcus-20260331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_019cd33b-5697-706e-87db-8338947fbdfd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_019cd33b-5697-765c-b0ef-3e516f992afb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019cd33b-5697-706e-87db-8338947fbdfd" xlink:to="loc_us-gaap_AssetsAbstract_019cd33b-5697-765c-b0ef-3e516f992afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_019cd33b-5697-7569-88bc-66be43d615e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019cd33b-5697-765c-b0ef-3e516f992afb" xlink:to="loc_us-gaap_AssetsCurrentAbstract_019cd33b-5697-7569-88bc-66be43d615e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cd33b-5697-70cd-9218-808016e46698" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019cd33b-5697-7569-88bc-66be43d615e6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cd33b-5697-70cd-9218-808016e46698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019cd33b-5697-7099-80f4-1b0ced85ede7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019cd33b-5697-7569-88bc-66be43d615e6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019cd33b-5697-7099-80f4-1b0ced85ede7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_019cd33b-5697-732b-a7fe-5d9119a15765" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019cd33b-5697-7569-88bc-66be43d615e6" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_019cd33b-5697-732b-a7fe-5d9119a15765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cd33b-5697-7083-b34c-c3176621616d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019cd33b-5697-7569-88bc-66be43d615e6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cd33b-5697-7083-b34c-c3176621616d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_019cd33b-5697-7a96-9e2f-c4f8168b0345" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_019cd33b-5697-7569-88bc-66be43d615e6" xlink:to="loc_us-gaap_AssetsCurrent_019cd33b-5697-7a96-9e2f-c4f8168b0345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_019cd33b-5697-7daf-b66f-bacb3f755d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019cd33b-5697-765c-b0ef-3e516f992afb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_019cd33b-5697-7daf-b66f-bacb3f755d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_019cd33b-5697-799e-a868-6f790c9c524f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019cd33b-5697-765c-b0ef-3e516f992afb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_019cd33b-5697-799e-a868-6f790c9c524f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_019cd33b-5697-7b5b-bc8a-200be6aa0126" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019cd33b-5697-765c-b0ef-3e516f992afb" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_019cd33b-5697-7b5b-bc8a-200be6aa0126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019cd33b-5697-72d3-a8a2-74bad617716d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_019cd33b-5697-765c-b0ef-3e516f992afb" xlink:to="loc_us-gaap_Assets_019cd33b-5697-72d3-a8a2-74bad617716d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_019cd33b-5697-73dc-a435-a5923d8341e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019cd33b-5697-706e-87db-8338947fbdfd" xlink:to="loc_us-gaap_LiabilitiesAbstract_019cd33b-5697-73dc-a435-a5923d8341e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_019cd33b-5697-73cb-9e56-b90d890b2970" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_019cd33b-5697-73dc-a435-a5923d8341e2" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_019cd33b-5697-73cb-9e56-b90d890b2970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019cd33b-5697-76e1-a0e6-36801c852e70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019cd33b-5697-73cb-9e56-b90d890b2970" xlink:to="loc_us-gaap_AccountsPayableCurrent_019cd33b-5697-76e1-a0e6-36801c852e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_019cd33b-5697-7946-b33d-471e92b4c4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019cd33b-5697-73cb-9e56-b90d890b2970" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_019cd33b-5697-7946-b33d-471e92b4c4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_019cd33b-5697-78e5-871f-d8b19232b534" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019cd33b-5697-73cb-9e56-b90d890b2970" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_019cd33b-5697-78e5-871f-d8b19232b534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_019cd33b-5697-79a6-89b3-add139ce6cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_019cd33b-5697-73cb-9e56-b90d890b2970" xlink:to="loc_us-gaap_LiabilitiesCurrent_019cd33b-5697-79a6-89b3-add139ce6cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_019cd33b-5697-7bfe-8548-5c57e67cf82a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_019cd33b-5697-73dc-a435-a5923d8341e2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_019cd33b-5697-7bfe-8548-5c57e67cf82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_019cd33b-5697-708e-930e-20aecb006f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_019cd33b-5697-73dc-a435-a5923d8341e2" xlink:to="loc_us-gaap_LongTermDebt_019cd33b-5697-708e-930e-20aecb006f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_019cd33b-5697-754b-afc0-8df7de400a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_019cd33b-5697-73dc-a435-a5923d8341e2" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_019cd33b-5697-754b-afc0-8df7de400a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_019cd33b-5697-758d-a5c8-b37380fae84c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_019cd33b-5697-73dc-a435-a5923d8341e2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_019cd33b-5697-758d-a5c8-b37380fae84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_019cd33b-5697-71da-8b3f-f597225457cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019cd33b-5697-706e-87db-8338947fbdfd" xlink:to="loc_us-gaap_StockholdersEquityAbstract_019cd33b-5697-71da-8b3f-f597225457cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_019cd33b-5697-773d-8d8d-4d47c887b9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019cd33b-5697-71da-8b3f-f597225457cf" xlink:to="loc_us-gaap_CommonStockValue_019cd33b-5697-773d-8d8d-4d47c887b9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019cd33b-5697-7b1e-86a2-8547355eee04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019cd33b-5697-71da-8b3f-f597225457cf" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_019cd33b-5697-7b1e-86a2-8547355eee04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019db20d-2879-7e3a-b6d3-571e7d7de66b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019cd33b-5697-71da-8b3f-f597225457cf" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_019db20d-2879-7e3a-b6d3-571e7d7de66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019cd33b-5697-7ab7-bafc-e36a7b8c388a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019cd33b-5697-71da-8b3f-f597225457cf" xlink:to="loc_us-gaap_StockholdersEquity_019cd33b-5697-7ab7-bafc-e36a7b8c388a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cd33b-5697-78eb-870d-20f93425d7be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_019cd33b-5697-71da-8b3f-f597225457cf" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_019cd33b-5697-78eb-870d-20f93425d7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="rcus-20260331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_019cd33b-5697-79a7-bef1-26ebd3ed4a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019cd33b-5697-7380-880b-d6dcb99b0327" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_019cd33b-5697-79a7-bef1-26ebd3ed4a2a" xlink:to="loc_us-gaap_StatementTable_019cd33b-5697-7380-880b-d6dcb99b0327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5697-7482-8dcd-ad3b0eb24211" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019cd33b-5697-7380-880b-d6dcb99b0327" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5697-7482-8dcd-ad3b0eb24211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019cd33b-5697-7215-befa-21895a17868a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5697-7482-8dcd-ad3b0eb24211" xlink:to="loc_us-gaap_RelatedPartyDomain_019cd33b-5697-7215-befa-21895a17868a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019cd33b-5697-7152-933d-eb8a2265a7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019cd33b-5697-7215-befa-21895a17868a" xlink:to="loc_us-gaap_RelatedPartyMember_019cd33b-5697-7152-933d-eb8a2265a7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019cd33b-5697-7d38-a021-d0537932153d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019cd33b-5697-7380-880b-d6dcb99b0327" xlink:to="loc_us-gaap_StatementLineItems_019cd33b-5697-7d38-a021-d0537932153d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019cd33b-5697-7719-a525-0d046fa7a2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-7d38-a021-d0537932153d" xlink:to="loc_us-gaap_AccountsPayableCurrent_019cd33b-5697-7719-a525-0d046fa7a2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_019cd33b-5697-78e6-b61d-c72cf1a5b3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-7d38-a021-d0537932153d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_019cd33b-5697-78e6-b61d-c72cf1a5b3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_019cd33b-5697-7347-b0db-b3ad4a58b036" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-7d38-a021-d0537932153d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_019cd33b-5697-7347-b0db-b3ad4a58b036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_019cd33b-5697-749e-aa05-4538d5897cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-7d38-a021-d0537932153d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_019cd33b-5697-749e-aa05-4538d5897cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_019cd33b-5697-74bb-a8f8-8e0c6884420f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-7d38-a021-d0537932153d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_019cd33b-5697-74bb-a8f8-8e0c6884420f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_019cd33b-5697-7cde-b07c-d65897654347" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-7d38-a021-d0537932153d" xlink:to="loc_us-gaap_CommonStockSharesIssued_019cd33b-5697-7cde-b07c-d65897654347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019cd33b-5697-7f38-aac8-efb0549bb958" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-7d38-a021-d0537932153d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019cd33b-5697-7f38-aac8-efb0549bb958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="rcus-20260331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_019cd33b-5697-71f7-8bc7-408fa1b4dc5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019cd33b-5697-7ef8-86e4-547ce089da8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_019cd33b-5697-71f7-8bc7-408fa1b4dc5b" xlink:to="loc_us-gaap_StatementTable_019cd33b-5697-7ef8-86e4-547ce089da8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_019cd33b-5697-79c7-94b4-1f31ae94c0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019cd33b-5697-7ef8-86e4-547ce089da8c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_019cd33b-5697-79c7-94b4-1f31ae94c0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_019cd33b-5697-78be-8760-13db77984fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_019cd33b-5697-79c7-94b4-1f31ae94c0cd" xlink:to="loc_us-gaap_EquityComponentDomain_019cd33b-5697-78be-8760-13db77984fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_019cd33b-5697-7d5c-81db-a20a91541179" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019cd33b-5697-78be-8760-13db77984fe2" xlink:to="loc_us-gaap_CommonStockMember_019cd33b-5697-7d5c-81db-a20a91541179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_019cd33b-5697-7a11-8724-be77d87750df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019cd33b-5697-78be-8760-13db77984fe2" xlink:to="loc_us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember_019cd33b-5697-7a11-8724-be77d87750df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_019cd33b-5697-7a2e-a969-5bd75d0029a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019cd33b-5697-78be-8760-13db77984fe2" xlink:to="loc_us-gaap_RetainedEarningsMember_019cd33b-5697-7a2e-a969-5bd75d0029a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019cd33b-5697-7701-b216-d9e7e7bc4dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_019cd33b-5697-78be-8760-13db77984fe2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_019cd33b-5697-7701-b216-d9e7e7bc4dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_019cd33b-5697-701d-9886-3c771331898a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019cd33b-5697-7ef8-86e4-547ce089da8c" xlink:to="loc_us-gaap_PlanNameAxis_019cd33b-5697-701d-9886-3c771331898a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_019cd33b-5697-7a11-970d-f61f2f086645" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_019cd33b-5697-701d-9886-3c771331898a" xlink:to="loc_us-gaap_PlanNameDomain_019cd33b-5697-7a11-970d-f61f2f086645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_EquityAwardProgramsMember_019cd33b-5697-7f85-8160-c7c70bd8a415" xlink:href="rcus-20260331.xsd#rcus_EquityAwardProgramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_019cd33b-5697-7a11-970d-f61f2f086645" xlink:to="loc_rcus_EquityAwardProgramsMember_019cd33b-5697-7f85-8160-c7c70bd8a415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019cd33b-5697-76b2-ba18-e0549e22ee4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019cd33b-5697-7ef8-86e4-547ce089da8c" xlink:to="loc_us-gaap_StatementLineItems_019cd33b-5697-76b2-ba18-e0549e22ee4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cd33b-5697-7e45-a479-9a759bd7e16d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5697-76b2-ba18-e0549e22ee4f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cd33b-5697-7e45-a479-9a759bd7e16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019cd33b-5697-7188-b4e1-77b140c313c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cd33b-5697-7e45-a479-9a759bd7e16d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019cd33b-5697-7188-b4e1-77b140c313c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019cd33b-5697-79b5-8a34-8662045df1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cd33b-5697-7e45-a479-9a759bd7e16d" xlink:to="loc_us-gaap_StockholdersEquity_019cd33b-5697-79b5-8a34-8662045df1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019cd33b-5697-7157-b16e-07733ddc3154" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cd33b-5697-7e45-a479-9a759bd7e16d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019cd33b-5697-7157-b16e-07733ddc3154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019cd33b-5697-7751-b375-56b9078adb38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cd33b-5697-7e45-a479-9a759bd7e16d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019cd33b-5697-7751-b375-56b9078adb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019cd33b-5697-7071-b2ea-10f134de098d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cd33b-5697-7e45-a479-9a759bd7e16d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_019cd33b-5697-7071-b2ea-10f134de098d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019cd33b-5697-736f-8cae-aae91ac3562c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cd33b-5697-7e45-a479-9a759bd7e16d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_019cd33b-5697-736f-8cae-aae91ac3562c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cd33b-5697-7ffd-8c0a-6619e8f6ec71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cd33b-5697-7e45-a479-9a759bd7e16d" xlink:to="loc_us-gaap_NetIncomeLoss_019cd33b-5697-7ffd-8c0a-6619e8f6ec71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_019cd33b-5697-785d-ab94-36fadc28a207" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cd33b-5697-7e45-a479-9a759bd7e16d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_019cd33b-5697-785d-ab94-36fadc28a207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_019cd33b-5697-7c2c-8282-4ed6af1d197a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_019cd33b-5697-7e45-a479-9a759bd7e16d" xlink:to="loc_us-gaap_StockholdersEquity_019cd33b-5697-7c2c-8282-4ed6af1d197a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="rcus-20260331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_019cd33b-5697-74dc-887d-4c2de3c052fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cd33b-5697-7370-9d9c-7adcab5e6cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019cd33b-5697-74dc-887d-4c2de3c052fc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cd33b-5697-7370-9d9c-7adcab5e6cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_019cd33b-5697-7b8a-a3e2-374ca83cbc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cd33b-5697-7370-9d9c-7adcab5e6cd3" xlink:to="loc_us-gaap_ProfitLoss_019cd33b-5697-7b8a-a3e2-374ca83cbc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cd33b-5697-71c5-86dd-bc0488da5b04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cd33b-5697-7370-9d9c-7adcab5e6cd3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cd33b-5697-71c5-86dd-bc0488da5b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_019cd33b-5697-7e8a-8271-d95c2279bea0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cd33b-5697-71c5-86dd-bc0488da5b04" xlink:to="loc_us-gaap_ShareBasedCompensation_019cd33b-5697-7e8a-8271-d95c2279bea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_019cd33b-5697-7341-9487-eddebddd4f45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cd33b-5697-71c5-86dd-bc0488da5b04" xlink:to="loc_us-gaap_DepreciationAndAmortization_019cd33b-5697-7341-9487-eddebddd4f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019cd33b-5697-73e9-84be-68dce8bca44e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cd33b-5697-71c5-86dd-bc0488da5b04" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_019cd33b-5697-73e9-84be-68dce8bca44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019cd33b-5697-7a31-99a8-d659894b1ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cd33b-5697-71c5-86dd-bc0488da5b04" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_019cd33b-5697-7a31-99a8-d659894b1ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_019cd33b-5697-73bd-8aa8-41c35cf42155" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cd33b-5697-71c5-86dd-bc0488da5b04" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_019cd33b-5697-73bd-8aa8-41c35cf42155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cd33b-5697-7253-9ba8-63e183a85a16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_019cd33b-5697-71c5-86dd-bc0488da5b04" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cd33b-5697-7253-9ba8-63e183a85a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_019cd33b-5697-7dd5-8e69-d9648de2cbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cd33b-5697-7253-9ba8-63e183a85a16" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_019cd33b-5697-7dd5-8e69-d9648de2cbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_019cd33b-5697-7723-b668-1d3688b900c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cd33b-5697-7253-9ba8-63e183a85a16" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_019cd33b-5697-7723-b668-1d3688b900c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019cd33b-5697-7727-95f7-3bc1d0e58769" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cd33b-5697-7253-9ba8-63e183a85a16" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019cd33b-5697-7727-95f7-3bc1d0e58769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_019cd33b-5697-7122-b4f1-66a6f28b80ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cd33b-5697-7253-9ba8-63e183a85a16" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_019cd33b-5697-7122-b4f1-66a6f28b80ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_019cd33b-5697-7d75-9738-f0d28b356ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_019cd33b-5697-7253-9ba8-63e183a85a16" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_019cd33b-5697-7d75-9738-f0d28b356ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cd33b-5697-77c6-b5b8-e319e054a211" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_019cd33b-5697-7370-9d9c-7adcab5e6cd3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_019cd33b-5697-77c6-b5b8-e319e054a211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019cd33b-5697-7cdf-af1b-871e0617efbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019cd33b-5697-74dc-887d-4c2de3c052fc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019cd33b-5697-7cdf-af1b-871e0617efbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_019cd33b-5697-71ea-931a-8f46ac0d3e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019cd33b-5697-7cdf-af1b-871e0617efbf" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_019cd33b-5697-71ea-931a-8f46ac0d3e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ProceedsFromMaturityOfMarketableSecurities_019cd33b-5697-7aa0-8a5d-6e554cc91ef5" xlink:href="rcus-20260331.xsd#rcus_ProceedsFromMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019cd33b-5697-7cdf-af1b-871e0617efbf" xlink:to="loc_rcus_ProceedsFromMaturityOfMarketableSecurities_019cd33b-5697-7aa0-8a5d-6e554cc91ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ProceedsFromSaleOfMarketableSecurities_019cd33b-5697-7ebb-a055-a23286499e51" xlink:href="rcus-20260331.xsd#rcus_ProceedsFromSaleOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019cd33b-5697-7cdf-af1b-871e0617efbf" xlink:to="loc_rcus_ProceedsFromSaleOfMarketableSecurities_019cd33b-5697-7ebb-a055-a23286499e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019cd33b-5697-74c8-a153-44686214fc0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019cd33b-5697-7cdf-af1b-871e0617efbf" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_019cd33b-5697-74c8-a153-44686214fc0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cd33b-5697-7e0a-92dd-4e1ca421fbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_019cd33b-5697-7cdf-af1b-871e0617efbf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_019cd33b-5697-7e0a-92dd-4e1ca421fbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cd33b-5697-771a-a48f-e985075145a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019cd33b-5697-74dc-887d-4c2de3c052fc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cd33b-5697-771a-a48f-e985075145a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019cd33b-5697-73b0-ab9b-53bdb93d1780" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cd33b-5697-771a-a48f-e985075145a8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019cd33b-5697-73b0-ab9b-53bdb93d1780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019cd33b-5697-7835-a658-b3b1eb8f1036" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cd33b-5697-771a-a48f-e985075145a8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_019cd33b-5697-7835-a658-b3b1eb8f1036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cd33b-5697-7c8f-a7b2-a14753a6c4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_019cd33b-5697-771a-a48f-e985075145a8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_019cd33b-5697-7c8f-a7b2-a14753a6c4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cd33b-5697-7466-b5c8-b83787426357" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019cd33b-5697-74dc-887d-4c2de3c052fc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_019cd33b-5697-7466-b5c8-b83787426357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019cd33b-5697-7b55-9d5d-62694a98a431" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019cd33b-5697-74dc-887d-4c2de3c052fc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019cd33b-5697-7b55-9d5d-62694a98a431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019cd33b-5697-7929-8fee-9b619b71df4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019cd33b-5697-74dc-887d-4c2de3c052fc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019cd33b-5697-7929-8fee-9b619b71df4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="rcus-20260331.xsd#CondensedConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_019cd33b-5742-7643-86e2-2a4540c92bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_019cd33b-5742-74ee-8025-45819c147a20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_019cd33b-5742-7643-86e2-2a4540c92bf6" xlink:to="loc_us-gaap_StatementTable_019cd33b-5742-74ee-8025-45819c147a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5742-7805-9320-cdd453c61ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019cd33b-5742-74ee-8025-45819c147a20" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5742-7805-9320-cdd453c61ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019cd33b-5742-71b8-a720-d03b19ecee53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5742-7805-9320-cdd453c61ce4" xlink:to="loc_us-gaap_RelatedPartyDomain_019cd33b-5742-71b8-a720-d03b19ecee53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019cd33b-5742-7740-a033-5e4db09477c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019cd33b-5742-71b8-a720-d03b19ecee53" xlink:to="loc_us-gaap_RelatedPartyMember_019cd33b-5742-7740-a033-5e4db09477c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_019cd33b-5742-7a57-8200-2d95661c6c49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_019cd33b-5742-74ee-8025-45819c147a20" xlink:to="loc_us-gaap_StatementLineItems_019cd33b-5742-7a57-8200-2d95661c6c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_019cd33b-5742-7641-a37e-6d3e4da0cd82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5742-7a57-8200-2d95661c6c49" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_019cd33b-5742-7641-a37e-6d3e4da0cd82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019cd33b-5742-7ff0-9355-cd732b76bf3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5742-7a57-8200-2d95661c6c49" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_019cd33b-5742-7ff0-9355-cd732b76bf3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_019cd33b-5742-749c-ade2-495109a7d2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5742-7a57-8200-2d95661c6c49" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_019cd33b-5742-749c-ade2-495109a7d2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019cd33b-5742-7017-9cc6-609500290e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_019cd33b-5742-7a57-8200-2d95661c6c49" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_019cd33b-5742-7017-9cc6-609500290e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/OrganizationLiquidityandCapitalResources" xlink:type="simple" xlink:href="rcus-20260331.xsd#OrganizationLiquidityandCapitalResources"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/OrganizationLiquidityandCapitalResources" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cd33b-5742-7900-ab00-eb790fb232ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_019cd33b-5742-79bd-ade6-9cfed95b5c47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cd33b-5742-7900-ab00-eb790fb232ba" xlink:to="loc_us-gaap_NatureOfOperations_019cd33b-5742-79bd-ade6-9cfed95b5c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="rcus-20260331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019cd33b-5742-7fa6-a6e9-c353f3f87edb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_019cd33b-5742-72b4-aa4f-d6180aeb9940" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019cd33b-5742-7fa6-a6e9-c353f3f87edb" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_019cd33b-5742-72b4-aa4f-d6180aeb9940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/RelatedPartyGileadSciencesInc" xlink:type="simple" xlink:href="rcus-20260331.xsd#RelatedPartyGileadSciencesInc"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/RelatedPartyGileadSciencesInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_019cd33b-5742-73ff-b9e0-493d720b2eba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_019cd33b-5742-7b07-b53a-8af9fcdecf46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_019cd33b-5742-73ff-b9e0-493d720b2eba" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_019cd33b-5742-7b07-b53a-8af9fcdecf46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/LicenseandCollaborations" xlink:type="simple" xlink:href="rcus-20260331.xsd#LicenseandCollaborations"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/LicenseandCollaborations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndCollaborationAgreementsAbstract_019cd33b-5742-732f-892f-a0ef94e22209" xlink:href="rcus-20260331.xsd#rcus_LicenseAndCollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_019cd33b-5742-72a0-9f41-6e1aaf6fc052" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsAbstract_019cd33b-5742-732f-892f-a0ef94e22209" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_019cd33b-5742-72a0-9f41-6e1aaf6fc052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/Revenues" xlink:type="simple" xlink:href="rcus-20260331.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019cd33b-5742-7211-8843-8837fc3042c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_019cd33b-5742-7a9e-969f-984dae405dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019cd33b-5742-7211-8843-8837fc3042c9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_019cd33b-5742-7a9e-969f-984dae405dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="rcus-20260331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019cd33b-5742-7379-a2a9-0eeb011b68ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_019cd33b-5742-754a-b11c-7aa8a4541622" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019cd33b-5742-7379-a2a9-0eeb011b68ea" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_019cd33b-5742-754a-b11c-7aa8a4541622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/NetLossPerShare" xlink:type="simple" xlink:href="rcus-20260331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019cd33b-5742-772c-8a61-6ad5c0cc77b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_019cd33b-5742-79fc-a98c-ee312deaea7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019cd33b-5742-772c-8a61-6ad5c0cc77b6" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_019cd33b-5742-79fc-a98c-ee312deaea7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="rcus-20260331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cd33b-5742-7a79-8df0-6bcc9323dbca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_019cd33b-5742-71f3-8e73-00cdb5ae7301" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cd33b-5742-7a79-8df0-6bcc9323dbca" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_019cd33b-5742-71f3-8e73-00cdb5ae7301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="rcus-20260331.xsd#CashCashEquivalentsandMarketableSecurities"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_019cd33b-5742-7ab1-86e8-5a6377e2ebaf" xlink:href="rcus-20260331.xsd#rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_019cd33b-5742-7c11-9f93-768461cba144" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_019cd33b-5742-7ab1-86e8-5a6377e2ebaf" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_019cd33b-5742-7c11-9f93-768461cba144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponents" xlink:type="simple" xlink:href="rcus-20260331.xsd#CondensedConsolidatedBalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_019cd33b-5742-737a-9f3c-2753f24add43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_019cd33b-5742-7c8f-baac-2360646bc4df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_019cd33b-5742-737a-9f3c-2753f24add43" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_019cd33b-5742-7c8f-baac-2360646bc4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/LongTermDebt" xlink:type="simple" xlink:href="rcus-20260331.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019cd33b-5742-7976-bdae-e801d27be71e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_019cd33b-5742-72dd-bb0b-a1d9d1976c13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019cd33b-5742-7976-bdae-e801d27be71e" xlink:to="loc_us-gaap_LongTermDebtTextBlock_019cd33b-5742-72dd-bb0b-a1d9d1976c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/Leases" xlink:type="simple" xlink:href="rcus-20260331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_019cd33b-5742-73c0-a477-005c835e1239" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_019cd33b-5742-761e-8946-5c929a2f1fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019cd33b-5742-73c0-a477-005c835e1239" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_019cd33b-5742-761e-8946-5c929a2f1fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="rcus-20260331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_019cd33b-5742-78ad-81a7-720d331a45e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_019cd33b-5742-7db2-bd71-d35d7997db46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019cd33b-5742-78ad-81a7-720d331a45e1" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_019cd33b-5742-7db2-bd71-d35d7997db46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="rcus-20260331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019cd33b-5742-7676-be07-333b4b088b45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_019cd33b-5742-7ef6-aaa3-607c408194b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019cd33b-5742-7676-be07-333b4b088b45" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_019cd33b-5742-7ef6-aaa3-607c408194b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/BusinessSegment" xlink:type="simple" xlink:href="rcus-20260331.xsd#BusinessSegment"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/BusinessSegment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019cd33b-5742-7a35-a460-37dcf19e2491" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_019cd33b-5742-70ec-a7b1-e23586ce3f64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019cd33b-5742-7a35-a460-37dcf19e2491" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_019cd33b-5742-70ec-a7b1-e23586ce3f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="rcus-20260331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_019cd33b-5742-7a51-b345-ba38281a7120" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019cd33b-5742-7180-983d-fadb0b05bfae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019cd33b-5742-7a51-b345-ba38281a7120" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019cd33b-5742-7180-983d-fadb0b05bfae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_019d18e3-21e5-785d-a6e4-7b4d4cd8425c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019cd33b-5742-7a51-b345-ba38281a7120" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_019d18e3-21e5-785d-a6e4-7b4d4cd8425c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_019cd33b-5742-7e33-9e8e-27634cd5a13c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019cd33b-5742-7a51-b345-ba38281a7120" xlink:to="loc_us-gaap_UseOfEstimates_019cd33b-5742-7e33-9e8e-27634cd5a13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019cd33b-5742-787b-8271-778aa73ad915" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_019cd33b-5742-7a51-b345-ba38281a7120" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_019cd33b-5742-787b-8271-778aa73ad915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/RevenuesTables" xlink:type="simple" xlink:href="rcus-20260331.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019cd33b-5742-7d24-966c-f03f4309285b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_019cd33b-5742-754e-8462-58f15068ee40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019cd33b-5742-7d24-966c-f03f4309285b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_019cd33b-5742-754e-8462-58f15068ee40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_019cd33b-5742-7d5d-8031-3b3cb299a66b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019cd33b-5742-7d24-966c-f03f4309285b" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_019cd33b-5742-7d5d-8031-3b3cb299a66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock_019cd33b-5742-7b4e-a2bc-aac9b75a1e10" xlink:href="rcus-20260331.xsd#rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019cd33b-5742-7d24-966c-f03f4309285b" xlink:to="loc_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock_019cd33b-5742-7b4e-a2bc-aac9b75a1e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="rcus-20260331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019cd33b-5742-7619-8c57-cff616c5627d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019cd33b-5742-784e-b56e-118b5296aba1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019cd33b-5742-7619-8c57-cff616c5627d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_019cd33b-5742-784e-b56e-118b5296aba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="rcus-20260331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cd33b-5742-7bfb-ac48-d553f7e613d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_019cd33b-5742-72a1-9c26-1722eca5d390" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cd33b-5742-7bfb-ac48-d553f7e613d3" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_019cd33b-5742-72a1-9c26-1722eca5d390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="rcus-20260331.xsd#CashCashEquivalentsandMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_019cd33b-5742-797f-9f21-0877d918ce63" xlink:href="rcus-20260331.xsd#rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_019cd33b-5742-755d-9e93-01157accf1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_019cd33b-5742-797f-9f21-0877d918ce63" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_019cd33b-5742-755d-9e93-01157accf1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_019cd33b-5742-7f97-b682-8c01ed8e9748" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_019cd33b-5742-797f-9f21-0877d918ce63" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_019cd33b-5742-7f97-b682-8c01ed8e9748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_019cd33b-5742-741c-bbb4-71892b876304" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_019cd33b-5742-797f-9f21-0877d918ce63" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_019cd33b-5742-741c-bbb4-71892b876304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsTables" xlink:type="simple" xlink:href="rcus-20260331.xsd#CondensedConsolidatedBalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_019cd33b-5742-7f08-b170-b9081ff327d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_019cd33b-5742-7b28-a0f7-311f23a9822f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_019cd33b-5742-7f08-b170-b9081ff327d0" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_019cd33b-5742-7b28-a0f7-311f23a9822f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_019cd33b-5742-7fc9-a0c2-6e10f6333283" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_019cd33b-5742-7f08-b170-b9081ff327d0" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_019cd33b-5742-7fc9-a0c2-6e10f6333283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/LongTermDebtTables" xlink:type="simple" xlink:href="rcus-20260331.xsd#LongTermDebtTables"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/LongTermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019cd33b-5742-78a2-b85e-bf58dbc03d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_019cd33b-5742-76e3-b7d0-a8cc6316200d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019cd33b-5742-78a2-b85e-bf58dbc03d3d" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_019cd33b-5742-76e3-b7d0-a8cc6316200d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/LeasesTables" xlink:type="simple" xlink:href="rcus-20260331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_019cd33b-5742-7477-8ddc-c728da20e5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock_019cd33b-5742-727a-9ed7-9e9b459357d5" xlink:href="rcus-20260331.xsd#rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019cd33b-5742-7477-8ddc-c728da20e5cc" xlink:to="loc_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock_019cd33b-5742-727a-9ed7-9e9b459357d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="rcus-20260331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019cd33b-5742-7b12-aea4-1f6469131d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_019cd33b-5742-7b59-b98e-c071ed7955aa" xlink:href="rcus-20260331.xsd#rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019cd33b-5742-7b12-aea4-1f6469131d8b" xlink:to="loc_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_019cd33b-5742-7b59-b98e-c071ed7955aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/BusinessSegmentTables" xlink:type="simple" xlink:href="rcus-20260331.xsd#BusinessSegmentTables"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/BusinessSegmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019cd33b-5742-7be3-9a5f-9a94074d1b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_019cd33b-5742-7d07-9b60-1cb847e2ddd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019cd33b-5742-7be3-9a5f-9a94074d1b0d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_019cd33b-5742-7d07-9b60-1cb847e2ddd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cd33b-5742-7910-9d60-a964235b900a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OrganizationTable_019cf9b3-28ef-7225-bce5-92da55f2e525" xlink:href="rcus-20260331.xsd#rcus_OrganizationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_019cd33b-5742-7910-9d60-a964235b900a" xlink:to="loc_rcus_OrganizationTable_019cf9b3-28ef-7225-bce5-92da55f2e525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_019cf9b5-a519-775f-93d3-d342dfd2f0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_OrganizationTable_019cf9b3-28ef-7225-bce5-92da55f2e525" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_019cf9b5-a519-775f-93d3-d342dfd2f0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_019cf9b5-a519-7790-90e0-c44b18b3e494" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_019cf9b5-a519-775f-93d3-d342dfd2f0b9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_019cf9b5-a519-7790-90e0-c44b18b3e494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember_019cf9b5-a519-7cb0-811d-e7673f184df5" xlink:href="rcus-20260331.xsd#rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_019cf9b5-a519-7790-90e0-c44b18b3e494" xlink:to="loc_rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember_019cf9b5-a519-7cb0-811d-e7673f184df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OrganizationLineItems_019cf9b5-a519-7583-ad27-728ef371e4d2" xlink:href="rcus-20260331.xsd#rcus_OrganizationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_OrganizationTable_019cf9b3-28ef-7225-bce5-92da55f2e525" xlink:to="loc_rcus_OrganizationLineItems_019cf9b5-a519-7583-ad27-728ef371e4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_019cf9b5-a519-7129-974d-d7ad95cc8f11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_OrganizationLineItems_019cf9b5-a519-7583-ad27-728ef371e4d2" xlink:to="loc_us-gaap_NumberOfOperatingSegments_019cf9b5-a519-7129-974d-d7ad95cc8f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_019cf9b5-a519-7af4-b599-fd98fe1f9368" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_OrganizationLineItems_019cf9b5-a519-7583-ad27-728ef371e4d2" xlink:to="loc_us-gaap_NumberOfReportableSegments_019cf9b5-a519-7af4-b599-fd98fe1f9368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_019cf9b5-a519-7dd8-8a95-cea03026d492" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_OrganizationLineItems_019cf9b5-a519-7583-ad27-728ef371e4d2" xlink:to="loc_us-gaap_InvestmentsAndCash_019cf9b5-a519-7dd8-8a95-cea03026d492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#RelatedPartyGileadSciencesIncDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_019cd33b-5742-7042-ac81-b9a3c1012902" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cd33b-5742-7fc0-8fc2-44f7706dd1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_019cd33b-5742-7042-ac81-b9a3c1012902" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cd33b-5742-7fc0-8fc2-44f7706dd1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_019cd33b-5742-77c6-8d23-c0b5c8f91db5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cd33b-5742-7fc0-8fc2-44f7706dd1dd" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_019cd33b-5742-77c6-8d23-c0b5c8f91db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_019cd33b-5742-75b1-883e-b461e8dc5fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_019cd33b-5742-77c6-8d23-c0b5c8f91db5" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_019cd33b-5742-75b1-883e-b461e8dc5fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CommonStockPurchaseAgreementMember_019cd33b-5742-741f-b872-4f5b74c1aaeb" xlink:href="rcus-20260331.xsd#rcus_CommonStockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019cd33b-5742-75b1-883e-b461e8dc5fe1" xlink:to="loc_rcus_CommonStockPurchaseAgreementMember_019cd33b-5742-741f-b872-4f5b74c1aaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionLicenseAndCollaborationAgreementMember_019cd33b-5742-7dd1-bddb-75b6c07dc9c4" xlink:href="rcus-20260331.xsd#rcus_OptionLicenseAndCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019cd33b-5742-75b1-883e-b461e8dc5fe1" xlink:to="loc_rcus_OptionLicenseAndCollaborationAgreementMember_019cd33b-5742-7dd1-bddb-75b6c07dc9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AmendedGileadCollaborationAgreementMember_019cd33b-5742-706c-ba4e-9164bdecd0d7" xlink:href="rcus-20260331.xsd#rcus_AmendedGileadCollaborationAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_019cd33b-5742-75b1-883e-b461e8dc5fe1" xlink:to="loc_rcus_AmendedGileadCollaborationAgreementMember_019cd33b-5742-706c-ba4e-9164bdecd0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5742-7a4c-82c3-a339f3851d45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cd33b-5742-7fc0-8fc2-44f7706dd1dd" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5742-7a4c-82c3-a339f3851d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_019cd33b-5742-769e-a61c-347b5ddfe6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_019cd33b-5742-7a4c-82c3-a339f3851d45" xlink:to="loc_us-gaap_RelatedPartyDomain_019cd33b-5742-769e-a61c-347b5ddfe6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_019cd33b-5742-780b-af14-23e889130823" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_019cd33b-5742-769e-a61c-347b5ddfe6a0" xlink:to="loc_us-gaap_RelatedPartyMember_019cd33b-5742-780b-af14-23e889130823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019cd33b-5742-7420-a58c-7c1e11936c03" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cd33b-5742-7fc0-8fc2-44f7706dd1dd" xlink:to="loc_dei_LegalEntityAxis_019cd33b-5742-7420-a58c-7c1e11936c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019cd33b-5742-72e9-a740-07eceee40306" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_019cd33b-5742-7420-a58c-7c1e11936c03" xlink:to="loc_dei_EntityDomain_019cd33b-5742-72e9-a740-07eceee40306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadSciencesIncMember_019cd33b-5742-7d3f-ad36-1e135254c5fd" xlink:href="rcus-20260331.xsd#rcus_GileadSciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_019cd33b-5742-72e9-a740-07eceee40306" xlink:to="loc_rcus_GileadSciencesIncMember_019cd33b-5742-7d3f-ad36-1e135254c5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019cd33b-5742-732a-ad66-287f3658b970" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cd33b-5742-7fc0-8fc2-44f7706dd1dd" xlink:to="loc_srt_CounterpartyNameAxis_019cd33b-5742-732a-ad66-287f3658b970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019cd33b-5742-7231-80b3-ebfac19dfeca" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_019cd33b-5742-732a-ad66-287f3658b970" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019cd33b-5742-7231-80b3-ebfac19dfeca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadSciencesIncMember_019cd33b-5742-7eae-9868-8a1d1dd7034c" xlink:href="rcus-20260331.xsd#rcus_GileadSciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019cd33b-5742-7231-80b3-ebfac19dfeca" xlink:to="loc_rcus_GileadSciencesIncMember_019cd33b-5742-7eae-9868-8a1d1dd7034c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019cd33b-5742-7170-a6ca-4d585dc3738c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cd33b-5742-7fc0-8fc2-44f7706dd1dd" xlink:to="loc_srt_RangeAxis_019cd33b-5742-7170-a6ca-4d585dc3738c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019cd33b-5742-79d6-afe3-87a63edc5ddb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019cd33b-5742-7170-a6ca-4d585dc3738c" xlink:to="loc_srt_RangeMember_019cd33b-5742-79d6-afe3-87a63edc5ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019cd33b-5742-71b4-bb41-50195c82df36" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019cd33b-5742-79d6-afe3-87a63edc5ddb" xlink:to="loc_srt_MaximumMember_019cd33b-5742-71b4-bb41-50195c82df36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_019cd33b-5742-7620-9c37-48acb0fe0b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cd33b-5742-7fc0-8fc2-44f7706dd1dd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_019cd33b-5742-7620-9c37-48acb0fe0b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019cd33b-5742-71f8-abee-7ab29ab90b26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019cd33b-5742-7620-9c37-48acb0fe0b3f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019cd33b-5742-71f8-abee-7ab29ab90b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019cd33b-5742-75fa-b810-33545b17e8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019cd33b-5742-71f8-abee-7ab29ab90b26" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019cd33b-5742-75fa-b810-33545b17e8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_019cd33b-5742-7fc0-8fc2-44f7706dd1dd" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_SaleOfStockNumberOfSharesAcquiredInTransaction_019cd33b-5742-71f4-90d2-32c72522e1bd" xlink:href="rcus-20260331.xsd#rcus_SaleOfStockNumberOfSharesAcquiredInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_SaleOfStockNumberOfSharesAcquiredInTransaction_019cd33b-5742-71f4-90d2-32c72522e1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019cd33b-5742-7656-9c64-7ca106f57e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019cd33b-5742-7656-9c64-7ca106f57e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NumberOfBoardMembers_019cd33b-5742-7fdb-a291-189c87bed3e7" xlink:href="rcus-20260331.xsd#rcus_NumberOfBoardMembers"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_NumberOfBoardMembers_019cd33b-5742-7fdb-a291-189c87bed3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PercentageOfOutstandingCommonStockOwned_019cd33b-5742-72d8-90ed-4c2aee7a327e" xlink:href="rcus-20260331.xsd#rcus_PercentageOfOutstandingCommonStockOwned"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_PercentageOfOutstandingCommonStockOwned_019cd33b-5742-72d8-90ed-4c2aee7a327e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms_019cd33b-5742-7190-81c7-a6b78acf8018" xlink:href="rcus-20260331.xsd#rcus_CollaborationTermForCurrentAndFutureClinicalPrograms"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms_019cd33b-5742-7190-81c7-a6b78acf8018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement_019cd33b-5742-7af8-9d8d-65ec749ffda0" xlink:href="rcus-20260331.xsd#rcus_OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement_019cd33b-5742-7af8-9d8d-65ec749ffda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement_019cd33b-5742-7d1f-8f8b-4efe2489e54b" xlink:href="rcus-20260331.xsd#rcus_OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement_019cd33b-5742-7d1f-8f8b-4efe2489e54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement_019cd33b-5742-7cfe-85cf-313b9790bb2f" xlink:href="rcus-20260331.xsd#rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement_019cd33b-5742-7cfe-85cf-313b9790bb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement_019cd33b-5742-7de5-9997-f3c0da1736a0" xlink:href="rcus-20260331.xsd#rcus_OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement_019cd33b-5742-7de5-9997-f3c0da1736a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_UpfrontCashPayment_019cd33b-5742-777b-a3a3-bf8f2f7a5d87" xlink:href="rcus-20260331.xsd#rcus_UpfrontCashPayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_UpfrontCashPayment_019cd33b-5742-777b-a3a3-bf8f2f7a5d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NumberOfExerciseOptionToPrograms_019cd33b-5742-7f53-90eb-0566ceb28251" xlink:href="rcus-20260331.xsd#rcus_NumberOfExerciseOptionToPrograms"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_NumberOfExerciseOptionToPrograms_019cd33b-5742-7f53-90eb-0566ceb28251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionPaymentReceived_019cd33b-5742-7c7a-9543-e6be96ea45f3" xlink:href="rcus-20260331.xsd#rcus_OptionPaymentReceived"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_OptionPaymentReceived_019cd33b-5742-7c7a-9543-e6be96ea45f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RemoveOptionContinuationPaymentUnderAgreement_019cd33b-5742-7e64-86f4-67abe76b6f4e" xlink:href="rcus-20260331.xsd#rcus_RemoveOptionContinuationPaymentUnderAgreement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_RemoveOptionContinuationPaymentUnderAgreement_019cd33b-5742-7e64-86f4-67abe76b6f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab_019cd33b-5742-74e5-8dc3-4baea8e50ca1" xlink:href="rcus-20260331.xsd#rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab_019cd33b-5742-74e5-8dc3-4baea8e50ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption_019cd33b-5742-74ea-bb22-472e6a5f5182" xlink:href="rcus-20260331.xsd#rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption_019cd33b-5742-74ea-bb22-472e6a5f5182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NumberOfResearchPrograms_019cd33b-5742-7b2d-92f3-80a0a253a923" xlink:href="rcus-20260331.xsd#rcus_NumberOfResearchPrograms"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_NumberOfResearchPrograms_019cd33b-5742-7b2d-92f3-80a0a253a923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionPaymentUponCompletionOfCertainINDEnablingActivities_019cd33b-5742-78f5-8f2d-60e5f8c2e9de" xlink:href="rcus-20260331.xsd#rcus_OptionPaymentUponCompletionOfCertainINDEnablingActivities"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_OptionPaymentUponCompletionOfCertainINDEnablingActivities_019cd33b-5742-78f5-8f2d-60e5f8c2e9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones_019cd33b-5742-7574-a961-efe6e151c185" xlink:href="rcus-20260331.xsd#rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones_019cd33b-5742-7574-a961-efe6e151c185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments_019cd33b-5742-7805-90e0-98b952c3d18d" xlink:href="rcus-20260331.xsd#rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments_019cd33b-5742-7805-90e0-98b952c3d18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TotalUpfrontCashPayment_019cd33b-5742-79e7-b3ee-6cb8cadf9ce2" xlink:href="rcus-20260331.xsd#rcus_TotalUpfrontCashPayment"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_TotalUpfrontCashPayment_019cd33b-5742-79e7-b3ee-6cb8cadf9ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RegulatoryAndCommercialMilestonePaymentsReceived_019cd33b-5742-7261-9c5c-c3d953e77644" xlink:href="rcus-20260331.xsd#rcus_RegulatoryAndCommercialMilestonePaymentsReceived"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_RegulatoryAndCommercialMilestonePaymentsReceived_019cd33b-5742-7261-9c5c-c3d953e77644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_019cd33b-5742-7c17-950d-101e7f543c52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_019cd33b-5742-7c17-950d-101e7f543c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts_019cd33b-5742-7e74-a28d-d8235b5e172f" xlink:href="rcus-20260331.xsd#rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts_019cd33b-5742-7e74-a28d-d8235b5e172f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_019cd33b-5742-799b-93d0-12e430f5ed06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_019cd33b-5742-7b3e-bbd5-4ff3e47e9d3c" xlink:to="loc_us-gaap_AccountsPayableCurrent_019cd33b-5742-799b-93d0-12e430f5ed06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/LicenseandCollaborationsDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#LicenseandCollaborationsDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/LicenseandCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndCollaborationAgreementsAbstract_019cd33b-5742-7cea-813a-55bfa81bb082" xlink:href="rcus-20260331.xsd#rcus_LicenseAndCollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndCollaborationAgreementsTable_019cd33b-5742-7836-911d-b990b7fd8f6e" xlink:href="rcus-20260331.xsd#rcus_LicenseAndCollaborationAgreementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsAbstract_019cd33b-5742-7cea-813a-55bfa81bb082" xlink:to="loc_rcus_LicenseAndCollaborationAgreementsTable_019cd33b-5742-7836-911d-b990b7fd8f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019d995c-d263-793f-9c58-4a023e84a9bb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsTable_019cd33b-5742-7836-911d-b990b7fd8f6e" xlink:to="loc_srt_CounterpartyNameAxis_019d995c-d263-793f-9c58-4a023e84a9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d995c-d263-74a3-b855-d73533394a8e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_019d995c-d263-793f-9c58-4a023e84a9bb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d995c-d263-74a3-b855-d73533394a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoPharmaceuticalCoLtdMember_019d995c-d263-7e63-afce-6b9884272109" xlink:href="rcus-20260331.xsd#rcus_TaihoPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d995c-d263-74a3-b855-d73533394a8e" xlink:to="loc_rcus_TaihoPharmaceuticalCoLtdMember_019d995c-d263-7e63-afce-6b9884272109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_STAR221DevelopmentActivitiesMember_019d995c-d263-74a7-acfb-f3e69f8423ab" xlink:href="rcus-20260331.xsd#rcus_STAR221DevelopmentActivitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d995c-d263-74a3-b855-d73533394a8e" xlink:to="loc_rcus_STAR221DevelopmentActivitiesMember_019d995c-d263-74a7-acfb-f3e69f8423ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_STAR121DevelopmentActivitiesMember_019d995c-d263-7f3f-b7e8-fafc51656a4a" xlink:href="rcus-20260331.xsd#rcus_STAR121DevelopmentActivitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d995c-d263-74a3-b855-d73533394a8e" xlink:to="loc_rcus_STAR121DevelopmentActivitiesMember_019d995c-d263-7f3f-b7e8-fafc51656a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AbmunoLicenseAgreementMember_019d995d-788d-73b8-bafe-17b7d9fc53d6" xlink:href="rcus-20260331.xsd#rcus_AbmunoLicenseAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d995c-d263-74a3-b855-d73533394a8e" xlink:to="loc_rcus_AbmunoLicenseAgreementMember_019d995d-788d-73b8-bafe-17b7d9fc53d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_WuXiBiologicsLicenseAgreementMember_019d995d-788d-73b4-bc39-fd8f1e53b019" xlink:href="rcus-20260331.xsd#rcus_WuXiBiologicsLicenseAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d995c-d263-74a3-b855-d73533394a8e" xlink:to="loc_rcus_WuXiBiologicsLicenseAgreementMember_019d995d-788d-73b4-bc39-fd8f1e53b019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_019d995c-d263-78cd-9ed9-102e2edb1b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsTable_019cd33b-5742-7836-911d-b990b7fd8f6e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_019d995c-d263-78cd-9ed9-102e2edb1b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019d995c-d263-7649-8bbb-7312a992c014" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019d995c-d263-78cd-9ed9-102e2edb1b6d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019d995c-d263-7649-8bbb-7312a992c014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionAndLicenseAgreementMember_019d995c-d263-7e03-aba1-0ffcae4b760b" xlink:href="rcus-20260331.xsd#rcus_OptionAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019d995c-d263-7649-8bbb-7312a992c014" xlink:to="loc_rcus_OptionAndLicenseAgreementMember_019d995c-d263-7e03-aba1-0ffcae4b760b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoCollaborationAgreementMember_019d995c-d263-76c6-911f-1d97b1ebbb50" xlink:href="rcus-20260331.xsd#rcus_TaihoCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019d995c-d263-7649-8bbb-7312a992c014" xlink:to="loc_rcus_TaihoCollaborationAgreementMember_019d995c-d263-76c6-911f-1d97b1ebbb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AstraZenecaAgreementMember_019d995d-3b45-7f67-bd37-7b942665f224" xlink:href="rcus-20260331.xsd#rcus_AstraZenecaAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019d995c-d263-7649-8bbb-7312a992c014" xlink:to="loc_rcus_AstraZenecaAgreementMember_019d995d-3b45-7f67-bd37-7b942665f224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_019d995c-d263-7b45-889d-d064932ec058" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsTable_019cd33b-5742-7836-911d-b990b7fd8f6e" xlink:to="loc_srt_RangeAxis_019d995c-d263-7b45-889d-d064932ec058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_019d995c-d263-7d7c-bdbf-77d722496b28" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_019d995c-d263-7b45-889d-d064932ec058" xlink:to="loc_srt_RangeMember_019d995c-d263-7d7c-bdbf-77d722496b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_019d995c-d263-75ec-a7fb-ba9745ee7297" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019d995c-d263-7d7c-bdbf-77d722496b28" xlink:to="loc_srt_MinimumMember_019d995c-d263-75ec-a7fb-ba9745ee7297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_019d995c-d263-79f6-923e-1a85ef505aca" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_019d995c-d263-7d7c-bdbf-77d722496b28" xlink:to="loc_srt_MaximumMember_019d995c-d263-79f6-923e-1a85ef505aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019d995d-788d-785b-a529-6db425e4315f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsTable_019cd33b-5742-7836-911d-b990b7fd8f6e" xlink:to="loc_srt_ProductOrServiceAxis_019d995d-788d-785b-a529-6db425e4315f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019d995d-788d-75a2-bce5-0ccfea75814f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019d995d-788d-785b-a529-6db425e4315f" xlink:to="loc_srt_ProductsAndServicesDomain_019d995d-788d-75a2-bce5-0ccfea75814f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AntiPDOneMember_019d995d-788d-76aa-8088-5e0186d620ca" xlink:href="rcus-20260331.xsd#rcus_AntiPDOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019d995d-788d-75a2-bce5-0ccfea75814f" xlink:to="loc_rcus_AntiPDOneMember_019d995d-788d-76aa-8088-5e0186d620ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AntiCDThirtyNineMember_019d995d-788d-7094-b633-0fb01a7cfb37" xlink:href="rcus-20260331.xsd#rcus_AntiCDThirtyNineMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019d995d-788d-75a2-bce5-0ccfea75814f" xlink:to="loc_rcus_AntiCDThirtyNineMember_019d995d-788d-7094-b633-0fb01a7cfb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:href="rcus-20260331.xsd#rcus_LicenseAndCollaborationAgreementsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsTable_019cd33b-5742-7836-911d-b990b7fd8f6e" xlink:to="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionPeriod_019d995c-d263-7cb8-b775-e56b3d29a528" xlink:href="rcus-20260331.xsd#rcus_OptionPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_OptionPeriod_019d995c-d263-7cb8-b775-e56b3d29a528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_NonRefundableAndNonCreditableCashPayments_019d995c-d263-787c-bb11-d7c4bf5bae81" xlink:href="rcus-20260331.xsd#rcus_NonRefundableAndNonCreditableCashPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_NonRefundableAndNonCreditableCashPayments_019d995c-d263-787c-bb11-d7c4bf5bae81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PaymentForOptionsExercised_019d995c-d263-7f30-9404-ab46ce1a0dff" xlink:href="rcus-20260331.xsd#rcus_PaymentForOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_PaymentForOptionsExercised_019d995c-d263-7f30-9404-ab46ce1a0dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement_019d995c-d263-7054-8d16-029b08856ec7" xlink:href="rcus-20260331.xsd#rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement_019d995c-d263-7054-8d16-029b08856ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ContingentMilestonePaymentsReceivable_019d995c-d263-70d3-9011-e7c186bd48dc" xlink:href="rcus-20260331.xsd#rcus_ContingentMilestonePaymentsReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_ContingentMilestonePaymentsReceivable_019d995c-d263-70d3-9011-e7c186bd48dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RoyaltiesPayableTerm_019d995c-d263-773f-b04b-e130d4124262" xlink:href="rcus-20260331.xsd#rcus_RoyaltiesPayableTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_RoyaltiesPayableTerm_019d995c-d263-773f-b04b-e130d4124262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_MilestonePayments_019d995c-d263-78e0-b7f4-0b7964b08aad" xlink:href="rcus-20260331.xsd#rcus_MilestonePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_MilestonePayments_019d995c-d263-78e0-b7f4-0b7964b08aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d995d-3b45-7d50-b244-228bc7b114fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019d995d-3b45-7d50-b244-228bc7b114fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ReimbursementOfResearchAndDevelopmentExpense_019d995d-3b45-755a-b480-e322636c5a4a" xlink:href="rcus-20260331.xsd#rcus_ReimbursementOfResearchAndDevelopmentExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_ReimbursementOfResearchAndDevelopmentExpense_019d995d-3b45-755a-b480-e322636c5a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_019d995d-3b45-70ad-9d3a-8aae545e065a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_019d995d-3b45-70ad-9d3a-8aae545e065a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_019d995d-3b45-75e8-95f6-476685e3afc3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_us-gaap_OtherLiabilities_019d995d-3b45-75e8-95f6-476685e3afc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019d995d-3b45-7b5a-9e5c-f8aa1d34ad3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_019d995d-3b45-7b5a-9e5c-f8aa1d34ad3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_019d995d-788d-736b-9513-06871e8146fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_019d995d-788d-736b-9513-06871e8146fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_019d995d-788d-7fd8-b2b2-70836364740a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_019d995d-788d-7fd8-b2b2-70836364740a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ClinicalRegulatoryMilestonePayments_019d995d-788d-736d-8c52-01d533c87337" xlink:href="rcus-20260331.xsd#rcus_ClinicalRegulatoryMilestonePayments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_ClinicalRegulatoryMilestonePayments_019d995d-788d-736d-8c52-01d533c87337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments_019d995d-788d-7f98-8011-e826def3632e" xlink:href="rcus-20260331.xsd#rcus_ClinicalRegulatoryAndCommercializationMilestonePayments"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments_019d995d-788d-7f98-8011-e826def3632e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments_019d995d-788d-7642-ab5f-2e51bc7126b2" xlink:href="rcus-20260331.xsd#rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments_019d995d-788d-7642-ab5f-2e51bc7126b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_MilestoneExpense_019d995d-788d-791e-a247-3421da548300" xlink:href="rcus-20260331.xsd#rcus_MilestoneExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019d995c-d263-71e9-ba8b-d12af536803d" xlink:to="loc_rcus_MilestoneExpense_019d995d-788d-791e-a247-3421da548300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019cd33b-5742-7bff-953e-4c450ded8c63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-7528-8eaa-1f7e3886b878" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019cd33b-5742-7bff-953e-4c450ded8c63" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-7528-8eaa-1f7e3886b878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019cd33b-5742-7251-8929-ac854057a427" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-7528-8eaa-1f7e3886b878" xlink:to="loc_srt_ProductOrServiceAxis_019cd33b-5742-7251-8929-ac854057a427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019cd33b-5742-7a1a-80f5-125902963d7d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019cd33b-5742-7251-8929-ac854057a427" xlink:to="loc_srt_ProductsAndServicesDomain_019cd33b-5742-7a1a-80f5-125902963d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndDevelopmentServicesMember_019cd33b-5742-79f1-8c0b-d980a00b9389" xlink:href="rcus-20260331.xsd#rcus_LicenseAndDevelopmentServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019cd33b-5742-7a1a-80f5-125902963d7d" xlink:to="loc_rcus_LicenseAndDevelopmentServicesMember_019cd33b-5742-79f1-8c0b-d980a00b9389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RDServicesMember_019d184d-6179-7173-ad43-172bbbe18e2e" xlink:href="rcus-20260331.xsd#rcus_RDServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019cd33b-5742-7a1a-80f5-125902963d7d" xlink:to="loc_rcus_RDServicesMember_019d184d-6179-7173-ad43-172bbbe18e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AccessRightsMember_019d99a9-e3ba-7515-a43e-65f052b88679" xlink:href="rcus-20260331.xsd#rcus_AccessRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019cd33b-5742-7a1a-80f5-125902963d7d" xlink:to="loc_rcus_AccessRightsMember_019d99a9-e3ba-7515-a43e-65f052b88679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OtherServicesMember_019cd33b-5742-78c3-b483-894a9d1d3477" xlink:href="rcus-20260331.xsd#rcus_OtherServicesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019cd33b-5742-7a1a-80f5-125902963d7d" xlink:to="loc_rcus_OtherServicesMember_019cd33b-5742-78c3-b483-894a9d1d3477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_019dd125-fc65-7726-a7eb-cbe2c31e9fac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019cd33b-5742-7a1a-80f5-125902963d7d" xlink:to="loc_us-gaap_LicenseMember_019dd125-fc65-7726-a7eb-cbe2c31e9fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_019cd33b-5742-775a-a2d9-074575299665" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-7528-8eaa-1f7e3886b878" xlink:to="loc_us-gaap_TypeOfArrangementAxis_019cd33b-5742-775a-a2d9-074575299665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019cd33b-5742-79e9-8d59-c3badc3f2588" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019cd33b-5742-775a-a2d9-074575299665" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019cd33b-5742-79e9-8d59-c3badc3f2588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadCollaborationMember_019cd33b-5742-7370-848a-283e476d6b9b" xlink:href="rcus-20260331.xsd#rcus_GileadCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019cd33b-5742-79e9-8d59-c3badc3f2588" xlink:to="loc_rcus_GileadCollaborationMember_019cd33b-5742-7370-848a-283e476d6b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoCollaborationMember_019cd33b-5742-72ac-a673-e462c03da071" xlink:href="rcus-20260331.xsd#rcus_TaihoCollaborationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019cd33b-5742-79e9-8d59-c3badc3f2588" xlink:to="loc_rcus_TaihoCollaborationMember_019cd33b-5742-72ac-a673-e462c03da071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_019cd33b-5742-78f7-bdaa-807ff0ad88d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-7528-8eaa-1f7e3886b878" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_019cd33b-5742-78f7-bdaa-807ff0ad88d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_019cd33b-5742-77d6-97d1-2d23e5ebb4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_019cd33b-5742-78f7-bdaa-807ff0ad88d0" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_019cd33b-5742-77d6-97d1-2d23e5ebb4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_019cd33b-5742-7ebf-9320-cce7256fab1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_019cd33b-5742-77d6-97d1-2d23e5ebb4d2" xlink:to="loc_us-gaap_TransferredOverTimeMember_019cd33b-5742-7ebf-9320-cce7256fab1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019cd33b-5742-7d7c-9519-3094234207dc" xlink:href="rcus-20260331.xsd#rcus_LicenseAndCollaborationAgreementsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-7528-8eaa-1f7e3886b878" xlink:to="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019cd33b-5742-7d7c-9519-3094234207dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019cd33b-5742-7c6f-8fe3-ff59a61eacee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019cd33b-5742-7d7c-9519-3094234207dc" xlink:to="loc_us-gaap_Revenues_019cd33b-5742-7c6f-8fe3-ff59a61eacee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_019cd33b-5742-7a36-81de-da9315bd563d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019cd33b-5742-7d7c-9519-3094234207dc" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_019cd33b-5742-7a36-81de-da9315bd563d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019cd33b-5742-7a31-9afc-be3977320fff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndCollaborationAgreementsLineItems_019cd33b-5742-7d7c-9519-3094234207dc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019cd33b-5742-7a31-9afc-be3977320fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/RevenuesAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#RevenuesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/RevenuesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019cd33b-5742-78e0-a714-8d395fd54a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-79f9-8701-9875f3ab7146" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019cd33b-5742-78e0-a714-8d395fd54a7f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-79f9-8701-9875f3ab7146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019dd193-7f18-7912-8e79-cef00971bee8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-79f9-8701-9875f3ab7146" xlink:to="loc_srt_CounterpartyNameAxis_019dd193-7f18-7912-8e79-cef00971bee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019dd193-7f18-7bc0-87e2-b6a38090cc8a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_019dd193-7f18-7912-8e79-cef00971bee8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019dd193-7f18-7bc0-87e2-b6a38090cc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadSciencesIncMember_019dd193-7f18-7e2c-b27d-d73d5318c58e" xlink:href="rcus-20260331.xsd#rcus_GileadSciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019dd193-7f18-7bc0-87e2-b6a38090cc8a" xlink:to="loc_rcus_GileadSciencesIncMember_019dd193-7f18-7e2c-b27d-d73d5318c58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_STAR221DevelopmentActivitiesMember_019dd194-2ea9-751b-ba52-80dc452ec521" xlink:href="rcus-20260331.xsd#rcus_STAR221DevelopmentActivitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019dd193-7f18-7bc0-87e2-b6a38090cc8a" xlink:to="loc_rcus_STAR221DevelopmentActivitiesMember_019dd194-2ea9-751b-ba52-80dc452ec521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoPharmaceuticalCoLtdMember_019dd194-461f-7a24-bab1-a95336f353f7" xlink:href="rcus-20260331.xsd#rcus_TaihoPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019dd193-7f18-7bc0-87e2-b6a38090cc8a" xlink:to="loc_rcus_TaihoPharmaceuticalCoLtdMember_019dd194-461f-7a24-bab1-a95336f353f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019dd193-7f18-7abc-bd70-551dd53618d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-79f9-8701-9875f3ab7146" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019dd193-7f18-7abc-bd70-551dd53618d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019dd193-7f18-7476-81b0-e9ee83a9da94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_019dd193-7f18-7abc-bd70-551dd53618d0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019dd193-7f18-7476-81b0-e9ee83a9da94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_019dd193-7f18-76df-bd36-4ac78d93be8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_019dd193-7f18-7476-81b0-e9ee83a9da94" xlink:to="loc_us-gaap_SalesRevenueNetMember_019dd193-7f18-76df-bd36-4ac78d93be8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_019dd193-7f18-7bdf-a066-2e505f2953bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-79f9-8701-9875f3ab7146" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_019dd193-7f18-7bdf-a066-2e505f2953bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_019dd193-7f18-7899-9e48-40d70c26eadf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_019dd193-7f18-7bdf-a066-2e505f2953bb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_019dd193-7f18-7899-9e48-40d70c26eadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_019dd193-7f18-7394-bd24-7497888bd676" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_019dd193-7f18-7899-9e48-40d70c26eadf" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_019dd193-7f18-7394-bd24-7497888bd676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_019dd193-dc02-7ba0-91c9-bd66d8a0e035" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-79f9-8701-9875f3ab7146" xlink:to="loc_us-gaap_TypeOfArrangementAxis_019dd193-dc02-7ba0-91c9-bd66d8a0e035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019dd193-dc02-7a6c-853a-76684a5b11da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_019dd193-dc02-7ba0-91c9-bd66d8a0e035" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019dd193-dc02-7a6c-853a-76684a5b11da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RDServicesMember_019dd193-dc02-7198-8ca3-187881e6281a" xlink:href="rcus-20260331.xsd#rcus_RDServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019dd193-dc02-7a6c-853a-76684a5b11da" xlink:to="loc_rcus_RDServicesMember_019dd193-dc02-7198-8ca3-187881e6281a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AccessRightsAndOptionContinuationPeriodsMember_019dd193-ff8d-7356-81a8-a55b02028b83" xlink:href="rcus-20260331.xsd#rcus_AccessRightsAndOptionContinuationPeriodsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019dd193-dc02-7a6c-853a-76684a5b11da" xlink:to="loc_rcus_AccessRightsAndOptionContinuationPeriodsMember_019dd193-ff8d-7356-81a8-a55b02028b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadCollaborationMember_019dd194-2ea9-7308-9611-3e99724f0734" xlink:href="rcus-20260331.xsd#rcus_GileadCollaborationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019dd193-dc02-7a6c-853a-76684a5b11da" xlink:to="loc_rcus_GileadCollaborationMember_019dd194-2ea9-7308-9611-3e99724f0734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RightsToCertainStudiesMember_019dd194-2ea9-718f-bc86-98cb845cdff0" xlink:href="rcus-20260331.xsd#rcus_RightsToCertainStudiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019dd193-dc02-7a6c-853a-76684a5b11da" xlink:to="loc_rcus_RightsToCertainStudiesMember_019dd194-2ea9-718f-bc86-98cb845cdff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoCollaborationAgreementMember_019dd194-2ea9-730d-9177-4f65eac02765" xlink:href="rcus-20260331.xsd#rcus_TaihoCollaborationAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019dd193-dc02-7a6c-853a-76684a5b11da" xlink:to="loc_rcus_TaihoCollaborationAgreementMember_019dd194-2ea9-730d-9177-4f65eac02765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember_019dd194-2ea9-71bc-bfa2-c8e37f0adf22" xlink:href="rcus-20260331.xsd#rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019dd193-dc02-7a6c-853a-76684a5b11da" xlink:to="loc_rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember_019dd194-2ea9-71bc-bfa2-c8e37f0adf22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionAndLicenseAgreementMember_019dd194-461f-74c8-86b5-3847f7dbb2e8" xlink:href="rcus-20260331.xsd#rcus_OptionAndLicenseAgreementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019dd193-dc02-7a6c-853a-76684a5b11da" xlink:to="loc_rcus_OptionAndLicenseAgreementMember_019dd194-461f-74c8-86b5-3847f7dbb2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoCollaborationMember_019dd194-6f33-724b-aa8b-e535f543913c" xlink:href="rcus-20260331.xsd#rcus_TaihoCollaborationMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_019dd193-dc02-7a6c-853a-76684a5b11da" xlink:to="loc_rcus_TaihoCollaborationMember_019dd194-6f33-724b-aa8b-e535f543913c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019dd194-2ea9-73d9-93ee-ed7435590088" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-79f9-8701-9875f3ab7146" xlink:to="loc_srt_ProductOrServiceAxis_019dd194-2ea9-73d9-93ee-ed7435590088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019dd194-2ea9-747f-abff-7b65576beb76" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019dd194-2ea9-73d9-93ee-ed7435590088" xlink:to="loc_srt_ProductsAndServicesDomain_019dd194-2ea9-747f-abff-7b65576beb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OtherServicesMember_019dd194-2ea9-7353-9561-4196c8c5f740" xlink:href="rcus-20260331.xsd#rcus_OtherServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019dd194-2ea9-747f-abff-7b65576beb76" xlink:to="loc_rcus_OtherServicesMember_019dd194-2ea9-7353-9561-4196c8c5f740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndDevelopmentServicesMember_019dd194-6f33-7a0f-bd94-f2265ab0d0b4" xlink:href="rcus-20260331.xsd#rcus_LicenseAndDevelopmentServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019dd194-2ea9-747f-abff-7b65576beb76" xlink:to="loc_rcus_LicenseAndDevelopmentServicesMember_019dd194-6f33-7a0f-bd94-f2265ab0d0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_019dd194-2ea9-72bd-9df4-7c1b7215416b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-79f9-8701-9875f3ab7146" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_019dd194-2ea9-72bd-9df4-7c1b7215416b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_019dd194-2ea9-7433-8f4d-e51715721b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_019dd194-2ea9-72bd-9df4-7c1b7215416b" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_019dd194-2ea9-7433-8f4d-e51715721b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_019dd194-2ea9-706a-9e70-a50edd2e9089" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_019dd194-2ea9-7433-8f4d-e51715721b8f" xlink:to="loc_us-gaap_TransferredOverTimeMember_019dd194-2ea9-706a-9e70-a50edd2e9089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_019dd6e3-0472-72e2-84ad-57f29a8e18d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-79f9-8701-9875f3ab7146" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_019dd6e3-0472-72e2-84ad-57f29a8e18d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_019dd6e3-0472-71c8-ae16-a6e328b02e37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_019dd6e3-0472-72e2-84ad-57f29a8e18d4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_019dd6e3-0472-71c8-ae16-a6e328b02e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_019dd6e3-2883-764c-9e59-9a919761466d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_019dd6e3-0472-71c8-ae16-a6e328b02e37" xlink:to="loc_us-gaap_SubsequentEventMember_019dd6e3-2883-764c-9e59-9a919761466d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_019dd193-7f18-75f2-841b-1e52949eafe6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_019cd33b-5742-79f9-8701-9875f3ab7146" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_019dd193-7f18-75f2-841b-1e52949eafe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_019dd193-7f18-7aa0-ae6c-c9c0102f6668" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019dd193-7f18-75f2-841b-1e52949eafe6" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_019dd193-7f18-7aa0-ae6c-c9c0102f6668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_019dd193-9ca8-79f6-99d6-dd5a7ce2f586" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019dd193-7f18-75f2-841b-1e52949eafe6" xlink:to="loc_us-gaap_ContractWithCustomerLiability_019dd193-9ca8-79f6-99d6-dd5a7ce2f586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_019dd193-9ca8-73af-b294-8a229f926640" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019dd193-7f18-75f2-841b-1e52949eafe6" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_019dd193-9ca8-73af-b294-8a229f926640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice_019dd193-9ca8-7e70-a840-3d8efeaeeb93" xlink:href="rcus-20260331.xsd#rcus_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019dd193-7f18-75f2-841b-1e52949eafe6" xlink:to="loc_rcus_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice_019dd193-9ca8-7e70-a840-3d8efeaeeb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_DeferredRevenueNonRefundablePayment_019dd193-dc02-7322-a6ec-1a3eb7fd2c7c" xlink:href="rcus-20260331.xsd#rcus_DeferredRevenueNonRefundablePayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019dd193-7f18-75f2-841b-1e52949eafe6" xlink:to="loc_rcus_DeferredRevenueNonRefundablePayment_019dd193-dc02-7322-a6ec-1a3eb7fd2c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019dd193-dc02-73bf-9b7f-eeb55922f3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019dd193-7f18-75f2-841b-1e52949eafe6" xlink:to="loc_us-gaap_Revenues_019dd193-dc02-73bf-9b7f-eeb55922f3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod_019dd193-ff8d-7f89-a8a9-953aee74bf05" xlink:href="rcus-20260331.xsd#rcus_CurrentAndFutureProgramsExclusiveAccessPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019dd193-7f18-75f2-841b-1e52949eafe6" xlink:to="loc_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod_019dd193-ff8d-7f89-a8a9-953aee74bf05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ContingentMilestonePaymentsReceivable_019dd193-ff8d-778a-a2bf-8276966c4751" xlink:href="rcus-20260331.xsd#rcus_ContingentMilestonePaymentsReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019dd193-7f18-75f2-841b-1e52949eafe6" xlink:to="loc_rcus_ContingentMilestonePaymentsReceivable_019dd193-ff8d-778a-a2bf-8276966c4751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement_019dd193-ff8d-75b4-89ef-14f7b423b794" xlink:href="rcus-20260331.xsd#rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019dd193-7f18-75f2-841b-1e52949eafe6" xlink:to="loc_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement_019dd193-ff8d-75b4-89ef-14f7b423b794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PaymentForOptionExercise_019dd194-461f-76ac-b018-732a8bbb804d" xlink:href="rcus-20260331.xsd#rcus_PaymentForOptionExercise"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_019dd193-7f18-75f2-841b-1e52949eafe6" xlink:to="loc_rcus_PaymentForOptionExercise_019dd194-461f-76ac-b018-732a8bbb804d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/RevenuesSummaryofRevenueRecognizedasaResultofChangesinDeferredRevenueDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#RevenuesSummaryofRevenueRecognizedasaResultofChangesinDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/RevenuesSummaryofRevenueRecognizedasaResultofChangesinDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019cd33b-5742-753f-ace7-422c6ecd9a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_019cd33b-5742-7e71-a463-6ed02a08dc36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019cd33b-5742-753f-ace7-422c6ecd9a4a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_019cd33b-5742-7e71-a463-6ed02a08dc36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019cd33b-5742-7f7f-bd1e-c9fa510ea39e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_019cd33b-5742-7963-833c-2891c0830428" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_019cd33b-5742-7f7f-bd1e-c9fa510ea39e" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_019cd33b-5742-7963-833c-2891c0830428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_019d185f-d58c-732d-91bf-dd45fb7d1e57" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_019cd33b-5742-7963-833c-2891c0830428" xlink:to="loc_srt_ProductOrServiceAxis_019d185f-d58c-732d-91bf-dd45fb7d1e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_019d185f-d58c-7c8f-ba7b-189175defbd2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_019d185f-d58c-732d-91bf-dd45fb7d1e57" xlink:to="loc_srt_ProductsAndServicesDomain_019d185f-d58c-7c8f-ba7b-189175defbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LicenseAndDevelopmentServicesMember_019d185f-d58c-7521-aafa-4a50ca6889c5" xlink:href="rcus-20260331.xsd#rcus_LicenseAndDevelopmentServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019d185f-d58c-7c8f-ba7b-189175defbd2" xlink:to="loc_rcus_LicenseAndDevelopmentServicesMember_019d185f-d58c-7521-aafa-4a50ca6889c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_019dd18f-4a4d-7cbe-9eec-7620e2c7126d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndDevelopmentServicesMember_019d185f-d58c-7521-aafa-4a50ca6889c5" xlink:to="loc_us-gaap_LicenseMember_019dd18f-4a4d-7cbe-9eec-7620e2c7126d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_DevelopmentServicesMember_019dd190-0122-7b08-8f4a-28c503f567fa" xlink:href="rcus-20260331.xsd#rcus_DevelopmentServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_LicenseAndDevelopmentServicesMember_019d185f-d58c-7521-aafa-4a50ca6889c5" xlink:to="loc_rcus_DevelopmentServicesMember_019dd190-0122-7b08-8f4a-28c503f567fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RDServicesMember_019d1876-bd3c-71cf-877f-5dd903dd26fc" xlink:href="rcus-20260331.xsd#rcus_RDServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019d185f-d58c-7c8f-ba7b-189175defbd2" xlink:to="loc_rcus_RDServicesMember_019d1876-bd3c-71cf-877f-5dd903dd26fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AccessRightsAndOptionContinuationPeriodsMember_019d185f-d58c-7c42-92fe-0ff05a5f7e0b" xlink:href="rcus-20260331.xsd#rcus_AccessRightsAndOptionContinuationPeriodsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019d185f-d58c-7c8f-ba7b-189175defbd2" xlink:to="loc_rcus_AccessRightsAndOptionContinuationPeriodsMember_019d185f-d58c-7c42-92fe-0ff05a5f7e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RightsToCertainStudiesMember_019d185f-d58c-74f6-8228-5fa3ec646c1a" xlink:href="rcus-20260331.xsd#rcus_RightsToCertainStudiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_019d185f-d58c-7c8f-ba7b-189175defbd2" xlink:to="loc_rcus_RightsToCertainStudiesMember_019d185f-d58c-74f6-8228-5fa3ec646c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019d1876-bd3c-73da-a3b0-4f6372105f7e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_019cd33b-5742-7963-833c-2891c0830428" xlink:to="loc_srt_CounterpartyNameAxis_019d1876-bd3c-73da-a3b0-4f6372105f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d1876-bd3c-7275-bffd-98ec96abd9bc" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_019d1876-bd3c-73da-a3b0-4f6372105f7e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d1876-bd3c-7275-bffd-98ec96abd9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TaihoPharmaceuticalCoLtdMember_019d1876-bd3c-792d-b8be-648d21d0d769" xlink:href="rcus-20260331.xsd#rcus_TaihoPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019d1876-bd3c-7275-bffd-98ec96abd9bc" xlink:to="loc_rcus_TaihoPharmaceuticalCoLtdMember_019d1876-bd3c-792d-b8be-648d21d0d769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_019d185f-8bbb-73d4-999c-bf59d3d70936" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_019cd33b-5742-7963-833c-2891c0830428" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_019d185f-8bbb-73d4-999c-bf59d3d70936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_019d185f-d58c-79e5-afc4-ee0859dc08cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_019d185f-8bbb-73d4-999c-bf59d3d70936" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_019d185f-d58c-79e5-afc4-ee0859dc08cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetIncomeLossperShareDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetIncomeLossperShareDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetIncomeLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019cd33b-5742-79c3-84e7-ff20115a1910" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019cd33b-5742-7e8e-8cbb-4645de17ccb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019cd33b-5742-79c3-84e7-ff20115a1910" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019cd33b-5742-7e8e-8cbb-4645de17ccb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019cd33b-5742-7176-aa52-baafadea95f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019cd33b-5742-7e8e-8cbb-4645de17ccb9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019cd33b-5742-7176-aa52-baafadea95f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cd33b-5742-7e4d-88f1-1f754766f3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_019cd33b-5742-7176-aa52-baafadea95f2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cd33b-5742-7e4d-88f1-1f754766f3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_019cd33b-5742-795b-becf-f884b01b873f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cd33b-5742-7e4d-88f1-1f754766f3f9" xlink:to="loc_us-gaap_StockCompensationPlanMember_019cd33b-5742-795b-becf-f884b01b873f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_019cd33b-5742-7f32-9b1d-bc18b64a3423" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cd33b-5742-7e4d-88f1-1f754766f3f9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_019cd33b-5742-7f32-9b1d-bc18b64a3423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_019cd33b-5742-7960-826e-9812403e4bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_019cd33b-5742-7e4d-88f1-1f754766f3f9" xlink:to="loc_us-gaap_EmployeeStockMember_019cd33b-5742-7960-826e-9812403e4bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019cd33b-5742-7ecf-b72a-f1512b002da1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019cd33b-5742-7e8e-8cbb-4645de17ccb9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019cd33b-5742-7ecf-b72a-f1512b002da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019cd33b-5742-7206-9f73-5709f380a910" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019cd33b-5742-7ecf-b72a-f1512b002da1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_019cd33b-5742-7206-9f73-5709f380a910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/StockBasedCompensationDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#StockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/StockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cd33b-5742-7260-9a72-152135aa4f44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019cd33b-5742-7be4-b42e-9c7841e975aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_019cd33b-5742-7260-9a72-152135aa4f44" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019cd33b-5742-7be4-b42e-9c7841e975aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_019cd33b-5742-7e36-b216-fde305c479cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019cd33b-5742-7be4-b42e-9c7841e975aa" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_019cd33b-5742-7e36-b216-fde305c479cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019cd33b-5742-7a02-a4e0-ba65b8dd9be1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019cd33b-5742-7e36-b216-fde305c479cc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019cd33b-5742-7a02-a4e0-ba65b8dd9be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019cd33b-5742-72b8-a069-b384882d074a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019cd33b-5742-7a02-a4e0-ba65b8dd9be1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019cd33b-5742-72b8-a069-b384882d074a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019cd33b-5742-7f14-a9ca-861bbbc39fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019cd33b-5742-7a02-a4e0-ba65b8dd9be1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019cd33b-5742-7f14-a9ca-861bbbc39fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019cd33b-5742-7729-aae8-0db6c3159898" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_019cd33b-5742-7be4-b42e-9c7841e975aa" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019cd33b-5742-7729-aae8-0db6c3159898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_019cd33b-5742-7837-9240-cb7f0bb866f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_019cd33b-5742-7729-aae8-0db6c3159898" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_019cd33b-5742-7837-9240-cb7f0bb866f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_019cd33b-5742-7364-8b0b-e61ebd5675d7" xlink:href="rcus-20260331.xsd#rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019cd33b-5742-7a90-8ef4-5b54c726414b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_019cd33b-5742-7364-8b0b-e61ebd5675d7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019cd33b-5742-7a90-8ef4-5b54c726414b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019cd33b-5742-7f91-86e4-15395b09e9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019cd33b-5742-7a90-8ef4-5b54c726414b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019cd33b-5742-7f91-86e4-15395b09e9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-712b-99e4-2e203669075a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019cd33b-5742-7f91-86e4-15395b09e9d0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-712b-99e4-2e203669075a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_019cd33b-5742-7a96-8d8d-65915bb12798" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-712b-99e4-2e203669075a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_019cd33b-5742-7a96-8d8d-65915bb12798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_019cd33b-5742-77be-ae16-8345bca44a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-712b-99e4-2e203669075a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_019cd33b-5742-77be-ae16-8345bca44a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CorporateSecuritiesAndCommercialPaperMember_019cd33b-5742-711c-86a0-c9ca1adf8152" xlink:href="rcus-20260331.xsd#rcus_CorporateSecuritiesAndCommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-712b-99e4-2e203669075a" xlink:to="loc_rcus_CorporateSecuritiesAndCommercialPaperMember_019cd33b-5742-711c-86a0-c9ca1adf8152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_019cd33b-5742-7c96-a638-f00e8d6bf346" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-712b-99e4-2e203669075a" xlink:to="loc_us-gaap_CertificatesOfDepositMember_019cd33b-5742-7c96-a638-f00e8d6bf346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019cd33b-5742-7ad0-8014-69e1cd88cea3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_019cd33b-5742-7a90-8ef4-5b54c726414b" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019cd33b-5742-7ad0-8014-69e1cd88cea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019cd33b-5742-78bd-991b-bee8d6049d33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019cd33b-5742-7ad0-8014-69e1cd88cea3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_019cd33b-5742-78bd-991b-bee8d6049d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019cd33b-5742-7183-a7d3-7d3d98164db3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019cd33b-5742-7ad0-8014-69e1cd88cea3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_019cd33b-5742-7183-a7d3-7d3d98164db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019cd33b-5742-7285-b0a4-5f245825733e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019cd33b-5742-7ad0-8014-69e1cd88cea3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_019cd33b-5742-7285-b0a4-5f245825733e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019cd33b-5742-7c69-9712-10249466dd8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_019cd33b-5742-7ad0-8014-69e1cd88cea3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_019cd33b-5742-7c69-9712-10249466dd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#CashCashEquivalentsandMarketableSecuritiesSummaryofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_019cd33b-5742-7aac-9557-b66f0a62f46c" xlink:href="rcus-20260331.xsd#rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019cd33b-5742-7d7d-871d-ee70fbbba584" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_019cd33b-5742-7aac-9557-b66f0a62f46c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_019cd33b-5742-7d7d-871d-ee70fbbba584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019cd33b-5742-7af8-b0cd-dda3840336d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_019cd33b-5742-7aac-9557-b66f0a62f46c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_019cd33b-5742-7af8-b0cd-dda3840336d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_019cd33b-5742-726b-92cd-4981712ed557" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_019cd33b-5742-7aac-9557-b66f0a62f46c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_019cd33b-5742-726b-92cd-4981712ed557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndAvailableForSaleInvestments_019cd33b-5742-7703-9d6a-361e05cc287a" xlink:href="rcus-20260331.xsd#rcus_CashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_019cd33b-5742-7aac-9557-b66f0a62f46c" xlink:to="loc_rcus_CashCashEquivalentsAndAvailableForSaleInvestments_019cd33b-5742-7703-9d6a-361e05cc287a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_019cd33b-5742-7010-86a1-8c6295b65510" xlink:href="rcus-20260331.xsd#rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_019cd33b-5742-7f4d-b1d6-beba83fb7eee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_019cd33b-5742-7010-86a1-8c6295b65510" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_019cd33b-5742-7f4d-b1d6-beba83fb7eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForLoanLossesExpensed_019cd33b-5742-72e8-937d-b57819232580" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForLoanLossesExpensed"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_019cd33b-5742-7010-86a1-8c6295b65510" xlink:to="loc_us-gaap_ProvisionForLoanLossesExpensed_019cd33b-5742-72e8-937d-b57819232580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#CashCashEquivalentsandMarketableSecuritiesSummaryofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_019cd33b-5742-7884-b3fe-dd8117d19851" xlink:href="rcus-20260331.xsd#rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cd33b-5742-7c1f-891c-e42a156938a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_019cd33b-5742-7884-b3fe-dd8117d19851" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_019cd33b-5742-7c1f-891c-e42a156938a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_019cd33b-5742-7845-896f-6c180eda0d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_019cd33b-5742-7884-b3fe-dd8117d19851" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_019cd33b-5742-7845-896f-6c180eda0d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019cd33b-5742-74d0-a50a-f02913aeaeb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_019cd33b-5742-7884-b3fe-dd8117d19851" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_019cd33b-5742-74d0-a50a-f02913aeaeb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList_019cd33b-5742-756c-84ec-6cbd2c1c4c33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract_019cd33b-5742-7884-b3fe-dd8117d19851" xlink:to="loc_us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList_019cd33b-5742-756c-84ec-6cbd2c1c4c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_019cd33b-5742-7c75-943d-0a0a169d0665" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PrepaidExpensesAndOtherCurrentAssets_019cd33b-5742-7561-a3e1-103b9bb62e02" xlink:href="rcus-20260331.xsd#rcus_PrepaidExpensesAndOtherCurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_019cd33b-5742-7c75-943d-0a0a169d0665" xlink:to="loc_rcus_PrepaidExpensesAndOtherCurrentAssets_019cd33b-5742-7561-a3e1-103b9bb62e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_019cd33b-5742-7229-9131-f99891dba03a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_019cd33b-5742-7c75-943d-0a0a169d0665" xlink:to="loc_us-gaap_InterestReceivableCurrent_019cd33b-5742-7229-9131-f99891dba03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cd33b-5742-753a-9561-6c81f3b6046a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_019cd33b-5742-7c75-943d-0a0a169d0665" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_019cd33b-5742-753a-9561-6c81f3b6046a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_019cd33b-5742-755f-98f9-97290346f660" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_AccruedResearchAndDevelopmentExpensesCurrent_019cd33b-5742-7bc9-872e-0c3c537c0c50" xlink:href="rcus-20260331.xsd#rcus_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_019cd33b-5742-755f-98f9-97290346f660" xlink:to="loc_rcus_AccruedResearchAndDevelopmentExpensesCurrent_019cd33b-5742-7bc9-872e-0c3c537c0c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019cd33b-5742-722b-ba19-b9ece0b22a41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_019cd33b-5742-755f-98f9-97290346f660" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_019cd33b-5742-722b-ba19-b9ece0b22a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_019cfa68-c5cd-79d0-b96f-837296a78e52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_019cd33b-5742-755f-98f9-97290346f660" xlink:to="loc_us-gaap_TaxesPayableCurrent_019cfa68-c5cd-79d0-b96f-837296a78e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_019cd33b-5742-7866-951a-a70ac2f92af7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_019cd33b-5742-755f-98f9-97290346f660" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_019cd33b-5742-7866-951a-a70ac2f92af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_019cd33b-5742-7ab6-a069-183547742352" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_019cd33b-5742-755f-98f9-97290346f660" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_019cd33b-5742-7ab6-a069-183547742352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_019cd33b-5742-7908-8b25-1ebfd84e47ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_019cd33b-5742-755f-98f9-97290346f660" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_019cd33b-5742-7908-8b25-1ebfd84e47ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/LongTermDebtSummaryofLongTermDebtInstrumentsDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#LongTermDebtSummaryofLongTermDebtInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/LongTermDebtSummaryofLongTermDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019cd33b-5742-76e0-a117-74f50983c226" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_019cd33b-5742-7dc7-8fcd-32f631293444" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019cd33b-5742-76e0-a117-74f50983c226" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_019cd33b-5742-7dc7-8fcd-32f631293444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_019cd33b-5742-7105-91ea-f8db48806be7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019cd33b-5742-76e0-a117-74f50983c226" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_019cd33b-5742-7105-91ea-f8db48806be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_019cd33b-5742-7788-9ea1-348def63fea5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019cd33b-5742-76e0-a117-74f50983c226" xlink:to="loc_us-gaap_LongTermDebt_019cd33b-5742-7788-9ea1-348def63fea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#LongTermDebtAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_019cd33b-5742-75d3-a79f-34045c02b124" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_019cd33b-5742-7330-8eb0-8c860d25b806" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_019cd33b-5742-75d3-a79f-34045c02b124" xlink:to="loc_us-gaap_DebtInstrumentTable_019cd33b-5742-7330-8eb0-8c860d25b806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_019d18b0-cfa0-749b-bae4-eb8bb9e3bcdc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019cd33b-5742-7330-8eb0-8c860d25b806" xlink:to="loc_us-gaap_DebtInstrumentAxis_019d18b0-cfa0-749b-bae4-eb8bb9e3bcdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_019d18b0-cfa0-7a0f-a88d-dc2f79410602" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_019d18b0-cfa0-749b-bae4-eb8bb9e3bcdc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_019d18b0-cfa0-7a0f-a88d-dc2f79410602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_HerculesAgreementMember_019d18b0-cfa0-7044-81e1-ef6301a3a487" xlink:href="rcus-20260331.xsd#rcus_HerculesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_019d18b0-cfa0-7a0f-a88d-dc2f79410602" xlink:to="loc_rcus_HerculesAgreementMember_019d18b0-cfa0-7044-81e1-ef6301a3a487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_019d18b0-cfa0-70ff-8fe4-7fa0cf0a299d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019cd33b-5742-7330-8eb0-8c860d25b806" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_019d18b0-cfa0-70ff-8fe4-7fa0cf0a299d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_019d18b0-cfa0-72ad-b2f1-e4acad0f99ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_019d18b0-cfa0-70ff-8fe4-7fa0cf0a299d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_019d18b0-cfa0-72ad-b2f1-e4acad0f99ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_019d18b0-cfa0-77fe-83ac-3bb38339dbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_019d18b0-cfa0-72ad-b2f1-e4acad0f99ec" xlink:to="loc_us-gaap_SecuredDebtMember_019d18b0-cfa0-77fe-83ac-3bb38339dbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_DebtInstrumentTrancheTypeAxis_019d18b0-cfa0-7588-856e-b47ca3a4e179" xlink:href="rcus-20260331.xsd#rcus_DebtInstrumentTrancheTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019cd33b-5742-7330-8eb0-8c860d25b806" xlink:to="loc_rcus_DebtInstrumentTrancheTypeAxis_019d18b0-cfa0-7588-856e-b47ca3a4e179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_DebtInstrumentTrancheTypeDomain_019d18b0-cfa0-7a43-a125-d4855b9067b8" xlink:href="rcus-20260331.xsd#rcus_DebtInstrumentTrancheTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_DebtInstrumentTrancheTypeAxis_019d18b0-cfa0-7588-856e-b47ca3a4e179" xlink:to="loc_rcus_DebtInstrumentTrancheTypeDomain_019d18b0-cfa0-7a43-a125-d4855b9067b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TrancheOneMember_019d18b0-cfa0-7711-99c0-3a0c123af078" xlink:href="rcus-20260331.xsd#rcus_TrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_DebtInstrumentTrancheTypeDomain_019d18b0-cfa0-7a43-a125-d4855b9067b8" xlink:to="loc_rcus_TrancheOneMember_019d18b0-cfa0-7711-99c0-3a0c123af078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_TrancheTwoMember_019d18b0-cfa0-747e-b0fe-9a75265308cb" xlink:href="rcus-20260331.xsd#rcus_TrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rcus_DebtInstrumentTrancheTypeDomain_019d18b0-cfa0-7a43-a125-d4855b9067b8" xlink:to="loc_rcus_TrancheTwoMember_019d18b0-cfa0-747e-b0fe-9a75265308cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_019d18b0-cfa0-70f9-addb-384603393cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_019cd33b-5742-7330-8eb0-8c860d25b806" xlink:to="loc_us-gaap_DebtInstrumentLineItems_019d18b0-cfa0-70f9-addb-384603393cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_019d18b0-cfa0-7203-91c1-8fd46ea78154" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d18b0-cfa0-70f9-addb-384603393cbc" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_019d18b0-cfa0-7203-91c1-8fd46ea78154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_019d18b0-cfa0-725b-bacf-eb91c68131b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d18b0-cfa0-70f9-addb-384603393cbc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_019d18b0-cfa0-725b-bacf-eb91c68131b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_DebtInstrumentAdditionalCommittedAmount_019d18b0-cfa0-7fbd-85f3-f5f13218a191" xlink:href="rcus-20260331.xsd#rcus_DebtInstrumentAdditionalCommittedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d18b0-cfa0-70f9-addb-384603393cbc" xlink:to="loc_rcus_DebtInstrumentAdditionalCommittedAmount_019d18b0-cfa0-7fbd-85f3-f5f13218a191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_DebtInstrumentFaceAmountContingentlyAvailable_019d18b0-cfa0-769c-8466-4fb36bcb6fdf" xlink:href="rcus-20260331.xsd#rcus_DebtInstrumentFaceAmountContingentlyAvailable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d18b0-cfa0-70f9-addb-384603393cbc" xlink:to="loc_rcus_DebtInstrumentFaceAmountContingentlyAvailable_019d18b0-cfa0-769c-8466-4fb36bcb6fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_DebtInstrumentMilestoneAchievementPeriod_019d18b0-cfa0-75c5-bc2b-d7e4c7d60831" xlink:href="rcus-20260331.xsd#rcus_DebtInstrumentMilestoneAchievementPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d18b0-cfa0-70f9-addb-384603393cbc" xlink:to="loc_rcus_DebtInstrumentMilestoneAchievementPeriod_019d18b0-cfa0-75c5-bc2b-d7e4c7d60831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_019d18b0-cfa0-72ef-98ca-0a259abd8953" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d18b0-cfa0-70f9-addb-384603393cbc" xlink:to="loc_us-gaap_InterestExpenseDebt_019d18b0-cfa0-72ef-98ca-0a259abd8953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_019d18b0-cfa0-7b3a-888f-7d5a17f7d649" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_019d18b0-cfa0-70f9-addb-384603393cbc" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_019d18b0-cfa0-7b3a-888f-7d5a17f7d649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/LeasesSummaryofCashandNoncashInformationRelatedtoOperatingLeasesDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#LeasesSummaryofCashandNoncashInformationRelatedtoOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/LeasesSummaryofCashandNoncashInformationRelatedtoOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_019cd33b-5742-789b-9f7f-cddefa438f31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_019cd33b-5742-767c-b84d-01e67fb9933d" xlink:href="rcus-20260331.xsd#rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019cd33b-5742-789b-9f7f-cddefa438f31" xlink:to="loc_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_019cd33b-5742-767c-b84d-01e67fb9933d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_019cd33b-5742-76b7-8eb9-6715efe4959d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_019cd33b-5742-7a72-aac9-3cc87ad8aabc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_019cd33b-5742-76b7-8eb9-6715efe4959d" xlink:to="loc_us-gaap_SecurityDeposit_019cd33b-5742-7a72-aac9-3cc87ad8aabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_019cd33b-5742-7cff-8506-5575085547ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_019cd33b-5742-7cb0-b44f-98d245a488e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_019cd33b-5742-7cff-8506-5575085547ed" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_019cd33b-5742-7cb0-b44f-98d245a488e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019cd33b-5742-7e37-9c3c-d7082d2d54b6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cd33b-5742-7cb0-b44f-98d245a488e3" xlink:to="loc_dei_LegalEntityAxis_019cd33b-5742-7e37-9c3c-d7082d2d54b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019cd33b-5742-7562-8f57-5793e7244536" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_019cd33b-5742-7e37-9c3c-d7082d2d54b6" xlink:to="loc_dei_EntityDomain_019cd33b-5742-7562-8f57-5793e7244536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadSciencesIncMember_019cd33b-5742-7a69-8da0-32e075cb4d42" xlink:href="rcus-20260331.xsd#rcus_GileadSciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_019cd33b-5742-7562-8f57-5793e7244536" xlink:to="loc_rcus_GileadSciencesIncMember_019cd33b-5742-7a69-8da0-32e075cb4d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_019cd33b-5742-743a-866a-5e1a93f0f05d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cd33b-5742-7cb0-b44f-98d245a488e3" xlink:to="loc_srt_CounterpartyNameAxis_019cd33b-5742-743a-866a-5e1a93f0f05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019cd33b-5742-70a0-afe0-0c07b91088ef" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_019cd33b-5742-743a-866a-5e1a93f0f05d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019cd33b-5742-70a0-afe0-0c07b91088ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_GileadSciencesIncMember_019cd33b-5742-789f-80d7-42f14e590b82" xlink:href="rcus-20260331.xsd#rcus_GileadSciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_019cd33b-5742-70a0-afe0-0c07b91088ef" xlink:to="loc_rcus_GileadSciencesIncMember_019cd33b-5742-789f-80d7-42f14e590b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_019cd33b-5742-76fc-b12a-69e6721af936" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_019cd33b-5742-7cb0-b44f-98d245a488e3" xlink:to="loc_us-gaap_ClassOfStockLineItems_019cd33b-5742-76fc-b12a-69e6721af936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019cd33b-5742-7aa3-94be-cccfc3a70b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cd33b-5742-76fc-b12a-69e6721af936" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_019cd33b-5742-7aa3-94be-cccfc3a70b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_019cd33b-5742-7241-b764-ab98aecfd66b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cd33b-5742-76fc-b12a-69e6721af936" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_019cd33b-5742-7241-b764-ab98aecfd66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019cd33b-5742-7528-91ea-41c65008c5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cd33b-5742-76fc-b12a-69e6721af936" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_019cd33b-5742-7528-91ea-41c65008c5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_SaleOfStockNumberOfSharesAcquiredInTransaction_019cd33b-5742-7cbd-b349-641c7a0aa7f5" xlink:href="rcus-20260331.xsd#rcus_SaleOfStockNumberOfSharesAcquiredInTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_019cd33b-5742-76fc-b12a-69e6721af936" xlink:to="loc_rcus_SaleOfStockNumberOfSharesAcquiredInTransaction_019cd33b-5742-7cbd-b349-641c7a0aa7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_019cd33b-5742-7d42-bb46-f26621031fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cd33b-5742-7ad2-9409-d063dbc81c32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_019cd33b-5742-7d42-bb46-f26621031fbe" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cd33b-5742-7ad2-9409-d063dbc81c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cd33b-5742-7ec2-aa80-bcb68e567886" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cd33b-5742-7ad2-9409-d063dbc81c32" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cd33b-5742-7ec2-aa80-bcb68e567886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cd33b-5742-7227-a12e-8710c580b735" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_019cd33b-5742-7ec2-aa80-bcb68e567886" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cd33b-5742-7227-a12e-8710c580b735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_019cd33b-5742-7b43-9e50-8a47ff62eabc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cd33b-5742-7227-a12e-8710c580b735" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_019cd33b-5742-7b43-9e50-8a47ff62eabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_019cd33b-5742-75a0-8961-02b0bf92e9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cd33b-5742-7227-a12e-8710c580b735" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_019cd33b-5742-75a0-8961-02b0bf92e9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_019cd33b-5742-7069-819c-7aba7a54ef70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019cd33b-5742-7227-a12e-8710c580b735" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_019cd33b-5742-7069-819c-7aba7a54ef70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_019cd33b-5742-7e0c-b849-47d9ee973bba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cd33b-5742-7ad2-9409-d063dbc81c32" xlink:to="loc_us-gaap_FinancialInstrumentAxis_019cd33b-5742-7e0c-b849-47d9ee973bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-7602-b104-959b5a4b9b34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_019cd33b-5742-7e0c-b849-47d9ee973bba" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-7602-b104-959b5a4b9b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_019cd33b-5742-79eb-9f41-979c72a8fa7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-7602-b104-959b5a4b9b34" xlink:to="loc_us-gaap_MoneyMarketFundsMember_019cd33b-5742-79eb-9f41-979c72a8fa7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_019cd33b-5742-7e91-8e89-88e20ccde690" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-7602-b104-959b5a4b9b34" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_019cd33b-5742-7e91-8e89-88e20ccde690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_CorporateSecuritiesAndCommercialPaperMember_019cd33b-5742-7e2a-9d16-14758d660ead" xlink:href="rcus-20260331.xsd#rcus_CorporateSecuritiesAndCommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-7602-b104-959b5a4b9b34" xlink:to="loc_rcus_CorporateSecuritiesAndCommercialPaperMember_019cd33b-5742-7e2a-9d16-14758d660ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_019cd33b-5742-79ac-bfea-37a81360f4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_019cd33b-5742-7602-b104-959b5a4b9b34" xlink:to="loc_us-gaap_CertificatesOfDepositMember_019cd33b-5742-79ac-bfea-37a81360f4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cd33b-5742-7a49-9f7a-a7671a5076f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_019cd33b-5742-7ad2-9409-d063dbc81c32" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cd33b-5742-7a49-9f7a-a7671a5076f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_019cd33b-5742-70ef-9777-5f57ec549077" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cd33b-5742-7a49-9f7a-a7671a5076f4" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_019cd33b-5742-70ef-9777-5f57ec549077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_019cd33b-5742-78cf-9ff7-8197bd7dfe07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_019cd33b-5742-7a49-9f7a-a7671a5076f4" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_019cd33b-5742-78cf-9ff7-8197bd7dfe07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/BusinessSegmentAdditionalInformationDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#BusinessSegmentAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/BusinessSegmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019cd33b-5742-79bd-a3d9-70e3548719f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019cd33b-5742-7509-ad33-0bc2daa68171" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019cd33b-5742-79bd-a3d9-70e3548719f0" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019cd33b-5742-7509-ad33-0bc2daa68171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019cd33b-5742-7513-b85a-cd623e46b098" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019cd33b-5742-7509-ad33-0bc2daa68171" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019cd33b-5742-7513-b85a-cd623e46b098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019cd33b-5742-79c3-a492-064a363cd4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019cd33b-5742-7513-b85a-cd623e46b098" xlink:to="loc_us-gaap_SegmentDomain_019cd33b-5742-79c3-a492-064a363cd4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ReportableSegmentMember_019cd33b-5742-7e33-ba72-9b9b4d92f889" xlink:href="rcus-20260331.xsd#rcus_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019cd33b-5742-79c3-a492-064a363cd4ae" xlink:to="loc_rcus_ReportableSegmentMember_019cd33b-5742-7e33-ba72-9b9b4d92f889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019cd33b-5742-7eac-b06b-8e7b6f5b7842" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019cd33b-5742-7509-ad33-0bc2daa68171" xlink:to="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019cd33b-5742-7eac-b06b-8e7b6f5b7842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_019cd33b-5742-7330-97df-ca035f909b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019cd33b-5742-7eac-b06b-8e7b6f5b7842" xlink:to="loc_us-gaap_NumberOfReportableSegments_019cd33b-5742-7330-97df-ca035f909b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_019cd33b-5742-710d-90f3-3fe4f74d56a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019cd33b-5742-7eac-b06b-8e7b6f5b7842" xlink:to="loc_us-gaap_NumberOfOperatingSegments_019cd33b-5742-710d-90f3-3fe4f74d56a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_019cd33b-5742-7c90-b391-996e27393559" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019cd33b-5742-7eac-b06b-8e7b6f5b7842" xlink:to="loc_us-gaap_Assets_019cd33b-5742-7c90-b391-996e27393559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails" xlink:type="simple" xlink:href="rcus-20260331.xsd#BusinessSegmentSummaryofSegmentReportingInformationDetails"/>
  <link:presentationLink xlink:role="http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_019cd33b-5742-7132-b043-7dbe63875c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019cd33b-5742-7183-91cc-c308b53eda63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_019cd33b-5742-7132-b043-7dbe63875c7a" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019cd33b-5742-7183-91cc-c308b53eda63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_019cd33b-5742-742a-bf68-a4ba9a7b1a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019cd33b-5742-7183-91cc-c308b53eda63" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_019cd33b-5742-742a-bf68-a4ba9a7b1a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_019cd33b-5742-71cf-a40c-fa7f03afbbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_019cd33b-5742-742a-bf68-a4ba9a7b1a0c" xlink:to="loc_us-gaap_SegmentDomain_019cd33b-5742-71cf-a40c-fa7f03afbbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_ReportableSegmentMember_019cd33b-5742-7161-8521-8dfa7775b5b8" xlink:href="rcus-20260331.xsd#rcus_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_019cd33b-5742-71cf-a40c-fa7f03afbbb0" xlink:to="loc_rcus_ReportableSegmentMember_019cd33b-5742-7161-8521-8dfa7775b5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019cd33b-5742-7d7a-8654-0963ffe5519f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_019cd33b-5742-7183-91cc-c308b53eda63" xlink:to="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019cd33b-5742-7d7a-8654-0963ffe5519f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019cd33b-5742-7104-a785-98184f64f884" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019cd33b-5742-7d7a-8654-0963ffe5519f" xlink:to="loc_us-gaap_Revenues_019cd33b-5742-7104-a785-98184f64f884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_019cd33b-5742-7cf0-9ebc-749685ed5684" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019cd33b-5742-7d7a-8654-0963ffe5519f" xlink:to="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_019cd33b-5742-7cf0-9ebc-749685ed5684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_LateStageDevelopmentPrograms_019cd33b-5742-753c-b8ce-a709e91c0bff" xlink:href="rcus-20260331.xsd#rcus_LateStageDevelopmentPrograms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_019cd33b-5742-7cf0-9ebc-749685ed5684" xlink:to="loc_rcus_LateStageDevelopmentPrograms_019cd33b-5742-753c-b8ce-a709e91c0bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_EarlyStageDevelopmentAndPreclinicalPrograms_019cd33b-5742-7e4d-9d36-7f216697405c" xlink:href="rcus-20260331.xsd#rcus_EarlyStageDevelopmentAndPreclinicalPrograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_019cd33b-5742-7cf0-9ebc-749685ed5684" xlink:to="loc_rcus_EarlyStageDevelopmentAndPreclinicalPrograms_019cd33b-5742-7e4d-9d36-7f216697405c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_019cd33b-5742-7ba5-b502-cd36dba2efb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_019cd33b-5742-7cf0-9ebc-749685ed5684" xlink:to="loc_us-gaap_LaborAndRelatedExpense_019cd33b-5742-7ba5-b502-cd36dba2efb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_019cd33b-5742-7aaa-91b2-728a53165a15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_019cd33b-5742-7cf0-9ebc-749685ed5684" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_019cd33b-5742-7aaa-91b2-728a53165a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_019dd136-a8d1-7232-99e9-c7612e523beb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_019cd33b-5742-7cf0-9ebc-749685ed5684" xlink:to="loc_us-gaap_InterestExpenseNonoperating_019dd136-a8d1-7232-99e9-c7612e523beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_019cd33b-5742-77b4-b70e-98c94e91a529" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_019cd33b-5742-7cf0-9ebc-749685ed5684" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_019cd33b-5742-77b4-b70e-98c94e91a529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_PartnershipReimbursements_019cfa98-cd5e-72ee-9b4b-f82db64e8578" xlink:href="rcus-20260331.xsd#rcus_PartnershipReimbursements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_019cd33b-5742-7cf0-9ebc-749685ed5684" xlink:to="loc_rcus_PartnershipReimbursements_019cfa98-cd5e-72ee-9b4b-f82db64e8578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019cd33b-5742-779a-ba4c-5b5e9d71ebb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_019cd33b-5742-7d7a-8654-0963ffe5519f" xlink:to="loc_us-gaap_NetIncomeLoss_019cd33b-5742-779a-ba4c-5b5e9d71ebb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_RobertC.GoeltzIIMember" xlink:href="rcus-20260331.xsd#rcus_RobertC.GoeltzIIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rcus_RobertC.GoeltzIIMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_JuanJaenMember" xlink:href="rcus-20260331.xsd#rcus_JuanJaenMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rcus_JuanJaenMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_rcus_JenniferJarrettMember" xlink:href="rcus-20260331.xsd#rcus_JenniferJarrettMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rcus_JenniferJarrettMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>rcus-20260331_g1.jpg
<TEXT>
begin 644 rcus-20260331_g1.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #__@ 23$5!1%1/3TQ3('8R,RXP /_; (0
M!04%" 4(# <'# P)"0D,#0P,# P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0$%" @*!PH,!P<,#0P*# T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-_\0!H@
M 04! 0$! 0$           $" P0%!@<("0H+ 0 # 0$! 0$! 0$!
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MM=;+5OSLM7;9)O9-F;DHVOHFTK]+O1+RUTUZM+=GHNT"H*$VCIZ4 &T9QWH
M78* $V@?C0 NP4 )M% !M!H 78* #8* #8* #8* #8* #8* #8* #8* #8*
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MFMM-UZZI^C3V9G?WG!IJ4=T_.Z3^]-=]-4=5L%04&P4 &P4 &P4 &P4 &P4
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M1QZTP(FMP!SVY[X^AII] $"=Q4@+L!..U,!-E.PC0J1A0 4 % !0 4 % !0
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MC>=EM9.52/I*#T>W(TXPIX1_9<I3](RM"+\[*%[K_GXO7Z>KG-PH * "@ H
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MS):KX3W_ ,)?\E!UG_KSM_\ T"UJ*/\  K?]A'ZUS!_%A_\ L&_6D>Z5!N%
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 $=J (_*6@"2@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 *I*G(X(IIN+NMT)J^C.OT#7Y8I5M[AB\;G )Y*D]"#Z>HZ <C&"
M&^ZR?.*M.K'"XF3E2F^5-ZN+>S3Z175?"HZJUFI?.X[ PE!UJ*49I7LM$TM]
M._9[MZ.]]/1:_63XLX?QLQ @ Z'S<_\ D.OS;BEM+#);/VU_E[(^KR=?Q7VY
M/_;S@J_-#ZP* "@#S^;Q=>WEQ+!HMD;R.U;9+*TBQJ6&<JF<9Z<$$D]=F,$_
M71RK#T*=.>9XGV$ZL>:$%!R:3V<[;>>B2_FT=O&GBZDJDJ.$I>T=-VE)R44G
M?5*]K[-7ONG9-:MLWCQ/[)?4H82)H95AE@D8@HY//S;<D>AVCD$$ @BJIY)+
MZXL#4J>Y*FZD*L5=2BMM+Z>:N_)M-,7U].A4K*%JE)I2IM[-R4=[>O1.Z:MU
M)+OQPB:=;:E;1B3[3,L#H6P8V*L6!(!R5(XX&5(;O65+)I/$8C"5Y.#HTY5(
MR2NII-<KU:LFGYV=UT(GF"CAEBX13?.H2BW;EERRD];>2MIJFGIL3ZCXKN1?
M/IND6IOIH #,QD$:(3T7+<$\]V'.0 Q!Q%#+*2P\,9F.(5"%1_NXJ#G*2_FL
MM4OD]+-M75]ZV+E&K]6PU/VE1*\M5%1O9K5Z7LUU5KI:NZ4MIXO7[#/>:A!+
M9/9G$D; G<2=J^4Q"A]S?+VVGJ=N&.=3*I?6*6%PE6%:-97C.+6B2O+G2<G&
MRUZW6VMTJIXN\*D\1"5)TOB3U3Z+E=DFV]+;7:UL[F.?&NHVT2ZA>:<T6G2%
M<2+*K2*K'AV3 .#QC<J Y W<C/HK)\+5E+"X7&*>*BI>XX.,9..\5*]M.MG+
MKIHSC^O5E'ZPZ#]AH^;F7-9OXK=GTT2>GO6=S?B\2B?5H],B16AEMA<+,&.2
M#D@!<=",'.>_2O(GE_L\$\=.34XUG2=.VS6^M][]+';];3KTJ$$G"K3]HI7Z
M>^UI;^[^)#K?BB6RNUTO3;<WMZR;RNX(D:]B['C)]"5&"OS9(!VP>6PJT'CL
M;65##J7*GRN4IOKRI?FE)Z/2R;#$8IT9QH48.I5DKJ-[)+75OY/3335M:79I
M/B[SI9K/583875K&974L'1HU&6=6 QP.< MD<AC@@5B<JY(TJ^!J+$4:TE",
MDN62FW91DGM?N[6>Z6EXHXMNH\/BH>RJ*/-O>+BE=M/R5WHWL];IHRH_&FIW
M<9O;+3))K(,0K^8/,< XW+&%9CSUVJX!!&[@D=TLHPE&7U7$8Z$,3:[CR/DB
M[7LYMI?>XO;W>ASK'5JJ=7#T'.DFU?FLY6WM&S?W*5G?S1KWOBIK&XLO-A:.
MTO\ "^9)E)(9#_!(A&!R5R<]-Q&0N3YU++%7I8ETZBE7P[OR1M*$X+[4))ZZ
M)].W<Z*F,=)4:DH-4ZCY9.5XRIOS3Z=;]HMKH6=$\0OK=Y=10Q@6EHWEB;<2
M9)!U &,8&"<Y/!0_Q<8XW 1P%&A*<VZ]6/.Z=DE"/2[O>[VV6JEV-:6(=:M4
MHPC^[IZ.=]Y;62M:R:EJF]D_M(ZFO"/1"@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H 4$J<C@TTW%WCHQ-7T9[KBOZ3/RHX7QM_P N_P#VU_\
M:=?FG%7_ #"_]QO_ '$?5Y/_ ,OO^X?_ +><'7YL?5A0 4 >4:;)J'@E[BS^
MQ3WUO+*TT$L +9W #;)M5BO  )/(() 92#7W^)CAL[5+%?6J5"I&$85(56HV
MM=WA=J^[M;1JUVG='SD?:X"I52I2J4ZDG.+@KM-])63\ETVND[Z9%[X>U :-
M=W$L+F[U"Z28P1J79%#,1D+DYR[$CL,;L-D#T*./PSQ]&G3J15##X>5)5)M0
M4I6BM'*W\JMW=[:69S2P]65#$UYP:J5Y0:IK5J,9W6BUO[STM>RN^J3?$WA:
M[M)X9-/CDDM;F2*66*-&;RIT&"Q502JL&8D\ '(. $%&7YE1K4:L<7.$:].G
M.G"<I*/M*<M8I-M<S325M[6:W9AC,'4C3C*A&34U!U(13;52,&E*RUUYI7TT
ME>^Z1T++?>$]5N[J*TEOK34"),P LZ.-Q(*@$XRS=<#!4@Y!6O)_V?-\)AZ,
M\13P]?#KD:JM1C*.BNFVE>R3TN[W35K,].:JX3$SQ$*<JE.JE?EUE%I=M?/L
MK-:W5BQ=VFK>+=)N([R%+-G97M8CN$AV'=B4LV!N'RC*H0V6*@8K*C5P648V
ME+#U)5HJ+C6GIRIR5KTTE=I/5ZRTT3;N:-5\=1JPJP5)2M[-._-I)2][LM$M
MD]6[62OE7^IZOK.GC15TZ>*XD58I)7!6!0A7+JY4+AMO3.!GY2YQGMP^'P6
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M+3CR1TC9JZM;73=MLWP%+V.'BFG&3;E*ZL[MVU3\DEZ)'35XQZ@4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0![Q7])GY2<'XV_Y=_\ MK_[
M3K\UXJ_YA?\ N-_[B/J\G_Y??]P__;S@Z_-CZL* "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M_P#D0_X1C3O^>/\ X_)_\71_867?\^/_ "I5_P#E@?VCBO\ GY_Y+#_Y$/\
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M_P">/_C\G_Q=']A9=_SX_P#*E7_Y8']HXK_GY_Y+#_Y$/^$8T[_GC_X_)_\
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M[U+?_",:=_SQ_P#'Y/\ XNN[^PLN_P"?'_E2K_\ +#G_ +1Q7_/S_P EA_\
M(A_PC&G?\\?_ !^3_P"+H_L++O\ GQ_Y4J__ "P/[1Q7_/S_ ,EA_P#(A_PC
M&G?\\?\ Q^3_ .+H_L++O^?'_E2K_P#+ _M'%?\ /S_R6'_R(?\ ",:=_P \
M?_'Y/_BZ/["R[_GQ_P"5*O\ \L#^T<5_S\_\EA_\B'_",:=_SQ_\?D_^+H_L
M++O^?'_E2K_\L#^T<5_S\_\ )8?_ "(?\(QIW_/'_P ?D_\ BZ/["R[_ )\?
M^5*O_P L#^T<5_S\_P#)8?\ R(?\(QIW_/'_ ,?D_P#BZ/["R[_GQ_Y4J_\
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MW_/C_P J5?\ Y8']HXK_ )^?^2P_^1#_ (1C3O\ GC_X_)_\71_867?\^/\
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M_P"2P_\ D0_X1C3O^>/_ (_)_P#%T?V%EW_/C_RI5_\ E@?VCBO^?G_DL/\
MY$/^$8T[_GC_ ./R?_%T?V%EW_/C_P J5?\ Y8']HXK_ )^?^2P_^1#_ (1C
M3O\ GC_X_)_\71_867?\^/\ RI5_^6!_:.*_Y^?^2P_^1#_A&-._YX_^/R?_
M !=']A9=_P ^/_*E7_Y8']HXK_GY_P"2P_\ D0_X1C3O^>/_ (_)_P#%T?V%
MEW_/C_RI5_\ E@?VCBO^?G_DL/\ Y$/^$8T[_GC_ ./R?_%T?V%EW_/C_P J
M5?\ Y8']HXK_ )^?^2P_^1#_ (1C3O\ GC_X_)_\71_867?\^/\ RI5_^6!_
M:.*_Y^?^2P_^1#_A&-._YX_^/R?_ !=']A9=_P ^/_*E7_Y8']HXK_GY_P"2
MP_\ D0_X1C3O^>/_ (_)_P#%T?V%EW_/C_RI5_\ E@?VCBO^?G_DL/\ Y$/^
M$8T[_GC_ ./R?_%T?V%EW_/C_P J5?\ Y8']HXK_ )^?^2P_^1#_ (1C3O\
MGC_X_)_\71_867?\^/\ RI5_^6!_:.*_Y^?^2P_^1#_A&-._YX_^/R?_ !='
M]A9=_P ^/_*E7_Y8']HXK_GY_P"2P_\ D0_X1C3O^>/_ (_)_P#%T?V%EW_/
MC_RI5_\ E@?VCBO^?G_DL/\ Y$/^$8T[_GC_ ./R?_%T?V%EW_/C_P J5?\
MY8']HXK_ )^?^2P_^1#_ (1C3O\ GC_X_)_\71_867?\^/\ RI5_^6!_:.*_
MY^?^2P_^1#_A&-._YX_^/R?_ !=']A9=_P ^/_*E7_Y8']HXK_GY_P"2P_\
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M/_*E7_Y8']HXK_GY_P"2P_\ D0_X1C3O^>/_ (_)_P#%T?V%EW_/C_RI5_\
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MW_/C_P J5?\ Y8']HXK_ )^?^2P_^1#_ (1C3O\ GC_X_)_\71_867?\^/\
MRI5_^6!_:.*_Y^?^2P_^1#_A&-._YX_^/R?_ !=']A9=_P ^/_*E7_Y8']HX
MK_GY_P"2P_\ D0_X1C3O^>/_ (_)_P#%T?V%EW_/C_RI5_\ E@?VCBO^?G_D
ML/\ Y$/^$8T[_GC_ ./R?_%T?V%EW_/C_P J5?\ Y8']HXK_ )^?^2P_^1#_
M (1C3O\ GC_X_)_\71_867?\^/\ RI5_^6!_:.*_Y^?^2P_^1#_A&-._YX_^
M/R?_ !=']A9=_P ^/_*E7_Y8']HXK_GY_P"2P_\ D0_X1C3O^>/_ (_)_P#%
MT?V%EW_/C_RI5_\ E@?VCBO^?G_DL/\ Y$/^$8T[_GC_ ./R?_%T?V%EW_/C
M_P J5?\ Y8']HXK_ )^?^2P_^1#_ (1C3O\ GC_X_)_\71_867?\^/\ RI5_
M^6!_:.*_Y^?^2P_^1#_A&-._YX_^/R?_ !=']A9=_P ^/_*E7_Y8']HXK_GY
M_P"2P_\ D0_X1C3O^>/_ (_)_P#%T?V%EW_/C_RI5_\ E@?VCBO^?G_DL/\
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M$8T[_GC_ ./R?_%T?V%EW_/C_P J5?\ Y8']HXK_ )^?^2P_^1#_ (1C3O\
MGC_X_)_\71_867?\^/\ RI5_^6!_:.*_Y^?^2P_^1*FH>';""VFD2+#I$[*=
M\AP0I(."Y'!'?BN'&9+@*.&KUJ=&TX4JDHOVE5VE&#:=G-IV:V::[G10Q^)G
M5IPE4O&4XIKEAJG))[1OL=37V9X)0D_X_(O^N,__ *';UYL_]\H_]>,1_P"G
M,*=<?X$_^OE+_P!)K%^O2.0* "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * *$G_'Y%_UQG_\ 0[>O
M-G_OE'_KQB/_ $YA3KC_  )_]?*7_I-8OUZ1R!0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % %"/_ (_)?^N,'_H=Q7FP_P!\K?\ 7C#_ /IS%'7+^!3_ .OE
M7_TFB7Z](Y H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@"AJO\ QYS_ /7&7_T!J\W,/]SQ/_7BM_Z;
MD=>&_CTO^OD/_2D7Z](Y"A)_Q^1?]<9__0[>O-G_ +Y1_P"O&(_].84ZX_P)
M_P#7RE_Z36+]>D<@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 4)/\ C\B_ZXS_ /H=O7FS_P!\
MH_\ 7C$?^G,*=<?X$_\ KY2_])K%^O2.0* "@ H * "@ H * "@ H * "@ H
M * "@ H H1_\?DO_ %Q@_P#0[BO-A_OE;_KQA_\ TYBCKE_ I_\ 7RK_ .DT
M2_7I'(% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MMI9HHYI,;(VD17;<=J[4)#'<>!@<G@<T 3W%S%9QF:X=(HUQN=V"*,D 99B
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MW^-+ZYB?^?\ 5_\ !D_\P]C2_DA_X"O\A/MMQ_SUD_[[;_&E]<Q/_/\ K?\
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MS[A_X#'_ "$^WW/_ #UE_P"^V_QI?7<5_P _ZW_@V?\ \D'L*7_/N'_@,?\
M(3[?<_\ /67_ +[;_&CZ[BO^?];_ ,&S_P#DA^PI?\^X?^ Q_P A/M]S_P ]
M9?\ OMO\:7UW%?\ 016_\&S_ /DA^PI?\^X?^ Q_R$_M"Y_YZR_]]M_C2^NX
MK_H(K?\ @V?_ ,D'L*7_ #[A_P" Q_R$_M"Y_P">TO\ WVW^-'UW%?\ 016_
M\&S_ /DA^PI?\^X?^ Q_R$_M"Y_Y[2_]]M_C2^O8K_H(K?\ @V?_ ,D/V%+_
M )]P_P# 8_Y"?VA=?\]I?^_C?XTOKV*_Z"*W_@V?_P D'L*7_/N'_@$?\@_M
M"Z_Y[2_]_&_QI?7L5_T$5O\ P;/_ .2'["C_ ,^X?^ 1_P A/[1NO^>TO_?Q
MO\:/KV*_Z"*W_@V?_P D/V%'_GW#_P  C_D)_:-U_P ]I?\ OX_^-+Z]B_\
MH(K?^#9__)!["C_S[A_X!'_(3^T;K_GM+_W\?_&E]>Q?_016_P#!L_\ Y(?U
M>C_S[A_X!'_(3^T;K_GM+_W\?_&CZ]B_^@BM_P"#9_\ R0_J]'_GW#_P"/\
MD)_:-U_SVE_[^/\ XTOKV+_Z"*W_ (-G_P#)!]7H_P#/N'_@$?\ (3^T;K_G
MM+_W\?\ QI?7L7_T$5O_  ;/_P"2']7H_P#/N'_@$?\ (3^TKK_GM+_W\?\
MQI?7L7_T$5O_  ;/_P"2']7H_P#/NG_X!'_(3^TKO_GM+_W\?_&CZ]B_^@BM
M_P"#9_\ R0?5Z/\ SZI_^ 1_R$_M*[_Y[2_]_'_QI?7\7_T$5_\ P;4_^2']
M7H_\^J?_ (!'_(3^TKO_ )[2_P#?Q_\ &E]?Q?\ T$5__!M3_P"2']7H_P#/
MJG_X!'_(3^TKO_GM-_W\?_&CZ_B_^@BO_P"#:G_R0?5Z/_/JG_X!'_(3^T[O
M_GO-_P!_'_QI?7\7_P!!%?\ \&U/_DA_5Z/_ #ZI_P#@$?\ (3^T[O\ Y[S?
M]_'_ ,:7U_%_]!%?_P &U/\ Y(?U>C_SZI_^ 1_R$_M.[_Y[S?\ ?Q_\:7U_
M%_\ 017_ /!M3_Y(/JU'_GU3_P# (_Y"?VG=_P#/>;_OX_\ C1]?Q?\ T$5_
M_!M3_P"2']6H?\^J?_@$?\A/[3N_^>\W_?Q_\:7U_%_]!-?_ ,&U/_DA_5J'
M_/JG_P" 1_R#^T[S_GO-_P!_'_QI?7\9_P!!-?\ \&U/_D@^K4/^?5/_ , C
M_D)_:EY_SWF_[^/_ (T?7\9_T$U__!M3_P"2']6H?\^J?_@$?\A/[4O/^>\W
M_?Q_\:7U_&?]!-?_ ,&U/_DA_5J'_/JG_P" 1_R$_M2\_P">\W_?Q_\ &E_:
M&,_Z":__ (-J?_)!]6H?\^J?_@$?\A/[4O/^>\W_ '\?_&E_:&,_Z":__@VI
M_P#)#^K4/^?5/_P"/^0G]J7G_/>;_OX_^-']H8S_ *":_P#X-J?_ "0_JU#_
M )]4_P#P"/\ D6;77[VU8-YK2 =5<E@?SR1^!KLP^<8W#24O;3FNL:C<T_\
MP*[7JF85,#AZJMR*+Z.*46ONT/3M+U%-3@$R<'HR_P!UAU'^'M7Z_@,;#,*$
M<13T>TH_RR6Z_5=T?$8FA+"U'2EZI]UW-"O4.,* "@ H * "@ H * "@"AJO
M_'G/_P!<9?\ T!J\W,/]SQ/_ %XK?^FY'7AOX]+_ *^0_P#2D7Z](Y"A)_Q^
M1?\ 7&?_ -#MZ\V?^^4?^O&(_P#3F%.N/\"?_7RE_P"DUB_7I'(% !0 4 %
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MM+F_#E/DLXMS4K;VE?TNK?J=Q7Z(?+A0 4 % !0 4 % !0 4 4-5_P"/.?\
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M/^%'U7$?\^:O_@N7^0>TA_-'[U_F)]EF_N/_ -\G_"E]4Q'_ #YJ_P#@N?\
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M ,%S_P @]K3_ )X_^!+_ #$^R3_\\W_[Y;_"CZIB?^?-7_P7/_(?M:?\\?\
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MG_\ (C]M2_GA_P"!+_,3[#<?\\I/^^&_PI?4L3_SXK?^"Y__ "(_;4OYX?\
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M ];_ ,%3_P#D1^WI?\_(?^!1_P Q/[/NO^>,O_?MO\*7U'%?] ];_P %3_\
MD0]O2_Y^0_\  X_YA_9]U_SQE_[]M_A2^HXK_H'K?^"I_P#R(_;T?^?D/_ X
M_P"8G]G77_/&7_OVW^%'U'%?] ];_P %3_\ D1^WH_\ /R'_ (''_,3^SKK_
M )XR_P#?MO\ "E]1Q?\ T#UO_!4__D0]O1_Y^0_\#C_F)_9UU_SQE_[]O_A2
M^HXO_H'K?^"I_P#R(_;T?^?D/_ X_P"8G]G77_/&7_OV_P#A1]1Q?_0/6_\
M!4__ )$?UBC_ ,_(?^!Q_P Q/[.NO^>,O_?M_P#"E]1Q?_0/6_\ !4__ )$/
MK%'_ )^0_P# X_YB?V;=?\\9?^_;_P"%+ZCB_P#H'K?^"I__ "(_K%'_ )^0
M_P# X_YB?V;=?\\9?^_;_P"%+ZCB_P#H'K?^"I__ "(_K%'_ )^4_P#P./\
MF)_9MU_SQE_[]O\ X4?4,7_T#UO_  5/_P"1#ZQ1_P"?E/\ \#C_ )B?V;=_
M\\9?^_;_ .%+ZAB_^@>M_P""I_\ R(_K%'_G[3_\#C_F)_9MW_SQE_[]O_A2
M^H8O_H'K_P#@JI_\B/ZQ1_Y^T_\ P./^8G]F7?\ SPE_[]O_ /$T?4,7_P!
M]?\ \%5/_D1_6*/_ #]I_P#@<?\ ,3^S+O\ YX3?]^W_ /B:7U#%_P#0/7_\
M%5/_ )$/K%'_ )^T_P#P./\ F)_9EW_SPF_[]O\ _$TOJ&+_ .@>O_X*J?\
MR(_K%'_G[3_\#C_F)_9EW_SPF_[]O_\ $TOJ&+_Z!J__ (*J?_(C^L4?^?M/
M_P #C_F)_9EW_P \)O\ OV__ ,31]0Q?_0-7_P#!53_Y$/K%'_G[3_\  X_Y
MB?V9=_\ /";_ +]O_P#$TOJ&+_Z!J_\ X*J?_(C^LT/^?M/_ ,#C_F)_9=W_
M ,\)O^_;_P#Q-+ZAC/\ H&K_ /@JI_\ (C^LT/\ G[3_ / X_P"8G]EWG_/"
M;_OV_P#\31]0QG_0-7_\%5/_ )$/K-#_ )^T_P#P./\ F']EWG_/";_OV_\
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M[;NV]VWU+244DM$M$NR0^D,* "@ H * "@ H * "@ H * *$G_'Y%_UQG_\
M0[>O-G_OE'_KQB/_ $YA3KC_  )_]?*7_I-8OUZ1R!0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % %"/_ (_)?^N,'_H=Q7FP_P!\K?\ 7C#_ /IS%'7+^!3_
M .OE7_TFB7Z](Y H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M % %"/\ X_)?^N,'_H=Q7FP_WRM_UXP__IS%'7+^!3_Z^5?_ $FB7Z](Y H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MQMO1G#RL)'1ONO(&=1A00H H O3Z;;W,@EE3<XV '<P_U;^8G ('#@,>/FP
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MRK[X^;"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * *&J_P#'G/\ ]<9?_0&KS<P_W/$_]>*W_IN1UX;^/2_Z^0_]*1?KTCD*
M$G_'Y%_UQG_]#MZ\V?\ OE'_ *\8C_TYA3KC_ G_ -?*7_I-8OUZ1R!0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MA4GK+E:N^O+*45^$4?G>-@J>(J1CM=/[TG^IKU[AYP4 % !0 4 % !0 4 %
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MTWJKE**5DDERWY;+:^]NU^MM^IS^M^#;34M-.C6:Q:?:2RQO,D$"*)$1U=T
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M "@ H * "@ H * "@"A)_P ?D7_7&?\ ]#MZ\V?^^4?^O&(_].84ZX_P)_\
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M][_S#[+#_P \T_[Y7_"E]4P__/FE_P""X?Y![2?\\O\ P)_YA]DA_P">:?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!0U7_
M (\Y_P#KC+_Z U>;F'^YXG_KQ6_]-R.O#?QZ7_7R'_I2+]>D<A0D_P"/R+_K
MC/\ ^AV]>;/_ 'RC_P!>,1_Z<PIUQ_@3_P"OE+_TFL7Z](Y H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H H2?\ 'Y%_UQG_ /0[>O-G_OE'_KQB/_3F%.N/\"?_ %\I?^DUB_7I
M'(% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 4(_^/R7_KC!_P"AW%>;#_?*
MW_7C#_\ IS%'7+^!3_Z^5?\ TFB7Z](Y H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@"AJO_'G/_P!<
M9?\ T!J\W,/]SQ/_ %XK?^FY'7AOX]+_ *^0_P#2D7Z](Y"A)_Q^1?\ 7&?_
M -#MZ\V?^^4?^O&(_P#3F%.N/\"?_7RE_P"DUB_7I'(% !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% %"3_C\B_ZXS_\ H=O7FS_WRC_UXQ'_ *<PIUQ_@3_Z^4O_ $FL7Z](Y H
M* "@ H * "@ H * "@ H * "@ H * "@"A'_ ,?DO_7&#_T.XKS8?[Y6_P"O
M&'_].8HZY?P*?_7RK_Z31+]>D<@4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MX0_]^D_^)H_L_!_] U#_ ,$T_P#Y$/K-?_G[4_\  Y?YA_95G_SPA_[])_\
M$T?V?@_^@:A_X)I__(A]9K_\_:G_ ('+_,/[*L_^>$/_ 'Z3_P")H_L_!_\
M0-0_\$T__D0^LU_^?M3_ ,#E_F']E6?_ #PA_P"_2?\ Q-']GX/_ *!J'_@F
MG_\ (A]9K_\ /VI_X'+_ ##^RK/_ )X0_P#?I/\ XFC^S\'_ - U#_P33_\
MD0^LU_\ G[4_\#E_F']E6?\ SPA_[])_\31_9^#_ .@:A_X)I_\ R(?6:_\
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M .1#ZS7_ .?M3_P.7^8?V59_\\(?^_2?_$T?V?@_^@:A_P"":?\ \B'UFO\
M\_:G_@<O\P_LJS_YX0_]^D_^)H_L_!_] U#_ ,$T_P#Y$/K-?_G[4_\  Y?Y
MA_95G_SPA_[])_\ $T?V?@_^@:A_X)I__(A]9K_\_:G_ ('+_,/[*L_^>$/_
M 'Z3_P")H_L_!_\ 0-0_\$T__D0^LU_^?M3_ ,#E_F']E6?_ #PA_P"_2?\
MQ-']GX/_ *!J'_@FG_\ (A]9K_\ /VI_X'+_ ##^RK/_ )X0_P#?I/\ XFC^
MS\'_ - U#_P33_\ D0^LU_\ G[4_\#E_F']E6?\ SPA_[])_\31_9^#_ .@:
MA_X)I_\ R(?6:_\ S]J?^!R_S#^RK/\ YX0_]^D_^)H_L_!_] U#_P $T_\
MY$/K-?\ Y^U/_ Y?YA_95G_SPA_[])_\31_9^#_Z!J'_ ()I_P#R(?6:_P#S
M]J?^!R_S#^RK/_GA#_WZ3_XFC^S\'_T#4/\ P33_ /D0^LU_^?M3_P #E_F'
M]E6?_/"'_OTG_P 31_9^#_Z!J'_@FG_\B'UFO_S]J?\ @<O\P_LJS_YX0_\
M?I/_ (FC^S\'_P! U#_P33_^1#ZS7_Y^U/\ P.7^8?V59_\ /"'_ +])_P#$
MT?V?@_\ H&H?^":?_P B'UFO_P _:G_@<O\ ,/[*L_\ GA#_ -^D_P#B:/[/
MP?\ T#4/_!-/_P"1#ZS7_P"?M3_P.7^92CTVT^UR+Y,6T10D#RTP"7G!(&,9
M( R>^!Z"O/A@<(\75@\/1Y51H-+V4+)N>)3:7+9-J,4WULK[(Z98BLJ,)>UJ
M7=2HF^>5[*-*RO?97=O5]R[_ &59_P#/"'_OTG_Q->A_9^#_ .@:A_X)I_\
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M\$T__D0^LU_^?M3_ ,#E_F']E6?_ #PA_P"_2?\ Q-']GX/_ *!J'_@FG_\
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MK_\ /VI_X'+_ ##^RK/_ )X0_P#?I/\ XFC^S\'_ - U#_P33_\ D0^LU_\
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MLU_^?M3_ ,#E_F']E6?_ #PA_P"_2?\ Q-']GX/_ *!J'_@FG_\ (A]9K_\
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MF']E6?\ SPA_[])_\31_9^#_ .@:A_X)I_\ R(?6:_\ S]J?^!R_S#^RK/\
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MO2.0* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M+\_][:UM+7N*=_;5EVJRYNR?+"W+Y=[GK5(H* "@ H * *$G_'Y%_P!<9_\
MT.WKS9_[Y1_Z\8C_ -.84ZX_P)_]?*7_ *36+]>D<@4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0!0C_ ./R7_KC!_Z'<5YL/]\K?]>,/_Z<Q1UR_@4_^OE7
M_P!)HE^O2.0* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M#6-"+B\4I;V@_E*.&:_!HNM)26&<=KS7S3Q"?XIFI\/6%]XJ\17\/_'OYT,
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M_P *G^T\7_S\_P#)(?\ R(_84_Y?Q?\ F']H3_WOT7_"C^T\7_S\_P#)(?\
MR(_84_Y?Q?\ F)_:$_\ >_1?\*7]IXO_ )^?^20_^1#V%/\ E_%_YB?VC<?W
MO_'5_P *7]IXO_GY_P"20_\ D1_5Z?\ +^+_ ,Q/[1N/[W_CJ_X4?VGB_P#G
MY_Y)3_\ D1_5Z?\ +^+_ ,Q/[1N/[_\ XZO^%+^T\7_S]_\ )*?_ ,B'U>E_
M+^+_ ,P_M*X_O_\ CJ_X4O[4Q?\ S]_\DI__ "(_J]+^7\7_ )B?VE<?W_\
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M7]JXS_G[_P"24_\ Y ?U:E_+^,O\Q/[5NO[_ /XZO_Q-+^U<9_S]_P#)*?\
M\@/ZK1_E_&7^8?VK=?W_ /QU?_B:/[5QG_/W_P DI_\ R ?5:/\ +^,O\Q/[
M6NO[_P#XZO\ \32_M;&?\_?_ "2G_P#(#^JT?Y?QE_F)_:UU_?\ _'4_^)H_
MM;&_\_?_ "2G_P#(!]5H_P OXR_S$_M>Z_O_ /CJ?_$TO[6QO_/W_P DI_\
MR _JM'^7\9?YB?VO=?W_ /QU/_B:7]K8W_G[_P"24_\ Y /JM'^7\9?YA_:]
MW_?_ /'4_P#B:/[6QO\ S]_\DI__ " _JM'^7\9?YB?VQ=_W_P#QU/\ XFE_
M:V-_Y^_^24__ ) ?U2C_ "_C+_,3^V+O^_\ ^.I_\32_M?&_\_?_ "2G_P#(
M!]4H_P G_DTO\Q/[8N_^>G_CJ?\ Q-']KXW_ )^_^24__D!_5*/\G_DTO\Q/
M[9N_^>G_ (ZG_P 32_M?&_\ /W_R2G_\@'U2C_)_Y-+_ ##^V;O_ )Z?^.I_
M\31_:^-_Y^_^24__ ) ?U2C_ "?^32_S$_MF[_YZ?^.I_P#$TO[7QO\ S]_\
MDI__ " _JE#^3_R:7^8G]M7G_/3_ ,=3_P")I?VOC?\ G[_Y)3_^0#ZG0_D_
M\FE_F)_;5Y_ST_\ '4_^)H_M?'?\_?\ R2G_ /(#^IT/Y/\ R:7^8G]M7G_/
M3_QU/_B:7]L8[_G[_P"24_\ Y /J=#^3_P FE_\ )"?VW>?\]/\ QU/_ (FC
M^V,=_P _O_)*?_R _J=#^3_R:7_R0?VW>?\ /3_QU/\ XFE_;&._Y_?^24__
M ) /J=#^3_R:7_R0G]MWG_/3_P =3_XFE_;&._Y_?^4Z?_R _J=#^3_R:7_R
M0G]N7O\ ST_\<3_XFC^V,=_S^_\ *=/_ .0']3H?R?\ DTO_ )(3^W+W_GI_
MXXG_ ,32_MC'?\_O_*=/_P"0#ZE0_D_\FE_\D)_;E[_ST_\ '$_^)I?VSCO^
M?W_E.E_\@/ZE0_D_\FE_\D']NWO_ #T_\<3_ .)H_MG'?\_O_*=+_P"0#ZE0
M_D_\FE_\D)_;M[_ST_\ '$_^)I?VSCO^?W_E.E_\@/ZEA_Y/_)I?_)"?V[>_
M\]/_ !Q/_B:/[9Q__/[_ ,ITO_D ^I8?^3_R:7_R0G]O7W_/3_QQ/_B:7]LX
M_P#Y_?\ E.E_\@/ZEA_Y/_)I?_)"?V]??\]/_'$_^)I?VSC_ /G]_P"4Z7_R
M _J.'_D_\FE_\D']O7W_ #T_\<3_ .)H_MK'_P#/[_RG2_\ D ^HX?\ D_\
M)I?_ "0G]OWW_/3_ ,<C_P#B:7]M8_\ Y_?^4Z7_ ,@/ZCA_Y/\ R:?_ ,D)
M_;]]_P ]?_'(_P#XBC^VL?\ \_O_ "G2_P#D ^HX?^3_ ,FG_P#)"?\ "07W
M_/7_ ,<C_P#B*7]M8_\ Y_?^4Z7_ ,@/ZCA_Y/\ R:?_ ,D)_P )!??\]?\
MQR/_ .(I?VUC_P#G]_Y3I?\ R _J.'_D_P#)I_\ R0?\)!?_ //7_P <C_\
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MNHH!+').5:JZJBVFDKI=;K3KU?=]QI6/2JXRSG;W_C\;_KC%_P"ASU\%FO\
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MAC:0Q*0Q*0"4#$I#$I#$I )2&)0,2D,2D E(8E(8VD,2@8E(!*0Q*0Q*0Q*
M$I#/0?!4C&.:,_=5D(^K!L_^@BOT_A><G3KTG\,90:]9*2?_ *2CY'-XI2IS
M6[4D_1-6_-G;5^AGS 4 % !0 4 % !0 4 % %#5?^/.?_KC+_P"@-7FYA_N>
M)_Z\5O\ TW(Z\-_'I?\ 7R'_ *4B_7I'(4)/^/R+_KC/_P"AV]>;/_?*/_7C
M$?\ IS"G7'^!/_KY2_\ 2:Q?KTCD"@ H YU)KW4TDGMI4MT1W2%6C#[S&Q1F
MF)((1G4@+'L8+ABY)VJ 49=1O%AFOTD7;%/Y4<&Q2D@5DB8!AMDWO+O"-N('
MRY0\B@"U*MW)>LEK=2;8P6D5TMVB1G4^7$ L22D\B0YFW! H)_> @ AL-2F@
MMKRYN'DD6V+!1.D23*R1AF5A"J1[6)4Q]6(.2QR, &7#XAO8TECG*&20".T8
M*!NE1TMY@1T.)VW@?W"1VH MGQ&_V<M\X>2Y*1N87$8A60AFWE?+;]S')(#N
M/7VH H#7KYUW!V615MU"^3F$S3X<K-)M^1462)>)%?.3AB0" ::WMW>?9VCF
M:+[5//@*D1 MX_,*O\Z,<D+'@YQ^\Y!XH 634+TV)U2.154 -%"4#>:FX*HD
M;(/F2\%1&$6-F"E9,<@$6F:U<:C=[(79AYLGF1-"42.V!D2*1)2B[VD=!@J\
MBL"W"[20 6[O4[BWO#',_P!EB#CRMT6^*>-8]\N9@3LE&'V*3'@)G;("< &4
MOB>[.F[]B?VB[E%3!V(&9/+=QG. LL0QGYI& X&2 #2'B!C?B(-']D59D9N-
M[30J'=ASQ&HWIR.65N< 9 +5G?W,QLHW($D\3W$PVCA J[4]B'E09ZG8?4T
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M.&.<Y)/I4RGS)1LDHWM:_7U;"UC:K,9SM[_Q^-_UQB_]#GKX+-?]\_[@4O\
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MRE_Z36+]>D<@4 % &3_8=GYIFV-DOYA3S9?)WYW;_(W^3NW?/N\O._Y\[N:
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M !0 4 % !0 4 4)/^/R+_KC/_P"AV]>;/_?*/_7C$?\ IS"G7'^!/_KY2_\
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MU7#_ //FG_X!'_(/:3_FE][#[-%_<3_OD?X4?5</_P ^:?\ X+C_ )![2?\
M-+[V'V:+^XG_ 'R/\*/JN'_Y\TO_  7'_(?M)_S2^]A]FB_N)_WR/\*/JN'_
M .?-+_P7'_(/:3_FE][#[-%_<3_OD?X4?5</_P ^:7_@N/\ D'M)_P TOO8?
M9H?[B?\ ?(_PH^JX?_GS2_\ !</\@]I/^:7WO_,3[+#_ '$_[Y'^%'U3#_\
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M_P "?^8?9(/^>:?]\K_A1]4PW_/FE_X+A_D'M:G\\O\ P)_YA]D@_P">:?\
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M3_S#[#;_ //*/_OA?\*/J6%_Y\4?_!</_D0]M5_Y^3_\"E_F'V&W_P">4?\
MWPO^%'U+"_\ /BC_ ."X?_(A[:K_ ,_)_P#@4O\ ,/L%M_SRC_[X7_"CZEA?
M^?%'_P %0_\ D1^VJ_\ /R?_ (%+_,/L%M_SRC_[X7_"CZEA?^?%'_P5#_Y$
M/;U?^?D__ I?YA]@MO\ GE'_ -\+_A1]2PO_ #XH_P#@J'_R(>WJ_P#/R?\
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MPO\ T#T?_!4/_D1^WK?\_)_^!R_S#^SK7_GC%_W[3_"CZCA/^@>C_P""H?\
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M$_LRT_YX0_\ ?M/\*/J&$_Z!J'_@JG_\B'UFM_S]J?\ @<O\P_LRT_YX0_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@"A)_Q^1?\ 7&?_ -#MZ\V?^^4?^O&(_P#3F%.N/\"?
M_7RE_P"DUB_7I'(% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 4(_P#C\E_Z
MXP?^AW%>;#_?*W_7C#_^G,4=<OX%/_KY5_\ 2:)?KTCD"@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M*&J_\><__7&7_P! :O-S#_<\3_UXK?\ IN1UX;^/2_Z^0_\ 2D7Z](Y"A)_Q
M^1?]<9__ $.WKS9_[Y1_Z\8C_P!.84ZX_P "?_7RE_Z36+]>D<@4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 4)/^/R+_KC/_Z';UYL_P#?*/\ UXQ'_IS"G7'^!/\ Z^4O_2:Q
M?KTCD"@ H * "@ H * "@ H * "@ H * "@ H * *$?_ !^2_P#7&#_T.XKS
M8?[Y6_Z\8?\ ].8HZY?P*?\ U\J_^DT2_7I'(% !0 4 % !0 4 % !0 4 %
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M8O[TW_@1<?\ QVCZC2_FK_\ A5B?_EP?6)]J?_@FE_\ (!_9L7]Z;_P(N/\
MX[1]1I?S5_\ PJQ/_P N#ZQ/M3_\$TO_ ) /[-B_O3?^!%Q_\=H^HTOYJ_\
MX58G_P"7!]8GVI_^":7_ ,@']FQ?WIO_  (N/_CM'U&E_-7_ /"K$_\ RX/K
M$^U/_P $TO\ Y /[-B_O3?\ @1<?_':/J-+^:O\ ^%6)_P#EP?6)]J?_ ()I
M?_(!_9L7]Z;_ ,"+C_X[1]1I?S5__"K$_P#RX/K$^U/_ ,$TO_D _LV+^]-_
MX$7'_P =H^HTOYJ__A5B?_EP?6)]J?\ X)I?_(!_9L7]Z;_P(N/_ ([1]1I?
MS5__  JQ/_RX/K$^U/\ \$TO_D _LV+^]-_X$7'_ ,=H^HTOYJ__ (58G_Y<
M'UB?:G_X)I?_ " ?V;%_>F_\"+C_ ..T?4:7\U?_ ,*L3_\ +@^L3[4__!-+
M_P"0#^S8O[TW_@1<?_':/J-+^:O_ .%6)_\ EP?6)]J?_@FE_P#(!_9L7]Z;
M_P "+C_X[1]1I?S5_P#PJQ/_ ,N#ZQ/M3_\ !-+_ .0#^S8O[TW_ ($7'_QV
MCZC2_FK_ /A5B?\ Y<'UB?:G_P"":7_R ?V;%_>F_P# BX_^.T?4:7\U?_PJ
MQ/\ \N#ZQ/M3_P#!-+_Y /[-B_O3?^!%Q_\ ':/J-+^:O_X58G_Y<'UB?:G_
M .":7_R ?V;%_>F_\"+C_P".T?4:7\U?_P *L3_\N#ZQ/M3_ /!-+_Y /[-B
M_O3?^!%Q_P#':/J-+^:O_P"%6)_^7!]8GVI_^":7_P @']FQ?WIO_ BX_P#C
MM'U&E_-7_P#"K$__ "X/K$^U/_P32_\ D _LV+^]-_X$7'_QVCZC2_FK_P#A
M5B?_ )<'UB?:G_X)I?\ R ?V;%_>F_\  BX_^.T?4:7\U?\ \*L3_P#+@^L3
M[4__  32_P#D _LV+^]-_P"!%Q_\=H^HTOYJ_P#X58G_ .7!]8GVI_\ @FE_
M\@']FQ?WIO\ P(N/_CM'U&E_-7_\*L3_ /+@^L3[4_\ P32_^0#^S8O[TW_@
M1<?_ !VCZC2_FK_^%6)_^7!]8GVI_P#@FE_\@']FQ?WIO_ BX_\ CM'U&E_-
M7_\ "K$__+@^L3[4_P#P32_^0#^S8O[TW_@1<?\ QVCZC2_FK_\ A5B?_EP?
M6)]J?_@FE_\ (!_9L7]Z;_P(N/\ X[1]1I?S5_\ PJQ/_P N#ZQ/M3_\$TO_
M ) /[-B_O3?^!%Q_\=H^HTOYJ_\ X58G_P"7!]8GVI_^":7_ ,@']FQ?WIO_
M  (N/_CM'U&E_-7_ /"K$_\ RX/K$^U/_P $TO\ Y /[-B_O3?\ @1<?_':/
MJ-+^:O\ ^%6)_P#EP?6)]J?_ ()I?_(!_9L7]Z;_ ,"+C_X[1]1I?S5__"K$
M_P#RX/K$^U/_ ,$TO_D _LV+^]-_X$7'_P =H^HTOYJ__A5B?_EP?6)]J?\
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MQ?WIO_ BX_\ CM'U&E_-7_\ "K$__+@^L3[4_P#P32_^0#^S8O[TW_@1<?\
MQVCZC2_FK_\ A5B?_EP?6)]J?_@FE_\ (!_9L7]Z;_P(N/\ X[1]1I?S5_\
MPJQ/_P N#ZQ/M3_\$TO_ ) /[-B_O3?^!%Q_\=H^HTOYJ_\ X58G_P"7!]8G
MVI_^":7_ ,@']FQ?WIO_  (N/_CM'U&E_-7_ /"K$_\ RX/K$^U/_P $TO\
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M _LV+^]-_P"!%Q_\=H^HTOYJ_P#X58G_ .7!]8GVI_\ @FE_\@']FQ?WIO\
MP(N/_CM'U&E_-7_\*L3_ /+@^L3[4_\ P32_^0#^S8O[TW_@1<?_ !VCZC2_
MFK_^%6)_^7!]8GVI_P#@FE_\@']FQ?WIO_ BX_\ CM'U&E_-7_\ "K$__+@^
ML3[4_P#P32_^0#^S8O[TW_@1<?\ QVCZC2_FK_\ A5B?_EP?6)]J?_@FE_\
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M^S8O[TW_ ($7'_QVCZC2_FK_ /A5B?\ Y<'UB?:G_P"":7_R ?V;%_>F_P#
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M .7!]8GVI_\ @FE_\@']FQ?WIO\ P(N/_CM'U&E_-7_\*L3_ /+@^L3[4_\
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M_P#PJQ/_ ,N#ZQ/M3_\ !-+_ .0#^S8O[TW_ ($7'_QVCZC2_FK_ /A5B?\
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M %QG_P#0[>O-G_OE'_KQB/\ TYA3KC_ G_U\I?\ I-8OUZ1R!0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % %"/\ X_)?^N,'_H=Q7FP_WRM_UXP__IS%'7+^
M!3_Z^5?_ $FB7Z](Y H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@"AJO_'G/_UQE_\ 0&KS<P_W/$_]
M>*W_ *;D=>&_CTO^OD/_ $I%^O2.0H2?\?D7_7&?_P!#MZ\V?^^4?^O&(_\
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MB<W!+^\DVU?_ +=>H0_>1]I#X>52^3:2_P#2D5[?QSI-SJY\/I*POPH?848
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M2_7I'(% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 4-5_X\Y_\ KC+_ .@-7FYA_N>)_P"O%;_TW(Z\
M-_'I?]?(?^E(OUZ1R%"3_C\B_P"N,_\ Z';UYL_]\H_]>,1_Z<PIUQ_@3_Z^
M4O\ TFL7Z](Y H * /EKP3XGT/1+/7K?6Y8@)KZX(MW&]YE(*X6/!W9;@'@
M\D@#(YE[V!I0CK/E=DMTW3I\K\M5H]+-;FSO'&59O2-UJ]M)U.9>>CU6MT]C
MDK"QN-&TWP]J>N1NVC0WMQ(R,I98XY6C:)W3!)1RKR*,'>H( .\ ^A=4Z]/V
MKM+V#BF^E2]5K7HTI4GW7+_<=N1IU*57V6WME)K^:"C3C\TG&I'6RO):^]<]
M$\7ZUIWB_P 1Z''X<=;J\MK@2S3P@XCME9&*N^ "  YV\[<E3@O@Y48M5W4V
M@J<U-])-JR5_1N-^KFDFVM+JM>P]G]J4H^S76+L];=->67=*#DTK*_FN@:C-
MX-U&Z\5QAI8(]2N[&YB7NDJF2(^V)5R23U"@=:YZ$G3PU./_ #]I.,;[*I3A
M3E"_KS-::J"G;L;5H^TKU.GLZD9/_!.=2$W\DE9=9-7V.E^'FBR)XIC_ +2S
M)-J^DS7ERK=S=R,2N#R/W97(/0DUT0I*,,3A-;0IQIM];_N'+YJ4FK^5S"=1
MRG0Q*T<JDIQ71*/MHQM_=:BFO)I&*)+LP#X9Y;S1K!0OCC['GS<_]]9G^E*D
M_K+P\ZBTI*I[5>=.ZM?T=2"Z+EAKJBZO^S>W]G_R\]G[.^O\2UO2UJ5_\4M7
M;3OOBA?13ZUI?AV*UN+^RTY5N[FULXC-(R*-D4?EC VJHPV2 $E'<@'.+]M6
MJ5:B;48RC==)U%S-OM:]-I][JPW'V-&%*#2<G&U]^2&FG=NT].\4]CE-#U5H
M?".O^'9TFMWL,RPQ7"&.9;>:12%>,\JRG#,.F91@D$&IK-SPU.<FG*%2E3FU
MM?VL6OQYXVZ**3+IVCB*BBFHSA5G%/=6IR3^7*X6[ZLY77K&^\*>&XHHLRZ3
MX@M[6?D_\>]Y'Y<D@'M*JD@<;AQ_RR.[6MI45"7V)>TIO^[*#C*/R<T_)6:U
ME*V=/6$JT=WS4YK_  U+PDO51:];WTY#T'QMJJ:KJ.BZ*UK<ZE:Z?:PWEY;V
M<1GD<O$HC5HP0-JC;N+$#;-CJ0#I42GB<3-I\L74I)KI.=[N^RM[KB]7S0:T
MU9G3O#"T(Q:4I^SGKUC"RLO5>T37:ST.7M]6=?!&L>'[A)89=-N(7CBG0QS+
M!-<QLJNAY5E<,S#H/,7!(P:PJ-U*>'J-IRC/V<^7574)M:_^!02Z*%O(WIVA
M6K1BFHSA*<4][>ZFO2W(_-R;NSM/B'K5AJ?@6WALKB"XEMQIZRI%(CM&?+(P
MZJ25.588;'(([5OB/>Q4)QUB\3*S6SO"JUKZ:F>%]V@X/27L(:/1Z3I)Z>3W
M.-\0PW%OXKU#6K/)FT6.QO-H_CC$=M'*I]MCDM_L!JFG)4G.M+X?K,Z<_P#!
M5E63MYW44NU[]".7VL*5%:-X53B^TZ?LY)OR2YG;JTEM<DBFEU[Q-I7BF4,B
MZKJLB6Z-_#;6I@CB[D DLX;!QN4D=:K#Q]C/EG\4J-:K/RYHU$EZ*,59O>#B
M%:7M82DM(TZF&IQ7GS<TWZ-M/R?,BGXGNO\ A,]0UK4%LK^^4!;33Y[6W::&
M VSJSM)("-F\+N^4,0DSDC!&>2%X4E67NSE45;F?NI02<;7[\EK[)3@FWO;K
MG_%5+>,*<H.*UESO5/T4^=><=+,V_%7B1O$5IX5U);A+.?S94EN9 K+!-$UL
MCRNKD(5#+YF&(!4C) KL>F*E.+45.BY+LN95+Q7SYJ:?<Y(?[M.FTY.%2G&W
M712Y6[=>5QD_F=;\,[M)?%VJ":XCUBZDMHV_M* *D)1?*4Q>5&/+#$E/F5VS
MY1&<EJ5+^#-)<MJJ;Z\U^=IJ^JL^;2VMWTC%MU/XE-M\WN-)+>.MW?OLE?=7
M2^TTM[0R(?B-JJS</+80-"3W15MPP7K_ !#G!'W2<>F=#^#6C]I5HM^EIV^5
MI0^]>A=;2=!_9]E-+_%SM_?:,WY+3UY+PCXDT;0-6\3+K<T444U\^(I!N,JB
M2Y#JL>&+_> *@'KS6<'%X.G!KF=YWBM]8P2]+M.SNK;W6YI436(YEI^ZI:[)
M/E3//;?3[BUT+3]4O(9#H2:T]P\+*2/LS^0J.4Y_=G9,@SPQ; /S@G:'[J>&
M^L.\E1E'FZ1DWS*ZZW?[Q*UW%/36QE/]Y'$_5UHY1:2TNH^T4K>B<(M]&O[K
MMZ-\0]?TKQA<Z/9>&Y$N]26\BDCD@4Y@A')#-M&P A7*'E!&68+QET4_K4*C
M^&*;J.^C7-%ZO[6G,NOQ<JUE9S5:^K3@MY64%LTVI+1=-;*SM?1[1NN%AN)?
M#GB35/%40=X]-UAHKF-?XK>ZDN$<\\9#*H4$@;F7TS6-"7LJ-)O6-55:;7]Z
M,83I^BO=R?\ =2ZV>]>/M)N*TE"%&HO2RC)>K32\DY/R-?P3;3OXPTS6+S(N
M-:BO;YE/\"2"X6)1_L^6JE?]E@.U=%&'L55H7NXT*;D^\YU(RD_)ZJZ_FN85
MI>U4:RT3KRA%=H4X1BK^:?,K]4D_-^F>&R)?B%K,D'^K2SMTE(Z>;M@Q^("L
M.W(-94/X%5]'75OE[52_\FYOO+K?Q**^TJ4[^CE%K\'!KR^X['P/I-YI)U,7
ML?E"YU:[N(/F5M\,NPH_RLV-Q!^5MK#'*BG'2C1@_BC!IKL^>3_)]!SUJRDO
MA<:>OG&"C)?*R.ZI""@ H * "@ H * *$G_'Y%_UQG_]#MZ\V?\ OE'_ *\8
MC_TYA3KC_ G_ -?*7_I-8OUZ1R%*XU.TLV\NXGAA?&=KR(AP>^&(..#S[52B
MWLG]PFTMVB:WNH;M=]O(DJ@XW(RL,^F5)&?:DTUHU8$T]B>D,"<<F@#!O_$5
MK9?*A\Z3^ZAR/Q;H/H,GVKHA1E+5Z+N_\CSJN,ITM$^>7:/ZO;\WY&0^I:EJ
M _=6Q5>V6E3_ ,>5XL_RK?DIPWGKZ)_A9G$ZV(K?!2:736<?Q4H7)$MM1_Y:
M1RK[Q79R/^ R22 _G^-)NGT:^</\DAJ&(^U&:_PUGI\I2DG]X\0:M -\$C2
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MF_\ BJ7]N8G^2E_X#/\ ^3#ZE3[R^]?_ "(G]O3_ -V/\F_^*H_MW$_R4O\
MP&?_ ,F/ZE3[R^]?_(B?V]/_ '8_R;_XJE_;N)_DI?\ @,__ )8'U*GWE]Z_
M^1#^WI_[L?Y-_P#%4?V[B?Y*7_@,_P#Y8/ZC3[S^]?\ R(G]OW']V/\ )O\
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M?V?2_FG]\?\ Y$/^$EN?[L7Y-_\ %T?ZP8K^2C_X#/\ ^6#_ +.I?S3^^/\
M\B)_PDUS_=B_)O\ XNE_K!BOY*/_ (#/_P"6!_9U+^:?WQ_^1$_X2:Y_NQ?D
MW_Q='^L.*_DH_P#@,_\ Y8/^SJ7\T_OC_P#(A_PD]S_=B_)O_BZ7^L.*_DH_
M^ S_ /E@?V=2_FG]\?\ Y$3_ (2>Z_NQ?DW_ ,71_K#BOY*/_@,__E@_[.I?
MS3^^/_R(G_"3W7]V+_OE_P#XNE_K#BOY*/\ X#/_ .6!_9M'^:?WQ_\ D0_X
M2BZ_NQ?]\O\ _%T?ZPXK^2C_ . S_P#E@_[-H_S3^^/_ ,B)_P )1=?W8O\
MOE__ (NE_K%B_P"2C_X#/_Y8']FT?YI_?'_Y$3_A*;K^Y%_WR_\ \71_K%B_
MY*/_ (#/_P"6#_LVC_-/[X__ "(?\)3=?W(O^^7_ /BZ7^L6+_DH_P#@,_\
MY8']F4?YI_?'_P"1$_X2JZ_N1?\ ?+__ !='^L6+_DH_^ S_ /E@_P"S*/\
M-/[X_P#R(G_"577]R+_OE_\ XNE_K'B_Y*/_ (#/_P"6!_9E'^:?WQ_^1#_A
M*[K^Y%_WR_\ \71_K'B_Y*/_ (#/_P"6#_LRC_-4^^/_ ,B)_P )7=_W(O\
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MQ?\ S[H?^ U/_E@_[*H?S5/OC_\ (!_PE]Y_<A_[Y?\ ^.4?ZRXS_GW0_P#
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MUKOE=U9]S\5]8TXRPR_V7>.+6VECDM#*T*27,Z1#SBTQPL:MDJ"I8E#YBA\
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MP?,55+3-Y:Y0CC).#P :27-[ PDNTA6 J2_ELQ:$CH#D#S0>A*JA4X^5AD@
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MLWF2HA(=E*C:G0F/(?S!@GR\\ !)K5RB2WBK&UK%/Y6WYEE(#K&SALE2PD+
M1[!NV_?!- %BUU:6ZN'LU11)!*XF/.U(AAHC_P!=)59=HS@8=CP & .@H *
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M#%6?C&]<D% JGRNC^YNHJ6O-O>VGD.',JO[RW-RZ6VM?[SWNO/.TY30-"OM
MT^WTR.Y@D2TB6)7:UD!8*, D"[P"?:MYSC.3FTU=W^)?_(DI6T+>E:++87MW
M?SRK*]]Y&52(QJ@@1D'664MNW9/(QZ&IE-.,8)6Y;];[_)#M;4Z"LAG.WO\
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M1")/N,<;!]@.%8@?+NP,D*<,H! W $YP* *5KH%M:2F:/?@F5MC$% 95C5\
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MLTM6E=22T\GF,6QUVJ@ P!\H5!@')Z\T 6J "@ H * "@ H * "@ H * "@
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M_P#/O_R>?_R0>WJ?S?@O\@^P0?W?U;_&C^S<)_S[_P#)Y_\ R0>WJ?S?@O\
M(3[!!_=_5O\ &C^S,)_S[_\ )Y__ "0_;U/YOP7^0?V?!_=_5O\ &C^S,)_S
M[_\ )Y__ "0>WJ?S?@O\@_L^#^[^K?XT?V9A/^??_D\__D@]O4_F_!?Y!_9T
M']W]6_QI?V9A/^??_D\__D@]O4_F_!?Y"?V=;_W?U;_&C^S,)_S[_P#)Y_\
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M^R[;^Y_X\W^-+^R\'_SZ_P#)ZG_R0?6:O\WX1_R#^R[;^Y_X\W_Q5']E8/\
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M_D)_8]I_SS_\>?\ ^*H_LC!?\^O_ ">I_P#)C^MUOY__ "6/^0?V-:?\\_\
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M/_//_P ??_XJC^Q<!_SY_P#*E7_Y,/KN(_G_ /)8_P#R(G]@6/\ SR_\??\
M^*H_L7 ?\^?_ "I5_P#DP^O8C^?_ ,EC_P#(A_8%C_SR_P#'Y/\ XJC^Q<!_
MSY_\J5?_ ),/KV(_G_\ )8?_ "(?V!8_\\O_ !^3_P"*H_L7 ?\ /G_RI5_^
M3#Z]B/Y__)8?_(A_PC]C_P \O_'Y/_BJ7]BX#_GS_P"5*O\ \F/Z]B/Y_P#R
M6'_R(G_"/V/_ #R_\?D_^*H_L7 ?\^?_ "I5_P#DP^O8C^?_ ,EA_P#(A_PC
M]A_SR_\ 'Y/_ (JC^Q,!_P ^?_*E7_Y,/KV(_G_\EA_\B'_"/6'_ #R_\?D_
M^*H_L3 ?\^?_ "I5_P#DP^OXC^?_ ,EA_P#(A_PCUA_SR_\ 'Y/_ (NC^Q,!
M_P ^?_*E7_Y,/K^(_G_\EA_\B)_PCUA_SR_\?D_^+I?V)E__ #Y_\J5?_DQ_
M7\3_ #_^2P_^1#_A';#_ )Y?^/R?_%T?V)E__/G_ ,J5?_DP^OXG^?\ \EA_
M\B'_  CMA_SR_P#'Y/\ XNC^Q,O_ .?/_E2K_P#)A]?Q/_/S_P EA_\ (B?\
M([I__/+_ ,?D_P#BZ/[#R_\ Y\_^5*O_ ,F'U_$_\_/_ "6'_P B'_".:?\
M\\O_ !^3_P"+I?V'E_\ SY_\J5?_ ),/K^)_Y^?^2P_^1#_A'-/_ .>7_C\G
M_P 71_8>7_\ /C_RI5_^3'_:&)_Y^?\ DL/_ )$/^$;T_P#YY?\ C\G_ ,71
M_8>7_P#/C_RI5_\ DP_M#$_\_/\ R6'_ ,B)_P (WI__ #R_\?D_^+H_L/+_
M /GQ_P"5*O\ \F']H8G_ )^?^2P_^1#_ (1O3_\ GE_X_)_\71_8>7_\^/\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * *&J_\><__ %QE_P#0&KS<P_W/$_\ 7BM_Z;D=>&_CTO\
MKY#_ -*1?KTCD*$G_'Y%_P!<9_\ T.WKS9_[Y1_Z\8C_ -.84ZX_P)_]?*7_
M *36+]>D<@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 4)/^/R+_KC/_P"AV]>;/_?*/_7C$?\
MIS"G7'^!/_KY2_\ 2:Q?KTCD"@ H * "@ H * "@ H * "@ H * "@ H * *
M$?\ Q^2_]<8/_0[BO-A_OE;_ *\8?_TYBCKE_ I_]?*O_I-$OUZ1R!0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % %#5?^/.?_KC+_Z U>;F'^YXG_KQ6_\ 3<CKPW\>E_U\A_Z4B_7I
M'(>3?$_Q#?>'FLY-.D\EY1<*S;$?*@VYQB16 YYR!GCKC.?8R_!T,3.5:O#F
MG3CRQ?-)6C4:<U9-)W=.&]VK:6N[Q.I*,>2+M%M-JRWBFE]RD_O]#RO_ (65
MXA_Y^_\ R!;_ /QFOHOJ&&_Y]_\ DT__ )(YN>7?\@_X65XA_P"?O_R!;_\
MQFCZAAO^??\ Y-/_ .2#GEW_ "#_ (65XA_Y^_\ R!;_ /QFCZAAO^??_DT_
M_D@YY=_R#_A97B'_ )^__(%O_P#&:/J&&_Y]_P#DT_\ Y(.>7?\ (/\ A97B
M'_G[_P#(%O\ _&:/J&&_Y]_^33_^2#GEW_(/^%E>(?\ G[_\@6__ ,9H^H8;
M_GW_ .33_P#D@YY=_P @_P"%E>(?^?O_ ,@6_P#\9H^H8;_GW_Y-/_Y(.>7?
M\@_X65XA_P"?O_R!;_\ QFCZAAO^??\ Y-/_ .2#GEW_ "#_ (65XA_Y^_\
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M_P"%E>(?^?O_ ,@6_P#\9H^H8;_GW_Y-/_Y(.>7?\@_X65XA_P"?O_R!;_\
MQFCZAAO^??\ Y-/_ .2#GEW_ "#_ (65XA_Y^_\ R!;_ /QFCZAAO^??_DT_
M_D@YY=_R#_A97B'_ )^__(%O_P#&:/J&&_Y]_P#DT_\ Y(.>7?\ (/\ A97B
M'_G[_P#(%O\ _&:/J&&_Y]_^33_^2#GEW_(/^%E>(?\ G[_\@6__ ,9H^H8;
M_GW_ .33_P#D@YY=_P @_P"%E>(?^?O_ ,@6_P#\9H^H8;_GW_Y-/_Y(.>7?
M\@_X65XA_P"?O_R!;_\ QFCZAAO^??\ Y-/_ .2#GEW_ "#_ (65XA_Y^_\
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M1]0PW_/O_P FG_\ )!SR[_D'_"RO$/\ S]_^0+?_ .,T?4,-_P ^_P#R:?\
M\D'/+O\ D'_"RO$/_/W_ .0+?_XS1]0PW_/O_P FG_\ )!SR[_D'_"RO$/\
MS]_^0+?_ .,T?4,-_P ^_P#R:?\ \D'/+O\ D'_"RO$/_/W_ .0+?_XS1]0P
MW_/O_P FG_\ )!SR[_D'_"RO$/\ S]_^0+?_ .,T?4,-_P ^_P#R:?\ \D'/
M+O\ D'_"RO$/_/W_ .0+?_XS1]0PW_/O_P FG_\ )!SR[_D'_"RO$/\ S]_^
M0+?_ .,T?4,-_P ^_P#R:?\ \D'/+O\ D'_"RO$/_/W_ .0+?_XS1]0PW_/O
M_P FG_\ )!SR[_D'_"RO$/\ S]_^0+?_ .,T?4,-_P ^_P#R:?\ \D'/+O\
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M_DT__D@YY=_R#_A97B'_ )^__(%O_P#&:/J&&_Y]_P#DT_\ Y(.>7?\ (/\
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M_DT__D@YY=_R#_A97B'_ )^__(%O_P#&:/J&&_Y]_P#DT_\ Y(.>7?\ (/\
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M_DT__D@YY=_R#_A97B'_ )^__(%O_P#&:/J&&_Y]_P#DT_\ Y(.>7?\ (/\
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M_DT__D@YY=_R#_A97B'_ )^__(%O_P#&:/J&&_Y]_P#DT_\ Y(.>7?\ (/\
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M_DT__D@YY=_R#_A97B'_ )^__(%O_P#&:/J&&_Y]_P#DT_\ Y(.>7?\ (/\
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MWVO^%U?U.>KK("@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * /N>OS(] \,^-/_+A_V\_^V]?3Y3_R]_[<_P#;SGJ=/G^AX77T
MQSA0 4 ?6"?\AJP_[!TW_H=O7P;^#$?]?*?YU3HC\%#Y_P#I$1NA75IK;3ZI
M" EVD<EI<J.YC8E&Q[@$J?0[2<I17C.A3C2?\.?+5AY7C[R_'7T3^T:QM*LK
M_%2<H+SC*<6F_P#P#[W+?0X_4;K3+7PSIAU:W>[C**$5'9"K^6?F)5TR,9&,
MGZ5Z"C5EC*JP\E"=GJTFK7C=:I];=.AE3LJ5Y:QYW=?]O3_2_P!YF6^GW&I^
M"(K>TC>:4W#$(@R<"9R3CT%;U)QIX]3FTHJ.K>VL&@I_!475VM]\&:?@G3G\
M.Z--=32PV-W=S>6K73B)5$+%2A)Q\Q(E( Z\'H*C&5%7K4Z45*<(14VH*[?,
MD]+=+<N^UWU(IQ_B2>FC@G?1.S5_)J3U75PMITT[W343Q9IVJVY5X;Z.7+H0
MR%TMY,,&'!#1E=I'7:36-*;6$Q.&G=2ARM)Z-)U875MU:5[_ .(WG[RA-=&H
MNUK=UYO[2](HU+Z&RFN3XH?&=+CNX77NTD3LD??&<%\=SYB>E<U-SC'ZE'_F
M(]DXOHN:W-Y[V3\HLMQ4Y*$G;V<KRMK[KBIJ^E_=34K=[V\[Z.?^$A9^_P#9
MBG_R.QK+;"R\JZ_]-LCXI4+]55_%T#.MH[*TN1XGBP3JRV<,:]P\TBK(?KMV
M$@<YC?/6NA\[B\O?_+N56;?3EA!R7WOFU_O1)5JB5=Z<M-II:^]?EUMIH[1O
MVN96GZ:A\5ZEJUP52&Q2,!W(5%=[>/+%SP D8;<>P8&M95'' TJ$+\U24E9;
MM*HW:V^LN6W?5$R7-62>T4I/_P !25UVW>NSC\UD^/+/^V-"BU 307D]A(5E
MEMG$B%9" 1D9PPS$Q!Z#)Z'G7!R^KXGV7+.$*D5937*[Q6_I=32MU=NAK\<9
MK2ZDYJVMHW?N^5HO5]>2]ETP_$7_ ")FF_\ 7?\ ]EN*[:7_ ",*O_7M?^XC
MCI?P7_U]E_Z54._TJYM[6UT%KG #1%(V;HLC6X"_B1E1[L*\FI&4JN*5/?EN
MTNJ4X-_Y^B-EI3BWLJJO\U52]?>:]-^AAZ-X>UVU\3R:A<EA:EYF>4R H\)#
M^6@7<3A<KA2 $V]L#/1.OAW@U15N?EBN7EU4U;FE?SU=[ZWMU*J1E*HFN^EN
MD>W3II:SN]==S9L?$%MI>F7VJ0*)+8:D^0.C))+$DC+V.=S.HZ'@< USRH2J
MU,/AZCM)T>O2RJ2BGZ62?7?J+FM*O.&\90VTNU"DI=M6[^]W][4Q?'UE:V/A
MJ*.P(:V>[$L6.FV832@+_LC?A?\ 9P#S71A)3GB_WVDXTW"7>\%&.OGIKW>I
MU1:E3K3CHI0B[>?/2OZ:INW3;H+X)LHK/P^KM#-?QZG,4GCB&?)4%XPX48?Y
M=JEBIW D,OW1F\;)SQ*@I1ING%2A*6EY-*5KZKR5]-&GO8XZ7NJ=3=_#RZ.\
M>MUUNI/U32:W:YCQ]X0@\/6T=SYMW=W$LI7S)"#&D8R55CL+;\$*/G 8AV"@
M?+73@L5*O-TU&G"*C=I+64M$VM4K==G965WN:S@N5S5]TDK[)]]-KZ+;=;V=
M]?PO_P BI_W$;?\ ]*;:HQ/^^4_^O4__ $FJ<4?X>(]5_P"DTST;7=*M?$UP
MMG,0LFG307!_VHG!RISV<HP/;Y17B4*LL*G7CM)3I^DDHM/Y<R:^9WS7.G0_
MF49+?^=Q=O/EYEY.2=BG>7Z:I-I%W']R2[G*>ZB&X53^*@'\:J--TG6A+=4+
MOR;=)M?)NQ#DI0=NE91_\ G.%UY/ENA=0M;*^O%UV8A3HIN4E7@Y*#='GO\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'W/
M7YD>@>;^./#'_"67EG9^=]F\N&[EW>7YF=KV:;=N],9WYSGMC'.1[&#Q'U2%
M2IR\UY4XVO;=5'>]GV,I1YFEZ_H<I_PI;_I__P#);_[HKO\ [6_Z=?\ D_\
M]H1[/S_#_@A_PI;_ *?_ /R6_P#NBC^UO^G7_D__ -H'L_/\/^"'_"EO^G__
M ,EO_NBC^UO^G7_D_P#]H'L_/\/^"'_"EO\ I_\ _);_ .Z*/[6_Z=?^3_\
MV@>S\_P_X(?\*6_Z?_\ R6_^Z*/[6_Z=?^3_ /V@>S\_P_X(?\*6_P"G_P#\
MEO\ [HH_M;_IU_Y/_P#:![/S_#_@A_PI;_I__P#);_[HH_M;_IU_Y/\ _:![
M/S_#_@A_PI;_ *?_ /R6_P#NBC^UO^G7_D__ -H'L_/\/^"'_"EO^G__ ,EO
M_NBC^UO^G7_D_P#]H'L_/\/^"'_"EO\ I_\ _);_ .Z*/[6_Z=?^3_\ V@>S
M\_P_X(?\*6_Z?_\ R6_^Z*/[6_Z=?^3_ /V@>S\_P_X(?\*6_P"G_P#\EO\
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MH'L_/\/^"'_"EO\ I_\ _);_ .Z*/[6_Z=?^3_\ V@>S\_P_X(?\*6_Z?_\
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MW_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\
M!#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']
MK?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P
M0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:
MW_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\
M!#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']
MK?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P
M0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:
MW_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\
M!#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']
MK?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P
M0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:
MW_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\
M!#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']
MK?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P
M0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:
MW_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\
M!#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']
MK?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P
M0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:
MW_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\
M!#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']
MK?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P
M0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:
MW_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\
M!#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']
MK?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P
M0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:
MW_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\
M!#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']
MK?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P
M0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:
MW_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\
M!#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']
MK?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P
M0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:
MW_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\
M!#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']
MK?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P
M0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:
MW_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\
M!#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']
MK?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P
M0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:
MW_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\
M!#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']
MK?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P
M0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:
MW_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\
M!#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']
MK?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P
M0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\ !#_A2W_3_P#^2W_W11_:
MW_3K_P G_P#M ]GY_A_P0_X4M_T__P#DM_\ =%']K?\ 3K_R?_[0/9^?X?\
M!#_A2W_3_P#^2W_W11_:W_3K_P G_P#M ]GY_A_P2AJGPC_LVSGO/MOF?9H9
M)=OV?;N\M&?;N\\XSC&<''7!Z5I3S/VDXT_9VYI*-^>]KM*]N43IV5[_ ('T
M%7RATF%<?\ABV_Z\[W_T=85U1_@S_P"OE/\ ])JD]5Z/]#=KE*"@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ,*W_P"0Q<_]
M>=E_Z.OZZI?P8?\ 7RI_Z32)ZOT7ZF[7*4% !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MMC_EY_\ (,'_ ,:JOJ5#^3_R:7_R0N=]R(^/]<'_ "\_^08/_C5/ZEA_Y/\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H PO%'_ "![[_KSN?\ T2]=6'_C4O\
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MNJ[C;5+E=E4M[;;3DI65MI<DN:5OLWU]YV4NC=SV>I*"@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H \4\?_ /(7'_7G!_Z.NJ^DP7\'_N)+_P!)@83W^7^9
MQ35Z1F0M5 0M5"(6J@(6JA$+50$+50$+50B%JH"%JH"%J8B%JH#Z6^$]S)/H
MI23)$-Q)&F?[NV-^/8,[5\;F45&O==8IOUNU^21U4]CTRO&-0H * "@ H *
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M=YNRN]E&ZYE%+:Z6GFHK9)+VV"T@MF=X8TC:9M\I154R/@+O<@ LVT ;FR<
M#. *S6BY5LFW;I=N[=N[>K[O5E[OF>]DK];+9>BZ+H6* "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * ,+Q1_R![[_KSN?_ $2]=6'_ (U+_KY#_P!*
M1,MGZ,W:Y2C"N/\ D,6W_7G>_P#HZPKJC_!G_P!?*?\ Z35)ZKT?Z&[7*4%
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MC"JNTR;702 C+8C;I(VT'9&?[[83WH L/J-LBR.9%VP*'D(Y"JPW*<C.<KR
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MA:=_SZVW_?F/_P")H]M5_GG_ .!/_,++LA/[!TW_ )]+;_OQ'_\ $T>VJ_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H PO%'_ "![[_KSN?\ T2]=6'_C4O\ KY#_ -*1,MGZ,W:Y2C"N/^0Q;?\
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MZQ SW*R!"Q+22X>1LMM7>1( #2UNVG=HQ:0R[XD;R9X)84\IR NV2.8A6B(
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MMCLMED%P_P BFX,.Z($XWOY),;!!\RJA8G@'O@ P(/#]PC-9R1H;26:"1RK
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M A-A R =1;VD@O9+B0 (L,<,6,8/+/(0 3M!)1<'!^3TP: ->@ H * "@ H
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M')JS]I**W5XJG2DM_.4M>OR!Z2BD[IPN]M'S-6TVT2=GKK?9H[BH*"@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 87BC_D#WW_7G<_\ HEZZL/\ QJ7_ %\A_P"E(F6S]&;M
M<I1A7'_(8MO^O.]_]'6%=4?X,_\ KY3_ /2:I/5>C_0W:Y2@H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#"M_\ D,7/_7G9
M?^CK^NJ7\&'_ %\J?^DTB>K]%^INURE!0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0<R[K[P_X2C1_P#G^L__  )A_P#BZ/J];_GU4_\  )?Y!S+NOO#_ (2C1_\
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M0<R[K[P_X2C1_P#G^L__  )A_P#BZ/J];_GU4_\  )?Y!S+NOO#_ (2C1_\
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M0<R[K[P_X2C1_P#G^L__  )A_P#BZ/J];_GU4_\  )?Y!S+NOO#_ (2C1_\
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M]X?\)1H__/\ 6?\ X$P__%T?5ZW_ #ZJ?^ 2_P @YEW7WA_PE&C_ //]9_\
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M/_Q='U>M_P ^JG_@$O\ (.9=U]X?\)1H_P#S_6?_ ($P_P#Q='U>M_SZJ?\
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M "#F7=?>'_"4:/\ \_UG_P"!,/\ \71]7K?\^JG_ (!+_(.9=U]X?\)1H_\
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M&C_\_P!9_P#@3#_\71]7K?\ /JI_X!+_ "#F7=?>'_"4:/\ \_UG_P"!,/\
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M_%T?5ZW_ #ZJ?^ 2_P @YEW7WA_PE&C_ //]9_\ @3#_ /%T?5ZW_/JI_P"
M2_R#F7=?>'_"4:/_ ,_UG_X$P_\ Q='U>M_SZJ?^ 2_R#F7=?>'_  E&C_\
M/]9_^!,/_P 71]7K?\^JG_@$O\@YEW7WA_PE&C_\_P!9_P#@3#_\71]7K?\
M/JI_X!+_ "#F7=?>'_"4:/\ \_UG_P"!,/\ \71]7K?\^JG_ (!+_(.9=U]X
M?\)1H_\ S_6?_@3#_P#%T?5ZW_/JI_X!+_(.9=U]X?\ "4:/_P _UG_X$P__
M !='U>M_SZJ?^ 2_R#F7=?>'_"4:/_S_ %G_ .!,/_Q='U>M_P ^JG_@$O\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * ,+Q1_R![[_ *\[G_T2]=6'_C4O^OD/_2D3+9^C-VN4HPKC
M_D,6W_7G>_\ HZPKJC_!G_U\I_\ I-4GJO1_H;M<I04 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!S)O;>RUBX^T2QP[K.SV
M^8ZIG$U_G&XC.,C..F1ZUV\DIT8<D6[5*E[)O[-+L1>S=^R_4TO[<T__ )^K
M?_O]'_\ %5C[&I_)/_P%_P"15UW0?V[IW_/U;?\ ?Z/_ .*H]C5_DG_X"_\
M(+KNA/[>TW_G[MO^_P#'_P#%4>QJ_P#/N?\ X#+_ ""Z[H3^W]-_Y^[;_O\
MQ?\ Q5'L*O\ S[G_ . R_P A77="?\)!IG_/W:_]_P"+_P"*I^PJ_P#/N?\
MX#+_ ""Z[H/^$ATS_G\M?^_\7_Q='L*O_/N?_@,O\@NNZ$_X2+2_^?RU_P"_
M\7_Q='L*O_/N?_@,O\@NNZ$_X2/2A_R^6O\ X$1?_%T>PK?\^Y_^ 2_R"Z[K
M[Q/^$DTK_G]M/_ B+_XNG]7K?\^Y_P#@$O\ (+KNOO#_ (272?\ G]M/_ B'
M_P"+H^KUO^?<_P#P"7^0<R[K[Q/^$FTD?\OMI_X$0_\ Q='U>M_S[J?^ 2_R
M#F7=?>:%K?VU\-UK+%.!WC=7'YJ364H2IZ3BX^J:_,=^Q;K,84 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!A>*/^0/??\ 7G<_^B7KJP_\
M:E_U\A_Z4B9;/T9NURE&%<?\ABV_Z\[W_P!'6%=4?X,_^OE/_P!)JD]5Z/\
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M,/8U\)B:/U>JZ?3=>CV_R.R+YE<Z.N,H* "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@#"\4?\ ('OO^O.Y_P#1+UU8?^-2_P"OD/\ TI$RV?HS
M=KE*,*X_Y#%M_P!>=[_Z.L*ZH_P9_P#7RG_Z35)ZKT?Z&[7*4% !0!X=J?\
MR4RQ_P"P9)_*YIX?_F*](_G0%7VP_P#CG_Z14.!UWP[=:[XSUB;2W:+4=-BM
M[NT(/WI(TMP8SG@[U)49XW8#?*6SE1;I4IXB"NX5FG'O"3K<ZLM=DG9:M7BM
M6FM:J52I3H3TC.B[/;EE&4.65^EKO7I?FU<4CCH-4?6M&\4ZA*GDR7,VGR/'
MS\C-<R%EYP>#GKR._-$DHT:*@[Q^L5&GOI*#DM5H]'OUW&FW6?.K25"47TUB
MJ<7ITNU>W3;4^DO!.CZW_9"+?ZF62:VM3:FWM[>.2W01Y*$RPS))N4HA9XV(
M"DJ0QS73B8MNI!ZU.>IS/:,KW5FELN:\O=L]E>VAQT6N2$HJT.166[7PM:^2
M36MT[WWLUM> _#=WX5TN*PO;@W,D8(VCR_)BR[MB%E@AE8,&!;SBY##";5X)
M.2E:W2,5=[^[",;::<J:?+IS-?$VS6WO2ET<YR_\"G*2;_O-/WDO=3ORI*QV
ME9%!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!XIX__P"0N/\ KS@_
M]'75?28+^#_W$E_Z3 PGO\O\SBFKTC,A:J A:J$0M5 0M5"(6J@(6J@(6JA$
M+50$+50$+4Q$+50'TS\*K*2TT7=("/M$\DJ@_P!TJB _0E"1]:^,S*:E7LOL
MQ47ZW;_4ZJ:LCTFO'-0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0!YEXD\/7&NZN_P!G:-/)L[;=YA89
MWS7F,;4;^Z<YQVZU[6'KQH45SIN]2=K6Z1I]VNYE)7>G9?J9!^'FH'_EI;_]
M]R?_ !JNCZ]3[3^Y?_)$\C\B,_#G43_RTMO^^Y/_ (U3^OTNT_N7_P D'(_(
MC/PWU(_\M+;_ +[D_P#C-/Z_2_EG]T?_ )(.1^0P_#34C_RTMO\ ON7_ .,T
M_P"T*7\L_NC_ /)"Y'Y$9^&6IG_EK:_]]R__ !FJ_M"E_+/[H_\ R0<C\B,_
M"_4_^>MK_P!]R_\ QFG_ &C2_EG]T?\ Y(.1^0P_"W5/^>MK_P!]R_\ QFG_
M &C2_EG]T?\ Y(/9OR(S\*M5_P">MI_WW+_\8I_VE1_EG]T?_DA>S?D1GX4:
MK_SUM/\ ON7_ .,4_P"TJ/\ +/[H_P#R0>S?D1GX2ZM_SUM/^^Y?_C%5_:='
M^6?W1_\ D@]F_(8?A'JW_/6T_P"^YO\ XQ3_ +3H_P M3[H__)![-^1M:-\(
MC'*)-4F1T7GRH=V&/H78*0/4!<GU%<U7,[KEH1:?>5M/DK_F4J?<]KAA2W18
MH@$1 %51P !P *^;;<FV]6]S<DI % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MB/M2:(GRYEVJQ=,EN Q*'#.I*G#=0 #7H * "@ H * "@ H * "@ H * "@
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M<8+FDTUH[+6R;=K6W1-?^([#39!!.[^:7""..&>9V<QM*%5(8W9CY:LWR@X
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MER6?2=[.+M?6+O>VB2;O9-K)MO'UE-Y3O'<10SVBW88V]RSJI8JV^)(&98T
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M$SNI19'\D-&I(+!%2%8LOC#,T;,5RN<<4 31Z,T=P+K[5<,X18W!%MB149V
M8"W!7ER#Y9CR .XS0 6VB"U90D]QY$;;D@W1B-><@;EC69E!)PCRLN.""
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M.^VB222\HI179;);)+LDM"4K7ONVV_63<GW>[ZMONV[LT*DH* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H PO
M%'_('OO^O.Y_]$O75A_XU+_KY#_TI$RV?HS=KE*,*X_Y#%M_UYWO_HZPKJC_
M  9_]?*?_I-4GJO1_H;M<I04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0!A6_P#R&+G_ *\[+_T=?UU2_@P_Z^5/_2:1/5^B
M_4W:Y2@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@#"\4?\@>^_Z\[G_P!$O75A_P"-2_Z^0_\ 2D3+
M9^C-VN4HPKC_ )#%M_UYWO\ Z.L*ZH_P9_\ 7RG_ .DU2>J]'^ANURE!0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &%;_\
M(8N?^O.R_P#1U_75+^##_KY4_P#2:1/5^B_4W:Y2@H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M>I_X+C_\M#7LOO\ ^ 'VC6/^?:S_ / V;_Y HY:/\]3_ ,%Q_P#EH:]E]_\
MP ^T:Q_S[6?_ (&S?_(%'+1_GJ?^"X__ "T->R^__@!]HUC_ )]K/_P-F_\
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M_P#P ^T:Q_S[6?\ X&S?_(%'+1_GJ?\ @N/_ ,M#7LOO_P" 'VC6/^?:S_\
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M>I_X+C_\M#7LOO\ ^ 'VC6/^?:S_ / V;_Y HY:/\]3_ ,%Q_P#EH:]E]_\
MP ^T:Q_S[6?_ (&S?_(%'+1_GJ?^"X__ "T->R^__@!]HUC_ )]K/_P-F_\
MD"CEH_SU/_!<?_EH:]E]_P#P ^T:Q_S[6?\ X&S?_(%'+1_GJ?\ @N/_ ,M#
M7LOO_P" 'VC6/^?:S_\  V;_ .0*.6C_ #U/_!<?_EH:]E]__ #[1K'_ #[6
M?_@;-_\ (%'+1_GJ?^"X_P#RT->R^_\ X ?:-8_Y]K/_ ,#9O_D"CEH_SU/_
M  7'_P"6AKV7W_\  #[1K'_/M9_^!LW_ ,@4<M'^>I_X+C_\M#7LOO\ ^ 'V
MC6/^?:S_ / V;_Y HY:/\]3_ ,%Q_P#EH:]E]_\ P ^T:Q_S[6?_ (&S?_(%
M'+1_GJ?^"X__ "T->R^__@!]HUC_ )]K/_P-F_\ D"CEH_SU/_!<?_EH:]E]
M_P#P ^T:Q_S[6?\ X&S?_(%'+1_GJ?\ @N/_ ,M#7LOO_P" 'VC6/^?:S_\
M V;_ .0*.6C_ #U/_!<?_EH:]E]__ #[1K'_ #[6?_@;-_\ (%'+1_GJ?^"X
M_P#RT->R^_\ X ?:-8_Y]K/_ ,#9O_D"CEH_SU/_  7'_P"6AKV7W_\  #[1
MK'_/M9_^!LW_ ,@4<M'^>I_X+C_\M#7LOO\ ^ 'VC6/^?:S_ / V;_Y HY:/
M\]3_ ,%Q_P#EH:]E]_\ P ^T:Q_S[6?_ (&S?_(%'+1_GJ?^"X__ "T->R^_
M_@!]HUC_ )]K/_P-F_\ D"CEH_SU/_!<?_EH:]E]_P#P ^T:Q_S[6?\ X&S?
M_(%'+1_GJ?\ @N/_ ,M#7LOO_P" 'VC6/^?:S_\  V;_ .0*.6C_ #U/_!<?
M_EH:]E]__ #[1K'_ #[6?_@;-_\ (%'+1_GJ?^"X_P#RT->R^_\ X!C03ZJ-
M5N"+>UW_ &6TW+]KE"A?-O=I#?8B222X92BA0JD,VXA.AJC[&'OSMSU+?NXW
MORT[Z>U]+.^MWHK:SK=Z+9=?7R-G[1K'_/M9_P#@;-_\@5S\M'^>I_X+C_\
M+2M>R^__ ( ?:-8_Y]K/_P #9O\ Y HY:/\ /4_\%Q_^6AKV7W_\ /M&L?\
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MX+C_ /+0U[+[_P#@!]HUC_GVL_\ P-F_^0*.6C_/4_\ !<?_ ):&O9??_P
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M_P"0*.6C_/4_\%Q_^6AKV7W_ / #[1K'_/M9_P#@;-_\@4<M'^>I_P""X_\
MRT->R^__ ( ?:-8_Y]K/_P #9O\ Y HY:/\ /4_\%Q_^6AKV7W_\ /M&L?\
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MX+C_ /+0U[+[_P#@!]HUC_GVL_\ P-F_^0*.6C_/4_\ !<?_ ):&O9??_P
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M_P"0*.6C_/4_\%Q_^6AKV7W_ / #[1K'_/M9_P#@;-_\@4<M'^>I_P""X_\
MRT->R^__ ( ?:-8_Y]K/_P #9O\ Y HY:/\ /4_\%Q_^6AKV7W_\ /M&L?\
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MX+C_ /+0U[+[_P#@!]HUC_GVL_\ P-F_^0*.6C_/4_\ !<?_ ):&O9??_P
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M_P"0*.6C_/4_\%Q_^6AKV7W_ / #[1K'_/M9_P#@;-_\@4<M'^>I_P""X_\
MRT->R^__ ( ?:-8_Y]K/_P #9O\ Y HY:/\ /4_\%Q_^6AKV7W_\ /M&L?\
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MX+C_ /+0U[+[_P#@!]HUC_GVL_\ P-F_^0*.6C_/4_\ !<?_ ):&O9??_P
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M+G?D1GXFZF/^65K_ -\2_P#QZJ_L^E_-/[X__(ASOR(S\3]3'_+*U_[XE_\
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M=GHT;CJ0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MTV4)^]))W2>CM9V[-=.Z\FM]WW-9&@4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0!XIX__P"0N/\ KS@_]'75?28+^#_W$E_Z3 PGO\O\SBFKTC,A:J A
M:J$0M5 0M5"(6J@(6J@(6JA$+50$+50$+4Q$+50'TW\++^2]T4)(<_9IGA4G
M^Z%1U'X"3 ]A7QF8P4*]U]J*D_6[3_(ZJ;NCT>O'-0H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % 'BGC_ /Y"X_Z\X/\ T==5])@OX/\ W$E_Z3 PGO\ +_,XIJ](
MS(6J@(6JA$+50$+50B%JH"%JH"%JH1"U4!"U4!"U,00V\EU(L,*F21SM55&2
M2>P%#DH)RD[);MAZ'UGX,T$^'=+BM)/]:<R2XZ;WQD#@?= "^^*^$Q=;ZQ5E
M47P[1]%_GN=D5RJQU-<)84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 87BC_D#WW_7G<_^B7KJP_\
M&I?]?(?^E(F6S]&;M<I1A7'_ "&+;_KSO?\ T=85U1_@S_Z^4_\ TFJ3U7H_
MT-VN4H* "@#S2[U&(7$T\3I=NIE=&221)[9D3RU@EA/2)Y!M&2F]V!\MS\]
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M".EV@$L@GCDD#Q)P@MKF$_=4*Q"*Q&6C+&)6#-0!N>&;*&&U%TD:H]R7DR%
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M[CA9-K&+]R#7:G?=ZRIJ;O\ :CJTES<RDK/FO-([BLS4* "@ H * "@ H *
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M45EHOY=(_P!U:K3MN]N[[FC2&% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % &%XH_Y ]]_P!>=S_Z)>NK#_QJ7_7R'_I2)EL_
M1F[7*485Q_R&+;_KSO?_ $=85U1_@S_Z^4__ $FJ3U7H_P!#=KE*"@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ,*W_Y#%S_
M ->=E_Z.OZZI?P8?]?*G_I-(GJ_1?J;M<I04 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!A>*/^0/??
M]>=S_P"B7KJP_P#&I?\ 7R'_ *4B9;/T9NURE',:I91WVJVL<ID4"UO6S%-+
M"V1+8CEX7C8CG[I)4G!(R 1VTYN%&;C;XZ:]Z,9+X:O22:^>Y#5VO1_H6O\
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M0"R\_O?^8?\ ".VO]^\_\#[[_P"2:/;S[4__  52_P#D LO/[W_F'_".VO\
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M_P #[[_Y)H]O/M3_ /!5+_Y ++S^]_YA_P ([:_W[S_P/OO_ ))H]O/M3_\
M!5+_ .0"R\_O?^8?\([:_P!^\_\  ^^_^2:/;S[4_P#P52_^0"R\_O?^8?\
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MWG_@???_ "31[>?:G_X*I?\ R 67G][_ ,P_X1VU_OWG_@???_)-'MY]J?\
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M_P#,/^$=M?[]Y_X'WW_R31[>?:G_ ."J7_R 67G][_S#_A';7^_>?^!]]_\
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M_P DT>WGVI_^"J7_ ,@%EY_>_P#,/^$=M?[]Y_X'WW_R31[>?:G_ ."J7_R
M67G][_S#_A';7^_>?^!]]_\ )-'MY]J?_@JE_P#(!9>?WO\ S#_A';7^_>?^
M!]]_\DT>WGVI_P#@JE_\@%EY_>_\P_X1VU_OWG_@???_ "31[>?:G_X*I?\
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M?:G_ ."J7_R 67G][_S#_A';7^_>?^!]]_\ )-'MY]J?_@JE_P#(!9>?WO\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H PO%'_ "![[_KSN?\ T2]=6'_C4O\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 >*>/_P#D+C_KS@_]'75?28+^#_W$E_Z3 PGO\O\ ,XIJ
M](S(6J@(6JA$+50$+50B%JH"%JH"%JH1"U4!"U4!"U,1"U4!]*_":&2+12SY
MQ)<2,F?[NV->/;<K5\=F;3KV72"3];M_DT=5/;YGIM>*:A0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M6_?9_-JSOW>[ZEW7_AYH/BB9+G5+43R0QB%")9X@L:EF50L,L:X!8XXSSC.
M "VKGUD[M]WM<+VBH+2,;V5K6O9?HC4TGPII.A6CZ?86L4-M*")$V[O-!!!$
MK.6:3()'SLW''2G+WUR2UCVV7373KHM=]%KHB8KD?/'26FO73;Y*[TVU?=F%
MH_PQ\-Z#=KJ%C9+'<(249I)I A/=$DD=%/H0N5_A(JHMP5H]K>=NNN^JT?=7
M3T822EK)=;VV5UJM-M'JNB>JV18U7X=>'M<O?[2OK*.:ZRI+[I%#E>AD1'6.
M0X !\Q&R  <@8J(+V;YH:.]_*_>STU>KTU>N^I4FYJTNBMV=O5:^FNBT6AVB
MJ%  & . !P !V%4W?5[DI)*RT2V0M(84 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y1XMT
M:[U?5V^QQ^9Y=G;[OF1<;IKO'WV7.=IZ9Z<]J]W"U84J*]H[7J3MHWM&GV3[
MF,DV].R_4YX^"]7_ .??_P BP_\ QRNOZW1_F_\ )9?Y$\K[$1\%:Q_S[_\
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MBS4#"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MD*2*I^1BJL5VM(O&&93@$ EM=>BN5@;:8_/CED<,0/)$.U9 _NKML/;@GH*
M([;Q#'=PB9(W!>Y6W5'PK'=A@^.<+Y1\W!^;;P0#D  TM3U!-+@:=PSD<*BX
MWNY^ZBY(&3ZD@  L2 ": *"Z_"UQ;6X5O],B\U7XVIN&Y%;T,@#[>V4(ZD4
M0IKLT[PB"!62Y61T9IMI"1-@N0(F^5@4*\DG< 0,$T 5QXIW)YR0[HU2)V_>
M /\ OBWEK&A7$CLH5MNY3\Z@9)H MS:]Y<;74<+R6D1(>7<JDA3AGC0\NB$'
M))0L 3&)!@D /[=*YF:$_91/Y E5P3N\SRMQC(7">9\N59V[[<4 3V>LK>NL
M,:'S T@E7/\ JA&[1Y8XY+NO[M>"PW-P%- &U0 4 % !0 4 % !0 4 % !0
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &%XH_Y ]]
M_P!>=S_Z)>NK#_QJ7_7R'_I2)EL_1F[7*485Q_R&+;_KSO?_ $=85U1_@S_Z
M^4__ $FJ3U7H_P!#=KE*"@ H Y,^%LDMYQW,DF[Y!M:5I))8Y6&[)\EI6*IG
M!(0EOE% %F'1+BQ+1V4ZPP2;-RF'?(I6-(LQ2>:J+E44@/%* V3R#M !5N/"
M<<MM+;12F$N\;12!<M$L<:Q[>6^;<OF;B2,^:QQGJ 6DT6XM_,@M[A8K25F8
MIY),R[_OB.;S0B@GD;H79<G!^[M '1:-/9,\=C.EO;2D,4\G?(A"+&?*D,H1
M1M1<"2&7!SU!  !&VA3R"X1YT*7,@F0B$B1)$,9CW,9F615$2@J(TW<\B@!;
MG0Y]1 ^W3I(RD!1'"8XPNY3)\K32L7D0&/<9-JHQPF2VX @F\++-<3R^<RPW
M17?$%QA<EI51]W G<(TGRG(5E_CR !?^$=GAF$UO<#B<S[9HFEY,"P8RLT7(
M 8@_[6,<9(!I7ND_;YEEEE=5B4B-$^7#L"'<GG<2ORJ,#:"_)W< &2/"Q^R/
M;&<^:8K>.*8)AHC;#,;A2Y#'>68C(!!VGU(!H'0]BE8I-FVS%I%\N?+Z[I/O
M#<6PG'&-GWCG@ S4\*[9B[/"8O-CD7%OB=1$L:QQK.9F"H!&-VV($@L 5W9H
M MPZ'.D*V4DZO91X"QB$K(RJ<JDLOFLK*. VR*,N!@D MN %L=#GACCM[N=)
MH8&$@6.$Q%W#%PTI::;=ASOPHCRX!.1\M &I8:>MCYK AGN)GE=@NW); 4'D
MYVH%7.><9P,XH T* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H PK?_ )#%S_UYV7_HZ_KJE_!A_P!?
M*G_I-(GJ_1?J;M<I1B^(M,?6;"2RC(5I3'R69,!94=L,GSJ=JG:5P0V,$=1+
M5W!](U*4W;1VA4C-V:ZVB[:K6VJW'>RFENZ=2*OJKSA**NGTNU?1Z7T>QCS^
M&VTZXAO=)2.66'SA(EW<3YD\Y8E\TW+I=S&2-85C3<K#RG= 4& :3<6TDN5Q
MMV:?,I7T6O-;W[ZMQIN_N),:35G>ZE&2>^D8U(\NKT7[QR5M+WTO)M8:^"[U
M89[</ %O;41N59U$,JW5U=+'&GE$26Y-SY))>-A&F0C;MJGPJ,(Z^SE0G%[.
M3HJE&SWY%)4KIKGY>;EL^6[&^;5Z<WUA2MK95HI76W-)6O*_+SR;E>-[%NU\
M+7LEW'?7@A#I<02,OGRW!,<$5TJGS'@@4N)+C*J(5VJI)E8[56HVBTUWJ-Z=
M9TU3775V7O/32RL[7<N\DX_W8)?*M"H[]E:/NK7WFWIS,)_"U\L\\L!MRERN
MH1X:1TV+>"!E<!87#,)(F\Q/E'S[P[-E3SRBW1G0TO*G*-^S]IB)P5OY7&M%
M-[QY7925C:,E&K&KTC4IRMW4:5*$OG>FW%;23U<2M+X4U);6338ULWAFN(+D
MSR22B56C:!F3RA RN5\HI#+YR%4* Q_)\W6Y)U(SV4*[JKNXRKRK-?W7:<HO
M62DE:\5-N'*HN-.4%\4J*IOLFJ*I;[N-XJ6R:;;UMKMIX>N$L(+,M'YD-^+I
MCEMIC%ZUS@'9G?Y; 8( W\;L?-6*T]E_T[I*#]?JLJ%UY<[3UL^76U]#1JZJ
MI?;J.:]'B8UM?/E5NOO:7MJ9%UX*N+C3;*Q5H$DM()8Y#ABCEU4[<!5+Q22*
MOG*=I9<G!;%/:<:B^S"FDMKRI5</42O9VC:C*-[-QYE:+U1;M+GCJE.K5E=;
MJ-2&(A?_ !+VT7:Z3L_>V;?=>&]2U2\-[<K:6S$6*;8999#BUO!<.3(UO#DE
M,K&NP;6'+8;*I12Y]7[^NG3]SB*5]]9?O8/FTNE:WN)SEWM%67NQFO7FE1DM
M.D?W<M-=[ZW=FGPOJ$MC%IKI8JMC%&D$V9)))C#+#(JR*84%O%/Y(%RJ/<[]
MW!^3YK<FY*M9*2<7RK2.C6BE:Z4;7IKE?)-0E=\EI%E[T+OEE[7WGJU[2,XW
MY=G+WW>7,KKF5ESWBL_A[5;J\EU-H[*.9C8,D*3RE6-I+<,_F3FU5OF29=C"
M!L;=A& '*A:#B_\ IY.;Z64\.Z.FNLDWS=$UI=;A+WXJ+TM&U]]JM*JNUE>$
MHVUY6^;7F<4Z'PWJ.G7%Q<VZ6ER;T3HR3RR(L:27,\ZE2MO+OWK/MFB(C!,:
M8D(Z9<MZ;H/125G*UVM9KX=.9)2O%<T;2<]^>ZOF]^-7K%II)VO^[H1?O6TM
M*CH^5W4D[)KE;X/!TUM8W5DKQN\XLUBE;<#_ *+!;QAI,*Q5M\3.@4OMR#D'
M..B4N::GM;$JLUO[O/3DU?2\G&#71/1-VVQM[KCIKAY4M-$I2]M:RZ07M(VW
M:2>CLKV-)T74M,NFE5+7[. ZHGG2-Q+<+)(Z&2V:6W&P,QMA//"\FP*857=6
M=/W8*$NU..G2-.,UH]')7<5%2UA&_OO[5RUDY1[SEVO*;3U6J3O?FG&W-NX:
MI09K'A.;4+^74$<<_8]L+33I#,L#S&:.YB3]VZLL@,;,DA5U&1LW*Y3]QIO7
M]ZYOJE%TZ4(RC?15(3@ZD;6NXP7,MX*?OIK_ *=*"Z/F4ZDFFUJX3C)0E>]E
M*;4;[NN/"DUQ:-;!HXW?49KLR*2&6.624Y4[ ?.$4FWTZKOV\UE*'-"%.]K0
MK0?_ '%IUHJRTNN:I&3VV;WM?52Y92FEO*A)+;^$Z#E?>U_922WW5[:VR(O!
MVHO$%F,"R6L$<5N?/FE5S'/;SX8&"(6\;&V1=H6Y9-Q*O\A$O2YMR=6WO2J4
MYN-]+0<FUSVNW[[47R*VK=^:T<5%1BJ5_=4*D.:VOOTW33Y;Z;WDN9W:BNB9
ML0:#?W&I1ZG>K;1^7/YOEQR22[5%I+;C#O!%N?>^[.Q %)')'S1"U/FZN2J?
M)S^JVZ]J$T_5::OE)WGR]$O9WUWY/K+[?S5H-?X6]&E<E\).]M%:H8X=E]>7
M+,F05CN?M@&SY1^\"W"9!PORL Q &<I0YH*FG9*@Z3\KT^71=N?WNFR=KFZG
MRRE.UVYTI^KA.E)W\VH-7UWUW9D7?A/4]2AB@F2QMQ:V%S9(T3RL7,T4<:-M
M-O'Y,8,>6B#2XR,.VWYMW)NK+$6M*7*^6^EXUZ59)RM=KW)13Y4XWORRYVHX
M1BH1A2O>,97YK:V]G4IWY;VYO?3:YK2MNK*]^Y\/ZG=+=0,EHL>J-%)-)YTK
M26[)'%&5A7[,HGV>4)(79[<H[DE/ERTQLG!/:%154^LFIJI9J^CNO9\UW^[4
M7R^[RL:?*UU=)TFNB34XW3[6GS.%E[W-[WO745MX9U'37F>!;2Y%XD\4@FDD
M41(]W=3H5Q!)YH9+G$L+>4"\8Q*0<C*47*DZ&BO"FN;^]&E&FU;K%./-!W37
M-+3WM-N:TU55_=E)I;74G%[ZVE[MGH[KE_EL](^';MM-T[3!+'&++[,;A@"X
M8VT8*"-64!E^T+&^7VX5.F3@=-27/6=972O4DEUYIIQ5^EE"<W=:J:A;2YA%
M<M-T^KLGT2C?F=O\5E!QV<)2N^CBTCPQ<V%S&T[Q2PVT5[#"P!$@2YE@E0;-
MNU1'LDCPKGY!'C.6"\[C>E.GM*5.G3OTM3]K&-^OP2I7[S4GVOK?WE+HJCJ6
M\Y17-\W-S:[1E96V&:/X:NK9$%X+<F/3%T\;'>0-L9OF.^&/"R+M+)AL'Y<N
M &+K7K*O;25:,-.D91]O=7W:_>QL[)Z2T5E=P:ISI/>-.=1^;4W1:TV3]R2:
MO;:S=W:'3?"5U9VHAD:$R_;+"X9@7.Y;6&TCD!8H&+EH)"F1@AEW,I) Z933
MJ1FM$IXF37_7Y8A1^:56'-Z.U[*_-&+5/V;WY*$+_P#7J=.4OE[LN7S>J5V5
M%\(WYA2*1;5_LT#PQCSYU\PB[M[F*0ND2/;OB$\IYWE2!& F7<M<T+PC%?:4
M,+'1VLZ$*M.33MLU.+LXM27-"5D^9[RUFW]EO%/U6(<))-=E:49-2O:TEKHN
MR\/V5U8VOEWIC,[22.WEE6&'<E0SK#;^:X7&Z0PHS'[VYLNVFEHI=%KI97<F
MW97:6^MK*4KR48\W*HUO)OJU;6[LHQCJ]WMI>[4;1N[7>W4E!0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 87BC_D#WW_7G<_\ HEZZL/\ QJ7_ %\A_P"E
M(F6S]&;M<I1A7'_(8MO^O.]_]'6%=4?X,_\ KY3_ /2:I/5>C_0W:Y2@H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#"M_\
MD,7/_7G9?^CK^NJ7\&'_ %\J?^DTB>K]%^INURE!0 4 % !0 4 % !0 4 %
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M_P#R;1[*'_/ZG]U7_P"5A=]G^'^8?VO=?] Z\_[[L?\ Y-H]E#_G]3^ZK_\
M*PN^S_#_ ##^U[K_ *!UY_WW8_\ R;1[*'_/ZG]U7_Y6%WV?X?YA_:]U_P!
MZ\_[[L?_ )-H]E#_ )_4_NJ__*PN^S_#_,/[7NO^@=>?]]V/_P FT>RA_P _
MJ?W5?_E87?9_A_F']KW7_0.O/^^['_Y-H]E#_G]3^ZK_ /*PN^S_  _S#^U[
MK_H'7G_?=C_\FT>RA_S^I_=5_P#E87?9_A_F']KW7_0.O/\ ONQ_^3:/90_Y
M_4_NJ_\ RL+OL_P_S#^U[K_H'7G_ 'W8_P#R;1[*'_/ZG]U7_P"5A=]G^'^8
M?VO=?] Z\_[[L?\ Y-H]E#_G]3^ZK_\ *PN^S_#_ ##^U[K_ *!UY_WW8_\
MR;1[*'_/ZG]U7_Y6%WV?X?YA_:]U_P! Z\_[[L?_ )-H]E#_ )_4_NJ__*PN
M^S_#_,/[7NO^@=>?]]V/_P FT>RA_P _J?W5?_E87?9_A_F']KW7_0.O/^^[
M'_Y-H]E#_G]3^ZK_ /*PN^S_  _S#^U[K_H'7G_?=C_\FT>RA_S^I_=5_P#E
M87?9_A_F']KW7_0.O/\ ONQ_^3:/90_Y_4_NJ_\ RL+OL_P_S#^U[K_H'7G_
M 'W8_P#R;1[*'_/ZG]U7_P"5A=]G^'^8?VO=?] Z\_[[L?\ Y-H]E#_G]3^Z
MK_\ *PN^S_#_ ##^U[K_ *!UY_WW8_\ R;1[*'_/ZG]U7_Y6%WV?X?YA_:]U
M_P! Z\_[[L?_ )-H]E#_ )_4_NJ__*PN^S_#_,/[7NO^@=>?]]V/_P FT>RA
M_P _J?W5?_E87?9_A_F']KW7_0.O/^^['_Y-H]E#_G]3^ZK_ /*PN^S_  _S
M#^U[K_H'7G_?=C_\FT>RA_S^I_=5_P#E87?9_A_F']KW7_0.O/\ ONQ_^3:/
M90_Y_4_NJ_\ RL+OL_P_S#^U[K_H'7G_ 'W8_P#R;1[*'_/ZG]U7_P"5A=]G
M^'^8?VO=?] Z\_[[L?\ Y-H]E#_G]3^ZK_\ *PN^S_#_ ##^U[K_ *!UY_WW
M8_\ R;1[*'_/ZG]U7_Y6%WV?X?YA_:]U_P! Z\_[[L?_ )-H]E#_ )_4_NJ_
M_*PN^S_#_,/[7NO^@=>?]]V/_P FT>RA_P _J?W5?_E87?9_A_F']KW7_0.O
M/^^['_Y-H]E#_G]3^ZK_ /*PN^S_  _S#^U[K_H'7G_?=C_\FT>RA_S^I_=5
M_P#E87?9_A_F']KW7_0.O/\ ONQ_^3:/90_Y_4_NJ_\ RL+OL_P_S#^U[K_H
M'7G_ 'W8_P#R;1[*'_/ZG]U7_P"5A=]G^'^8?VO=?] Z\_[[L?\ Y-H]E#_G
M]3^ZK_\ *PN^S_#_ ##^U[K_ *!UY_WW8_\ R;1[*'_/ZG]U7_Y6%WV?X?YA
M_:]U_P! Z\_[[L?_ )-H]E#_ )_4_NJ__*PN^S_#_,/[7NO^@=>?]]V/_P F
MT>RA_P _J?W5?_E87?9_A_F']KW7_0.O/^^['_Y-H]E#_G]3^ZK_ /*PN^S_
M  _S#^U[K_H'7G_?=C_\FT>RA_S^I_=5_P#E87?9_A_F']KW7_0.O/\ ONQ_
M^3:/90_Y_4_NJ_\ RL+OL_P_S#^U[K_H'7G_ 'W8_P#R;1[*'_/ZG]U7_P"5
MA=]G^'^8?VO=?] Z\_[[L?\ Y-H]E#_G]3^ZK_\ *PN^S_#_ ##^U[K_ *!U
MY_WW8_\ R;1[*'_/ZG]U7_Y6%WV?X?YA_:]U_P! Z\_[[L?_ )-H]E#_ )_4
M_NJ__*PN^S_#_,/[7NO^@=>?]]V/_P FT>RA_P _J?W5?_E87?9_A_F']KW7
M_0.O/^^['_Y-H]E#_G]3^ZK_ /*PN^S_  _S#^U[K_H'7G_?=C_\FT>RA_S^
MI_=5_P#E87?9_A_F']KW7_0.O/\ ONQ_^3:/90_Y_4_NJ_\ RL+OL_P_S,:#
M5+D:K</]@NB3:V@*;[+<H$MZ0Q_TO;AMQ"X8ME&W*H*%NATX^Q@O:P^.IK:I
M;X:>G\.^EM=+:JS>MIOJ]'LNWGYFS_:]U_T#KS_ONQ_^3:Y_90_Y_4_NJ_\
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M\_J?W5?_ )6%WV?X?YA_:]U_T#KS_ONQ_P#DVCV4/^?U/[JO_P K"[[/\/\
M,/[7NO\ H'7G_?=C_P#)M'LH?\_J?W5?_E87?9_A_F']KW7_ $#KS_ONQ_\
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M=]G^'^8?VO=?] Z\_P"^['_Y-H]E#_G]3^ZK_P#*PN^S_#_,/[7NO^@=>?\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MS78R<N5_)?J4S\2<?\NG_D?_ .TUI]0_Z>?^2_\ VPN?R&'XEX_Y=/\ R/\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * /%/'_P#R%Q_UYP?^CKJOI,%_!_[B2_\ 28&$]_E_F<4U>D9D+50$+50B
M%JH"%JH1"U4!"U4!"U4(A:J A:J A:F(A:J ^I/AKJTFJZ,AF)9[:1H"QR20
M@5ER3U(1U&?:OB<?25*N^7122E;UNG^*9UP=T=]7E&@4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % &%XH_P"0/??]>=S_ .B7KJP_\:E_U\A_
MZ4B9;/T9NURE&%<?\ABV_P"O.]_]'6%=4?X,_P#KY3_])JD]5Z/]#=KE*"@
M/-2US)Q>S37W@?..@7.N?"LWFD#2;K5;>6XDN+2XM%9U;>%4+-L1RG"KNW?,
MK;L*ZE6HC*4J4*35JD%RW^R]6[_>V]]FD^5J[N:3JRK)^Y4?,TOB3U;7XVZ+
M2ZO>R;XY3Q)JVEZ5?:E8,]Y#J(N'M;"*65HX44%?,PTV';![A1N53A@U6K4L
M31J*[4(R<VMK\]-\J?HN^K3M=*[S=ZM"M3TCS.*BGO;DJ)R?E=K2UUI?5V6H
M(=8^(?B"PU*73Y](T_1B\@:\4I-+*VTA1$0#C<B\@%0H<E]Q5*4(NFZE9-*4
MJ<J<%OJXSCS/LESWU71)7NVB;4XQHI.RJ1G)[:1<967?X;:/K=VMKY[XI^'G
MB[2=.N2[0ZF-2NXY;@6L4T]T[@LR,3Y (B0@\ A5+8 P:4/==&G'3DGS1?13
M::<IOK=-W;OKKNVWL_>E4J)VO&UG_*I1:C%=+::+[,>R1W>LV&O^%M:L?$YL
MVUF0V M+Q+,-N$H).]$"%]I!7!\O VL&VDJ2U)4YUE%.U6,;/IS)4^;:^G-3
MNF[:3T^%HYU'GI46W9TF_=>_(^;EWM[R4VG;K'SN<-K/A+6Y= N-2FLKC[9J
MNM)>FTBC>66*$1W!!=$4LOS2$?,JD?+N"EL!T[8=X6'Q>R<IR:6EW[/3=J[4
M+[];;IFE_:O$3^%3I0IQ3W]R6GGHG;9-\K=K6;^F/#/B$^(H7E:SO=.\I@FR
M^@\AW^4'<B[FW+SC/J"*IK3FNM6U;JK6=VNSOIZ/L91=O<L]$M>CO=63[JVO
MJNYTE0:!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >*>/_ /D+C_KS@_\
M1UU7TF"_@_\ <27_ *3 PGO\O\SBFKTC,A:J A:J$0M5 0M5"(6J@(6J@(6J
MA$+50$+50$+4Q$>TL0J@DDX '))/0 56VK ^K/ &B2:#I$<,XVS2LTTB]U+@
M *?<*J@^^:^%QM95ZSE'X4E%/O;K][9UP7*K':5YQH% !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0!A>*/^0/??]>=S_Z)>NK#_P :E_U\A_Z4
MB9;/T9NURE&%<?\ (8MO^O.]_P#1UA75'^#/_KY3_P#2:I/5>C_0W:Y2@H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M (=EDN;<W)9S!,P>!96#R)'M4;78%LL7#'!=RH(4MD8 !OT % !0 4 % !0
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M_7G<_P#HEZZL/_&I?]?(?^E(F6S]&;M<I1A7'_(8MO\ KSO?_1UA75'^#/\
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M NR)5102=J@*,DDDX&!DDDGU))/- $E !0 4 % !0 4 % !0 4 % !0 4 %
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M4HQ3O>ZBI-*+NEI972LW[S;?6]^FLMWI]I[\WQ7;=[MWFO- L-09WN81*93
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M=O\ %BLM]K:)+1)/>T5I&^FR6BBMHJVM2&% !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M&%XH_P"0/??]>=S_ .B7KJP_\:E_U\A_Z4B9;/T9NURE&%<?\ABV_P"O.]_]
M'6%=4?X,_P#KY3_])JD]5Z/]#=KE*"@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * ,*W_ .0Q<_\ 7G9?^CK^NJ7\&'_7RI_Z
M32)ZOT7ZF[7*4% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 87BC_D#WW_7G<_^B7KJP_\ &I?]?(?^
ME(F6S]&;M<I1S^L/]@GM]2;_ %4 DAG;^Y%/Y9\P_P"RDL46\_PH6<\*:ZZ2
MYXRHKXI6E%=Y1OIZN,I6[NRZDO2S-]6# $'(/((Z$>HKDVT*%H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#"M_^0Q<_]>=E
M_P"CK^NJ7\&'_7RI_P"DTB>K]%^INURE!0 4 % !0 4 % !0 4 % !0 4 %
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M_P A4>UA_P ^:?WU?_E@6?=_A_D']D77_01O/^^+'_Y"H]K#_GS3^^K_ /+
ML^[_  _R#^R+K_H(WG_?%C_\A4>UA_SYI_?5_P#E@6?=_A_D']D77_01O/\
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MR#^R+K_H(WG_ 'Q8_P#R%1[6'_/FG]]7_P"6!9]W^'^0?V1=?]!&\_[XL?\
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M%C_\A4>UA_SYI_?5_P#E@6?=_A_D']D77_01O/\ OBQ_^0J/:P_Y\T_OJ_\
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MY!_9%U_T$;S_ +XL?_D*CVL/^?-/[ZO_ ,L"S[O\/\@_LBZ_Z"-Y_P!\6/\
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M "P+/N_P_P @_LBZ_P"@C>?]\6/_ ,A4>UA_SYI_?5_^6!9]W^'^0?V1=?\
M01O/^^+'_P"0J/:P_P"?-/[ZO_RP+/N_P_R#^R+K_H(WG_?%C_\ (5'M8?\
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#9__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Apr. 30, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Arcus Biosciences, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3898435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3928 Point Eden Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hayward<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">694-6200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.0001 Per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RCUS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,773,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001724521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (Includes $&#8212; and ($5) from a related party)</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative (Includes $&#8212; and $&#8212; from a related party)</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(134)<span></span>
</td>
<td class="num">(122)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_InterestAndOtherIncomeExpenseNonoperatingNet', window );">Interest and other income, net</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating income, net</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(128)<span></span>
</td>
<td class="num">(112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (128)<span></span>
</td>
<td class="num">$ (112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (1.02)<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (1.02)<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used to compute net loss per share, basic (in shares)</a></td>
<td class="nump">125.4<span></span>
</td>
<td class="nump">98.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used to compute net loss per share, diluted (in shares)</a></td>
<td class="nump">125.4<span></span>
</td>
<td class="nump">98.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesMember', window );">License and development services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_OtherCollaborationRevenueMember', window );">Other collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_InterestAndOtherIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and other income (expense) nonoperating net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_InterestAndOtherIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_OtherCollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_OtherCollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ResearchAndDevelopmentExpenseRecoveries', window );">Research and development expense, net of recoveries</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesMember', window );">License and development services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesMember', window );">License and development services | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_OtherCollaborationRevenueMember', window );">Other collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_OtherCollaborationRevenueMember', window );">Other collaboration | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_ResearchAndDevelopmentExpenseRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Recoveries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_ResearchAndDevelopmentExpenseRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_OtherCollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_OtherCollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (128)<span></span>
</td>
<td class="num">$ (112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (129)<span></span>
</td>
<td class="num">$ (112)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 201<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">621<span></span>
</td>
<td class="nump">759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Receivable from collaboration partners</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">844<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term marketable securities</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">997<span></span>
</td>
<td class="nump">1,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable ($11 and $24 to a related party)</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue ($27 and $35 to a related party)</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent ($36 and $43 to a related party)</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 125.5 shares in 2026 and 125.3 shares in 2025 issued and outstanding</a></td>
<td class="nump">2,138<span></span>
</td>
<td class="nump">2,116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,613)<span></span>
</td>
<td class="num">(1,485)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">524<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 997<span></span>
</td>
<td class="nump">$ 1,139<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable, current</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400.0<span></span>
</td>
<td class="nump">400.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">125.5<span></span>
</td>
<td class="nump">125.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">125.5<span></span>
</td>
<td class="nump">125.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable, current</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Equity Award Programs</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th">
<div>Common stock </div>
<div>Equity Award Programs</div>
</th>
<th class="th"><div>Common stock and additional paid-in capital</div></th>
<th class="th">
<div>Common stock and additional paid-in capital </div>
<div>Equity Award Programs</div>
</th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">$ 485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,132)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(112)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(112)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">$ 531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,244)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2025</a></td>
<td class="nump">125.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2025</a></td>
<td class="nump">$ 631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,485)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2026</a></td>
<td class="nump">125.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2026</a></td>
<td class="nump">$ 524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,613)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (128)<span></span>
</td>
<td class="num">$ (112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Noncash lease expense</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of discounts on marketable securities</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other items, net</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Receivable from collaboration partners ($&#8212; and $2 from a related party)</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable (($13) and $&#8212; to a related party)</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue (($15) and ($28) to a related party)</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other liabilities</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(138)<span></span>
</td>
<td class="num">(132)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(353)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ProceedsFromMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ProceedsFromSaleOfMarketableSecurities', window );">Proceeds from sales of marketable securities</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock ($&#8212; and $14 from a related party)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock pursuant to equity award plans</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="num">(21)<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_ProceedsFromMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from maturity of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_ProceedsFromMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_ProceedsFromSaleOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_ProceedsFromSaleOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, classified as other, in reconciling net income to reflect cash provided by (used in) operating activity when indirect cash flow method is applied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Receivable from collaboration partners</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Receivable from collaboration partners</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Liquidity and Capital Resources<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization, Liquidity and Capital Resources</a></td>
<td class="text">Organization, liquidity and capital resources<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Arcus Biosciences, Inc. (referred to as "Arcus," "we," "our," "us," or the "Company") is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Our most advanced molecules are in Phase 3 registrational studies for various cancer indications and we expect our next wave of clinical-stage molecules to come from our inflammation and autoimmune disease programs. Our vision is to leverage our internal small-molecule discovery capabilities to create, develop and commercialize highly differentiated therapies that can have a meaningful impact on patients.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We operate and manage our business as one reportable and operating segment, which is the business of developing and commercializing highly differentiated therapies that have a meaningful impact on patients. See Note 15, Business segment, for more information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026, we had cash, cash equivalents and marketable securities of $876 million, which we believe will be sufficient to fund our planned operations for a period of at least twelve months following the date of filing of this report.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of significant accounting policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These interim financial statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2025 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on February&#160;25, 2026. There have been no significant changes to our summary of significant accounting policies as disclosed in that filing. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and include all normal and recurring adjustments that management believes are necessary for a fair presentation of the periods presented. The Condensed Consolidated Balance Sheet as of December&#160;31, 2025 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating results for the three months ended March&#160;31, 2026 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2026 or for any future period. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed and updated each period to reflect current information. Actual results may differ materially from those estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2024-03 &#8212; Income Statement &#8212; Reporting Comprehensive Income &#8212; Expense Disaggregation Disclosures (Subtopic 220-40) &#8212; Disaggregation of Income Statement Expenses. This ASU requires disclosure, in the notes to financial statements, of specified information about certain costs and expenses. We plan to adopt this guidance beginning with our 2027 Annual Report to be filed in early 2028 and all quarterly and Annual Reports thereafter. We expect the adoption of this standard to result in increased disclosures in the Notes to our Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the FASB issued ASU 2025-07 &#8212; Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract. This ASU refines the scope of the guidance on derivatives in Topic 815 and clarifies the guidance on share-based payments from a customer in ASC 606. We have adopted this standard during the current quarter with no significant impact on our Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party - Gilead Sciences, Inc.<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party - Gilead Sciences, Inc.</a></td>
<td class="text">Related party - Gilead Sciences, Inc.<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we and Gilead Sciences, Inc. ("Gilead") entered into an Option, License and Collaboration Agreement (the "Gilead Collaboration Agreement"), Common Stock Purchase Agreement (the "Stock Purchase Agreement"), and Investor Rights Agreement (the "Investor Rights Agreement").</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Gilead Collaboration Agreement was amended in 2021 (the "First Gilead Collaboration Agreement Amendment"), in 2023 (the "Second Gilead Collaboration Agreement Amendment"), in 2024 (the "Third Gilead Collaboration Agreement Amendment") and (the "Fourth Gilead Collaboration Agreement Amendment"), and in 2025 (the "Fifth Gilead Collaboration Agreement Amendment"). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Stock Purchase Agreement was amended in 2021 (the "First Stock Purchase Agreement Amendment"), in 2023 (the "Second Stock Purchase Agreement Amendment"), and was amended and restated in 2024 (the "Third Stock Purchase Agreement Amendment").</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Investor Rights Agreement was amended in 2022 (the "First Investor Rights Agreement Amendment") and was amended and restated in 2024 (the "Second Investor Rights Agreement Amendment").</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We refer to these agreements collectively as the "Gilead Agreements".</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Purchase and Investor Rights Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter 2025, through our underwritten offering, Gilead purchased 1.4 million shares of our common stock for total gross proceeds of $15&#160;million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Investor Rights Agreement entered into in 2020 and subsequent amendments, Gilead has the right to designate three members of our board of directors and registration rights for shares that it purchases. Gilead has exercised its rights to appoint all three board members and we have registered all shares purchased to date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026, Gilead held approximately 25.0% of our outstanding common stock. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into the Gilead Collaboration Agreement, which gave Gilead an exclusive license to develop and commercialize zimberelimab (the anti-PD-1 program) in certain markets and time-limited options to acquire exclusive licenses to develop and commercialize any of our then-current and future clinical programs arising during the 10-year collaboration term, contingent upon $100 million option continuation payments payable on each of the second, fourth, sixth and eighth anniversaries of the agreement. The period to determine Gilead's option rights under the Gilead Collaboration Agreement will end on July 14, 2026, following Gilead&#8217;s decision to not make the option continuation payment due on the sixth anniversary. Upon closing of the transaction in 2020, Gilead made an upfront payment of $175 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we entered into the First Gilead Collaboration Agreement Amendment pursuant to which Gilead exercised its option to three programs&#8212;providing Gilead with exclusive licenses to develop and commercialize domvanalimab and AB308 (collectively, the anti-TIGIT program), etrumadenant (the adenosine receptor antagonist program) and quemliclustat (the CD73 program), in certain markets&#8212;for a total payment of $725 million that was received in 2022. The amendment also (i) provided for a slight reduction in the royalties for these three programs, such that Gilead will pay us tiered royalties as a percentage of revenues ranging from the mid-teens to the low twenties; and (ii) removed the $100 million option continuation payment that was otherwise due on the second anniversary of the Gilead Collaboration Agreement. With respect to domvanalimab, we are also eligible to receive up to $500 million in potential U.S. regulatory approval milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gilead's option to acquire exclusive licenses to develop and commercialize AB801 (an investigational small molecule AXL inhibitor) and AB598 (an investigational anti-CD39 monoclonal antibody), will expire after a prescribed period following the achievement of a clinical development milestone in such program and our delivery to Gilead of the requisite data package. Gilead may exercise its option to these programs at any time prior to expiration of the option and will pay Arcus an option fee of $150 million per program. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For each program that Gilead opts in to, both companies will co-develop and equally share global development costs, subject to certain opt-out rights that we have, caps on our spending and related subsequent adjustments, and certain other exceptions. For each program, provided we have not exercised our opt-out rights, we have the option to co-promote in the U.S. with equal sharing of related profits and losses. Gilead has the right to exclusively commercialize outside of the U.S., subject to the rights of our existing partners in any territories and will pay us tiered royalties as a percentage of revenues ranging from the high teens to the low twenties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the First Gilead Collaboration Agreement Amendment, Gilead also has option rights to two oncology research programs for which we will lead discovery and early development activities. With respect to these two research programs, Gilead has the right to exercise its option, on a program-by-program basis, either (i) upon our completion of certain investigational new drug ("IND")-enabling activities for an option payment of $60 million or (ii) following the achievement of a clinical development milestone for an option payment of $150 million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we entered into the Second Gilead Collaboration Agreement Amendment pursuant to which we expanded our collaboration to provide Gilead with options to license up to four jointly selected research-stage programs that target inflammatory diseases for which we will lead discovery and early development activities. We will receive an upfront payment of $17.5 million for each initiated program and Gilead will have an option to license each program at two separate, prespecified time points. We received a total upfront payment of $35 million for an initial two research programs in 2023. Gilead&#8217;s options to the other two research programs, as amended under the Fourth Gilead Collaboration Agreement Amendment expired in May 2025. For the two research programs, including AB102 (an investigational MRGPRX2 antagonist), Gilead has the right, on a program-by-program basis, either (i) to exercise its option upon our completion of certain IND-enabling activities for an option payment of $45 million or (ii) to extend its option and exercise it following the achievement of a clinical development milestone for an option payment of $150 million. If Gilead exercises its option at the earlier time point for the first two programs, we would be eligible to receive up to $375 million in regulatory and commercial milestone payments as well as tiered royalties for each optioned program. For any other program option exercise by Gilead, the parties would have rights to co-develop and share global development costs and to co-promote and share profits in the U.S. for that program. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, we entered into the Third Gilead Collaboration Agreement Amendment. The Third Gilead Collaboration Agreement Amendment, among other things, (i) required Gilead to pay the $100 million option continuation payment due on the fourth anniversary of the Gilead Collaboration Agreement, which was received in 2024, (ii) provides that we will operationalize and fund the Phase 3 PRISM-1 study evaluating quemliclustat in pancreatic cancer subject to Gilead's right to reinstate the study as part of the parties' joint development activities upon regulatory approval, (iii) provides that we will solely fund our share of PACIFIC-8, subject to Gilead&#8217;s right to reinstate PACIFIC-8 as part of the parties&#8217; joint development activities for the TIGIT Program upon regulatory approval, and (iv) provides that we will fund certain other activities. All other terms of the existing collaboration agreements, remain unchanged.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026, Gilead has licenses to domvanalimab, AB308, quemliclustat and zimberelimab. In the second quarter 2025, Gilead returned its license to the adenosine receptor antagonist program, which includes etrumadenant. After July 14, 2026, Gilead will maintain its existing time-limited options to programs including AB801, AB598, AB102 and an investigational TNF small molecule inhibitor. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2026 and 2025, under the Gilead Agreements we recognized revenue of $15 million and $28 million, respectively. For a more detailed discussion on revenues recognized under the Gilead Agreements, see Note 5, Revenues, for more information.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2025, we recognized net reimbursements from Gilead of $5 million. Expenses and reimbursements from Gilead are recognized in Operating expense, allocated between Research and Development ("R&amp;D") and General and Administrative ("G&amp;A") based upon the activity that generated the net expense or reimbursement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> At March&#160;31, 2026 and December&#160;31, 2025, we had net payables to Gilead of $11 million and $24 million, respectively, recorded in Accounts payable on our Condensed Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaborations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsAbstract', window );"><strong>License and Collaboration Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaborations</a></td>
<td class="text">License and collaborations<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We enter into licensing agreements, strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain investigational products. These arrangements: may be collaborative and involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities; are performed with no guarantee of either technological or commercial success; and are each unique in nature. Such arrangements may include: non-refundable upfront payments; payments for options to acquire certain rights; potential development and regulatory milestone payments and/or sales-based milestone payments; royalty payments; revenue or profit-sharing arrangements; expense reimbursements; and cost-sharing arrangements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line items in the Condensed Consolidated Statements of Operations, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our significant arrangements are discussed below. For a more detailed discussion on revenues recognized under these arrangements, see Note 5, Revenues.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gilead Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3, Related party - Gilead Sciences, Inc., for more information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taiho Collaboration </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into an agreement with Taiho Pharmaceutical Co., Ltd ("Taiho" and the "Taiho Agreement") pursuant to which Taiho obtained an exclusive option to in-license development and commercialization rights to programs for Japan and certain other Asian countries, excluding China (the "Taiho Territory") for which IND-enabling studies had begun during a five-year term which ended in September 2022, for an upfront payment of $35 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For each option to a program that Taiho exercises, except for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">casdatifan (the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">HIF-2&#945; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">program) discussed below</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, they will be obligated to make a payment of $3 million to $15 million, depending on the development stage of the optioned program. Upon exercise, Taiho is solely responsible for continued development and commercialization in the Taiho Territory, unless they opt to participate in a global study, in which case they would become obligated to reimburse us for their portion of the global study costs. In addition, for each optioned program we would be eligible to receive clinical and regulatory milestones of up to $130 million and commercial milestone payments of up to $145 million with the achievement of certain sales thresholds in the Taiho Territory. We will also receive royalties ranging from high single-digits to mid-teens on net sales of licensed products in the Taiho Territory. Royalties will be payable by product and country commencing on the first commercial sale and ending upon the later of: (a) 10 years; and (b) expiration of the last-to-expire valid claim of our patents covering the manufacture, use or sale.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, Taiho opted to participate in two global Phase 3 trials of domvanalimab and zimberelimab combinations, STAR-121 and STAR-221, and in 2024, Taiho opted to participate in the global Phase 3 trial of quemliclustat, PRISM-1. For each of these trials, Taiho became obligated to reimburse us for their portion of the global trial costs, and to make milestone payments contingent upon successfully satisfying the related clinical milestones. The clinical milestones were met: for domvanalimab and zimberelimab for the STAR-221 trial in 2023, and Taiho became obligated to pay us $28 million; domvanalimab and zimberelimab for the STAR-121 trial in 2024, and Taiho became obligated to pay us $26 million; and for quemliclustat for the PRISM-1 trial in the first quarter 2025, and became obligated to make milestone payments totaling $19 million. All the milestone payments due have been fully received. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter 2025, Taiho exercised its option for </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">HIF-2&#945;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> inhibitor program (including casdatifan) for the Taiho Territory, for an option payment of $15 million. We and Taiho concurrently entered into the Second Amendment where: (i) we will lead development for two indications in Japan and be responsible for the global study costs; (ii) we may also be eligible to receive clinical and regulatory milestones of up to $172 million, commercial milestone payments of up to $145 million upon the achievement of certain sales thresholds in the Taiho Territory and royalties ranging from high single-digits to mid-teens on net sales of the licensed product in the Taiho Territory. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of these arrangements, a portion of these clinical milestones were determined to be advance cost sharing payments for Taiho's share of the related global study R&amp;D costs under the collaboration and are deferred and recognized as a reduction in R&amp;D expense as the related global studies are performed, calculated as an estimated percentage of completion based on the estimated total ef</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">fort for the programs. See Note 5, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenues, for more information.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026, Taiho has licenses for the Taiho Territory to (i) HIF-2&#945; inhibitor program (including casdatifan); (ii) anti-TIGIT program (including domvanalimab and AB308); (iii) anti-PD-1 program (including zimberelimab); (iv) CD73 program (including quemliclustat); and (v) adenosine receptor antagonist program (including etrumadenant).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under this arrangement, for the three months ended March&#160;31, 2026, we recognized revenue of $2 million. We recognized net reimbursements including amortization of advance cost share payments from Taiho for the three months ended March&#160;31, 2026 and 2025 of $5 million and $9 million, respectively, recognized as a reduction in R&amp;D expense.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2026 and December&#160;31, 2025, we had $3&#160;million and $10&#160;million, respectively, related to this arrangement recorded in Receivable from collaboration partners on our Condensed Consolidated Balance Sheets. At March&#160;31, 2026 and December&#160;31, 2025, we had liabilities of $23&#160;million and $44 million, respectively related to certain advance cost sharing payments under this arrangement recorded in Other liabilities, allocated between current and noncurrent based on the expected timing of future recognition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca Collaboration </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a collaboration with AstraZeneca to evaluate domvanalimab, our investigational anti-TIGIT antibody, in combination with AstraZeneca&#8217;s durvalumab in a registrational Phase 3 clinical trial in patients with unresectable Stage 3 non-small cell lung cancer ("NSCLC"), known as the PACIFIC-8 trial. The terms of this agreement were amended in 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration, as amended, each company will retain existing rights to their respective molecules and any future commercial economics. AstraZeneca will conduct the trial, and each company will supply their respective investigational product to support the trial. We may be obligated to pay milestones of up to $24&#160;million upon the achievement of certain clinical trial progress milestones or under certain circumstances if the agreement is terminated early and we will reimburse AstraZeneca annually for a portion of the trial costs. The portion of the costs that we consider to be unavoidable is accrued as incurred and milestones that are deemed probable of occurring are accrued in advance of the achievement of the milestone.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prior to January 2024, the PACIFIC-8 trial formed part of the Arcus and Gilead joint development program for domvanalimab and our portion of the trial costs was shared with Gilead. Under the Third Gilead Collaboration Agreement Amendment, we agreed to solely fund our share of PACIFIC-8, subject to Gilead&#8217;s right to reinstate PACIFIC-8 as part of the parties&#8217; joint development activities for the TIGIT Program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We recognized R&amp;D expense for the three months ended March&#160;31, 2026 and 2025 of $5 million and $4 million, respectively, under this arrangement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2026 and December&#160;31, 2025, we have recognized a total liability of $17 million and $12 million, respectively, related to our obligation to AstraZeneca including the first milestone, recorded in Other current liabilities and Other noncurrent liabilities on our Condensed Consolidated Balance Sheets based on the expected timing of payment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">WuXi Biologics License - anti-PD-1 </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into an agreement with WuXi Biologics Ireland Limited ("WuXi Biologics") which, as amended, provides us with exclusive rights to (i) develop, use and manufacture products that include an anti-PD-1 antibody, including zimberelimab, worldwide and (ii) commercialize any such products worldwide, except in Greater China. As of March&#160;31, 2026, under this arrangement, we may incur (i) additional regulatory milestone payments of up to $50&#160;million and commercialization milestone payments of up to $375 million, (ii) tiered royalties that range from the high single-digits to low teens on net sales of the licensed products and (iii) fees related to any sublicenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any milestones or royalties due under this arrangement for the three months ended March&#160;31, 2026 and 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">WuXi Biologics License - anti-CD39</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into an agreement with WuXi Biologics, under which we obtained the exclusive worldwide license to develop and commercialize anti-CD39 antibodies discovered under this arrangement. As of March&#160;31, 2026, under this arrangement we may incur additional clinical and regulatory milestone payments of up to $14 million and royalty payments in the low single digits on net sales of the licensed products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any milestones or royalties due under this arrangement for the three months ended March&#160;31, 2026 and 2025. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Abmuno License</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we entered into an agreement (the "Abmuno Agreement") with Abmuno Therapeutics LLC ("Abmuno"), under which we obtained the exclusive worldwide license to develop, use, manufacture, and commercialize products that include an anti-TIGIT antibody, including domvanalimab. As of March&#160;31, 2026, under this arrangement we may incur additional clinical, regulatory and commercialization milestone payments of up to $88 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any milestones or royalties due under this arrangement for the three months ended March&#160;31, 2026 and 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_LicenseAndCollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_LicenseAndCollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text">Revenues <div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenues by collaboration, category of revenue, and the method of recognition (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Over time</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Point in time</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Collaboration</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License and development services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D services</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Access rights</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 2.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Taiho Collaboration</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues from collaborations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues from a customer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from Gilead accounted for 88% and 100% of Total revenues for the three months ended March&#160;31, 2026 and 2025, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the revenue recognized as a result of changes in the deferred revenue balance (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.051%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from amounts in deferred revenue at the beginning of the period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We had $79&#160;million and $78&#160;million of deferred revenue remaining on our Condensed Consolidated Balance Sheets at March&#160;31, 2026 and December&#160;31, 2025, respectively, allocated between current and noncurrent based on the expected timing of future recognition.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from the Gilead Collaboration</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Termination of rights to etrumadenant</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter 2025, Gilead terminated its rights to etrumadenant (the adenosine receptor antagonist program), which we determined was a significant reduction in the scope of the arrangement, which met the accounting definition of a contract modification and we accounted for this as both a modification of the existing contract and the creation of a new contract. Under the applicable accounting rules for such contract modifications, we did not adjust the accounting for completed performance obligations that were distinct from the modified goods or services. Accordingly, we allocated the updated transaction price of $256 million, which was comprised of the deferred revenue remaining as of the modification date, to the remaining unsatisfied and partially satisfied performance obligations and updated the measure of progress as of the modification date, which resulted in a cumulative catch-up to revenue of $143 million for the quarter ended June 30, 2025. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of the updated transaction price to the remaining unsatisfied and partially satisfied performance obligations (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Allocation to performance obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Distinct</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Combined</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">192&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Development services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Access right and option continuation periods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Rights to certain studies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.44pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total transaction price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">256&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for each performance obligation as follows:</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Development Services - Etrumadenant, Quemliclustat and Domvanalimab</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Gilead Collaboration Agreement, Gilead obtained options to the exclusive rights: to our adenosine receptor antagonist program, etrumadenant; to our CD73 program, quemliclustat; and to our anti-TIGIT program, domvanalimab and AB308. Effective December 2021, under the First Gilead Collaboration Agreement Amendment, Gilead exercised these options and obtained exclusive licenses to these programs for a total non-refundable payment totaling $725&#160;million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We determined the standalone selling price of each license using a discounted cash flow method and the R&amp;D services for each program, using an expected cost-plus margin approach. For domvanalimab, we determined that the license was distinct based on an evaluation of the delivery of the license, noting that the program was in the later stages of development and the ongoing R&amp;D services do not significantly modify or customize the related intellectual property. Accordingly, we recognized the allocated transaction price as revenue in the year ended December 31, 2021. For etrumadenant and quemliclustat programs, we determined that the license and R&amp;D services were combined at the inception of the agreement based on an evaluation of the delivery of the license, due to the early stage of the technology and the specialized nature of our know-how. We recognize the amounts allocated to R&amp;D services for domvanalimab and the combined license and R&amp;D for etrumadenant and quemliclustat as each performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for each program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2026 and 2025, we recognized revenue of $8 million and $20 million, respectively, within License and development services revenue in our Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Access Rights and Option Continuation Periods</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the Gilead Collaboration Agreement entered into in 2020 and related amendments, Gilead has exclusive access to our current programs as well as any future programs for a period of ten years, contingent upon option continuation payments totaling $300 million, consisting of a $100 million payment on each of the fourth (paid in third quarter 2024), sixth, and eighth anniversaries of the Gilead Collaboration Agreement. Following Gilead&#8217;s decision to not make the option continuation payment due on the sixth anniversary, on July 14, 2026, Gilead will lose certain rights to access and obtain licenses to the programs arising from our R&amp;D pipeline. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The standalone selling price of the ongoing R&amp;D pipeline access and the option continuation material rights were determined using an expected cost-plus margin approach, with the option continuation material rights probability-adjusted for the likelihood of exercise. We use a time-elapsed input method to measure progress toward satisfying the access rights performance obligation, which is the method we believe most faithfully depicts our performance in transferring the promised services during the time period in which Gilead has access to our R&amp;D pipeline. Accordingly, the revenue allocated to the initial four-year access rights performance obligation was recognized using this input method over the remaining period through July 2024, and for the fourth anniversary access rights continuation, over the two-year period commencing July 2024. For the option continuation material rights, following Gilead's decision in April 2026 to not make the continuation payment, we will recognize the $18 million of revenue allocated to those material rights.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2026 and 2025, we recognized revenue of $3 million and $6 million, respectively, within Other collaboration revenue in our Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rights to Certain Studies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 2024, under the Third Gilead Collaboration Agreement Amendment, we will solely fund certain studies, but Gilead retains exclusive rights to reinstate into the collaboration each study beginning at specified time-points for a payment amount based on the cost incurred. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that these are material rights and we estimated the standalone selling price of these performance obligations using a discounted cash flow method probability-adjusted for the likelihood of exercise. We recognize the amount allocated to each right if and when the related study is reinstated into the parties' co-development plans or if the option effectively lapses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2026, we recognized revenue of $2 million within License and development services revenue in our Condensed Consolidated Statements of Operations. As of March&#160;31, 2026, we had $14 million of deferred revenue on our Condensed Consolidated Balance Sheet related to these performance obligations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">R&amp;D Services - Inflammation Programs </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we entered into the Second Gilead Collaboration Agreement Amendment pursuant to which we expanded our collaboration to provide Gilead with options to license two jointly selected research-stage programs that target inflammatory diseases for which we will lead discovery and early development activities, see Note 3, Related party - Gilead Sciences, Inc., for more information. We received a total upfront payment of $35 million. We determined that the Second Gilead Collaboration Agreement Amendment represented a separate contract. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We determined that we have two separate distinct performance obligations to perform R&amp;D services for Gilead related to discovery and early development activities for each research program for which they have made an upfront payment and, at the amendment closing date, we allocated the transaction price of $35 million equally to the two performance obligations created by this amendment based upon the respective standalone selling prices. The standalone selling prices of these obligations were determined using an expected cost-plus margin approach. We recognize the amounts allocated to these services as the performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for the program. The options to acquire additional licenses or services did not result in additional performance obligations because they did not provide a material right at contract inception, primarily due to the very early stages of the programs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2026 and 2025, we recognized revenue of $2 million and $2 million, respectively, within Other collaboration revenue in our Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from the Taiho Collaboration</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Casdatifan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter 2025, Taiho exercised its option under the collaboration arrangement and obtained an exclusive license to casdatifan (the HIF-2&#945; inhibitor) for the Taiho Territory and concurrently entered into the second amendment whereby we will lead development for two indications in Japan including the global Phase 3 trial of casdatifan PEAK-1. In exchange, Taiho made an option exercise payment of $15&#160;million which was received in fourth quarter 2025. We determined that the option exercise and amendment represented a single contract under which we have two separate distinct performance obligations, a license with a customer and R&amp;D services for a collaborative partner related to the global study activities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of the transaction price of $15&#160;million to the performance obligations (in millions):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Allocation to performance obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Distinct</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Combined</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.44pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total transaction price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the license for casdatifan was distinct based on an evaluation of the delivery of the license, noting that the program was in the later stages of development and the ongoing R&amp;D services do not significantly modify or customize the related intellectual property. We determined the standalone selling price of this license using a discounted cash flow method. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We recognized as revenue the allocated transaction price of $7&#160;million in the fourth quarter 2025, within License and development services revenue in our Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The standalone selling price of the R&amp;D services obligation was determined using an expected cost-plus margin approach. We recognize the amounts allocated to these services as the performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for the program. We determined that these services are with a collaborative partner and not a customer and in accordance with our policy recognize these amounts as R&amp;D expense reimbursements. See Note 4, License and collaborations, for more information.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License</span></div>For the three months ended March&#160;31, 2026, we recognized revenue of $2&#160;million within License and development services revenue in our Condensed Consolidated Statements of Operations related to programs optioned by Taiho.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income taxes<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision or benefit for interim periods is determined using an estimate of our annual effective tax rate, adjusted for discrete items, if any, that are taken into consideration in the relevant period. Each quarter, we update the estimate of the annual effective tax rate, and if the estimated tax rate changes, we record a cumulative adjustment to the provision or benefit.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We did not record a provision for income taxes for the three months ended March&#160;31, 2026 and 2025 because of forecasted full year net operating losses ("NOLs"), which consider the timing of recognition of deferred revenue for tax purposes and the effects of the option to capitalize and amortize U.S. R&amp;D expenses as allowed by the One Big Beautiful Bill Act of 2025 ("OBBBA"), which was enacted on July 4, 2025. The effective tax rate differs from the U.S. statutory tax rate primarily due to the valuation allowances on our deferred tax assets and state income taxes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026 and December&#160;31, 2025, we have provided a valuation allowance against U.S. federal and state deferred tax assets. We continue to evaluate the realizability of deferred tax assets and the related valuation allowance. If our assessment of the deferred tax assets or the corresponding valuation allowance were to change, we would record the related adjustment to income during the period in which we make the determination. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We recognize interest and penalties associated with uncertain tax benefits as part of the income tax provision. To date, we have not recognized any interest and penalties, nor have we accrued for or made payments for interest and penalties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have not been audited by the Internal Revenue Service, any state, or foreign tax authority. We are subject to taxation in the U.S. and in Australia. Due to NOLs and research credit carryforwards, all of our tax years, from 2015 to 2025, remain open to U.S. federal and California state tax examinations. In addition, our fiscal years from 2021 to 2025 are open to examination in Australia.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net loss per share<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potentially dilutive securities excluded from the computation of diluted net loss per share calculations because they would have been antidilutive (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Common stock options issued and outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock purchase plan shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total potentially dilutive securities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22.6</span></td></tr></table></div>We have also excluded from the calculation at March&#160;31, 2025 the effect of Gilead&#8217;s right to purchase additional shares of our common stock, which expired in July 2025, as these rights had no intrinsic value.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-based compensation <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the components of stock-based compensation expense recognized in our Condensed Consolidated Statements of Operations (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.051%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash, Cash Equivalents and Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash, Cash Equivalents and Marketable Securities</a></td>
<td class="text">Cash, cash equivalents and marketable securities <div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, gross unrealized gains and losses and the fair value of our cash, cash equivalents and marketable securities, all of which are considered available for sale, by type of securities (in millions): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Types of securities as of March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gain</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Loss </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">171&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">171&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate securities and commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">877&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">876&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Types of securities as of December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gain</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Loss </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">155&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">155&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate securities and commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,010&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,010&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair values of our cash, cash equivalents and marketable securities by location in the Condensed Consolidated Balance Sheets and contractual maturity (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Location in Condensed Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Contractual Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">201&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">222&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Within one year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Between one and three years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">876&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,010&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains or losses recognized on the sale of available-for-sale marketable securities were not material for the three months ended March&#160;31, 2026 and 2025 and are included in Interest and other income, net, in the Condensed Consolidated Statements of Operations. The cost of a security sold is determined using the specific-identification method.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We limit the credit risk associated with our investments by placing them with banks and institutions we believe are highly creditworthy and investing in highly rated investments. We held a total of 100 and 31 positions in securities which were in unrealized loss positions as of March&#160;31, 2026 and December&#160;31, 2025, respectively. We do not intend to sell our securities with unrealized loss positions and have concluded we will not be required to sell the securities before recovery of the amortized cost for the investment at maturity. No credit related losses have been recognized for any of the periods presented.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the Condensed Consolidated Balance Sheets to the total shown in the Condensed Consolidated Statements of Cash Flows (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">201&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">192&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-443"><span style="-sec-ix-hidden:f-444">Restricted cash (included in Other noncurrent assets)</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">204&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">195&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash at March&#160;31, 2026 and 2025 represents cash balances held as security in connection with our facility lease agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalent, and debt and equity securities, including realized and unrealized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Condensed Consolidated Balance Sheet Components</a></td>
<td class="text">Condensed consolidated balance sheet components<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consisted of the following (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued research and development</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">93&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">89&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued personnel expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">136&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">154&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt</a></td>
<td class="text">Long-term debt<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our borrowings (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt (Contractual maturity 2030)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized discounts, issuance costs, charges and payment-in-kind interest, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">99&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, we entered into a loan and security agreement with Hercules which we subsequently amended in the fourth quarter 2025 (the "Hercules Agreement"). Under the Hercules Agreement, Hercules agreed to lend us up to $250 million in term loans in various tranches subject to minimum draw requirements. At closing, we drew $50 million and we drew an additional $50 million in the second quarter 2025. The remaining $150&#160;million is available as follows: (i) $50&#160;million will be available upon the achievement of certain Biologic License Application ("BLA") enabling clinical milestones related to our ongoing Phase 3 studies, drawable through the earlier of March 15, 2028 or 90 days following the achievement of the applicable milestone; (ii) $50&#160;million will be available upon the FDA's approval of a BLA or New Drug Application ("NDA") for an Arcus investigational product, drawable through the earlier of December 15, 2028 or 90 days following such approval; and (iii) $50 million remains available through the loan's maturity date, subject to lender approval. Any amounts from future expired tranches that were not drawn will remain available through the loan's maturity date, subject to lender approval and the achievement of any milestones associated with the original tranches.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2026 and 2025, we recognized $3 million and $2 million of interest expense, respectively. The effective interest rate of the debt, including amortization of the debt discount and issuance costs </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">and payment-in-kind interest, was 12.85% commencing with the modification which occurred in the fourth quarter 2025, compared to 13.08% commencing the second quarter 2025 and 13.39% for all periods prior to the second quarter 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash and non-cash information related to our operating leases (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in measurement of lease liabilities</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2026 and December&#160;31, 2025, we have provided deposits for letters of credit totaling $3 million to secure our obligations under our leases, which are included in Other noncurrent assets on the Condensed Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' equity<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Underwritten Offering</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter 2025, we sold through an underwritten offering, 13.6 million shares of our common stock at a price of $11.00 per share, for total gross proceeds of approximately $150 million, before deducting underwriting discounts, commissions and offering expenses. As part of this underwritten offering, Gilead purchased 1.4 million shares of our common stock for total gross proceeds of $15&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair value measurements<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1 inputs include unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair value measurement as of March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate securities and commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">171&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">705&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">876&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair value measurement as of December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate securities and commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">155&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">855&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,010&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-term debt</span></div>We determine the fair value of our long-term debt, for disclosure purposes only, based on other inputs that are observable, and thus categorized as Level 2 in the fair value hierarchy. As of March&#160;31, 2026 and December&#160;31, 2025, the estimated fair value of our long-term debt approximated the carrying amount.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Segment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Business Segment</a></td>
<td class="text">Business segment<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We operate and manage our business as one reportable and operating segment, which is the business of developing and commercializing highly differentiated therapies that have a meaningful impact on patients. Our chief operating decision maker ("CODM") is the Chief Executive Officer, who decides how to allocate resources and assesses segment performance based on the net loss reported in the Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below is a summary of the segment net loss, including significant segment expenses (in millions):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 2.44pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted for expense (income):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9.36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Late-stage development programs </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9.36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Early-stage development and preclinical programs </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and personnel costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9.36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other segment items </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Partnership reimbursements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Segment net loss and Consolidated net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(128)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(112)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">(1) R&amp;D expenses incurred related to a Phase 3 clinical program intended to result in registration of a new product. This includes all unallocated program-level expense not directly attributable to a specific clinical trial once the related program enters into one or more Phase 3 clinical trials.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">(2) R&amp;D expenses incurred for activities ranging from early-stage development and preclinical to Phase 2 clinical trials. This includes all unallocated program-level expense not directly attributable to a specific clinical trial unless the related program has entered into one or more Phase 3 clinical trials.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">(3) Other segment items includes non-allocated program costs and other G&amp;A costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total segment assets at March&#160;31, 2026 and 2025 were $1.0 billion and $1.2 billion, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The adoption, modification or termination of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers and directors for the three months ended March&#160;31, 2026, which are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"></td><td style="width:31.419%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.640%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Name and Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Action</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total Shares to be Sold</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Robert C. Goeltz II</span></div><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adoption</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">January 26, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">56,163</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Juan Jaen</span></div><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">President</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adoption</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">February 27, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">139,781</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">June 4, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Jennifer Jarrett</span></div><div style="padding-left:7.37pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chief Operating Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adoption</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">January 23, 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">188,277</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">November 23, 2026</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=rcus_RobertC.GoeltzIIMember', window );">Robert C. Goeltz II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Robert C. Goeltz II<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Financial Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">January 26, 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">March 31, 2028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">795 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">56,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=rcus_JuanJaenMember', window );">Juan Jaen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Juan Jaen<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">President<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">February 27, 2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">June 4, 2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">462 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">139,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=rcus_JenniferJarrettMember', window );">Jennifer Jarrett [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Jennifer Jarrett<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Operating Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">January 23, 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">November 23, 2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">304 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">188,277<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=rcus_RobertC.GoeltzIIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=rcus_RobertC.GoeltzIIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=rcus_JuanJaenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=rcus_JuanJaenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=rcus_JenniferJarrettMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=rcus_JenniferJarrettMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These interim financial statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2025 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on February&#160;25, 2026. There have been no significant changes to our summary of significant accounting policies as disclosed in that filing. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and include all normal and recurring adjustments that management believes are necessary for a fair presentation of the periods presented. The Condensed Consolidated Balance Sheet as of December&#160;31, 2025 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements.</span></div>Operating results for the three months ended March&#160;31, 2026 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2026 or for any future period.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These interim financial statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2025 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on February&#160;25, 2026. There have been no significant changes to our summary of significant accounting policies as disclosed in that filing. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and include all normal and recurring adjustments that management believes are necessary for a fair presentation of the periods presented. The Condensed Consolidated Balance Sheet as of December&#160;31, 2025 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements.</span></div>Operating results for the three months ended March&#160;31, 2026 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2026 or for any future period.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed and updated each period to reflect current information. Actual results may differ materially from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2024-03 &#8212; Income Statement &#8212; Reporting Comprehensive Income &#8212; Expense Disaggregation Disclosures (Subtopic 220-40) &#8212; Disaggregation of Income Statement Expenses. This ASU requires disclosure, in the notes to financial statements, of specified information about certain costs and expenses. We plan to adopt this guidance beginning with our 2027 Annual Report to be filed in early 2028 and all quarterly and Annual Reports thereafter. We expect the adoption of this standard to result in increased disclosures in the Notes to our Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the FASB issued ASU 2025-07 &#8212; Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract. This ASU refines the scope of the guidance on derivatives in Topic 815 and clarifies the guidance on share-based payments from a customer in ASC 606. We have adopted this standard during the current quarter with no significant impact on our Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Revenues by Collaboration, Category of Revenue and Method of Recognition</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our revenues by collaboration, category of revenue, and the method of recognition (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Over time</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Point in time</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Collaboration</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License and development services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D services</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Access rights</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 2.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Taiho Collaboration</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues from collaborations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues from a customer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of Revenue Recognized as a Result of Changes in Deferred Revenue</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the revenue recognized as a result of changes in the deferred revenue balance (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.051%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from amounts in deferred revenue at the beginning of the period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock', window );">Summary of Transaction Price and Allocation of Transaction Price to the Performance Obligations</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of the updated transaction price to the remaining unsatisfied and partially satisfied performance obligations (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Allocation to performance obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Distinct</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Combined</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">192&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Development services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Access right and option continuation periods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Rights to certain studies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.44pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total transaction price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">256&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the allocation of the transaction price of $15&#160;million to the performance obligations (in millions):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Allocation to performance obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Distinct</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Combined</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">License</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.44pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total transaction price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of transaction price and allocated to transaction price to performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potentially dilutive securities excluded from the computation of diluted net loss per share calculations because they would have been antidilutive (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Common stock options issued and outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock purchase plan shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">0.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total potentially dilutive securities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22.6</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the components of stock-based compensation expense recognized in our Condensed Consolidated Statements of Operations (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.051%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash, Cash Equivalents and Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Our Cash, Cash Equivalents and Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, gross unrealized gains and losses and the fair value of our cash, cash equivalents and marketable securities, all of which are considered available for sale, by type of securities (in millions): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Types of securities as of March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gain</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Loss </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">171&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">171&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate securities and commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">877&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">876&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Types of securities as of December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Gain</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Loss </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">155&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">155&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate securities and commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,010&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,010&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Summary of Fair Values of Our Cash, Cash Equivalents and Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair values of our cash, cash equivalents and marketable securities by location in the Condensed Consolidated Balance Sheets and contractual maturity (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Location in Condensed Consolidated Balance Sheets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Contractual Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">201&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">222&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Within one year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Between one and three years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">876&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,010&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Summary of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the Condensed Consolidated Balance Sheets to the total shown in the Condensed Consolidated Statements of Cash Flows (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">201&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">192&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-443"><span style="-sec-ix-hidden:f-444">Restricted cash (included in Other noncurrent assets)</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">204&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">195&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash, cash equivalent, and investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Summary of Prepaid and Other Current Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Summary of Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consisted of the following (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued research and development</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">93&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">89&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued personnel expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">136&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">154&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Summary of Long-Term Debt Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our borrowings (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt (Contractual maturity 2030)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized discounts, issuance costs, charges and payment-in-kind interest, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">99&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock', window );">Summary of Cash and Non-cash Information Related to Operating Leases</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash and non-cash information related to our operating leases (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in measurement of lease liabilities</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental cash flow disclosures and non-cash financing activities related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in millions):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair value measurement as of March 31, 2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate securities and commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">171&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">705&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">876&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Fair value measurement as of December 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Corporate securities and commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Certificate of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">155&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">855&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1,010&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value assets and liabilities measured on recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Segment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summary of Segment Reporting Information</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below is a summary of the segment net loss, including significant segment expenses (in millions):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2026</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 2.44pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted for expense (income):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9.36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Late-stage development programs </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9.36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Early-stage development and preclinical programs </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and personnel costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9.36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other segment items </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Partnership reimbursements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Segment net loss and Consolidated net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(128)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(112)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">(1) R&amp;D expenses incurred related to a Phase 3 clinical program intended to result in registration of a new product. This includes all unallocated program-level expense not directly attributable to a specific clinical trial once the related program enters into one or more Phase 3 clinical trials.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">(2) R&amp;D expenses incurred for activities ranging from early-stage development and preclinical to Phase 2 clinical trials. This includes all unallocated program-level expense not directly attributable to a specific clinical trial unless the related program has entered into one or more Phase 3 clinical trials.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">(3) Other segment items includes non-allocated program costs and other G&amp;A costs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Liquidity and Capital Resources - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OrganizationLineItems', window );"><strong>Organization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember', window );">Cash Cash Equivalents and Investments in Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OrganizationLineItems', window );"><strong>Organization [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Cash and investments | $</a></td>
<td class="nump">$ 876<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_OrganizationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_OrganizationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party - Gilead Sciences, Inc. (Details)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>program </div>
<div>member</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments', window );">Number of programs, eligible to receive regulatory and commercial milestone payments | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from amounts in deferred revenue at the beginning of the period</a></td>
<td class="nump">$ 17.0<span></span>
</td>
<td class="nump">28.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable, current</a></td>
<td class="nump">$ 39.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember', window );">Gilead</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rcus_GileadSciencesIncMember', window );">Gilead</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_SaleOfStockNumberOfSharesAcquiredInTransaction', window );">Sale of stock, number of shares acquired in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_PercentageOfOutstandingCommonStockOwned', window );">Percentage of outstanding common stock held</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable, current</a></td>
<td class="nump">$ 11.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts', window );">Reimbursement from related party for shared costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=rcus_CommonStockPurchaseAgreementMember', window );">Purchase Agreement | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_NumberOfBoardMembers', window );">Number of board members | member</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=rcus_OptionLicenseAndCollaborationAgreementMember', window );">Gilead Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OptionPaymentUponCompletionOfCertainINDEnablingActivities', window );">Option payment upon completion of certain IND-enabling activities</a></td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones', window );">Option payment upon achievement of certain development milestones</a></td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=rcus_OptionLicenseAndCollaborationAgreementMember', window );">Gilead Collaboration Agreement | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms', window );">Collaboration term for current and future clinical programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement', window );">Option continuation payment due upon second anniversary of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement', window );">Option continuation payment due upon fourth anniversary of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement', window );">Option continuation payment due upon sixth anniversary of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement', window );">Option continuation payment due upon eighth anniversary of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_UpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption', window );">Option fee per program for all other programs entering clinical development to exercise option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_NumberOfResearchPrograms', window );">Number of research programs | program</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from amounts in deferred revenue at the beginning of the period</a></td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="nump">$ 28.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=rcus_OptionLicenseAndCollaborationAgreementMember', window );">Gilead Collaboration Agreement | Related Party | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab', window );">Potential regulatory approval milestones payment receivable related to domvanalimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=rcus_AmendedGileadCollaborationAgreementMember', window );">Amended Gilead Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_NumberOfExerciseOptionToPrograms', window );">Number of exercise option to programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OptionPaymentReceived', window );">Option payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 725.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_RemoveOptionContinuationPaymentUnderAgreement', window );">Removal of option continuation payment under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones', window );">Option payment upon achievement of certain development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments', window );">Number of programs, eligible to receive regulatory and commercial milestone payments | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=rcus_AmendedGileadCollaborationAgreementMember', window );">Amended Gilead Collaboration Agreement | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_UpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_NumberOfResearchPrograms', window );">Number of research programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OptionPaymentUponCompletionOfCertainINDEnablingActivities', window );">Option payment upon completion of certain IND-enabling activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_TotalUpfrontCashPayment', window );">Total upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=rcus_AmendedGileadCollaborationAgreementMember', window );">Amended Gilead Collaboration Agreement | Related Party | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_RegulatoryAndCommercialMilestonePaymentsReceived', window );">Regulatory and commercial milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_CollaborationTermForCurrentAndFutureClinicalPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration term for current and future clinical programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_CollaborationTermForCurrentAndFutureClinicalPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_NumberOfBoardMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Board Members</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_NumberOfBoardMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_NumberOfExerciseOptionToPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of exercise option to programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_NumberOfExerciseOptionToPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of programs, eligible to receive regulatory and commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_NumberOfResearchPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of research programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_NumberOfResearchPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option continuation payment due upon Eighth anniversary of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option continuation payment due upon Fourth anniversary of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option continuation payment due upon second anniversary of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option continuation payment due upon Sixth anniversary of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option fee per program for all other programs entering clinical development to exercise option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_OptionPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_OptionPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option payment upon achievement of certain development milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_OptionPaymentUponCompletionOfCertainINDEnablingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option payment upon completion of certain IND-enabling activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_OptionPaymentUponCompletionOfCertainINDEnablingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_PercentageOfOutstandingCommonStockOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding common stock owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_PercentageOfOutstandingCommonStockOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential regulatory approval milestones payment receivable related to domvanalimab.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_RegulatoryAndCommercialMilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regulatory and commercial milestone payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_RegulatoryAndCommercialMilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party transaction reimbursement from related party for shared costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_RemoveOptionContinuationPaymentUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remove option continuation payment under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_RemoveOptionContinuationPaymentUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_SaleOfStockNumberOfSharesAcquiredInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Shares Acquired In Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_SaleOfStockNumberOfSharesAcquiredInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_TotalUpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Upfront Cash Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_TotalUpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_UpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront cash payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_UpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rcus_GileadSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rcus_GileadSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rcus_CommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rcus_CommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rcus_OptionLicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rcus_OptionLicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=rcus_AmendedGileadCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=rcus_AmendedGileadCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaborations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Receivable from collaboration partners</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rcus_TaihoCollaborationAgreementMember', window );">Taiho Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Receivable from collaboration partners</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rcus_AstraZenecaAgreementMember', window );">AstraZeneca Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Development cost recorded within research and development expenses</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_TaihoPharmaceuticalCoLtdMember', window );">Taiho Pharmaceutical Co., Ltd | Taiho Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OptionPeriod', window );">Option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_NonRefundableAndNonCreditableCashPayments', window );">Non refundable and non creditable cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_PaymentForOptionsExercised', window );">Payment for option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_RoyaltiesPayableTerm', window );">Royalties payable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ReimbursementOfResearchAndDevelopmentExpense', window );">Reimbursement of research and development expense</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_TaihoPharmaceuticalCoLtdMember', window );">Taiho Pharmaceutical Co., Ltd | Taiho Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_PaymentForOptionsExercised', window );">Payment for option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_TaihoPharmaceuticalCoLtdMember', window );">Taiho Pharmaceutical Co., Ltd | Taiho Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_PaymentForOptionsExercised', window );">Payment for option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Additional clinical and regulatory milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ContingentMilestonePaymentsReceivable', window );">Contingent milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_STAR221DevelopmentActivitiesMember', window );">STAR-221 Development Activities | Taiho Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_STAR121DevelopmentActivitiesMember', window );">STAR-121 Development Activities | Taiho Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_AbmunoLicenseAgreementMember', window );">Abmuno License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments', window );">Additional clinical, regulatory and commercialization milestone payments</a></td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_MilestoneExpense', window );">Development milestone expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_WuXiBiologicsLicenseAgreementMember', window );">WuXi Biologics License Agreement | anti-PD-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_MilestoneExpense', window );">Development milestone expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_WuXiBiologicsLicenseAgreementMember', window );">WuXi Biologics License Agreement | anti-CD39</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_MilestoneExpense', window );">Development milestone expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_WuXiBiologicsLicenseAgreementMember', window );">WuXi Biologics License Agreement | Maximum | anti-PD-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ClinicalRegulatoryMilestonePayments', window );">Clinical regulatory milestone payments</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments', window );">Clinical, regulatory and commercialization milestone payments</a></td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_WuXiBiologicsLicenseAgreementMember', window );">WuXi Biologics License Agreement | Maximum | anti-CD39</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments', window );">Additional clinical, regulatory and commercialization milestone payments</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional clinical and milestone payments received under license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional clinical regulatory and commercialization milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_ClinicalRegulatoryAndCommercializationMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical regulatory and commercialization milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_ClinicalRegulatoryAndCommercializationMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_ClinicalRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Regulatory Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_ClinicalRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_ContingentMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_ContingentMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_LicenseAndCollaborationAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_LicenseAndCollaborationAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_MilestoneExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_MilestoneExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_NonRefundableAndNonCreditableCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non refundable and non creditable cash payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_NonRefundableAndNonCreditableCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_OptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_OptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_PaymentForOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for option exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_PaymentForOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_ReimbursementOfResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of research and development expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_ReimbursementOfResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_RoyaltiesPayableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties Payable Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_RoyaltiesPayableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_TaihoCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_TaihoCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_AstraZenecaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_AstraZenecaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rcus_TaihoPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rcus_TaihoPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_OptionAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_OptionAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rcus_STAR221DevelopmentActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rcus_STAR221DevelopmentActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rcus_STAR121DevelopmentActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rcus_STAR121DevelopmentActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rcus_AbmunoLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rcus_AbmunoLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rcus_WuXiBiologicsLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rcus_WuXiBiologicsLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_AntiPDOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_AntiPDOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_AntiCDThirtyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_AntiCDThirtyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Summary of Revenues by Collaboration, Category of Revenue and Method of Recognition (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Total revenues from collaborations</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues from a customer</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesMember', window );">License and development services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesMember', window );">License and development services | Gilead Collaboration | Over time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesMember', window );">License and development services | Taiho Collaboration | Over time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_RDServicesMember', window );">R&amp;D services | Gilead Collaboration | Over time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_AccessRightsMember', window );">Access rights | Gilead Collaboration | Over time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_OtherServicesMember', window );">Other | Gilead Collaboration | Over time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License | Taiho Collaboration | Over time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_LicenseAndCollaborationAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_LicenseAndCollaborationAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_GileadCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_GileadCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_TaihoCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_TaihoCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_RDServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_RDServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_AccessRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_AccessRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_OtherServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_OtherServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Total transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice', window );">Contract with customer, liability, cumulative catch-up adjustment to revenue, change in measure of progress and change in estimate of transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_DeferredRevenueNonRefundablePayment', window );">Deferred revenue, non-refundable payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesMember', window );">License and development services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Total transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rcus_AccessRightsAndOptionContinuationPeriodsMember', window );">Access right and option continuation periods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rcus_GileadCollaborationMember', window );">Gilead Collaboration | Other | Over time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rcus_GileadCollaborationMember', window );">Gilead Collaboration | License and development services | Over time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rcus_TaihoCollaborationMember', window );">Taiho Collaboration | License and development services | Over time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember', window );">Gilead | R&amp;D services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember', window );">Gilead | Access right and option continuation periods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod', window );">Current and future programs exclusive access period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_ContingentMilestonePaymentsReceivable', window );">Contingent milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement', window );">Option continuation payment receivable upon sixth anniversary of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember', window );">Gilead | Access right and option continuation periods | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember', window );">Gilead | Rights to certain studies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember', window );">Gilead | R&amp;D Activities for Inflammation Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember', window );">Gilead | Revenue Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_STAR221DevelopmentActivitiesMember', window );">STAR-221 Development Activities | Taiho Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_TaihoPharmaceuticalCoLtdMember', window );">Taiho Pharmaceutical Co., Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Total transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_TaihoPharmaceuticalCoLtdMember', window );">Taiho Pharmaceutical Co., Ltd | Taiho Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_PaymentForOptionExercise', window );">Payment for option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_ContingentMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_ContingentMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Cumulative Catch-up Adjustment To Revenue, Change In Measure Of Progress And Change In Estimate Of Transaction Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_CurrentAndFutureProgramsExclusiveAccessPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current and future programs exclusive access period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_CurrentAndFutureProgramsExclusiveAccessPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_DeferredRevenueNonRefundablePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Revenue, Non-Refundable Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_DeferredRevenueNonRefundablePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option continuation payment receivable upon sixth anniversary of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_PaymentForOptionExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for option exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_PaymentForOptionExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_AccessRightsAndOptionContinuationPeriodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_AccessRightsAndOptionContinuationPeriodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_GileadCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_GileadCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_OtherServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_OtherServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_TaihoCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_TaihoCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_RDServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_RDServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_RightsToCertainStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_RightsToCertainStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rcus_STAR221DevelopmentActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rcus_STAR221DevelopmentActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_TaihoCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_TaihoCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rcus_TaihoPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rcus_TaihoPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rcus_OptionAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rcus_OptionAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Summary of Revenue Recognized as a Result of Changes in Deferred Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from amounts in deferred revenue at the beginning of the period</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenues - Summary of Transaction Price and Allocation of Transaction Price to the Performance Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Total transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_TaihoPharmaceuticalCoLtdMember', window );">Taiho Pharmaceutical Co., Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Total transaction price</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesMember', window );">License and development services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Total transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License | Taiho Pharmaceutical Co., Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Total transaction price</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_DevelopmentServicesMember', window );">Development services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Total transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_RDServicesMember', window );">R&amp;D services | Taiho Pharmaceutical Co., Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Total transaction price</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_AccessRightsAndOptionContinuationPeriodsMember', window );">Access right and option continuation periods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Total transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rcus_RightsToCertainStudiesMember', window );">Rights to certain studies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Total transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rcus_TaihoPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rcus_TaihoPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_LicenseAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_DevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_DevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_RDServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_RDServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_AccessRightsAndOptionContinuationPeriodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_AccessRightsAndOptionContinuationPeriodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rcus_RightsToCertainStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rcus_RightsToCertainStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Income (Loss) per Share (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share (in shares)</a></td>
<td class="nump">23.4<span></span>
</td>
<td class="nump">22.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Common stock options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share (in shares)</a></td>
<td class="nump">18.3<span></span>
</td>
<td class="nump">18.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share (in shares)</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share (in shares)</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Marketable Securities - Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Our Cash, Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 877<span></span>
</td>
<td class="nump">$ 1,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">876<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=rcus_CorporateSecuritiesAndCommercialPaperMember', window );">Corporate securities and commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">395<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=rcus_CorporateSecuritiesAndCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=rcus_CorporateSecuritiesAndCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Marketable Securities - Summary of Fair Values of Our Cash, Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash, Cash Equivalents and Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 201<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">621<span></span>
</td>
<td class="nump">759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term marketable securities</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_CashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash, cash equivalents and marketable securities</a></td>
<td class="nump">$ 876<span></span>
</td>
<td class="nump">$ 1,010<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_CashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_CashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Marketable Securities - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>position</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash, Cash Equivalents and Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of positions in securities in unrealized loss | position</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForLoanLossesExpensed', window );">Credit related losses | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForLoanLossesExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of credit loss expense (reversal of expense) for financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForLoanLossesExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Marketable Securities - Summary of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash, Cash Equivalents and Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 201<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash (included in Other noncurrent assets)</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
<td class="nump">$ 153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList', window );">Restricted Cash, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other noncurrent assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other noncurrent assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes cash restricted to withdrawal or usage, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components - Summary of Prepaid and Other Current Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_PrepaidExpensesAndOtherCurrentAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivable</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_PrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_PrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheet Components - Summary of Other Current Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_AccruedResearchAndDevelopmentExpensesCurrent', window );">Accrued research and development</a></td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued personnel expenses</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total other current liabilities</a></td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481573/470-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Summary of Long-Term Debt Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt (Contractual maturity 2030)</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized discounts, issuance costs, charges and payment-in-kind interest, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 99<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.39%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.85%<span></span>
</td>
<td class="nump">13.08%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=rcus_HerculesAgreementMember', window );">Hercules Agreement | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from issuance of secured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_DebtInstrumentAdditionalCommittedAmount', window );">Debt Instrument, additional committed amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_DebtInstrumentFaceAmountContingentlyAvailable', window );">Debt instrument, face amount, contingently available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=rcus_HerculesAgreementMember', window );">Hercules Agreement | Secured Debt | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_DebtInstrumentFaceAmountContingentlyAvailable', window );">Debt instrument, face amount, contingently available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_DebtInstrumentMilestoneAchievementPeriod', window );">Debt instrument, milestone achievement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=rcus_HerculesAgreementMember', window );">Hercules Agreement | Secured Debt | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_DebtInstrumentAdditionalCommittedAmount', window );">Debt Instrument, additional committed amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_DebtInstrumentFaceAmountContingentlyAvailable', window );">Debt instrument, face amount, contingently available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_DebtInstrumentMilestoneAchievementPeriod', window );">Debt instrument, milestone achievement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_DebtInstrumentAdditionalCommittedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Additional Committed Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_DebtInstrumentAdditionalCommittedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_DebtInstrumentFaceAmountContingentlyAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Face Amount, Contingently Available</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_DebtInstrumentFaceAmountContingentlyAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_DebtInstrumentMilestoneAchievementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Milestone Achievement Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_DebtInstrumentMilestoneAchievementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rcus_HerculesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rcus_HerculesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_DebtInstrumentTrancheTypeAxis=rcus_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_DebtInstrumentTrancheTypeAxis=rcus_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_DebtInstrumentTrancheTypeAxis=rcus_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_DebtInstrumentTrancheTypeAxis=rcus_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Cash and Non-cash Information Related to Operating Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities', window );">Cash paid for amounts included in measurement of lease liabilities</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Deposits for letters of credit</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="nump">13.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction | $</a></td>
<td class="nump">$ 150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember', window );">Gilead</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction | $</a></td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=rcus_GileadSciencesIncMember', window );">Gilead</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_SaleOfStockNumberOfSharesAcquiredInTransaction', window );">Sale of stock, number of shares acquired in transaction (in shares) | shares</a></td>
<td class="nump">1.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_SaleOfStockNumberOfSharesAcquiredInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Shares Acquired In Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_SaleOfStockNumberOfSharesAcquiredInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rcus_GileadSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rcus_GileadSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rcus_GileadSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 876<span></span>
</td>
<td class="nump">$ 1,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=rcus_CorporateSecuritiesAndCommercialPaperMember', window );">Corporate securities and commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate securities and commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">705<span></span>
</td>
<td class="nump">855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate securities and commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate securities and commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=rcus_CorporateSecuritiesAndCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=rcus_CorporateSecuritiesAndCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Segment - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets | $</a></td>
<td class="nump">$ 997<span></span>
</td>
<td class="nump">$ 1,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=rcus_ReportableSegmentMember', window );">Reportable segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets | $</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAssetReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=rcus_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=rcus_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Segment - Summary of Segment Reporting Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Adjusted for expense (income):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest income, net</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(128)<span></span>
</td>
<td class="num">(112)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=rcus_ReportableSegmentMember', window );">Reportable segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Adjusted for expense (income):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_LateStageDevelopmentPrograms', window );">Late-stage development programs</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_EarlyStageDevelopmentAndPreclinicalPrograms', window );">Early-stage development and preclinical programs</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Compensation and personnel costs</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest income, net</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rcus_PartnershipReimbursements', window );">Partnership reimbursements</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (128)<span></span>
</td>
<td class="num">$ (112)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_EarlyStageDevelopmentAndPreclinicalPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Early Stage Development And Preclinical Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_EarlyStageDevelopmentAndPreclinicalPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_LateStageDevelopmentPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Late Stage Development Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_LateStageDevelopmentPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rcus_PartnershipReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Partnership Reimbursements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rcus_PartnershipReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rcus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAssetReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=rcus_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=rcus_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>190</ContextCount>
  <ElementCount>233</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>63</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Condensed Consolidated Statements of Operations (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Organization, Liquidity and Capital Resources</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/OrganizationLiquidityandCapitalResources</Role>
      <ShortName>Organization, Liquidity and Capital Resources</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Related Party - Gilead Sciences, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/RelatedPartyGileadSciencesInc</Role>
      <ShortName>Related Party - Gilead Sciences, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - License and Collaborations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/LicenseandCollaborations</Role>
      <ShortName>License and Collaborations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Cash, Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CashCashEquivalentsandMarketableSecurities</Role>
      <ShortName>Cash, Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Condensed Consolidated Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponents</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Business Segment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/BusinessSegment</Role>
      <ShortName>Business Segment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://arcusbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcusbio.com/role/Revenues</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcusbio.com/role/NetLossPerShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcusbio.com/role/StockBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesTables</Role>
      <ShortName>Cash, Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcusbio.com/role/CashCashEquivalentsandMarketableSecurities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Condensed Consolidated Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsTables</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponents</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/LongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcusbio.com/role/LongTermDebt</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcusbio.com/role/Leases</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcusbio.com/role/FairValueMeasurements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Business Segment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/BusinessSegmentTables</Role>
      <ShortName>Business Segment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arcusbio.com/role/BusinessSegment</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Organization, Liquidity and Capital Resources - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails</Role>
      <ShortName>Organization, Liquidity and Capital Resources - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Related Party - Gilead Sciences, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails</Role>
      <ShortName>Related Party - Gilead Sciences, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcusbio.com/role/RelatedPartyGileadSciencesInc</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - License and Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/LicenseandCollaborationsDetails</Role>
      <ShortName>License and Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcusbio.com/role/LicenseandCollaborations</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Revenues - Summary of Revenues by Collaboration, Category of Revenue and Method of Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails</Role>
      <ShortName>Revenues - Summary of Revenues by Collaboration, Category of Revenue and Method of Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Revenues - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/RevenuesAdditionalInformationDetails</Role>
      <ShortName>Revenues - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Revenues - Summary of Revenue Recognized as a Result of Changes in Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/RevenuesSummaryofRevenueRecognizedasaResultofChangesinDeferredRevenueDetails</Role>
      <ShortName>Revenues - Summary of Revenue Recognized as a Result of Changes in Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Revenues - Summary of Transaction Price and Allocation of Transaction Price to the Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails</Role>
      <ShortName>Revenues - Summary of Transaction Price and Allocation of Transaction Price to the Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Income (Loss) per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetIncomeLossperShareDetails</Role>
      <ShortName>Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Income (Loss) per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcusbio.com/role/StockBasedCompensationTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Our Cash, Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails</Role>
      <ShortName>Cash, Cash Equivalents and Marketable Securities - Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Our Cash, Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Summary of Fair Values of Our Cash, Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesDetails</Role>
      <ShortName>Cash, Cash Equivalents and Marketable Securities - Summary of Fair Values of Our Cash, Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Cash, Cash Equivalents and Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Summary of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Cash, Cash Equivalents and Marketable Securities - Summary of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Condensed Consolidated Balance Sheet Components - Summary of Prepaid and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components - Summary of Prepaid and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Condensed Consolidated Balance Sheet Components - Summary of Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Condensed Consolidated Balance Sheet Components - Summary of Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Long-Term Debt - Summary of Long-Term Debt Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/LongTermDebtSummaryofLongTermDebtInstrumentsDetails</Role>
      <ShortName>Long-Term Debt - Summary of Long-Term Debt Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Long-Term Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails</Role>
      <ShortName>Long-Term Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Leases - Summary of Cash and Non-cash Information Related to Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/LeasesSummaryofCashandNoncashInformationRelatedtoOperatingLeasesDetails</Role>
      <ShortName>Leases - Summary of Cash and Non-cash Information Related to Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcusbio.com/role/StockholdersEquity</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arcusbio.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Business Segment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/BusinessSegmentAdditionalInformationDetails</Role>
      <ShortName>Business Segment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="rcus-20260331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Business Segment - Summary of Segment Reporting Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails</Role>
      <ShortName>Business Segment - Summary of Segment Reporting Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="rcus-20260331.htm">rcus-20260331.htm</File>
    <File>rcus-20260331.xsd</File>
    <File>rcus-20260331_cal.xml</File>
    <File>rcus-20260331_def.xml</File>
    <File>rcus-20260331_lab.xml</File>
    <File>rcus-20260331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>rcus-20260331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="442">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>78
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "rcus-20260331.htm": {
   "nsprefix": "rcus",
   "nsuri": "http://arcusbio.com/20260331",
   "dts": {
    "inline": {
     "local": [
      "rcus-20260331.htm"
     ]
    },
    "schema": {
     "local": [
      "rcus-20260331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "rcus-20260331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "rcus-20260331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "rcus-20260331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rcus-20260331_pre.xml"
     ]
    }
   },
   "keyStandard": 178,
   "keyCustom": 55,
   "axisStandard": 22,
   "axisCustom": 1,
   "memberStandard": 24,
   "memberCustom": 35,
   "hidden": {
    "total": 10,
    "http://xbrl.sec.gov/dei/2025": 5,
    "http://xbrl.sec.gov/ecd/2025": 3,
    "http://fasb.org/us-gaap/2025": 2
   },
   "contextCount": 190,
   "entityCount": 1,
   "segmentCount": 63,
   "elementCount": 494,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 442,
    "http://xbrl.sec.gov/dei/2025": 29,
    "http://xbrl.sec.gov/ecd/2025": 25
   },
   "report": {
    "R1": {
     "role": "http://arcusbio.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations",
     "longName": "9952151 - Statement - Condensed Consolidated Statements of Operations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
     "longName": "9952152 - Statement - Condensed Consolidated Statements of Operations (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Operations (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "rcus:ResearchAndDevelopmentExpenseRecoveries",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "longName": "9952153 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "9952154 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "9952155 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "longName": "9952156 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows",
     "longName": "9952157 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
     "longName": "9952158 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncreaseDecreaseInContractWithCustomerAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:IncreaseDecreaseInContractWithCustomerAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "unique": true
     }
    },
    "R10": {
     "role": "http://arcusbio.com/role/OrganizationLiquidityandCapitalResources",
     "longName": "9952159 - Disclosure - Organization, Liquidity and Capital Resources",
     "shortName": "Organization, Liquidity and Capital Resources",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://arcusbio.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952160 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://arcusbio.com/role/RelatedPartyGileadSciencesInc",
     "longName": "9952161 - Disclosure - Related Party - Gilead Sciences, Inc.",
     "shortName": "Related Party - Gilead Sciences, Inc.",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://arcusbio.com/role/LicenseandCollaborations",
     "longName": "9952162 - Disclosure - License and Collaborations",
     "shortName": "License and Collaborations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://arcusbio.com/role/Revenues",
     "longName": "9952163 - Disclosure - Revenues",
     "shortName": "Revenues",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://arcusbio.com/role/IncomeTaxes",
     "longName": "9952164 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://arcusbio.com/role/NetLossPerShare",
     "longName": "9952165 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://arcusbio.com/role/StockBasedCompensation",
     "longName": "9952166 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecurities",
     "longName": "9952167 - Disclosure - Cash, Cash Equivalents and Marketable Securities",
     "shortName": "Cash, Cash Equivalents and Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponents",
     "longName": "9952168 - Disclosure - Condensed Consolidated Balance Sheet Components",
     "shortName": "Condensed Consolidated Balance Sheet Components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://arcusbio.com/role/LongTermDebt",
     "longName": "9952169 - Disclosure - Long-Term Debt",
     "shortName": "Long-Term Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://arcusbio.com/role/Leases",
     "longName": "9952170 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://arcusbio.com/role/StockholdersEquity",
     "longName": "9952171 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://arcusbio.com/role/FairValueMeasurements",
     "longName": "9952172 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://arcusbio.com/role/BusinessSegment",
     "longName": "9952173 - Disclosure - Business Segment",
     "shortName": "Business Segment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://arcusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ConsolidationPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ConsolidationPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://arcusbio.com/role/RevenuesTables",
     "longName": "9955512 - Disclosure - Revenues (Tables)",
     "shortName": "Revenues (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://arcusbio.com/role/NetLossPerShareTables",
     "longName": "9955513 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://arcusbio.com/role/StockBasedCompensationTables",
     "longName": "9955514 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesTables",
     "longName": "9955515 - Disclosure - Cash, Cash Equivalents and Marketable Securities (Tables)",
     "shortName": "Cash, Cash Equivalents and Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsTables",
     "longName": "9955516 - Disclosure - Condensed Consolidated Balance Sheet Components (Tables)",
     "shortName": "Condensed Consolidated Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://arcusbio.com/role/LongTermDebtTables",
     "longName": "9955517 - Disclosure - Long-Term Debt (Tables)",
     "shortName": "Long-Term Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://arcusbio.com/role/LeasesTables",
     "longName": "9955518 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "rcus:ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "rcus:ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://arcusbio.com/role/FairValueMeasurementsTables",
     "longName": "9955519 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "rcus:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "rcus:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://arcusbio.com/role/BusinessSegmentTables",
     "longName": "9955520 - Disclosure - Business Segment (Tables)",
     "shortName": "Business Segment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails",
     "longName": "9955521 - Disclosure - Organization, Liquidity and Capital Resources - Additional Information (Details)",
     "shortName": "Organization, Liquidity and Capital Resources - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-46",
      "name": "us-gaap:InvestmentsAndCash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails",
     "longName": "9955522 - Disclosure - Related Party - Gilead Sciences, Inc. (Details)",
     "shortName": "Related Party - Gilead Sciences, Inc. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-57",
      "name": "rcus:NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments",
      "unitRef": "program",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://arcusbio.com/role/LicenseandCollaborationsDetails",
     "longName": "9955523 - Disclosure - License and Collaborations (Details)",
     "shortName": "License and Collaborations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-70",
      "name": "rcus:MilestonePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails",
     "longName": "9955524 - Disclosure - Revenues - Summary of Revenues by Collaboration, Category of Revenue and Method of Recognition (Details)",
     "shortName": "Revenues - Summary of Revenues by Collaboration, Category of Revenue and Method of Recognition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
     "longName": "9955525 - Disclosure - Revenues - Additional Information (Details)",
     "shortName": "Revenues - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://arcusbio.com/role/RevenuesSummaryofRevenueRecognizedasaResultofChangesinDeferredRevenueDetails",
     "longName": "9955526 - Disclosure - Revenues - Summary of Revenue Recognized as a Result of Changes in Deferred Revenue (Details)",
     "shortName": "Revenues - Summary of Revenue Recognized as a Result of Changes in Deferred Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R42": {
     "role": "http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails",
     "longName": "9955527 - Disclosure - Revenues - Summary of Transaction Price and Allocation of Transaction Price to the Performance Obligations (Details)",
     "shortName": "Revenues - Summary of Transaction Price and Allocation of Transaction Price to the Performance Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-103",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-121",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetIncomeLossperShareDetails",
     "longName": "9955528 - Disclosure - Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Income (Loss) per Share (Details)",
     "shortName": "Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Income (Loss) per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://arcusbio.com/role/StockBasedCompensationDetails",
     "longName": "9955529 - Disclosure - Stock-Based Compensation (Details)",
     "shortName": "Stock-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails",
     "longName": "9955530 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Our Cash, Cash Equivalents and Marketable Securities (Details)",
     "shortName": "Cash, Cash Equivalents and Marketable Securities - Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Our Cash, Cash Equivalents and Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesDetails",
     "longName": "9955531 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Summary of Fair Values of Our Cash, Cash Equivalents and Marketable Securities (Details)",
     "shortName": "Cash, Cash Equivalents and Marketable Securities - Summary of Fair Values of Our Cash, Cash Equivalents and Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetails",
     "longName": "9955532 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Additional Information (Details)",
     "shortName": "Cash, Cash Equivalents and Marketable Securities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "unitRef": "position",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "unitRef": "position",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofCashCashEquivalentsandRestrictedCashDetails",
     "longName": "9955533 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Summary of Cash, Cash Equivalents and Restricted Cash (Details)",
     "shortName": "Cash, Cash Equivalents and Marketable Securities - Summary of Cash, Cash Equivalents and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails",
     "longName": "9955534 - Disclosure - Condensed Consolidated Balance Sheet Components - Summary of Prepaid and Other Current Assets (Details)",
     "shortName": "Condensed Consolidated Balance Sheet Components - Summary of Prepaid and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "rcus:PrepaidExpensesAndOtherCurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "rcus:PrepaidExpensesAndOtherCurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails",
     "longName": "9955535 - Disclosure - Condensed Consolidated Balance Sheet Components - Summary of Other Current Liabilities (Details)",
     "shortName": "Condensed Consolidated Balance Sheet Components - Summary of Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "rcus:AccruedResearchAndDevelopmentExpensesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "rcus:AccruedResearchAndDevelopmentExpensesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://arcusbio.com/role/LongTermDebtSummaryofLongTermDebtInstrumentsDetails",
     "longName": "9955536 - Disclosure - Long-Term Debt - Summary of Long-Term Debt Instruments (Details)",
     "shortName": "Long-Term Debt - Summary of Long-Term Debt Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails",
     "longName": "9955537 - Disclosure - Long-Term Debt - Additional Information (Details)",
     "shortName": "Long-Term Debt - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://arcusbio.com/role/LeasesSummaryofCashandNoncashInformationRelatedtoOperatingLeasesDetails",
     "longName": "9955538 - Disclosure - Leases - Summary of Cash and Non-cash Information Related to Operating Leases (Details)",
     "shortName": "Leases - Summary of Cash and Non-cash Information Related to Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "rcus:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rcus:ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "rcus:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rcus:ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://arcusbio.com/role/LeasesAdditionalInformationDetails",
     "longName": "9955539 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:SecurityDeposit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:SecurityDeposit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://arcusbio.com/role/StockholdersEquityDetails",
     "longName": "9955540 - Disclosure - Stockholders' Equity (Details)",
     "shortName": "Stockholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://arcusbio.com/role/FairValueMeasurementsDetails",
     "longName": "9955541 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rcus:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rcus:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://arcusbio.com/role/BusinessSegmentAdditionalInformationDetails",
     "longName": "9955542 - Disclosure - Business Segment - Additional Information (Details)",
     "shortName": "Business Segment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfOperatingSegments",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-183",
      "name": "us-gaap:Assets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails",
     "longName": "9955543 - Disclosure - Business Segment - Summary of Segment Reporting Information (Details)",
     "shortName": "Business Segment - Summary of Segment Reporting Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-181",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rcus-20260331.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "rcus_AbmunoLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "AbmunoLicenseAgreementMember",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Abmuno License Agreement",
        "label": "Abmuno License Agreement [Member]",
        "documentation": "Abmuno license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_AccessRightsAndOptionContinuationPeriodsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "AccessRightsAndOptionContinuationPeriodsMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Access right and option continuation periods",
        "label": "Access Rights And Option Continuation Periods [Member]",
        "documentation": "Access Rights And Option Continuation Periods"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_AccessRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "AccessRightsMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Access rights",
        "label": "Access Rights [Member]",
        "documentation": "Access Rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets",
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable ($11 and $24 to a related party)",
        "verboseLabel": "Accounts payable, current",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r788"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of discounts on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "rcus_AccruedResearchAndDevelopmentExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development",
        "label": "Accrued Research And Development Expenses Current",
        "documentation": "Accrued research and development expenses current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r50",
      "r105",
      "r577",
      "r617",
      "r618",
      "r1059"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8",
      "r15",
      "r452",
      "r455",
      "r511",
      "r613",
      "r614",
      "r918",
      "r919",
      "r920",
      "r975",
      "r976",
      "r977",
      "r978"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "rcus_AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional clinical and regulatory milestone payments receivable",
        "label": "Additional Clinical And Milestone Payments Received Under License Agreement",
        "documentation": "Additional clinical and milestone payments received under license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_AdditionalClinicalRegulatoryAndCommercializationMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "AdditionalClinicalRegulatoryAndCommercializationMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional clinical, regulatory and commercialization milestone payments",
        "label": "Additional Clinical Regulatory And Commercialization Milestone Payments",
        "documentation": "Additional clinical regulatory and commercialization milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r817",
      "r827",
      "r837",
      "r869"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r820",
      "r830",
      "r840",
      "r872"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r821",
      "r831",
      "r841",
      "r865",
      "r873",
      "r877",
      "r885"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r396",
      "r397"
     ]
    },
    "rcus_AmendedGileadCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "AmendedGileadCollaborationAgreementMember",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended Gilead Collaboration Agreement",
        "label": "Amended Gilead Collaboration Agreement [Member]",
        "documentation": "Amended gilead collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_AntiCDThirtyNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "AntiCDThirtyNineMember",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "anti-CD39",
        "label": "Anti C D Thirty Nine [Member]",
        "documentation": "Anti CD thirty nine."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_AntiPDOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "AntiPDOneMember",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "anti-PD-1",
        "label": "Anti P D One [Member]",
        "documentation": "Anti PD one."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of diluted net loss per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcusbio.com/role/BusinessSegmentAdditionalInformationDetails",
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "terseLabel": "Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r79",
      "r101",
      "r126",
      "r128",
      "r129",
      "r164",
      "r177",
      "r195",
      "r199",
      "r238",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r428",
      "r432",
      "r491",
      "r563",
      "r564",
      "r572",
      "r658",
      "r734",
      "r735",
      "r747",
      "r788",
      "r795",
      "r796",
      "r808",
      "r1016",
      "r1017",
      "r1075"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r106",
      "r126",
      "r128",
      "r129",
      "r238",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r428",
      "r432",
      "r491",
      "r788",
      "r1016",
      "r1017",
      "r1075"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/FairValueMeasurementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets measured at fair value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468",
      "r776"
     ]
    },
    "rcus_AstraZenecaAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "AstraZenecaAgreementMember",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AstraZeneca Agreement",
        "label": "Astra Zeneca Agreement [Member]",
        "documentation": "AstraZeneca Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gain",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized Loss",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r247",
      "r571"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r247",
      "r467",
      "r486",
      "r487",
      "r488",
      "r489",
      "r557",
      "r710",
      "r776",
      "r779",
      "r786",
      "r992",
      "r1064",
      "r1065",
      "r1066"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "rcus_CashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0,
       "order": 1.0
      },
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r247"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "rcus_CashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term marketable securities",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r207",
      "r247"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position Location, Balance [Axis]",
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance is reported."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r434",
      "r436",
      "r437",
      "r438",
      "r439",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r490",
      "r773",
      "r774",
      "r897",
      "r1091"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position Location, Balance [Domain]",
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance is reported."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r434",
      "r436",
      "r437",
      "r438",
      "r439",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r490",
      "r773",
      "r774",
      "r897",
      "r1091"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]",
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://arcusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofCashCashEquivalentsandRestrictedCashDetails",
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r98",
      "r712"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": "rcus_CashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r488",
      "r489",
      "r1062",
      "r1063"
     ]
    },
    "rcus_CashCashEquivalentsAndAvailableForSaleInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "CashCashEquivalentsAndAvailableForSaleInvestments",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofFairValuesofOurCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash, cash equivalents and marketable securities",
        "label": "Cash Cash Equivalents And Available For Sale Investments",
        "documentation": "Cash, cash equivalents and available for sale investments."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember",
     "presentation": [
      "http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Cash Equivalents and Investments in Marketable Securities",
        "label": "Cash Cash Equivalents And Investments In Marketable Securities [Member]",
        "documentation": "Cash, cash equivalents and investments in marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_CashCashEquivalentsAndMarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents and Marketable Securities [Abstract]",
        "label": "Cash, Cash Equivalents and Marketable Securities [Abstract]",
        "documentation": "Cash, cash equivalents and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents and Marketable Securities",
        "label": "Cash, Cash Equivalent, and Marketable Security [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalent, and debt and equity securities, including realized and unrealized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/FairValueMeasurementsDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents, and short-term investments",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofCashCashEquivalentsandRestrictedCashDetails",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r57",
      "r123"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r57"
     ]
    },
    "rcus_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/LeasesSummaryofCashandNoncashInformationRelatedtoOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in measurement of lease liabilities",
        "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities",
        "documentation": "Cash paid for amounts included in measurement of lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcusbio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificate of deposit",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r802",
      "r803",
      "r804",
      "r805"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://arcusbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r166",
      "r309",
      "r315",
      "r316",
      "r317",
      "r319",
      "r322",
      "r327",
      "r329",
      "r450",
      "r624",
      "r625",
      "r626",
      "r627",
      "r748",
      "r895",
      "r968",
      "r970"
     ]
    },
    "rcus_ClinicalRegulatoryAndCommercializationMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "ClinicalRegulatoryAndCommercializationMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical, regulatory and commercialization milestone payments",
        "label": "Clinical Regulatory And Commercialization Milestone Payments",
        "documentation": "Clinical regulatory and commercialization milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_ClinicalRegulatoryMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "ClinicalRegulatoryMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical regulatory milestone payments",
        "label": "Clinical Regulatory Milestone Payments",
        "documentation": "Clinical Regulatory Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "rcus_CollaborationTermForCurrentAndFutureClinicalPrograms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "CollaborationTermForCurrentAndFutureClinicalPrograms",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration term for current and future clinical programs",
        "label": "Collaboration Term For Current And Future Clinical Programs",
        "documentation": "Collaboration term for current and future clinical programs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and Collaborations",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r424",
      "r425"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r72",
      "r575",
      "r645"
     ]
    },
    "us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockIncludingAdditionalPaidInCapitalMember",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock and additional paid-in capital",
        "label": "Common Stock Including Additional Paid in Capital [Member]",
        "documentation": "Common stock held by shareholders with par value plus amounts in excess of par value or issuance value (in cases of no-par value stock)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r798",
      "r799",
      "r800",
      "r802",
      "r803",
      "r804",
      "r805",
      "r975",
      "r976",
      "r978",
      "r1060",
      "r1121",
      "r1125"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "rcus_CommonStockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "CommonStockPurchaseAgreementMember",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Agreement",
        "label": "Common Stock Purchase Agreement [Member]",
        "documentation": "Common stock purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r646"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r45",
      "r646",
      "r664",
      "r1125",
      "r1126"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock and additional paid-in capital: $0.0001 par value per share; 400.0 shares authorized; 125.5 shares in 2026 and 125.3 shares in 2025 issued and outstanding",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r307",
      "r312",
      "r576",
      "r788"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r109",
      "r111",
      "r117",
      "r561",
      "r587",
      "r588"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r205",
      "r621",
      "r622",
      "r706",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r205",
      "r621",
      "r622",
      "r706",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r205",
      "r621",
      "r622",
      "r706",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of revenues",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r205",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r205",
      "r621",
      "r622",
      "r706",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://arcusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r722"
     ]
    },
    "rcus_ContingentMilestonePaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "ContingentMilestonePaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent milestone payments receivable",
        "label": "Contingent Milestone Payments Receivable",
        "documentation": "Contingent milestone payments receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://arcusbio.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Revenue Recognized as a Result of Changes in Deferred Revenue",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerAssetNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets",
      "http://arcusbio.com/role/LicenseandCollaborationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable from collaboration partners",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r333",
      "r335",
      "r346"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, liability",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r335",
      "r346"
     ]
    },
    "rcus_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, liability, cumulative catch-up adjustment to revenue, change in measure of progress and change in estimate of transaction price",
        "label": "Contract With Customer, Liability, Cumulative Catch-up Adjustment To Revenue, Change In Measure Of Progress And Change In Estimate Of Transaction Price",
        "documentation": "Contract With Customer, Liability, Cumulative Catch-up Adjustment To Revenue, Change In Measure Of Progress And Change In Estimate Of Transaction Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets",
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue ($27 and $35 to a related party)",
        "verboseLabel": "Deferred revenue, current",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r335",
      "r346"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets",
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, noncurrent ($36 and $43 to a related party)",
        "verboseLabel": "Deferred revenue, noncurrent",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r335",
      "r346"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails",
      "http://arcusbio.com/role/RevenuesSummaryofRevenueRecognizedasaResultofChangesinDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized from amounts in deferred revenue at the beginning of the period",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "rcus_CorporateSecuritiesAndCommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "CorporateSecuritiesAndCommercialPaperMember",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcusbio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate securities and commercial paper",
        "label": "Corporate Securities And Commercial Paper [Member]",
        "documentation": "Corporate securities and commercial paper."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails",
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails",
      "http://arcusbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r126",
      "r133",
      "r134",
      "r285",
      "r317",
      "r518",
      "r537",
      "r570",
      "r713",
      "r714",
      "r715",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r1055",
      "r1056",
      "r1057",
      "r1058"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_CurrentAndFutureProgramsExclusiveAccessPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "CurrentAndFutureProgramsExclusiveAccessPeriod",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current and future programs exclusive access period",
        "label": "Current And Future Programs Exclusive Access Period",
        "documentation": "Current and future programs exclusive access period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r982"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_DebtInstrumentAdditionalCommittedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "DebtInstrumentAdditionalCommittedAmount",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, additional committed amount",
        "label": "Debt Instrument, Additional Committed Amount",
        "documentation": "Debt Instrument, Additional Committed Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r38",
      "r39",
      "r69",
      "r71",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r787",
      "r968",
      "r969",
      "r971",
      "r974",
      "r1010",
      "r1011",
      "r1012",
      "r1072",
      "r1073",
      "r1084"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/LongTermDebtSummaryofLongTermDebtInstrumentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/LongTermDebtSummaryofLongTermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt (Contractual maturity 2030)",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r71",
      "r299"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, face amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r504",
      "r505",
      "r743",
      "r744",
      "r787"
     ]
    },
    "rcus_DebtInstrumentFaceAmountContingentlyAvailable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "DebtInstrumentFaceAmountContingentlyAvailable",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, face amount, contingently available",
        "label": "Debt Instrument, Face Amount, Contingently Available",
        "documentation": "Debt Instrument, Face Amount, Contingently Available"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, interest rate, effective percentage",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r302",
      "r504",
      "r505",
      "r787"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r450",
      "r566",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r787",
      "r968",
      "r969",
      "r971",
      "r974",
      "r1072",
      "r1073"
     ]
    },
    "rcus_DebtInstrumentMilestoneAchievementPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "DebtInstrumentMilestoneAchievementPeriod",
     "presentation": [
      "http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, milestone achievement period",
        "label": "Debt Instrument, Milestone Achievement Period",
        "documentation": "Debt Instrument, Milestone Achievement Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r787",
      "r968",
      "r969",
      "r971",
      "r974",
      "r1010",
      "r1011",
      "r1012",
      "r1072",
      "r1073",
      "r1084"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r30",
      "r33",
      "r36",
      "r63",
      "r64",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r450",
      "r566",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r787",
      "r968",
      "r969",
      "r971",
      "r974",
      "r1072",
      "r1073"
     ]
    },
    "rcus_DebtInstrumentTrancheTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "DebtInstrumentTrancheTypeAxis",
     "presentation": [
      "http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Tranche Type [Axis]",
        "label": "Debt Instrument, Tranche Type [Axis]",
        "documentation": "Debt Instrument, Tranche Type"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_DebtInstrumentTrancheTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "DebtInstrumentTrancheTypeDomain",
     "presentation": [
      "http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Tranche Type [Domain]",
        "label": "Debt Instrument, Tranche Type [Domain]",
        "documentation": "Debt Instrument, Tranche Type [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/LongTermDebtSummaryofLongTermDebtInstrumentsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/LongTermDebtSummaryofLongTermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unamortized discounts, issuance costs, charges and payment-in-kind interest, net",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r300",
      "r503",
      "r504",
      "r505",
      "r743",
      "r744",
      "r787"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Our Cash, Cash Equivalents and Marketable Securities",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of positions in securities in unrealized loss",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r249"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Prepaid and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_DeferredRevenueNonRefundablePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "DeferredRevenueNonRefundablePayment",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, non-refundable payment",
        "label": "Deferred Revenue, Non-Refundable Payment",
        "documentation": "Deferred Revenue, Non-Refundable Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r25"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r120",
      "r164",
      "r182",
      "r199",
      "r716",
      "r734",
      "r735"
     ]
    },
    "rcus_DevelopmentServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "DevelopmentServicesMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development services",
        "label": "Development Services [Member]",
        "documentation": "Development Services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r345",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r345",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://arcusbio.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Revenues by Collaboration, Category of Revenue and Method of Recognition",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://arcusbio.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r364",
      "r392",
      "r393",
      "r394",
      "r764"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "rcus_EarlyStageDevelopmentAndPreclinicalPrograms": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "EarlyStageDevelopmentAndPreclinicalPrograms",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Early-stage development and preclinical programs",
        "label": "Early Stage Development And Preclinical Programs",
        "documentation": "Early Stage Development And Preclinical Programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r118",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r153",
      "r155",
      "r157",
      "r158",
      "r159",
      "r163",
      "r305",
      "r395",
      "r418",
      "r423",
      "r464",
      "r465",
      "r562",
      "r589",
      "r725"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r118",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r155",
      "r157",
      "r158",
      "r159",
      "r163",
      "r305",
      "r395",
      "r418",
      "r423",
      "r464",
      "r465",
      "r562",
      "r589",
      "r725"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://arcusbio.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r160",
      "r161",
      "r162"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued personnel expenses",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://arcusbio.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock purchase plan shares",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails",
      "http://arcusbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "rcus_EquityAwardProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "EquityAwardProgramsMember",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Award Programs",
        "label": "Equity Award Programs [Member]",
        "documentation": "Equity Award Programs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r91",
      "r92",
      "r93",
      "r112",
      "r113",
      "r114",
      "r136",
      "r137",
      "r138",
      "r140",
      "r147",
      "r149",
      "r151",
      "r165",
      "r239",
      "r240",
      "r262",
      "r304",
      "r330",
      "r395",
      "r408",
      "r409",
      "r415",
      "r416",
      "r417",
      "r419",
      "r422",
      "r423",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r463",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r506",
      "r508",
      "r511",
      "r585",
      "r613",
      "r614",
      "r615",
      "r634",
      "r687"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r817",
      "r827",
      "r837",
      "r869"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r824",
      "r834",
      "r866"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468",
      "r478",
      "r776"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468",
      "r478",
      "r776"
     ]
    },
    "rcus_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "label": "Fair Value Assets and Liabilities Measured On Recurring Basis [Table Text Block]",
        "documentation": "Fair value assets and liabilities measured on recurring basis."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r477",
      "r478",
      "r480",
      "r487",
      "r524",
      "r525",
      "r526",
      "r710",
      "r743",
      "r744",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r776",
      "r779",
      "r786"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r473",
      "r475",
      "r476",
      "r477",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r556",
      "r776",
      "r780"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r350",
      "r355",
      "r357",
      "r468",
      "r478",
      "r487",
      "r524",
      "r710",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r776",
      "r786"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r350",
      "r355",
      "r357",
      "r359",
      "r468",
      "r469",
      "r478",
      "r487",
      "r525",
      "r710",
      "r743",
      "r744",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r776",
      "r786"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r468",
      "r469",
      "r470",
      "r471",
      "r478",
      "r487",
      "r526",
      "r710",
      "r743",
      "r744",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r776",
      "r779",
      "r786"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://arcusbio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r477",
      "r478",
      "r480",
      "r487",
      "r524",
      "r525",
      "r526",
      "r710",
      "r743",
      "r744",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r776",
      "r779",
      "r786"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcusbio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r241",
      "r242",
      "r244",
      "r245",
      "r246",
      "r248",
      "r250",
      "r251",
      "r298",
      "r327",
      "r450",
      "r461",
      "r485",
      "r490",
      "r493",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r569",
      "r586",
      "r740",
      "r776",
      "r777",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r789",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1061",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r821",
      "r831",
      "r841",
      "r873"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r821",
      "r831",
      "r841",
      "r873"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r821",
      "r831",
      "r841",
      "r873"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r821",
      "r831",
      "r841",
      "r873"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r821",
      "r831",
      "r841",
      "r873"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative (Includes $\u2014 and $\u2014 from a related party)",
        "verboseLabel": "General and administrative expense",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r667"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://arcusbio.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "rcus_GileadCollaborationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "GileadCollaborationMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gilead Collaboration",
        "label": "Gilead Collaboration [Member]",
        "documentation": "Gilead Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_GileadSciencesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "GileadSciencesIncMember",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gilead",
        "label": "Gilead Sciences Inc [Member]",
        "documentation": "Gilead Sciences, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_HerculesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "HerculesAgreementMember",
     "presentation": [
      "http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hercules Agreement",
        "label": "Hercules Agreement [Member]",
        "documentation": "Hercules Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r74",
      "r78",
      "r563",
      "r565",
      "r582",
      "r718",
      "r720",
      "r721",
      "r729",
      "r734",
      "r980",
      "r987",
      "r988",
      "r989",
      "r990"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails",
      "http://arcusbio.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r265",
      "r266",
      "r435",
      "r440",
      "r441",
      "r449",
      "r472",
      "r474",
      "r479",
      "r492",
      "r493",
      "r494",
      "r610",
      "r612",
      "r672",
      "r709",
      "r710",
      "r766",
      "r767",
      "r774",
      "r775",
      "r778",
      "r786",
      "r1052",
      "r1053",
      "r1092"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails",
      "http://arcusbio.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r266",
      "r435",
      "r440",
      "r441",
      "r449",
      "r472",
      "r474",
      "r479",
      "r492",
      "r493",
      "r494",
      "r610",
      "r612",
      "r672",
      "r709",
      "r710",
      "r766",
      "r767",
      "r774",
      "r775",
      "r778",
      "r786",
      "r1052",
      "r1053",
      "r1092"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://arcusbio.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r130",
      "r400",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r410",
      "r412",
      "r413",
      "r414",
      "r568",
      "r620",
      "r629",
      "r765"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r88",
      "r126",
      "r150",
      "r151",
      "r164",
      "r185",
      "r199",
      "r401",
      "r402",
      "r411",
      "r590",
      "r718",
      "r720",
      "r721",
      "r765"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable (($13) and $\u2014 to a related party)",
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Receivable from collaboration partners ($\u2014 and $2 from a related party)",
        "negatedTerseLabel": "Receivable from collaboration partners",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue (($15) and ($28) to a related party)",
        "verboseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r964"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r821",
      "r831",
      "r841",
      "r865",
      "r873",
      "r877",
      "r885"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r889"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r889"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r889"
     ]
    },
    "rcus_InterestAndOtherIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "InterestAndOtherIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and other income, net",
        "label": "Interest and Other Income Expense Nonoperating Net",
        "documentation": "Interest and other income (expense) nonoperating net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense, debt",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r295",
      "r303",
      "r745",
      "r746",
      "r1124"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      },
      "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "terseLabel": "Interest income, net",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r718",
      "r721",
      "r922"
     ]
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest receivable",
        "label": "Interest Receivable, Current",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "us-gaap_InvestmentsAndCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsAndCash",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and investments",
        "label": "Investments and Cash",
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r1086",
      "r1089"
     ]
    },
    "rcus_JenniferJarrettMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "JenniferJarrettMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jennifer Jarrett [Member]",
        "documentation": "Jennifer Jarrett"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_JuanJaenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "JuanJaenMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Juan Jaen [Member]",
        "documentation": "Juan Jaen"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation and personnel costs",
        "label": "Labor and Related Expense",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r720",
      "r921"
     ]
    },
    "rcus_LateStageDevelopmentPrograms": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "LateStageDevelopmentPrograms",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Late-stage development programs",
        "label": "Late Stage Development Programs",
        "documentation": "Late Stage Development Programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails",
      "http://arcusbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://arcusbio.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r73",
      "r579",
      "r788",
      "r795",
      "r796",
      "r968",
      "r973",
      "r1009",
      "r1071"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r97",
      "r126",
      "r128",
      "r129",
      "r238",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r429",
      "r432",
      "r433",
      "r491",
      "r788",
      "r1016",
      "r1075",
      "r1076"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_LicenseAndCollaborationAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "LicenseAndCollaborationAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License And Collaboration Agreements [Abstract]",
        "label": "License and Collaboration Agreements [Abstract]",
        "documentation": "License and collaboration agreements."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_LicenseAndCollaborationAgreementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "LicenseAndCollaborationAgreementsLineItems",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails",
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License And Collaboration Agreements [Line Items]",
        "label": "License and Collaboration Agreements [Line Items]",
        "documentation": "License and collaboration agreements."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_LicenseAndCollaborationAgreementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "LicenseAndCollaborationAgreementsTable",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License And Collaboration Agreements [Table]",
        "label": "License and Collaboration Agreements [Table]",
        "documentation": "License and collaboration agreements."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_LicenseAndDevelopmentServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "LicenseAndDevelopmentServicesMember",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails",
      "http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and development services",
        "label": "License And Development Services [Member]",
        "documentation": "License And Development Services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LicenseMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails",
      "http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r1020",
      "r1021"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      },
      "http://arcusbio.com/role/LongTermDebtSummaryofLongTermDebtInstrumentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets",
      "http://arcusbio.com/role/LongTermDebtSummaryofLongTermDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "totalLabel": "Total long-term debt",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r71",
      "r127",
      "r135",
      "r289",
      "r301",
      "r566",
      "r743",
      "r744",
      "r787",
      "r1087"
     ]
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://arcusbio.com/role/LongTermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt",
        "label": "Long-Term Debt [Text Block]",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r1010",
      "r1011",
      "r1012"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r27",
      "r1010",
      "r1011",
      "r1012"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails",
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r172",
      "r269",
      "r270",
      "r271",
      "r272",
      "r361",
      "r387",
      "r388",
      "r389",
      "r398",
      "r471",
      "r553",
      "r609",
      "r611",
      "r619",
      "r637",
      "r638",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r702",
      "r703",
      "r704",
      "r705",
      "r707",
      "r708",
      "r739",
      "r748",
      "r763",
      "r766",
      "r768",
      "r769",
      "r779",
      "r780",
      "r784",
      "r785",
      "r791",
      "r1018",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "rcus_MilestoneExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "MilestoneExpense",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development milestone expense",
        "label": "Milestone Expense",
        "documentation": "Milestone expense."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_MilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "MilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments",
        "label": "Milestone Payments",
        "documentation": "Milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r172",
      "r269",
      "r270",
      "r271",
      "r272",
      "r361",
      "r387",
      "r388",
      "r389",
      "r398",
      "r471",
      "r553",
      "r609",
      "r611",
      "r619",
      "r637",
      "r638",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r702",
      "r703",
      "r704",
      "r705",
      "r707",
      "r708",
      "r739",
      "r748",
      "r763",
      "r766",
      "r768",
      "r769",
      "r779",
      "r780",
      "r784",
      "r791",
      "r1018",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcusbio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1022",
      "r1023"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://arcusbio.com/role/OrganizationLiquidityandCapitalResources"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Liquidity and Capital Resources",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r168",
      "r726",
      "r727"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r59"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      },
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r59",
      "r75",
      "r93",
      "r95",
      "r107",
      "r110",
      "r114",
      "r126",
      "r128",
      "r129",
      "r132",
      "r139",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r150",
      "r151",
      "r156",
      "r238",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r305",
      "r308",
      "r310",
      "r313",
      "r395",
      "r418",
      "r423",
      "r465",
      "r491",
      "r584",
      "r665",
      "r685",
      "r686",
      "r718",
      "r720",
      "r721",
      "r806",
      "r1016"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://arcusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r821",
      "r831",
      "r841",
      "r865",
      "r873"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "rcus_NonRefundableAndNonCreditableCashPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "NonRefundableAndNonCreditableCashPayments",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non refundable and non creditable cash payments",
        "label": "Non Refundable And Non Creditable Cash Payments",
        "documentation": "Non refundable and non creditable cash payments."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-operating income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "rcus_NumberOfBoardMembers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "NumberOfBoardMembers",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of board members",
        "label": "Number Of Board Members",
        "documentation": "Number Of Board Members"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_NumberOfExerciseOptionToPrograms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "NumberOfExerciseOptionToPrograms",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of exercise option to programs",
        "label": "Number Of Exercise Option To Programs",
        "documentation": "Number of exercise option to programs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://arcusbio.com/role/BusinessSegmentAdditionalInformationDetails",
      "http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r986"
     ]
    },
    "rcus_NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of programs, eligible to receive regulatory and commercial milestone payments",
        "label": "Number Of Programs, Eligible To Receive Regulatory And Commercial Milestone Payments",
        "documentation": "Number of programs, eligible to receive regulatory and commercial milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://arcusbio.com/role/BusinessSegmentAdditionalInformationDetails",
      "http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r738",
      "r986"
     ]
    },
    "rcus_NumberOfResearchPrograms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "NumberOfResearchPrograms",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of research programs",
        "label": "Number Of Research Programs",
        "documentation": "Number of research programs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r718",
      "r721",
      "r729",
      "r980",
      "r987",
      "r988",
      "r989",
      "r990"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncash lease expense",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "rcus_OptionAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "OptionAndLicenseAgreementMember",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taiho Agreement",
        "label": "Option And License Agreement [Member]",
        "documentation": "Option and license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option continuation payment due upon eighth anniversary of agreement",
        "label": "Option Continuation Payment Due Upon Eighth Anniversary Of Agreement",
        "documentation": "Option continuation payment due upon Eighth anniversary of agreement."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option continuation payment due upon fourth anniversary of agreement",
        "label": "Option Continuation Payment Due Upon Fourth Anniversary Of Agreement",
        "documentation": "Option continuation payment due upon Fourth anniversary of agreement."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option continuation payment due upon second anniversary of agreement",
        "label": "Option Continuation Payment Due Upon Second Anniversary Of Agreement",
        "documentation": "Option continuation payment due upon second anniversary of agreement."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option continuation payment due upon sixth anniversary of agreement",
        "label": "Option Continuation Payment Due Upon Sixth Anniversary Of Agreement",
        "documentation": "Option continuation payment due upon Sixth anniversary of agreement."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option continuation payment receivable upon sixth anniversary of agreement",
        "label": "Option Continuation Payment Receivable Upon Sixth Anniversary Of Agreement",
        "documentation": "Option continuation payment receivable upon sixth anniversary of agreement."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option fee per program for all other programs entering clinical development to exercise option",
        "label": "Option Fee Per Program For All Other Programs Entering Clinical Development To Exercise Option",
        "documentation": "Option fee per program for all other programs entering clinical development to exercise option."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_OptionLicenseAndCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "OptionLicenseAndCollaborationAgreementMember",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gilead Collaboration Agreement",
        "label": "Option License And Collaboration Agreement [Member]",
        "documentation": "Option, license and collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_OptionPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "OptionPaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option payments received",
        "label": "Option Payment Received",
        "documentation": "Option payment received."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_OptionPaymentUponAchievementOfCertainDevelopmentMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "OptionPaymentUponAchievementOfCertainDevelopmentMilestones",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option payment upon achievement of certain development milestones",
        "label": "Option Payment Upon Achievement Of Certain Development Milestones",
        "documentation": "Option payment upon achievement of certain development milestones."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_OptionPaymentUponCompletionOfCertainINDEnablingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "OptionPaymentUponCompletionOfCertainINDEnablingActivities",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option payment upon completion of certain IND-enabling activities",
        "label": "Option Payment Upon Completion Of certain IND-enabling Activities",
        "documentation": "Option payment upon completion of certain IND-enabling activities."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_OptionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "OptionPeriod",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option period",
        "label": "Option Period",
        "documentation": "Option period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_OrganizationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "OrganizationLineItems",
     "presentation": [
      "http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization [Line Items]",
        "label": "Organization [Line Items]",
        "documentation": "Organization [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_OrganizationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "OrganizationTable",
     "presentation": [
      "http://arcusbio.com/role/OrganizationLiquidityandCapitalResourcesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization [Table]",
        "label": "Organization [Table]",
        "documentation": "Organization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other noncurrent assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "rcus_OtherCollaborationRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "OtherCollaborationRevenueMember",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other collaboration",
        "verboseLabel": "Other collaboration",
        "label": "Other Collaboration Revenue [Member]",
        "documentation": "Other Collaboration Revenue [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r12",
      "r108",
      "r111",
      "r116",
      "r147",
      "r495",
      "r496",
      "r501",
      "r560",
      "r585",
      "r918",
      "r919"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r8",
      "r66",
      "r108",
      "r111",
      "r147"
     ]
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Other Current Liabilities",
        "label": "Other Current Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other Liabilities",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r573",
      "r641",
      "r642",
      "r747",
      "r795",
      "r796",
      "r808",
      "r1088",
      "r1122"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails",
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets",
      "http://arcusbio.com/role/LicenseandCollaborationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "totalLabel": "Total other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r788"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets",
      "http://arcusbio.com/role/LicenseandCollaborationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other noncurrent liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-operating income (expense):",
        "label": "Other Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other items, net",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Other Item",
        "documentation": "Amount of cash inflow (outflow) from operating activity, classified as other, in reconciling net income to reflect cash provided by (used in) operating activity when indirect cash flow method is applied."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "rcus_OtherServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "OtherServicesMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Services [Member]",
        "documentation": "Other Services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherSundryLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Sundry Liabilities, Current",
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r39"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r819",
      "r829",
      "r839",
      "r871"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r822",
      "r832",
      "r842",
      "r874"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r822",
      "r832",
      "r842",
      "r874"
     ]
    },
    "rcus_PartnershipReimbursements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "PartnershipReimbursements",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Partnership reimbursements",
        "label": "Partnership Reimbursements",
        "documentation": "Partnership Reimbursements"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "rcus_PaymentForOptionExercise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "PaymentForOptionExercise",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for option exercise",
        "label": "Payment For Option Exercise",
        "documentation": "Payment for option exercise."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_PaymentForOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "PaymentForOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for option exercise",
        "label": "Payment For Options Exercised",
        "documentation": "Payment for option exercise."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "rcus_PercentageOfOutstandingCommonStockOwned": {
     "xbrltype": "percentItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "PercentageOfOutstandingCommonStockOwned",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of outstanding common stock held",
        "label": "Percentage Of Outstanding Common Stock Owned",
        "documentation": "Percentage of outstanding common stock owned."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "rcus_PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential regulatory approval milestones payment receivable related to domvanalimab",
        "label": "Potential Regulatory Approval Milestones Payment Receivable Related To Domvanalimab",
        "documentation": "Potential regulatory approval milestones payment receivable related to domvanalimab."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails",
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "rcus_PrepaidExpensesAndOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "PrepaidExpensesAndOtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofPrepaidandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other assets",
        "label": "Prepaid Expenses And Other Current Assets",
        "documentation": "Prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock ($\u2014 and $14 from a related party)",
        "verboseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of secured debt",
        "label": "Proceeds from Issuance of Secured Debt",
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock pursuant to equity award plans",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r10"
     ]
    },
    "rcus_ProceedsFromMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "ProceedsFromMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities of marketable securities",
        "label": "Proceeds From Maturity Of Marketable Securities",
        "documentation": "Proceeds from maturity of marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_ProceedsFromSaleOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "ProceedsFromSaleOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales of marketable securities",
        "label": "Proceeds From Sale Of Marketable Securities",
        "documentation": "Proceeds from sale of marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
      "http://arcusbio.com/role/LicenseandCollaborationsDetails",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails",
      "http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r555",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r711",
      "r717",
      "r720",
      "r721",
      "r749",
      "r751",
      "r790",
      "r791",
      "r792",
      "r794",
      "r797",
      "r896",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r1014",
      "r1015",
      "r1090",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
      "http://arcusbio.com/role/LicenseandCollaborationsDetails",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails",
      "http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r555",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r711",
      "r717",
      "r720",
      "r721",
      "r749",
      "r751",
      "r790",
      "r791",
      "r792",
      "r794",
      "r797",
      "r896",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r1014",
      "r1015",
      "r1090",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r95",
      "r107",
      "r110",
      "r121",
      "r126",
      "r128",
      "r129",
      "r132",
      "r139",
      "r147",
      "r150",
      "r151",
      "r238",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r305",
      "r395",
      "r418",
      "r423",
      "r427",
      "r430",
      "r431",
      "r465",
      "r491",
      "r563",
      "r565",
      "r583",
      "r633",
      "r665",
      "r685",
      "r686",
      "r770",
      "r771",
      "r807",
      "r920",
      "r1016"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r510",
      "r567",
      "r581",
      "r788"
     ]
    },
    "us-gaap_ProvisionForLoanLossesExpensed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProvisionForLoanLossesExpensed",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit related losses",
        "label": "Financing Receivable, Credit Loss, Expense (Reversal)",
        "documentation": "Amount of credit loss expense (reversal of expense) for financing receivable."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r243",
      "r558"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "rcus_RDServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "RDServicesMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails",
      "http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D services",
        "label": "R&amp;D Services [Member]",
        "documentation": "R&amp;D Services"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails",
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r172",
      "r269",
      "r270",
      "r271",
      "r272",
      "r349",
      "r361",
      "r387",
      "r388",
      "r389",
      "r394",
      "r398",
      "r471",
      "r527",
      "r536",
      "r553",
      "r609",
      "r611",
      "r619",
      "r637",
      "r638",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r702",
      "r703",
      "r704",
      "r705",
      "r707",
      "r708",
      "r739",
      "r748",
      "r763",
      "r766",
      "r768",
      "r769",
      "r779",
      "r780",
      "r784",
      "r785",
      "r791",
      "r800",
      "r1013",
      "r1018",
      "r1065",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails",
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r172",
      "r269",
      "r270",
      "r271",
      "r272",
      "r349",
      "r361",
      "r387",
      "r388",
      "r389",
      "r394",
      "r398",
      "r471",
      "r527",
      "r536",
      "r553",
      "r609",
      "r611",
      "r619",
      "r637",
      "r638",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r702",
      "r703",
      "r704",
      "r705",
      "r707",
      "r708",
      "r739",
      "r748",
      "r763",
      "r766",
      "r768",
      "r769",
      "r779",
      "r780",
      "r784",
      "r785",
      "r791",
      "r800",
      "r1013",
      "r1018",
      "r1065",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082"
     ]
    },
    "us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationFromSegmentTotalsToConsolidatedAbstract",
     "presentation": [
      "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjusted for expense (income):",
        "label": "Segment Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTable",
     "presentation": [
      "http://arcusbio.com/role/BusinessSegmentAdditionalInformationDetails",
      "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Assets from Segment to Consolidated [Table]",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table]",
        "documentation": "Disclosure of information about identification, description, and amounts of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r824",
      "r834",
      "r866"
     ]
    },
    "rcus_RegulatoryAndCommercialMilestonePaymentsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "RegulatoryAndCommercialMilestonePaymentsReceived",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory and commercial milestone payments received",
        "label": "Regulatory And Commercial Milestone Payments Received",
        "documentation": "Regulatory and commercial milestone payments received."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_ReimbursementOfResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "ReimbursementOfResearchAndDevelopmentExpense",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursement of research and development expense",
        "label": "Reimbursement Of Research And Development Expense",
        "documentation": "Reimbursement of research and development expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r131",
      "r132",
      "r206",
      "r356",
      "r360",
      "r515",
      "r516",
      "r574",
      "r580",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r663",
      "r694",
      "r1123"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r131",
      "r132",
      "r515",
      "r516",
      "r517",
      "r518",
      "r574",
      "r580",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r663",
      "r694"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Axis]",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r131",
      "r132",
      "r515",
      "r516",
      "r1074"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Domain]",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r131",
      "r132",
      "r1074"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r131",
      "r132",
      "r206",
      "r515",
      "r516",
      "r518",
      "r668",
      "r669",
      "r672"
     ]
    },
    "rcus_RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursement from related party for shared costs",
        "label": "Related Party Transaction Reimbursement From Related Party For Shared Costs",
        "documentation": "Related party transaction reimbursement from related party for shared costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r131",
      "r132",
      "r206",
      "r356",
      "r360",
      "r515",
      "r516",
      "r574",
      "r580",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r663",
      "r694",
      "r1074",
      "r1123"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesInc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party - Gilead Sciences, Inc.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r513",
      "r514",
      "r516",
      "r519",
      "r630",
      "r631",
      "r632",
      "r670",
      "r671",
      "r672",
      "r691",
      "r693"
     ]
    },
    "rcus_RemoveOptionContinuationPaymentUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "RemoveOptionContinuationPaymentUnderAgreement",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Removal of option continuation payment under agreement",
        "label": "Remove Option Continuation Payment Under Agreement",
        "documentation": "Remove option continuation payment under agreement."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://arcusbio.com/role/BusinessSegmentAdditionalInformationDetails",
      "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails",
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails",
      "http://arcusbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r126",
      "r133",
      "r134",
      "r285",
      "r317",
      "r518",
      "r537",
      "r570",
      "r713",
      "r714",
      "r715",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r1055",
      "r1056",
      "r1057",
      "r1058"
     ]
    },
    "rcus_ResearchAndDevelopmentActivitiesForInflammationProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "ResearchAndDevelopmentActivitiesForInflammationProgramsMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D Activities for Inflammation Programs",
        "label": "Research And Development Activities For Inflammation Programs [Member]",
        "documentation": "Research and development activities for inflammation programs member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development (Includes $\u2014 and ($5) from a related party)",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r709",
      "r718",
      "r719",
      "r734",
      "r1083"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development cost recorded within research and development expenses",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r1051"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails",
      "http://arcusbio.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "verboseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_ResearchAndDevelopmentExpenseRecoveries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "ResearchAndDevelopmentExpenseRecoveries",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense, net of recoveries",
        "label": "Research And Development Expense, Recoveries",
        "documentation": "Research And Development Expense, Recoveries"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r815",
      "r825",
      "r835",
      "r867"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r826",
      "r836",
      "r868"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r823",
      "r833",
      "r843",
      "r875"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash (included in Other noncurrent assets)",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r906",
      "r966"
     ]
    },
    "us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "label": "Restricted Cash, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes cash restricted to withdrawal or usage, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units issued",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r65",
      "r578",
      "r616",
      "r618",
      "r628",
      "r647",
      "r788"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r136",
      "r137",
      "r138",
      "r140",
      "r147",
      "r149",
      "r151",
      "r239",
      "r240",
      "r262",
      "r304",
      "r395",
      "r408",
      "r409",
      "r415",
      "r416",
      "r417",
      "r419",
      "r422",
      "r423",
      "r451",
      "r453",
      "r454",
      "r456",
      "r463",
      "r506",
      "r508",
      "r613",
      "r615",
      "r634",
      "r1125"
     ]
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenues from collaborations",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r1054"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails",
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenues",
        "verboseLabel": "Total revenues from a customer",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r164",
      "r178",
      "r179",
      "r193",
      "r199",
      "r202",
      "r204",
      "r205",
      "r343",
      "r344",
      "r345",
      "r555",
      "r718",
      "r721"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://arcusbio.com/role/Revenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r345",
      "r348"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total transaction price",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "presentation": [
      "http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "presentation": [
      "http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenues",
        "verboseLabel": "Revenue",
        "totalLabel": "Total revenues",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r115",
      "r126",
      "r128",
      "r129",
      "r164",
      "r178",
      "r179",
      "r193",
      "r199",
      "r202",
      "r204",
      "r205",
      "r238",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r491",
      "r563",
      "r565",
      "r734",
      "r772",
      "r795",
      "r796",
      "r1016"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_RightsToCertainStudiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "RightsToCertainStudiesMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rights to certain studies",
        "label": "Rights To Certain Studies [Member]",
        "documentation": "Rights To Certain Studies"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_RobertC.GoeltzIIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "RobertC.GoeltzIIMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Robert C. Goeltz II [Member]",
        "documentation": "Robert C. Goeltz II"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_RoyaltiesPayableTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "RoyaltiesPayableTerm",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties payable term",
        "label": "Royalties Payable Term",
        "documentation": "Royalties Payable Term"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "rcus_STAR121DevelopmentActivitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "STAR121DevelopmentActivitiesMember",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STAR-121 Development Activities",
        "label": "STAR-121 Development Activities [Member]",
        "documentation": "STAR-121 Development Activities"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_STAR221DevelopmentActivitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "STAR221DevelopmentActivitiesMember",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STAR-221 Development Activities",
        "label": "STAR-221 Development Activities [Member]",
        "documentation": "STAR-221 Development Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails",
      "http://arcusbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, consideration received on transaction",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_SaleOfStockNumberOfSharesAcquiredInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "SaleOfStockNumberOfSharesAcquiredInTransaction",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails",
      "http://arcusbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, number of shares acquired in transaction (in shares)",
        "label": "Sale Of Stock, Number Of Shares Acquired In Transaction",
        "documentation": "Sale Of Stock, Number Of Shares Acquired In Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://arcusbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://arcusbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Benchmark",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r982",
      "r983"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://arcusbio.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Outstanding Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219"
     ]
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Fair Values of Our Cash, Cash Equivalents and Marketable Securities",
        "label": "Cash, Cash Equivalent, and Investment [Table Text Block]",
        "documentation": "Tabular disclosure of cash, cash equivalent, and investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://arcusbio.com/role/LongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Long-Term Debt Instruments",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r30",
      "r33",
      "r36",
      "r63",
      "r64",
      "r743",
      "r745",
      "r969",
      "r974",
      "r1072",
      "r1084"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://arcusbio.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://arcusbio.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]",
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r131",
      "r132",
      "r515",
      "r516",
      "r518",
      "r668",
      "r669",
      "r672"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Cash, Cash Equivalents and Restricted Cash",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r67",
      "r1089"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://arcusbio.com/role/BusinessSegmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Segment Reporting Information",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://arcusbio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r63",
      "r64",
      "r65",
      "r102",
      "r103",
      "r104",
      "r166",
      "r315",
      "r316",
      "r317",
      "r319",
      "r322",
      "r327",
      "r329",
      "r450",
      "r624",
      "r625",
      "r626",
      "r627",
      "r748",
      "r895",
      "r968",
      "r970"
     ]
    },
    "rcus_ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock",
     "presentation": [
      "http://arcusbio.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Cash and Non-cash Information Related to Operating Leases",
        "label": "Schedule Of Supplemental Cash Flow Disclosures And Non-Cash Financing Activities Related To Operating Leases [Table Text Block]",
        "documentation": "Schedule of supplemental cash flow disclosures and non-cash financing activities related to operating leases."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock",
     "presentation": [
      "http://arcusbio.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Transaction Price and Allocation of Transaction Price to the Performance Obligations",
        "label": "Schedule Of Transaction Price And Allocated To Transaction Price To Performance Obligations [Table Text Block]",
        "documentation": "Schedule of transaction price and allocated to transaction price to performance obligations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Debt",
        "label": "Secured Debt [Member]",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://arcusbio.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits for letters of credit",
        "label": "Security Deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://arcusbio.com/role/BusinessSegmentAdditionalInformationDetails",
      "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r79",
      "r164",
      "r174",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r205",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r267",
      "r268",
      "r420",
      "r421",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r731",
      "r734",
      "r735",
      "r741",
      "r793",
      "r1090",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingAssetReconcilingItemLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAssetReconcilingItemLineItems",
     "presentation": [
      "http://arcusbio.com/role/BusinessSegmentAdditionalInformationDetails",
      "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, Asset Reconciling Item [Line Items]",
        "label": "Segment Reporting, Asset Reconciling Item [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://arcusbio.com/role/BusinessSegment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Segment",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r164",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r189",
      "r191",
      "r192",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r730",
      "r732",
      "r733",
      "r734",
      "r736",
      "r737",
      "r738"
     ]
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other segment items",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r191",
      "r192",
      "r199",
      "r734"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Award Types",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://arcusbio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://arcusbio.com/role/BusinessSegmentAdditionalInformationDetails",
      "http://arcusbio.com/role/BusinessSegmentSummaryofSegmentReportingInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r79",
      "r94",
      "r164",
      "r174",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r205",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r264",
      "r267",
      "r268",
      "r420",
      "r421",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r731",
      "r734",
      "r735",
      "r741",
      "r793",
      "r1090",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r45",
      "r47",
      "r48",
      "r91",
      "r92",
      "r93",
      "r112",
      "r113",
      "r114",
      "r136",
      "r137",
      "r138",
      "r140",
      "r147",
      "r149",
      "r151",
      "r165",
      "r239",
      "r240",
      "r262",
      "r304",
      "r330",
      "r395",
      "r408",
      "r409",
      "r415",
      "r416",
      "r417",
      "r419",
      "r422",
      "r423",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r463",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r506",
      "r508",
      "r511",
      "r585",
      "r613",
      "r614",
      "r615",
      "r634",
      "r687"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r165",
      "r306",
      "r307",
      "r309",
      "r311",
      "r508",
      "r555",
      "r623",
      "r635",
      "r636",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r646",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r666",
      "r667",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r687",
      "r720",
      "r721",
      "r801",
      "r1123"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperationsParenthetical",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r165",
      "r206",
      "r306",
      "r307",
      "r309",
      "r311",
      "r508",
      "r555",
      "r623",
      "r635",
      "r636",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r646",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r666",
      "r667",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r687",
      "r720",
      "r721",
      "r801",
      "r1123"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r828",
      "r838",
      "r870"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049"
     ]
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://arcusbio.com/role/NetLossPerShareSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromComputationofDilutedNetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock options issued and outstanding",
        "label": "Share-Based Payment Arrangement [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r44",
      "r45",
      "r65",
      "r624",
      "r687",
      "r700"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r44",
      "r45",
      "r65",
      "r634",
      "r687",
      "r700",
      "r807"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets",
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r47",
      "r48",
      "r60",
      "r648",
      "r664",
      "r688",
      "r689",
      "r788",
      "r808",
      "r968",
      "r972",
      "r973",
      "r1009",
      "r1071",
      "r1125"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Note [Abstract]",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://arcusbio.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r314",
      "r316",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r330",
      "r450",
      "r462",
      "r690",
      "r692",
      "r701"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r520"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r520"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r520"
     ]
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Consolidated Balance Sheet Components",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "rcus_TaihoCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "TaihoCollaborationAgreementMember",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taiho Collaboration Agreement",
        "label": "Taiho Collaboration Agreement [Member]",
        "documentation": "Taiho Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_TaihoCollaborationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "TaihoCollaborationMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taiho Collaboration",
        "label": "Taiho Collaboration [Member]",
        "documentation": "Taiho Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_TaihoPharmaceuticalCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "TaihoPharmaceuticalCoLtdMember",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofTransactionPriceandAllocationofTransactionPricetothePerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taiho Pharmaceutical Co., Ltd",
        "label": "Taiho Pharmaceutical Co Ltd [Member]",
        "documentation": "Taiho Pharmaceutical Co., Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedBalanceSheetComponentsSummaryofOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes payable",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39"
     ]
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TimingOfTransferOfGoodOrServiceAxis",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of Transfer of Good or Service [Axis]",
        "label": "Timing of Transfer of Good or Service [Axis]",
        "documentation": "Information by timing of transfer of good or service to customer."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r749",
      "r756"
     ]
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TimingOfTransferOfGoodOrServiceDomain",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of Transfer of Good or Service [Domain]",
        "label": "Timing of Transfer of Good or Service [Domain]",
        "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r749",
      "r756"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "rcus_TotalUpfrontCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "TotalUpfrontCashPayment",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total upfront cash payment",
        "label": "Total Upfront Cash Payment",
        "documentation": "Total Upfront Cash Payment"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://arcusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "rcus_TrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "TrancheOneMember",
     "presentation": [
      "http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche One",
        "label": "Tranche One [Member]",
        "documentation": "Tranche One"
       }
      }
     },
     "auth_ref": []
    },
    "rcus_TrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "TrancheTwoMember",
     "presentation": [
      "http://arcusbio.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche Two",
        "label": "Tranche Two [Member]",
        "documentation": "Tranche Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransferredOverTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransferredOverTimeMember",
     "presentation": [
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over time",
        "label": "Transferred over Time [Member]",
        "documentation": "Contract with customer in which good or service is transferred over time."
       }
      }
     },
     "auth_ref": [
      "r749",
      "r750",
      "r756"
     ]
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcusbio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r298",
      "r327",
      "r450",
      "r461",
      "r485",
      "r490",
      "r493",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r569",
      "r586",
      "r776",
      "r777",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r789",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1061",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails",
      "http://arcusbio.com/role/RevenuesAdditionalInformationDetails",
      "http://arcusbio.com/role/RevenuesSummaryofRevenuesbyCollaborationCategoryofRevenueandMethodofRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://arcusbio.com/role/CashCashEquivalentsandMarketableSecuritiesSummaryofAmortizedCostGrossUnrealizedGainsandLossesandFairValueofOurCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://arcusbio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. treasury securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r723",
      "r724",
      "r758",
      "r760",
      "r762",
      "r776",
      "r1085"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "rcus_UpfrontCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "UpfrontCashPayment",
     "crdr": "credit",
     "presentation": [
      "http://arcusbio.com/role/RelatedPartyGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront cash payment",
        "label": "Upfront Cash Payment",
        "documentation": "Upfront cash payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://arcusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r167",
      "r170",
      "r171",
      "r172",
      "r563",
      "r565",
      "r728"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares used to compute net loss per share, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r159"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://arcusbio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares used to compute net loss per share, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r159"
     ]
    },
    "rcus_WuXiBiologicsLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://arcusbio.com/20260331",
     "localname": "WuXiBiologicsLicenseAgreementMember",
     "presentation": [
      "http://arcusbio.com/role/LicenseandCollaborationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WuXi Biologics License Agreement",
        "label": "Wu Xi Biologics License Agreement [Member]",
        "documentation": "WuXi Biologics license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-10"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479428/808-10-45-3"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-4"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "SubTopic": "310",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>79
<FILENAME>0001724521-26-000034-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001724521-26-000034-xbrl.zip
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M58@B*;\'''=!I\%W HW!(1-7-. 8)!!*A$N*8H04M$2 9I-8AC$S!7W,^T]
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MJ'&YW'&F,@(&67 T=<HYH!X6"2>JAUO.B$6:1P]?-"S7.O@V$B0(-D9_$;V
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M5[M\Y1I<^>EOY!VXFX#_!5!+ P04    " !U@:5<VDXK:HX$  #)$0  %0
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M75R6-1*5K\TC]WQ9J4E)2<W.2F(TY*1-J^J6>0/#5%&HK94H2TD[L/&S NB
M'AFG\Y -4=4ZS14SSLLEL(7IY( GG",'))6!T8*2A>44)2WRH[5%AS*"F>V
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M@G5F7C=>$(#A>A_T/N'R>[0^XFNP0RG5DM/E,4,,\WP:0^C<9OWDI>$'A$T
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M\+:+-$-9KC&8RAE<3SB<$=;MV^@/95>Y^!9[<U7&@HJ3O+#$>N+JOBO0*"[
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M($2_!*FV'0>,.6S1.[\8#(?D[]RD7+LW;X49O<*&6#8,9X_G,I8FHV+159#
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M?H5>>I[IS'/ B=AQ9O$<$N,J9C)MMW%.=3]?^@128%0I)$J+;>K7O_=&A(0
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MO^S 7=J8RD:XLPAUSW9F6!D2M;DM'6SU*77PI3L"8,@.%J2-=KQ*_5B1!7.
M\J#N[?B*SFPW&"\+@)<V]""7J$\S-5.3-A@@GZA/%>[2NNBRB_I4L2"MVRVA
MJ$\5\#+T%7F[>Y/>8;.:M"[I%1UYL2+@-^!TWP2^3^O>IK DS+8>/>I,<>:8
M@SXH<*B./QZ4S&MIDKFTSNN[PNX2H]>2,WHM34:7UJ=^5Z1PH&8;-6D]]^-A
M5_0(BDZ'729AUPL<\V(Z_FT*UU_+15"I:@YI@Q Y0;T#925M)$9>ZGMXML^
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MN(O3)P0@"OOR!4@TQ;5-0U>"?9P8,*OZ(5[=)=?S0I/,U<J(,52HY^L\S0'
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M:;@-DZV\E/O4R]@17=_H(S&YN<$:0>?VAO0<5FF=D[V1?9Q@YS@N];JYV,N
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MKX>FV*PVJL.9=&;,H-OL!FB[N$31W X8T2@/3(@SI;H\POD\B>#.$8H2+7$
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M"L%+D]!UF@&=ET8.)3]+9 Q[NR3F,YF[*,:B$ %P1)&8#/Z;X30>'P).'%/
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MJ>*[NGPI,Q 35D\]XN$^WV.Q*= GD1L_;I\MJH<X+5462,6&G/6+];OL_T]
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M9Q,PEJB46H]O.DH7B'(CS,I\V>&X,4F\LK?\@2]-NC[6&0WG,05R^7$F6?]
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MR=B%STT?L4?15%^*]02 J]U  /63H!9*@"#<)<>=D+0"_29G(4]0.@5'!H^
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M2'J'Q3^B?ZN;3#<8I:13C%+2*>Z1#[9X)9$6>9^R5ZXZO:'D;=>C.XY"6/G
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MOI8Y -*:'$Q:6U#\Q&Z0&G6*0)WBM<QAT1ZY&M>.B&NO2H%L:VIF$JDP$)I
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MBN4V[/(<X"K$_.I(>DU0IRM4W9>@,(I>\"R/B@?1SX4*-YH&9I-.!5=4M>F
M\F$\H8I?A[7WB3+(\M=O 1PW=WT;]AO7!P<$ZKAVR1!D1\^E7 @R:%P?K'A4
M-K!]KM/F@>UE5L=,'=>NXUKGE#AQ)2SN.]W"6K"<O:BN;>>.1M71Z)IJRT:U
M.]2 /:GVJGA71"5CR&6(E,6#8I\,=8KQW&B3Q?R1L:C]''GBAF&-PU'5PU]?
M8@J5&>[XY8:[1NW)I* JW,N>)'@AX9XZW/6"PUW2_X:I1(0':&7J[(F9]A(3
M7>IH5^V<WS/:)5#KF\ LS%4,\4JZ[+>HFN/&]>3@JHHZZE435DEV75C4ZU#"
MFC2NQP5[7NKHUT'2=\D<%S-TS<#;6P>_]G%%?E@L37O%V#?>XBYBP&XFAZM.
M$8[(.@I6,DS9X?[:"U.ZC>O^A=5YEI4SWE'+9L53?\#CENIJ[X2 RY^QLX,G
M/B (OW((;L%M3(DIR0R=>OS2B9A@1M3HEP<U+EP?E+[\)?9YYHTI>7&6F>+<
MKS7#'%Q0E$9:CY\0GE+<K[9@/8ZH*(NPK]7"$W'$_&@R+!&:7+A.2+&Z6@G<
MB_TAZ.X!(LXJFZES56"&=*T/E@5+=G&_O%@R BP9EP1+BIR\687\4'M3YL)9
MAZ-=3NBA'AUWB*S)QC^P)4F_GO)83WFL2?5\ C\;J4XP\;.H8J%SDVJ&S,^#
MNMZ,2MSUIINWZ\TGVWI\8,X")\(E4T!'G61[FU$GV=X&G]+"$8F D%-OK^XU
M_+$I+SM@. YNZLYR88V+]%DXH\1.JI;BFC8+Q_47L'1XB$NMH(#<'/KZPB?,
MU+FM=6YKG=OZ4G);XR)'>873UU!O\<%ZEE,R 2C]SNN#LIYZ<?WD4I7LW%N_
M# UZA[$;UQ_D^(:;!4 N38T>]=*'^!:0?+?M+*J0TUJ3T263T0Y#-"\9]2M#
M1J?.6"!%_<28\*L53J;6L1^Q3[,S#=?UJ7<I3JN&O[4Y*/JBD<%27>%)@V74
M^FY88?^7IF(Q+VYUU(D.^PNDR,F\%P?SU6$+PU]0UCA<*LZ(.J%^9EYL&/6;
MF?&#Z:T_F&.G$>&@ 00W[G5[;TL2_Z[3)+8@V:OC\>L]L"R)3<.T++/LFGFY
M4B@X-O3+J[#P&**YYI0KL'Z_5NX.!TQI>4F1 BOJ7D[C"U='4/4./9ERVU,U
M0=8$>8!LWT60H\;UY"2-FTY@F%W4!)$["UV\@Z;RS!1R0O.^FK:B@J"'E:#=
M%0P%"<9]\($@_V".YINPC.>YH<WQ":X_==GO/EQAPM5PI9A)R5NA^ [<]+NO
M.O :/H_D%7[1")YS(Y_?>-U6?H6;';HS^7TS_(S6I"NP8A->I_BNXB_QKS_G
MDS>Y+*2/JL8V^QG&C>O>,"E\9(2,X('J$\+7Q;^>5,>P8>&> _KN'/8$8/PW
MTSS<QL*PC(4/NI:C/BL.3JMSQ, 5Y<93<,8$X#.=GNX ,N3<]<Y^3S:0G.Y^
M=.R%5,>_S.X1'9B^B=0GC>MMNT>$DJM%_ *"Q M L<RY]JLMU<[QX[H)WG%K
M+Q:&YS%]X^F-.]N7+Y 92,*&C421N:U@T!1.1X4CLQX+0L"4[838=TMA[4<B
MMYLGU3"1,:5MBIJ!;]*'@JT!,<F'X"P@'O]UWRBOC-=Y=S,ZYFYZJ4<4W\PS
M_%2F++(C?VGSLU.UN<&>.!^S9XH&S!Z.3'EG +=]-#3EDZ%A.;5RLUR:( 5H
MMZ\:[S[=-%X#BX1GX>EJ\"^*"$0,YGJV!63K\+I0)%L,D(-(M/'2KW.LQND#
M4_=U@[E-HF5:DC<'^?8XIU4QU3$-0"58$0] =H<4?1LKMK,C^6(PW@+?7^3Z
M;L)M?X6GV'K,;8.#AM_HOJ.KJQ#0?9#:G74)I\ E;C0Y( E2^HA##[<9@.@M
MH%)^7)H<$Y<&A^'2Q_<W?W5QKX[]A/FU,Y";@"EX9BB;WSO^XQH>?7Z/> 20
M1^YW@YL GO($\#$>5<$(X6&ZKWF[$26(U&;'%1P^=!1<&6;!%=?';D$"6F])
M%@!&'!,E<O'^J^V\G_/V*)>,G@N*<\"%($B,H[B:45&.^@E.!!';!P%NH9)$
MCF]E!B)6F?EP+\-^#@;J88$^X,U54+E -U,LVR.L$$C)5U30@N@X4JA9A65&
MN)SJNK9F$*,C+1#OL$%O-A!UY9+;&9. RJD4OP> "<X& &7 P>"6N:MP?7;;
MA#W2Q!Q0#AXMBFSDP^ML3;A%MY8-^M=XE#97.J9^Y5M4,:M"I7CSJ@#+@F;^
MHIM)$]N++7'^X!,S5URY NN/?Q!I_0^(*$4.^B.;\)68>JD(![,JRV+E-4&\
MB: 1CS@I6>88"DP4.#/ [+,E*.)XP1M2 F")8=+97^+I?\)N[82WJ%,P47UO
M\RV;:88G#@D*N?[[U/GI>@_*BSWEA'36O5J#=N3?N1/F33VRUM1AZO>6.H-U
MOE'-9Q K:(]'=P=;BQY(-EANWO-L=HP]<Z@#/=E\Z.H;'UDP7@4K4<NP# 48
M'A#^GW9G+ .CH1:O2%JH;_$)D^IUVIENSL[MY4R./3V6;@\]/X.EM)&?6CZJ
M9]N=:8/MOH9@] (PN@^2_X%2AC0+A!'P6@!DP&PQ[[[7'B=[+O\%AX'"4S5D
MCX'T7MBZ,9,:*O?EV!H5B6USWC1IL*CJ<(,G+P@Z_>/"8((=FOKM3K+2, :#
M#;8\"8:<6XJ/<C["CKJTHW[2C?H7;DZ /K@D9=T%"\* 3^!8-ODJBIO6.^J4
MN&ZAE[MN@;DN8_&*_I0$_TDO65,PZ:44,-#]>Q4NT.,REBB0W1/6)T1'#N-(
M\(]@?47&#=]8^F?;HB] 9R<ZN$'\HVH>T=OJP5Z'07HS[TG_!50Z\-':0$)P
M$BWZP["X.<RMPKC71\*-=V&Y\.*(4;<-3*"8.H0><.O2%4?@HHY7'#&I7''
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MG+0YTWV3?9FMLZD[B^,.O.'=2GR9PK FZZRI:OSD 0#.,7D*>/F,F* JKK^
MM:\0SG@@\BCEB37AI#33UPGC83N4(P/?R^O8CR6>GZN\@A.%Y9IX3*_?).5A
M5CA5I5?EJ-L& ;ZK16$I\[@*OBH3N+J]=F=<NMZ0N*A">D/NZ!UU^ E,JM>%
M;NXPIOP"U\U=Y0/P/9TK[MB#,D]SNI.!N/Q7Q2SZ7MRDWY9E62J\0',M2^@\
MRUYWM6R[$'@-\]!+KKR/7GLP**][DR=A.*!&@Y&8I2E"60GW\*LRY%9EQO8+
M2[P:[RAP^";P)\4G.^S@W*2"\JKR<)NRY^F]6%S:D<2W#9>ZP*O'5<"E$Q51
MG^O ;W0T)='3:SO2/D7S5+,7+&*9OD0I<F@EW3GN/U'548"M$6>%>$0+KW\S
M:9_':_-)]5C+]=#U*QR*W-?FV(^.NG"#T$-1R[K"6.'.=;VE^BA@<&\<9JKH
M07R+S*K5;Z<X7= 7B ]H7+_JOEZ+M+U$,GS9B?*;]#5'\]TWB.WWB.SO0US_
M*E ]3>CV&M=7!T?4ZUJ*LJ'(!C5L+Q3I-ZX/3X4L5^U$9879!]4Q5RG2#,-)
M2X=I< =NHZK2K5=+MY?>;F&K="/T7^==-Y;^-43];9QLT+CN'FQAU@TZRH8Q
MVX3=@1B#38)Z)<&8(OW6W0X)L+*Z(&[M!;H=> X2R3;FN+9E,1-V[F::150N
MGEY;/Z?R5G]2I[8#!/X-%0^F?^#^JS3:OL(IXB71:VO3YU0>Z.SX,0+3^.!I
MM^6R>ZK ^]\S-&2,D/>K"TPS^X,^J!G_RU7S=C#^*-[ [R;#7X#0;R+HDT;F
MX\9U632\VB8XE138%UDFC>M^29"E;M97@JM>D$UVASE=S/44'@EN8HIS+8XO
M2<]^=: \QOQV^&V=UTK$$:KV9]L*BBQ26.Q5!]3N!(M]71MDU464A"PN!E&Z
MC>N48N"38THMATMPU4N/"WZANF%95&1XK'*AOWX=^GOQ1ML."W^][I"0_@YP
M_8;JRM-D1 _S_TMBL-76_:FL^ST0I0^(4A8W4+%&97DMRJ^JXUG,<>?&4G&8
ML9CZCLNKEFN[\@6;"[OL2HKK1W#G6PQUTH@;\SZ2W7]KF[+"2+++ILR/),/&
M=3^9'%0V<S)?I&]27N9_O]8H@4)]L286\IN7* QVG?;6YF4'5I^5"4N*;="7
M S"7PB>S.FD_,^^._/J?@.+2V.,5R-"4\KSL_+'8 ZIB]\R:+FNZS.L3WTF7
M(Z#+;M)RK1)=IG3"S-GQJ# 79[:C[KY6OOV'NEB^?1_V;S(LS7=PQH7#$\NH
M[Y?R=:ZZ3.DKZX49<+G'J*<+7.8PUS<QK@J_/1JNQYMU84<I%92@9[Q']S6O
MK3S,#5?TD\(68J8)2"9[B^GRT2V3.D'*PEW+AI,T'*9YYDI1/<\QICYO$$4+
M=)> A3/L_B57"%? OS;V(,.&5G([<N'4V@-7 ;>#OJ+8CK*P'9;<*3UGO>-8
MN<^UM^U<L1H:B>N)#Y9V5.L1FWK-'!N DK$L!V#&X=1+P.F4A^M;)K;82SM>
M6!T_8NHQ=X%GW'^MI 5+ L #$VTEP,ZSSGD#0[KY9T*3&_[YVOXS=_$M:9<[
M:AHCH2,F^*C>QJZQV%]'>0:$4?Z<3P3V8R)PG-XX.A!YDU#DC4'DM9->?67*
MV^?1JG*N9;#O6B:XEJ3XE6MI(G,'*L0XF+E*092-79+%F0PP:I8,J06M]_X2
M#T8*\=T);U&G(*E];_,MFW&2MW$2&'C]]ZGST_4>E!Y[R@GQ&"N]8M"._)N]
MP3 H:O*FN1.&?!]9:^HP]7M+G<'FWJCFL[IR49>)@@3@$3W%; >P&5"SV3$
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M.CG="[*!I0>456D2>@![$_"N&=A],\-"$<X/-W*6H39 '1?I+%7NTB3L!&
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MWUSV ((;?&<^XA6]CDG?KW51/UV@G?CQ?WW^)P0/^89]HD\>^:\\^E3B M2
M&C+;2^I\Q9/2FLYBX]4RDUYDB3QH%4NY"0WLVFW5;HM%N2H+*T8U3 C%>W#3
M:O@3%G\FX51X7Q U^)<.SQ.<Q6[3,=LK:%MJHNP#;<N2H[PJG.!D13PM MJ9
M;\MB%08C# R,[@MF5./4$CZ+499\QJ-$G;C;L,>)H(,Z^ZD)#:]'^??P7MQ?
M2UWW#6YF4Q/G_+S7\5-=LK-VWX8-FXE;3Y1=MV$L$(2&KRR*,*X\+5Q2I/5!
MW!J2;0UV+0Q9C/TR6%)U8S,$10WR 9A^)+?0%P].3%DBZ:-@OVP*HNDI%GG'
MZ2\[8];E!D>L,&3F_)CNYRU>I:#PT!(-MCW]D^M#]I_17Q*9<R8 R:M]IIN!
MR/N:F[PJ?^9;Q.!H6>Q EGF-A!$6SSK\#OPEQ\U%WU+HH_Z*\1V_\V"HSWLQ
MVTIR/'12*5\0KQ07!< -P78M8XJ8IBE!R+,#MX<MF<QE,-HN7.@.!@&S98<Z
MR$T7Y=8660W'XC<U5?I62&&%7R$!/#FI@^7D^4B2$^,5,:4^_CR_>OR%DF%U
M6_"](H.F]XU9K#!P?GA^X0O!H(0Q*9:14>N$UP#SN8V!IMA<OBEN I!EG;=E
M%H*^ IDK[^PR15$PT%4>#12M;N=/Q^R?2PDJ%>-T,1&S 2/F?%].G)*])R8@
MG^';!RO\EH[*73W\0?:P![WP5;S#I,I??I.DRN,O+DF5?Z.DRGM?O.-AY,NG
MK][,GC\7!:$7;_[Q]:O9\W]^\^+5]T_?/'_QSU\>-?_UXXV:'U_/O@LQQYK#
MY8*<A_./E[4&PQF9'1T4<)YP? 2O.E83UGCWK7OWV3=#XC3F5 ON-KAKR^JN
M7M]Q%#KXO26.)$0=J:O38:6U]>O9*T1\:W.S=LST3"4EKM,C@F""LHK8Z NZ
M3%19Z PRLBQ6S+!(BA+%;K<NHE)'%KP>^J4XCM%II-J3$@!61/E&_LZVFU,%
MA>C,PJG9[92>\#9O-AR8^=K<+T\G/7G\$6^,'CWA1[\I'@AZ^__J;M;>@DPQ
M.$R$ R'NFV#SH=JR2XARD'.5V>Y+0%#LBH6^8Q)PEV>ITOBG%YT\H 9/2R[L
M9V2W@I>ZJS.?V^4[\YJE/"BVH<^$,A*@7DB"EDNXU=[H)9/W;(5A$FO=;]7,
M^9)6:<U\<3DE$OUC\&%OFOI^!YP8Y:YV7*7E! ,QG*?57]K"7/P=3P>37YN7
M%1N>,,P$I;M:US4*UVT<+:5_W>3+HC<)DA6CJXE- YYAP!5Y/1M;'C35,F9^
M15#^8-&4<\K<W18QJI6)-E/W(;F!#^[W5YCV5U']B1[[.\KZA'_&YH)_ +40
M;&)<HR^UF) R<B-SQY-QRDN3E1LQ&Q\#\5?DQF3,QMZM\S D5"JADX,+&D18
M:PRX2VRQA/I6V&V% A>!?R4)C<BB"^)+8>?%>@3D).'3Y;M:79[J+VU1P 5=
M=3M*E)YW<DD\F-RH.D5U;%[66S)+^0+*4+!#1+R[5R6FM:S9.$$Z:QA=V^_E
M#I:F7 2[@_( []A"TD^+A4OZ& IPQ_32;$)J8&!$W8<'?78G4)C]]>PI6XI#
M%,=X12IIQ#Z/3 Q]Y;$?3$!:(,6//'W18.O1(J+49,/?)9KDARP_KLK)Y_'E
M/,8L(<E6!FS0K@\HL#-34U**5E05HN(7V_,VU<2*Q-E# NQKJNT]!)U--SP*
MEA1N\"7@Q;*- "Y^$IN(Z$)_^/R+SR-3**E[<29L37,[12]O%\^KI, 2_%)R
M)OE&UW\.RUA8@W^X#0.I!Q'Z@%@ BYQL# W>)TP-_C<F2(41_&ED$E?L'+</
MV0=X(EX1=)9&'FVQ*9XQ'/Z$R?<AJ]>.&3M.*[&:UT]A,=&JRUEVPDI1$V9)
M-+U$4>K@[N#ER<U6:F3#N,QQ_+/TEFIDR;434WPKA.D#8]J/(SC'J;@\8,=O
MZW48Z!91\%^^-. ^7:UNWG)_%PZZC]XC/L:6+_$<UQZIQDK#ORJYWX5V0E@A
MK;A<0 IR)!C^IE:+$6;!AI CM]X[^Q2>A().,3F8,7^$"1S 0 ?DHI8B8R:5
M/P&<SLTB!\^<13 :9-6IR'0;[EI4-VG7@?>TZ8!8%XR*:PHS2"HFEUBI'9NH
MH]3T]9S&!-(:> O<76BB=?5#Q&CJ HD 8N:O@LAUO>8T,GFI=EK0=3W!N3S%
MV"/@*N&N[6K/%]T3Z&-W%;_:. \-*@)T079?,-968:9HVHVKSC85Y^X+_UT_
M\7!\JP)B"753'!_0>_\ IB 0SR:MZ/L%1':!I#J#N6<FZ5KYOMVBU>4LI_+S
MRH01[*8A'B+89$'V52Q697#?++H)I5B@[9JJY"R*L@P>\[YU"8&W%4DXT;^[
MBO];5R@=N,\Q:,OXH,GCC9S1<63J';C0C08=+TAC8!)JZ;6P>:4(05J 5","
M=$:V,:S9M*_IS@4]U^-+8G#"*#+:HDY,@6QK)S]QV,"O\G(-8,8O,$;!'%-T
M9J)A=.880IEKW.P<,L!!51-*4=>2D0IW;O*2HDLVZED$FWB1R'!.$)8CH[=7
M$5[S#.LF#F*J3!&\A;X&ICVB]"SA$?GQ@O6I77CL3R-Z3D*F< S:P$V2]RR]
M-ME)9]+''6^Q*9! E(W<4,[$[28&F[/S)&6SKM*MPG/K?J^J'XC4Z394;;/\
M)IG9!=^:0&Y-*1H;+K.!UNQUCM0@%#F)&ID"CPJE6Q;[Q!X>$WP^\\CLS5 N
M=!B4348\96O#3\7*J@U3=CU[749G<%%LS3JS=&O;5[:)?21HL_?Z33TA&W%W
M67 J:M*:R72710^P56_AV*["8(E3VQX)Y,2?55$#/I><\G=-@=:-B(;R*DQ]
M#EW-TV<ZI&$X97?T+!VX^>[8].<T9REM:)SZMSU I@?14+/9"[*<MR=\/*#[
MPU__\F>+#V7E#37)IB7)LNBZ:?_.N!29HH]4M.E$U3%VGL/_69<183S*[5J\
MH!!%A>?X.<'-6-U#*"G8AQ C1;%W\5-.OG/<B]L<N]$$2IP= #\\X8[S,(^Y
M2@N7E)^EHV\31H02M"&^QWR&Y0E37!%"!1J&BZ[M/96J9\9M9)O&]#?%6V#1
M+??X_ZCO33PJW(5.B)O@#(4'*WJ)-OH(A\W($8&0>#5KZRS]C?/$AN=3-'!^
M:B^ BW<&N/CK12#D IUX+Z[LP75H?DDS$^TLH*R#/Z.VHA-0*^"N>N*/>:LC
M+JI<EM2N<X;DX0XP<!P&);[K 0>UI2"KMEJ6CW&B2+VEM$?<!0Z$>L$TYP/8
MD%)9HXDF<LH#S_ )O(FA]21OG .A90@0<6,I2_F@*#ODI*=9I&!2RRK\(9S8
M8 .S_DER1$.$SI5(@J@7!).H#V4FD\.1WYP [$L+\63PR $C,#-+$-8CPI*4
MR>+J95&5D+$Z)'2EVH+W);)+Y-HE@3;=IEARJ;;<@7JJ;ML2\R!(Y3;EL6F2
M7]GIQL*PC.#-JQD[9^C';JS,K5U&6I7E9-L=3O_6YD5KH#&)O%H7/Y56)K''
M)\0V!\(5>-I@$QKK).HS\.AYS..;#CNM'?@K/-'4<E&@7WA1*,ZUO"O7!6$\
MD9]:Y7?!ALDP59)X&YL ]N_V4K!&\<:M3K\R'9 >,IK<WG#*B@#4?:_O8E)C
M(W,_G+IEL2VXAUSR,+$A>HA:"1.]KR5P$L2H]Y?"H"VQL6(C.XOJP<YE1F#6
MS()9Z6*6K_?@;$Q,?3/3((;]84Y[B)G:Q1XWTUH\L!LX!D$W 2=!D%B1M))8
M+[$F/MTY'"D:;1D2%P)Q JD5Q("QM8G3J^OZ@'ZIIJ#_=JHS)32&5T0U^;>_
MC*=HDFCIZF'ATE,*-</YEE?MU>"0>WS2(4<UD2=_-H+&]WK$IN/S^9/KQU_0
MVR->[ZC2%V+51; S&;H.::YPGM'FX 1@*UD#BR+TN(N*VV,3Z>@AEDTGPH#!
M1NVSI*+@HZ%^REQ48U&'9N:R+R<7Q;M>!;^5O_-1+05;"5@!"F_"]B4+ B>C
M0=7HJ/#R96;>S<R("85WB",$,,RAEC:WO>%,717H1+'D[J  _BP1V;:J]U0U
M_#*U[V9J:9]E?H(%Q,OLIJ:OVQ1W97B&(QG,+W&%RTR]LYDBX%*]*'-M-!Z6
M;H_ILH<K1;C*,%?]07&.#RPWO4AB$T=<*.4@C6,*].CEZOFCOS7&.HG3F+CE
MD?\10MI<WX>OOW<BYHFLML(HLQ!A+ZY]A[F5;>WA8O,ZL7PQ:IE([78YIX^3
M9^$F6H UV)-=Y>%=LL05%ZRC[S ;!<H\%-/Z<2;^GX=#H[LA.,N3SY[\B6LG
M7GV>AM.FQ8.JDOFB"5H&VR?U'1K &SV%H%RZ T *?\SL;&)Y\7:V#C^+#?W#
MN\T^H6LH^HSYO!Y]QS]^]"DCNT=^14R:5-\*2T0:0(2E(-S(R)O B/D)KA@O
M0=^C2QRXN-%^YKR::0F2%+KIQ(?EU6W!JNT%Y8':#HM'E=\3P?9%F(8PF7"1
MFXWZ[!J^9C%F[.G++YV^_&Q)D(OY?M:U_6?7M[)Q@$^".RE>C5$'95^('F^&
MW;N(S)E.ECYZ)?B2CL$#7FYJG-.]7[8VV.$-T]JE2^8Q-5MZ=Q&^+WX*(6D;
M[[BAP)VFRU/GC4QWN//K8KO3-?/Y9[(#\L@&<P5. NG_YJ*5_\F3OZJ9$=,5
MMKY,0SVXMGMR!LH@M23O$"DPG&=A55+'DS[[;SR%UJ[(/I9+'BAG(!T;:#:Y
MW?TLR,,I&Z)R]<4)MG/!I0 R<GGI;LB_$)W!#7*7+BN1XW)C7<4,N*W*3;?A
MBN,G\Q"P5!738J[!:_N73QDYS)RY !\H\O>3V-TAL",MW.N0NH&,X_<I6RK]
M3C@%RA;?<(U3G$?5[2,V"3_3491UYI]>QP=@ -T"6,3W.7@O2FWKYPP6'X:Q
M6,V$P+E;"(0/;BGO%HVKWG%L0.P!9"DR4DXNA/I]OD8C-4SYILB94"KA;QQ_
M. P8:)&E*M=+DD]L+TF@^D5DZ5/DLJL^8.E([M>^L2Z+^'O+;0ME)ZR$$GKJ
M/$<@$7](W6_-XI;0$DBI+PMBL*#86E)K:69:\YE&$J4KGJRGW"(\Q(;HEY>#
MFQ%0*N<L,SDS?)LPG,&K"*=-M6SC?3SX &_8>YYX6^61)-YC@EH)K)=/QW)9
MA@UL)7#]#N/EA*I2OV;M4O(E'KRB87S'(O9PJ7'<ZY@08QFN"8O&50F!<0W-
M.!-N]@8WUB56]F!ZV4,CC+NU>H3NE-N '5(JS'N68^EK@ ?$_@]FP/0ME%:
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ML%#PTC#EZ/W'7O(UDA>T!5OJ7^,E?@0-]S2D7VEA&</U58JR)YO^O&?37RH
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M9U=_Q1JC_WKRV:<G+QV71>H/D79O.;EWFWEJPMH42OB))*OWHT #H]J'3E$
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M-,Z-8LZ\I^G,D*6%N!G>NLZ#;X#D(+XA!Q=1*?+OPRE9D6LQ< ]%"TJEM;2
MKM(]HJ#7X[\[5EB,3EQ:;QVK&)UW4GZ0S'Y0"GLTO72JX+#DM7]QMKJ?K,YF
M)V2J%^1Z@V_7I:IE$%C&+'Q0<M5[C"7Q0++>UKXBA:VD_V-XT'8I_+7QW;D?
MOQ\[CB60A.OKY&;IG) J J87>V>$,Z[Q>8*'YFAKQ6VQ(;*0_9C L[BYK55&
MB86X;@=;E_Z^JQ<D'Q?<8!6F#\/__)]?P1P,>: <T&@VWCM^I!,T#8 FXI^Q
M\3\R\\'EQ (JP=Q4WRO/^^1*8H93NN(I;^O#&2@8J5:G,HN(,OE.M%K:F.0=
MKQ5%R>,( RDB7$9M=_^Q,Y8AY'',F[(5B#_;8&:-F!AY /1;5L]KS/(7' 8-
MDFN6Q#_U3-$7#JN^UH4X=6(<+?#SZSC^M_0,&"N6 )4%NC&!9 R^P?.20X*[
MX=1@I#R,S.]G?9;\8-6(MU5];]0V&+2)R9#BS V9RHI+8<S<JW5 5&S:8'&6
MG>BFJA+NFR@/MJJ;9'%(/B+LBB7QQ1G#3UPL8UDF5P7!?G=9I2%GA"[-*./S
MMY,G[X)J_:6HU@2@95Z;0T$F9$/@]")H ;L&>A+.[LJ[6L[GNS(<5KQ:>CU$
M8KO%.97,=#ZQ?BZM0.]\ZIV'2D>LDD6<Y*XJVR- 0>)^<'%U<8LK0H@A^)^=
M$<"/DT\*#9"$<5]>=OQ[H0YXL)^G'6*86_.>2SH -LK"/\4K<YG3=SZGK)W,
M%1_CID?SI>['JB]S]^S5BS%D2/#2=H44%5DC*XI$\XGN1!%BB%D5-[4:=U7G
M9I;5U.E#.T1,X=A#N'M?ULN[7R\Q"B!!'QHG +;#4=]TI:E=45$1YT,;_L@]
M#+I6HJM?'Y+JO4S8;W]6)\<S2?;&>E-+U6H)OH2J<%[GS;*=??+H^:N_M\36
M3!F=W2V1K[*,WJ[@9I4Q,W#9BN]^9L.\,(6HM"-)%3#3Z%[ <);:%70#S](X
M<0?-7::4NB@C1J1!CP%35/2,Y)GD&^4699. _^VFET7Q[A>%LH^")TX4,\WK
MFLCZ7>;E/<R+I3')/%(ZJN0M:>IVZ9S &6OJ[99+[;S]+MOH?4V7NL3S/0(3
M>)MA$VV+AI+T*$8"52&HYN 5W]2U\XBWU()-X-I/'GW[[.6C3U.I4(Z51SK9
M&I8C#AX4(8<EC6FE"V/3NKA-[WP!I,647]3;RXDN<[\FKY$P&X/"6,L<E,0?
MPO N^_]]M.R+2+!K]V9?B)-5&Y9:G;$8-F/J=K%7X;ZP9C>0.=@UFB*L**8_
MW-;M[FH7XFPF&&>1WRN"G<7$]MACC-W\8A#>^8H09 E57.NZU<R(TQGVY-:<
MM([=YPG=)8'TI!QU%$='ZT3)5T7>!;DW1DE>#,-[7P:*,<Z7X4 'N+KC2(L+
MV(#,4PX[];2M)XS!F3>TZU7S%UVR,L/%90K?HVVW#G>86K 3H/XOI,E3A,FI
MTNQEU[V/)!8K^:+.M+()>OHUPQ&L/VG(<P$)"=/(839K=::U.<'A)E#LKH@1
M&UT()Y)67V#+[VPI?O[D EO^=X<M7\SF+Z?_7T=U.G-)HB 9+)^"\((Y(Z1B
ML33]=?\C%MDQ# ;J=TNT%TLK8-)X!U!.OLLO9^/[2U5)-H+V&?C_OD\R&"^:
MFW#:"3#XDT?/OG_QZ%-DM'"(#5+#RH[#38JCF8N1')ABQ+^E7%AZ_Y<Q(;;X
M]ON75$]RPEE.\\GGQ6+*[$M*BEW6TKM'>)3-DB/.0H.5KB)@H!23(AM?2Z(Q
MJ[T)*?*JZV JUN(D">1?"!N8+6]#X,/FO('Z/Q3B+T*B+;BEE)@M8MO%:A@!
MEJV6Y8H4=@N7E-HB1%*'JJUJ3%U=UG4* HWK&CEYFLS%Q97RV5>$HWO-X/SO
MZZK<U=B'?Z>J+LL%VV5$N^67P'NN9Z_'R"W+S1:MS/C,=9,D]4@CNTS@G=(L
M[;-@KJU9,>(CU:P1>Y3H[TWFWR>J8M3Z*I$>,;@2I0D7:Z+H:SN$'TI]YQ<.
M9Q8V&'VCI:Y.55!AG+?O94[44B>:OG/KP.=664U93;(;.=W"&X*AH[4*<(#$
M3.=+4LUD>=*[0G@<6F[!.B$U,IRX7O?RE'RBFS[6 Q9-1UIN" ^Y4UF:KJN"
M.5U0 YV<82,YVAM511A>>8+KV=-80!UV*Y"C,]?^I4,W<+W33#R*'<Z$,L1:
M(7O!-Q8(OZ#U$&2.VR;L*:+&6G7K'HRZ;W+.',!NQ$RRY4?RG;1&=#]9;2R3
MSO.XXD#U.M%I\)N?O4].>KG9!SGS'_V/6)H2CI368SH@NQ*5E1D+.&SL&+2(
MO,&VX5^SU>9][CQ3KIU03D63;V-SAQV[9*6@VA=3=3LY'B.05PD<<,'VXK;(
MU[M;: I1L%(N1(LD?+MKJ-\L+.Z:^'W!G@1[&%^^9]?F71,6/]VQK1<ESFF8
MB!'[31T1FT*8$L@N[2*33EB%]:9<\.#X,^V>R0S6Q5VNFAF+V^&(](SC1OKY
M>'2958335]3P@V*3-"5%'*;9%W\,,R%8'O&>)S"(C6F#P0&B@&_#*N/:$L6$
M?E7)"* QKM8CBKY/J[V/)=FQDD3<>-]I&P[17<%D"QS!*K.!55[HB<&>P+QM
MQMA!.\2 Z=)"61S1=7Y>2<,4\8-EVI%*A1FCR9A'IN.Y4KP+CT,M7!?:K294
M&<;X%7M;[\H\I?XZTBM%.-L$.=L4%. )V:Z1HL6,:BO#(IU02FB;N9XH,L&E
M(70?UFW[$7=.OPS[C\[5G+HGP[/2-S)IXV.BHY0_:M@**@K(QG)*Y;J..<H'
M?()"NF(0Z#Q<@ZDB[^B%5/,;U)=AX::)Z=A4K9&Y=Y1@#DI:#,S#(C!J_@89
M3: \M3<>WYD78'(4.L#UF=.9?C-*WJA3L1V99^XY.F66)<3!Q;2>B[ K<ABZ
M&_038M65#3'N$_>XMADSOPZ7EBS0D.Y=6"B]H5L[,K.,&>"N&4PQ6:"FN!5H
MO0!YO4Y[;)%C^1UCUA%.A+I1YS$A5=-!X^T?7U:NN6'^^][2#L^_*JVC^=@Z
M=QQ:PQ7-(:ZC;!Z(!!9^8@>/R*1P=U0U6N]U79!-?.Z7 *CIZ4!SKV+4_ZQ#
MZ$#3,JPQ0\KDJ&Q.W:/&73A&WR5>*L_X"=N4>+HBE:.LX.D)TD6FEJHIT%3'
MTDTTA#Q^*;MA4DKSO(GAB)4CAA:6ND3!]\",!I>%",![MJCI/SU.S8$5FQ>[
M>PIZW33QLV*QBFE.]UDTTWXKN7N/-0\/SCE'-ZY=\K]3<LSOA15US(6B::J#
M=W@%D:YDTL63Z=&%S<O\S-DV_' PV=46]("#1GO$D^LU_2\887MD@O:U\2&T
MM-V\%C),W>"\@F,W3-JI[;]9MD*"K1C^0WBAHN1$.C%VEZUC4Q,<@S"X$,_9
M]>Q%?. 3..)HTJ.U#J?#S0UW_9+/S=!%$/M)<@I9?4)5M!P?1&/:CZH.O-/U
M[*4BKT#&3-SB);OP9=BJ^\V68CIZ.GCVY49>=<-:$Y)AE*Z$$'6QD#F"$AU1
M#!6%#)+Q,E >G0^N6XES,\9[QP\=23NLU:' BS&W'$QZ9,6[(27UL:>Q7^)8
M4/))$27)=V%.YMVN2 12K9=R:N">IY'7C:A/K8IB;0>"D<E91R:"="OX&(4(
M:D5,TP<+3FN!XVN3EK3OZG7]->_!OE?QR@#KN 1D0YV)<,W(KJBGJN =)6\;
M8758T@E=8 R7-04;J6D/D)$LRQ;SA%\1\I;V^6 _Q^[U>^+<&!'83!@*QR[
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M5!AMPZ(&%$WJ2BSB7D?-FK8P7!2M8N9-.:Y+$.[TGZVW,>J_J8U)!EYZM$*
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MS?ME)H8"HPBEZA,.ZN: WLIIEIS[7BZ0NF2$8"K*8SMR-;U3/"7 N\R"TG(
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M.,+4TFFO"I[ON64!95B?S%*A,(E<U/]<U%?R&W%/K1]J55(5H!*0QISTV<,
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M<8*Q#3]I&::_=Q5U?M,S-P/_K$FM#\IL0,0=S61(2Q0O%S0KML)R=L143)U
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M=^X,MGFK%"/I)@;KD--90S^?;&C/?R 'CUK,DX[S"&NFJPFW:7@\MH[> O>
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M@N$HJ5)'\"@#&=*8TY=Q/6XXZO"-ZH\$U$JCG"TV<Y\@DQ8B>&G%7*@2<D<
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MOD6RI(_UT.Q(_R*Y2025E7+_.C90=6$]%V1D4C$F_E0%)=[ZZVJ2/??>R9?
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MP(3<2M+NT^*"^$9@I@OIM"PN2 #&=B*X0*YL!/!CT4\;[3E%@TIOO5I#()1
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MVHN[@^:L$'EQD;AF!F9R:L 7"Q+;BN"WS-+&3+6!=8UFN =RLW*0,JG9\,#
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M>0#*$1P4753*CP2!(_U\"':)O/Y<F1LH-TZ7;;,H-F@A'Y\AQ0PENZJM[$@
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M3/W.ND0$K1E<#5'A._B[K@!Y7O;"&WXR_4D4$;2HZG1!J#V:.$G+P^@-74"
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MA,AA3Y,)EQZN//6]N(Y(OK$/]]%""<='LJ"V,.]18I-#,N*-C6(N]T#NU 5
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M%WU+;(F!AY_PN1YGC/4PG:?4>9A5<]-Y/,*.GH@T^\KUAIEYQ7XB#;T925
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M;<705.\X(16\LY4S8I0 NA<MHJO1ZTZQ%MBEFH!F"/D9HG5G)Y#WC=MOI$E
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M(2G%70A$7?7)=T?KLIZ@N2_E3@#9P6QP0R##EW/^1"&9'Z0M\Y1.L@3,WRZ
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M1J^_K7HGXOAIZ-F"C+AT4L;;XG=N-=BP=-;'8.PB("81%BV1?H(D:=A00=
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M9$WCG\J'O#D^@)#4Q9]_^2]02P,$%     @ =8&E7.?:#)G!%   0^$  !4
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M"3QC6-$>Z.UV1P]70,B'%Q8&P+I<&#H[A6B"(0@+&ZSBBA#A-ZE[OZ:?[DZ
MF3]$);*81^2X48(*2KB'WJGNX4Z 7AW:(W ([M* S5H<QAU>'4ZE C*1!H1C
M8:20GE,"O:#]#._P&C#A]M0E7/'0E;>QW)F<G.,XJIII'9:D47!D),=(>,6M
M\Z3 !'K98FMP3WY:[ D8UH_FAN13KOZ3AW62CNL^[H+H"3S%O04VA/J7=[D
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MS2P%V'-MH"0"V]RDV /I4FB14_*[Q,#9]XIM0,83(*G!$94WA@>#J,IMW.V
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M.[5RW>6.(5"1D8!*;0T,/IH&N1LX-\"Y_&TUMTYZ*/Q> ZWFCJ8*7$]7V8W
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MV<8B.-<&(T/<41XGS8P^AXKJ_GMA7&0[D?;"KV]'<;#D^FTGL@['"1N7"!.
MB'^-JX/B!F=[.\^AG4AN_34*+'<[D2BIC=88ZT"8MT"+8(#12E#FO<!*9-#<
MQJ G;2?27NQ%#IEE[KBUT]=DX]HYQ(T $P^0ELP'!IG.TD_O?'K!'*>\HV66
M^<W[6!9N;F?7Y6=??HU;_?IJ\N#]E<P S; "W!F*F:<$L5:%L_?HL&KL2[1Q
M.LLX<RO5%9YDO*\033?O%!I!931^:H$,;PIUU]&NPC,)N)\W?C\XIC$PUC,
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MO]0_]>US)[TV\N1@^?9@*&\BVBD2VHRKITOC.DRGN0#NJK-&"G04^ D)H6$
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M*-P3^<@01T R'/]P$940S+"676"?AX^L6>9'^,@:!=:#%^23_^HG<U]QY*9
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MB1IH-SQ>1GD/<>UJOJOFP1YR]31H8*@W!S7]*]!V&2ND[],EHE+C  A#BS\
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M%E/-:549.?/FJ1IYF,FK4[&N%T_!=7AY^#'%":,]EN'$(S:@=&3<,SI<@6'
MV;H\>";6X8> HC$R$AQ-<K?L"5GJF5D&#I[6ZX;=X?$QHX-H,S^?[9%.%)T/
M.FBTH6#(J_2[KS6Q6@@<:?_HL<<WN@[T^+6%)U@@)50/+!6'M8_$+^TM?*[9
MMRM;RK(6](=P]N_P6<RHZ<!H!7UZC3ASP).'0B_U]84M>$B\*8#;[[??G[*?
MEWUPEFFRBVD!?\G^1K5&>%)2V3V)W=*#<BESYX?(-P^ISXZ.:./.4KV:K:NF
M&]9X-YPQ:#2SVE"-MC$H8O'N,2IK,,H.7[/T-ZL K^>$/9&SMMM= ?D:>%R+
M::OEB%("XKQ.A[K>:2NG9*DFHTI^DLG1&X'H-0/MN^SS+61O:1N=28RSR)L_
M"90\R$;?7ZBD"'[^\#W%9@$-2H6EXN/KHH_7=N?J%4(3 X';*4VJYS_01/5]
MU(Q;9E?,LKI]&J %'I#\T^)' )JT#^A0K(<3!* <Z3ZX?_4D $D <AYZZNRG
M[?/!%JI9;"= IYT4.)_?ZQ-W6)[JK<C-2.V1]8K[-G6Y[-S01P,0VQI/D^]U
M8=F7$!=<6Y')$LB69RA PA/;$"@<J#>H9(/;MU[3V[W9<P'2BEG-X4?V?-M4
MF^_Q\7&X9O<T ,3GZTT O@R(CJ0H?QU5@5#?%+GN:TW]M71%<';YT2?$2YXT
M?LBG;^6>N4HM> O%RW"\:1#.@V-[1DVIM7;!3]PN;\A6CTX'5*KK'H9WV-14
M7BI:C34<M/-<?FR:<DN+"#I TD.@GKVZ^HYWL)$/W.]DL^-E"'A?)]GO5=.W
M8Q=FL9XHMA0^V$=7\Y.BU=&31/.5DO*VK"*;,=IA3[Z^O&,#[M91_)Y@[1AN
MT S=7H35BG.0"5L:'.6LB6?V9W!F1]UESP1.";@U/W^IS/%Y88NO\1LM\UQG
MZ%M3CU 4QV#%XG! 79L&NLFG&\DL %]+..K(E.=5'HEVXAC6#5]-$,@\[MR"
M=N*NF.HNA4]HRD_'DU6%[3"JFMD\T_Q2&UQ*1MI&D1Q\4^O.-2-H6"J7&S30
M$+Z#XBON:L5V>FEFAK_['!P[MD2#1LPI@?T*< J17)XR\?#,QLGX[@!M-P%&
MBW=6U ZC-D6,*:4M6VNW,X/61,I(UV)(WWB_*+3B%#>M2"G@S2JJLV8::@G4
MG79P"O+3B#^"2%5!^=R,<CAYU8^DU351@H6HV/IXG;!Z=)!_/MS7W2!,Q7?L
MR^47<?!9T;<<V.F8E&FKU^RRM0;=X?#/BDZ(:GU-%2U#?&%BU"Y:LV,1Q5K4
MQK)M("7>6=2#<++$'*:F!(Z;44DV>X^R5$)SMU>T.MI]+E7!]V;D=K]$D#\V
MM$>\I>FK['D_KDF;LY+.N:HW$V?=#7(3!-5VC/B/#D+L'70W(F5>U_MI/7!?
M[(?#I"UZY@<U4J(_:WAD.B:NOCQ5:V)LWK3KZ2TXL[:%?ICV(/]B\4BJFKC^
M]-S+"&1!I.F'ACA3C4WG82X<FBO+0&8@-$Q_BJMNY2P!0(OCLN#.7_=D8D+^
M.&-^+KK+O=H&D*?[DUNZY>MQ1KKV1I6#NR!(QZ%0CF.]2Z*J;O=+IK'V9MPB
M.\75V='&6?VQ6F5!J#'D3#T/SN+('MNS6QY7$5HDZ%CPK;"D57=TS[A]U%^P
M."X)$5^7?SQ\*T?&(B(5%*RI>,,>+5&Y]Z9Y=2%\SE,DMY&DZB8/.P$P5(]!
MHUR4W/6_?!9.?) G9(13X]4/= GR:S=<3JH,UW(L246<0[4S])HO981%3"9H
MF"B?U_!<*^9"E/QP"*+;N(#P$[T;R#GS7<-'"H%^U>V=8]C(?J9EI-D,>&X.
M8J$Y3[_8Y\!54VS2['R2( Q.ZG9*QYZ,@/WD:2*6#V7S\\PP!PFM8X\BV-IU
M:K]O$P":CN_V!5DM'+=KE<[?]PDV&5Q-CKC2%H.ZZDJUY:-@9%B>UL3HB4G+
M1"HM;.U&'_6$:1WG7>-/%,O+#1 M,$HYR$> CI2FL["H85U?LT:)43[4AGA4
MZIIG'@?UC[;I\EK%064VDZ<<7]]%$]OI@X_%?M(J5%KE/:X%TK7VV J_"K"Y
M&:(A%1>%:"NE2+:LYM-BFD];72XY+DW4..;/Z]V_@(>]]L=%SDRFL3=6JK+Z
MJ& >Z8/Z*\_))]Y8 H>U>94ZK6Q^9C&*G+-%P1&JA^H75=#L6C=S7L!LV_2V
M(XK(&V1Y+);P0<*6.07)(SS >]*G%,!?ERW6B+1-7LN3ZP2@YZU3:C'1&LT-
MV^^8:8.X\11IA_>B^!OK*0:\>K.6&/MVG1R06/:A)L>R@V)&#MZYBF>W'Y)>
M_6&BIIO_7L1Q\4O0HG%B^4!FB*IL@$QS!L3KR+F]%RRPOP#=0&HQWM&Z-3A9
M$P>N#43@M7.2?57N) Y_-AKE_I X[WBE>9)<YYJ?V[W9RVYL/. E[GAP>$&Q
M1%ZSD;AX@X]Z2F4!?;-+!=WC/B/[:B5++X<N)YR+)A]BD9L ",U)TM9T_9@?
M\UGCJ#DJ-5V6_330/;R8>*]&O!.!FCX*ZOF LP1K>D96= @]NI)-S_& N5*V
MA5[JR7&P.HXK1Y<6?]%.\$JIQ7(U5U(91%8B-6^()_O 4BQE/ <4G::\C3A
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MC9[\-,<I><U?Q%?;12Y0SI#A>V'?HF(A.U]WY<8+LUDC D!UQ&MB&</7ER?
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M/FS<G0#<TK:[.!,]\N+H7L,8[&B> $2RFGZ!=2VF[8M:SH+^NG?_;WO"18]
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MGP%OLVC1V0NVGFD[#?!RL*X"S_X\5B9 $>5RN7 -&:D DH>4SK$('6/>\1,
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M):!DE-4M(VP?I?U4ME@2*Z C1YD2'AED5F"T'.73EBT^& DIX'U<P/OKDW$
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M'F+2[QF8TF -!L=[#(]-C*@O2O@[O>=WC<**9_'=K,N$!]6LE7@&U2<;2.I
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MQ).7]\$_2/=6>8A;Y!3.P+\:O7X$2"=##2C9U_D7$HXP>?0&#\DJ$,Z.G\_
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M9)WAH+1K^,Y28!AY(?"2O8K >D(]&AV6D@!"C1$:#<:2&LW0#:*@R&8>#(J
MXF/H!ID,,$Z2>T6*VG@?0AE5#/H5+L%Z7Q_4DE 32;(+NKD!6=4 $THBX007
M+T*_@(MR(;-!1EL(<'UHQCAX[G(HGG3O-,Y[N;L@PCDS3]NQ#1C! ;Q;TR[(
MIP?+=E#.F9TF.S1A8;VG+<[R@#;)/[7"[+?R1SU,QZ[ZXW'I0(2>9,$1_08
MM5>EB3,IP^(RO^OCZ\&[2>[I8]WQ.P?@!!G+@F!?>O_>IA'_A5#2?&87!"\F
MP*12#_E-@ Q+N5]3. " 7@)>%8&\@3P<!* ]#EF!00AE@,< JWK!JYI@_!V)
M(B.\#X$)8!H8F1ASP'8&@NW[Q7AT."*5[Y:=V>F _# _.MF7@=94\];<NT-H
M4H2OL)I^<3(U=Y<\Q[(<M;Q:7/60794-_D%4YG_;-KO_D7-)X#_=L'CH-G@;
M&X,OK]L%O1_6CB/;:H-O3I+M@M)Y9?2A3Y7QM8#'W18Q_YOGF/PW??P/I@+^
M)TZ=)9RM"]UL)L.=GJC^!JG5(ORH#,&)!(A.8TDAF^OY^(@[_[P:Y/_:ATH?
M9/(K9&>2!_^D;V:&;MDM:6=-;Q>D^'FQ 7(Y!N?ECX\DA*.?05^UMI ]Y^="
MU@ 'H@SC!-2D,'W06*+W8G.C:NK+IBY?M]LIFA<EY>W5Y)#C40BFOB48-$YL
M7LDIHS=*1)X'IJ8=:#D4G1=C0 (IS"'4#X.WYL';L7 ,^'N*40123.>!\UCH
M!K4@R'HZS$825I%N<!N\<Q185SP#TLTZPV8L,.6ATO''>)!D2]E@]#@9;D<9
M?S5T"?L]#?'_*0WYHS23]K(H<(>=DT'YD.&?9D#&8@D9T@SZ>Q9E[]S/HL#T
M\RKY#X;](?=%_<A]<OO%ML\)Q;9TVU<)9=QT.OG -&"U=TC*-7Q;T?>4F[(+
MFK# =P*W+"'IGOMKTM793[K=0-*%F(_M@N8N^.-)]HKV^PE\+["DO;GG('+@
MHE7(QBG 7.(>PKSY"[E?R/U"[O]QY")3>FR.#%LQ!%H&F,A$OV&Z 2+G#7JB
M1/8H2=W0:U58*C#UB']RV]R C2>K3LD-/L4\/0,V.9;NY:&B-.& T68'5 EW
MEKH<LFU>N*^R!N6BO6$0"#U@GL<?[6,1^A4G_S/CY/_CR+V5%Q?L03CP1)SO
MHF BX[I&XEY';TI#?S)Q^_*SZNW[CT.IM,C(9*)4WW6C5 IMW2)A^J6*&4U"
M_6T8QK1[ 6U!S @K@]Z,N-FHI63YMJU!@Z&^+>Y=T('1$)C[XW#$PW\-\*];
MXQ=ROY#[A=POY'XA]PNY7\C]0NX7<K^0^_\E<FQ6NC8I+A%\#>2%30S$TD^>
MG0F[143__+>!I)!/XPPO&I6H/7@C+?HLLU04!4CX>U0K+1=BO\TW3'#(E["V
MY4HGR%Z-G^I1DI_/7K+5[KJL\U_P!OT__/C%N/3?4^)V637;2Z>XJ":Z0:FP
MMB^QH\ )]3@FY.*#:YQ\<FK'14C?$A\3%G[9*B_1HZELY([X4#.@X%Z:5Z*M
M93M]6;L5M0N*R>_L;#7LE#%WRAGVTNY6EWVN7ZIC2U]>H2!)35K8Q,$A.*A1
M>DBE0DSGZ<E4N6,"E<^=V;J,UK?&8Q2[!_*"!^=[2N):WK)J9BS71.JG5,+F
M+7OTYG#J??QEFYW40W.ZJ7ZO.1UN5":+-B^663T:2D#3(ZN"B.ZENRM=,E;L
M];&4=BA$XH8P78Y;#!="+15OC]K4&?7 C1Q%+A%-?%Z[F!&MJY7*1";Z:>#$
MA6+>\#::A-ZPPT=/CM0C=9MO]-N-* K&=5DDS?35.)$F53F&-H[!+.V<\=ZG
MH"18Z8]K-KC1&&*'6_8F>E<4RU]K2=+RV9@\SBT3J6L(]9("CZII3A9-]V3-
M:!M%&/'P4X*=5;L\1^5Q/%1F-8:+K1)-;K4L\\A%*H^+O&WKEFN*G.'!B7K4
M%/POH8*(3^'Q3X38$!UF:0GL40,-2GPQ\9$/DM-SERL%,FT%,Y4"M[/D>0TB
M(O6C\ I&XJ?$.5H$867^\,:N)O9;%(Z?36QJC<]0G3Q*HE_:$.(9U!\%<8A,
M+)L>PG1/WU''+<6?CW89P+(;908ZKYG>+>Y>VA0,F)!S5H2;%;W24O"'39,=
M>O:T_%!\N-PAS9?T(BPT66R.<LW7>U(>4C)#FMR+=ZYV!ZH]S\)]RY07W;2/
M""P;\6D5\-954CPW$1R2R]44C]KR\-Y,(7ML8SMY5G8NP*"Z.O']3>'[_L<<
MEE4:[\8&B_0KOU57;.7JBQD9M$NVFC<P_!"72:JH!^/_,/H5N NE,1:;M7ZE
M49-Q-GH-*Q,6$U'T 2)3O(+P:R]/^!$1Y^D9MX@W6_;AVM0\X#%V*PI1I$DK
M#\:*BTJAXVHX^9A=T%DNSAMB5 &7:6)'[6G.GDJ\C[SX[JN>'?&#L8T/^<L/
MCXN[HVULXWM'E%OU>MGP*+[8+NDMM'($TG6#=S,TT"76IF<0-FBX<,J:7-&E
M?XYTJ'DA/YII7>/:R):*(W+U&UT56_KJ;=NX&!FFX4>E&+E43\&>0JN.U!56
M@34E4BMQ=UUEHPAEA>7*C_T27'J6+F$+JO>,#.XIDRJ@(H,X5:-=@IHX> \]
MU#;(X9.6A<G2AQM.Q3.G976F5'Q(BW>90XWHI$7<M=^:2*43RRN8=G'%7>ZP
M+NC9MFYF-"J.Q7N*Y0H>/_O@E,M3XM>1YGS2CGXWDYDVICQZ,C%O1#K=D(9@
M2X<4%+(F)M9"!;<429_O8ZC=A12,2FH5FNJ*&X.\TKHLAKD]V,+)IWO$)!PQ
MO(#YV%X2>KM<9$YV\X-<<UQ.U!+,7F]T0 $_VL>S^K$2E=B&R4[O2EG"]N7%
M02%ZC@Y>)NMY THVM)I4(:G=1.2O=(XZ++P=UIZVO=ERK#O2>W%]L7W-W7 (
M->*]6*&FG\O25YPD8XV WX&_']HN:F)IJ*6+T^-],WWO;'* JI].*JP@Y7F?
M0?,:OOUDO_.*\M9CR];V<#[=W)&I_.1B]?!:%'MPEJZ#(O-EL\10Z_7:CBJ9
MUJ+([I*N,;K34EG;L0L3R\O;.3FIL3)\\D*YU6>CCS\]MW*H@.^T+"UH+MM*
M+>0"287,R J;G(Y<Z6:ABT(;3*05?L$U(]50D;7&4TK&4"/&G<O&.C>IBC9;
MEZ5)3_'V#M=UU:*:KF7N(I1=Z1U3N8IZ7]-G-)5DD>_M(D5,WF6TQ*XI.C89
MM.26#$W%]0^)&=:Q.:1>K6E>2NU)VP5YP%"5MI_GG, 7]!:A, D--1G<:_ZP
MUBJ[KUU^3&DD8PCAD><=]Z>BC@1@N.2&\JNH6]'>R0]I^W?*8%L"\RNE,2,V
M2H+*0:6WF]MV.#@J0C(Y5QM.F@C&>'&^E"9RT"^'45TM+9I1D4<T)"FUJ0=B
M*FA]I"W3:;ZB5.+OKXRJSAA-+^CT27!*O9]?6] -28!8,)=;._L]N#>--B5W
M?W(=I#*508^;OI):0G.;:GN2#>(KK1H(U<.TYE\)MY$WN#)1HQ\YFAA?N9.<
MN<83PGE#(#FMBGL^=V:].BK4=MZKJ\)EF=[[2T7K&-N*/.'(&CG/X:^B3H4V
M4$4N'X0K)7BT!<9%'GJ]=@'!H5<S$CN?;\IS=SO"/!,^O_/H\=W0;%WO0D&;
M.%5>-MCVHV5<%^9=B(RXM>:)BA:\=S.YCY75*;T.Q^P=/I$8)BNGR%E%'F$Q
MH;F=\YMTY'H+HM6U9YH:J<AA-$U?>*8CCSU1C7KNK_Y,&&;_/$SVQKQH6];S
M:2=$?M(R;--PI]*E4I%6,*/25N&M1FVB(6YE2%9,(,OF>LPJV4N!N$5:W'GM
M !MKJ?)UXC(Q;(4IMXL<@_(HN2;3(3\%8YI7S*]@^/XHT35YKEJ=EJ+@BES;
M4I==$,6##5V:DJ4LI: XJ^%5[]ZH20@36F\A6>!2E_FXGE6HG4BEM7D1QF#N
MB*Y9TE>]\/0C>&5Z4!TXD-9Q-$K,DY3,P%(RIDJ_CZ<3A\BUX?(,<$7UQ5@5
MSBPE<7*U3X_.YJJQ_B(!_.\C ;SPEB,MHJ1'&S%S[$OMV37-LGI32+); ,?+
M:>M,;H:$*]QELFU957KTY"Y3Y"[/ON1I/B5^T9.L%*N5(- V5JR]#.6HF:0N
M\8[J#43U9*/8K5*'=,3 "HB\/.WNCO5CMZ&]U;RN^4.?FFEK'CH3EX7./"P+
M[92YGT4F$V']^%I!##U]AS[X&SX3 9X><HBJ9).."T%U94&X+>"YP#J\N)VR
M-;TX+;,94\%6NK%B:3V2%J.P13;!*L'LEBY;T66:D+M1P%FFUGJY-]3MY)DP
MV9%(F$C#=:_4)TRW Y_GZV OUZLH5TUE%0./.:^&/-G$=*PIF3N4$GC*$!2Q
M2Y&99?FX\LTAC3(7X5W0"X_2"%-.54.K&%29G=<=K;,T$JV"N)=^FO=T2%S%
M]/AX2"L^T>3%>C3'^E?CXO-2BWW$2P<]%S%P>[=@]O[(FF^99<Y5JJZN\)+$
M. N3^1[];1.]3JIO>6A.9^MLG;!PRO?E6H-5@P]1TV^]CSSNBO"['!"2"(O,
MA&?%6W;'7S LBUAI;X>X]>=HRF\"SU0QZK[*&.?>S N!?=E2+E7>IW9!IRS"
M+70'0R:O+LPV# BY,M>NQ4Y^>5VT_"Z+SCD[(TI4&'9FVU(598T?";YL+9']
MMJVSY.6+!/EO\MVCJ;8^,"$=J:'4B0CK*L]'EF[7FW9T5A5;_%^T8.[H+/!,
MH1U,;0=3.M\6M6/B)WT\G2>*&_'KL8_[;JG-S-N--GEMA@]5"$,<\FO2;\!Y
MDI:A9'YZJ(WK3J8\?N<:1KD2:;B=OG'.E+UIK(*-Q%J',3$^.824)J&_E%-Q
M4N/2-+-\\:0XI2Z_QL/!+*<:.#:F+[.U24(KR)1*[86[@-.B5D2HTRR7CVYM
M:S.5U9:X&MG+,VY?1EM2O\DQ1Y[7IMUDNQET=-WH[(<W[;Q,3T-Y]8Z\R0#9
MCN=2;7H@8RIKXM$0Z/+0:A]<(R>B*%SF(1NS;A#CBH2;$$QB"RM06F4[(%?T
M<MM]@O:4>CV?FQ+L-JRZ?V"<?I">^&-4K[OOC3R-T,F5D)*>5TJY8CW:*/L7
M*=&H8-G1]NP^':YEXUM9FMXXB@5=GO35_OQ"_;PMQ)RC4.)51;OZZ%J2DK)*
MT5Z'EA.?3!CMHAA,OG@\#7IPAM2K:379GITGIS>9W<:A)296V6*]VRD!;[L%
M&RK>H!3:M- ,5H0+A(\@-30I8SZ4E-GV5_8.K[7/U]+U78UZV.O$92)V#YO]
MYI:UP:WDX,-I?>V7FC2I"^X]57N@!O>X.!2ETU5IFQU3&&-H*8?DCH7'Z2V,
M1"T'!G&17LLM3$M&4 T6JUEN>E7IZ QRN>OK=&^7J?26*/LAG',90E!2+SZ3
M+G$>Z29VN0F2=B*=ODG$\N0=X@1YI+F<C+*'D$'*?-OBU);!I8%;XW'A&:/9
MT5[YE3U&M?,2F6S6GC'5GCFMZ=O<[<HE1_(V+3B7)E2W7KJ%M88D:+A#=(Y8
M!P1FOW)BK,[ZJFB3PN*]X[E,51M?5L577Z)P.EM!ZH*JD8CTB$#WC0[WU+GM
M!%J,PB<\8_>R\R4PYDK_\J@X]UW]AL=%?$^R.:C+I7FFR6DSM-A;9IHCI]+5
M<L5K\J% YN9X%A 0ZDW%(N,.SSP7&,RJC/<6D]?ER*R0U];+U9]-':BB[#%<
M4=\%A;\UW07=;P5'=9CZ[X+>Y,OBG4Y9(X"O%W=!&P%^T.9%2^X;7(]-B=%\
MMQ@/X;JN/!]Z-TPR_^1ZO%G%#)I=-0XFH X15N)8L>'1"@GPR'JM5R[FE4H#
MQD9SO:$[:Q*-&I)<4PQ2]#1/:[WTY;=&H7,G7CX@9]_ZQEB'7[[UB-5$- 6?
M'Q YFZ,;+P*-JK56F$G]DABP%E S%2)OCRHW,KW$LBSF.JTHSY.'7]0;;"_X
MZA;7A#*B<!9GD?M-2SJ<MJ0RVI)"9OK*R<H\.9/;SSI"3K ?X59N4WU^[^5
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MV(L\.**NG_[W?_=_&F\",=<%S/L[;3ZC95ALTG[Q[J(1>I(*AU$& !!6/@C
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MSFVQV GFF0$RB^^])+P^W;TD*\@V83\=/=U@ <3##GL<B*W)8N^#!I'E*)>
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M"V3DV[U57F5Z-FZBBN^,SM+&11.5.*GZ%VA:&"[SLU5((!-DVY1;%_*@L3-
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M!GR,;5I(;!^SAL0]9G_ OMSSVF,V$HGM,K,C;?Y2+?G?=8-E%;7^Z<#U3;Z
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M+*O-#ERL ]!?8\T'&X)L_)291S;%+\6"\[TBDDZ?CTSKC3\:>HGT^8EOV3Q
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MY!BE1-LD<:3Q[.V#]YVC<V?O')Q?Y[_]/D<'L--AY_"<?]UQ[YVC<_:O.VX
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M'D<FTF&1Y9#)GOU&M'G/_@::KJ/0MY"%W2_$]8YO7&]012WGVRB?9PS4JC;
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M@6XA[7RM5+&VLWQ*^J+WSVVZ X*3#YA3> "J[Q1]]G4&W2CG1&?<)-J_:=/
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ML?,+],:H"Q9L>IE5=0']1<-;/-KJ04/@]\I81/^]9$R2>T?^1'PJ_:^L,B(
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M6=9F<&VO>E[I@L$1SF=ZG9^U>)./":$OM'U 5\+)F=>L>90]TSS #A>^'_(
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MIU=\@ER'-C)>,*2^#/;KPE2Y#:)S>C#ZWIJ+U=B5D1%\?'.J]$SE.FJ8PMK
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MXQPH#9BE Q<G1%;[P,]![40<N"$7"G^1W>;W 9V/]^YV$5GV 2?,#MB.ZCZ
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M<5WM8.-N9GNNW7>C,\^Q 6_E:^T#T]CUWFD3$.VH5*I^Z67XUH !2G@3R9=
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M3BELB-?@"&^OW"A$GTB3JIU<)29,I]<Z7:B80T.!Y] #V$Q3[$:@_-@8I+E
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MG_1/=I>R6DBS-7T#.[E[G--4C_),: Z-S=]\$ZSW=:Z)LG$E7RS)ML7KG&X
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MF<N&9R0>O;-4^X1;XW+]A8F6D/=/ /$<D<G93@_X"R2)S06:!YLX[ZR&JP/
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M4)I"C='61PFX8HRBY,BY7PH_[Q:,Z1SPAQOZV>8;*F.'AP<^GHLT!/J!^A#
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M7:A[%<KL'1SI0T-<;AI75V#6%[1J3!)2X-&;MDU;-&=:MH#S\8:&0=\JVY=
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M7"II(OM)W,SCC,@4_1-K@WL >86XY?US?_7HUPRS3C7N1_OKGUJZ1)[F[">
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M<?C-RS%?F>_=U]N$CXL[/7EYO-B^33U@E%-_$!SZ="%:D<SQX?RIIHNFR+S
M^!2'- GE S*_,FBSD Q1]=F1R<EG?OI#+]9-@4ZHW.#3R@:@O".]!AHL6F@C
M 1?N<=4Q6TIKBTUW!4U82_B_OOCH@>PBFDCQ(AV,R9GU,)V$[V?G2A(OOG)'
MUU9>]#K$O_6!>$90LD[TCGV.B51)Z@V3I[I%3X'IGVP>=5<W7G3X=)@%CL1Y
MF"1&^DFL,&$99*0[#^'CL;/'VF.81;['A0.YSR<_X#JSR0KV=]W:! L'#.*L
M-WVAY"(5PJ\O:0BP*%!\?\)O!C"';ZR3PB6&4'VRK >R"D/O^4Q'A7="D@5X
M.;G46>_4[]PY>'38C1^HE?ZTL3'CW5$D,6&4?O$Q*>EH?^'13(/C[DT9OEB7
MO@R:9,$T.=UX._XXAM(5]BS]JZSGQIT[R9\/;1L%ZS8^[1TP21D5]!LS=Q^5
MGR)IR=TT<YM9N4=ZR5TVXL<^1C0.#CR*ALN\.NX8GCMW%W%6I/[M2K4]H.[Q
MO 'OPC7FIZ8@CG2)!HJQ Z>>C:7*',73);^$8-'X3JSQY;%7#:V);O6>!=+G
M(>*/@/S&GN&*XHFV>88ZKSV$#P'"#]6&/3)02!!/-8EP1T9O3=1]Z)-M,GZE
M?__=A425;'ZCY*LR(OZ'C0<.\&,# ^\JX>L140]ENE)?#9< SQGI-X==X1D_
MG$T6L+U503XC%G!D#_#,'3$[-H8*YNB^>!CY^%,&RPK_A9\BP!T )3\Z2S &
M'-GYSTUK^-JWGRK$+?;N3^),7*@V[8]/_=[<#[3 $DN[;^VW]V<M6GN LQ,4
MS'P]U*!3W%*1NWSVZ@D9,3X0MI%02VNVSTR6UK'1\#R,Q5AG09&,,FL>)+*
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M[D^[%OBM4%[3-@N#F<J29&"EG=7QC/@H_X&3002"6:BHUQY ):B,323G(.E
M;^>()O9;W!F:(5I).?(92UG8,-$P8\"ND3_^LXKACT+U<54[$=6'#@Y%BZ%U
MP1;KSFM\6D%=R\A&XXK V2Q_BEI_L"V^GO$:[],J/EL]LFYQ0L]6,?$"DP*.
M$^SS7FFZ.2OYBP1C\VI[G:7=U-/Y!<?8C+N).GIZ.3Q^TY!B)@'9@"3-RR0N
M _7L.(HRF6DJLWY*F4G]X];4+.>59-3*DPNHRG&D>S>MF>F4H&6D5A4SQ)Z
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MBMK?0<G7B/.8TI^0BW=U._184X:T89Z-'*MA\OX5YBTDO@+"8T3PEKD0H_9
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M+D1:G^)^^7-.4$OH;*AEE;N0HK2QF56<M#BK?O%EB$]Q<M&.>)Y;&PP_0<#
M34P)PS=B7FIZ)5SY8:[*JS#YE$ONU/F']C%,!OZ-QJ&'\?#(IE$LK1]'BQD>
M"(NQCBK1GO=#6\[6>#1KJU<WJ1-\2W042Q\^/"GP29UIB(B/2 C[\%S$M^J<
M2:#XPQ*[\(#)%XAQXGPL%&<U0Q1[!)X)9"8F/9,U4P*.BB,&QBW\H7X+T='4
M=N5"FG53%#YP9%SX#<X]P]HD0]S!$-&G,^!O&$%5!LFEVEH##W;9=W'5'^8&
MED4Y,K2:0A',S!@Z4+;5&BB?CFUB%[59(7+,\24UF.J-!LO)?+W)[AKAHZY*
M]^JZ<]L^5]3+<F3<%'MBF?'0@"QD<[7'DYP'U?C>0)8/\0[*R]_>K !U+E_T
M)/?#<)O4#Q@AJ6$SGN1[>X#O@IUJ..RRI%UNQSFG)8>I:*64'"7=C@]]_'T*
MQO'N/*I)S%)Q-X4P!?NOX):^W$)6\&H9S6F,U0D7)K->C^K!H&K2+GJV%-)Z
MI):N*X7BL1&6FLC"(>K[(:9>(TG'(<?V *%G)[QLQ[;-)%38O4N%XXA]4MN:
M]$Z+L?:Q-/'HXB6&;.0NJX&Q.+)-2UGL+J2A55N8O14NE DSL&,(_49+P?E!
MYB-9DR>J_#]:K(I5TGD&*>Y:O@2;:3G@A>M'<RSM8ELJ-!Q5LUY)>.!!9GGG
M$+C,1-CR_;;EEK$)3VGI4MIH:05(LSVTW)'NV*)W9O!NG 8% 3R%1.=,S7KJ
M&19Y/8PL#:,A3KP+)B*.74J'P2H6*_N]-SVYVI91)=/AV!P7#_7<D*4<9V #
M >T>831/!S'ZHT4Q#\AW/4R,D\5ZM$N\/BC9\S#="$*V8DN+_(QRHK#=_G30
M9SVT>7;#,7"C3?X<R*?),@0+8JSJ58-JZL8RK?WTN8*L$?"R4&E%O"PNXN8?
M!U8R57IFEI'5U3FN,RHMXA:#0EE= WK'&[0M!LP>');R4<.4S."V+'12VC:>
M-0TV!?97<E&AYZA0X>2J&CQ&D 2!.9OU$&8*.W)"9A (45=15[[.#Q+;<\JF
M=8*8FY=5$.,0E)$XZQ9G]ZB\/ 8!6^3/S 1VSLMJF8>L94+4GX6W,M;J%[""
M'0N0,LJQ\1YHIT:D..79C=H5Y@-#?NW\@GOE[D<IABF X^_OV*2<Y:!=;56V
M\&8O@!9**Z#+O1@AZ<BM?HL^$SBX*E>\$3R6FM_>L(E6W+64#Z?&\%6^G\SE
MBN3NEZN8F;DW.^=]2LE=EC>2+IHR8Z1XWBSC$\ $;(G*BOE0? &M6)!AG7R[
ME5U4,I#4Y.@ E=585I^ 3)36,>;7"[8G^.CAS>$YJP9OAH3&9WFDL][V-1 X
MB1X1$8R'^.PZP('AQ#:FYJLHK.:W:0VK2%#G=5+D2J<"F>JX< I2AGNU-)&G
M* U9S@P?WPD!/XKCAFV<:,WHWR SBPHB7F0_A]GF2%OE:+A;]RLIS1RJ3RRP
M02N.UH-"O*VS&"-]XWFT5E:/>%7N33@QEFBQI3KDRC'H^)&1?!M?X\:@-21-
MPM5530<DDPT_UYW-<7._:C1C:#MB,,US1ACP)51._$3#G'F;ISYN9G:;*2%(
M7O3(>>+/W^A_EA4#)*3JGK?1CJKP*S*C.P8%@1RJUTW)%SGK?1K%0]T)/EZ7
M4BXW-";4"H^I)HFF&BH;[P9MI_:6G4">][B<Y4KRJ:R4JHH4LT!J&EO=-T=>
MKXG4%::.9X (0ZBT"3A61'5V3HH?GT)O2_%&%2P0<&T"@Q@23\L?+K'?) L8
M[Y0^\AS_#A2N$)Q*^,.[0Z76OOS."8UJUD[EPL_9S+R:;6IFT,BZOSFG5Q6B
MCEE7-XC4[&)4Y3J&P'4I9[ZIWZ:;N/5G/1TK3Z(@3 N47[YV0TD!;0DH:_+7
MNOHCXBH'=1TS&7"X*A[K[DZ!:X75.7H]],J[K[N,96Q6TYO;E6?;-D8VI$F3
M\NJF XH*1O;#F=*!P<*FU9T,SQ"D\U?M>FU.&JB;_5'B2Z8Y ^-CK%[']#YG
MI+DM+TZS@^Q':34HE$T+CR8U0\NCS;V6J.]%F"GY&O$AH\"[PA^ZNSM?%D2%
M;2)4W2<X:M\D5UD]/JWG; 7QF\RYV*0+)EK:;);)I&7K2BSWPH.=QP;,2#@N
M!MWRZ;A3;3)?.YJ1#$:U9H;?1^E/7AS\H QY?J/S6E=U16_QZ8HJR-6W7?WQ
MT!0A,/C65[;0J\6PC>!UM*->E+$."0M.3QR@@/#A LW$E14?['0D(7\YJK&7
MQ6A>&+V]RZ.K[=%3SYYHH:PWUP98,%YHZ,71CL,WH^NE_W!E?K6&Z9X;& "/
MJBDX^[GAD)NNL3[S@MBB*O@O?VRCOX_+)%&50.Q4G$62=,1*-6F7(QH.7>T+
MY(+SB(MJW)310+DFJGFMUB;**J.$RRGC<(JSIY1$_ZKC!D2MM,?!QZV:/1A8
M!^4%_G2JAFLO1_7&_F0O5WXA7HSWE7>KS1*ZFYV=B*#@W"*]XTV5-LU>UV;)
MD&]IBFZ623+]/-B%:LN>W;.SS%#L9JX/E*^X3E+ZQG8%F:S."'HM$U;?EBIK
M.TSXG6TWSDLH8,@5.75L6#DYJ0[TJ-8=>_,V$H%#:-W+^'"SC>/P4&#\Y;!\
MK;52YI51B65-DM2@IX('@\ZTPN=_'I[6W /HV(12&;,@;!AXM@X"6O4/^^GV
M?2>+Z.+G%JS^]==J*8\ )S/AW)CI)=C!Z"+CY(8#L?[(0'6@&EQ$F0H)EL10
MXIYEJQ?*U_3(;ENWZL)C42N_W'N$Z5'FME&CF%''A.]AV<PJ44F;%)V7_ NL
M8'[@Z4:'=P@^$B=W?)&1AXT1^%(;\3XK:C%*?1 1;GU_V[K9QYCU\CZLTIOF
M0*8R\8W^;BQAV1)6#,BHOZK_HEHR!\J++7CD#G>M8++OU8DKM[GC9"9/CO%=
M(D!I];O.47%TME\L,53R9VL-I@HK+1$%"\E<L[IE3NY/= QKVW!3^15EV8@"
MSC[1R3S*Z^<I^OA#>H-LLQ]W8-':M)#@/6 N!*XQBAMF<JH7S*_>?@QRZ/QH
MC&^%-KM@L"OK"2Y->,>$LI A?"NRT/45#=9Q_?BGK@!^DQS87 ;R^O$"WQ7@
M):.QSEM7;>6Z 7) \:RI><ID>!-MFR1)=R0,F&VT(LSO),T@\L)3L*,.$T9U
MU"CY^]D_?MVT2+SR]7H _ZF?)BQBFYNK%RB#LIZF)B8#4))]3O=&E#PP4I_9
M+*B!$*G9I4/MV1IG6;*5"WC?K"P[F7Z8>W]0::;Y$JYD>#@_OR!'J#;B',G/
MW0,, 3\:/S:=.#6K4B>F%9)+R=#Y0N\1_/-%YU69 TP3TX;6F*W1Q8OV \46
MG)W?QF)R&;H7V4M^VV0@GKT<WEVZ8%NN)>W7V#@8YF./U?V2RQL!L4#XXP2_
MJ/_"?*FW2,\6'65^N@/D/[C(?,GM*G<C7OQA(FQT(CQ2-[0^QSML/XSWR-*H
M09GC(+R['\3!P02D@"+1HV ^XR/@7[95,-J) J28N7=U%>6-?P[,]HPVP1#Q
M:9$[<O<8\DR\8,=KSJA*9"A^N3*Z_#6C%5K-"A_><(U=G8O:ZJMKR0D*<W0&
M23+P=;*T7RZ6]5;G?310=28RQ6,,T^<_VE\\545XF'[?9AE4Q"X>;+$2"30R
M69(UJ30?)2.KV2R2E$@C.].PE>VQ.]C2)+DY;#[JX%(@XW)_%#<@?T1]2&&9
MS2?,LC+Q?>FY<Z-<L?U2]( VTM=-<#HI+YF3Z=P;4E)= 22;%SLE\K@$9;85
M7L S0<.T/*D+Y\6\-D ]I.TV8844X$XIZ.@S7_@4XK")6\$!N.1F:48.WZKZ
MJTAQS^G>](."5SFX)VWD2:NE&"RS>YOIU<5:#BL6WO!>!M-?[+*Z;O5_G%S"
MMR)HI"4"Q%<I6J6L9.JK\>1C?\XYRYEG=&+WEG[V3.2+OF6=UJT$.#U!31ZJ
MNDM5VVY<[J-LMXP-M,NW2<N7L!',.D<(:CP:Q9S=]7.VI^?L ;CCD(X_"4@X
M;.;8;?]1T:LW5Y5&>5966FH9NQ7ZV40-"A75TZBE(=5"7!W9 ^1^XZ]C?BO4
MZ!VPV\(HRL=P)T0+8_YH@Q@N/%640"HHB#E<IIS.E MZG6V\\?:%WJ&K@AR)
M%&302DR!?1=#7O"*$6; 3"EQSGD/T"S0$U%:DSVQG^2:V2U& GL=UX/@*]O7
MFF75+78%!@OCV(SH0>$+F6.2%_EL4DW7S=IL7O'=HO"3+AA3/<Z#4QKU/-M5
M\M=QF)X>'U],GX)7I;%3[_S8DRSKQ%&C&Q,,D%HL6UY*2)NL#O;^H+R?\:&4
MSIA(Z@5\<!JK)(M_?"&5_H=X@QWM%2HL_32@2_.5UR!4?G^\9)-(SOI<^^E'
M]6!X5NZ(=?/6<M3X<K;VE7G%Q&O&LL98ROY@5YK9\3ND/A>50A'BP.C\M[T\
M8I?!4#D_7:A2^H1$VJ?O!N<>%15KJB[WKZ_-?2LRY6WU[9E^Y=LCS7?OJ-35
M/;EM/G-WZ]OL3Y^.70=6,9-<UQH[;[EXVG35"9ZN#I_)OH:<<F\[EF6J:$KE
MYVY<=D6Z3VS5NVN?=^>'W?:,W;ZZS+OL/X.8MNZW;9VZ0O[5KIG2+S=%::Q=
MM':MQR 9C:#1S3IK_S,\,2S^SQ!7%O_+ZM^NI7\DZJ^?FO_+5ZEJO^NOV;3<
MW$&[!7;G7_-_XWS[5>T_0RC#),G;OR?Z/YUO\)]ATZ2C8I__:$2>Y\I>-^EY
MSXKU76%3PBO=?E7M.!7V[LVN25\VFU]M9G \8=-D)?A*>W(NEQC-EN%QW?_G
M+&[_]7GJ?X;%ZU^OBC_8_K=FY7^&)9?45W^)7TG+/2#D4S+?.U*%#_^=+F]\
MOUGLWB.Q _/"OH3T;&#YD*(Q-R(\EO6T?LX_J:K[O^^G:9_=7;/NE]#O<BNI
M)QI.S#QRC@^:W0XD]K+F_MBT8\<FY_\,.H\R;AF^F7A>Y+3$?X8T@^[[,K->
M?3L7?Z1%[?=)DW]Y1MUUZ][,CLY>\.\$:.-6[_._'Y/_,YP(J8ZH/S^KOC;^
M7X18[?V'_QS_3BS]S^ H??[WH^/ '+;BVX;_#/--_OW:_V>#SN_]A_\T_U9Z
M_:_)?/[WH_W_&10#WR;^9[#+_/NU_F="Y/?Z]I_LWURO_V7)MW_?+?_/:?&M
MP_]J+O]^]9_ATX'-[_XS\'_B?].]_A?'O?K[8O9_6MVWMO_YN?S[U?\,3QO3
M[_Z3?R)_4SS^BR!HXY9._4^N_FS^GY_]WZ_^SW":Z?SN/_8G[#?I[7^A7/F?
MH28":**HW#7YS\_FWP__SS"-=7[YC_H)]2FQ]1?</O_[ =JXI66[QO[Y6?M]
MZX$!PVWW_L-_!H51CX]Z?-3CHQX?]3BI'A?0;W_F.>M)_#W.%)?>V;G3-24G
M3DA^4R%A=**(0;U<I<$P[I[-*KE3<R?G:E^YNV3^GSW_7OUNNIL'"A1U5(>%
MV@TJCXW8&!WU^*C'1ST^ZO%1CX]Z?-3CHQX??!YO_7=BY_L5<8(OMYVH6YW&
M\8?#I!KHC/.KZFO]KRV(/@MT?LS&2P\NGS9)G!5IN"]2<LG4CQ>,-ZIG_!.1
M</TGRK1IKF?(IC+/7)%)75^\UY?O?G5L:B_7B?3_-P%02P,$%     @ =8&E
M7-*QT55KQP  P$ ( !4   !R8W5S+3(P,C8P,S,Q7VQA8BYX;6S4O7MSW#B2
M+_K_^12XO1.[W1%"-Q_%U^SCA"S+O8YC6[J2NF?G.&YT@"0H<;J*U) LV9I/
M?P&05<4JOI HD.[YH]VV1"(S?V0F$XE\_,?__KI9HQ=:E&F>_>=WYH_&=XAF
M41ZGV>-_?O?+PSOL?_>__^M__:__^'\P_I\W=Q_0VSS:;FA6H:N"DHK&Z$M:
M/:'JB:*_Y,7OZ0M!MVM2)7FQP?B_Q&U7^?-KD3X^5<@R+'=WV>ZWQ9\-,XAB
MVPZQXU +>Z[O8K)R8FQ3=T6CE9$8OG_Q^&<GBITP(A3'MD_Q:F7[.*"FA=E?
M+#NV LM, K'H.LU^_S/_(R0E14R\K!3__,_OGJKJ^<\__?3ERY<?OX;%^L>\
M>/S),@S[I]W5WS67?^U<_\465YM!$/PD?KN_M$S[+F3+FC_]S\</]]$3W1"<
M9F5%LH@3*-,_E^*''_*(5 +U2;[0X!7\7WAW&>8_P@P3V_SQ:QE_]U__"Z$:
MCB)?TSN:(/[_7^[>#Y(,?N)7_)311_YL;VF1YO%]18KJ PGIFG$O5JM>G^E_
M?E>FF^<UW?WLJ:!)_[+KHCA:E7,9<"Y-EW/Y+T/$?CJ#?4W\5EU>-3 GQ/VD
MB\<Q3#]I8_>!60@Z/\,M,F>S7+]0UUF\U+N[)W4VZ_-SK.NUR"NR7N"U.)!I
ML;SF/_C _M:0X0N-&%-!IS'=+5;IUXIF,:VMY='2*(W_\SOVM]^*:%O^]B&-
M:%;2RRR^RM?LIWDAK/?E8T$I_R"6C!/ZOJ*;\K?#%\U+5MA;V28.8LO'GI'8
M2>AZKF7%OU7[5_TWFN%?[G=<"=)*=+\#X% -Z'-!RWQ;1/67D/'"O8":O?]J
M&$&,$W3$"CKP@CYS;I!@Y__[CY\. ND#=_VM(%LKH46^+5IQXZZ)"[X%:D<,
M**$7':%']NS\.(A8'AW167-'*R].Y<XC5;EK>\9OQMRE->S:W_H7Z'(_=9[S
M9;%CG131!+S-%3]%.7,LGRM\]'XF1;XY2\8J/^O5J)%G+'Z'\B*F!=M:](B[
M?ZT9DH^$//]VGSYF:9)&)*LNHRC?9A7;A]SFZS1*:?G 3/4;)M+OIP;67GDX
MC&,+&\XJ"1TG3,Q5)&-@861GMJ_WV\V&%*\H3U"+'W1@".TXDC,50$S'[>I\
M2,',Z@0RZ#/G 0DFABVJM'U0D_K@[I1,;"%R0LI0R-VLR.2WG)_HNBIW/^&6
MQ!%6!$AT$2.B!L3.ABC>#3,A95']=L=>%?J1;D):M&W$RL*>'UHX"/T0FW:<
M1*%M6F9DR=B(DW7G-@+\0UE6#*,U^DA)N2V$@46?W^8;DF:27L(I%N.Z?8:$
M0.55%4Y:80=$&=-(=DM+&]F_#IIXNMHBJC8@PDZ7AGZM]KU]2\/JGD;;(JV8
M"EZ^D)3]=DW?Y<4]6=,'_O?!KZYCK#!9)18.J>$;U*&>&X*^NA#BRWU[+S=Y
M4:7_H-QM+ZL+]'.1ER7Z)2LH68L?_\Q>U5)XIA_8;VC]UW<D+="O9+VE?(V;
M;8&N2/ET(?Y$UW_?IB],).[R\XL_DN)W6G'YT$%^V$<=].#D/NUS/0Z8C>!<
MM%"Y0'M&<)(7F+/"/O("NUD^]2HH:/K@@T@O^ME7 >7TXZ^T!LRJT2C^[?(+
M*>*'S>-M0>.JV&3QNS5YE+%*@S?/;'H$3?20;H0?RPA3M@C[!XWE+,*PT.-J
MKT5>F&X/BXH^<\H:U'A2JAY=+6GTXV/^\A.[MU'3*#YHY_"*BZC@I$ [/9N^
M4,U%N*-K$>(F1?7Z4)"L))'8^W]-.X'.T/*P;T0F=CW/L5=A$KBN#?$(1FC-
MK(4-921(HQ9M])E3E_2[93"3^QAK0@*FG\H@@+^R$N)I^JB.45KT&RHA\NDG
M4^86F%+'-/WMFFV[J]=WZ9I^VO;ME,V8'U?$$3;#P X2(XE,WY?1XK[%9U;;
MFASB]%!-4$Y1>W$8U\QSI8.I(D P:>4;DV#DL\ANJQ6-_>6@7[V++:)08V+L
M-&CT&KA3R;S3[9H4']*R.ME:23J6@PO,K!\-7<0)7R!!6MZK')9ZVK/4(C!,
M9=JRSK)%E))+R;\<7G4Q'W-2L+:?.7VQFJ_Y@9*2[0W#LBK8IZYSS&,GV*=6
MA&W+=QW/=$W/\R#NY?'R<Q^7"V+,<VK( 5W($RCDO$9U 6&J)B\;V#/L%T&3
M,WBR^*+^7[]@IR[?P%4P=1)GMCSRR/]K!1\OL_A]]D++2IS9OL\.<<A#8*9U
M>I($X8HY@;:/O57,=G9AZ./("2/+-1/7=0SI%):S6)E9346 MC=*V^(/I=DY
M05L-SV-<_Y=%&68K^@&^/ 'X_0# Z'/-'R0]YCRD 1DSBR&NED13GT!$''IZ
M\FZGQ^_VY@!]N6=35WZ-%I1&4V[.H[!<%HX6)(X2<_2LJ.:L?:)?6J?X19ZQ
MOT9U.I XTW^M_^P]/^1Q!MLGV%^M IQXCF.$'O5B(A5G4&5@]A!B1$^R4HYX
M@OE_8'3E/,0Y,8-]%Q@GPUA=U!D]K^AS\_]9SOI4P=#DC8+)+^JOJH)SZM$J
MKZ-FE=YG4<%]Z+>T_O_[K*%>WI)7;@5/=Y5)$N+03USFY 9!2")*_<2!F*%)
MBG,?(#;4T'--#GW__9],^P?QG?_3O_Z+;YG6OZ,J1P0537S_F0>4?X#9(S"N
M)C$Q"2(?AY%M^*&=4.(DO[W0(LR_";)MRLK8ZL9,SFAKQ0%FI7>DT?<[XC]P
MAW&/R^T$+F";+"VK)B,\36]1JRLM_JF9E;]1(9; <S?>9V55B%T(/XJ*GN@#
M6VAW"AR;?FC@*"$&\^L\FQG4V,+!R@W,)'1]RY;*"YLF-;,E%;E'!^(7J"&/
M.'W00; $:A([>FU8P'1^41@ VVUM<*AMIT=AT;17EA)Q="\\OL)R>UTI28[V
MLG)WJ'F%5WDF JI_2:NGJVU9Y1M:7)8EK3[1ZFI;%(S@J?_B>X2Y+M3#L>]9
M<6S%'HDIQ"^4H+G CC1]$3XA?SHGE53<"\S8HC"?1@9).:]&,S[ J&1#O&Y?
ML"-_@00#%X@D#&YTN5[G7WC9/DKR@C<\B--*)/U>H(9!?7X/  U-GH\,Q45]
M'P $I]X/Y%;%RK2*[4VO\LTSS4JA/[?L?>HO-0D<'P<)L;$=$7,5N2O+"D%I
M<".TYCX-R3<;9AI*S@#*GSGM$J5EN66[1KZ?S+<5;V3!NX, B]!&X),S%YI
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M[1IEC'Y.UY3$Z#Y**7M<S ][GT7#F<MG ROWR9L)+I@2#U9SE^C QTP-TQ0
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M_@5V$]K:7Y; M["?>"&FH>G$;NROJ <*J<S(Z]S.98NP<I' G(]*;O?X!WD
M0!^W'WMM+247!$=7Z_49.5VV(?O\D'?:M"] \HQ144_YFMU1\MJ(ZK4S&Y?:
MF)A&@ .2&+83KF+'C'ZK>!Z29$R[0P)D-_>$@#E298NLF"SL_3NB@KS"-*A1
MA +3QH'C!]B+DL3Q[<@-W>2W9UJD>7Q?D:): J=3<M)HO:&/:2;J$4*RYH>@
MNN%QW!@3WTDP]9W =1([BCW2P'.=28Y%T0'.CIA\Z%4,#].&B^01R%F2PKYR
M]?H7Z+*JBC3<UN6(5<[;L&H=&#@LD\[Y8,<$EA\+UBM@[S2P_BO5<[E:GX23
M@2"][= BB[=.2A)L.BZEH4UB+PP@/K4$S9E]8XG!.6K]T63@E%-DS2#!-%L'
M/DIY4)(2:\QUFJ*X>#Z3) 1].4NRM\*/6-YG9<JN;.:4B.0(1N6VR*,/:4;?
M5W0CT]-?8I7YWNF&.-K-M-F1%UE^G <:;PN^1^.\(,&,IB,(@-A*AQ$RZR]V
M+ $0MGU  ;E-,>JT%D^)QOU) DV*QFERLF'%.(C8'ZZ;T,B@D4_(ZK<76H2Y
M= A)BC#DQ6^35]G7]&3K ,-"<EA*1GBTXP,S#)/) MJS=V 2ZXK R!%=-I@"
M J(3%X'=K9J-R^=$"[];D"DOM]537O!LX%/'V H]'"2QC4V?><;NRN#.,2P9
M=Y#6S YQ>QKV13TWBWT8]]3%9*WZI\!Q6F/PR9D'3:# ;$*#1],WN*:+#H1U
M9N=.2J<M.7>8TL*YN9,B=U-SIV]1C&">=,BZ+$O*_L5%2=>\8Q;S/ XN[HES
MX+@A]HW8Q]2RR,KR;#YY")2P"Z$^LPGH=(UCNS[.#FKQ(]QB.0]9 ]J2$:^Y
M, 1Z$7KA@P?)5&#0%3\#T5XVM*8"2R?JIK3(&4<JO**(QF_99E[TBN&A>6'V
M/M$OXE>=<VXO,7'H)P$F21!'CA4%H1'!MBERA&??INQ+[7A>2<LK47=!)!$%
MQ->UH@0T,P*+F@%4<X!J%G9N"J]._%)?,7S8KQ:#EY9;9UQ^FNCRL7II('KC
M]_)W*T8ZN'DJK[8%/X:Y#$M1_]UI$V?9. C#"/M.9#B.8;JF#\N,Z:,R]S:E
MIH:(H"TY?70<%LD8Q;G"PK2\)G>!=O)^WI'4F3LR)I*NF$,OC65##&-B=B(*
MHQ>K:>.'E(3,2Q!1^2P>/_#FBNGZ!@[BT,&6Z08DL%8K$CF0C(DI@HOD3ZP/
M3(@ NZY\BDDTY?19)T8PU?YP LSU. A@M9:53).&3Y);5-EEA3_5>^G[ODG"
M:V_\033(]D(<&$Z$8]N+5J%G1"XW%8MEMRX5FAA*I]PQBM[5;9/VK/("@!VS
MW#VN7>,S A?:GJ"DN_$-G@O00YEZ),GI(\G5'\G2>;%SQ4FTL?7/E/$Z&5W1
MOKZFEJ%O7M_0+'K:D.+WT]("[J=YH8L)30SLVX8;KH+0M1VIHC59@K,?^9QV
MST1[\E.)ZFH RI[WZ(,%>NBCCLCY344'Q)RKL>@IN6_;7'1 ^,D&HT/W*52S
M7D91L:7Q'2TIN_%)]'9ZH>O\N>ZL)\Z2=UO#SD%0%. @X..DK2"THL".J-RD
M$C#EN3VMFA54-+R(+4I\X 90-@G"<]PTS(H2T.]I -JQ@2Y%C[@]([MDD7(7
MNYD+,4!MZ5S(J9633KUBN[Y!)8IJEG25CZK ,%HQ"EIPN2)1%3F/ZD*5%E"P
MN)^VO/''3?(F)T5<=P'I;'$-A^+0B2CV?(?&IIFX3B0_K+>/PLP6M";)=SLA
M)XHV-56 &>B%1<) GBLLS! V<K*-MJ"'/NJ1$V#6SI57S7Q!Y8;9J#&91FU1
M[XW+V9PQOH]LR^B%BANW[G F9KJJ(HTJ&O-?, -V_(/6E>^SIF7RV[1\SDNR
M_KG(M\_<Y/%6GVQGFC%+>/-,F_;HIXY?Z%B8N-3"T2JA*^(GADM]>/'>DB)
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M#@^)3BMFB$-7>/VQX9J>ZS(W6%]X:)B1/T1TB+.W2'!HY('HB WI@7F.T)!
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M4GV8-SC8XHE2'/JF@2T[L>+(<RQB@B:CP5F867E%7Z)DG7\I$7]:*-^W4R?
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MN<)XGC'!SAC+T[OLPN-XQD3KCN$9O1H>J+YC*L\TGEN MY2]_)LT$W$[/H9
M-@(]ML;,NM<BC8YHBSD*\H'@41BF([RZ$(#&2I2$!\579213"IR.+KQ81%1&
MO':H4^IZY5+":)W7QU3M"'K30I'/U"M%LZN0E+RC8IVLWI?UR#^E!DFPSS?_
MAA>L@I7I>.$*U+/F/'9F5GM!&+_AE'<E*^BR*/B!GOB[1/+=',] TK%?#%F8
M.=$ JDH-H@8L]!4GGL/,TE6+&H#K*6?4L:IRBG>^H?<[^SJ4S^T%! =VE&!J
MVQ[_B^'[4LF+$W1F-EE-QO&>K+*-&H))SOAH$!YF553D5DF,'I-*7Q9T+Y6E
M4Y['1.W);QZ]_!Q5?2!?F_CE&YK1).VJJF7CD"DHIL2((L?RR,JR?\MXM325
M['X[0$GJ?0WJ][5-#_K:5N3K[L1!14N["$&T5$WJ<[2443S,^VZ(:ASJ/2&6
M5C7M4OD&:CHH:K^:#E^N>/C:?* ?\F9$]T=2_$XKWIS@,!BA,Z\@"#%QK0#'
MIF.9MIL$D>O!E%:*[NPJ?,M^_D3X46&>H,V>@]:D#N!1H12:DH>%VA!2.R[<
M%:97.6H80 <.6L-@-!X70B36=6 H17/9(T,(#)U#0]#-"G5*/ ,V>J(/7_)#
M!E6[/-VP5^R#'@?8C T246)&5A1)%PZ=KCZSQ]V00XP>H/ZA \&X0I\M&$QQ
M6S*I-,'N" >HMCA'2+7R!YD'""LY&))AM :@<]-R2?E#_!YER0]>I.8T,">$
MELS2<*O23BI*B.OCR(DH]DQCA7W?=S#Q_-A-_,A)B ?9@O?06&;[77'"O"\+
MIPS[_/?A(O>Q/U-:H(40$C;49DC[&1%&TU>[C\*BW^@1$4^_R&.7*O32SLKL
M,OY;>?\27945L*UVS[TSZ]0MVZGPTZ9#X4W)7,?B)8THXJ%"0/OM/L''E4N'
MS$"G>4)<W1V[1X13:][=M^!R?;Q'Q#EJZ3UV'4RERJ+BC8+C;53Q@J_F695O
M\PU)L],#LY"LV.<L8!\VVTSBQ/42DDAU]!ZE,K<&UG1%NF=#6$[IQJ$9USQM
M @/5KRLK^EP3U:!Q4D*-?>#8 JV/&_O70?G&UUY$ Z7$VZFAW,5JWN5^,/J;
MU_U?_SNE!5OHZ56,2>^;P!+X!B9NX./0CFW+]%=1F(#.?.3(SJRMG#(2I-&>
MMGB=/UW^"O-%)5&4<T_U8P-3[#%8M(][@0FKR:.5)+JHDPL#XM3O!=ZM..NS
M*?F^XA+Q2G!Q%)V6OW?+^[B1\ T+$R<,,0UL>Q4:?A2'H+JA"7HS6X<==71$
M'G'ZP$F+$[#)606-8,#,P0@.,]0"2HJI:^KB!+5E!R_*B=Z9O2AYFTJ;K'H'
MS7R.=]MJ6U#1K8%LRNNOT7I;IB_T,HIX[NN^=6I;_2W390Z\N<(1M6PSB)W0
M-Z22Q^&D9[<$33T;^P8F@INZ911C!]$=/X@(AN!=5&$@2T2_9X,.:C=JU'@C
MFYH1M.,$[5E!-2_PKJHPU"!-C.9"3['E$/S=T]746@F)\>X]H!47[+6C(NEQ
M9QRE%93F#QP&N+?ZX]S1=!-NF67C;Q@?PM2^[EU>B"3!.E^PDYGLKIB;EGC8
M<2V+4#.*7$.J"X,F?F8VWD><U&/$BIH7],R9$0U1Q 1MWC2^E*U7UO4P).SY
MLA##C'Q#$PFB1YW)CG'G_*'CBQF+]?3N6$1K%\8=-.M@2?Q5IQ^T7^EVM\H"
M^O[KFXF@"[:)*0EGDUER;H(N3$XF*6A;5C$R0,HG_A]O3/5"UB()/8OOG_*B
M>J#%YGWV0IL3FM/L-M-:8=^E#K9]Q_-#PIXME2IT@Y.>>Y? F+BH!\#1 R\7
MPG,K.3N8UR>A], 0,(P@C[%D1&$6Y(";! &:Z/E]?0J:X 1S5M!["=#@H0:P
M_+JB#O*$EPU @ 'IQ"+@*R@/"$[2ZD->=@R*:X;8-VF(K=!W+,<*0B^2"CMT
MEY[98/"^]VM&!CS4=R>YG)JKR0-3XU8+_^\YI1]$8_[U-N8=^&_9TQ?G]%55
MI.&V3FFM<O2)O96\H6B^7O/+=@T/M [S/9%<W]3>W<)+C^<]$:AG#N_I%>?5
MH.>T_)17=U2DM_*9#2^T>#V,<U2H2!]?<?;=X*%$.V:<B.:91<T+VC&C5J8^
M@=2XLLX'$G0_URIAY_@P+M#="3[HL];YEVJRGUWD/D'FFY2\RXD^5  O>;?:
M%_>F>"19^@^Q+;W*LS)?I['X!_O W[(W:K=EO4G>I1G)^"2W?95;;U4\_U@[
ML8G])#"P'[.?NKP!J 7J *J%JYEM3IO'"W3$I?!SVWSRTI@]IX<BS5*Y.E7/
M8Y/S-!9_&##;MM1S /LI6G'3Y.+HX6E1[T@KC*>.E=[%5<YBQ8ST-'Z7%Y>;
M?,M6K3UL&N_;Z7-:-\D'/C;IPV'TV&F\WZ3,YA+7PTX8KBSB10&A*_ES654V
M%HB^(-%RD\<S2<T:2AO>6@-_A&O#M'LMIH:U1K1!#A^5GX7,\>T2",.C-'7S
M>1ZT;[A".[9:$TP$N#<)$JRA#PN#"SGE70)DQ1/?L]]D;0? YX(T?ABLO/J"
M!\/G(G!\2'SV:HJN^VZ"GECW+GU\8C1^*:GH;LLX*:KFP]84NY]^,;S(PH2Z
M"38L.Z!F8L0) 4WLA#(P=^"-/7FN9+7B*+63 $,JZ4'/"!306=X/T!2L7"#!
M#,X3S-BIFUA?-%D[:83N*$].9WQI=(H5H=#E_T+)+^OJ*H+3\6I5UX$'%7G[
MJLNHVI+U^I4;P5_+J_R>UJ-J&N,'#BM"UIS;_VS/V-GQ5/M,+^6/8@0/R5[1
MCKN=PR0?:@3A-QULG LZH&.IAMH, 4@5/)1"D"!"BP4A5<1OAR&5[E?9!;-?
MI!%9W]%'/H(G+U[YY+A\LZ$%WW(WUFH_]7S7H*/33M\/<&"9_(\D\BT_BDS#
ME]\#JS$QMP5JN+I Q9ZO>J+M*6=HLV.-5]X#4A'.>@0R6]_Y@07:IX8A=."H
M'LS9@73/U*Y5YQ*00C:\\T.KN-W=0:SPUFK;Z)X'SO@V5W'M!3>YYTE_O,4]
M<RWX-(,KWH.]H.1T?@$W\ZO8QX'/-JZV2[TDIM1/0JGDLM.%YS;=HFL_HP4<
M4' D^[A]/4<BH,V4$P8T<Z"/<Z4I T<++397H(_]]B2!WM_#MUAB'NC#YO&_
M\R\?L^?T*BMC]F_HIFI\E9DU01!'#^F&[4DO$&,!??QT^UX<UJ4QGUDJOV&:
M0&-ZBZ0/")@"36(PP_9'3E:E#<_$THMM<>1$;&]J).]04-3U^J$@/#FNU<^]
MA/47&EMC;B5=KU%#N]V07M+CG01 0C,UR0[4RP&Q-?<9DA%.31''%EY.#27$
M.U)"F>OA*KB?AWP9_^U=!OY(#MP^L^(=S_UN];VZ0._RO,IRR(B=(02FU4^#
M\##-DY![AF_BA)A*.CBTYF+J-R%46_.F+H4KG9@<*ZJ.GO(UN^6NRGXM;RDM
M?B[R[3-8"267FUDIZW&X+3;0':VV189^Y67M[)^"&WF]E 5I6D]GP >FMW+0
MS*"Z0,F55%F6QF*J#12ZK>K06Q4B]Q_2J)FL>Y6OV4_SNE')Y6-!ZT_Z Z\+
MZ90'QBL<)H&);<<P#-,Q>"=\Z4"]',V9[4/#1!,W;K&!#GPP%>"<0%I'2^(I
M$777CQ+,2NP (M\$($ ,73]0:B'S-F#1$6!DSXJNT#A,YM%(N.12RP6^8;(=
MQ;F!MRK8R_OHB<;;-;U)6A7=MP6CRXBR31%_;#1^R$]_^Y#?TB+)BPUA -R$
MZ_11<%8S=/ >3E*\(M/ 062&.$Z"Q')=&D2!_""!>7F=V3[?;S<;4KSR3,IV
M_PK!H%"Q1H"F*J![396CZDF,V]Z)@EJR "S6S(]<XE/PQWF0L$_(CF^>>]Q]
M0)>'ATAC])#W7,)^./#\FB\/DO%1%W^D@(_7'^?1JGWT]H^8Z6"[O\GS7D_)
M_A%SC>Q<PG[XW'K$^4$47=_*92 >_<;.S,)RW^9EL#SZIB]$4GT,T$U&^\<
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M#>T_5@P\!P<T=G$<1$8<.59D1:"6+L?+SZR8G!CBU!03_D^PD-L3J$L(TSN
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MIN^!![BH/@(,*L6=XM&\5.FC''C;&Q#]53_1H )D#<2K5B"#F0"M/UZ@;:$
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MV9*2NVR^TK1ZH_4[-ZP!Y3?3.QB6Y^$% %QB,T/W\LFKAV28H Y@HAXH@K
M=.(N4ZATZ,YLN]JYNTS:\.B5>%I](,)A</DGDM+V_9V-W.5)1EYB88_ZD>NG
M0>0G,73&P1@@TZ<MCQ85>[A7*&>0$0&(Z2*G),]6#?0#SU1.^MV = Y4FWC*
MTJ6QP_\HF-6;]L\1.]:'?_9Y'4([WAE2=-#/$QQG[#\."1,W3_.$6%(3")<
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M_RDR&3[XT  W=,U+U(G:NF,6#3#U;#JC"1B*'6'IDQAN-ZH9O3C%26!1[-'
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MK0AO;N/U"O$DR#LJQI-Y_H*S]KG:L!7-[3]WQ?;]2[6E8\W^N24?^P&.XC3
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MU\'40$:+W[[1=%>S ]QVDL=B>^Y*M-P()Z[KXL *(NKEON<2J7C0V.:&Q5O
MX)45MO,A^0'UT.4$>I09\\)[*8DP0852)RV:<V3,G*=L62N!["\'P1O=;!4A
MFR.C%ZC99Q0=]H3[UD17DB\[;O?V#:)$!7AV5PY<;:?"Y>0)CF/"#M4TIFYN
M^TGB>B _/0"X:?<\:;].T2GG"I4"'?$#@9!HO=>VU=P.7,S<7]8^ '22@=@N
MZ9<WQ$R8F/=\_-;R\<N>CRTN;4<'P<<!.AI=] I,T.69AX!>UR&OP)0S/[S*
M'BIY\/43*8M_"5/A$!S,X\3%3D1S9L2'(4["(,1Y%K ;6Q+YGEQ3\O'M#:N5
M(3Q8*&^"&Q(^NHMHA$F[=O(@6=B7D*F8=ST J2N_>HJ*^8SJLU4KYE!/87R<
M-3WYE)Z8'+!%P]3R->-*1MHS+!%F*+3T?5HS+!&[%%S2U);A2U7NZW3;HN<N
M>^NL82GU<>Q%!/M)%N9!&A(_(Y BY$E(H&-+M1BYK$I\*$@N!'QF&E/@O+=I
M=LG)KA8FP(1W"'+?_J"#.FWI@X5WD3)-TCL-9U7Q723W5'Z7%UR:I79=;@N1
M_%"\T>YF7="F'8).LW9(^LOK;MOESITJE$,KKQ/)]RT?1ZYMXX#PH5.!GWH$
M=C76CJ+I"_3NY874[_RJ-^S9^U!M>8MILMF\MVD5O*'(@0S4T]$VN!]0PC?J
MD@%$QQ'>5^)PEJJFPVE[WY)W\N_Z%H$W]SY!D3%^B*WTVQJS>(3IA[2VC#//
M6^VI>MH0_$YY?+H9/)WDIQV2XEC!-U)L^*?[J:JYY^. "I\@?OC7R.!!KOT=
MZN+(<3+LI!;ULSS(" 55:@+A&U;M/Y/Z'[1M[=3L00-G$P(9*J=>#;()ICLY
MN(&>O$)[S'!>U9CC9F+XH1KYNL8C J&O.T!1C35G(Q85MU'3.LS$K2EIZ$?:
M_GE7WE2EN+#^M=@^W^R:+;. Z[[;X/O9;3,A.([YV'&:1*$39)8?2.4=*<(W
MK'4^TIPRKF:H[CH;?/CP)]O_011(??B3$_W ^\P1]MLV__^59W\#HS 7,IS[
MHZ/8#[ 5V)GOT<1W4UNNM\@*+%=J-W+*=+/\E-/R!GD$T_(](NA#C\H//)#5
M8X-^9^B@'I\KM,=(G\979(4FC0^%OJK&5V3-J<97W49E"E)_-?Y*GW8;_N;?
MKU]?Z^J-;'XN-I1!*FG3%8M^I2DMWOA)U!6[/%8?JY<W4I)-\<(V/(G,>VF"
M(]]R<1KGL94&>>:00'Y2DC[$#)\1>TR9ONI11:3#%;WLD66G0UMS6^_1W1\<
M[!3)!AA#1@II?($2<;WO]%I@.O+P1@Y8HAY-=,!S7P5]P'1?^/A8H8_?_XU
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M^7@3=S=S<.*&+L[RF%TFHH!Z,:B@=A*289'CP-"VD,T[7&:,W-U "[DPP1N
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MXR"SG-RR?RM%I_U,3@\!H$O)5=S*U1 '0-@[I<6;\,UT^9/#/KFOI-Z6S/A
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M]?2M,P=)?WMG6-;.N2.OQ99L.(I]5R$#0]!-<E!7Q: 1'-<M-S3)YK-:1:/
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M<)C%?N;83"<YF6Q7U%E(AC5/"YM==?] Q]"[V+-\W]1Y?LVK%:U<@*D/90:
M.JU*$:?4>75^Y]4ZL4H1..S,*K?@XN&S!^W =4>QY3'XL^$WHMB!!)CD28!M
MW[>#,/23,)&*>T" &A;FLQ&C S,B[3%!!'"1 7%T7L9-\4G!7S%DT<!.V",!
MNNN!6*0\L%8+JS0-KE5AV27C:Q=I!XRQG=[K>XVS7:1N9JSM\EH]7J N-^(^
MO^5-65.1,7&A VABR^_D^^DKH?A<J0,^>IP^4\Q3\_=HX)L>5X\BRR[V\2PP
M0)M[9PK.=_7L+!"_Y-196JY<P_&)\J[<#W7U5),7!OEZL[G?/N]_TC!KC];L
MLG;#MF&6WF8P5)5C1>NT8&B)K4X-,RNU<>+3 .>.[82^D_EI*%5Z9@8]PPJJ
MJPK(:=MZ_[5%$+&WA<AF@RJ.=?_3!M$.;Y1VB!_-(&9"2CO<4?4ZV[9JC?<J
M81Y^U[<%4XO=BV*XBGD '6Z(H<L3/I% N/]I@WJ448_ST6CN1ZY-NQ=U__U?
M%+B*YCN]L(OJ;@Q)F-[*'0.,E:CUT0EU[>H@ QP;J2<R >7B6,H#J>_K;UN>
M7?87LME-SJ<)O1 G3N#@P,J)Y5#B1!ZH[D@"YHKQDBO>SPR]<>A:9M3(<!0<
M)-'!)_6PR!7/ A6#PP4&2*!@8HP-@&+]D8])B-\KUK'$@IGHQN+2B[5%6WIT
MUS2[\\8OJ>=C$B<6MMR,]T?T?#<&#0*?@+.J5FB+"U$A(*N7&TZQ#*P"5!EQ
MB=BW,*]0"]6(G(^1I5^VCZ!\+WD>(W5&AD<?5Y/;7\2=O=D6+TPC-.>U>!03
M-W6PGX>!3YT@#4-0.L3Q]H:E])?.9]2#@XGC"2?DI%"=/ICPG9)VU;8,?$>_
M=G\:&>XP3ITF&3S9?%71&R?L5.(FGE+MZ,R^:-IL.T?9EZK<CQPZD[K,9E)G
M4TS#/$P=PHQIVU%J'CP)4NI+O;A9<(\ N\H*#*!M@:4Y%L0ICI(HPU[@NI[C
MA98;)Q ]=2FK+FF1VO&H*-/JA5[QQ@;Z^"2GQ311#U-I>\([J*+#TQZNSD;(
MB\1I:WP\#6GE1L>+))\W-EY>HC*51O2WO:YK2-/3XU6&Y6]D3 N@!^H)@<N!
M-W7:8-(U-GU&9U?4<3H4A\T<;;7BE)DQ$H['RXP^H2 '? 2+L-J?JPU;\G5;
M H+<XZM-RP4'B@90T5>ZW=4E.' ]0;N$J%Q,-E!D%"F&R<TL46KR,[[E>G(T
M2]*1/,T_>4&C_%Y./Q<EO=O2%QE5/+W8I-%SW/A]H)X;]"M'  D,=/=ZGR3Q
MLB;OY]NNW]U]DK31MN[33\/SN+NFE>^W?Z3/_"U^(2_TU.$9$H*CS,NP[=MV
MXB4IB6RI;D93  RK_1XDZF$B#E0^5WN4)_.RJ(-2F!0"B03E8\]1HI2&/;KA
M:MG7<^0,DZYGGU/L+5UNBZS8[+;%VZ!;+-_XO+\,%S6:13C)P@![N1>$69#;
M40:*+2P!-"QZ0_!'W9#E)5":=7)^ 9T,@4GH+"\,])F1I517V^<E<.LV>98D
M_JREL^PZA>2_K]4[V?#M'LA[VP*A?CF;M^D&./$3#P=IX/EVYCJV)>7UFX1@
M6,+W(-%K"Q/Q-O& C*Q1KLS+LA9:8<)[(+,#)^;>7DHF('?L4G+5TK^ 9,.R
MMN9(FDV\&EVX7N[4'-Y'Z4^S#ZHH$%J\)#LFHOQ%\A9X#64;/%^7V2!EJO-V
MGH838MO")+=RG/J$\)++T$YC><4"@&Q:X0Q1X0'$ND-&E((/\PU!$1HX@V5T
ME"&V 777$<=$5]6.8[S5_#"U]M8LQR#JSA#G%-6@MF\.J"$5N#"O.2$;KJA1
M%>@\UK0J&RCT:BN;\CK[>_-0U]_>TINFGZ0@V[%M?+EAA?G B!:=E;._[YIM
MZY9[J N>X-@U8^:]4P&=VR:8L.R=U$ _3//)D:ZQQ84$E6I=W2;V7*^WVSQ1
M1QW>%AY5\YS<]Z';3HJ;?:NWT^%;:8J)F_G8#:PLB&S;\T*IYA*+D S+Z1YN
M?X@TDD';91;)N4:T$ X3T /-/4PC/?$6*=/D YF&LZKS8Y'<4Z_'\@*%R;#;
M>L,O/,U]_EAGUW4-;G ZO8-A2?R9\((4LA&7W8;;>R.Q+<!0V6E.+)^9>I@
MDTHI^M&OVCNA+M.J-J5V>MOUAM8NDG8TPW;Y:07WP4-->7NTO8R7F2C#NFE'
MTXD![\U9<8-OXSAP0_9/W_?"),R=*)!V&\A -&W]MBCLSU1Q8VO+%HF #[CL
M2C%0PBV@FRU H[CCR/[$Y5Z M@*WPP!=&^$,X/JOFT-JU_Z9;Z>;Y]A]0[KJ
M6"%DS][SI39:[WX/H>OH7@]:J* 2Q:#)&UX#F52U^#C&>VC2W,9)X%+LT# @
M:1SDH2\?EIF"8ECUM5,TC^ "1'J2-1(*3@?!,*4V0JO*R,Q)H@&Z2P?Q:OH*
M\L)ABFF)IEEE-+EX/06TA/^1TEE\6-&#P377YX(DQ48$E6_.AX=S56-'(8X9
M"W'@.VF0)!DE0/_%.!S3WHNC8W%S  _T8<@R*<.1%S@XL;TT<]S(2J+\MRW/
MQ5R/27MH\@(JTG$KLZR2=/9<S@"@JT=0/8!XU9N;&OT\\T3I\O),0%G7QS-/
MZIF'9^'Q"U3:MUV9U>_+,NN3!),DB+#G$#<CEN_0R <KMBEH:Z@W!?F<9 Y
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M]:2*/JF?2%G\BYS[4_(X\;"=N!&?%QOCQ,\2G-D1R8CC>X$OE=0V#<*T/AG
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MZRQA.LYQ3&B&B4<S/Z<T2OT84N0@"Q@DD_"JAT^DJ-ND06#'3UF^R0FJ"6[
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M);'&XMQ-@U]6'Q= 0^MY.^6GF] +@,M&T"5%3*:VFOB-B\BWNJ<HD65 <N>
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MV&M@.3O5)3<,.@JV _E8A>FY1(.VM\-&=_MV[..&Z08RH/4[I?>#01AHKRE
M@5.N$$%.YDXA'J(GR'+'/'_PZN:YEGP;-\*CL-WE]&L*&C9Q)RS+-U])4V0J
MWD&D!Q8*%#>$8DSK5@8O S%OIV7(4=AL6+5SZZA$8[75P:.[F=K_0;D[C QH
MFMKVDC#1P5::A?B'HE!0ATS^F\Y0?49>SO&M%3Y/EVG323GO'IZ$?;!  ,;3
MV' (D#62"H^=RQX3[DCJV^A'<A1#A^^ PRFM1--TV=SH:?7/Q\_XQZ)RU?PA
M369>17F_^EF]:&P\"%S\1OP9/5F3QP<_U]6DDR7+LFYOPY>?^TQV<IVPC>X
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M@<26 $V("D0RY+*/3FQ/W;CVJQCGO*_>"D/D_FW+E0>:(PL(%88Y%SS7N=-
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MLOL/K3WN_+3S'1-99#\R=K[Z^^TPY39+!W8802#Z2@1X$[1%*OI=ME4!RBN
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MM8*7^/,<DEEU-':P)LTDN@S+G,6G^K3E]+;9A?W'HHK$?)ZN\;B[72E0T&%
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MB#.NJ6Z-G.-KC=/$X8S(R2CJL9%S8>X6T_K).]P=;)88<=$1E/$/8B0P.GB
MA!%.16:(XZTP<VR5<3HXG DMV<0[-D[^:_'?U;NJGM0WE9VUY8<"8XD"Z=J
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M!""!C3$>2=\R2K7]R856;W:#02^QC:WS"YL>%K]6-[?SS>Y76@%/C(Y'*F)
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MRB7HL1&S6^?\_$YY"/\NNH)" !HX\SK*36QW36E=4;ZUU#@M=,Z.G;PB'QM
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M=N^IH][,US[U>Y1I6NA3W5S']?<>TEI!('V@@!E&K<"<(FHR'R$MR!JQ"]'
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M-&XK[H:^SKU"XHC#L,X,RB%U]X:@^5L]M?LYQ-P A2.'--Y!H[?D'6LW-G8
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M@H]D8O/QHV/1O_75U<,ZY"3CJ@BB_&HO'W9[*ZW*#R^]3KI2!=3T]&3@.3
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M?C"&L$YL/D9JRB)/$R8[L"AR-F-JRD$S,Z2FM'<#/#5EOZDC&P'(46F6/^D
M=RN>[XN&VGN?EJY)&DLG;X>GOCWQ0C^8;]+S6UYM586)]_=O19/P_T2>._";
MWZ-O?Z#^HZ04__<__P%02P$"% ,4    " !U@:5<,SI]:@0(  #_)P  %0
M            @ $     83(P,C9Q,65X:&EB:70S,3$N:'1M4$L! A0#%
M  @ =8&E7)E$A:?_!P  $"@  !4              ( !-P@  &$R,#(V<3%E
M>&AI8FET,S$R+FAT;5!+ 0(4 Q0    ( '6!I5S:3BMJC@0  ,D1   5
M          "  6D0  !A,C R-G$Q97AH:6)I=#,R,2YH=&U02P$"% ,4
M" !U@:5<Y3";F(@$  #1$0  %0              @ $J%0  83(P,C9Q,65X
M:&EB:70S,C(N:'1M4$L! A0#%     @ =8&E7,_M1DHS(@  W:L   D
M         ( !Y1D  &5X,3 Q+FAT;5!+ 0(4 Q0    ( '6!I5P2<&ALV<0!
M .:[$  1              "  3\\  !R8W5S+3(P,C8P,S,Q+FAT;5!+ 0(4
M Q0    ( '6!I5P;Q0S^A1(  !+0   1              "  4<! @!R8W5S
M+3(P,C8P,S,Q+GAS9%!+ 0(4 Q0    ( '6!I5SGV@R9P10  $/A   5
M          "  ?L3 @!R8W5S+3(P,C8P,S,Q7V-A;"YX;6Q02P$"% ,4
M" !U@:5<,X1F<]U   !!.0, %0              @ 'O* ( <F-U<RTR,#(V
M,#,S,5]D968N>&UL4$L! A0#%     @ =8&E7 F;KY!?U@$ Y>T" !0
M         ( !_VD" ')C=7,M,C R-C S,S%?9S$N:G!G4$L! A0#%     @
M=8&E7-*QT55KQP  P$ ( !4              ( !D$ $ ')C=7,M,C R-C S
M,S%?;&%B+GAM;%!+ 0(4 Q0    ( '6!I5Q>^:A97FX  %'.!0 5
M      "  2X(!0!R8W5S+3(P,C8P,S,Q7W!R92YX;6Q02P4&      P #  /
) P  OW8%

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>rcus-20260331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rcus="http://arcusbio.com/20260331"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rcus-20260331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <instant>2026-04-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherCollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherCollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherCollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherCollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rcus:EquityAwardProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rcus:CashCashEquivalentsAndInvestmentsInMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:AmendedGileadCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:AmendedGileadCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:AmendedGileadCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:AmendedGileadCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rcus:OptionLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:STAR221DevelopmentActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:TaihoCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:STAR121DevelopmentActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:TaihoCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:TaihoCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:TaihoCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:TaihoCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AstraZenecaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AstraZenecaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AstraZenecaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AstraZenecaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AstraZenecaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:WuXiBiologicsLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AntiPDOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:WuXiBiologicsLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AntiPDOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:WuXiBiologicsLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AntiPDOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:WuXiBiologicsLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AntiCDThirtyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:WuXiBiologicsLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AntiCDThirtyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:WuXiBiologicsLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AntiCDThirtyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:AbmunoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:AbmunoLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:GileadCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:GileadCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:RDServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:GileadCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:RDServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:GileadCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AccessRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:GileadCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AccessRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:GileadCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:GileadCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:OtherServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:GileadCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:TaihoCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:TaihoCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:LicenseAndDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:DevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:AccessRightsAndOptionContinuationPeriodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:RightsToCertainStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:RDServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:RDServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AccessRightsAndOptionContinuationPeriodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AccessRightsAndOptionContinuationPeriodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AccessRightsAndOptionContinuationPeriodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AccessRightsAndOptionContinuationPeriodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:AccessRightsAndOptionContinuationPeriodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:RightsToCertainStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:STAR221DevelopmentActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:TaihoCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentActivitiesForInflammationProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:GileadSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:ResearchAndDevelopmentActivitiesForInflammationProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rcus:RDServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rcus:TaihoPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rcus:OptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rcus:HerculesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rcus:HerculesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rcus:HerculesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rcus:DebtInstrumentTrancheTypeAxis">rcus:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rcus:HerculesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rcus:DebtInstrumentTrancheTypeAxis">rcus:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rcus:HerculesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rcus:DebtInstrumentTrancheTypeAxis">rcus:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rcus:HerculesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rcus:DebtInstrumentTrancheTypeAxis">rcus:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rcus:HerculesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rcus:CorporateSecuritiesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rcus:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rcus:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rcus:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rcus:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rcus:RobertC.GoeltzIIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rcus:RobertC.GoeltzIIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rcus:JuanJaenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rcus:JuanJaenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rcus:JenniferJarrettMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001724521</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rcus:JenniferJarrettMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>rcus:segment</measure>
    </unit>
    <unit id="member">
        <measure>rcus:member</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="program">
        <measure>rcus:program</measure>
    </unit>
    <unit id="position">
        <measure>rcus:position</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0001724521</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-26">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="c-1" id="f-27">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-28">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-29">Q1</dei:DocumentFiscalPeriodFocus>
    <us-gaap:RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList contextRef="c-31" id="f-443">http://fasb.org/us-gaap/2025#OtherAssetsNoncurrent</us-gaap:RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList contextRef="c-14" id="f-444">http://fasb.org/us-gaap/2025#OtherAssetsNoncurrent</us-gaap:RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList>
    <ecd:TrdArrDuration contextRef="c-187" id="f-592">P462D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-185" id="f-593">P795D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-189" id="f-594">P304D</ecd:TrdArrDuration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2026-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38419</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">Arcus Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">47-3898435</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">3928 Point Eden Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Hayward</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">94545</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">694-6200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, Par Value $0.0001 Per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">RCUS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">125773162</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues contextRef="c-3" decimals="-6" id="f-30" unitRef="usd">10000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-4" decimals="-6" id="f-31" unitRef="usd">20000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-5" decimals="-6" id="f-32" unitRef="usd">12000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-6" decimals="-6" id="f-33" unitRef="usd">20000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-7" decimals="-6" id="f-34" unitRef="usd">5000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-8" decimals="-6" id="f-35" unitRef="usd">8000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-9" decimals="-6" id="f-36" unitRef="usd">5000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-10" decimals="-6" id="f-37" unitRef="usd">8000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-6" id="f-38" unitRef="usd">17000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-11" decimals="-6" id="f-39" unitRef="usd">28000000</us-gaap:Revenues>
    <rcus:ResearchAndDevelopmentExpenseRecoveries contextRef="c-12" decimals="-6" id="f-40" unitRef="usd">0</rcus:ResearchAndDevelopmentExpenseRecoveries>
    <rcus:ResearchAndDevelopmentExpenseRecoveries contextRef="c-13" decimals="-6" id="f-41" unitRef="usd">-5000000</rcus:ResearchAndDevelopmentExpenseRecoveries>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-6" id="f-42" unitRef="usd">122000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-11" decimals="-6" id="f-43" unitRef="usd">122000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-12" decimals="-6" id="f-44" unitRef="usd">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-13" decimals="-6" id="f-45" unitRef="usd">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-6" id="f-46" unitRef="usd">29000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-11" decimals="-6" id="f-47" unitRef="usd">28000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-6" id="f-48" unitRef="usd">151000000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-11" decimals="-6" id="f-49" unitRef="usd">150000000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-6" id="f-50" unitRef="usd">-134000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-11" decimals="-6" id="f-51" unitRef="usd">-122000000</us-gaap:OperatingIncomeLoss>
    <rcus:InterestAndOtherIncomeExpenseNonoperatingNet contextRef="c-1" decimals="-6" id="f-52" unitRef="usd">9000000</rcus:InterestAndOtherIncomeExpenseNonoperatingNet>
    <rcus:InterestAndOtherIncomeExpenseNonoperatingNet contextRef="c-11" decimals="-6" id="f-53" unitRef="usd">11000000</rcus:InterestAndOtherIncomeExpenseNonoperatingNet>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-6" id="f-54" unitRef="usd">3000000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-11" decimals="-6" id="f-55" unitRef="usd">1000000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-6" id="f-56" unitRef="usd">6000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-11" decimals="-6" id="f-57" unitRef="usd">10000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-58" unitRef="usd">-128000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-11" decimals="-6" id="f-59" unitRef="usd">-112000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-60" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-11" decimals="-6" id="f-61" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-62" unitRef="usd">-128000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="-6" id="f-63" unitRef="usd">-112000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-64"
      unitRef="usdPerShare">-1.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-65"
      unitRef="usdPerShare">-1.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-11"
      decimals="2"
      id="f-66"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-11"
      decimals="2"
      id="f-67"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-68" unitRef="shares">125400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-69" unitRef="shares">125400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-11" decimals="-5" id="f-70" unitRef="shares">98400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-11" decimals="-5" id="f-71" unitRef="shares">98400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-72" unitRef="usd">-128000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="-6" id="f-73" unitRef="usd">-112000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-6" id="f-74" unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-11" decimals="-6" id="f-75" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-6" id="f-76" unitRef="usd">-129000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-11" decimals="-6" id="f-77" unitRef="usd">-112000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-14" decimals="-6" id="f-78" unitRef="usd">201000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-15" decimals="-6" id="f-79" unitRef="usd">222000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-14" decimals="-6" id="f-80" unitRef="usd">621000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-15" decimals="-6" id="f-81" unitRef="usd">759000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-14" decimals="-6" id="f-82" unitRef="usd">3000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-15" decimals="-6" id="f-83" unitRef="usd">11000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-14" decimals="-6" id="f-84" unitRef="usd">19000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-15" decimals="-6" id="f-85" unitRef="usd">15000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-14" decimals="-6" id="f-86" unitRef="usd">844000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-15" decimals="-6" id="f-87" unitRef="usd">1007000000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="c-14" decimals="-6" id="f-88" unitRef="usd">54000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="c-15" decimals="-6" id="f-89" unitRef="usd">29000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-14" decimals="-6" id="f-90" unitRef="usd">38000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-15" decimals="-6" id="f-91" unitRef="usd">40000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-14" decimals="-6" id="f-92" unitRef="usd">61000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-15" decimals="-6" id="f-93" unitRef="usd">63000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-14" decimals="-6" id="f-94" unitRef="usd">997000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-15" decimals="-6" id="f-95" unitRef="usd">1139000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-16" decimals="-6" id="f-96" unitRef="usd">11000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-17" decimals="-6" id="f-97" unitRef="usd">24000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-14" decimals="-6" id="f-98" unitRef="usd">39000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-15" decimals="-6" id="f-99" unitRef="usd">42000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-16" decimals="-6" id="f-100" unitRef="usd">27000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-17" decimals="-6" id="f-101" unitRef="usd">35000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-14" decimals="-6" id="f-102" unitRef="usd">34000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-15" decimals="-6" id="f-103" unitRef="usd">35000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-14" decimals="-6" id="f-104" unitRef="usd">136000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-15" decimals="-6" id="f-105" unitRef="usd">154000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-14" decimals="-6" id="f-106" unitRef="usd">209000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-15" decimals="-6" id="f-107" unitRef="usd">231000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-16" decimals="-6" id="f-108" unitRef="usd">36000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-17" decimals="-6" id="f-109" unitRef="usd">43000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-14" decimals="-6" id="f-110" unitRef="usd">45000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-15" decimals="-6" id="f-111" unitRef="usd">43000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LongTermDebt contextRef="c-14" decimals="-6" id="f-112" unitRef="usd">100000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-15" decimals="-6" id="f-113" unitRef="usd">99000000</us-gaap:LongTermDebt>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-14" decimals="-6" id="f-114" unitRef="usd">119000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-15" decimals="-6" id="f-115" unitRef="usd">135000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies contextRef="c-14" id="f-116" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-15" id="f-117" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-14"
      decimals="INF"
      id="f-118"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-15"
      decimals="INF"
      id="f-119"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-15" decimals="-5" id="f-120" unitRef="shares">400000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-14" decimals="-5" id="f-121" unitRef="shares">400000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-14" decimals="-5" id="f-122" unitRef="shares">125500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-14" decimals="-5" id="f-123" unitRef="shares">125500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-15" decimals="-5" id="f-124" unitRef="shares">125300000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-15" decimals="-5" id="f-125" unitRef="shares">125300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-14" decimals="-6" id="f-126" unitRef="usd">2138000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-15" decimals="-6" id="f-127" unitRef="usd">2116000000</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-14" decimals="-6" id="f-128" unitRef="usd">-1613000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-15" decimals="-6" id="f-129" unitRef="usd">-1485000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-14" decimals="-6" id="f-130" unitRef="usd">-1000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-15" decimals="-6" id="f-131" unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-6" id="f-132" unitRef="usd">524000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-6" id="f-133" unitRef="usd">631000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-14" decimals="-6" id="f-134" unitRef="usd">997000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-15" decimals="-6" id="f-135" unitRef="usd">1139000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-18" decimals="-5" id="f-136" unitRef="shares">92200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-6" id="f-137" unitRef="usd">1617000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-6" id="f-138" unitRef="usd">-1132000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-6" id="f-139" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-6" id="f-140" unitRef="usd">485000000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-23" decimals="-5" id="f-141" unitRef="shares">13600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-24" decimals="-6" id="f-142" unitRef="usd">142000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-11" decimals="-6" id="f-143" unitRef="usd">142000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-25" decimals="-5" id="f-144" unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-24" decimals="-6" id="f-145" unitRef="usd">16000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-11" decimals="-6" id="f-146" unitRef="usd">16000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-26" decimals="-6" id="f-147" unitRef="usd">-112000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="-6" id="f-148" unitRef="usd">-112000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-27" decimals="-5" id="f-149" unitRef="shares">105900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-6" id="f-150" unitRef="usd">1775000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-6" id="f-151" unitRef="usd">-1244000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-6" id="f-152" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-6" id="f-153" unitRef="usd">531000000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-32" decimals="-5" id="f-154" unitRef="shares">125300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-6" id="f-155" unitRef="usd">2116000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-6" id="f-156" unitRef="usd">-1485000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-6" id="f-157" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-6" id="f-158" unitRef="usd">631000000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-36" decimals="-5" id="f-159" unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-37" decimals="-6" id="f-160" unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-38" decimals="-6" id="f-161" unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-39" decimals="-6" id="f-162" unitRef="usd">19000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-6" id="f-163" unitRef="usd">19000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-40" decimals="-6" id="f-164" unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-6" id="f-165" unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-41" decimals="-6" id="f-166" unitRef="usd">-128000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-167" unitRef="usd">-128000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-42" decimals="-5" id="f-168" unitRef="shares">125500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-6" id="f-169" unitRef="usd">2138000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-6" id="f-170" unitRef="usd">-1613000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-6" id="f-171" unitRef="usd">-1000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-6" id="f-172" unitRef="usd">524000000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-173" unitRef="usd">-128000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-11" decimals="-6" id="f-174" unitRef="usd">-112000000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-6" id="f-175" unitRef="usd">19000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-11" decimals="-6" id="f-176" unitRef="usd">16000000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-6" id="f-177" unitRef="usd">2000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-11" decimals="-6" id="f-178" unitRef="usd">3000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-6" id="f-179" unitRef="usd">2000000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-11" decimals="-6" id="f-180" unitRef="usd">2000000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-6" id="f-181" unitRef="usd">3000000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-11" decimals="-6" id="f-182" unitRef="usd">4000000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-1" decimals="-6" id="f-183" unitRef="usd">1000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-11" decimals="-6" id="f-184" unitRef="usd">0</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="c-12" decimals="-6" id="f-185" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="c-13" decimals="-6" id="f-186" unitRef="usd">-2000000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="c-1" decimals="-6" id="f-187" unitRef="usd">-8000000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="c-11" decimals="-6" id="f-188" unitRef="usd">-5000000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-1" decimals="-6" id="f-189" unitRef="usd">3000000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-11" decimals="-6" id="f-190" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-12" decimals="-6" id="f-191" unitRef="usd">-13000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-13" decimals="-6" id="f-192" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-6" id="f-193" unitRef="usd">-3000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-11" decimals="-6" id="f-194" unitRef="usd">3000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-12" decimals="-6" id="f-195" unitRef="usd">-15000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-13" decimals="-6" id="f-196" unitRef="usd">-28000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-6" id="f-197" unitRef="usd">-17000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-11" decimals="-6" id="f-198" unitRef="usd">-28000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-1" decimals="-6" id="f-199" unitRef="usd">-16000000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-11" decimals="-6" id="f-200" unitRef="usd">-17000000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-6" id="f-201" unitRef="usd">-138000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-11" decimals="-6" id="f-202" unitRef="usd">-132000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-1" decimals="-6" id="f-203" unitRef="usd">150000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-11" decimals="-6" id="f-204" unitRef="usd">353000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <rcus:ProceedsFromMaturityOfMarketableSecurities contextRef="c-1" decimals="-6" id="f-205" unitRef="usd">257000000</rcus:ProceedsFromMaturityOfMarketableSecurities>
    <rcus:ProceedsFromMaturityOfMarketableSecurities contextRef="c-11" decimals="-6" id="f-206" unitRef="usd">360000000</rcus:ProceedsFromMaturityOfMarketableSecurities>
    <rcus:ProceedsFromSaleOfMarketableSecurities contextRef="c-1" decimals="-6" id="f-207" unitRef="usd">7000000</rcus:ProceedsFromSaleOfMarketableSecurities>
    <rcus:ProceedsFromSaleOfMarketableSecurities contextRef="c-11" decimals="-6" id="f-208" unitRef="usd">26000000</rcus:ProceedsFromSaleOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-6" id="f-209" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-11" decimals="-6" id="f-210" unitRef="usd">1000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-6" id="f-211" unitRef="usd">114000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-11" decimals="-6" id="f-212" unitRef="usd">32000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-12" decimals="-6" id="f-213" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-13" decimals="-6" id="f-214" unitRef="usd">14000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-6" id="f-215" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-11" decimals="-6" id="f-216" unitRef="usd">142000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="-6" id="f-217" unitRef="usd">3000000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-11" decimals="-6" id="f-218" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-6" id="f-219" unitRef="usd">3000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-11" decimals="-6" id="f-220" unitRef="usd">142000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-6" id="f-221" unitRef="usd">-21000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-11" decimals="-6" id="f-222" unitRef="usd">42000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-15" decimals="-6" id="f-223" unitRef="usd">225000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-22" decimals="-6" id="f-224" unitRef="usd">153000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-14" decimals="-6" id="f-225" unitRef="usd">204000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-31" decimals="-6" id="f-226" unitRef="usd">195000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-227">Organization, liquidity and capital resources&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arcus Biosciences, Inc. (referred to as "Arcus," "we," "our," "us," or the "Company") is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Our most advanced molecules are in Phase 3 registrational studies for various cancer indications and we expect our next wave of clinical-stage molecules to come from our inflammation and autoimmune disease programs. Our vision is to leverage our internal small-molecule discovery capabilities to create, develop and commercialize highly differentiated therapies that can have a meaningful impact on patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate and manage our business as one reportable and operating segment, which is the business of developing and commercializing highly differentiated therapies that have a meaningful impact on patients. See Note 15, Business segment, for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2026, we had cash, cash equivalents and marketable securities of $876 million, which we believe will be sufficient to fund our planned operations for a period of at least twelve months following the date of filing of this report.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-228"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-229"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:InvestmentsAndCash contextRef="c-46" decimals="-6" id="f-230" unitRef="usd">876000000</us-gaap:InvestmentsAndCash>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-231">Summary of significant accounting policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These interim financial statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2025 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on February&#160;25, 2026. There have been no significant changes to our summary of significant accounting policies as disclosed in that filing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and include all normal and recurring adjustments that management believes are necessary for a fair presentation of the periods presented. The Condensed Consolidated Balance Sheet as of December&#160;31, 2025 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating results for the three months ended March&#160;31, 2026 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2026 or for any future period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed and updated each period to reflect current information. Actual results may differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2024-03 &#x2014; Income Statement &#x2014; Reporting Comprehensive Income &#x2014; Expense Disaggregation Disclosures (Subtopic 220-40) &#x2014; Disaggregation of Income Statement Expenses. This ASU requires disclosure, in the notes to financial statements, of specified information about certain costs and expenses. We plan to adopt this guidance beginning with our 2027 Annual Report to be filed in early 2028 and all quarterly and Annual Reports thereafter. We expect the adoption of this standard to result in increased disclosures in the Notes to our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2025, the FASB issued ASU 2025-07 &#x2014; Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract. This ASU refines the scope of the guidance on derivatives in Topic 815 and clarifies the guidance on share-based payments from a customer in ASC 606. We have adopted this standard during the current quarter with no significant impact on our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-233">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These interim financial statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2025 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on February&#160;25, 2026. There have been no significant changes to our summary of significant accounting policies as disclosed in that filing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and include all normal and recurring adjustments that management believes are necessary for a fair presentation of the periods presented. The Condensed Consolidated Balance Sheet as of December&#160;31, 2025 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;Operating results for the three months ended March&#160;31, 2026 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2026 or for any future period.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-232">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These interim financial statements should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto for the year ended December&#160;31, 2025 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on February&#160;25, 2026. There have been no significant changes to our summary of significant accounting policies as disclosed in that filing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and include all normal and recurring adjustments that management believes are necessary for a fair presentation of the periods presented. The Condensed Consolidated Balance Sheet as of December&#160;31, 2025 has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;Operating results for the three months ended March&#160;31, 2026 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2026 or for any future period.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-234">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed and updated each period to reflect current information. Actual results may differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-235">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2024-03 &#x2014; Income Statement &#x2014; Reporting Comprehensive Income &#x2014; Expense Disaggregation Disclosures (Subtopic 220-40) &#x2014; Disaggregation of Income Statement Expenses. This ASU requires disclosure, in the notes to financial statements, of specified information about certain costs and expenses. We plan to adopt this guidance beginning with our 2027 Annual Report to be filed in early 2028 and all quarterly and Annual Reports thereafter. We expect the adoption of this standard to result in increased disclosures in the Notes to our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2025, the FASB issued ASU 2025-07 &#x2014; Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract. This ASU refines the scope of the guidance on derivatives in Topic 815 and clarifies the guidance on share-based payments from a customer in ASC 606. We have adopted this standard during the current quarter with no significant impact on our Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-236">Related party - Gilead Sciences, Inc.&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we and Gilead Sciences, Inc. ("Gilead") entered into an Option, License and Collaboration Agreement (the "Gilead Collaboration Agreement"), Common Stock Purchase Agreement (the "Stock Purchase Agreement"), and Investor Rights Agreement (the "Investor Rights Agreement").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Gilead Collaboration Agreement was amended in 2021 (the "First Gilead Collaboration Agreement Amendment"), in 2023 (the "Second Gilead Collaboration Agreement Amendment"), in 2024 (the "Third Gilead Collaboration Agreement Amendment") and (the "Fourth Gilead Collaboration Agreement Amendment"), and in 2025 (the "Fifth Gilead Collaboration Agreement Amendment"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Stock Purchase Agreement was amended in 2021 (the "First Stock Purchase Agreement Amendment"), in 2023 (the "Second Stock Purchase Agreement Amendment"), and was amended and restated in 2024 (the "Third Stock Purchase Agreement Amendment").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Investor Rights Agreement was amended in 2022 (the "First Investor Rights Agreement Amendment") and was amended and restated in 2024 (the "Second Investor Rights Agreement Amendment").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We refer to these agreements collectively as the "Gilead Agreements".&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Purchase and Investor Rights Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter 2025, through our underwritten offering, Gilead purchased 1.4 million shares of our common stock for total gross proceeds of $15&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Investor Rights Agreement entered into in 2020 and subsequent amendments, Gilead has the right to designate three members of our board of directors and registration rights for shares that it purchases. Gilead has exercised its rights to appoint all three board members and we have registered all shares purchased to date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2026, Gilead held approximately 25.0% of our outstanding common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we entered into the Gilead Collaboration Agreement, which gave Gilead an exclusive license to develop and commercialize zimberelimab (the anti-PD-1 program) in certain markets and time-limited options to acquire exclusive licenses to develop and commercialize any of our then-current and future clinical programs arising during the 10-year collaboration term, contingent upon $100 million option continuation payments payable on each of the second, fourth, sixth and eighth anniversaries of the agreement. The period to determine Gilead's option rights under the Gilead Collaboration Agreement will end on July 14, 2026, following Gilead&#x2019;s decision to not make the option continuation payment due on the sixth anniversary. Upon closing of the transaction in 2020, Gilead made an upfront payment of $175 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, we entered into the First Gilead Collaboration Agreement Amendment pursuant to which Gilead exercised its option to three programs&#x2014;providing Gilead with exclusive licenses to develop and commercialize domvanalimab and AB308 (collectively, the anti-TIGIT program), etrumadenant (the adenosine receptor antagonist program) and quemliclustat (the CD73 program), in certain markets&#x2014;for a total payment of $725 million that was received in 2022. The amendment also (i) provided for a slight reduction in the royalties for these three programs, such that Gilead will pay us tiered royalties as a percentage of revenues ranging from the mid-teens to the low twenties; and (ii) removed the $100 million option continuation payment that was otherwise due on the second anniversary of the Gilead Collaboration Agreement. With respect to domvanalimab, we are also eligible to receive up to $500 million in potential U.S. regulatory approval milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gilead's option to acquire exclusive licenses to develop and commercialize AB801 (an investigational small molecule AXL inhibitor) and AB598 (an investigational anti-CD39 monoclonal antibody), will expire after a prescribed period following the achievement of a clinical development milestone in such program and our delivery to Gilead of the requisite data package. Gilead may exercise its option to these programs at any time prior to expiration of the option and will pay Arcus an option fee of $150 million per program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each program that Gilead opts in to, both companies will co-develop and equally share global development costs, subject to certain opt-out rights that we have, caps on our spending and related subsequent adjustments, and certain other exceptions. For each program, provided we have not exercised our opt-out rights, we have the option to co-promote in the U.S. with equal sharing of related profits and losses. Gilead has the right to exclusively commercialize outside of the U.S., subject to the rights of our existing partners in any territories and will pay us tiered royalties as a percentage of revenues ranging from the high teens to the low twenties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the First Gilead Collaboration Agreement Amendment, Gilead also has option rights to two oncology research programs for which we will lead discovery and early development activities. With respect to these two research programs, Gilead has the right to exercise its option, on a program-by-program basis, either (i) upon our completion of certain investigational new drug ("IND")-enabling activities for an option payment of $60 million or (ii) following the achievement of a clinical development milestone for an option payment of $150 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2023, we entered into the Second Gilead Collaboration Agreement Amendment pursuant to which we expanded our collaboration to provide Gilead with options to license up to four jointly selected research-stage programs that target inflammatory diseases for which we will lead discovery and early development activities. We will receive an upfront payment of $17.5 million for each initiated program and Gilead will have an option to license each program at two separate, prespecified time points. We received a total upfront payment of $35 million for an initial two research programs in 2023. Gilead&#x2019;s options to the other two research programs, as amended under the Fourth Gilead Collaboration Agreement Amendment expired in May 2025. For the two research programs, including AB102 (an investigational MRGPRX2 antagonist), Gilead has the right, on a program-by-program basis, either (i) to exercise its option upon our completion of certain IND-enabling activities for an option payment of $45 million or (ii) to extend its option and exercise it following the achievement of a clinical development milestone for an option payment of $150 million. If Gilead exercises its option at the earlier time point for the first two programs, we would be eligible to receive up to $375 million in regulatory and commercial milestone payments as well as tiered royalties for each optioned program. For any other program option exercise by Gilead, the parties would have rights to co-develop and share global development costs and to co-promote and share profits in the U.S. for that program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2024, we entered into the Third Gilead Collaboration Agreement Amendment. The Third Gilead Collaboration Agreement Amendment, among other things, (i) required Gilead to pay the $100 million option continuation payment due on the fourth anniversary of the Gilead Collaboration Agreement, which was received in 2024, (ii) provides that we will operationalize and fund the Phase 3 PRISM-1 study evaluating quemliclustat in pancreatic cancer subject to Gilead's right to reinstate the study as part of the parties' joint development activities upon regulatory approval, (iii) provides that we will solely fund our share of PACIFIC-8, subject to Gilead&#x2019;s right to reinstate PACIFIC-8 as part of the parties&#x2019; joint development activities for the TIGIT Program upon regulatory approval, and (iv) provides that we will fund certain other activities. All other terms of the existing collaboration agreements, remain unchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2026, Gilead has licenses to domvanalimab, AB308, quemliclustat and zimberelimab. In the second quarter 2025, Gilead returned its license to the adenosine receptor antagonist program, which includes etrumadenant. After July 14, 2026, Gilead will maintain its existing time-limited options to programs including AB801, AB598, AB102 and an investigational TNF small molecule inhibitor. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2026 and 2025, under the Gilead Agreements we recognized revenue of $15 million and $28 million, respectively. For a more detailed discussion on revenues recognized under the Gilead Agreements, see Note 5, Revenues, for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2025, we recognized net reimbursements from Gilead of $5 million. Expenses and reimbursements from Gilead are recognized in Operating expense, allocated between Research and Development ("R&amp;amp;D") and General and Administrative ("G&amp;amp;A") based upon the activity that generated the net expense or reimbursement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; At March&#160;31, 2026 and December&#160;31, 2025, we had net payables to Gilead of $11 million and $24 million, respectively, recorded in Accounts payable on our Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <rcus:SaleOfStockNumberOfSharesAcquiredInTransaction contextRef="c-47" decimals="-5" id="f-237" unitRef="shares">1400000</rcus:SaleOfStockNumberOfSharesAcquiredInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-48" decimals="-6" id="f-238" unitRef="usd">15000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <rcus:NumberOfBoardMembers
      contextRef="c-49"
      decimals="INF"
      id="f-239"
      unitRef="member">3</rcus:NumberOfBoardMembers>
    <rcus:NumberOfBoardMembers
      contextRef="c-49"
      decimals="INF"
      id="f-240"
      unitRef="member">3</rcus:NumberOfBoardMembers>
    <rcus:PercentageOfOutstandingCommonStockOwned contextRef="c-16" decimals="3" id="f-241" unitRef="number">0.250</rcus:PercentageOfOutstandingCommonStockOwned>
    <rcus:CollaborationTermForCurrentAndFutureClinicalPrograms contextRef="c-50" id="f-242">P10Y</rcus:CollaborationTermForCurrentAndFutureClinicalPrograms>
    <rcus:OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement contextRef="c-51" decimals="-6" id="f-243" unitRef="usd">100000000</rcus:OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement>
    <rcus:OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement contextRef="c-51" decimals="-6" id="f-244" unitRef="usd">100000000</rcus:OptionContinuationPaymentDueUponSixthAnniversaryOfAgreement>
    <rcus:OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement contextRef="c-51" decimals="-6" id="f-245" unitRef="usd">100000000</rcus:OptionContinuationPaymentDueUponEighthAnniversaryOfAgreement>
    <rcus:OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement contextRef="c-51" decimals="-6" id="f-246" unitRef="usd">100000000</rcus:OptionContinuationPaymentDueUponSecondAnniversaryOfAgreement>
    <rcus:UpfrontCashPayment contextRef="c-50" decimals="-6" id="f-247" unitRef="usd">175000000</rcus:UpfrontCashPayment>
    <rcus:NumberOfExerciseOptionToPrograms
      contextRef="c-52"
      decimals="INF"
      id="f-248"
      unitRef="program">3</rcus:NumberOfExerciseOptionToPrograms>
    <rcus:OptionPaymentReceived contextRef="c-52" decimals="-6" id="f-249" unitRef="usd">725000000</rcus:OptionPaymentReceived>
    <rcus:NumberOfExerciseOptionToPrograms
      contextRef="c-52"
      decimals="INF"
      id="f-250"
      unitRef="program">3</rcus:NumberOfExerciseOptionToPrograms>
    <rcus:RemoveOptionContinuationPaymentUnderAgreement contextRef="c-52" decimals="-6" id="f-251" unitRef="usd">100000000</rcus:RemoveOptionContinuationPaymentUnderAgreement>
    <rcus:PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab contextRef="c-53" decimals="-6" id="f-252" unitRef="usd">500000000</rcus:PotentialRegulatoryApprovalMilestonesPaymentReceivableRelatedToDomvanalimab>
    <rcus:OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption contextRef="c-54" decimals="-6" id="f-253" unitRef="usd">150000000</rcus:OptionFeePerProgramForAllOtherProgramsEnteringClinicalDevelopmentToExerciseOption>
    <rcus:NumberOfResearchPrograms
      contextRef="c-55"
      decimals="INF"
      id="f-254"
      unitRef="program">2</rcus:NumberOfResearchPrograms>
    <rcus:NumberOfResearchPrograms
      contextRef="c-55"
      decimals="INF"
      id="f-255"
      unitRef="program">2</rcus:NumberOfResearchPrograms>
    <rcus:OptionPaymentUponCompletionOfCertainINDEnablingActivities contextRef="c-56" decimals="-6" id="f-256" unitRef="usd">60000000</rcus:OptionPaymentUponCompletionOfCertainINDEnablingActivities>
    <rcus:OptionPaymentUponAchievementOfCertainDevelopmentMilestones contextRef="c-56" decimals="-6" id="f-257" unitRef="usd">150000000</rcus:OptionPaymentUponAchievementOfCertainDevelopmentMilestones>
    <rcus:NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments
      contextRef="c-57"
      decimals="INF"
      id="f-258"
      unitRef="program">4</rcus:NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments>
    <rcus:UpfrontCashPayment contextRef="c-58" decimals="-5" id="f-259" unitRef="usd">17500000</rcus:UpfrontCashPayment>
    <rcus:TotalUpfrontCashPayment contextRef="c-58" decimals="-6" id="f-260" unitRef="usd">35000000</rcus:TotalUpfrontCashPayment>
    <rcus:NumberOfResearchPrograms
      contextRef="c-58"
      decimals="INF"
      id="f-261"
      unitRef="program">2</rcus:NumberOfResearchPrograms>
    <rcus:NumberOfResearchPrograms
      contextRef="c-58"
      decimals="INF"
      id="f-262"
      unitRef="program">2</rcus:NumberOfResearchPrograms>
    <rcus:NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments
      contextRef="c-59"
      decimals="INF"
      id="f-263"
      unitRef="program">2</rcus:NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments>
    <rcus:OptionPaymentUponCompletionOfCertainINDEnablingActivities contextRef="c-58" decimals="-6" id="f-264" unitRef="usd">45000000</rcus:OptionPaymentUponCompletionOfCertainINDEnablingActivities>
    <rcus:OptionPaymentUponAchievementOfCertainDevelopmentMilestones contextRef="c-59" decimals="-6" id="f-265" unitRef="usd">150000000</rcus:OptionPaymentUponAchievementOfCertainDevelopmentMilestones>
    <rcus:NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments
      contextRef="c-59"
      decimals="INF"
      id="f-266"
      unitRef="program">2</rcus:NumberOfProgramsEligibleToReceiveRegulatoryAndCommercialMilestonePayments>
    <rcus:RegulatoryAndCommercialMilestonePaymentsReceived contextRef="c-60" decimals="-6" id="f-267" unitRef="usd">375000000</rcus:RegulatoryAndCommercialMilestonePaymentsReceived>
    <rcus:OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement contextRef="c-61" decimals="-6" id="f-268" unitRef="usd">100000000</rcus:OptionContinuationPaymentDueUponFourthAnniversaryOfAgreement>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-55" decimals="-6" id="f-269" unitRef="usd">15000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-62" decimals="-6" id="f-270" unitRef="usd">28000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <rcus:RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts contextRef="c-63" decimals="-6" id="f-271" unitRef="usd">-5000000</rcus:RelatedPartyTransactionReimbursementFromRelatedPartyForSharedCosts>
    <us-gaap:AccountsPayableCurrent contextRef="c-16" decimals="-6" id="f-272" unitRef="usd">11000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-17" decimals="-6" id="f-273" unitRef="usd">24000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-274">License and collaborations&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into licensing agreements, strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain investigational products. These arrangements: may be collaborative and involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities; are performed with no guarantee of either technological or commercial success; and are each unique in nature. Such arrangements may include: non-refundable upfront payments; payments for options to acquire certain rights; potential development and regulatory milestone payments and/or sales-based milestone payments; royalty payments; revenue or profit-sharing arrangements; expense reimbursements; and cost-sharing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line items in the Condensed Consolidated Statements of Operations, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our significant arrangements are discussed below. For a more detailed discussion on revenues recognized under these arrangements, see Note 5, Revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Gilead Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 3, Related party - Gilead Sciences, Inc., for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Taiho Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, we entered into an agreement with Taiho Pharmaceutical Co., Ltd ("Taiho" and the "Taiho Agreement") pursuant to which Taiho obtained an exclusive option to in-license development and commercialization rights to programs for Japan and certain other Asian countries, excluding China (the "Taiho Territory") for which IND-enabling studies had begun during a five-year term which ended in September 2022, for an upfront payment of $35 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each option to a program that Taiho exercises, except for &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;casdatifan (the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;HIF-2&#x3b1; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;program) discussed below&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, they will be obligated to make a payment of $3 million to $15 million, depending on the development stage of the optioned program. Upon exercise, Taiho is solely responsible for continued development and commercialization in the Taiho Territory, unless they opt to participate in a global study, in which case they would become obligated to reimburse us for their portion of the global study costs. In addition, for each optioned program we would be eligible to receive clinical and regulatory milestones of up to $130 million and commercial milestone payments of up to $145 million with the achievement of certain sales thresholds in the Taiho Territory. We will also receive royalties ranging from high single-digits to mid-teens on net sales of licensed products in the Taiho Territory. Royalties will be payable by product and country commencing on the first commercial sale and ending upon the later of: (a) 10 years; and (b) expiration of the last-to-expire valid claim of our patents covering the manufacture, use or sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, Taiho opted to participate in two global Phase 3 trials of domvanalimab and zimberelimab combinations, STAR-121 and STAR-221, and in 2024, Taiho opted to participate in the global Phase 3 trial of quemliclustat, PRISM-1. For each of these trials, Taiho became obligated to reimburse us for their portion of the global trial costs, and to make milestone payments contingent upon successfully satisfying the related clinical milestones. The clinical milestones were met: for domvanalimab and zimberelimab for the STAR-221 trial in 2023, and Taiho became obligated to pay us $28 million; domvanalimab and zimberelimab for the STAR-121 trial in 2024, and Taiho became obligated to pay us $26 million; and for quemliclustat for the PRISM-1 trial in the first quarter 2025, and became obligated to make milestone payments totaling $19 million. All the milestone payments due have been fully received. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter 2025, Taiho exercised its option for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;HIF-2&#x3b1;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; inhibitor program (including casdatifan) for the Taiho Territory, for an option payment of $15 million. We and Taiho concurrently entered into the Second Amendment where: (i) we will lead development for two indications in Japan and be responsible for the global study costs; (ii) we may also be eligible to receive clinical and regulatory milestones of up to $172 million, commercial milestone payments of up to $145 million upon the achievement of certain sales thresholds in the Taiho Territory and royalties ranging from high single-digits to mid-teens on net sales of the licensed product in the Taiho Territory. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the nature of these arrangements, a portion of these clinical milestones were determined to be advance cost sharing payments for Taiho's share of the related global study R&amp;amp;D costs under the collaboration and are deferred and recognized as a reduction in R&amp;amp;D expense as the related global studies are performed, calculated as an estimated percentage of completion based on the estimated total ef&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fort for the programs. See Note 5, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues, for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2026, Taiho has licenses for the Taiho Territory to (i) HIF-2&#x3b1; inhibitor program (including casdatifan); (ii) anti-TIGIT program (including domvanalimab and AB308); (iii) anti-PD-1 program (including zimberelimab); (iv) CD73 program (including quemliclustat); and (v) adenosine receptor antagonist program (including etrumadenant).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this arrangement, for the three months ended March&#160;31, 2026, we recognized revenue of $2 million. We recognized net reimbursements including amortization of advance cost share payments from Taiho for the three months ended March&#160;31, 2026 and 2025 of $5 million and $9 million, respectively, recognized as a reduction in R&amp;amp;D expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2026 and December&#160;31, 2025, we had $3&#160;million and $10&#160;million, respectively, related to this arrangement recorded in Receivable from collaboration partners on our Condensed Consolidated Balance Sheets. At March&#160;31, 2026 and December&#160;31, 2025, we had liabilities of $23&#160;million and $44 million, respectively related to certain advance cost sharing payments under this arrangement recorded in Other liabilities, allocated between current and noncurrent based on the expected timing of future recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AstraZeneca Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we entered into a collaboration with AstraZeneca to evaluate domvanalimab, our investigational anti-TIGIT antibody, in combination with AstraZeneca&#x2019;s durvalumab in a registrational Phase 3 clinical trial in patients with unresectable Stage 3 non-small cell lung cancer ("NSCLC"), known as the PACIFIC-8 trial. The terms of this agreement were amended in 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the collaboration, as amended, each company will retain existing rights to their respective molecules and any future commercial economics. AstraZeneca will conduct the trial, and each company will supply their respective investigational product to support the trial. We may be obligated to pay milestones of up to $24&#160;million upon the achievement of certain clinical trial progress milestones or under certain circumstances if the agreement is terminated early and we will reimburse AstraZeneca annually for a portion of the trial costs. The portion of the costs that we consider to be unavoidable is accrued as incurred and milestones that are deemed probable of occurring are accrued in advance of the achievement of the milestone.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to January 2024, the PACIFIC-8 trial formed part of the Arcus and Gilead joint development program for domvanalimab and our portion of the trial costs was shared with Gilead. Under the Third Gilead Collaboration Agreement Amendment, we agreed to solely fund our share of PACIFIC-8, subject to Gilead&#x2019;s right to reinstate PACIFIC-8 as part of the parties&#x2019; joint development activities for the TIGIT Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized R&amp;amp;D expense for the three months ended March&#160;31, 2026 and 2025 of $5 million and $4 million, respectively, under this arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2026 and December&#160;31, 2025, we have recognized a total liability of $17 million and $12 million, respectively, related to our obligation to AstraZeneca including the first milestone, recorded in Other current liabilities and Other noncurrent liabilities on our Condensed Consolidated Balance Sheets based on the expected timing of payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;WuXi Biologics License - anti-PD-1 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, we entered into an agreement with WuXi Biologics Ireland Limited ("WuXi Biologics") which, as amended, provides us with exclusive rights to (i) develop, use and manufacture products that include an anti-PD-1 antibody, including zimberelimab, worldwide and (ii) commercialize any such products worldwide, except in Greater China. As of March&#160;31, 2026, under this arrangement, we may incur (i) additional regulatory milestone payments of up to $50&#160;million and commercialization milestone payments of up to $375 million, (ii) tiered royalties that range from the high single-digits to low teens on net sales of the licensed products and (iii) fees related to any sublicenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not have any milestones or royalties due under this arrangement for the three months ended March&#160;31, 2026 and 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;WuXi Biologics License - anti-CD39&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, we entered into an agreement with WuXi Biologics, under which we obtained the exclusive worldwide license to develop and commercialize anti-CD39 antibodies discovered under this arrangement. As of March&#160;31, 2026, under this arrangement we may incur additional clinical and regulatory milestone payments of up to $14 million and royalty payments in the low single digits on net sales of the licensed products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not have any milestones or royalties due under this arrangement for the three months ended March&#160;31, 2026 and 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Abmuno License&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, we entered into an agreement (the "Abmuno Agreement") with Abmuno Therapeutics LLC ("Abmuno"), under which we obtained the exclusive worldwide license to develop, use, manufacture, and commercialize products that include an anti-TIGIT antibody, including domvanalimab. As of March&#160;31, 2026, under this arrangement we may incur additional clinical, regulatory and commercialization milestone payments of up to $88 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not have any milestones or royalties due under this arrangement for the three months ended March&#160;31, 2026 and 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <rcus:OptionPeriod contextRef="c-64" id="f-275">P5Y</rcus:OptionPeriod>
    <rcus:NonRefundableAndNonCreditableCashPayments contextRef="c-64" decimals="-6" id="f-276" unitRef="usd">35000000</rcus:NonRefundableAndNonCreditableCashPayments>
    <rcus:PaymentForOptionsExercised contextRef="c-65" decimals="-6" id="f-277" unitRef="usd">3000000</rcus:PaymentForOptionsExercised>
    <rcus:PaymentForOptionsExercised contextRef="c-66" decimals="-6" id="f-278" unitRef="usd">15000000</rcus:PaymentForOptionsExercised>
    <rcus:AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement contextRef="c-66" decimals="-6" id="f-279" unitRef="usd">130000000</rcus:AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <rcus:ContingentMilestonePaymentsReceivable contextRef="c-67" decimals="-6" id="f-280" unitRef="usd">145000000</rcus:ContingentMilestonePaymentsReceivable>
    <rcus:RoyaltiesPayableTerm contextRef="c-64" id="f-281">P10Y</rcus:RoyaltiesPayableTerm>
    <rcus:MilestonePayments contextRef="c-68" decimals="-6" id="f-282" unitRef="usd">28000000</rcus:MilestonePayments>
    <rcus:MilestonePayments contextRef="c-69" decimals="-6" id="f-283" unitRef="usd">26000000</rcus:MilestonePayments>
    <rcus:MilestonePayments contextRef="c-70" decimals="-6" id="f-284" unitRef="usd">19000000</rcus:MilestonePayments>
    <rcus:PaymentForOptionsExercised contextRef="c-71" decimals="-6" id="f-285" unitRef="usd">15000000</rcus:PaymentForOptionsExercised>
    <rcus:AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement contextRef="c-72" decimals="-6" id="f-286" unitRef="usd">172000000</rcus:AdditionalClinicalAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <rcus:ContingentMilestonePaymentsReceivable contextRef="c-73" decimals="-6" id="f-287" unitRef="usd">145000000</rcus:ContingentMilestonePaymentsReceivable>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-74" decimals="-6" id="f-288" unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <rcus:ReimbursementOfResearchAndDevelopmentExpense contextRef="c-74" decimals="-6" id="f-289" unitRef="usd">5000000</rcus:ReimbursementOfResearchAndDevelopmentExpense>
    <rcus:ReimbursementOfResearchAndDevelopmentExpense contextRef="c-75" decimals="-6" id="f-290" unitRef="usd">9000000</rcus:ReimbursementOfResearchAndDevelopmentExpense>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-76" decimals="-6" id="f-291" unitRef="usd">3000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-77" decimals="-6" id="f-292" unitRef="usd">10000000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:OtherLiabilities contextRef="c-76" decimals="-6" id="f-293" unitRef="usd">23000000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities contextRef="c-77" decimals="-6" id="f-294" unitRef="usd">44000000</us-gaap:OtherLiabilities>
    <rcus:MilestonePayments contextRef="c-78" decimals="-6" id="f-295" unitRef="usd">24000000</rcus:MilestonePayments>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-79" decimals="-6" id="f-296" unitRef="usd">5000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-80" decimals="-6" id="f-297" unitRef="usd">4000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-81" decimals="-6" id="f-298" unitRef="usd">17000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-82" decimals="-6" id="f-299" unitRef="usd">12000000</us-gaap:OtherLiabilitiesNoncurrent>
    <rcus:ClinicalRegulatoryMilestonePayments contextRef="c-83" decimals="-6" id="f-300" unitRef="usd">50000000</rcus:ClinicalRegulatoryMilestonePayments>
    <rcus:ClinicalRegulatoryAndCommercializationMilestonePayments contextRef="c-83" decimals="-6" id="f-301" unitRef="usd">375000000</rcus:ClinicalRegulatoryAndCommercializationMilestonePayments>
    <rcus:MilestoneExpense contextRef="c-84" decimals="-6" id="f-302" unitRef="usd">0</rcus:MilestoneExpense>
    <rcus:MilestoneExpense contextRef="c-85" decimals="-6" id="f-303" unitRef="usd">0</rcus:MilestoneExpense>
    <rcus:AdditionalClinicalRegulatoryAndCommercializationMilestonePayments contextRef="c-86" decimals="-6" id="f-304" unitRef="usd">14000000</rcus:AdditionalClinicalRegulatoryAndCommercializationMilestonePayments>
    <rcus:MilestoneExpense contextRef="c-87" decimals="-6" id="f-305" unitRef="usd">0</rcus:MilestoneExpense>
    <rcus:MilestoneExpense contextRef="c-88" decimals="-6" id="f-306" unitRef="usd">0</rcus:MilestoneExpense>
    <rcus:AdditionalClinicalRegulatoryAndCommercializationMilestonePayments contextRef="c-89" decimals="-6" id="f-307" unitRef="usd">88000000</rcus:AdditionalClinicalRegulatoryAndCommercializationMilestonePayments>
    <rcus:MilestoneExpense contextRef="c-90" decimals="-6" id="f-308" unitRef="usd">0</rcus:MilestoneExpense>
    <rcus:MilestoneExpense contextRef="c-89" decimals="-6" id="f-309" unitRef="usd">0</rcus:MilestoneExpense>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-310">Revenues &lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our revenues by collaboration, category of revenue, and the method of recognition (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.235%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Over time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Point in time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gilead Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License and development services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Access rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 2.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Taiho Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues from collaborations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues from a customer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from Gilead accounted for 88% and 100% of Total revenues for the three months ended March&#160;31, 2026 and 2025, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the revenue recognized as a result of changes in the deferred revenue balance (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.022%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized from amounts in deferred revenue at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had $79&#160;million and $78&#160;million of deferred revenue remaining on our Condensed Consolidated Balance Sheets at March&#160;31, 2026 and December&#160;31, 2025, respectively, allocated between current and noncurrent based on the expected timing of future recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue from the Gilead Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2025 Termination of rights to etrumadenant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter 2025, Gilead terminated its rights to etrumadenant (the adenosine receptor antagonist program), which we determined was a significant reduction in the scope of the arrangement, which met the accounting definition of a contract modification and we accounted for this as both a modification of the existing contract and the creation of a new contract. Under the applicable accounting rules for such contract modifications, we did not adjust the accounting for completed performance obligations that were distinct from the modified goods or services. Accordingly, we allocated the updated transaction price of $256 million, which was comprised of the deferred revenue remaining as of the modification date, to the remaining unsatisfied and partially satisfied performance obligations and updated the measure of progress as of the modification date, which resulted in a cumulative catch-up to revenue of $143 million for the quarter ended June 30, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the allocation of the updated transaction price to the remaining unsatisfied and partially satisfied performance obligations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Allocation to performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Distinct&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Combined&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License and development services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Development services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Access right and option continuation periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rights to certain studies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.44pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total transaction price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for each performance obligation as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License and Development Services - Etrumadenant, Quemliclustat and Domvanalimab&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Gilead Collaboration Agreement, Gilead obtained options to the exclusive rights: to our adenosine receptor antagonist program, etrumadenant; to our CD73 program, quemliclustat; and to our anti-TIGIT program, domvanalimab and AB308. Effective December 2021, under the First Gilead Collaboration Agreement Amendment, Gilead exercised these options and obtained exclusive licenses to these programs for a total non-refundable payment totaling $725&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined the standalone selling price of each license using a discounted cash flow method and the R&amp;amp;D services for each program, using an expected cost-plus margin approach. For domvanalimab, we determined that the license was distinct based on an evaluation of the delivery of the license, noting that the program was in the later stages of development and the ongoing R&amp;amp;D services do not significantly modify or customize the related intellectual property. Accordingly, we recognized the allocated transaction price as revenue in the year ended December 31, 2021. For etrumadenant and quemliclustat programs, we determined that the license and R&amp;amp;D services were combined at the inception of the agreement based on an evaluation of the delivery of the license, due to the early stage of the technology and the specialized nature of our know-how. We recognize the amounts allocated to R&amp;amp;D services for domvanalimab and the combined license and R&amp;amp;D for etrumadenant and quemliclustat as each performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for each program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2026 and 2025, we recognized revenue of $8 million and $20 million, respectively, within License and development services revenue in our Condensed Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Access Rights and Option Continuation Periods&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Gilead Collaboration Agreement entered into in 2020 and related amendments, Gilead has exclusive access to our current programs as well as any future programs for a period of ten years, contingent upon option continuation payments totaling $300 million, consisting of a $100 million payment on each of the fourth (paid in third quarter 2024), sixth, and eighth anniversaries of the Gilead Collaboration Agreement. Following Gilead&#x2019;s decision to not make the option continuation payment due on the sixth anniversary, on July 14, 2026, Gilead will lose certain rights to access and obtain licenses to the programs arising from our R&amp;amp;D pipeline. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The standalone selling price of the ongoing R&amp;amp;D pipeline access and the option continuation material rights were determined using an expected cost-plus margin approach, with the option continuation material rights probability-adjusted for the likelihood of exercise. We use a time-elapsed input method to measure progress toward satisfying the access rights performance obligation, which is the method we believe most faithfully depicts our performance in transferring the promised services during the time period in which Gilead has access to our R&amp;amp;D pipeline. Accordingly, the revenue allocated to the initial four-year access rights performance obligation was recognized using this input method over the remaining period through July 2024, and for the fourth anniversary access rights continuation, over the two-year period commencing July 2024. For the option continuation material rights, following Gilead's decision in April 2026 to not make the continuation payment, we will recognize the $18 million of revenue allocated to those material rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2026 and 2025, we recognized revenue of $3 million and $6 million, respectively, within Other collaboration revenue in our Condensed Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rights to Certain Studies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 2024, under the Third Gilead Collaboration Agreement Amendment, we will solely fund certain studies, but Gilead retains exclusive rights to reinstate into the collaboration each study beginning at specified time-points for a payment amount based on the cost incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have determined that these are material rights and we estimated the standalone selling price of these performance obligations using a discounted cash flow method probability-adjusted for the likelihood of exercise. We recognize the amount allocated to each right if and when the related study is reinstated into the parties' co-development plans or if the option effectively lapses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2026, we recognized revenue of $2 million within License and development services revenue in our Condensed Consolidated Statements of Operations. As of March&#160;31, 2026, we had $14 million of deferred revenue on our Condensed Consolidated Balance Sheet related to these performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;R&amp;amp;D Services - Inflammation Programs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2023, we entered into the Second Gilead Collaboration Agreement Amendment pursuant to which we expanded our collaboration to provide Gilead with options to license two jointly selected research-stage programs that target inflammatory diseases for which we will lead discovery and early development activities, see Note 3, Related party - Gilead Sciences, Inc., for more information. We received a total upfront payment of $35 million. We determined that the Second Gilead Collaboration Agreement Amendment represented a separate contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined that we have two separate distinct performance obligations to perform R&amp;amp;D services for Gilead related to discovery and early development activities for each research program for which they have made an upfront payment and, at the amendment closing date, we allocated the transaction price of $35 million equally to the two performance obligations created by this amendment based upon the respective standalone selling prices. The standalone selling prices of these obligations were determined using an expected cost-plus margin approach. We recognize the amounts allocated to these services as the performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for the program. The options to acquire additional licenses or services did not result in additional performance obligations because they did not provide a material right at contract inception, primarily due to the very early stages of the programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2026 and 2025, we recognized revenue of $2 million and $2 million, respectively, within Other collaboration revenue in our Condensed Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue from the Taiho Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Casdatifan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter 2025, Taiho exercised its option under the collaboration arrangement and obtained an exclusive license to casdatifan (the HIF-2&#x3b1; inhibitor) for the Taiho Territory and concurrently entered into the second amendment whereby we will lead development for two indications in Japan including the global Phase 3 trial of casdatifan PEAK-1. In exchange, Taiho made an option exercise payment of $15&#160;million which was received in fourth quarter 2025. We determined that the option exercise and amendment represented a single contract under which we have two separate distinct performance obligations, a license with a customer and R&amp;amp;D services for a collaborative partner related to the global study activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the allocation of the transaction price of $15&#160;million to the performance obligations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Allocation to performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Distinct&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Combined&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.44pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total transaction price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined that the license for casdatifan was distinct based on an evaluation of the delivery of the license, noting that the program was in the later stages of development and the ongoing R&amp;amp;D services do not significantly modify or customize the related intellectual property. We determined the standalone selling price of this license using a discounted cash flow method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized as revenue the allocated transaction price of $7&#160;million in the fourth quarter 2025, within License and development services revenue in our Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The standalone selling price of the R&amp;amp;D services obligation was determined using an expected cost-plus margin approach. We recognize the amounts allocated to these services as the performance obligation is satisfied, calculated as an estimated percentage of completion based on management's estimated total effort for the program. We determined that these services are with a collaborative partner and not a customer and in accordance with our policy recognize these amounts as R&amp;amp;D expense reimbursements. See Note 4, License and collaborations, for more information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License&lt;/span&gt;&lt;/div&gt;For the three months ended March&#160;31, 2026, we recognized revenue of $2&#160;million within License and development services revenue in our Condensed Consolidated Statements of Operations related to programs optioned by Taiho.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-311">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our revenues by collaboration, category of revenue, and the method of recognition (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.235%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Over time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Point in time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gilead Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License and development services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Access rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 2.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Taiho Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues from collaborations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues from a customer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues contextRef="c-91" decimals="-6" id="f-312" unitRef="usd">8000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-92" decimals="-6" id="f-313" unitRef="usd">20000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-93" decimals="-6" id="f-314" unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-94" decimals="-6" id="f-315" unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-95" decimals="-6" id="f-316" unitRef="usd">3000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-96" decimals="-6" id="f-317" unitRef="usd">6000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-97" decimals="-6" id="f-318" unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-98" decimals="-6" id="f-319" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-99" decimals="-6" id="f-320" unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-100" decimals="-6" id="f-321" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-6" id="f-322" unitRef="usd">17000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-11" decimals="-6" id="f-323" unitRef="usd">28000000</us-gaap:Revenues>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-1" decimals="-6" id="f-324" unitRef="usd">10000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-11" decimals="-6" id="f-325" unitRef="usd">20000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-6" id="f-326" unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-6" id="f-327" unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-101" decimals="2" id="f-328" unitRef="number">0.88</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-102" decimals="2" id="f-329" unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c-1" id="f-330">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the revenue recognized as a result of changes in the deferred revenue balance (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.022%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized from amounts in deferred revenue at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="-6" id="f-331" unitRef="usd">17000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-11" decimals="-6" id="f-332" unitRef="usd">28000000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability contextRef="c-14" decimals="-6" id="f-333" unitRef="usd">79000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-15" decimals="-6" id="f-334" unitRef="usd">78000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-103" decimals="-6" id="f-335" unitRef="usd">256000000</us-gaap:RevenueRemainingPerformanceObligation>
    <rcus:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice contextRef="c-104" decimals="-6" id="f-336" unitRef="usd">143000000</rcus:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgressAndChangeInEstimateOfTransactionPrice>
    <rcus:ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock contextRef="c-1" id="f-337">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the allocation of the updated transaction price to the remaining unsatisfied and partially satisfied performance obligations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Allocation to performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Distinct&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Combined&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License and development services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Development services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Access right and option continuation periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rights to certain studies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.44pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total transaction price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the allocation of the transaction price of $15&#160;million to the performance obligations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Allocation to performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Distinct&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Combined&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.44pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total transaction price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</rcus:ScheduleOfTransactionPriceAndAllocatedToTransactionPriceToPerformanceObligationsTableTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-105" decimals="-6" id="f-338" unitRef="usd">192000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-106" decimals="-6" id="f-339" unitRef="usd">17000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-107" decimals="-6" id="f-340" unitRef="usd">30000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-108" decimals="-6" id="f-341" unitRef="usd">17000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-103" decimals="-6" id="f-342" unitRef="usd">256000000</us-gaap:RevenueRemainingPerformanceObligation>
    <rcus:DeferredRevenueNonRefundablePayment contextRef="c-109" decimals="-6" id="f-343" unitRef="usd">725000000</rcus:DeferredRevenueNonRefundablePayment>
    <us-gaap:Revenues contextRef="c-110" decimals="-6" id="f-344" unitRef="usd">8000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-111" decimals="-6" id="f-345" unitRef="usd">20000000</us-gaap:Revenues>
    <rcus:CurrentAndFutureProgramsExclusiveAccessPeriod contextRef="c-112" id="f-346">P10Y</rcus:CurrentAndFutureProgramsExclusiveAccessPeriod>
    <rcus:ContingentMilestonePaymentsReceivable contextRef="c-113" decimals="-6" id="f-347" unitRef="usd">300000000</rcus:ContingentMilestonePaymentsReceivable>
    <rcus:OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement contextRef="c-113" decimals="-6" id="f-348" unitRef="usd">100000000</rcus:OptionContinuationPaymentReceivableUponSixthAnniversaryOfAgreement>
    <us-gaap:Revenues contextRef="c-114" decimals="-6" id="f-349" unitRef="usd">18000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-115" decimals="-6" id="f-350" unitRef="usd">3000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-116" decimals="-6" id="f-351" unitRef="usd">6000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-97" decimals="-6" id="f-352" unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability contextRef="c-117" decimals="-6" id="f-353" unitRef="usd">14000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-118" decimals="-6" id="f-354" unitRef="usd">35000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-118" decimals="-6" id="f-355" unitRef="usd">35000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:Revenues contextRef="c-119" decimals="-6" id="f-356" unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-120" decimals="-6" id="f-357" unitRef="usd">2000000</us-gaap:Revenues>
    <rcus:PaymentForOptionExercise contextRef="c-71" decimals="-6" id="f-358" unitRef="usd">15000000</rcus:PaymentForOptionExercise>
    <rcus:PaymentForOptionExercise contextRef="c-71" decimals="-6" id="f-359" unitRef="usd">15000000</rcus:PaymentForOptionExercise>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-121" decimals="-6" id="f-360" unitRef="usd">7000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-122" decimals="-6" id="f-361" unitRef="usd">8000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-123" decimals="-6" id="f-362" unitRef="usd">15000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiability contextRef="c-124" decimals="-6" id="f-363" unitRef="usd">7000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:Revenues contextRef="c-99" decimals="-6" id="f-364" unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-365">Income taxes&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax provision or benefit for interim periods is determined using an estimate of our annual effective tax rate, adjusted for discrete items, if any, that are taken into consideration in the relevant period. Each quarter, we update the estimate of the annual effective tax rate, and if the estimated tax rate changes, we record a cumulative adjustment to the provision or benefit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not record a provision for income taxes for the three months ended March&#160;31, 2026 and 2025 because of forecasted full year net operating losses ("NOLs"), which consider the timing of recognition of deferred revenue for tax purposes and the effects of the option to capitalize and amortize U.S. R&amp;amp;D expenses as allowed by the One Big Beautiful Bill Act of 2025 ("OBBBA"), which was enacted on July 4, 2025. The effective tax rate differs from the U.S. statutory tax rate primarily due to the valuation allowances on our deferred tax assets and state income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2026 and December&#160;31, 2025, we have provided a valuation allowance against U.S. federal and state deferred tax assets. We continue to evaluate the realizability of deferred tax assets and the related valuation allowance. If our assessment of the deferred tax assets or the corresponding valuation allowance were to change, we would record the related adjustment to income during the period in which we make the determination. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize interest and penalties associated with uncertain tax benefits as part of the income tax provision. To date, we have not recognized any interest and penalties, nor have we accrued for or made payments for interest and penalties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have not been audited by the Internal Revenue Service, any state, or foreign tax authority. We are subject to taxation in the U.S. and in Australia. Due to NOLs and research credit carryforwards, all of our tax years, from 2015 to 2025, remain open to U.S. federal and California state tax examinations. In addition, our fiscal years from 2021 to 2025 are open to examination in Australia.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-366">Net loss per share&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potentially dilutive securities excluded from the computation of diluted net loss per share calculations because they would have been antidilutive (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.022%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock options issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee stock purchase plan shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;We have also excluded from the calculation at March&#160;31, 2025 the effect of Gilead&#x2019;s right to purchase additional shares of our common stock, which expired in July 2025, as these rights had no intrinsic value.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-367">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potentially dilutive securities excluded from the computation of diluted net loss per share calculations because they would have been antidilutive (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.022%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock options issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee stock purchase plan shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-125"
      decimals="-5"
      id="f-368"
      unitRef="shares">18300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-126"
      decimals="-5"
      id="f-369"
      unitRef="shares">18000000.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-127"
      decimals="-5"
      id="f-370"
      unitRef="shares">4600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-128"
      decimals="-5"
      id="f-371"
      unitRef="shares">4300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-129"
      decimals="-5"
      id="f-372"
      unitRef="shares">500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-130"
      decimals="-5"
      id="f-373"
      unitRef="shares">300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-5" id="f-374" unitRef="shares">23400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-11" decimals="-5" id="f-375" unitRef="shares">22600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-376">Stock-based compensation &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects the components of stock-based compensation expense recognized in our Condensed Consolidated Statements of Operations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.022%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-377">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects the components of stock-based compensation expense recognized in our Condensed Consolidated Statements of Operations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.022%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-131" decimals="-6" id="f-378" unitRef="usd">9000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-132" decimals="-6" id="f-379" unitRef="usd">8000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-133" decimals="-6" id="f-380" unitRef="usd">10000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-134" decimals="-6" id="f-381" unitRef="usd">8000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-6" id="f-382" unitRef="usd">19000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-11" decimals="-6" id="f-383" unitRef="usd">16000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="c-1" id="f-384">Cash, cash equivalents and marketable securities &lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amortized cost, gross unrealized gains and losses and the fair value of our cash, cash equivalents and marketable securities, all of which are considered available for sale, by type of securities (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Types of securities as of March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Loss &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate securities and commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Types of securities as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Loss &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate securities and commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair values of our cash, cash equivalents and marketable securities by location in the Condensed Consolidated Balance Sheets and contractual maturity (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Location in Condensed Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contractual Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between one and three years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains or losses recognized on the sale of available-for-sale marketable securities were not material for the three months ended March&#160;31, 2026 and 2025 and are included in Interest and other income, net, in the Condensed Consolidated Statements of Operations. The cost of a security sold is determined using the specific-identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We limit the credit risk associated with our investments by placing them with banks and institutions we believe are highly creditworthy and investing in highly rated investments. We held a total of 100 and 31 positions in securities which were in unrealized loss positions as of March&#160;31, 2026 and December&#160;31, 2025, respectively. We do not intend to sell our securities with unrealized loss positions and have concluded we will not be required to sell the securities before recovery of the amortized cost for the investment at maturity. No credit related losses have been recognized for any of the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the Condensed Consolidated Balance Sheets to the total shown in the Condensed Consolidated Statements of Cash Flows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-443"&gt;&lt;span style="-sec-ix-hidden:f-444"&gt;Restricted cash (included in Other noncurrent assets)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash at March&#160;31, 2026 and 2025 represents cash balances held as security in connection with our facility lease agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-385">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amortized cost, gross unrealized gains and losses and the fair value of our cash, cash equivalents and marketable securities, all of which are considered available for sale, by type of securities (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Types of securities as of March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Loss &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate securities and commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Types of securities as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Loss &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate securities and commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-135" decimals="-6" id="f-386" unitRef="usd">171000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-135" decimals="-6" id="f-387" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-135" decimals="-6" id="f-388" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-135" decimals="-6" id="f-389" unitRef="usd">171000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-136" decimals="-6" id="f-390" unitRef="usd">305000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-136" decimals="-6" id="f-391" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-136" decimals="-6" id="f-392" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-136" decimals="-6" id="f-393" unitRef="usd">305000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-137" decimals="-6" id="f-394" unitRef="usd">395000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-137" decimals="-6" id="f-395" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-137" decimals="-6" id="f-396" unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-137" decimals="-6" id="f-397" unitRef="usd">394000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-138" decimals="-6" id="f-398" unitRef="usd">6000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-138" decimals="-6" id="f-399" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-138" decimals="-6" id="f-400" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-138" decimals="-6" id="f-401" unitRef="usd">6000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-14" decimals="-6" id="f-402" unitRef="usd">877000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-14" decimals="-6" id="f-403" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-14" decimals="-6" id="f-404" unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-14" decimals="-6" id="f-405" unitRef="usd">876000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-139" decimals="-6" id="f-406" unitRef="usd">155000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-139" decimals="-6" id="f-407" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-139" decimals="-6" id="f-408" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-139" decimals="-6" id="f-409" unitRef="usd">155000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-140" decimals="-6" id="f-410" unitRef="usd">359000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-140" decimals="-6" id="f-411" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-140" decimals="-6" id="f-412" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-140" decimals="-6" id="f-413" unitRef="usd">359000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-141" decimals="-6" id="f-414" unitRef="usd">487000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-141" decimals="-6" id="f-415" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-141" decimals="-6" id="f-416" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-141" decimals="-6" id="f-417" unitRef="usd">487000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-142" decimals="-6" id="f-418" unitRef="usd">9000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-142" decimals="-6" id="f-419" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-142" decimals="-6" id="f-420" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-142" decimals="-6" id="f-421" unitRef="usd">9000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-15" decimals="-6" id="f-422" unitRef="usd">1010000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-15" decimals="-6" id="f-423" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-15" decimals="-6" id="f-424" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-15" decimals="-6" id="f-425" unitRef="usd">1010000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="c-1" id="f-426">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair values of our cash, cash equivalents and marketable securities by location in the Condensed Consolidated Balance Sheets and contractual maturity (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Location in Condensed Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contractual Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between one and three years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-14" decimals="-6" id="f-427" unitRef="usd">201000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-15" decimals="-6" id="f-428" unitRef="usd">222000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-14" decimals="-6" id="f-429" unitRef="usd">621000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-15" decimals="-6" id="f-430" unitRef="usd">759000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="c-14" decimals="-6" id="f-431" unitRef="usd">54000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="c-15" decimals="-6" id="f-432" unitRef="usd">29000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <rcus:CashCashEquivalentsAndAvailableForSaleInvestments contextRef="c-14" decimals="-6" id="f-433" unitRef="usd">876000000</rcus:CashCashEquivalentsAndAvailableForSaleInvestments>
    <rcus:CashCashEquivalentsAndAvailableForSaleInvestments contextRef="c-15" decimals="-6" id="f-434" unitRef="usd">1010000000</rcus:CashCashEquivalentsAndAvailableForSaleInvestments>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="c-14"
      decimals="INF"
      id="f-435"
      unitRef="position">100</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="c-15"
      decimals="INF"
      id="f-436"
      unitRef="position">31</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:ProvisionForLoanLossesExpensed contextRef="c-1" decimals="INF" id="f-437" unitRef="usd">0</us-gaap:ProvisionForLoanLossesExpensed>
    <us-gaap:ProvisionForLoanLossesExpensed contextRef="c-11" decimals="INF" id="f-438" unitRef="usd">0</us-gaap:ProvisionForLoanLossesExpensed>
    <us-gaap:ProvisionForLoanLossesExpensed contextRef="c-143" decimals="INF" id="f-439" unitRef="usd">0</us-gaap:ProvisionForLoanLossesExpensed>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="c-1" id="f-440">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the Condensed Consolidated Balance Sheets to the total shown in the Condensed Consolidated Statements of Cash Flows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-443"&gt;&lt;span style="-sec-ix-hidden:f-444"&gt;Restricted cash (included in Other noncurrent assets)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-14" decimals="-6" id="f-441" unitRef="usd">201000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-31" decimals="-6" id="f-442" unitRef="usd">192000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-14" decimals="-6" id="f-445" unitRef="usd">3000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-31" decimals="-6" id="f-446" unitRef="usd">3000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-14" decimals="-6" id="f-447" unitRef="usd">204000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-31" decimals="-6" id="f-448" unitRef="usd">195000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-449">Condensed consolidated balance sheet components&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued personnel expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c-1" id="f-450">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <rcus:PrepaidExpensesAndOtherCurrentAssets contextRef="c-14" decimals="-6" id="f-451" unitRef="usd">15000000</rcus:PrepaidExpensesAndOtherCurrentAssets>
    <rcus:PrepaidExpensesAndOtherCurrentAssets contextRef="c-15" decimals="-6" id="f-452" unitRef="usd">10000000</rcus:PrepaidExpensesAndOtherCurrentAssets>
    <us-gaap:InterestReceivableCurrent contextRef="c-14" decimals="-6" id="f-453" unitRef="usd">4000000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent contextRef="c-15" decimals="-6" id="f-454" unitRef="usd">5000000</us-gaap:InterestReceivableCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-14" decimals="-6" id="f-455" unitRef="usd">19000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-15" decimals="-6" id="f-456" unitRef="usd">15000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-457">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued personnel expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <rcus:AccruedResearchAndDevelopmentExpensesCurrent contextRef="c-14" decimals="-6" id="f-458" unitRef="usd">93000000</rcus:AccruedResearchAndDevelopmentExpensesCurrent>
    <rcus:AccruedResearchAndDevelopmentExpensesCurrent contextRef="c-15" decimals="-6" id="f-459" unitRef="usd">89000000</rcus:AccruedResearchAndDevelopmentExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-14" decimals="-6" id="f-460" unitRef="usd">19000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-15" decimals="-6" id="f-461" unitRef="usd">33000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-14" decimals="-6" id="f-462" unitRef="usd">1000000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-15" decimals="-6" id="f-463" unitRef="usd">1000000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-14" decimals="-6" id="f-464" unitRef="usd">13000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-15" decimals="-6" id="f-465" unitRef="usd">13000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-14" decimals="-6" id="f-466" unitRef="usd">10000000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-15" decimals="-6" id="f-467" unitRef="usd">18000000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-14" decimals="-6" id="f-468" unitRef="usd">136000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-15" decimals="-6" id="f-469" unitRef="usd">154000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LongTermDebtTextBlock contextRef="c-1" id="f-470">Long-term debt&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our borrowings (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt (Contractual maturity 2030)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unamortized discounts, issuance costs, charges and payment-in-kind interest, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2024, we entered into a loan and security agreement with Hercules which we subsequently amended in the fourth quarter 2025 (the "Hercules Agreement"). Under the Hercules Agreement, Hercules agreed to lend us up to $250 million in term loans in various tranches subject to minimum draw requirements. At closing, we drew $50 million and we drew an additional $50 million in the second quarter 2025. The remaining $150&#160;million is available as follows: (i) $50&#160;million will be available upon the achievement of certain Biologic License Application ("BLA") enabling clinical milestones related to our ongoing Phase 3 studies, drawable through the earlier of March 15, 2028 or 90 days following the achievement of the applicable milestone; (ii) $50&#160;million will be available upon the FDA's approval of a BLA or New Drug Application ("NDA") for an Arcus investigational product, drawable through the earlier of December 15, 2028 or 90 days following such approval; and (iii) $50 million remains available through the loan's maturity date, subject to lender approval. Any amounts from future expired tranches that were not drawn will remain available through the loan's maturity date, subject to lender approval and the achievement of any milestones associated with the original tranches.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2026 and 2025, we recognized $3 million and $2 million of interest expense, respectively. The effective interest rate of the debt, including amortization of the debt discount and issuance costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and payment-in-kind interest, was 12.85% commencing with the modification which occurred in the fourth quarter 2025, compared to 13.08% commencing the second quarter 2025 and 13.39% for all periods prior to the second quarter 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-471">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our borrowings (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt (Contractual maturity 2030)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unamortized discounts, issuance costs, charges and payment-in-kind interest, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-14" decimals="-6" id="f-472" unitRef="usd">100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-15" decimals="-6" id="f-473" unitRef="usd">100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-14" decimals="-6" id="f-474" unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-15" decimals="-6" id="f-475" unitRef="usd">1000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt contextRef="c-14" decimals="-6" id="f-476" unitRef="usd">100000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-15" decimals="-6" id="f-477" unitRef="usd">99000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-144" decimals="-6" id="f-478" unitRef="usd">250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt contextRef="c-145" decimals="-6" id="f-479" unitRef="usd">50000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <rcus:DebtInstrumentAdditionalCommittedAmount contextRef="c-146" decimals="-6" id="f-480" unitRef="usd">50000000</rcus:DebtInstrumentAdditionalCommittedAmount>
    <rcus:DebtInstrumentFaceAmountContingentlyAvailable contextRef="c-144" decimals="-6" id="f-481" unitRef="usd">150000000</rcus:DebtInstrumentFaceAmountContingentlyAvailable>
    <rcus:DebtInstrumentFaceAmountContingentlyAvailable contextRef="c-147" decimals="-6" id="f-482" unitRef="usd">50000000</rcus:DebtInstrumentFaceAmountContingentlyAvailable>
    <rcus:DebtInstrumentMilestoneAchievementPeriod contextRef="c-148" id="f-483">P90D</rcus:DebtInstrumentMilestoneAchievementPeriod>
    <rcus:DebtInstrumentFaceAmountContingentlyAvailable contextRef="c-149" decimals="-6" id="f-484" unitRef="usd">50000000</rcus:DebtInstrumentFaceAmountContingentlyAvailable>
    <rcus:DebtInstrumentMilestoneAchievementPeriod contextRef="c-150" id="f-485">P90D</rcus:DebtInstrumentMilestoneAchievementPeriod>
    <rcus:DebtInstrumentAdditionalCommittedAmount contextRef="c-149" decimals="-6" id="f-486" unitRef="usd">50000000</rcus:DebtInstrumentAdditionalCommittedAmount>
    <us-gaap:InterestExpenseDebt contextRef="c-1" decimals="-6" id="f-487" unitRef="usd">3000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-11" decimals="-6" id="f-488" unitRef="usd">2000000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-15" decimals="4" id="f-489" unitRef="number">0.1285</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-103" decimals="4" id="f-490" unitRef="number">0.1308</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-31" decimals="4" id="f-491" unitRef="number">0.1339</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-492">Leases&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our cash and non-cash information related to our operating leases (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2026 and December&#160;31, 2025, we have provided deposits for letters of credit totaling $3 million to secure our obligations under our leases, which are included in Other noncurrent assets on the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <rcus:ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock contextRef="c-1" id="f-493">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our cash and non-cash information related to our operating leases (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</rcus:ScheduleOfSupplementalCashFlowDisclosuresAndNonCashFinancingActivitiesRelatedToOperatingLeasesTableTextBlock>
    <rcus:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities contextRef="c-1" decimals="-6" id="f-494" unitRef="usd">4000000</rcus:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <rcus:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities contextRef="c-11" decimals="-6" id="f-495" unitRef="usd">4000000</rcus:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <us-gaap:SecurityDeposit contextRef="c-14" decimals="-6" id="f-496" unitRef="usd">3000000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit contextRef="c-15" decimals="-6" id="f-497" unitRef="usd">3000000</us-gaap:SecurityDeposit>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-498">Stockholders' equity&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Underwritten Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter 2025, we sold through an underwritten offering, 13.6 million shares of our common stock at a price of $11.00 per share, for total gross proceeds of approximately $150 million, before deducting underwriting discounts, commissions and offering expenses. As part of this underwritten offering, Gilead purchased 1.4 million shares of our common stock for total gross proceeds of $15&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c-11" decimals="-5" id="f-499" unitRef="shares">13600000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-31"
      decimals="2"
      id="f-500"
      unitRef="usdPerShare">11.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-11" decimals="-6" id="f-501" unitRef="usd">150000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <rcus:SaleOfStockNumberOfSharesAcquiredInTransaction contextRef="c-47" decimals="-5" id="f-502" unitRef="shares">1400000</rcus:SaleOfStockNumberOfSharesAcquiredInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-48" decimals="-6" id="f-503" unitRef="usd">15000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-504">Fair value measurements&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 1 inputs include unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value measurement as of March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate securities and commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value measurement as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate securities and commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-term debt&lt;/span&gt;&lt;/div&gt;We determine the fair value of our long-term debt, for disclosure purposes only, based on other inputs that are observable, and thus categorized as Level 2 in the fair value hierarchy. As of March&#160;31, 2026 and December&#160;31, 2025, the estimated fair value of our long-term debt approximated the carrying amount.</us-gaap:FairValueDisclosuresTextBlock>
    <rcus:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-505">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value measurement as of March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate securities and commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value measurement as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate securities and commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</rcus:FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-151" decimals="-6" id="f-506" unitRef="usd">171000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-152" decimals="-6" id="f-507" unitRef="usd">0</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-153" decimals="-6" id="f-508" unitRef="usd">0</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-135" decimals="-6" id="f-509" unitRef="usd">171000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-154" decimals="-6" id="f-510" unitRef="usd">0</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-155" decimals="-6" id="f-511" unitRef="usd">305000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-156" decimals="-6" id="f-512" unitRef="usd">0</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-136" decimals="-6" id="f-513" unitRef="usd">305000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-157" decimals="-6" id="f-514" unitRef="usd">0</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-158" decimals="-6" id="f-515" unitRef="usd">394000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-159" decimals="-6" id="f-516" unitRef="usd">0</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-137" decimals="-6" id="f-517" unitRef="usd">394000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-160" decimals="-6" id="f-518" unitRef="usd">0</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-161" decimals="-6" id="f-519" unitRef="usd">6000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-162" decimals="-6" id="f-520" unitRef="usd">0</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-138" decimals="-6" id="f-521" unitRef="usd">6000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-163" decimals="-6" id="f-522" unitRef="usd">171000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-164" decimals="-6" id="f-523" unitRef="usd">705000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-165" decimals="-6" id="f-524" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-14" decimals="-6" id="f-525" unitRef="usd">876000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-166" decimals="-6" id="f-526" unitRef="usd">155000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-167" decimals="-6" id="f-527" unitRef="usd">0</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-168" decimals="-6" id="f-528" unitRef="usd">0</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-139" decimals="-6" id="f-529" unitRef="usd">155000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-169" decimals="-6" id="f-530" unitRef="usd">0</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-170" decimals="-6" id="f-531" unitRef="usd">359000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-171" decimals="-6" id="f-532" unitRef="usd">0</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-140" decimals="-6" id="f-533" unitRef="usd">359000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-172" decimals="-6" id="f-534" unitRef="usd">0</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-173" decimals="-6" id="f-535" unitRef="usd">487000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-174" decimals="-6" id="f-536" unitRef="usd">0</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-141" decimals="-6" id="f-537" unitRef="usd">487000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-175" decimals="-6" id="f-538" unitRef="usd">0</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-176" decimals="-6" id="f-539" unitRef="usd">9000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-177" decimals="-6" id="f-540" unitRef="usd">0</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-142" decimals="-6" id="f-541" unitRef="usd">9000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-178" decimals="-6" id="f-542" unitRef="usd">155000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-179" decimals="-6" id="f-543" unitRef="usd">855000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-180" decimals="-6" id="f-544" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-15" decimals="-6" id="f-545" unitRef="usd">1010000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-546">Business segment&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate and manage our business as one reportable and operating segment, which is the business of developing and commercializing highly differentiated therapies that have a meaningful impact on patients. Our chief operating decision maker ("CODM") is the Chief Executive Officer, who decides how to allocate resources and assesses segment performance based on the net loss reported in the Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below is a summary of the segment net loss, including significant segment expenses (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 2.44pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjusted for expense (income):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Late-stage development programs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Early-stage development and preclinical programs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation and personnel costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other segment items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Partnership reimbursements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment net loss and Consolidated net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(1) R&amp;amp;D expenses incurred related to a Phase 3 clinical program intended to result in registration of a new product. This includes all unallocated program-level expense not directly attributable to a specific clinical trial once the related program enters into one or more Phase 3 clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(2) R&amp;amp;D expenses incurred for activities ranging from early-stage development and preclinical to Phase 2 clinical trials. This includes all unallocated program-level expense not directly attributable to a specific clinical trial unless the related program has entered into one or more Phase 3 clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(3) Other segment items includes non-allocated program costs and other G&amp;amp;A costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total segment assets at March&#160;31, 2026 and 2025 were $1.0 billion and $1.2 billion, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-547"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-548"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-549">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below is a summary of the segment net loss, including significant segment expenses (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 2.44pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjusted for expense (income):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Late-stage development programs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Early-stage development and preclinical programs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation and personnel costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.36pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9.36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other segment items &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Partnership reimbursements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment net loss and Consolidated net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(1) R&amp;amp;D expenses incurred related to a Phase 3 clinical program intended to result in registration of a new product. This includes all unallocated program-level expense not directly attributable to a specific clinical trial once the related program enters into one or more Phase 3 clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(2) R&amp;amp;D expenses incurred for activities ranging from early-stage development and preclinical to Phase 2 clinical trials. This includes all unallocated program-level expense not directly attributable to a specific clinical trial unless the related program has entered into one or more Phase 3 clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%"&gt;(3) Other segment items includes non-allocated program costs and other G&amp;amp;A costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues contextRef="c-181" decimals="-6" id="f-550" unitRef="usd">17000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-182" decimals="-6" id="f-551" unitRef="usd">28000000</us-gaap:Revenues>
    <rcus:LateStageDevelopmentPrograms contextRef="c-181" decimals="-6" id="f-552" unitRef="usd">60000000</rcus:LateStageDevelopmentPrograms>
    <rcus:LateStageDevelopmentPrograms contextRef="c-182" decimals="-6" id="f-553" unitRef="usd">55000000</rcus:LateStageDevelopmentPrograms>
    <rcus:EarlyStageDevelopmentAndPreclinicalPrograms contextRef="c-181" decimals="-6" id="f-554" unitRef="usd">18000000</rcus:EarlyStageDevelopmentAndPreclinicalPrograms>
    <rcus:EarlyStageDevelopmentAndPreclinicalPrograms contextRef="c-182" decimals="-6" id="f-555" unitRef="usd">42000000</rcus:EarlyStageDevelopmentAndPreclinicalPrograms>
    <us-gaap:LaborAndRelatedExpense contextRef="c-181" decimals="-6" id="f-556" unitRef="usd">70000000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-182" decimals="-6" id="f-557" unitRef="usd">66000000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-181" decimals="-6" id="f-558" unitRef="usd">2000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-182" decimals="-6" id="f-559" unitRef="usd">3000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InterestExpenseNonoperating contextRef="c-181" decimals="-6" id="f-560" unitRef="usd">-6000000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-182" decimals="-6" id="f-561" unitRef="usd">-10000000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-181" decimals="-6" id="f-562" unitRef="usd">20000000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-182" decimals="-6" id="f-563" unitRef="usd">22000000</us-gaap:SegmentReportingOtherItemAmount>
    <rcus:PartnershipReimbursements contextRef="c-181" decimals="-6" id="f-564" unitRef="usd">-19000000</rcus:PartnershipReimbursements>
    <rcus:PartnershipReimbursements contextRef="c-182" decimals="-6" id="f-565" unitRef="usd">-38000000</rcus:PartnershipReimbursements>
    <us-gaap:NetIncomeLoss contextRef="c-181" decimals="-6" id="f-566" unitRef="usd">-128000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-182" decimals="-6" id="f-567" unitRef="usd">-112000000</us-gaap:NetIncomeLoss>
    <us-gaap:Assets contextRef="c-183" decimals="-8" id="f-568" unitRef="usd">1000000000.0</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-184" decimals="-8" id="f-569" unitRef="usd">1200000000</us-gaap:Assets>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-1" id="f-570">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The adoption, modification or termination of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers and directors for the three months ended March&#160;31, 2026, which are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.868%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.868%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.868%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.335%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.868%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.767%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Name and Title&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Action&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total Shares to be Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:7.37pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Robert C. Goeltz II&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:7.37pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chief Financial Officer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adoption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;January 26, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56,163&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March 31, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:7.37pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Juan Jaen&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:7.37pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;President&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adoption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;February 27, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139,781&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 4, 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:7.37pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Jennifer Jarrett&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:7.37pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chief Operating Officer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adoption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;January 23, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;188,277&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;November 23, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-571">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-572">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-573">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrIndName contextRef="c-185" id="f-574">Robert C. Goeltz II</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-185" id="f-575">Chief Financial Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-185" id="f-576">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-185" id="f-577">January 26, 2026</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-186"
      decimals="INF"
      id="f-578"
      unitRef="shares">56163</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate contextRef="c-185" id="f-579">March 31, 2028</ecd:TrdArrExpirationDate>
    <ecd:TrdArrIndName contextRef="c-187" id="f-580">Juan Jaen</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-187" id="f-581">President</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-187" id="f-582">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-187" id="f-583">February 27, 2026</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-188"
      decimals="INF"
      id="f-584"
      unitRef="shares">139781</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate contextRef="c-187" id="f-585">June 4, 2027</ecd:TrdArrExpirationDate>
    <ecd:TrdArrIndName contextRef="c-189" id="f-586">Jennifer Jarrett</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-189" id="f-587">Chief Operating Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-189" id="f-588">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-189" id="f-589">January 23, 2026</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-190"
      decimals="INF"
      id="f-590"
      unitRef="shares">188277</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate contextRef="c-189" id="f-591">November 23, 2026</ecd:TrdArrExpirationDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
